{
    "data": [
        {
            "uri": "7580888801",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-06",
            "time": "17:08:00",
            "dateTime": "2023-06-06T17:08:00Z",
            "dateTimePub": "2023-06-06T17:07:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.moneycontrol.com/news/business/markets/trade-setup-for-wednesday-top-15-things-to-know-before-the-opening-bell-39-10754031.html",
            "title": "Trade setup for Wednesday: Top 15 things to know before the opening bell",
            "body": "Based on the OI percentage, 58 stocks, including Mphasis, Indian Energy Exchange, Persistent Systems, Chambal Fertilizers, and Aarti Industries, saw a short build-up.\n\nThe recovery in late trade amid consolidation helped the market close flat with a positive bias on June 6, as the three-day meeting of the Monetary Policy Committee members started a discussion over interest rate decisions.\n\nThe benchmark indices continued the uptrend for the third consecutive session. The BSE Sensex was up 5.4 points at 62,793, while the Nifty50 rose 5.2 points to 18,599 and formed a Doji candlestick pattern on the daily charts, indicating the tug-of-war between bulls and bears for market direction as the closing was similar to opening levels.\n\n\"Normally, such Doji formations after a reasonable up move or down move calls for reversal. Having formed this pattern amidst a range movement, the predictive value of this pattern could be less,\" Nagaraj Shetti, Technical Research Analyst at HDFC Securities said.\n\nHe feels immediate supports like daily 10 and 20-day EMAs (exponential moving average) are intact and the intraday buying has been emerging so far from this support in the short term.\n\nOn the upper side, repeated testing of crucial hurdle around the 18,600-18,700 levels is expected to result in a decisive upside breakout, while immediate support is at 18,500 levels, Shetti said.\n\nWe have seen a continued uptrend in broader markets with the Nifty Midcap 100 and Smallcap 100 indices rising 0.06 percent and 0.54 percent, respectively.\n\nWe have collated 15 data points to help you spot profitable trades:\n\nNote: The open interest (OI) and volume data of stocks in this article are the aggregates of three-month data and not just the current month.\n\nKey support, resistance levels on Nifty\n\nThe Nifty may get support at 18,550, followed by 18,528 and 18,493. If the index advances, then 18,619 will be the key resistance followed by 18,641 and 18,676.\n\nNifty Bank\n\nWe have also seen an upward journey in the Bank Nifty for the third day in a row. The index climbed 63 points to 44,165 amid volatility and formed a Doji candlestick pattern on the daily scale for yet another session.\n\n\"The Doji candle formation suggests that the overall trend is expected to remain sideways, without a clear direction in the index's movement,\" Rupak De, Senior Technical at LKP Securities said.\n\nHe feels the support level is identified at 44,000 and if the index falls below this level, it might drop towards 43,700. On the other hand, the resistance levels are observed at 44,300 and 44,500 acting as barriers to further upward movement, he said.\n\nAs per the pivot point calculator, the Bank Nifty is expected to take support at 44,050, followed by 43,997 and 43,910, while the resistance is likely to be at 44,223, then 44,277 and 44,363.\n\nCall options data\n\nOn the weekly options front, the maximum Call open interest (OI) was at 18,600 strike, with 1.01 crore contracts, which is expected to be a crucial resistance level for the Nifty.\n\nThis was followed by 18,800 strike comprising 89.43 lakh contracts and 18,700 strike with more than 84 lakh contracts.\n\nThe meaningful Call writing was seen at 18,800 strike, which added 21.1 lakh contracts, followed by 18,900 strike, which added 15.11 lakh contracts, and 19,000 strike, which added 9.3 lakh contracts.\n\nCall unwinding was at 19,500 strike, which shed 41.33 lakh contracts, followed by 18,500 strike, which shed 17.66 lakh contracts, and 19,300 strike, which shed 5.58 lakh contracts.\n\nPut option data\n\nOn the Put side, the maximum open interest was at 18,500 strike, with 1 crore contracts, which is expected to be an important support level in the coming sessions.\n\nIt was followed by the 18,600 strike, comprising 93.86 lakh contracts and the 18,400 strike with 70.35 lakh contracts.\n\nPut writing was seen at 18,400 strike, which added 18.28 lakh contracts, followed by 18,200 strike, which added 17.84 lakh contracts and 18,100 strike, which added 9.43 lakh contracts.\n\nPut unwinding was seen at 18,500 strike, which shed 14.51 lakh contracts, followed by 18,700 strike, which shed 7.4 lakh contracts and 17,600 strike which shed 3.41 lakh contracts.\n\nA high delivery percentage suggests that investors are showing interest in the stock. The highest delivery was seen in Larsen & Toubro, Petronet LNG, Cummins India, Coal India and United Breweries among others.\n\nAn increase in open interest (OI) and price indicates a build-up of long positions. Based on the OI percentage, 45 stocks, including JK Cement, Maruti Suzuki India, ACC, Tata Communications and Syngene International saw long buildups.\n\nA decline in OI and price generally indicate a long unwinding. Based on the OI percentage, 28 stocks, including Birlasoft, Escorts, Apollo Hospitals Enterprises, Hindustan Copper and Oracle Financial saw a long unwinding.\n\n58 stocks see a short build-up\n\nAn increase in OI along with a price decrease indicates a build-up of short positions. Based on the OI percentage, 58 stocks, including Mphasis, Indian Energy Exchange, Persistent Systems, Chambal Fertilizers and Aarti Industries saw a short build-up.\n\nA decrease in OI along with a price increase is an indication of short-covering. Based on the OI percentage, 58 stocks were on the short-covering list. These included India Cements, ICICI Prudential Life Insurance Company, AU Small Finance Bank, REC and Titan Company.\n\nGravita India: Promoter Rajat Agrawal has sold 13 lakh equity shares or 1.88 percent shareholding in the lead metal manufacturer via open market transaction at an average price of Rs 586.04 per share, which amounted to Rs 76.18 crore. However, Jupiter India Fund has acquired 10 lakh shares or 1.44 percent stake in the company at an average price of Rs 585 per share.\n\nCeinsys Tech: The information technology company remained in focus as Zodius Technology Fund continued to be a seller in the firm, offloading 1.96 lakh shares or a 1.27 percent stake at an average price of Rs 199.37 per share. Zodius has been selling its stake in the company since May, so far selling 9.12 lakh shares or 5.91 percent stake. As of March 2023, it held 10.94 lakh shares or a 7.09 percent stake.\n\nIFB Industries: Societe Generale, the Europe-based financial services group, has bought 3 lakh shares or a 0.74 percent stake in the manufacturer of household appliances, machine tools, and automobile parts. These shares were bought at an average price of Rs 800 per share.\n\nShemaroo Entertainment: The management of the company will meet Lucky Securities.\n\nTata Steel, Metropolis Healthcare, Dr Reddy's Laboratories: Officials of companies will attend Morgan Stanley India Investment Forum.\n\nPersistent Systems, Adani Ports and Special Economic Zone: Companies' officials will attend Nomura Conference.\n\nCMS Info Systems: Officials of the company will interact with Abakkus Asset Manager LLP, SBI Mutual Fund, Bajaj Finserv, Aequitas Investments and 360 One Asset.\n\nAllcargo Logistics: Company's officials will meet Abakkus, Aequitas Investments, Ainios Alpha, Caprize Investments, Care PMS, Deep Financial, Entrust Family Office, Nidara Capital, Nirmal Bang, Phillip Capital and Seraphic Management & Advisory.\n\nStocks in the news\n\nJSW Ispat Special Products: Kiran Menon has resigned as the Chief Financial Officer (CFO) of the sponge iron, steel and ferro alloys manufacturerwith effect from June 6. Menon resigned to pursue opportunities outside the group.\n\nGMR Airports Infrastructure: GMR Hyderabad International Airport (GHIAL), a step-down subsidiary of the company, has divested approximately 8.18 lakh square feet of warehouse facility at the Hyderabad Airport to ILP Core Ventures I PTE Limited for Rs 188.1 crore. ILP Core is a step-down subsidiary of Indospace Core PTE Limited, India's largest operator of core logistics and industrial real estate vehicle.\n\nWipro: The technology services and consulting company launched the Wipro Industry Innovation Experience for Financial Services solution on Microsoft Cloud. Microsoft and Wipro will develop new solutions to help financial services clients accelerate growth and deepen client relationships.\n\nEngineers India: National Aluminium Company (NALCO) has selected the company for providing consultancy services for the updation of a detailed project report (DPR) for Pottangi bauxite mines for enhancing raw-ore production. Jindal Steel and Power (JSPL) has signed a contract with Engineers India for the supply of basic engineering and detail engineering for a direct reduced iron plant at Angul, Orissa. These orders are worth Rs 20.55 crore.\n\nDeepak Fertilisers & Petrochemicals Corporation: Subsidiary Performance Chemiserve has raised Rs 900 crore via the issuance of non-convertible debentures (NCDs) on a private placement basis to qualified institutional buyers. NCDs are to be listed on BSE Limited.\n\nG R Infraprojects: Subsidiary GR Hasapur Badadal Highway has executed the concession agreement with the National Highways Authority of India (NHAI). The bid project cost is Rs 872.2 crore. The said highway project in Maharashtra is to be executed in Hybrid Annuity Mode under Bharatmala Pariyojana.\n\nTorrent Power: The company has signed a Memorandum of Understanding (MoU) with the Government of Maharashtra for the development of three pumped storage hydro projects of 5,700 MW capacity in Maharashtra. The projects would entail an investment of about Rs 27,000 crore. Torrent intends to execute these projects over a period of 5 years.\n\nForeign institutional investors (FIIs) bought shares worth Rs 385.71 crore, whereas domestic institutional investors (DIIs) sold shares worth Rs 489.02 crore on June 6, provisional data from the National Stock Exchange shows.\n\nStocks under F&O ban on NSE\n\nThe National Stock Exchange has retained Indiabulls Housing Finance, India Cements and Manappuram Finance to its F&O ban list for June 7. Securities in the ban period under the F&O segment include companies in which the security has crossed 95 percent of the market-wide position limit.",
            "source": {
                "uri": "moneycontrol.com",
                "dataType": "news",
                "title": "MoneyControl"
            },
            "authors": [],
            "image": "https://images.moneycontrol.com/static-mcnews/2021/03/Trading-770x433.jpg",
            "eventUri": null,
            "sentiment": 0.3725490196078431,
            "wgt": 423767280,
            "relevance": 1
        },
        {
            "uri": "7580472421",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-06",
            "time": "12:35:00",
            "dateTime": "2023-06-06T12:35:00Z",
            "dateTimePub": "2023-06-06T12:32:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.expresspharma.in/jb-pharma-betting-big-on-india/",
            "title": "JB Pharma: Betting big on India - Express Pharma",
            "body": "Pegged as one of India's fastest growing pharma companies, JB Pharma's recently released fourth quarter and year ended March 31, 2023 results continue to beat market growth rates.\n\nAs per IQVIA MAT March 2023 data, JB Pharma continued to be the fastest growing company amongst the Top 25 in FY23, outperforming the Indian Pharma Market (IPM), growing at 22 per cent versus 8 per cent, aided by the organic business growing at 21 per cent. India business (domestic sales) of the overall sector grew by 15 per cent for Q4 FY23, whereas JB Pharma's domestic business grew double at 30 per cent. (See BOX: JB Pharma Business highlights: Q4 FY23 and FY23).\n\nWill JB Pharma's dream run continue? And what are the risks of pursuing an acquisition-driven growth strategy? As pharma promoters in the India pharma sector contemplate bringing strategic investors on board, JB Pharma's transition strategy and steady rise up the ranks is being closely observed and could well become a success story worth emulating by its peers in the sector.\n\nNikhil Chopra, CEO and Wholetime Director, JB Pharma commented that this \"market-beating performance\" is \"pivoted around their strategy to make big brands becoming bigger, and significant demand acceleration in the acquired portfolio.\" He pointed out that each of their top seven brands (Rantac, Cilacar, Cilacar-T, Metrogyl, Nicardia, Azmarda and Sporlac) have ascended through the ranks. Further, Sporlac, the acquired business in probiotics and pediatric segment, is the newest entrant to IQVIA's Top 300 brands from their portfolio.\n\nTill 2020, JB Pharma was like many promoter-driven pharma companies. Started in 1976 by the late JB Mody as JB Chemicals & Pharmaceuticals Laboratories (JBCPL), the company made a name for itself with brands like Metrogyl (1977), Nicardia (1980), Rantac (1989), Cilacar (2007). Overseas, the company's Doktor Mom and Rinza brands were able to tap into the Russia and CIS OT market.\n\nFounder JB Mody carefully steered the ship through the choppy seas of evolving regulations, spiralling prices and increasing price control. Cut to July 2020, when the JBCPL founders sold controlling stakes to private equity firm Kohlberg Kravis Roberts and co (KKR).\n\nWith KKR at the helm, and a new management team headed by Chopra, the company jumped nine ranks in two years, from rank #32 in MAT 2021, to #23 in 2023. The company's prescriptions continue to grow at a market-beating pace; with the company ending FY23 ranked #15 in the IPM.\n\nAnalysing JB Pharma's transformation strategy post KKR acquiring majority controlling stakes in the company, Chopra highlights three major initiatives.\n\n1. Transformation of India business by establishing a new go-to-market model, making big brands bigger.\n\nAfter KKR came on board in July 2020, Chopra reveals how they took up a restructuring exercise both internally and externally. Showing its aggressive intent, the new management had initiated a series of measures to transform the entire business.\n\nHe narrates how the management put forth an accelerated growth strategy where they would not only build upon core competencies but also leverage strengths to enter into new therapeutic areas. Backed by over 5,000 employees including a 2,500-strong sales force, Chopra says JB Pharma has put in place a new 'go-to-market' model, where they focus on life-cycle management for big brands and evaluate new growth opportunities to further enhance productivity.\n\nGiving more granular detail, Chopra explains how their focus on making \"big brands ... bigger was substantiated by launching line extensions of existing franchises and focussing on sales force excellence and automation. Furthermore, expansion into tier 4 and rural towns helped India business in increasing the reach and availability for current brands.\"\n\nChopra analyses how one of the pillars of strategy has been acquisition-led growth. JB Pharma completed four major acquisitions (brands from Sanzyme, Azmarda, Razel franchise and paediatric portfolio from Dr Reddy's Laboratories), thus foraying into the fast-growing probiotics, paediatric and the niche of the heart failure segment. These portfolios offer deep geographic and distribution synergies along with prescriber overlap. In six months, Sporlac now is among the top three brands in the probiotic segment, providing significant opportunities to expand through line extensions.\n\nChopra revealed that he emphasised a 'beyond the pill' marketing approach in the Indian pharma industry, which involved organic and inorganic initiatives to enhance patient awareness, education, diagnosis and adherence through various 'phygital' initiatives.\n\nOther areas of expertise include digitalisation of the pharma field force and engagement with doctors, nurturing talent and creating cross-functional collaborations and propagating technology in improving healthcare access and awareness.\n\nHe stresses that for JB Pharma, the domestic formulations business remains a key focus area and it has been consistently growing at better than industry growth rate over the last several years.\n\nHe also refers to another trend in the IPM. While India has historically been a market dominated by acute therapies, the trend has been shifting to a larger contribution from chronic drugs in the consumption base. As per IQVIA IMS data, the share of chronic therapies in the IPM has expanded from 31 per cent to 36 per cent in the period between FY13 and FY21. This is in line with the trend in several global economies that have seen a larger incidence of lifestyle diseases on the back of improved diagnoses and better compliance by patients.\n\nJB Pharma's international business contributes around 50 per cent of the total revenue, comprises three segments: export formulations, API and contract manufacturing. The business grew by 16 per cent to Rs 382 crores in Q4 FY23 versus Rs 330 crores in Q4 FY22. The international formulations business was at Rs 255 crores in Q4 Fy23 versus Rs 218 crores in Q4 FY22 recording growth of 17 per cent.\n\nJB Pharma operates distinct operating models across multiple international businesses with a direct presence in Russia and South Africa as well as distributor relationships in the US and a large number of markets across Asia, Africa and Latin America. According to Chopra, JB Pharma has a leading global position in the contract manufacturing market driven by marquee client relationships.\n\n3. Development beyond financial metrics to a new cultural identity\n\nJB Pharma also recently marked one year of a new corporate identity as JB, centred on being \"simple, reliable and agile\" while building on the strong foundation of \"integrity, trust and reliability\" nurtured over the past 45 odd years.\n\nExplaining the vision behind the new identity, Chopra said, \"The company offerings and capabilities are becoming more diverse to cater to the evolving needs of customers, manufacturing processes are becoming more robust, and lean, and our vision of looking at the healthcare industry is becoming more progressive globally.\n\nWe are adapting ourselves to become more responsive to the needs of the healthcare world. In sync with the evolving healthcare industry and the changing need of customers, JB has re-visioned the cause of spreading good health in India. JB aims to support healthcare providers and enrich patients' lives in innovative new ways while remaining committed to its core values of integrity, trust and reliability built over 45 years.\"\n\nThis was inculcated in terms of initiatives within the organisation that made employees and departments agile and cultivated a cross-collaborative culture. As CEO, Chopra reportedly played an active role in developing this and led leadership culture-building exercises such as OneJBWay (a leadership transformational programme). Furthermore, the same OneJBWay culture is cascaded to the second in line of leaders (N-2) through a forward-looking leadership training and excellence programme called LEAP.\n\n4. Publishing inaugural sustainability (ESG) report\n\nChopra explains how the ESG report was prepared following the international reporting standards framework, the Global Reporting Initiative (GRI) as its Core Standard, and linkages with the Sustainable Development Goals (SDGs).\n\nAs per Chopra, from FY 2020 to FY 2022, the organisation has reduced energy consumption by 9.2 per cent and augmented green energy through solar power. Additionally, its Scope 1 and Scope 2 emissions have reduced by 14.6 per cent and 10.7 per cent during the same period. During the reporting period, waste sent for co-processing stood at 757.65 MT. All sites are Zero Liquid Discharge.\n\nLooking ahead, Chopra is emphatic that \"our biggest bet is India as 50 per cent of our revenue comes from here. We will continue to leverage opportunities that lead us to organic growth and diversify into newer categories that can be in generic formulations, wellness etc. We will also be looking for acquisition opportunities, which are a strategic fit and assure returns within the payback period. The other strategy is to grow our big brands such as Cilacar, Cilacar-T, Rantac, Metrogyl, Nicardia and Azmarda.\"\n\nSpelling out the goals for the next few years, Chopra says that they plan on accelerating towards their 50th year in 2025. \"In the next three years, we want to increase our market share by being among the top 20 companies in the IPM market. Under the new strategy, our major focus is to strengthen our core therapy segments i.e., hypertension, respiratory, gastroenterology, nephrology, cardiology, dentistry, and paediatrics.\n\nIf FY21 was about realigning the structure and portfolio to ensure sustainable growth and focussing strongly on the lifecycle management of their flagship brands, the next priority is to scale up R&D and business development initiatives towards building a progressive portfolio for the US, Russia, South Africa, and API. Chopra says that they will focus on consolidating their business areas through a deeper presence in existing geographies and this will be aided by multiple new launches over the next two to three years.\n\nWith four brand acquisitions in 15 months and close to 1500+ appointments, across businesses and geographies in the last year, JB Pharma's new identity is evidently an attempt to ensure common brand values across a rapidly expanding workforce.\n\nChopra says that each brand acquisition came with a sales force from different companies that was relevant to their existing salesforce team and gave geographical synergies. This added almost 500-600 people across divisions of heart failure, hypertension, wellness, respiratory etc.\n\nAnd Chopra reveals that there could be more acquisitions, as the company will continue to evaluate (further brand acquisition) opportunities and see if there are assets available within the space of paediatrics, cardiology, metabolics, respiratory, and anti-infectives.\n\nIt will be interesting to observe how JB Pharma is able to assimilate the 'acquired' sales force into a cohesive entity. Talent retention will be a key component, given the cutthroat competition in the IPM. According to Chopra, the company's continuous focus/endeavours on talent retention led to 200+ promotions in FY23. Most pharma companies struggle to increase productivity per sales professional, leading to high attrition rates.\n\nChopra reiterates, \"Our current philosophy has a strong foundation of the legacy brand on which the new identity has been built and carried forward. This is highlighted best in three aspects - our people, our results and our products. We are the fastest growing company with fast-tracked growth for careers as well. This is supplemented by strong learning and development programmes across levels and locations. Last but not the least, a healthy work-life balance is critical to increased productivity which is catered to by our wellness initiatives. We are also in the process of introducing a competency matrix which would aid in talent retention.\"",
            "source": {
                "uri": "expresspharma.in",
                "dataType": "news",
                "title": "Express Pharma"
            },
            "authors": [],
            "image": "https://cdn.expresspharma.in/wp-content/uploads/2021/11/12182826/Growth-1.jpg",
            "eventUri": null,
            "sentiment": 0.2549019607843137,
            "wgt": 423750900,
            "relevance": 26
        },
        {
            "uri": "7580406844",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-06",
            "time": "11:56:00",
            "dateTime": "2023-06-06T11:56:00Z",
            "dateTimePub": "2023-06-06T11:54:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.taiwannews.com.tw/en/news/4911652",
            "title": "Peripheral Neuropathy Market Thrives with Exemplary Growth | PledPharma, Solasia Pharma, Helixmith | Taiwan News | 2023-06-06 10:35:48",
            "body": "The Peripheral Neuropathy Market research study from Astute Analytica provides a detailed analysis of the sector, taking into account crucial elements like market size, industry share, and key competitors.\n\nThe Global Peripheral Neuropathy Market is estimated to grow at a CAGR of around 3.4% during the forecast period 2021-2027. Astute Analytica predicted that the market accounted for US$ 0.976 Bn in the year 2019 and is anticipated to reach US$ 1.3 Bn by the end of the year 2027.\n\nRequest For a Sample Report Here- https://www.astuteanalytica.com/request-sample/peripheral-neuropathy-market\n\nThe comprehensive analysis of the Peripheral Neuropathy Market focuses extensively on key industry players, encompassing a range of factors including competitors' strategies, target market, sales volume, production costs, distribution channels, and various growth drivers. Additionally, it provides insights into the company's market position, financial status, size, market share, and product portfolio, highlighting their significance within the industry.\n\nList of Key Players\n\nPledPharma Solasia Pharma Helixmith Asahi Kasei Pharma America Corporation Lexicon Pharmaceuticals Abbott Laboratories Cipla Limited Eli Lilly and Company GlaxoSmithKline plc Lupin Limited Merck and Co. Inc. Novartis, Pfizer Inc. Dr. Reddy's Laboratories Bristol Myers Squibb\n\nThe in-depth study not only presents projections, benchmarking, company shares, and recent market trends but also takes into account the human element. It explores sustainability initiatives, conducts a competitive analysis, and examines their impact on market expansion and competitiveness. To provide a comprehensive view, the research adopts a meticulous data triangulation approach, ensuring accurate and reliable market estimations.\n\nWith a keen focus on regional areas, the study delves into the effects of COVID-19 and provides detailed market segmentation by Type, Diagnosis, Treatment, and End-User. This report serves as an invaluable resource for gaining a deeper understanding of the Market. By offering valuable insights into the present market scenario and future prospects until 2033, this study equips stakeholders with crucial data to make informed decisions.\n\nBrowse the Full Report- https://www.astuteanalytica.com/industry-report/peripheral-neuropathy-market\n\nSegmentation Outline\n\nBy Type\n\nChemotherapy-induced Diabetic HIV/AIDS Associated Idiopathic\n\nBy Diagnosis\n\nBlood test Biopsy Imaging Others\n\nBy Treatment\n\nMedications Antidepressants Anti-seizure medication Pain reliever Topical treatment Therapies Nerve stimulation Plasma exchange Physical Therapy Surgery Others\n\nBy End-User\n\nHospitals Clinics Ambulatory Centres\n\nAccess Sample Report- https://www.astuteanalytica.com/request-sample/peripheral-neuropathy-market\n\nAbout Astute Analytica:\n\nAstute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth, and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the globe.\n\nThey are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of the best cost-effective, value-added package from us, should you decide to engage with us.\n\nGet in touch with us:\n\nPhone number: +18884296757\n\nEmail: sales@astuteanalytica.com\n\nVisit our website: https://www.astuteanalytica.com/\n\nClick Here for More Related Reports: -\n\nAir Cushion Packaging Market\n\nNorth America Garage Furniture Market",
            "source": {
                "uri": "taiwannews.com.tw",
                "dataType": "news",
                "title": "Taiwan News"
            },
            "authors": [],
            "image": null,
            "eventUri": null,
            "sentiment": 0.2627450980392156,
            "wgt": 423748560,
            "relevance": 26
        },
        {
            "uri": "7580362962",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-06",
            "time": "11:27:00",
            "dateTime": "2023-06-06T11:27:00Z",
            "dateTimePub": "2023-06-06T11:18:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://finance.yahoo.com/news/10-top-rated-stocks-billionaires-111839609.html",
            "title": "10 Top-Rated Stocks Billionaires Are Loading Up On",
            "body": "In this piece, we will take a look at the ten top rated stocks billionaires are loading up on. For more stocks, head on over to 5 Top-Rated Stocks Billionaires Are Loading Up On.\n\nThe U.S. economy has undergone several shocks over the past couple of years. This turmoil started after the onset of the coronavirus pandemic in 2019 which led to lockdowns and a broader downturn in economic activity in 2020. The slowdown led to investors fleeing away from the stock market due to the potential impact of lockdowns and stay at home orders on general productivity. They, however, returned back in droves after it became clear that the technology sector would be the biggest beneficiary of the chaos.\n\nThen, as the world wearily looked towards normalcy in 2022, the after effects of expansionary fiscal policy during the pandemic and the Russian invasion of Ukraine dealt a massive inflationary blow to the economy. This blow led the Federal Reserve - which had initially mistaken the inflation as transitory - to aggressively increase interest rates in an attempt to curtail economic activity and reign in the beast of inflation.\n\nYet, as if all this wasn't enough, 2023 started off with another crisis a.k.a. the debt ceiling. The specter (and spectacle?) of a default by the largest economy in the world almost scared the daylights out of both government officials and investors. Thankfully though, this crisis is over as legislation in Capitol Hill to raise the debt ceiling cleared Senate and Congress in June 2023.\n\nWith the debt ceiling out of the way, the only worry that remains is that of a potential recession. The Federal Reserve is quite optimistic that it can avoid this outcome. However, its fight just took a complicated turn in June when the labor data for May 2023 came in. This data shows that in May, 339,000 new jobs were added to the economy, smashing Wall Street estimates of 195,000 out of the park. Yet, at the same time, the unemployment percentage of 3.7% surpassed estimates of 3.5% - making sure that the latest report remained stuck smack in the middle when it comes to looking in the crystal ball to see what the Fed might do in its upcoming meeting later this month.\n\nAmidst this chaos, some economists pointed to the upcoming data for the consumer price index (CPI) figures due in the second week of June, and others shared that don't be fooled to believe that a recession is on its way. This voice belongs to the chief economist of the financial research firm FWDBONDS LLC who shared with Bloomberg:\n\nEven then, as most folks struggle with inflation, hedge funds are busy making money. And as they say, to make money, you have to spend money. And despite the turmoil in the financial market, the funds are out with the big bucks. Just how big? Well, some are eager to guarantee top stock investing talent a stunning $120 million in payouts\n\nSo it would make sense to follow what the professionals are doing and see how they are placing their bets. Well, that's what we've done in today's piece but we have narrowed down our focus to only include hedge fund managers that are worth more than a billion dollars. And there are plenty of those in the industry, including several whose firms are making multimillion dollar payouts. Some hedge funds included in our list are Fisher Investments, Renaissance Technologies, D.E. Shaw, and Bridgewater Associates. And, some of their top stock picks are DexCom, Inc. (NASDAQ:DXCM), Alphabet Inc. (NASDAQ:GOOG), and Cameco Corporation (NYSE:CCJ).\n\nOur Methodology\n\nTo compile our list of high-rated stocks that billionaires are buying, we first used a stock screener to sift out the top forty most valuable companies whose shares have a Strong Buy rating. Then, the number of billionaires that had invested in them was determined using Insider Monkey's database of billionaire-owned stocks. Out of the resultant dataset 10 stocks with the highest number of billionaire investors were selection.\n\nNumber of Billionaire Investors In Q1 2023: 6\n\nDr. Reddy's Laboratories Limited (NYSE:RDY) is an Indian company headquartered in Hyderabad. The firm is a pharmaceutical company that operates in several portions of the drug supply chain. Dr. Reddy's Laboratories Limited (NYSE:RDY)'s business model includes making and selling both prescription and over the counter medicines. Additionally, it also makes raw materials for pharmaceutical products and has a biologics division as well.\n\nBy the end of this year's first quarter, 17 of the 943 hedge funds part of Insider Monkey's database had held a stake in Dr. Reddy's Laboratories Limited (NYSE:RDY). Out of these, the largest investor is billionaire Jim Simons' Renaissance Technologies which owns 1.6 million shares that are worth $95 million.\n\nAlong with Dr. Reddy's Laboratories Limited (NYSE:RDY), Alphabet Inc. (NASDAQ:GOOG), DexCom, Inc. (NASDAQ:DXCM), Alphabet Inc. (NASDAQ:GOOG), and Cameco Corporation (NYSE:CCJ) are some top-rated stocks that billionaires are piling into.\n\nNumber of Billionaire Investors In Q1 2023: 7\n\nBritish American Tobacco p.l.c. (NYSE:BTI) is one of the largest tobacco companies in the world. It is also one of the oldest tobacco companies since it was set up in 1802. The firm has a variety of cigarette brands in its portfolio and it also provides vaping products.\n\nInsider Monkey took a look at 943 hedge funds for their first quarter of 2023 shareholdings to discover that 22 had invested in the tobacco company. Billionaire Rajiv Jain's GQG Partners is British American Tobacco p.l.c. (NYSE:BTI)'s largest shareholder with an $882 million stake.\n\nNumber of Billionaire Investors In Q1 2023: 8\n\nVodafone Group Public Limited Company (NASDAQ:VOD) is a telecommunications company that is one of Europe's most iconic brands. The firm was set up in 1984 and is headquartered in Newbury, the United Kingdom. It provides a wide variety of communications products and services and such as connectivity for mobile phones, data services, messaging services, data broadband services, and satellite connectivity. Alongside this, it also provides Internet of Things (IoT) products, security solutions, logistics management, and a breadth of other services.\n\nAfter digging through 943 hedge funds for their March 2023 investments, Insider Monkey discovered that 28 had held a stake in the company. Vodafone Group Public Limited Company (NASDAQ:VOD)'s largest hedge fund investor is billionaire Jim Simons' Renaissance Technologies which owns 18 million shares that are worth $201 million.\n\nNumber of Billionaire Investors In Q1 2023: 10\n\nZTO Express (Cayman) Inc. (NYSE:ZTO) is a Chinese freight company operating out of Shanghai, China. It provides freight delivery and forward services.\n\n23 of the 943 hedge funds part of Insider Monkey's database had bought ZTO Express (Cayman) Inc. (NYSE:ZTO)'s shares during Q1 2023. Kerr Neilson's Platinum Asset Management is its largest shareholder since it owns a $461 million stake that comes through 16 million shares.\n\nNumber of Billionaire Investors In Q1 2023: 10\n\nNew Oriental Education & Technology Group Inc. (NYSE:EDU), as the name suggests, is a new age company. It is part of the handful of firms that are providing online education services. The firm operates primarily in China, is headquartered in Beijing, and was set up in 1993. Its services include test preparation courses, tutoring courses, English language classes, and more. Despite facing a shock that saw China restrict private education, seems like New Oriental Education & Technology Group Inc. (NYSE:EDU) is still a favorite for both billionaires and analysts as they continue to provide it with strong ratings and cold, hard, cash.\n\n31 of the 943 hedge funds part of Insider Monkey's database had invested in New Oriental Education & Technology Group Inc. (NYSE:EDU) by the end of Q1 2023. Out of these, the largest investor is Seth Klarman's Baupost Group with a $209 million stake.\n\nDexCom, Inc. (NASDAQ:DXCM), New Oriental Education & Technology Group Inc. (NYSE:EDU), Alphabet Inc. (NASDAQ:GOOG), and Cameco Corporation (NYSE:CCJ) are some top-rated stocks that are also top billionaire stock picks.\n\nClick to continue reading and see the 5 Top-Rated Stocks Billionaires Are Loading Up On.",
            "source": {
                "uri": "finance.yahoo.com",
                "dataType": "news",
                "title": "Yahoo! Finance"
            },
            "authors": [],
            "image": "https://s.yimg.com/ny/api/res/1.2/SWr2m7F0XplPUJ6BYkacWg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/insidermonkey.com/a46da9068c58072daab2f794893d76d8",
            "eventUri": null,
            "sentiment": -0.1137254901960785,
            "wgt": 423746820,
            "relevance": 75
        },
        {
            "uri": "7580306584",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-06",
            "time": "10:51:00",
            "dateTime": "2023-06-06T10:51:00Z",
            "dateTimePub": "2023-06-06T10:49:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.livemint.com/market/stock-market-news/many-nifty50-constituents-trade-at-a-discount-to-their-historical-average-check-names-here-11686040939117.html",
            "title": "Many Nifty50 constituents trade at a discount to their historical average; check names here",
            "body": "The Nifty is trading at a 12-month forward P/E ratio of 18.6x, below its long-period average (LPA) of 20x, while the P/B ratio, at 2.9x, is at an 8% premium to its historical average.\n\nThe 12-month trailing P/E for the Nifty, at 22.2x, is near to its LPA of 21.8x and at 3.3x, the 12-month trailing P/B ratio for the Nifty is above its historical average of 3x, the report highlighted.\n\nThe report comes when the benchmark Nifty is trading just around 300 points below its life-time high of 18,887.60. The index has gained 4.8% in the last three months led by persistent foreign capital inflows, better than estimated corporate earnings for the March quarter and improving domestic macroeconomic scenario.\n\nInflows from foreign portfolio investors (FPI) in the Indian equities remained robust as they purchased equities worth â‚¹41,206.76 crore in the month of May.\n\nAlso Read: FPI flows to drive markets as US seen at interest rate peak\n\nOver the last twelve months, the MSCI India index was up 7% and has outperformed the MSCI EM index that was down 11%. Over the last 10 years, it has outperformed the MSCI EM index by 173%, the Motilal Oswal report said.\n\nIn P/E terms, the MSCI India index is trading at a 100% premium to the MSCI EM index, above its historical average of 70%, it noted.\n\nMeanwhile, Nifty companies trading at a significant premium to their historical average include Divi's Laboratories(+51%), Grasim Industries (+47%), Reliance Industries (+45%), Nestle (+24%), and Tech Mahindra (+23%).\n\nWhereas, companies trading at a significant discount to their historical average include ONGC (-56%), Tata Steel (-52%), Coal India (-33%), Apollo Hospital (-29%), and Dr Reddy's Laboratories (-28%).\n\nCatch Live Market Updates here\n\nThe Auto sector is trading at a P/E of 21.1x, below its 10-year historical average of 26.5x, while on a P/B basis, it is trading at a 13% premium to its 10-year average of 3.3x. \"We believe 2W volume should continue to see sequential growth, led by a recovery in rural demand and a pickup in exports,\" Motilal Oswal said.\n\nThe consumer sector's P/E ratio, at 42.3x, represents a 6% premium to its 10-year average of 39.7x. On a P/B basis, it is trading at 11.4x, a premium of 12% against its historical average of 10.2x.\n\n\"Management commentary suggests that demand is recovering in rural markets. Unseasonal rainfall has affected beverages demand in some parts of the country. Companies have started to pass on the benefits of lower commodity costs to consumers,\" the brokerage added.\n\nThe PSU Banks sector is trading at a P/B ratio of 1.0x, a 20% premium to its historical average of 0.8x. The Private Banks sector is trading at a P/B ratio of 2.5x, its 10-year average. ROE is at a 10-year high of 16% for private banks.\n\n\"Earnings for PSU Banks remained healthy, led by a broad-based improvement in key parameters, such as margin, operating profitability, and credit cost. Improving profitability and a reduction in risk-weight intensity have further boosted capital ratios for PSU banks,\" it added.\n\nWith the Reserve Bank of India (RBI) keeping policy rates unchanged, the brokerage house believes systemic interest rates have likely peaked. However, garnering deposits will be important. The rise in deposit costs (due to lag in re-pricing), along with a pause in rate hikes may keep margin under pressure in FY24, it said.",
            "source": {
                "uri": "livemint.com",
                "dataType": "news",
                "title": "mint"
            },
            "authors": [
                {
                    "uri": "ankit_gohel@livemint.com",
                    "name": "Ankit Gohel",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://www.livemint.com/lm-img/img/2023/06/06/600x338/sensex_1661846646875_1686041185422.jpg",
            "eventUri": null,
            "sentiment": 0.419607843137255,
            "wgt": 423744660,
            "relevance": 26
        },
        {
            "uri": "7579192914",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-05",
            "time": "17:33:00",
            "dateTime": "2023-06-05T17:33:00Z",
            "dateTimePub": "2023-06-05T03:52:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.moneycontrol.com/europe/?url=https:%2F%2Fwww.moneycontrol.com%2Fnews%2Fbusiness%2Fwwdc-2023-live-updates-apple-inc-announces-15-inch-macbook-air-laptop-priced-at-361299_17069591.html",
            "title": "Trade setup for Tuesday: Top 15 things to know before the opening bell",
            "body": "The buying interest in the market amid consolidation continued for yet another session on June 5, backed by auto, select banking and financial services, metal and pharma stocks. Positive Asian cues also aided the northward journey of the Indian equity benchmarks. The BSE Sensex rose 240 points to 62,787, while the Nifty50 climbed 60 points to 18,594 and formed a bearish candlestick pattern with an upper shadow on the daily charts but negated lower highs of the previous three consecutive sessions. \"Technically, this pattern indicates a lacklustre type movement in the market at the highs. The upper area of 18,600-18,700 has been acting as a crucial hurdle as of now,\" Nagaraj Shetti, Technical Research Analyst at HDFC Securities said. He says the Nifty's short-term trend continues to be positive with rangebound action. \"The present consolidation movement is expected to continue within a high low range of 18,700-18,500 levels in the next 1-2 sessions. A decisive move above 18,700-18,800 is expected to bring more upside for the near term,\" Shetti said. The broader markets continued the uptrend for more than a couple of weeks now, with the Nifty Midcap 100 index up 0.14 percent and Smallcap 100 index rising 0.36 percent. We have collated 15 data points to help you spot profitable trades: Note: The open interest (OI) and volume data of stocks in this article are the aggregates of three-month data and not just the current month. Key support, resistance levels on Nifty The Nifty may get support at 18,584, followed by 18,570 and 18,548. If the index advances, 18,628 will be the key resistance followed by 18,641 and 18,663. Nifty Bank The Bank Nifty continued its uptrend for the second consecutive session and rose 164 points to 44,102, forming a Doji candlestick pattern on the daily scale making higher high and higher low formation, as the market participants were cautious ahead of the outcome of a three-day policy meeting by the RBI. \"The Bank Nifty index is expected to continue to trade within the range of 43,700-44,300. This suggests that the index is likely to move sideways, lacking a clear trend,\" Kunal Shah, Senior Technical &amp; Derivative Analyst at LKP Securities said. However, he says that a break on either side of this range can lead to a directional move, potentially indicating a shift in the market sentiment and momentum. As per the pivot point calculator, the Bank Nifty is expected to take support at 44,074, followed by 44,029 and 43,955, while the resistance is likely to be at 44,221, then 44,266, and 44,339. Call options data On the weekly options front, the maximum Call open interest (OI) was at 18,600 strike, with 1.03 crore contracts, which is expected to be a crucial resistance level for the Nifty. This was followed by 18,700 strike comprising 82.41 lakh contracts and 18,500 strike with more than 68.68 lakh contracts. The meaningful Call writing was seen at 18,700 strike, which added 19.89 lakh contracts, followed by 18,900 strike, which added 12.77 lakh contracts, and 19,000 strike, which added 10.02 lakh contracts. Call unwinding was at 18,500 strike, which shed 8.45 lakh contracts, followed by 18,400 strike, which shed 1.33 lakh contracts, and 18,300 strike, which shed 1.07 lakh contracts. Put option data On the Put side, the maximum open interest was at 18,500 strike, with 1.15 crore contracts, which is expected to be an important support level in the coming sessions. It was followed by the 18,600 strike, comprising 91.99 lakh contracts, and the 18,000 strike with 55.52 lakh contracts. Put writing was seen at 18,600 strike, which added 34 lakh contracts, followed by 18,700 strike, which added 13.55 lakh contracts, and 18,500 strike, which added 13.1 lakh contracts. Put unwinding was seen at 17,800 strike, which shed 5.78 lakh contracts, followed by 18,100 strike, which shed 2.77 lakh contracts, and 17,900 strike which shed 1.78 lakh contracts. Stocks with high delivery percentage A high delivery percentage suggests that investors are showing interest in the stock. The highest delivery was seen in Power Grid Corporation of India, HDFC, Bharti Airtel, Sun Pharmaceutical Industries and JK Cement, among others. 53 stocks see a long build-up An increase in open interest (OI) and price indicates a build-up of long positions. Based on the OI percentage, 53 stocks, including Oracle Financial, India Cements, Indiabulls Housing Finance, Lupin and Deepak Nitrite saw long buildups. 42 stocks see long unwinding A decline in OI and price generally indicate a long unwinding. Based on the OI percentage, 42 stocks, including Hero MotoCorp, Info Edge India, IndiaMART InterMESH, Nestle India, and AU Small Finance Bank, saw a long unwinding. 40 stocks see a short build-up An increase in OI along with a price decrease indicates a build-up of short positions. Based on the OI percentage, 40 stocks, including Manappuram Finance, L&amp;T Finance Holdings, Hindalco Industries, Mphasis and Max Financial Services, saw a short build-up. 50 stocks see short-covering A decrease in OI along with a price increase is an indication of short-covering. Based on the OI percentage, 50 stocks were on the short-covering list. These included Ipca Laboratories, Dixon Technologies, Ashok Leyland, Bosch, and ICICI Prudential Life Insurance Company. Bulk deals Ceinsys Tech: Zodius Technology Fund sold another 1.42 lakh shares in the software solutions provider via open market transaction at an average price of Rs 187.15 per share. So far, Zodius offloaded 7.15 lakh shares in the company since May, against its shareholding as of March 2023 at 10.94 lakh shares. MTAR Technologies: Ahmedabad-based Plutus Wealth Management LLP has bought 13.15 lakh shares or 4.27 percent stake in the precision engineering company via open market transactions at an average price of Rs 1,880.02 per share, which amounted to Rs 247.22 crore. However, three promoters Usha Reddy Chigarapalli, Anitha Reddy Dwaram, and Kavitha Reddy Gangapatnam sold 11.2 lakh shares or 3.64 percent stake in the company. (For more bulk deals, click here) Investors Meetings on June 6 Kotak Mahindra Bank, Bharat Forge, Info Edge India: Officials of these companies will attend Morgan Stanley India Investment Forum. Cummins India: The company's officials will meet Goldman Sachs. Dr Reddy's Laboratories: The company's officials will participate in a non-deal roadshow organised by Nomura. eMudhra: Officials of the company will interact with Turtle Wealth. Adani Ports and Special Economic Zone: The company's officials will attend Nomura Conference. SJVN: Officials of the company will be participating in non-deal road shows and meeting prospective investors. Can Fin Homes: The company's officials will interact with Nuvama Institutional Equities. Barbeque-Nation Hospitality: Officials of the company will interact with Tata Mutual Fund, Abakkus Asset Managers, India First Life Insurance, and ICICI Prudential. Trent: The company's officials will meet BlackRock. Elin Electronics: Management of the company to meet representatives of HDFC Standard Life Insurance. Stocks in the news SBI Cards and Payment Services: The company said the board has approved the raising of funds up to Rs 3,000 crore via the issuance of non-convertible debentures (NCDs). The fundraising will take place in one or more tranches, on a private placement basis. JK Cement: The cement company has received board approval to sign and execute a Share Purchase Agreement with Toshali Cements for the acquisition of 100 percent shareholding in Toshali, from all the existing shareholders. After an investment of Rs 157 crore, Toshali will become a subsidiary of JK Cement, and the acquisition will help the company expand its footprint into the eastern region. BL Kashyap and Sons: The civil engineering and construction company has secured new order worth Rs 147 crore, from Nzuri Pune Knowledge Park. With this, the total order book of the company stands at Rs 2774 crore till date. Godrej Consumer Products: The board of directors has appointed Aasif Malbari as Chief Financial Officer (CFO) of the FMCG company with effect from August 10, 2023. Sameer Shah ceased as the CFO of the company as he will move to a group role leading consumer investments. Wipro: The IT services company said its dynamic digital signage solution, Wipro VisionEDGE, will power Bowling Center TV (BCTV), a new digital out-of-home television network distributed across bowling centres in the United States. BCTV is a partnership between Strike Ten Entertainment, the Bowling Proprietors' Association of America (BPAA), and Equity Sports Partners. Indian Energy Exchange: The energy exchange achieved 8,251 MU overall volume in May, increasing 8 percent over a year-ago month. The price in May 2023 was Rs 4.74 per unit, declining 30 percent from Rs 6.76 per unit in May 2022 due to an improving supply-side scenario leading to increased liquidity, as well as cooler weather conditions. State Bank of India: The country's largest lender said the board of directors will meet on June 9 to consider raising funds during FY24 via the issuance of debt instruments (including capital instruments) in INR and /or foreign currency, on a private placement basis. Fund Flow FII and DII data Foreign institutional investors (FIIs) sold shares worth Rs 700.98 crore, whereas domestic institutional investors (DIIs) bought shares worth Rs 1,195.98 crore on June 5, provisional data from the National Stock Exchange shows. Stocks under F&amp;O ban on NSE The National Stock Exchange has added Indiabulls Housing Finance, India Cements, and Manappuram Finance to its F&amp;O ban list for June 6. Securities in the ban period under the F&amp;O segment include companies in which the security has crossed 95 percent of the market-wide position limit. Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.",
            "source": {
                "uri": "moneycontrol.com",
                "dataType": "news",
                "title": "MoneyControl"
            },
            "authors": [],
            "image": "https://images.moneycontrol.com/static-mcnews/2022/03/385817382-770x433.jpg",
            "eventUri": null,
            "sentiment": 0.2627450980392156,
            "wgt": 423682380,
            "relevance": 1
        },
        {
            "uri": "7579186967",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-05",
            "time": "17:28:00",
            "dateTime": "2023-06-05T17:28:00Z",
            "dateTimePub": "2023-06-05T17:27:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.moneycontrol.com/news/business/markets/trade-setup-for-tuesday-top-15-things-to-know-before-the-opening-bell-36-10747181.html",
            "title": "Trade setup for Tuesday: Top 15 things to know before the opening bell",
            "body": "Based on the OI percentage, 53 stocks including Oracle Financial, India Cements, Indiabulls Housing Finance, Lupin and Deepak Nitrite saw long buildups.\n\nThe buying interest in the market amid consolidation continued for yet another session on June 5, backed by auto, select banking and financial services, metal and pharma stocks. Positive Asian cues also aided the northward journey of the Indian equity benchmarks.\n\nThe BSE Sensex rose 240 points to 62,787, while the Nifty50 climbed 60 points to 18,594 and formed a bearish candlestick pattern with an upper shadow on the daily charts but negated lower highs of the previous three consecutive sessions.\n\n\"Technically, this pattern indicates a lacklustre type movement in the market at the highs. The upper area of 18,600-18,700 has been acting as a crucial hurdle as of now,\" Nagaraj Shetti, Technical Research Analyst at HDFC Securities said.\n\nHe says the Nifty's short-term trend continues to be positive with rangebound action.\n\n\"The present consolidation movement is expected to continue within a high low range of 18,700-18,500 levels in the next 1-2 sessions. A decisive move above 18,700-18,800 is expected to bring more upside for the near term,\" Shetti said.\n\nThe broader markets continued the uptrend for more than a couple of weeks now, with the Nifty Midcap 100 index up 0.14 percent and Smallcap 100 index rising 0.36 percent.\n\nWe have collated 15 data points to help you spot profitable trades:\n\nNote: The open interest (OI) and volume data of stocks in this article are the aggregates of three-month data and not just the current month.\n\nKey support, resistance levels on Nifty\n\nThe Nifty may get support at 18,584, followed by 18,570 and 18,548. If the index advances, 18,628 will be the key resistance followed by 18,641 and 18,663.\n\nNifty Bank\n\nThe Bank Nifty continued its uptrend for the second consecutive session and rose 164 points to 44,102, forming a Doji candlestick pattern on the daily scale making higher high and higher low formation, as the market participants were cautious ahead of the outcome of a three-day policy meeting by the RBI.\n\n\"The Bank Nifty index is expected to continue to trade within the range of 43,700-44,300. This suggests that the index is likely to move sideways, lacking a clear trend,\" Kunal Shah, Senior Technical & Derivative Analyst at LKP Securities said.\n\nHowever, he says that a break on either side of this range can lead to a directional move, potentially indicating a shift in the market sentiment and momentum.\n\nAs per the pivot point calculator, the Bank Nifty is expected to take support at 44,074, followed by 44,029 and 43,955, while the resistance is likely to be at 44,221, then 44,266, and 44,339.\n\nOn the weekly options front, the maximum Call open interest (OI) was at 18,600 strike, with 1.03 crore contracts, which is expected to be a crucial resistance level for the Nifty.\n\nThis was followed by 18,700 strike comprising 82.41 lakh contracts and 18,500 strike with more than 68.68 lakh contracts.\n\nThe meaningful Call writing was seen at 18,700 strike, which added 19.89 lakh contracts, followed by 18,900 strike, which added 12.77 lakh contracts, and 19,000 strike, which added 10.02 lakh contracts.\n\nCall unwinding was at 18,500 strike, which shed 8.45 lakh contracts, followed by 18,400 strike, which shed 1.33 lakh contracts, and 18,300 strike, which shed 1.07 lakh contracts.\n\nOn the Put side, the maximum open interest was at 18,500 strike, with 1.15 crore contracts, which is expected to be an important support level in the coming sessions.\n\nIt was followed by the 18,600 strike, comprising 91.99 lakh contracts, and the 18,000 strike with 55.52 lakh contracts.\n\nPut writing was seen at 18,600 strike, which added 34 lakh contracts, followed by 18,700 strike, which added 13.55 lakh contracts, and 18,500 strike, which added 13.1 lakh contracts.\n\nPut unwinding was seen at 17,800 strike, which shed 5.78 lakh contracts, followed by 18,100 strike, which shed 2.77 lakh contracts, and 17,900 strike which shed 1.78 lakh contracts.\n\nA high delivery percentage suggests that investors are showing interest in the stock. The highest delivery was seen in Power Grid Corporation of India, HDFC, Bharti Airtel, Sun Pharmaceutical Industries and JK Cement, among others.\n\n53 stocks see a long build-up\n\nAn increase in open interest (OI) and price indicates a build-up of long positions. Based on the OI percentage, 53 stocks, including Oracle Financial, India Cements, Indiabulls Housing Finance, Lupin and Deepak Nitrite saw long buildups.\n\nA decline in OI and price generally indicate a long unwinding. Based on the OI percentage, 42 stocks, including Hero MotoCorp, Info Edge India, IndiaMART InterMESH, Nestle India, and AU Small Finance Bank, saw a long unwinding.\n\nAn increase in OI along with a price decrease indicates a build-up of short positions. Based on the OI percentage, 40 stocks, including Manappuram Finance, L&T Finance Holdings, Hindalco Industries, Mphasis and Max Financial Services, saw a short build-up.\n\n50 stocks see short-covering\n\nA decrease in OI along with a price increase is an indication of short-covering. Based on the OI percentage, 50 stocks were on the short-covering list. These included Ipca Laboratories, Dixon Technologies, Ashok Leyland, Bosch, and ICICI Prudential Life Insurance Company.\n\nCeinsys Tech: Zodius Technology Fund sold another 1.42 lakh shares in the software solutions provider via open market transaction at an average price of Rs 187.15 per share. So far, Zodius offloaded 7.15 lakh shares in the company since May, against its shareholding as of March 2023 at 10.94 lakh shares.\n\nMTAR Technologies: Ahmedabad-based Plutus Wealth Management LLP has bought 13.15 lakh shares or 4.27 percent stake in the precision engineering company via open market transactions at an average price of Rs 1,880.02 per share, which amounted to Rs 247.22 crore. However, three promoters Usha Reddy Chigarapalli, Anitha Reddy Dwaram, and Kavitha Reddy Gangapatnam sold 11.2 lakh shares or 3.64 percent stake in the company.\n\nKotak Mahindra Bank, Bharat Forge, Info Edge India: Officials of these companies will attend Morgan Stanley India Investment Forum.\n\nCummins India: The company's officials will meet Goldman Sachs.\n\nDr Reddy's Laboratories: The company's officials will participate in a non-deal roadshow organised by Nomura.\n\neMudhra: Officials of the company will interact with Turtle Wealth.\n\nAdani Ports and Special Economic Zone: The company's officials will attend Nomura Conference.\n\nSJVN: Officials of the company will be participating in non-deal road shows and meeting prospective investors.\n\nCan Fin Homes: The company's officials will interact with Nuvama Institutional Equities.\n\nBarbeque-Nation Hospitality: Officials of the company will interact with Tata Mutual Fund, Abakkus Asset Managers, India First Life Insurance, and ICICI Prudential.\n\nTrent: The company's officials will meet BlackRock.\n\nElin Electronics: Management of the company to meet representatives of HDFC Standard Life Insurance.\n\nStocks in the news\n\nSBI Cards and Payment Services: The company said the board has approved the raising of funds up to Rs 3,000 crore via the issuance of non-convertible debentures (NCDs). The fundraising will take place in one or more tranches, on a private placement basis.\n\nJK Cement: The cement company has received board approval to sign and execute a Share Purchase Agreement with Toshali Cements for the acquisition of 100 percent shareholding in Toshali, from all the existing shareholders. After an investment of Rs 157 crore, Toshali will become a subsidiary of JK Cement, and the acquisition will help the company expand its footprint into the eastern region.\n\nBL Kashyap and Sons: The civil engineering and construction company has secured new order worth Rs 147 crore, from Nzuri Pune Knowledge Park. With this, the total order book of the company stands at Rs 2774 crore till date.\n\nGodrej Consumer Products: The board of directors has appointed Aasif Malbari as Chief Financial Officer (CFO) of the FMCG company with effect from August 10, 2023. Sameer Shah ceased as the CFO of the company as he will move to a group role leading consumer investments.\n\nWipro: The IT services company said its dynamic digital signage solution, Wipro VisionEDGE, will power Bowling Center TV (BCTV), a new digital out-of-home television network distributed across bowling centres in the United States. BCTV is a partnership between Strike Ten Entertainment, the Bowling Proprietors' Association of America (BPAA), and Equity Sports Partners.\n\nIndian Energy Exchange: The energy exchange achieved 8,251 MU overall volume in May, increasing 8 percent over a year-ago month. The price in May 2023 was Rs 4.74 per unit, declining 30 percent from Rs 6.76 per unit in May 2022 due to an improving supply-side scenario leading to increased liquidity, as well as cooler weather conditions.\n\nState Bank of India: The country's largest lender said the board of directors will meet on June 9 to consider raising funds during FY24 via the issuance of debt instruments (including capital instruments) in INR and /or foreign currency, on a private placement basis.\n\nForeign institutional investors (FIIs) sold shares worth Rs 700.98 crore, whereas domestic institutional investors (DIIs) bought shares worth Rs 1,195.98 crore on June 5, provisional data from the National Stock Exchange shows.\n\nStocks under F&O ban on NSE\n\nThe National Stock Exchange has added Indiabulls Housing Finance, India Cements, and Manappuram Finance to its F&O ban list for June 6. Securities in the ban period under the F&O segment include companies in which the security has crossed 95 percent of the market-wide position limit.",
            "source": {
                "uri": "moneycontrol.com",
                "dataType": "news",
                "title": "MoneyControl"
            },
            "authors": [],
            "image": "https://images.moneycontrol.com/static-mcnews/2022/03/385817382-770x433.jpg",
            "eventUri": null,
            "sentiment": 0.1843137254901961,
            "wgt": 423682080,
            "relevance": 1
        },
        {
            "uri": "7579114988",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-05",
            "time": "16:33:00",
            "dateTime": "2023-06-05T16:33:00Z",
            "dateTimePub": "2023-06-05T16:25:00Z",
            "dataType": "news",
            "sim": 0.843137264251709,
            "url": "https://www.thehindu.com/business/phase-1-study-of-dr-reddys-tocilizumab-biosimilar-candidate-completed/article66935137.ece",
            "title": "Phase 1 study of Dr. Reddy's tocilizumab biosimilar candidate completed",
            "body": "Dr. Reddy's Laboratories on Monday said its tocilizumab biosimilar candidate, DRL_TC, for treating rheumatoid arthritis, has successfully met its primary and secondary endpoints in a Phase I study.\n\nThis Phase I study used an intravenous formulation to evaluate the pharmacokinetic equivalence, safety and immunogenicity of the biosimilar candidate in comparison to reference products. The drugmaker is developing the proposed biosimilar as both intravenous and subcutaneous formulations.\n\n\"Tocilizumab is an important antirheumatic agent that has a unique place in treating patients with rheumatoid arthritis and other diseases. By developing the formulation in both subcutaneous and intravenous formulations, we aim to reach more patients around the world,\" said Jayanth Sridhar, Global Head of Biologics at Dr. Reddy's.\n\nWhile the reference product for the study in the U.S. was Actemra, in the European Union, RoActemra was the reference medicinal product. The successful outcome of this study is important milestone in Dr. Reddy's commitment to make highquality biosimilar products more accessible and affordable to healthcare providers and patients around the world, the company said in a release.",
            "source": {
                "uri": "thehindu.com",
                "dataType": "news",
                "title": "The Hindu"
            },
            "authors": [],
            "image": "https://www.thehindu.com/theme/images/og-image.png",
            "eventUri": "eng-8673477",
            "sentiment": 0.2784313725490195,
            "wgt": 423678780,
            "relevance": 51
        },
        {
            "uri": "7578828703",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-05",
            "time": "13:22:00",
            "dateTime": "2023-06-05T13:22:00Z",
            "dateTimePub": "2023-06-05T13:12:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.finanznachrichten.de/nachrichten-2023-06/59260801-pharmatech-associates-board-of-directors-appoints-sireesha-yadlapalli-as-chief-executive-officer-004.htm",
            "title": "Pharmatech Associates' Board of Directors Appoints Sireesha Yadlapalli as Chief Executive Officer",
            "body": "The Board of Directors of Pharmatech Associatestoday announced the appointment of Sireesha Yadlapalli as chief executive officer, effective June 5, 2023. Ms. Yadlapalli will succeed Bikash Chatterjee, who will remain with the organization as President and chief science officer.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230605005056/en/\n\nSireesha Yadlapalli (Photo: Business Wire)\n\nYadlapalli brings industry and regulatory experience to Pharmatech gained during her over 20-year career in the biopharmaceutical industry in positions in finance, business development, strategic marketing, and regulatory affairs. Prior to taking on her new role, Yadlapalli served on the organization's Board of Directors and as Vice President, International Government and Regulatory Affairs at U.S. Pharmacopeia (USP). While at USP, she served as the Regional Director of South Asia. Before joining USP, Sireesha held senior-level positions at Dr. Reddy's Laboratories, Valeant Pharmaceuticals International, and Johnson Johnson.\n\n\"On behalf of the Board, I am thrilled to welcome Sireesha as she directs the growth trajectory of Pharmatech to support manufacturers to efficiently bring life-saving medicines to market,\" said Emily Kaine, M.D., chairperson of the Board of Directors, Pharmatech Associates and senior vice president, USP's Global Health and Manufacturing Services. \"Sireesha is a strong leader and has brought global regulatory, market insights, and business understanding to the board of directors which has been extremely valuable.\"\n\nPharmatech, a wholly owned subsidiary of USP, is poised to expand significantly to support U.S. and globally based drug sponsors and manufacturers with development, quality, and regulatory compliance consulting services to supply quality medicines to all major markets. Pharmatech's collaborative efforts with USP and other healthcare stakeholders help lower barriers to the adoption of Advanced Manufacturing Technologies such as pharmaceutical continuous manufacturing to bring more quality products to market.\n\nAs a partner with deep domain expertise ranging from small molecule to cell and gene therapy, biologics, and advanced manufacturing technologies, Pharmatech empowers clients to address complex challenges in the development of quality medicines. Services include regulatory strategy, compliance, and remediation to address manufacturing quality, CMC, process, equipment and facility development, analytical method qualification; and advanced manufacturing strategy, planning and control services.\n\n\"To remain competitive requires a mix of technical knowledge, practical business experience, broad regulatory compliance understanding, and a culture of precise execution,\" said Ronald T. Piervincenzi, Ph.D., USP's chief executive officer. \"Sireesha brings outstanding talent, a wealth of knowledge and leadership experience in pharmaceutical and biologics industries across the U.S. and international markets, that she'll put to use to grow Pharmatech as a leading consultancy to advance the supply of quality medicines.\"\n\nAbout Pharmatech Associates a USP Company\n\nPharmatech Associates is a global consultancy for the life science industry that meets the complex needs of clients with highly experienced scientists and engineering subject matter experts. Pharmatech's team specializes in Product and Process Development, Facilities and Capital Projects, Quality Compliance, and Regulatory Affairs. Pharmatech advises clients that range in size from startups to large multi-national corporations on projects in Asia, Europe, and North America from its headquarters in the San Francisco Bay Area.\n\nLearn more at www.pharmatechassociates.com.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230605005056/en/\n\nContacts:\n\nJudy Curtis-SIPR for Pharmatech\n\n+ 1 650-274-1509\n\njudy@sipr.com\n\nDas ultimative Rendite-Paket fÃ¼r unruhige ZeitenBig Pharma Boom! Stabile ErtrÃ¤ge, gÃ¼nstige Bewertung. Chart-Profi Stefan Klotter hat fÃ¼r Sie exklusiv fÃ¼nf Blue Chips aus der Pharma-Branche gefunden. Jetzt kostenlos herunterladen!Hier klicken",
            "source": {
                "uri": "finanznachrichten.de",
                "dataType": "news",
                "title": "FinanzNachrichten.de"
            },
            "authors": [],
            "image": "https://cts.businesswire.com/ct/CT?id=bwnews&sty=20230605005056r1&sid=gefi2&distro=ftp",
            "eventUri": null,
            "sentiment": 0.3098039215686275,
            "wgt": 423667320,
            "relevance": 51
        },
        {
            "uri": "7578653194",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-05",
            "time": "11:21:00",
            "dateTime": "2023-06-05T11:21:00Z",
            "dateTimePub": "2023-06-05T11:00:00Z",
            "dataType": "news",
            "sim": 0.8666666746139526,
            "url": "https://www.wallstreet-online.de/nachricht/17012912-dr-reddy-s-successfully-completes-phase-i-study-iv-route-of-drl-tc-a-proposed-biosimilar-of-tocilizumab",
            "title": "Dr. Reddy's Successfully Completes Phase I Study (IV Route) of DRL_TC, a Proposed Biosimilar of Tocilizumab",
            "body": "Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as \"Dr. Reddy's\"), a global pharmaceutical company, announced that its tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary endpoints in a Phase I study. This Phase I study used an intravenous (IV) formulation to evaluate the pharmacokinetic equivalence, safety and immunogenicity of Dr. Reddy's tocilizumab biosimilar candidate in comparison to reference products.\n\nThe Phase I study entitled 'A Phase I, Double Blind, Randomized, Parallel-group, Single dose, Three arm, Comparative Pharmacokinetic and Pharmacodynamic Study of Dr. Reddy's Tocilizumab (DRL_TC), USA sourced Reference Tocilizumab (Actemra) and EU sourced Reference Tocilizumab (RoActemra) Administered by the Intravenous Route to Normal Healthy Male Volunteers' met all primary and secondary endpoints. Pharmacokinetic equivalence of DRL_TC to the EU reference medicinal product* and the U.S. reference product** was successfully demonstrated. The clinical trial also confirmed the similarity between DRL_TC and the EU* and U.S.** reference products in terms of pharmacodynamic parameters and found no noteworthy differences in safety and immunogenicity across these three treatment groups.\n\nThe successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make high-quality biosimilar products more accessible and affordable to healthcare providers and patients around the world.\n\nDr. Reddy's is developing the proposed tocilizumab biosimilar as both intravenous and subcutaneous formulations.\n\nDr. Jayanth Sridhar, Global Head of Biologics at Dr. Reddy's, said: \"Tocilizumab is an important anti-rheumatic agent that has a unique place in treating patients with rheumatoid arthritis and other diseases. By developing the formulation in both subcutaneous and intravenous formulations, we aim to reach more patients around the world. With our recent milestones in our proposed biosimilars of tocilizumab and rituximab, our partner's launch of pegfilgrastim in the U.S and Europe, we look forward to maintaining our momentum as part of our goal to serve over 1.5 billion patients by 2030.\"",
            "source": {
                "uri": "wallstreet-online.de",
                "dataType": "news",
                "title": "wallstreet:online"
            },
            "authors": [],
            "image": "https://assets.wallstreet-online.de/_media/6/source1280/size_645/businesswire-1280.png",
            "eventUri": "eng-8673477",
            "sentiment": 0.4431372549019608,
            "wgt": 423660060,
            "relevance": 100
        },
        {
            "uri": "7578633667",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-05",
            "time": "11:16:00",
            "dateTime": "2023-06-05T11:16:00Z",
            "dateTimePub": "2023-06-05T11:06:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.marketscreener.com//quote/stock/DR-REDDY-S-LABORATORIES-6492671/news/Dr-Reddy-s-Successfully-Completes-Phase-I-Study-IV-Route-of-DRL_TC-a-Proposed-Biosimilar-of-Toci-44039177/",
            "title": "Dr. Reddy's Successfully Completes Phase I Study (IV Route) of DRL_TC, a Proposed Biosimilar of Tocilizumab | MarketScreener",
            "body": "Tocilizumab is an important anti-rheumatic agent used in the treatment of adult patients with moderate to severe active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Phase I study conducted by Dr. Reddy's demonstrated pharmacokinetic equivalence and similarity in pharmacodynamic parameters, safety and immunogenicity between Dr. Reddy's proposed biosimilar candidate (DRL_TC) and European Union (EU) reference medicinal product* and United States (U.S.) reference product** by the intravenous route (IV) In December 2022, the company had announced the successful completion of the Phase I study of DRL_TC via the subcutaneous route Global Phase III study is being initiated to compare efficacy, safety, tolerability and immunogenicity of DRL_TC with the reference product\n\nDr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as \"Dr. Reddy's\"), a global pharmaceutical company, announced that its tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary endpoints in a Phase I study. This Phase I study used an intravenous (IV) formulation to evaluate the pharmacokinetic equivalence, safety and immunogenicity of Dr. Reddy's tocilizumab biosimilar candidate in comparison to reference products.\n\nThe Phase I study entitled 'A Phase I, Double Blind, Randomized, Parallel-group, Single dose, Three arm, Comparative Pharmacokinetic and Pharmacodynamic Study of Dr. Reddy's Tocilizumab (DRL_TC), USA sourced Reference Tocilizumab (ActemraÂ®) and EU sourced Reference Tocilizumab (RoActemraÂ®) Administered by the Intravenous Route to Normal Healthy Male Volunteers' met all primary and secondary endpoints. Pharmacokinetic equivalence of DRL_TC to the EU reference medicinal product* and the U.S. reference product** was successfully demonstrated. The clinical trial also confirmed the similarity between DRL_TC and the EU* and U.S.** reference products in terms of pharmacodynamic parameters and found no noteworthy differences in safety and immunogenicity across these three treatment groups.\n\nThe successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make high-quality biosimilar products more accessible and affordable to healthcare providers and patients around the world.\n\nDr. Reddy's is developing the proposed tocilizumab biosimilar as both intravenous and subcutaneous formulations.\n\nDr. Jayanth Sridhar, Global Head of Biologics at Dr. Reddy's, said: \"Tocilizumab is an important anti-rheumatic agent that has a unique place in treating patients with rheumatoid arthritis and other diseases. By developing the formulation in both subcutaneous and intravenous formulations, we aim to reach more patients around the world. With our recent milestones in our proposed biosimilars of tocilizumab and rituximab, our partner's launch of pegfilgrastim in the U.S and Europe, we look forward to maintaining our momentum as part of our goal to serve over 1.5 billion patients by 2030.\"\n\nDr Reddy's has already demonstrated pharmacokinetic equivalence and similarity in pharmacodynamic parameters, safety and immunogenicity by subcutaneous route. The company is now initiating a global Phase III study with the aim of comparing the efficacy, safety, tolerability and immunogenicity of DRL_TC with the reference product in patients with moderate to severe active rheumatoid arthritis.\n\n*EU reference medicinal product is RoActemraÂ®\n\n**U.S. reference product is ActemraÂ®\n\nActemraÂ® and RoActemraÂ® are registered trademarks of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group.\n\nAbout Dr. Reddy's biosimilars programme:\n\nDr. Reddy's biosimilars business is part of our key strategic initiatives expected to drive both near-term and long-term growth. Over the last 20 years, our Biologics team has developed into a fully integrated organisation with robust capabilities in the development, manufacture and commercialisation of a range of biosimilar products in oncology and immunology. We have a current portfolio of six commercial products marketed in India and over 27 Emerging Markets. In addition, we have several products in the pipeline in oncology and auto-immune diseases in various stages of development for global launches across regulated as well as emerging markets. In December 2022, we announced the successful completion of Phase I study and initiation of Phase III study of DRL_TC, our proposed biosimilar of tocilizumab via the subcutaneous route, for global markets. In January 2023, we announced the successful completion of the full set of clinical studies of our rituximab biosimilar for filing in the U.S. and Europe. We are also ramping up manufacturing capacity to support our global expansion plans.\n\nAbout Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of 'Good Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include - USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.\n\nDisclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words \"may\", \"will\", \"should\", \"expects\", \"plans\", \"intends\", \"anticipates\", \"believes\", \"estimates\", \"predicts\", \"potential\", or \"continue\" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the \"Risk Factors\" and \"Forward-Looking Statements\" sections of our Annual Report on Form 20-F for the year ended March 31, 2022. The company assumes no obligation to update any information contained herein.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230605005412/en/",
            "source": {
                "uri": "marketscreener.com",
                "dataType": "news",
                "title": "Market Screener"
            },
            "authors": [],
            "image": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "eventUri": null,
            "sentiment": 0.3960784313725489,
            "wgt": 423659760,
            "relevance": 100
        },
        {
            "uri": "7578612893",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-05",
            "time": "10:54:00",
            "dateTime": "2023-06-05T10:54:00Z",
            "dateTimePub": "2023-06-05T09:53:00Z",
            "dataType": "news",
            "sim": 0.9176470637321472,
            "url": "https://www.businessworld.in/article/Dr-Reddy-s-Completes-Phase-I-Study-Of-Biosimilar-Of-Tocilizumab/05-06-2023-479235/",
            "title": "Dr Reddy's Completes Phase I Study Of Biosimilar Of Tocilizumab",
            "body": "Dr Reddy's Laboratories, a global pharmaceutical company, said that its tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary endpoints in Phase I clinical study, the company said in an exchange filing on Monday.\n\nThis Phase I study used an intravenous (IV) formulation to evaluate the pharmacokinetic equivalence, safety and immunogenicity of Dr Reddy's tocilizumab biosimilar candidate in comparison to reference products. The study was administered by the intravenous route to normal healthy male volunteers and the study met all primary and secondary endpoints.\n\nThe clinical trial also confirmed the similarity between DRL_TC and the EU (RoActemra) and US (Actemra ) reference products in terms of pharmacodynamic parameters and found no noteworthy differences in safety and immunogenicity across these three treatment groups.\n\nDr Reddy's is developing the proposed tocilizumab biosimilar as both intravenous and subcutaneous formulations. Dr Jayanth Sridhar, Global Head of Biologics at Dr. Reddy's, said: \"Tocilizumab is an important antirheumatic agent that has a unique place in treating patients with rheumatoid arthritis and other diseases. By developing the formulation in both subcutaneous and intravenous formulations, we aim to reach more patients around the world. With our recent milestones in our proposed biosimilars of tocilizumab and rituximab, our partner's launch of pegfilgrastim in the U.S and Europe, we look forward to maintaining our momentum as part of our goal to serve over 1.5 billion patients by 2030.\"\n\nDr Reddy's has already demonstrated pharmacokinetic equivalence and similarity in pharmacodynamic parameters, safety and immunogenicity by subcutaneous route. The company is now initiating a global Phase III study with the aim of comparing the efficacy, safety, tolerability and immunogenicity of DRL_TC with the reference product in patients with moderate to severe active rheumatoid arthritis\n\nTocilizumab is an immunosuppressive drug, taken for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, a severe form of arthritis in children, and COVIDâ€‘19.",
            "source": {
                "uri": "businessworld.in",
                "dataType": "news",
                "title": "BW Businessworld"
            },
            "authors": [],
            "image": "https://static.businessworld.in/article/article_extra_large_image/1499761577_0YiUDR_pharma-shutterstock.jpg",
            "eventUri": "eng-8673477",
            "sentiment": 0.2156862745098038,
            "wgt": 423658440,
            "relevance": 75
        },
        {
            "uri": "7578603108",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-05",
            "time": "10:47:00",
            "dateTime": "2023-06-05T10:47:00Z",
            "dateTimePub": "2023-06-05T10:46:00Z",
            "dataType": "news",
            "sim": 0.8901960849761963,
            "url": "https://www.moneycontrol.com/news/companies-2/dr-reddys-completes-phase-i-study-in-proposed-biosimilar-of-tocilizumab-10745301.html",
            "title": "Dr Reddy's completes Phase-I study in proposed biosimilar of tocilizumab",
            "body": "Dr Reddy's Laboratories Ltd On Monday announced that its tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary endpoints in a Phase-I study.\n\nA press release from the drug maker said the Phase-I study used an intravenous (IV) formulation to evaluate the pharmacokinetic equivalence, safety and immunogenicity of Dr Reddy's Tocilizumab biosimilar candidate in comparison to reference products.\n\nTocilizumab is an important anti-rheumatic agent that has a unique place in treating patients with rheumatoid arthritis and other diseases.\n\nThe clinical trial also confirmed the similarity between DRL_TC and the EU and USA reference products in terms of pharmacodynamic parameters and found no noteworthy differences in safety and immunogenicity across these three treatment groups, it said.\n\nDr Jayanth Sridhar, Global Head of Biologics at Dr Reddy's, said: \"By developing the formulation in both subcutaneous and intravenous formulations, we aim to reach more patients around the world. With our recent milestones in our proposed biosimilars of tocilizumab and rituximab, our partner's launch of pegfilgrastim in the US and Europe, we look forward to maintaining our momentum as part of our goal to serve over 1.5 billion patients by 2030.\"\n\nDr Reddy's has already demonstrated pharmacokinetic equivalence and similarity in pharmacodynamic parameters, safety and immunogenicity by subcutaneous route.\n\nThe company is now initiating a global Phase-III study with the aim of comparing the efficacy, safety, tolerability and immunogenicity of DRL_TC with the reference product in patients with moderate to severe active rheumatoid arthritis.",
            "source": {
                "uri": "moneycontrol.com",
                "dataType": "news",
                "title": "MoneyControl"
            },
            "authors": [],
            "image": "https://images.moneycontrol.com/static-mcnews/2022/07/Dr.-Reddys-770x417.jpg",
            "eventUri": "eng-8673477",
            "sentiment": 0.2156862745098038,
            "wgt": 423658020,
            "relevance": 51
        },
        {
            "uri": "7578566024",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-05",
            "time": "10:22:00",
            "dateTime": "2023-06-05T10:22:00Z",
            "dateTimePub": "2023-06-05T10:12:00Z",
            "dataType": "news",
            "sim": 0.9176470637321472,
            "url": "https://www.thehindubusinessline.com/companies/dr-reddys-successfully-completes-phase-1-study-of-tocilizumab-biosimilar/article66932941.ece",
            "title": "Dr Reddy's successfully completes phase-1 study of tocilizumab biosimilar",
            "body": "The tocilizumab biosimilar candidate of Dr. Reddy's Laboratories, DRL_TC, successfully met its primary and secondary endpoints in a phase-I study.\n\nThe study used an intravenous (IV) formulation to evaluate the pharmacokinetic equivalence, safety and immunogenicity of Hyderabad-based Dr. Reddy's tocilizumab biosimilar candidate in comparison to reference products, the company said on Monday.\n\n\"Tocilizumab is an important anti-rheumatic agent that has a unique place in treating patients with rheumatoid arthritis and other diseases. By developing the formulation in both subcutaneous and intravenous formulations, we aim to reach more patients around the world,\" Jayanth Sridhar, Global Head of Biologics at Dr. Reddy's, said in a release.\n\n\"With our recent milestones in our proposed biosimilars of tocilizumab and rituximab, our partner's launch of pegfilgrastim in the US and Europe, we look forward to maintaining our momentum as part of our goal to serve over 1.5 billion patients by 2030,\" he added.\n\nThe clinical trial also confirmed the similarity between DRL_TC and the EU and US reference products in terms of pharmacodynamic parameters and found no noteworthy differences in safety and immunogenicity across these three treatment groups. \"The successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make high-quality biosimilar products more accessible and affordable to healthcare providers and patients around the world,\" the company said.\n\nDr Reddy's has already demonstrated pharmacokinetic equivalence and similarity in pharmacodynamic parameters, safety and immunogenicity by subcutaneous route which was announced in December 2022. The company is now initiating a global phase-III study aimed at comparing the efficacy, safety, tolerability and immunogenicity of DRL_TC with the reference product in patients with moderate to severe active rheumatoid arthritis.\n\nSHARE Copy linkEmailFacebookTwitterTelegramLinkedInWhatsAppRedditPublished on June 5, 2023",
            "source": {
                "uri": "thehindubusinessline.com",
                "dataType": "news",
                "title": "@businessline"
            },
            "authors": [],
            "image": "https://bl-i.thgim.com/public/incoming/rtgv92/article66933489.ece/alternates/LANDSCAPE_1200/IMG_bl_Tocilizumab.jfif_2_1_I59G7NO5.jpg",
            "eventUri": "eng-8673477",
            "sentiment": 0.2627450980392156,
            "wgt": 423656520,
            "relevance": 100
        },
        {
            "uri": "7578276815",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-05",
            "time": "07:04:00",
            "dateTime": "2023-06-05T07:04:00Z",
            "dateTimePub": "2023-06-05T06:49:00Z",
            "dataType": "news",
            "sim": 0.729411780834198,
            "url": "https://www.cnbctv18.com/business/dr-reddy-rheumatoid-arthritis-drug-meets-all-endpoints-in-phase-1-study-16848511.htm",
            "title": "Dr Reddy's rheumatoid arthritis drug meets all endpoints in Phase 1 study",
            "body": "According to the company, the study demonstrated equivalence and similarity in pharmacodynamic parameters, safety and immunogenicity between its proposed biosimilar candidate (DRL_TC) and European Union (EU) reference medicinal product and United States (US) reference product by the intravenous route (IV)Dr Reddy's Laboratories has disclosed that its Tocilizumab Biosimilar candidate 'DRL_TC' successfully met its primary and secondary endpoints in the Phase-I study of Intravenous route. This biosimilar candidate, which is used in the treatment of adult patients with moderate-to-severe active rheumatoid arthritis, has been evaluated on the parameters of pharmacokinetic equivalence, safety and immunogenicity in comparison to reference products.",
            "source": {
                "uri": "cnbctv18.com",
                "dataType": "news",
                "title": "cnbctv18.com"
            },
            "authors": [],
            "image": "https://images.cnbctv18.com/wp-content/uploads/2020/02/paracetamol-medicines-drugs-pharma-pharceuticals-e1587487275172.jpg",
            "eventUri": "eng-8673477",
            "sentiment": 0.7490196078431373,
            "wgt": 423644640,
            "relevance": 26
        },
        {
            "uri": "7578171299",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-05",
            "time": "05:32:00",
            "dateTime": "2023-06-05T05:32:00Z",
            "dateTimePub": "2023-06-05T05:24:00Z",
            "dataType": "news",
            "sim": 0.9215686321258545,
            "url": "https://www.expresspharma.in/dr-reddys-completes-phase-i-study-of-drl_tc-a-tocilizumab-biosimilar-candidate/",
            "title": "Dr Reddy's completes Phase I study of DRL_TC, a tocilizumab biosimilar candidate - Express Pharma",
            "body": "Dr Reddy's Laboratories announced that its tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary endpoints in a Phase I study. This Phase I study used an intravenous (IV) formulation to evaluate the pharmacokinetic equivalence, safety and immunogenicity of Dr Reddy's tocilizumab biosimilar candidate in comparison to reference products.\n\nThe Phase I study titled 'A Phase I, Double-Blind, Randomized, Parallel-group, Single dose, Three arm, Comparative Pharmacokinetic and Pharmacodynamic Study of Dr Reddy's Tocilizumab (DRL_TC), USA sourced Reference Tocilizumab (Actemra) and EU sourced Reference Tocilizumab (RoActemra) Administered by the Intravenous Route to Normal Healthy Male Volunteers' met all primary and secondary endpoints. Pharmacokinetic equivalence of DRL_TC to the EU reference medicinal product* and the US reference product** was successfully demonstrated. The clinical trial also confirmed the similarity between DRL_TC and the EU* and US** reference products in terms of pharmacodynamic parameters and found no noteworthy differences in safety and immunogenicity across these three treatment groups.\n\nA company statement said, \"The successful outcome of this study represents an important milestone in Dr Reddy's commitment to make high-quality biosimilar products more accessible and affordable to healthcare providers and patients around the world. Dr Reddy's is developing the proposed tocilizumab biosimilar as both intravenous and subcutaneous formulations.\"\n\nDr Jayanth Sridhar, Global Head of Biologics at Dr Reddy's, said, \"Tocilizumab is an important antirheumatic agent that has a unique place in treating patients with rheumatoid arthritis and other diseases. By developing the formulation in both subcutaneous and intravenous formulations, we aim to reach more patients around the world. With our recent milestones in our proposed biosimilars of tocilizumab and rituximab, our partner's launch of pegfilgrastim in the US and Europe, we look forward to maintaining our momentum as part of our goal to serve over 1.5 billion patients by 2030.\"\n\nDr Reddy's has already demonstrated pharmacokinetic equivalence and similarity in pharmacodynamic parameters, safety and immunogenicity by subcutaneous route. The company is now initiating a global Phase III study with the aim of comparing the efficacy, safety, tolerability and immunogenicity of DRL_TC with the reference product in patients with moderate to severe active rheumatoid arthritis.",
            "source": {
                "uri": "expresspharma.in",
                "dataType": "news",
                "title": "Express Pharma"
            },
            "authors": [],
            "image": "https://cdn.expresspharma.in/wp-content/uploads/2020/08/21144641/research.jpg",
            "eventUri": "eng-8673477",
            "sentiment": 0.3960784313725489,
            "wgt": 423639120,
            "relevance": 51
        },
        {
            "uri": "7578139658",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-05",
            "time": "05:02:00",
            "dateTime": "2023-06-05T05:02:00Z",
            "dateTimePub": "2023-06-05T05:01:00Z",
            "dataType": "news",
            "sim": 0.8705882430076599,
            "url": "https://www.moneycontrol.com/news/business/stocks/dr-reddys-shares-gain-after-phase-i-study-of-antirheumatic-biosimilar-ends-10742781.html",
            "title": "Dr Reddy's shares gain after Phase I study of antirheumatic biosimilar ends",
            "body": "Dr Reddy's Laboratories share price gained 1 percent intraday on June 5 after the company successfully completed Phase I study (IV route) of DRL_TC, a proposed biosimilar of tocilizumab.\n\nDr Reddy's Laboratories announced that its tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary endpoints in a Phase I study.\n\nThis Phase I study used an intravenous (IV) formulation to evaluate the pharmacokinetic equivalence, safety and immunogenicity of Dr. Reddy's tocilizumab biosimilar candidate in comparison to reference products, company said.\n\nThe clinical trial also confirmed the similarity between DRL_TC and the EU and US reference products in terms of pharmacodynamic parameters and found no noteworthy differences in safety and immunogenicity across these three treatment groups.\n\nThe company is developing the proposed tocilizumab biosimilar as both intravenous and subcutaneous formulations.\n\nCatch all the market action on our live blog\n\n\"Tocilizumab is an important antirheumatic agent that has a unique place in treating patients with rheumatoid arthritis and other diseases. By developing the formulation in both subcutaneous and intravenous formulations, we aim to reach more patients around the world,\" said Dr Jayanth Sridhar, Global Head of Biologics at Dr Reddy's.\n\n\"With our recent milestones in our proposed biosimilars of tocilizumab and rituximab, our partner's launch of Pegfilgrastim in the US and Europe, we look forward to maintaining our momentum as part of our goal to serve over 1.5 billion patients by 2030,\" he said.\n\nFinancials\n\nDr Reddy's Laboratories recorded a manifold rise in its net profit to Rs 959.2 crore for the fourth quarter that ended March 31, from Rs 87.5 crore last year. Revenue surged 15.81 percent year-on-year to Rs 6,296.8 crore, up from Rs 5,436.8 crore in Q4 of FY22.\n\nThe board of the company recommended a final dividend of Rs 40 per share.\n\nAt 10:11am, Dr Reddy's Laboratories was quoting at Rs 4,631.10, up Rs 22.05, or 0.48 percent on the BSE.\n\nThe share touched a 52-week high of Rs 4,987 and a 52-week low of Rs 3,996.10 on May 5, 2023 and September 19, 2022. It is trading 7.14 percent below its 52-week high and 15.89 percent above its 52-week low.",
            "source": {
                "uri": "moneycontrol.com",
                "dataType": "news",
                "title": "MoneyControl"
            },
            "authors": [],
            "image": "https://images.moneycontrol.com/static-mcnews/2023/06/pharma_tablet-770x433.jpg",
            "eventUri": "eng-8673477",
            "sentiment": 0.2627450980392156,
            "wgt": 423637320,
            "relevance": 100
        },
        {
            "uri": "7577737293",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-04",
            "time": "19:54:00",
            "dateTime": "2023-06-04T19:54:00Z",
            "dateTimePub": "2023-06-04T19:51:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://investorplace.com/2023/06/the-3-most-undervalued-value-stocks-to-buy-in-june-2023/",
            "title": "The 3 Most Undervalued Value Stocks to Buy in June 2023",
            "body": "With the market facing myriad pressure points - predominantly stubbornly high inflation along with general anxieties about an incoming recession - the bright side is that investors have options regarding the best undervalued value stocks for June. Still, you don't want to just chase deflated entities just because they're down.\n\nInstead, the main focus for the top bargain stocks for June centers on discovering solid businesses that, for whatever reason, don't get the respect they deserve. Perhaps they fell under hard times through no fault of their own. Or in other cases simply lack the excitement that the flavors of the week provide.\n\nIn fairness, sometimes entities can be discounted for good reason. However, with thousands of securities listed in various exchanges, it's practically inevitable that certain good companies will be overlooked. Naturally, this dynamic offers an excellent entry point for astute investors. And on that note, below are the best value stocks to buy in June.\n\nFounded in 1984, India-based Dr. Reddy's Laboratories (NYSE:RDY) is a multinational pharmaceutical company. According to its public profile, Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company has over 190 medications, and 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology. Since the start of the year, RDY gained nearly 8%.\n\nSlipping a bit below the performance of the U.S. benchmark S&P 500, RDY ranks among the best undervalued value stocks for June on a technical (price chart) basis. From a financial perspective, Dr. Reddy's delivers strong operational stats. Its three-year revenue growth rate pings at 12%, above 68% of its peers. Also, its EBITDA growth rate clocks in at 33.1%, better than 79.39% of rivals.\n\nStill, RDY trades at a trailing multiple of 16.62. As a discount to earnings, the pharma ranks better than 64.88% of the competition. It also features a price-earnings-growth ratio of 0.88 times, below the sector median of 1.87 times. Notably, Wall Street analysts rate RDY as a moderate buy. Their average price target lands at $67, implying 20% upside potential.\n\nBased in Brazil, Ternium (NYSE:TX) is Latin America's leading flat steel producer, with operating facilities in Mexico, Brazil, Argentina, Colombia, the southern U.S., and Central America. Per its public profile, Ternium offers a broad range of high value-added steel products for customers active in the automotive, home appliances, HVAC, construction, capital goods, container, food, and energy industries through its various facilities and distribution networks.\n\nGaining almost 30% since the January opener, TX might not seem like one of the best undervalued value stocks for June. However, the market prices TX at a trailing multiple of 5.56, ranking better than 73.47% of the competition in terms of earnings discount. As well, TX trades at 0.68 times tangible book value. In contrast, the sector median stat is 0.99 times.\n\nOperationally, Ternium makes a compelling case for high return undervalued stocks because of its three-year revenue growth rate of 17.2%. This stat comes in above 73.58% of companies listed in the steel industry. Also, its book growth rate during the same period impresses at 21.5%. Lastly, analysts peg TX as a consensus strong buy. Their average price target hits $50.70, implying nearly 31% upside potential.\n\nArguably the most compelling name among the best undervalued value stocks for June, InMode (NASDAQ:INMD) is a leading global provider of innovative medical technologies. Per its corporate profile, InMode develops, manufactures, and markets devices harnessing novel radio frequency technology. Further, the medical specialist strives to enable new emerging surgical procedures as well as improve existing treatments.\n\nTo be fair, it's one of the riskiest examples of undervalued stocks with growth potential. Since the beginning of this year, INMD slipped nearly 9%. At the same time, the company delivers strong operational stats. For example, its three-year revenue growth rate pings at 37.3%, ranked better than 89.9% of its peers. As well, its EBITDA growth rate over the same period impresses at 43.5%.\n\nNevertheless, the market prices INMD at a forward multiple of 12.28. As a discount to projected earnings, InMode ranks better than 94.9% of the competition. Combined with a cash-rich balance sheet, INMD makes for one of the best value stocks to buy in June. On a final note, analysts peg INMD as a unanimous strong buy. Their average price target clocks in at $47, implying 46% upside potential.",
            "source": {
                "uri": "investorplace.com",
                "dataType": "news",
                "title": "InvestorPlace"
            },
            "authors": [
                {
                    "uri": "josh_enomoto@investorplace.com",
                    "name": "Josh Enomoto",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://investorplace.com/wp-content/uploads/2021/09/undervalued-stocks.jpg",
            "eventUri": null,
            "sentiment": 0.2784313725490195,
            "wgt": 423604440,
            "relevance": 100
        },
        {
            "uri": "7577431653",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-04",
            "time": "14:13:00",
            "dateTime": "2023-06-04T14:13:00Z",
            "dateTimePub": "2023-06-04T14:13:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://in.investing.com/analysis/portfolio-3-biggest-pharma-cos-to-keep-a-tab-on-200586635",
            "title": "Portfolio: 3 BIGGEST Pharma Cos. to Keep a Tab on!",
            "body": "The pharma sector is considered to be a defensive one and investors keep some of the strong companies from this sector in their portfolios for the diversification purpose. This is not an action-packed sector but delivers steady growth over the long haul.\n\nIn case you are looking for some blue-chip pharma stocks, here are the 3 biggest pharma companies, as per their revenues in FY23.\n\nSun Pharmaceutical Industries Limited\n\nSun Pharmaceutical Industries Ltd. (NS: SUN ) is the biggest pharma company in India, having a market capitalization of INR 2,36,982.31 crores and trading at a P/E ratio of 27.81. It also clocked a record-high revenue of INR 44,520.2 crores in FY23, which was the highest revenue by any listed-pharma company in the country.\n\nThe net income was reported at INR 8,521.48 crores, translating into a profit margin of 19.14%, the highest margin since FY17. FIIs have consistently been increasing their stake, notching it up from 13% in December 2021 to 16.89% in March 2023. The stock has been an outperformer in the last 12 months, delivering a return of 16.2%, compared to Nifty Pharma's return of 3.9%.\n\nDr Reddy's Laboratories Limited\n\nDr. Reddy's Laboratories Ltd (NS: REDY ) is not the second-largest pharma co. in terms of market cap, but it is so when FY23 revenue is concerned. This INR 75,635.38 crores big drug manufacturer clocked a revenue of INR 25,762.2 crores, a 16.5% YoY jump, while net profit more than doubled to INR 4,507.3 crores.\n\nThis translated into a profit margin of 17.5%, the highest since FY15, at least. FIIs are holding a massive stake of 38.55% which could be due to its valuation, as the current P/E ratio is just 16.78, compared to the sector's average of 33.94.\n\nAurobindo Pharma Limited\n\nAurobindo Pharma Ltd. (NS: ARBN ) is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs), having a market capitalization of INR 38,595 crores. It clocked a revenue of INR 25,145.97 crores which was the third-highest revenue in this sector in FY23.\n\nHowever, the company's profit margins of 7.67% were subdued and lowest in the last few years. Despite this, the stock was able to attract some FIIs' interest this quarter, as they ramped up their stake from 22.32% in December 2022 to 23.03% in March 2023. It has also been a good performer in the last 12 months, delivering a sector-beating return of 26.7%.",
            "source": {
                "uri": "in.investing.com",
                "dataType": "news",
                "title": "Investing.com India"
            },
            "authors": [
                {
                    "uri": "aayush_khanna@in.investing.com",
                    "name": "Aayush Khanna",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://i-invdn-com.investing.com/redesign/images/seo/investingcom_analysis_og.jpg",
            "eventUri": null,
            "sentiment": 0.2,
            "wgt": 423583980,
            "relevance": 51
        },
        {
            "uri": "7577247967",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-04",
            "time": "11:11:00",
            "dateTime": "2023-06-04T11:11:00Z",
            "dateTimePub": "2023-06-04T11:11:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.moneycontrol.com/europe/?url=https:%2F%2Fwww.moneycontrol.com%2Fnews%2Fbusiness%2Fmarkets%2Ftrade-setup-for-monday-top-15-things-to-know-before-the-opening-bell-45-10738921.html",
            "title": "Trade setup for Monday: Top 15 things to know before the opening bell",
            "body": "The market recouped the previous day's losses and snapped a two-day losing streak on June 2, on broad-based buying, with the Sensex closing 119 points higher at 62,547 and the Nifty50 ending at 18,534, up 46 points. The Nifty, which traded within the previous day's range, formed a small bodied bearish candlestick with minor upper and long lower shadows on the daily charts. The pattern indicates formation of Inside Bar candle with overlapping candles. \"The positive chart pattern like higher tops and bottoms continued as per daily timeframe chart and the present consolidation could be in line with the higher bottom formation of the pattern. The higher bottom reversal pattern has not been confirmed yet,\" Nagaraj Shetti, Technical Research Analyst, HDFC Securities, said. Considering the recent consolidation and the subsequent negation of such bearish patterns, one can expect a bounce in the market in the coming week, he said. For Nifty, immediate support is at 18,400-18,300 and the upside hurdle is at 18,650-18,850, Shetti said. The broader market outperformed the benchmark. Nifty midcap 100 and smallcap 100 indices gained half a percent each. We have collated 15 data points to help you spot profitable trades: Note: The open interest (OI) and volume data of stocks in this article are the aggregates of three-month data and not just the current month. Key support, resistance levels on Nifty The Nifty may get support at 18,492 followed by 18,470 and 18,433. If the index advances, 18,565 will be the key resistance followed by 18,588 and 18,624. Nifty Bank The Bank Nifty also traded in line with benchmarks, rising 148 points to 43,938 on June 2 and formed a small bearish candlestick with upper and lower shadows, which resembled the Inside Bar pattern on the daily scale, indicating rangebound trade. It continued forming llower highs for the third straight day. \"At this juncture, the Bank Nifty has rising trendline support at 43,700. Going ahead, a close below 43,700 might spoil the party for the bulls and we might witness profit booking in the markets,\" Jigar S Patel, Senior Manager - Equity Research, AnandRathi, said. On the upside, 44,500 would be an initial resistance on way to the 45,000 milestone. As per the pivot point calculator, the Bank Nifty is expected to take support at 43,841 followed by 43,776 and 43,670. Resistance will be at 44,052 then 44,117, and 44,223. Call options data On the weekly options front, the maximum Call open interest (OI) was at 19,500 strike, with 1.06 crore contracts, which is expected to be a crucial resistance level for the Nifty. This was followed by 18,600 strike comprising 1.03 crore contracts and 18,500 strike with more than 77.14 lakh contracts. Meaningful call writing was seen at 18,600 strike, which added 42.43 lakh contracts, followed by 19,500 strike, which added 41.63 lakh contracts, and 18,800 strike, which added 24.66 lakh contracts. Call unwinding was at 18,300 strike, which shed 21,750 contracts, followed by 18,100 strike, which shed 17,250 contracts, and 17,700 strike, which shed 6,400 contracts. Put option data On the put side, the maximum open interest was at 18,500 strike, with 1.02 crore contracts, which is expected to be an important support level in the coming sessions. It was followed by the 18,600 strike, comprising 57.99 lakh contracts, and the 18,000 strike with 44.12 lakh contracts. Put writing was seen at 18,500 strike, which added 46.89 lakh contracts, followed by 18,600 strike, which added 34.3 lakh contracts, and 18,000 strike, which added 18.73 lakh contracts. Put unwinding was seen at 19,000 strike, which shed 2,450 contracts, followed by 19,600 strike, which shed 50 contracts. Stocks with high delivery percentage A high delivery percentage suggests that investors are showing interest in the stock. The highest delivery was seen in Container Corporation of India, Sun Pharmaceutical Industries, Cholamandalam Investment and Finance, Infosys and Shriram Finance among others. 66 stocks see a long build-up An increase in open interest (OI) and price indicates a build-up of long positions. Based on the OI percentage, 66 stocks, including DLF, Polycab India, Navin Fluorine International, Godrej Properties and Power Finance Corporation, saw long buildups. 20 stocks see long unwinding A decline in OI and price generally indicate a long unwinding. Based on the OI percentage, 20 stocks, including MCX India, Shree Cement, Can Fin Homes, Infosys, and Hindustan Petroleum Corporation, saw a long unwinding. 33 stocks see a short build-up An increase in OI along with a price decrease indicates a build-up of short positions. Based on the OI percentage, 33 stocks, including Indraprastha Gas, Biocon, Voltas, Syngene International and Gujarat Gas, saw a short build-up. 67 stocks see short-covering A decrease in OI along with a price increase is an indication of short-covering. Based on the OI percentage, 67 stocks were on the short-covering list. These included Hindustan Aeronautics, Dixon Technologies, ACC, Hero MotoCorp, and SAIL. Bulk deals Jtekt India: Malabar India Fund sold 22.05 lakh equity shares, or a 0.9 percent stake, in the auto ancillary company via open market transaction at an average price of Rs 125.03 a share. Lyka Labs: Quant Mutual Fund-Quant Small Cap Fund sold 1.5 lakh shares in the pharma company at an average price of Rs 101.93 per share. Quant Mutual Fund through Quant Active Fund holds 8.86 lakh shares, or a 2.68 percent stake, in the company. Speciality Restaurants: Promoter Anjan Chatterjee has offloaded 5 lakh shares, or a 1.06 percent stake, in the fine and casual dining restaurants chain through an open market transaction at an average price of Rs 226.99 a share. Promoters' shareholding in the company stood at 52.53 percent as of March 2023. Ceinsys Tech: Alternate investment fund Zodius Technology Fund has been offloading its stake in the company since May. In the latest transaction, it sold 1.8 lakh shares in the software solutions provider at an average price of Rs 168.25 a share. Zodius has sold 5.73 lakh shares since May, out of 10.94 lakh held as of March 2023. (For more bulk deals, click here) Investors Meetings on June 5 Bajaj Electricals: Officials of the company will participate in Nuvama India Conference 2023. Dr Reddy's Laboratories: Company officials will participate in non-deal roadshow organised by Nomura. Nazara Technologies: Officials of the company will interact with SBI MF. KPIT Technologies, Adani Ports and Special Economic Zone: Companies' officials will attend Nomura Conference. Asahi Songwon Colors: The company will hold the earnings conference call on the performance in Q4FY23 with investors and analysts. SJVN: The company's officials will participate in non-deal road shows and meet prospective investors. Can Fin Homes: Officials of the company will interact with Tata AIA Life Insurance. Stocks in the news Tech Mahindra: The IT company said subsidiary Comviva Technologies along with the company's step-down subsidiary Comviva Technologies BV agreed to sell 0.04 percent and 99.96 percent shareholding in Comviva Technologies do Brasil IndÃºstria, ComÃ©rcio, ImportaÃ§Ã£o e ExportaÃ§Ã£o Ltda. The buyer is Druid Internet Systems ComÃ©rcio E ServiÃ§os Ltda. The transaction is expected to be completed by August 2023. The company will exit the product line without impacting its customers being served, it said. Wipro: The IT services company has fixed June 16, 2023 as the record date for determining the entitlement and the names of equity shareholders who are eligible for the buyback offer. On April 27, the company received approval from the board for the share buy back worth up to Rs 12,000 crore, at a price of Rs 445 per share. SBI Life Insurance Company: Insurance Regulatory and Development Authority of India has identified SBI Life as the acquirer insurer of the life insurance business of Sahara India Life Insurance Company (SlLIC) to protect the interest of the policyholders. SBI Life will take over the policy liabilities of around 2 lakh policies of SILIC, backed by the policyholders' assets, with immediate effect. Zydus Lifesciences: The US Food and Drug Administration (USFDA) has closed the inspection of the company's animal health drug manufacturing facility in Ahmedabad, with nil observations. The USFDA inspected the plant from May 30 to June 2. Indian Overseas Bank: The Reserve Bank of India (RBI) has imposed a penalty of Rs 2.20 crore on Indian Overseas Bank for deficiencies in regulatory compliance. Lupin: The pharma major has launched Darunavir tablets, in 600 mg and 800 mg strength, to market a generic equivalent of Prezista tablets of Janssen Products, LP, which reduces the amount of HIV in the blood. Darunavir tablets had estimated annual sales of $308 million in the US, as per IQVIA MAT March 2023. IIFL Finance: The board has approved Tranche II public issue of non-convertible debentures of Rs 300 crore with a green-shoe option of up to Rs 1,200 crore. This is within the shelf limit of Rs 5,000 crore. The issue will open on June 9 and close June 22. Wonderla Holidays: The Tamil Nadu government has granted a waiver of local body tax (LBT) of 10 percent to its Chennai project for 10 years from the commencement of commercial operations. This is subject to the condition that the commercial operation shall commence within two years from June 2. Fund Flow FII and DII data Foreign institutional investors (FIIs) sold shares worth Rs 658.88 crore, whereas domestic institutional investors (DIIs) bought shares worth Rs 581.85 crore on June 2, provisional data from the National Stock Exchange shows. Stocks under F&amp;O ban on NSE The National Stock Exchange has not added any stock to its F&amp;O ban list for June 5. Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions. Disclaimer: MoneyControl is a part of the Network18 group. Network18 is controlled by Independent Media Trust, of which Reliance Industries is the sole beneficiary.",
            "source": {
                "uri": "moneycontrol.com",
                "dataType": "news",
                "title": "MoneyControl"
            },
            "authors": [],
            "image": "https://images.moneycontrol.com/static-mcnews/2022/10/sensex1-1-770x433.jpg",
            "eventUri": null,
            "sentiment": 0.2784313725490195,
            "wgt": 423573060,
            "relevance": 1
        },
        {
            "uri": "7577049529",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-04",
            "time": "07:53:00",
            "dateTime": "2023-06-04T07:53:00Z",
            "dateTimePub": "2023-06-04T07:51:00Z",
            "dataType": "news",
            "sim": 0.5686274766921997,
            "url": "https://www.freepressjournal.in/business/dr-reddys-allots-shares-worth-rs-83330-to-employees-as-stock-options",
            "title": "Dr Reddy's allots shares worth Rs 83,330 to employees as stock options",
            "body": "Dr. Reddy's Laboratories Limited on Saturday allotted 16,666 worth Rs 83,330 to employees as stock options, the company announced through an exchange filing. The shares of Rs 5 each were divided into two different schemes.\n\n15,562 equity shares were allocated under the Dr. Reddy's Employee Stock Option Scheme 2002 and 1,104 shares each underlying 1,104 ADRs to Dr. Reddy's Employees ADR Stock Option Scheme, 2007.\n\nThe total issued shares moved to 16,65,44,742 and the total issued share capital increased to Rs 83,27,23,710.\n\nDr. Reddy's shares\n\nThe shares of Dr. Reddy's Laboratories on Friday closed at Rs 4,618, up by 1.45 per cent.",
            "source": {
                "uri": "freepressjournal.in",
                "dataType": "news",
                "title": "Free Press Journal"
            },
            "authors": [],
            "image": "https://gumlet.assettype.com/freepressjournal/2023-01/5ca5a4ff-d363-44e6-acd9-06f89770063c/drreddy.jpg?rect=0%2C0%2C3900%2C2194&w=1200&auto=format%2Ccompress&ogImage=true",
            "eventUri": "eng-8673477",
            "sentiment": 0.4039215686274509,
            "wgt": 423561180,
            "relevance": 100
        },
        {
            "uri": "7575711168",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-03",
            "time": "05:43:00",
            "dateTime": "2023-06-03T05:43:00Z",
            "dateTimePub": "2023-06-03T05:38:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.apnnews.com/pharmalytica-2023-unlocking-doorway-to-a-comprehensive-understanding-of-indias-evolving-pharma-landscape/",
            "title": "PharmaLytica 2023: Unlocking Doorway to a Comprehensive Understanding of India's Evolving Pharma Landscape",
            "body": "Hyderabad : The 9th edition of PharmaLytica, a premier pharmaceutical exhibition, commenced with an unwavering commitment to adapt to the changing healthcare landscape, and meet dynamic patient and business requirements. Organised by Informa Markets in India, the three-day event is taking place at HITEX, Hyderabad, hosting over 150 exhibitors. Allied to South Asia's largest Pharma event, the CPhI & P-MEC India show, PharmaLytica is expected to witness over 6000 domestic and international visitors from 16 countries and 21 Indian states, and approximately 250 delegates over the duration of the expo.\n\nThis event serves as a testament to India's vision of becoming the pharmacy of the world, providing a platform that contributes significantly to achieving this ambitious objective. The future of pharma will leverage Robotics and Digitalization to a significantly high degree. These include the use of automated systems, data analytics, and cloud-based architecture, which attendees can witness at PharmaLytica 2023.\n\nThe Event had participation from key stakeholders from the Pharmaceutical Industry including Chief Guest Shri Jayesh Ranjan, IAS, Principal Secretary, Industries & Commerce Dept, Government of Telangana; R.K. Agrawal, National President, Bulk Drug Manufacturers Association of India (BDMAI); Harish Jain, President, Karnataka Drugs & Pharmaceutical Manufactures (KDPMA); Avinash Kumar Talwar, Vice President, Dr. Reddy's Laboratories, Shankar Gupta, Chief Sales Officer, ACG; Yogesh Mudras, Managing Director, Informa Markets in India and Rahul Deshpande, Senior Group Director, Informa Markets in India.\n\nHighlighting the importance of technology, Shri Jayesh Ranjan, IAS, Principal Secretary, Industries & Commerce Dept, Government of Telangana said, \"The pharmaceutical, biotechnology, and medical devices industry in Telangana has experienced remarkable growth, surpassing initial expectations. Initially projected to reach $100 billion in ten years, the industry has already reached a substantial size of $80 billion, prompting a revision of the target to $250 billion. This buoyancy reflects the industry's potential and highlights the need for the sector to showcase advanced and sophisticated technologies, moving beyond bulk manufacturing. The pharmaceutical industry plays a pivotal role as part of the government's \"Atmanirbhar\" strategy, necessitating introspection and revaluation to propel further growth. Additionally, the increasing importance of Environmental, Social, and Governance (ESG) standards, driven primarily by European buyers, is shaping the future trajectory of the pharmaceutical sector. The industry must prioritize the integration of cutting-edge knowledge and technology into their processes, and participants in this exhibition will greatly benefit from the extensive showcase of advanced technology, equipment, and machinery.\"\n\nR.K. Agrawal, National President, BDMAI said, \"The pharmaceutical industry is moving towards transparency and visibility, where maintain comprehensive and digitalized records becomes imperative to showcase processes, testing and manufacturing to regulatory authorities during audits. Further, automation and technological advancements contribute to increased efficiency and reduced reliance on manual labor. Despite a highly regulated industry, with approximately 30 Government Departments monitoring operations, the Pharma sector has embraced stringent pollution norms, resulting in improved conditions within pharmaceutical plants. Furthermore, the Indian Government's supportive policies such as streamlining regulatory processes, promoting research and development, and encouraging investments create a conducive environment for industry growth. India is already being recognized as the Pharmacy of the world, and the country is a net exporter of drugs to over 195 countries, which is widely accepted. The sector was growing at a rate of 5% during the Pandemic, and now expected to grow at a rate of 8 to 10%. The Indian drug industry can provide good quality drugs at an affordable price thereby changing the landscape of affordability by providing anti-viral drugs at 1/10th of price to countries like Africa. Bulk Drugs constitute 25% ($15 Billion) of the Indian Pharma industry. Also, once the new Pharma City comes up in Telangana, investment of more than INR. 15000-20000 crores are easily possible by the local API manufacturers, which will further attract more FDI.\"\n\nFocused on achieving the aspirational growth, Harish Jain, President, Karnataka Drugs and Pharmaceutical Manufacturers Association (KDPMA), said, \"India's aspirations in the pharmaceutical industry go beyond its current ranking of 14th in value. The aim is to break into the top five and elevate its position in the value chain. While India is poised for a substantial 8 to 10% volume growth, the focus lies on achieving aspirational growth through innovation rather than traditional generics. This entails embracing new drug delivery systems to propel the industry forward. Research and development, along with awareness of cutting-edge equipment and testing methods, play a crucial role in realizing this vision. Events like PharmaLytica serve to enhance awareness about the latest advancements in equipment, testing methods, and machinery, enabling us to stay informed about emerging technologies.\"\n\nMr. Avinash Kumar Talwar, Vice President, Dr. Reddy's Laboratories said, \"Hyderabad is the biggest market for pharmaceuticals, and the city is known as the Pharma hub of India. The Indian Pharmaceutical industry is valued at around $50 Billion and is expected to grow at a CAGR of 10.7% by 2030. The pharmaceutical market in India is expected to reach $65 Billion by 2024, and $130 Billion by 2030. As the growth of Pharma market is coming from complex molecules, it will force them to invest and build future state-of-the art labs. The demand for sophisticated equipments and instruments to aid in the process of drug discovery, development, analysis and modelling of the compounds will continue to grow at the same pace. We should be proud that in total there are 214 US FDA approved facilities in Hyderabad which is impressive and that is another reason why Hyderabad is known as the Pharma hub of India. There are many small laboratories in Hyderabad and other South Indian cities like Chennai and Bengaluru who probably cannot visit the overseas equipment manufacturers and other such great expos. Hence, events like PharmaLytica will help provide them with the opportunity to participate and modernize their labs with technologies that will be displayed during the exhibition. Buyers and sellers can exchange their views and explore business opportunities through this event. Pharma packaging involves all the operations, from productions to drug distribution channels to the end customer. Factors such as rising number of pharmaceutical industries in an emerging economy, and rising demand for drug deliver devices, packaging are the major drivers for the pharma packaging market. The current challenge for the packaging industry is to have sustainable packaging at the optimum price along with new industry trends like ESG, and I am sure events like this would help the industry align better and take it to new heights.\"\n\nShankar Gupta, Chief Sales Officer, ACG said, \"We are proud of India's pharmaceutical industry, which has gained immense recognition during the COVID-19 pandemic. Our country has earned global fame by supplying medicines, including COVID vaccines, not only to our own citizens but also to people worldwide. The pharmaceutical industry in India is experiencing remarkable growth, being the third largest producer by volume and 14th largest by value. However, we strive to further expand our presence and increase the value of our products. Going global is crucial for this endeavor. Events like the one organized by Informa Markets are instrumental in promoting the Indian pharmaceutical industry on an international scale. The tremendous footfall and networking opportunities at this event are a testament to the team's remarkable efforts. We are determined to seize this opportunity and propel ourselves to greater heights\"\n\nPharmaLytica featured a wide array of industry-leading exhibitors showcasing their innovations. Notable participants included Advanced Expertise Technology, Allyone Environmental Technologies, Burkert India, IFB Industries, Indu IonPure, Integrated Cleanroom Technology, Labtop Instruments, Lennox Clean Air Technologies, Nicomac Taikisha Clean Rooms, NKP Pharma, Peppermint Robots, Petals Engineers, Scientific Research Instruments Company, Standard Group of Companies, TESTO India, Watermass Systems, and many more.\n\nOn the 9th edition of PharmaLytica, Mr. Yogesh Mudras, Managing Director, Informa Markets, India, stated, \"With a current value of around $50 billion, India is the third largest pharmaceutical industry in the world. Current projections state this will grow in revenue to $130 billion by 2030. As the Indian pharmaceutical industry charts its path towards becoming a global powerhouse, this expo stands as a crucial event for industry players, investors, and stakeholders to come together, capitalize on the projected revenue growth, and contribute to this remarkable success story. All this is made possible through the expo's pan-India footprint ensuring unparalleled exposure and access to a broad range of industry professionals from around the world which we witnessed here today. The growth potential of the Indian pharmaceutical industry is attributed to its large domestic market, cost-effective manufacturing capabilities, and skilled workforce. Supported by the government's policies and initiatives like 'Pharma Vision 2020' and 'Make in India', India aims to become a global pharmaceutical hub. PharmaLytica 2023 offers a unique platform to explore the factors driving the industry's growth and foster discussions, collaborations, and partnerships.\"\n\nPharmaLytica boasts a diverse lineup of visionary speakers who will share their expertise and insights. Esteemed speakers include Prasad S Deshpande, - SVP | Global Head of Procurement, Supply Chain, Contract Manufacturing & Central Engineering, Biocon, Anish Agarwal, Global Head of Analytics, Dr. Reddy's Laboratories, Nasir Ali - Associate Vice President - API R&D, Aurobindo Pharma, Krishna Bhavanasi, - VP Head Formulation R&D, Natco Pharma, Ram Kumar - Director MSTG, Cipla and several others.\n\nPharmaLytica is well-supported by the key Government body, Invest Telangana along with associations such as Bulk Drug Manufactures Association of India (BDMAI) and Karnataka Drugs and Pharmaceutical Manufactures Associations (KDPMA).",
            "source": {
                "uri": "apnnews.com",
                "dataType": "news",
                "title": "apnnews.com"
            },
            "authors": [],
            "image": "https://cdn.apnnews.com/wp-content/uploads/2023/06/Inaugural-ceremony-1.jpg",
            "eventUri": null,
            "sentiment": 0.192156862745098,
            "wgt": 423466980,
            "relevance": 51
        },
        {
            "uri": "7575526096",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-03",
            "time": "01:36:00",
            "dateTime": "2023-06-03T01:36:00Z",
            "dateTimePub": "2023-06-03T01:15:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.benzinga.com/pressreleases/23/06/n32702920/global-small-molecule-active-pharmaceutical-ingredient-market-report-2023-increasing-prevalence-of",
            "title": "Global Small Molecule Active Pharmaceutical Ingredient Market Report 2023: Increasing Prevalence of Diseases is a Major Driver ",
            "body": "This report provides strategists, marketers and senior management with the critical information they need to assess the market.\n\nThe global small molecule active pharmaceutical ingredient market is expected to grow from $167.59 billion in 2022 to $180.76 billion in 2023 at a compound annual growth rate (CAGR) of 7.9%. The small molecule active pharmaceutical ingredient market is expected to grow to $241.11 billion in 2027 at a CAGR of 7.5%.\n\nMajor players in the market are Albemarle Corporation, Aurobindo Pharma Limited, Dr Reddy's Laboratories Limited, GSK plc, Merck KGaA, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Johnson Matthey, Gilead Sciences Inc., Allergan Plc, Cambrex Corporation, Siegfried Holding AG, BASF SE, Sanofi SA, Albany Molecular Research Inc., AstraZeneca Plc, and Hoffmann-La Roche Limited.\n\nReasons to Purchase\n\nA small molecule active pharmaceutical ingredient (API) is any substance or mixture of organic substances or compounds with low molecular weight intended to be used as the active ingredient in the manufacture of a drug or medicinal product. A small molecule active pharmaceutical ingredient (API) is used as raw materials in the manufacturing of pharmaceutical drugs.\n\nThe main types of small molecule active pharmaceutical ingredient markets are synthetic, chemical, and biological. Synthetics are engaged in the manufacturing of pharmaceutical drugs. Synthetic chemical APIs, also known as small molecules, constitute a large part of the pharmaceutical market, with many small molecule drugs commercially available in the market.\n\nThe various therapeutic types are autoimmune diseases, oncology, metabolic diseases, ophthalmology, cardiovascular diseases, infectious diseases, neurology, respiratory disorders, dermatology, and urology. The manufacturing methods are in-house and contract. The applications are clinical and commercial.\n\nThe small molecule active pharmaceutical ingredient market research report is one of a series of new reports that provides small molecule active pharmaceutical ingredient market statistics, including small molecule active pharmaceutical ingredient industry global market size, regional shares, competitors with an small molecule active pharmaceutical ingredient market share, detailed small molecule active pharmaceutical ingredient market segments, market trends and opportunities, and any further data you may need to thrive in the small molecule active pharmaceutical ingredient industry.\n\nThis small molecule active pharmaceutical ingredient market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.\n\nStrategic partnerships and collaborations have emerged as the key trend gaining popularity in the small molecule active pharmaceutical ingredient market. Key players operating in the small molecule active pharmaceutical ingredient sector are focused on partnerships and collaborations to reinforce their position.\n\nFor instance, in May 2022, NovAliX, a France-based drug discovery company, Alysophil a France-based company creating new industrial chemistry based on continuous flow chemistry, De Dietrich Process Systems, a France-based provider of solutions for the fine chemical and pharmaceutical industries, and Bruker, a US-based manufacturer of scientific instruments for molecular and materials research collaborated.\n\nThrough this partnership, the companies aim to jointly develop a new approach to active pharmaceutical ingredient (API) production and offer complete, standalone, and location-independent API manufacturing solutions to pharmaceutical companies or contract manufacturing organizations (CMO).\n\nNorth America was the largest region in the small molecule active pharmaceutical ingredient market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the small molecule active pharmaceutical ingredient market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.\n\nThe countries covered in the small molecule active pharmaceutical ingredient market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.\n\nThe increasing prevalence of diseases is a major driver propelling the small molecule active pharmaceutical ingredient (API) market. A disease is a particular abnormal condition, a disorder of a structure or function, that affects the body of the patient. Active pharmaceutical ingredients (APIs) are the active components in a pharmaceutical drug that produce the required effect on the body to treat various conditions.\n\nFor instance, according to the data by World health Organization (WHO), a body of the United Nations responsible for international public health, Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. And, in 2020, the bulk of the approximately 422 million individuals with diabetes globally reside in low- and middle-income nations, and diabetes is directly responsible for 1.5 million fatalities annually. Cardiovascular diseases have resulted in the deaths of 17.9 million people worldwide. Therefore, the increasing prevalence of diseases will continue to be the key driver in the small molecule API market.\n\nThe small molecule active pharmaceutical ingredient market consists of sales of standard API, HPAPI (high potency active pharmaceutical ingredients), branded synthetic API, generic synthetic API, and semi-synthetic API. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.\n\nThe market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).\n\nThe revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.\n\n1. Executive Summary\n\n2. Small Molecule Active Pharmaceutical Ingredient Market Characteristics\n\n3. Small Molecule Active Pharmaceutical Ingredient Market Trends And Strategies\n\n4. Small Molecule Active Pharmaceutical Ingredient Market - Macro Economic Scenario\n\n4.1. COVID-19 Impact On Small Molecule Active Pharmaceutical Ingredient Market\n\n4.2. Ukraine-Russia War Impact On Small Molecule Active Pharmaceutical Ingredient Market\n\n4.3. Impact Of High Inflation On Small Molecule Active Pharmaceutical Ingredient Market\n\n5. Small Molecule Active Pharmaceutical Ingredient Market Size And Growth\n\n5.1. Global Small Molecule Active Pharmaceutical Ingredient Historic Market, 2017-2022, $ Billion\n\n5.1.1. Drivers Of The Market\n\n5.1.2. Restraints On The Market\n\n5.2. Global Small Molecule Active Pharmaceutical Ingredient Forecast Market, 2022-2027F, 2032F, $ Billion\n\n5.2.1. Drivers Of The Market\n\n5.2.2. Restraints On the Market\n\n6. Small Molecule Active Pharmaceutical Ingredient Market Segmentation\n\n6.1. Global Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion\n\n6.2. Global Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Therapeutic Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion\n\n6.3. Global Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Manufacturing Method, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion\n\n6.4. Global Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion\n\n7. Small Molecule Active Pharmaceutical Ingredient Market Regional And Country Analysis\n\n7.1. Global Small Molecule Active Pharmaceutical Ingredient Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion\n\n7.2. Global Small Molecule Active Pharmaceutical Ingredient Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion\n\nFor more information about this report visit https://www.researchandmarkets.com/r/fqu32a\n\nAbout ResearchAndMarkets.com\n\nResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.",
            "source": {
                "uri": "benzinga.com",
                "dataType": "news",
                "title": "Benzinga"
            },
            "authors": [],
            "image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "eventUri": null,
            "sentiment": 0.1843137254901961,
            "wgt": 423452160,
            "relevance": 51
        },
        {
            "uri": "7574786027",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-02",
            "time": "13:32:00",
            "dateTime": "2023-06-02T13:32:00Z",
            "dateTimePub": "2023-06-02T13:26:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.thehindu.com/business/indian-pharma-industry-likely-to-grow-to-130-billion-in-size-by-2030/article66921093.ece",
            "title": "'Indian pharma industry likely to grow to $130  billion in size by 2030'",
            "body": "The Indian pharmaceutical industry is projected to grow at a CAGR of over 10% to reach a size of $130 billion by 2030, industry officials said. They said technology would play a crucial role to achieve this target.\n\n\"The Indian Pharmaceutical industry is valued at around $50 billion and is expected to grow at a CAGR of 10.7% by 2030. The pharmaceutical market in India is expected to reach $65 billion by 2024, and $130 billion by 2030,\" Avinash Kumar Talwar, Vice-President, Dr. Reddy's Laboratories said while speaking at the ninth edition of PharmaLytica in Hyderabad according to a statement.\n\n\"As the growth of pharma market is coming from complex molecules, it will force companies to invest and build future state-of-the art labs. The demand for sophisticated equipment and instruments to aid in the process of drug discovery, development, analysis and modelling of the compounds will continue to grow at the same pace,\" he said.\n\nYogesh Mudras, Managing Director, Informa Markets, India, the organisers of PharmaLytica in a press statement released here said, \"The growth potential of the Indian pharmaceutical industry is attributed to its large domestic market, cost-effective manufacturing capabilities, and skilled workforce. Supported by the government's policies and initiatives like 'Pharma Vision 2020' and 'Make in India', India aims to become a global pharmaceutical hub.\"\n\nStating that the pharmaceutical industry is moving towards transparency and visibility, R.K. Agrawal, National President, Bulk Drug Manufacturers Association (India) said automation and technological advancements contribute to increased efficiency and reduced reliance on manual labour.\n\n\"Despite a highly regulated industry, with approximately 30 Government Departments monitoring operations, the pharma sector has embraced stringent [anti-] pollution norms, resulting in improved conditions within pharmaceutical plants,\" he said.\n\n\"Also, once the new Pharma City comes up in Telangana, investment of more than â‚¹15,000 to â‚¹20,000 crore are easily possible by the local API manufacturers, which will further attract more FDI,\" he added.\n\nFocused on achieving the aspirational growth, Harish Jain, President, Karnataka Drugs and Pharmaceutical Manufacturers Association (KDPMA), said, \"India's aspirations in the pharmaceutical industry go beyond its current ranking of 14th in value.\n\n\"The aim is to break into the top five and elevate its position in the value chain. While India is poised for a substantial 8 to 10% volume growth, the focus lies on achieving aspirational growth through innovation rather than traditional generics,\" he said.\n\nShankar Gupta, Chief Sales Officer ACG said, \"The pharmaceutical industry in India is experiencing remarkable growth, being the third largest producer by volume and 14th largest by value. However, we strive to further expand our presence and increase the value of our products. Going global is crucial for this endeavour,\" he added.\n\nHighlighting the importance of technology, Jayesh Ranjan, IAS, Principal Secretary, Industries & Commerce Department, Government of Telangana in the statement said, \"The pharmaceutical, biotechnology, and medical devices industry in Telangana has experienced remarkable growth, surpassing initial expectations.\"\n\n\"Initially projected to reach $100 billion in 10 years, the industry has already reached a substantial size of $80 billion, prompting a revision of the target to $250 billion. This buoyancy reflects the industry's potential and highlights the need for the sector to showcase advanced and sophisticated technologies, moving beyond bulk manufacturing,\" he said.\n\nIndustry insiders said in future pharma sector will leverage robotics and digitalisation to a significantly high degree. These include the use of automated systems, data analytics, and cloud-based architecture.",
            "source": {
                "uri": "thehindu.com",
                "dataType": "news",
                "title": "The Hindu"
            },
            "authors": [],
            "image": "https://www.thehindu.com/theme/images/og-image.png",
            "eventUri": null,
            "sentiment": 0.3098039215686275,
            "wgt": 423408720,
            "relevance": 51
        },
        {
            "uri": "7574776406",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-02",
            "time": "13:26:00",
            "dateTime": "2023-06-02T13:26:00Z",
            "dateTimePub": "2023-06-02T13:25:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.moneycontrol.com/news/business/markets/why-contract-drug-manufacturers-meet-fda-norms-easily-while-others-struggle-10733151.html",
            "title": "Why contract drug manufacturers meet FDA norms easily while others struggle",
            "body": "Contract development and manufacturing organisations undergo several rounds of inspections before they are engaged by client companies to make key drug ingredients.\n\nOver the past year, the US Food and Drug Administration has slapped restrictions on the manufacturing facilities of some Indian generic drug companies that sell medicines in the US for failing to meet good manufacturing practices.\n\nIn almost stark contrast, contract development and manufacturing organisations (CDMO), which make key drug ingredients for pharmaceutical client companies after carrying out innovation and development work, hardly fail to meet the FDA's rigorous manufacturing standards.\n\nConsequently, generic drug companies lose revenue because the launch of their new products is delayed until the curbs on their manufacturing facilities are lifted by the US regulator.\n\nIn India, examples of CDMOs include Laurus Labs and Suven Pharmaceuticals. Cipla, Dr Reddy's Laboratories and Sun Pharmaceutical Industries are among the main generic drug manufacturers.\n\nSun Pharma said on April 23 it will temporarily halt production at its Mohali manufacturing unit to implement corrective measures, as guided by the FDA, before it can release further product batches into the US.\n\nAlso Read: Is dual drug filing the right tactic for pharma companies now?\n\nA pharma analyst for a domestic brokerage, who spoke on condition of anonymity, explained that CDMOs undergo several rounds of inspections by their clients before they go ahead with checks from the FDA.\n\nAfter going through so many inspections by their clients, the manufacturing units become well-equipped to clear the FDA's checks, the analyst said.\n\nAlso Read: Delayed drug launches to hurt Cipla's earnings in FY24\n\n\"Drawing a comparison over the inspection results of CDMOs and US generic players is like comparing the results of a student who has taken several mock tests before giving an exam while the other has landed straight to writing the paper,\" the analyst said.\n\nVineet Gala, the founder of Xylem Investment Managers who tracks the pharma sector, said client inspections help but he majorly attributed the relatively easier ride for CDMOs to the lower scrutiny they face because the production process for each drug is different.\n\n\"CDMO players supplying intermediates/APIs (active pharmaceutical ingredients) generally face lower scrutiny from the US FDA versus what a typical generic formulations player would,\" Gala said. \"As for players doing formulations in CDMO, many have their plants in the US or the European Union, where standards of compliance are higher even for their employees, giving them an edge over generic players.\"\n\nDisclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.",
            "source": {
                "uri": "moneycontrol.com",
                "dataType": "news",
                "title": "MoneyControl"
            },
            "authors": [],
            "image": "https://images.moneycontrol.com/static-mcnews/2012/04/pharma-drugs_slide_300-250_75128568.jpg",
            "eventUri": null,
            "sentiment": -0.07450980392156858,
            "wgt": 423408360,
            "relevance": 26
        },
        {
            "uri": "7574079083",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-02",
            "time": "05:11:00",
            "dateTime": "2023-06-02T05:11:00Z",
            "dateTimePub": "2023-06-02T05:10:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://economictimes.indiatimes.com/markets/stocks/stock-watch/share-market-update-most-active-stocks-on-d-street-today-in-terms-of-volume/articleshow/100694506.cms",
            "title": "Share market update: Most active stocks on D-Street today in terms of volume",
            "body": "NEW DELHI: Suzlon Energy(number of shares traded: 13.60 crore), Zomato(number of shares traded: 9.10 crore), South Indian Bnk(number of shares traded: 3.94 crore), YES Bank(number of shares traded: 1.74 crore), Bank of Maharashtra(number of shares traded: 1.68 crore), Coal India Ltd(number of shares traded: 1.45 crore), HUDCO(number of shares traded: 1.33 crore), Hind Const Co(number of shares traded: 1.25 crore), NBCC (number of shares traded: 1.23 crore) and Tata Steel(number of shares traded: 1.08 crore) were among the most traded securities on the National Stock Exchange at 10:35AM in Friday's session.\n\nThe NSE Nifty index was trading 7.6 points up at 18495.35, while BSE Sensex was up 11.55 points at 62440.09 at the time of writing this report.\n\nIn the Nifty index, Hero MotoCorp Ltd.(up 2.63 per cent), Hindalco Industries Ltd.(up 2.01 per cent), Bajaj Auto Ltd.(up 0.89 per cent), Hindustan Unilever Ltd.(up 0.85 per cent) and Dr. Reddy's Laboratories Ltd.(up 0.82 per cent) were among the top gainers.\n\nWhile Infosys Ltd.(down 1.37 per cent), Eicher Motors Ltd.(down 1.08 per cent), HDFC Life Insurance Company Ltd.(down 0.89 per cent), Cipla Ltd.(down 0.83 per cent) and IndusInd Bank Ltd.(down 0.60 per cent) were among the top losers in the index.",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-83746920,width-1070,height-580,imgsize-779300,overlay-etmarkets/photo.jpg",
            "eventUri": null,
            "sentiment": 0.4431372549019608,
            "wgt": 423378660,
            "relevance": 1
        },
        {
            "uri": "7573111805",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-01",
            "time": "13:58:00",
            "dateTime": "2023-06-01T13:58:00Z",
            "dateTimePub": "2023-06-01T13:54:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.taiwannews.com.tw/en/news/4907621",
            "title": "Sapropterin Market Size Is Projected To Reach $$ Million By 2031 | BioMarin Pharmaceutical, Par | Taiwan News | 2023-06-01 13:47:08",
            "body": "This market research study on Sapropterin Market offers a thorough assessment and improvement of important producers, rivals, international suppliers, and risks. Additionally, this paper makes an aggressive appraisal of current innovations, technology, and future scope. It also looks at dangers and obstacles to access.\n\nAccording to the Centers for Medicare and Medicaid Services, US healthcare spending increased by 4.6% in 2019 to reach US$ 3.8 trillion, or US$ 11,582 per person and represented 17.7% of GDP. Additionally, households paid for 28.4% of all health expenditures, followed by the federal government for 29.0%. 16.1% of all healthcare costs were paid for by state and municipal governments, while 7.5% came from other private sources.\n\nDownload Free Sample of This Strategic Report:- https://reportocean.com/industry-verticals/sample-request?report_id=23948\n\nDue to advancements spurred by AI/ML, the impact of digital health technology will grow. Data from the Department for Promotion of Industry and Internal Trade show that FDI in the medicines and medication sector totaled US$19.12 billion (DPIIT).\n\nThis study considers the Sapropterin value generated from the sales of the following segments:\n\nSegmentation by product type:\n\nTablets\n\nPowder for Oral Solution\n\nSegmentation by application:\n\nHospital\n\nDrug store\n\nDownload Sample of This Strategic Report:- https://reportocean.com/industry-verticals/sample-request?report_id=23948\n\nThis report also splits the market by region:\n\nAmericas\n\nUnited States\n\nCanada\n\nMexico\n\nBrazil\n\nAPAC\n\nChina\n\nJapan\n\nKorea\n\nSoutheast Asia\n\nIndia\n\nAustralia\n\nEurope\n\nGermany\n\nFrance\n\nUK\n\nItaly\n\nRussia\n\nSpain\n\nMiddle East & Africa\n\nEgypt\n\nSouth Africa\n\nIsrael\n\nTurkey\n\nGCC Countries\n\nYou Can Browse The Sample Report here:- https://reportocean.com/industry-verticals/sample-request?report_id=23948\n\nThe report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market.\n\nBioMarin Pharmaceutical\n\nPar\n\nDr Reddy's Laboratories\n\n...\n\nIn addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.\n\nKey Points:\n\nProvide enterprise external environment analysis and PEST analysis. Provide strategies for company to deal with the impact of COVID-19. Provide market dynamic analysis, including market driving factors, market development constraints. Provide market entry strategy analysis for new players or players who are ready to enter the market, including market segment definition, client analysis, distribution model, product messaging and positioning, and price strategy analysis. Keep up with international market trends and provide analysis of the impact of the COVID-19 epidemic on major regions of the world. Analyze the market opportunities of stakeholders and provide market leaders with details of the competitive landscape.\n\nRequest full Report-https://reportocean.com/industry-verticals/sample-request?report_id=23948\n\nAbout Report Ocean:\n\nWe are the best market research reports provider in the industry. Report Ocean believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in today's competitive environment. Report Ocean is a 'one-stop solution' for individuals, organizations, and industries that are looking for innovative market research reports.\n\nGet in Touch with Us:\n\nReport Ocean:\n\nEmail:sales@reportocean.com\n\nAddress: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 - UNITED STATES\n\nTel:+1 888 212 3539 (US - TOLL FREE)\n\nWebsite:https://www.reportocean.com\n\nAutomatic Food Washing Machine market\n\nSalting Machine market\n\nLeather Animal Rug market\n\nNDT and Ultrasonic Testing market\n\nGarbage Recycling Crusher market\n\nCourtyard Lighting System market\n\nHigh Quality Suit market",
            "source": {
                "uri": "taiwannews.com.tw",
                "dataType": "news",
                "title": "Taiwan News"
            },
            "authors": [],
            "image": null,
            "eventUri": null,
            "sentiment": 0.1058823529411765,
            "wgt": 423323880,
            "relevance": 26
        },
        {
            "uri": "7572914818",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-06-01",
            "time": "11:54:00",
            "dateTime": "2023-06-01T11:54:00Z",
            "dateTimePub": "2023-06-01T11:53:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.marketscreener.com//quote/stock/DR-REDDY-S-LABORATORIES-6492671/news/Dr-Reddy-Laboratories-Intimation-under-Regulation-30-of-the-Securities-and-Exchange-Board-of-India-44014983/",
            "title": "Dr Reddy Laboratories : Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Schedule of Analyst / Institutional Investor Meetings - Form 6-K | MarketScreener",
            "body": "Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Schedule of Analyst / Institutional Investor Meetings\n\nThis is to inform you that the Company's management will be participating in the following investor conference and group / institutional investor meetings:\n\nDate Meeting Organized by Location Timing June 5, 2023 Nomura (Non-Deal Roadshow) Mumbai 1:30 pm to 6:30 pm June 6, 2023 9:30 am to 6:00 pm June 7, 2023\n\nMorgan Stanley India Investment Forum\n\n(Conference)\n\nMumbai\n\n10am to 5:20 pm\n\nPlease note that the schedule of the aforesaid meeting is subject to change due to any exigencies on the part of Investors / Company.\n\nThis is for your information.\n\nThanking you.\n\nYours faithfully,\n\nFor Dr. Reddy's Laboratories Limited\n\n/s/ K Randhir Singh K Randhir Singh Company Secretary, Compliance Officer and Head CSR CC:- New York Stock Exchange Inc.(Stock Code :RDY) NSE IFSC Ltd\n\nAttachments\n\nOriginal Link Original Document Permalink\n\nDisclaimer\n\nDr. Reddy's Laboratories Limited published this content on 01 June 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 June 2023 11:52:00 UTC.",
            "source": {
                "uri": "marketscreener.com",
                "dataType": "news",
                "title": "Market Screener"
            },
            "authors": [],
            "image": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "eventUri": null,
            "sentiment": 0.2627450980392156,
            "wgt": 423316440,
            "relevance": 1
        },
        {
            "uri": "7570807898",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-31",
            "time": "08:40:00",
            "dateTime": "2023-05-31T08:40:00Z",
            "dateTimePub": "2023-05-31T08:35:00Z",
            "dataType": "news",
            "sim": 0.8588235378265381,
            "url": "https://www.thehindubusinessline.com/news/national/glenmark-joins-sbti-commits-to-cut-emissions/article66914944.ece",
            "title": "Glenmark joins SBTi, commits to cut emissions ",
            "body": "Glenmark Pharmaceuticals has joined the Science-Based Targets initiative (SBTi) by committing to reduce its use of greenhouse gas (GHG) emissions, by 2035.\n\nThe SBTi is a partnership between CDP (a global non-profit working with companies and governments on GHGs and to safeguard natural resources), the United Nations Global Compact, World Resources Institute (WRI), and the World Wide Fund for Nature (WWF).\n\nThe SBTi has approved Glenmark's commitment to reduce its absolute scope 1 and 2 GHG emissions by 35 per cent by the financial year 2035 (from 2021), the company said.\n\n\"The target boundary includes biogenic landâ€related emissions and removals from bioenergy feedstock. The approval also extends to our pledge to reduce scope 3 GHG emissions from purchased goods and services, fuel- and energy-related activities, downstream transportation and distribution, and investments by 28 per cent per tonne of pharmaceutical products within the same timeframe,\" it added.\n\nGlenmark is the second Indian pharmaceutical company to receive this approval (after Dr Reddy's Laboratories). The company was certified through a five-stage review, it said.\n\nAlso read\n\nGlenmark Pharma expects at least one out-licensing deal this year\n\nAgreements inked during pandemic for Covid therapies poised for change\n\nClimate action\n\nThe SBTi \"drives ambitious climate action\" in the private sector by helping companies set science-based emission reduction targets in line with the Paris Agreement goals -- \"limiting global warming to well below 2Â°C above pre-industrial levels and pursuing efforts to limit warming to 1.5Â°C.\"\n\nGlenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals, said, \"This certification gives us an impetus to further pursue our ESG goals, while also benchmarking us at a global scale.\"\n\nMore than 4,000 businesses around the world work with SBTi, according to its website.\n\nSHARE Copy linkEmailFacebookTwitterTelegramLinkedInWhatsAppRedditPublished on May 31, 2023",
            "source": {
                "uri": "thehindubusinessline.com",
                "dataType": "news",
                "title": "@businessline"
            },
            "authors": [],
            "image": "https://bl-i.thgim.com/public/incoming/pbgnge/article66915001.ece/alternates/LANDSCAPE_1200/6610_19-9-2016_14-0-9_GLENNSALDANHA3.JPG",
            "eventUri": "eng-8662218",
            "sentiment": 0.4431372549019608,
            "wgt": 423218400,
            "relevance": 26
        },
        {
            "uri": "7570747355",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-31",
            "time": "08:00:00",
            "dateTime": "2023-05-31T08:00:00Z",
            "dateTimePub": "2023-05-31T07:59:00Z",
            "dataType": "news",
            "sim": 0.6941176652908325,
            "url": "https://thenelsonpost.ca/news/322160/venetoclax-api-market-promising-regions-for-companies-in-2023/",
            "title": "Venetoclax API market: Promising Regions for Companies in 2023",
            "body": "\"The report on the Global Venetoclax API Market Insights, Forecast to 2029 is comprehensively prepared with main focus on the competitive landscape, geographical growth, segmentation, and market dynamics, including drivers, restraints, and opportunities. It sheds light on key production, revenue, and consumption trends so that players could improve their sales and growth in the global Venetoclax API market. It offers detailed analysis of the competition and leading companies of the global Venetoclax API market. Here, it concentrates on the recent developments, sales, market value, production, gross margin, and other important factors of the business of top players operating in the global Venetoclax API market.\n\nVenetoclax(CASï¼š1257044-40-8) is an oral selective BCL-2 inhibitor and antineoplastic agent used in the therapy of refractory chronic lymphocytic leukemia (CLL).\n\nThe global Venetoclax API market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.\n\nThe US & Canada market for Venetoclax API is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.\n\nThe China market for Venetoclax API is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.\n\nThe Europe market for Venetoclax API is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.\n\nThe global key manufacturers of Venetoclax API include Aarti Industries Limited, Dr. Reddy's Laboratories, Beijing Mesochem Technology, Hetero Drugs, Hikma Pharmaceuticals, Laurus Labs, Mylan, Teva and Transo-Pharm USA LLC, etc. In 2022, the global top five players had a share approximately % in terms of revenue.\n\nIn terms of production side, this report researches the Venetoclax API production, growth rate, market share by manufacturers and by region (region level and country level), from 2018 to 2023, and forecast to 2029.\n\nIn terms of consumption side, this report focuses on the sales of Venetoclax API by region (region level and country level), by company, by Type and by Application. from 2018 to 2023 and forecast to 2029.\n\nReport Includes:\n\nThis report presents an overview of global market for Venetoclax API, capacity, output, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.\n\nThis report researches the key producers of Venetoclax API, also provides the consumption of main regions and countries. Highlights of the upcoming market potential for Venetoclax API, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.\n\nThis report focuses on the Venetoclax API sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2023. Identification of the major stakeholders in the global Venetoclax API market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.\n\nThis report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2018 to 2029. Evaluation and forecast the market size for Venetoclax API sales, projected growth trends, production technology, application and end-user industry.\n\nDescriptive company profiles of the major global players, including Aarti Industries Limited, Dr. Reddy's Laboratories, Beijing Mesochem Technology, Hetero Drugs, Hikma Pharmaceuticals, Laurus Labs, Mylan, Teva and Transo-Pharm USA LLC, etc.\n\nBy Company\n\nAarti Industries Limited\n\nDr. Reddy's Laboratories\n\nBeijing Mesochem Technology\n\nHetero Drugs\n\nHikma Pharmaceuticals\n\nLaurus Labs\n\nMylan\n\nTeva\n\nTranso-Pharm USA LLC\n\nVeranova\n\nLEBSA\n\nAlembic Pharmaceuticals Limited\n\nChangzhou Pharmaceutical Factory\n\nSegment by Type\n\nAbove 98 %\n\nAbove 99 %\n\nSegment by Application\n\nTablets\n\nOthers\n\nProduction by Region\n\nNorth America\n\nEurope\n\nChina\n\nIndia\n\nIsrael\n\nSales by Region\n\nUS & Canada\n\nU.S.\n\nCanada\n\nChina\n\nAsia (excluding China)\n\nJapan\n\nSouth Korea\n\nChina Taiwan\n\nSoutheast Asia\n\nIndia\n\nEurope\n\nGermany\n\nFrance\n\nU.K.\n\nItaly\n\nRussia\n\nMiddle East, Africa, Latin America\n\nBrazil\n\nMexico\n\nTurkey\n\nIsrael\n\nGCC Countries\n\nChapter Outline\n\nChapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.\n\nChapter 2: Venetoclax API production/output of global and key producers (regions/countries). It provides a quantitative analysis of the production and development potential of each producer in the next six years.\n\nChapter 3: Sales (consumption), revenue of Venetoclax API in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.\n\nChapter 4: Detailed analysis of Venetoclax API manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.\n\nChapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.\n\nChapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.\n\nChapter 7: North America (US & Canada) by type, by application and by country, sales and revenue for each segment.\n\nChapter 8: Europe by type, by application and by country, sales and revenue for each segment.\n\nChapter 9: China by type and by application sales and revenue for each segment.\n\nChapter 10: Asia (excluding China) by type, by application and by region, sales and revenue for each segment.\n\nChapter 11: Middle East, Africa, Latin America by type, by application and by country, sales and revenue for each segment.\n\nChapter 12: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Venetoclax API sales, revenue, price, gross margin, and recent development, etc.\n\nChapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.\n\nChapter 14: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.\n\nChapter 15: The main points and conclusions of the report.\n\nPlease enquire for Venetoclax API Market Study: https://qyresearch.com/reports/1015465/venetoclax-api\n\nWith deep quantitative and qualitative analysis, the report provides encyclopedic and accurate research study on important aspects of the global Venetoclax API market. It brings to light key factors affecting the growth of different segments and regions in the global Venetoclax API market. It also offers SWOT, Porter's Five Forces, and PESTLE analysis to thoroughly examine the global Venetoclax API market. It gives a detailed study on manufacturing cost, upstream and downstream buyers, distributors, marketing strategy, and marketing channel development trends of the global Venetoclax API market. Furthermore, it provides strategic advices and recommendations for players to ensure success in the global Venetoclax API market.\n\nAbout Us:\n\nQY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), expert's resources (included energy automotive chemical medical ICT consumer goods etc.",
            "source": {
                "uri": "thenelsonpost.ca",
                "dataType": "news",
                "title": "Finance BC"
            },
            "authors": [],
            "image": null,
            "eventUri": "eng-8661904",
            "sentiment": 0.3411764705882352,
            "wgt": 423216000,
            "relevance": 75
        },
        {
            "uri": "7570432086",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-31",
            "time": "03:40:00",
            "dateTime": "2023-05-31T03:40:00Z",
            "dateTimePub": "2023-05-31T03:12:00Z",
            "dataType": "news",
            "sim": 0.9058823585510254,
            "url": "https://www.moneycontrol.com/europe/?url=https:%2F%2Fwww.moneycontrol.com%2Fnews%2Frecommendations%2Fhold-nocil-targetrs-210-prabhudas-lilladher_17052431.html",
            "title": "Hold NOCIL; target of Rs 210: Prabhudas Lilladher",
            "body": "MSCI reshuffling may see Kotak Bank weightage double, Adani exit, inflows to Max Healthcare\n\nKotak Mahindra Bank is expected to witness a potential doubling of its weightage from 1.38 percent to 2.68 percent in the MSCI Global Standard Index, potentially resulting in inflows of $800 million, according to Nuvama Research. The reshuffling exercise is scheduled for May 31. As part of the reshuffling exercise, Adani Transmission, Adani Total Gas, and Indus Towers will be removed from the MSCI Global Standard Index, while Max Healthcare Institute, Hindustan Aeronautics (HAL), and Sona BLW Precision Forgings will be included, as mentioned in the Nuvama report. The removal of Adani companies from the MSCI Global Standard Index is expected to lead to outflows of $189 million for Adani Transmission and $167 million for Adani Total Gas. The Nuvama report explains that if Adani Total Gas or Adani Transmission trades at the lower price limit for a cumulative duration of at least 5 minutes on the given day, MSCI will delete these securities at the lowest system price as of the close of May 31, 2023. Otherwise, MSCI will use the official closing prices, following the MSCI Index Calculation methodology. According to Nuvama, the inclusion of Max Healthcare in the MSCI Global Standard Index is projected to result in inflows of $312 million and the addition of 47 million shares. Max Healthcare will carry a weight of 0.52 in the index. Additionally, the inclusion of HAL and Sona BLW is expected to bring inflows of $196 million and $171 million, respectively, with HAL carrying a weight of 0.33 and Sona BLW having a weight of 0.29 in the index. In terms of weight adjustments, 16 stocks are expected to see an increase, while 21 stocks will experience a reduction within the MSCI Global Standard Index. Several other stocks are predicted to have increased weights in the MSCI Global Standard Index. These include Maruti Suzuki India, Zomato, Interglobe Aviation, Samvardhana Motherson International, Cipla, Yes Bank, Bandhan Bank, and NTPC, among others. The weights of Reliance Industries, Infosys, ICICI Bank, JSW Steel, Axis Bank, Hindustan Unilever, Tech Mahindra, Dr Reddy's Laboratories, and Bharti Airtel are expected to decrease within the MSCI Global Standard Index.",
            "source": {
                "uri": "moneycontrol.com",
                "dataType": "news",
                "title": "MoneyControl"
            },
            "authors": [],
            "image": "https://www.moneycontrol.com/news_image_files/2022/200x200/h/hold-2-1_200.jpg",
            "eventUri": "eng-8661615",
            "sentiment": -0.0117647058823529,
            "wgt": 423200400,
            "relevance": 1
        },
        {
            "uri": "7570424641",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-31",
            "time": "03:32:00",
            "dateTime": "2023-05-31T03:32:00Z",
            "dateTimePub": "2023-05-31T03:31:00Z",
            "dataType": "news",
            "sim": 0.9058823585510254,
            "url": "https://www.moneycontrol.com/europe/?url=https:%2F%2Fwww.moneycontrol.com%2Fnews%2Fopinion%2Fmarketing-musings-why-is-johnny-walker-so-long-single-now-ready-to-mingle-10704561.html",
            "title": "Marketing Musings: Why is Johnny Walker, so long single, now ready to mingle?",
            "body": "MSCI reshuffling may see Kotak Bank weightage double, Adani exit, inflows to Max Healthcare\n\nKotak Mahindra Bank is expected to witness a potential doubling of its weightage from 1.38 percent to 2.68 percent in the MSCI Global Standard Index, potentially resulting in inflows of $800 million, according to Nuvama Research. The reshuffling exercise is scheduled for May 31. As part of the reshuffling exercise, Adani Transmission, Adani Total Gas, and Indus Towers will be removed from the MSCI Global Standard Index, while Max Healthcare Institute, Hindustan Aeronautics (HAL), and Sona BLW Precision Forgings will be included, as mentioned in the Nuvama report. The removal of Adani companies from the MSCI Global Standard Index is expected to lead to outflows of $189 million for Adani Transmission and $167 million for Adani Total Gas. The Nuvama report explains that if Adani Total Gas or Adani Transmission trades at the lower price limit for a cumulative duration of at least 5 minutes on the given day, MSCI will delete these securities at the lowest system price as of the close of May 31, 2023. Otherwise, MSCI will use the official closing prices, following the MSCI Index Calculation methodology. According to Nuvama, the inclusion of Max Healthcare in the MSCI Global Standard Index is projected to result in inflows of $312 million and the addition of 47 million shares. Max Healthcare will carry a weight of 0.52 in the index. Additionally, the inclusion of HAL and Sona BLW is expected to bring inflows of $196 million and $171 million, respectively, with HAL carrying a weight of 0.33 and Sona BLW having a weight of 0.29 in the index. In terms of weight adjustments, 16 stocks are expected to see an increase, while 21 stocks will experience a reduction within the MSCI Global Standard Index. Several other stocks are predicted to have increased weights in the MSCI Global Standard Index. These include Maruti Suzuki India, Zomato, Interglobe Aviation, Samvardhana Motherson International, Cipla, Yes Bank, Bandhan Bank, and NTPC, among others. The weights of Reliance Industries, Infosys, ICICI Bank, JSW Steel, Axis Bank, Hindustan Unilever, Tech Mahindra, Dr Reddy's Laboratories, and Bharti Airtel are expected to decrease within the MSCI Global Standard Index.",
            "source": {
                "uri": "moneycontrol.com",
                "dataType": "news",
                "title": "MoneyControl"
            },
            "authors": [],
            "image": null,
            "eventUri": "eng-8661615",
            "sentiment": -0.0117647058823529,
            "wgt": 423199920,
            "relevance": 1
        },
        {
            "uri": "7569277975",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-30",
            "time": "11:08:00",
            "dateTime": "2023-05-30T11:08:00Z",
            "dateTimePub": "2023-05-30T11:08:00Z",
            "dataType": "news",
            "sim": 0.6745098233222961,
            "url": "https://www.rttnews.com/3367032/sensex-nifty-extend-gains-for-fourth-day.aspx",
            "title": "Sensex, Nifty Extend Gains For Fourth Day ",
            "body": "Indian shares ended Tuesday's session modestly higher despite muted cues from global markets.\n\nA cautious undertone prevailed as investor waited to see if a tentative debt ceiling deal in the U.S. can be implemented by the June 5 deadline.\n\nThe odds of a U.S. default currently remain low, but the consequences could be dire.\n\nThe benchmark S&P BSE Sensex rose 122.75 points, or 0.20 percent, to 62,969.13 - extending gains for a fourth consecutive session.\n\nThe broader NSE Nifty index settled 35.20 points, or 0.19 percent, higher at 18,633.85 led by financials.\n\nThe BSE mid-cap and small-cap indexes hit fresh 52-week highs before closing up around 0.2 percent each.\n\nBajaj Finance, Kotak Mahindra Bank, Bajaj FinServ, HDFC Life and ITC climbed 1-2 percent in the Nifty pack, while Dr Reddy's Laboratories, Tech Mahindra, Tata Steel, Adani Enterprises and Hindalco all fell over 1 percent.\n\nFor comments and feedback contact: editorial@rttnews.com",
            "source": {
                "uri": "rttnews.com",
                "dataType": "news",
                "title": "RTTNews"
            },
            "authors": [],
            "image": "https://cdn.rttnews.com/images/v4/RTTNews-logo-512x512.png",
            "eventUri": "eng-8659401",
            "sentiment": 0.08235294117647052,
            "wgt": 423140880,
            "relevance": 1
        },
        {
            "uri": "7568820265",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-30",
            "time": "06:03:00",
            "dateTime": "2023-05-30T06:03:00Z",
            "dateTimePub": "2023-05-30T06:00:00Z",
            "dataType": "news",
            "sim": 0.6745098233222961,
            "url": "https://economictimes.indiatimes.com/markets/stocks/stock-watch/share-market-update-most-active-stocks-of-the-day-in-terms-of-total-traded-value/articleshow/100612430.cms",
            "title": "Share market update: Most active stocks of the day in terms of total traded value",
            "body": "NEW DELHI: HDFC Bank(Rs. 964.73 crore), Kotak Bank(Rs. 566.60 crore), ICICI Bank(Rs. 559.65 crore), Macrotech Developers(Rs. 453.05 crore), RIL(Rs. 426.39 crore), HAL(Rs. 399.44 crore), Krishna Institute(Rs. 378.12 crore), HDFC(Rs. 345.57 crore), ITC(Rs. 340.12 crore) and SBI(Rs. 338.49 crore) were among the most traded securities on the National Stock Exchange at 11:16AM in Tuesday's session.\n\nThe NSE Nifty index traded 12.2 points up at 18610.85, while BSE Sensex was up 15.02 points at 62861.4 as of 11:16AM(IST)on May 30.\n\nIn the Nifty index, Apollo Hospitals Enterprise Ltd.(up 1.56 per cent), JSW Steel Ltd.(up 1.34 per cent), UltraTech Cement Ltd.(up 1.20 per cent), Oil And Natural Gas Corporation Ltd.(up 1.19 per cent) and Britannia Industries Ltd.(up 0.94 per cent) were among the top gainers.\n\nOn the other hand, HDFC Life Insurance Company Ltd.(down 1.17 per cent), Tech Mahindra Ltd.(down 1.05 per cent), Hindalco Industries Ltd.(down 0.96 per cent), Dr. Reddy's Laboratories Ltd.(down 0.93 per cent) and Adani Ports & Special Economic Zone Ltd.(down 0.88 per cent) were among the top losers.",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-83769615,width-1070,height-580,imgsize-98874,overlay-etmarkets/photo.jpg",
            "eventUri": "eng-8654080",
            "sentiment": 0.07450980392156858,
            "wgt": 423122580,
            "relevance": 1
        },
        {
            "uri": "7568785447",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-30",
            "time": "05:32:00",
            "dateTime": "2023-05-30T05:32:00Z",
            "dateTimePub": "2023-05-30T05:17:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://thenelsonpost.ca/news/320189/healthcare-cmo-market-is-projected-to-expand-at-a-steady-cagr-of-over-12-2-through-2027/",
            "title": "Healthcare CMO Market is projected to Expand at a Steady CAGR of over 12.2% Through 2027",
            "body": "According to The Insight Partners market research study titled 'Healthcare CMO Market to 2027 - Global Analysis and Forecasts by Service and Geography. The global healthcare CMO market is expected to reach US$ 223,355.6 Mn in 2027 from US$ 80,479.4 in 2018. The market is estimated to grow with a CAGR of 12.2% from 2019-2027. The report highlights the trends prevalent in the global healthcare CMO market and the factors driving the market along with those that act as challenges to its growth.\n\nDownload Sample PDF Brochure of this research study at - https://www.theinsightpartners.com/sample/TIPRE00003263/\n\nGlobal healthcare CMO market, based on service was segmented as, pharmaceutical contract manufacturing services and medical device contract manufacturing services. In 2018, the pharmaceutical contract manufacturing services held the largest share of the market, by service. Additionally, the segment is also expected to grow at the fastest CAGR during the forecast period owing to advantaged offered by the contract manufacturing companies.\n\nThe market for healthcare CMO is expected to grow significantly due to factor as increasing inclination of pharmaceutical and medical device manufacturers towards outsourcing, increasing patent cliffs and rising geriatric population coupled with the increasing production of drugs & medical devices. However, the challenge such as lack of skilled professionals for CMO likely to impact the growth of the market in the forecast period.\n\nThe global Healthcare CMO Market is segmented based on. The segmentation in this research study has been finalized post in-depth secondary research and extensive primary research. In addition, the market is also segmented on the basis of technology offered by the leading participants in the industry in order to understand widely used market specific terminologies. Thus, we have incorporated the segments of the research and have finalized the market segmentation.\n\nInquire before Buying Copy of Healthcare CMO Market: https://www.theinsightpartners.com/inquiry/TIPRE00003263/\n\nSome of the key players in this market include Company: Royal DSM, Catalent, Inc, Boehringer Ingelheim International GmbH, Recipharm AB (publ), Fareva, Lonza, Piramal Enterprises Ltd, Dr. Reddy's Laboratories Ltd., Almac Group, FAMAR Health Care Services. The market is has provided inorganic growth strategies to these companies by various market consolidations. For instance, during February 2018, Lonza and Denali Therapeutics entered into a partnership for neurodegenerative diseases that covers all stages of the development and manufacturing.\n\nHealthcare CMO Market Research Report Scenario includes:\n\n* The report provides qualitative and quantitative trends of global Healthcare CMO Market across type, type of products, service, and geography.\n\n* The report starts with the key takeaways (Chapter Two), highlighting the key trends and outlook of the global Healthcare CMO Market.\n\n* Chapter Three provides the research methodology of the study.\n\n* Chapter Four further provides PEST analysis for each region.\n\n* Chapter Five highlights the key industry dynamics in the Healthcare CMO Market, including factors that are driving the market, prevailing deterrent, potential opportunities as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.\n\n* Chapter Six discusses the global Healthcare CMO Market scenario, in terms of historical market revenues, and forecast till the year 2028.\n\nThe report also covers a detailed chapter of the analysis on COVID-19 impact on this market at global and regional level in our final reports.\n\nOrder a Copy of this Research Study at - https://www.theinsightpartners.com/buy/TIPRE00003263/\n\nAbout Us:\n\nThe Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.",
            "source": {
                "uri": "thenelsonpost.ca",
                "dataType": "news",
                "title": "Finance BC"
            },
            "authors": [],
            "image": null,
            "eventUri": null,
            "sentiment": 0.1294117647058823,
            "wgt": 423120720,
            "relevance": 26
        },
        {
            "uri": "7568677754",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-30",
            "time": "03:44:00",
            "dateTime": "2023-05-30T03:44:00Z",
            "dateTimePub": "2023-05-30T03:44:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.rediff.com/business/report/over-one-third-nifty50-stocks-look-weak-on-charts-time-to-be-cautious/20230530.htm",
            "title": "Over one-third Nifty50 stocks look weak on charts. Time to be cautious?",
            "body": "The domestic benchmark indices -- the S&P BSE Sensex and the National Stock Exchange Nifty50 -- had lost close to 1.5 per cent in three days recently before gaining slightly.\n\nIllustration: Dominic Xavier/Rediff.com\n\nNotwithstanding weakness and volatility, the Nifty50 has managed to hold on to the 18,000 mark, while the Sensex has managed to stay above the 61,000 level.\n\nThe performance of the stocks that comprise these front-line indices remains polarised.\n\nThe 20 stocks that comprise the Nifty50 index appear weak, according to their technical chart patterns.\n\nSixteen of these stocks, which include Tata Steel, Hindalco Industries, JSW Steel, Eicher Motors, Sun Pharmaceutical Industries, and Cipla, have breached their respective 200-day moving averages (DMA) on the downside.\n\nFor long-term investors, the simple 200-DMA provides a broad outlook on the market or stock trend. Investors and traders prefer stocks holding above their respective 200-DMA as they tend to perform better in a trending market.\n\nRisk management, hence, becomes comparatively easier.\n\nAlternatively, Dr Reddy's Laboratories, Larsen & Toubro, Titan Company, and Grasim Industries appear weak as their relative strength indicator (RSI) has slipped below 50.\n\nThe RSI typically oscillates between zero and 100.\n\nA stock or index is considered overbought when RSI is above 70 and oversold when it is below 30.\n\nThe contribution from the information technology sector to the markets recently has been nothing to write home about.\n\nInfosys, Wipro, and Tata Consultancy Services have been rangebound with a negative bias.\n\nShares of Adani Group stocks, such as Adani Enterprises and Adani Ports and Special Economic Zone, too, remain volatile and will continue to be so until they move past their key resistance levels.\n\nAnalysts believe the market is likely to remain choppy in the near term, and bears may have the upper hand. The 6 per cent rally in the Nifty from March lows, observes V K Vijayakumar, chief investment strategist at Geojit Financial Services, has been used as a profit-booking opportunity by domestic institutional investors (DIIs) and traders.\n\nThis trend, he believes, is evident from the 'buy the rumour, sell the news' in major stocks like State Bank of India (SBI) and ITC in spite of good 2022-23 (FY23) January-March quarter (fourth quarter, or Q4) results.\n\n\"The Nifty is finding it difficult to break the 18,100-18,400 range despite favourable global cues and good Q4FY23 results.\n\n\"The US 10-year bond yield has risen to 3.64, and the rupee has weakened to 82.65 to the dollar.\n\n\"This currency movement is not supportive of the equity market. Foreign institutional investor buying is being neutralised by DII selling.\n\n\"The 'sell on rally' strategy of bears has worked well this week.\n\n\"The near-term outlook remains cloudy,\" says Vijayakumar.\n\nThe Nifty has until now found some support from select fast-moving consumer goods stocks such as ITC, Britannia Industries, and NestlÃ© India in the past few weeks.\n\nThese counters have formed 'higher highs and higher lows' in line with their technical chart pattern and are still in bullish mode from a medium-to-long-term perspective.\n\nAmong banking majors, Axis Bank, ICICI Bank, HDFC Bank, and SBI appear on track to hit new all-time highs in the weeks ahead, the charts indicate.\n\nTechnical analysts suggest that the markets could find some support at lower levels and that the current weakness will eventually get bought into.\n\n\"If global markets support us, we may see this decline getting bought into, and this time there may be a genuine attempt to retest the higher levels of 18,240-18,300 on the Nifty.\n\n\"On the flip side, 18,100 followed by 18,050 can be considered a strong support zone for the index,\" says Sameet Chavan, head-research, technicals, and derivatives, Angel One.\n\nDisclaimer: This article is meant for information purposes only. This article and information do not constitute a distribution, an endorsement, an investment advice, an offer to buy or sell or the solicitation of an offer to buy or sell any securities/schemes or any other financial products/investment products mentioned in this article to influence the opinion or behaviour of the investors/recipients.\n\nAny use of the information/any investment and investment related decisions of the investors/recipients are at their sole discretion and risk. Any advice herein is made on a general basis and does not take into account the specific investment objectives of the specific person or group of persons. Opinions expressed herein are subject to change without notice.",
            "source": {
                "uri": "rediff.com",
                "dataType": "news",
                "title": "Rediff.com India Ltd."
            },
            "authors": [
                {
                    "uri": "puneet_wadhwa@rediff.com",
                    "name": "Puneet Wadhwa",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://im.rediff.com/money/2022/may/18nifty50.jpg",
            "eventUri": null,
            "sentiment": 0.04313725490196085,
            "wgt": 423114240,
            "relevance": 51
        },
        {
            "uri": "7568351516",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-29",
            "time": "20:35:00",
            "dateTime": "2023-05-29T20:35:00Z",
            "dateTimePub": "2023-05-29T20:24:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://newsdaemon.com/2023/05/29/lets-look-at-the-key-reasons-that-are-pushing-dr-reddys-laboratories-limited-rdy-to-new-highs/",
            "title": "Let's look at the key reasons that are pushing Dr. Reddy's Laboratories Limited (RDY) to new highs - News Daemon",
            "body": "On May 26, 2023, Dr. Reddy's Laboratories Limited (NYSE: RDY) opened at $54.75, higher 0.07% from the last session. During the day, the shares moved up to $54.97 and dropped to $54.36 before settling in for the closing price of $54.46. Price fluctuations for RDY have ranged from $49.79 to $61.40 over the past 52 weeks.\n\nOver the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 11.60%. Company's average yearly earnings per share was noted 91.20% at the time writing. With a float of $166.00 million, this company's outstanding shares have now reached $166.12 million.\n\nConsidering the fact that the conglomerate employs 24795 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is +56.67, operating margin of +21.12, and the pretax margin is +24.40.\n\nA key investor's attitude towards the stock of the Drug Manufacturers - Specialty & Generic industry is another important factor to consider. The insider ownership of Dr. Reddy's Laboratories Limited is 27.70%, while institutional ownership is 10.30%.\n\nIf we go through the results of last quarter, which was made public on 3/30/2023, the company posted $0.7 earnings per share (EPS) for the quarter, besting the agreed prediction (set at $0.63) by $0.07. This company achieved a net margin of +18.33 while generating a return on equity of 21.38. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.76 per share during the current fiscal year.\n\nAccording to the Wall Street analysts, stocks earnings will be around 91.20% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company's EPS will surge by 34.70% during the next five years compared to 32.30% growth over the previous five years of trading.\n\nCheck out the current performance indicators for Dr. Reddy's Laboratories Limited (RDY). In the past quarter, the stock posted a quick ratio of 1.80. In addition, a publicly-traded company's price to sales ratio for the trailing twelve months stands at 3.05.\n\nFor the trailing twelve months, Company's Diluted EPS (Earnings per Share) is 3.27, a number that is poised to hit 0.75 in the next quarter and is forecasted to reach 3.39 in one year's time.\n\nCompared to the last year's volume of 0.22 million, its volume of 0.21 million showed lagged in the last five days. As of the previous 9 days, the stock's Stochastic %D was 65.78%. Additionally, its Average True Range was 0.92.\n\nDuring the past 100 days, Dr. Reddy's Laboratories Limited's (RDY) raw stochastic average was set at 32.55%, which indicates a significant increase from 18.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 32.16% in the past 14 days, which was higher than the 19.61% volatility it showed in the past 100 days.\n\nAt the time of writing, stock's 50-day Moving Average is $57.50, while its 200-day Moving Average is $54.48. Nevertheless, the first resistance level for the watch stands at $54.86 in the near term. At $55.22, the stock is likely to face the second major resistance level. The third major resistance level sits at $55.47. If the price goes on to break the first support level at $54.25, it is likely to go to the next support level at $54.00. Now, if the price goes above the second support level, the third support stands at $53.64.\n\nThere are currently 166,587K shares outstanding in the company with a market cap of 9.05 billion. Presently, the company's annual sales total 3,073 M according to its annual income of 563,340 K. Last quarter, the company's sales amounted to 766,000 K and its income totaled 117,000 K.",
            "source": {
                "uri": "newsdaemon.com",
                "dataType": "news",
                "title": "newsdaemon.com"
            },
            "authors": [
                {
                    "uri": "shaun_noe@newsdaemon.com",
                    "name": "Shaun Noe",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": null,
            "eventUri": null,
            "sentiment": 0.1529411764705881,
            "wgt": 423088500,
            "relevance": 100
        },
        {
            "uri": "7567189256",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-29",
            "time": "05:01:00",
            "dateTime": "2023-05-29T05:01:00Z",
            "dateTimePub": "2023-05-29T05:00:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.livemint.com/market/stock-market-news/nifty-pharma-sees-muted-performance-in-2023-can-pharma-stocks-change-course-going-ahead-11685335436651.html",
            "title": "Nifty Pharma sees muted performance in 2023; can the stocks change course going ahead?",
            "body": "While most sectoral indices rose with healthy gains, the Nifty Pharma index fell almost by a per cent in the early trade on Monday (May 29), dragged by losses in shares of select heavyweights, including Aurobindo Pharma, Sun Pharma and Divi's Laboratories.\n\nThe pharma sector appears to have lost its mojo after a dream run during the Covid-19 pandemic due to elevated raw material prices, regulatory concerns and price erosion in the generics business in key US markets.\n\nHowever, many analysts now believe that one should look at pharma stocks for the medium to long term as the growth prospects of Indian pharma companies have improved while the valuations of their shares have come down due to the correction.\n\n\"One should look at pharma stocks with a medium-long term horizon as valuations are attractive, earnings are expected to improve and multiples may expand gradually,\" said Cyndrella Carvalho, a pharma research analyst at JM Financial Institutional Securities.\n\n\"The medium-term outlook for the pharma sector is positive. We expect a gradual US recovery as the pace of ANDA approvals accelerates and price erosion stabilises. US business growth will primarily come from complex generics and innovation; we believe those companies with strong R&D capabilities and low compliance risk can participate in this growth,\" said the analyst.\n\nCarvalho expects the Indian Pharmaceutical Market (IPM) to grow in double digits led by 6-7 per cent price growth, 2-3 per cent new launches and 2-4 per cent volume growth in FY24.\n\n\"India markets will see field force expansion, participation in patent expiries and increased mergers and acquisitions. We expect emerging markets and the rest of the world markets to report double-digit growth as supply chain challenges and adverse forex impact eases,\" said Carvalho.\n\nCarvalho observed that the March quarter earnings of the pharma sector players have been mixed primarily due to concerns around margins and lacklustre US base business growth.\n\n\"US business surprised on the upside primarily due to higher gRevlimid contribution. While other business revenues were broadly in line, EBITDA margins (ex-Revlimid) were weak due to subdued US base business growth and NLEM's impact on domestic business,\" Carvalho pointed out.\n\n\"Gross margins improved marginally as high-cost inventory got exhausted and we expect this trend to continue going forward. EM/ ROW markets performed well during the quarter. Notably, most companies under our coverage have strengthened their balance sheet and are scouting for inorganic opportunities,' Carvalho said.\n\nGirish Sodani, Head of Equity Market at Swastika Investmart underscored that the pharmaceutical market in India had revenues dip for the second consecutive month in March 2022 after expanding for 17 consecutive months up until that point.\n\n\"The industry's revenue decreased by 2 per cent. The net sales and net earnings of the major companies, including Sun Pharma, Cipla, Dr. Reddy's Lab, and Abott India, decreased. Other publicly traded drug manufacturers also reported a single-digit reduction, demonstrating the extremely slow expansion of the pharmaceutical industry in India,\" Sodani observed.\n\n\"Low growth in the pharmaceutical industry on the basis of a few points: volumes fell for important treatments including antibiotics and supplements, a surplus of Covid-19 medicines in stock, a spike in raw material prices and lots more. The biggest challenge has been the expensive valuations in select pockets of pharma space where stocks went up three, or four times in a very short period of time because of Covid-led products driving or expected to drive their substantial growth,\" Sodani pointed out.\n\nSodani is positive about the Indian pharma players.\n\n\"The outlook is definitely positive for the pharma sector. We are expecting double-digit earnings growth over the next couple of years. That should help in maintaining the valuations of the industry. Our expectation is that it will grow at around 10-11 per cent and there will be certain companies which will be growing faster than that also depending on the portfolio,\" said Sodani.\n\nHe said India is more of a structural growth story and it will remain so, which is why Indian pharma companies' valuations are at a much premium compared to the generic companies.\n\nSodani expects double-digit earnings growth over the next couple of years which should help in maintaining the valuations and there will be some pockets in terms of companies who will be doing much better and that is why we are positive on select stocks.\n\nThe immense growth potential of the sector is a key positive for the sector.\n\nRead more: Indian Pharma industry expected to reach about 13% in global pharma market: Report\n\n\"139 new pharma projects worth â‚¹7,000 crore got the nod in FY23. According to the EY FICCI Report, the Indian pharmaceutical market is anticipated to reach $130 billion in value by the end of 2023 along with a few government policies which give direct benefits like Export Promotion Council for Medical Devices & National Medical Device Policy 2023,\" said Sodani.\n\n\"Picks from the pharma sector can be Zydus Life and Cipla for the mid to long-term for an upside of 10-15 per cent,\" Sodani said.\n\nRead all market-related news here",
            "source": {
                "uri": "livemint.com",
                "dataType": "news",
                "title": "mint"
            },
            "authors": [
                {
                    "uri": "nishant_kumar@livemint.com",
                    "name": "Nishant Kumar",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://www.livemint.com/lm-img/img/2023/05/29/600x338/pill-k7lB--621x414LiveMint_1685335644797_1685335644939.jpg",
            "eventUri": null,
            "sentiment": 0.4901960784313726,
            "wgt": 423032460,
            "relevance": 1
        },
        {
            "uri": "7567181357",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-29",
            "time": "04:52:00",
            "dateTime": "2023-05-29T04:52:00Z",
            "dateTimePub": "2023-05-29T04:43:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.thehindubusinessline.com/portfolio/personal-finance/growth-vs-value-the-age-old-investing-debate/article66906872.ece",
            "title": "Growth vs. value, the age-old investing debate",
            "body": "There are two broad classifications for long-term equity investments: growth and value stocks.\n\nGrowth stocks are those that offer higher-than-market average growth in terms of earnings and revenue. They are generally characterised by high price-to-earnings ratios (reflecting the higher growth rate), low-cost structures due to network effects (hence lower capital requirements), low dividend yields and lower reliance on debt to fund capital requirements.\n\nTherefore, these companies tend to have manageable debt levels and raise capital predominantly through issuing equity rather than borrowing (lower cost of capital due to low dividend yields).\n\nValue companies\n\nOn the other hand, value companies tend to have higher working-capital requirements, greater reliance on borrowing to fund capital requirement, high dividend yields and low price-to-earnings ratios. They generally have lower profit margins than growth companies due to many factors. Value companies tend to operate in commodity markets (resembling perfect competition) rather than the technology industry leading to low product differentiation reducing pricing power (thus, lowering profit margins). Companies in India such as Tata Steel, Tata Chemicals and Vedanta fall in this category. These firms would prefer to fund capital requirement through borrowing rather than equity due to high capital requirements stemming from capital expenditure and working capital necessities.\n\nAlso read: PI Industries: Why investors can add on this stock\n\nSome exceptions\n\nThere are, however, exceptions to the rule with firms such as ITC, which have low debt and an average growth rate.\n\nOver the past decade, the interest rate in the U.S. had been next to zero leading to treasuries not being a viable option to yield returns. Value stocks, with low price-to-earnings ratio and high dividend yields, proved to be a way of capturing higher returns.\n\nGrowth stocks showed remarkable increases in revenue and profit but did not pose a great alternative to treasuries due to the low dividend yield. Moreover, growth stocks require one to engage in discounted cash-flow valuations (covered in an earlier piece), which prove to be scarcely reliable. A change in the discount rate by a few basis points leads to vastly differing company valuations. Additionally, it is difficult to accurately predict a company's growth percentages over a few years. Value stocks' earnings are not volatile and tend to be more predictable than growth stocks. Therefore, value stocks seemed like an attractive prospect to an investor looking to produce reliable returns.\n\nRising interest rates\n\nHowever, interest rates in the recent past have been rising, leading to the real debt of value companies to increase. The effect of rising interest rates on value companies can be seen as twofold.\n\nThe first effect is the curbing of inflation erosion in their value of debt (lower commodity prices), and the second effect is lower profit from muted economic activity. On the other hand, growth companies are not as adversely affected due to low borrowings and high free cash flow, notwithstanding the rise in interest rates.\n\nIn the past year, the U.S. has seen a resurgence in growth stocks despite layoffs and a decline in the performance of value stocks. The case for Indian investors stays entirely different to those in the U.S.\n\nAlso read: Tech Query: Canara Bank: Will the uptrend resume?\n\nIndian investors will find they do not have access to the growth companies mentioned above. Most high-growth companies in India (apart from a handful such as Infosys and Dr. Reddy's in the past) tend to prefer private equity funding rather than a public listing.\n\nFor example, companies such as Paperboat have made headway in the FMCG industry over the past decade and have chosen to remain privately owned. The supposed growth companies publicly listed in India, such as Nykaa, have done extremely poorly since listing. Others such as Zomato and Paytm are not worth mentioning, with negative profit and cash flows. Another problem Indian investors find is a lack of transparency in financial documents such as balance sheets (with some exceptions such as ITC and Tata firms), leading to poor decision-making.\n\nThe Indian retail investor, therefore, is left playing a value game without wanting to do so and must navigate a minefield of non-transparent balance sheets. However, the lack of access to growth stocks does not imply a lack of returns for the investor.\n\nOne must heed the advice of the erudite investor Howard Marks who stated that any asset is an excellent asset at the right price. The Indian investor stands to make exceptional returns through prudent and meticulous analysis of stocks and patiently waiting for appropriate prices.\n\n(Anand Srinivasan is a consultant, while Sashwath Swaminathan is a research assistant at Aionion Investment Services)\n\nSHARE Copy linkEmailFacebookTwitterTelegramLinkedInWhatsAppRedditPublished on May 29, 2023",
            "source": {
                "uri": "thehindubusinessline.com",
                "dataType": "news",
                "title": "@businessline"
            },
            "authors": [],
            "image": "https://bl-i.thgim.com/public/news/9oh35/article66906871.ece/alternates/LANDSCAPE_1200/Business.jpg",
            "eventUri": null,
            "sentiment": 0.2078431372549019,
            "wgt": 423031920,
            "relevance": 1
        },
        {
            "uri": "7567173568",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-29",
            "time": "04:45:00",
            "dateTime": "2023-05-29T04:45:00Z",
            "dateTimePub": "2023-05-29T04:40:00Z",
            "dataType": "news",
            "sim": 0.8627451062202454,
            "url": "https://economictimes.indiatimes.com/markets/stocks/news/msci-rejig-on-may-31-adani-transmission-adani-total-to-exit-hal-max-health-to-be-included/articleshow/100581675.cms",
            "title": "MSCI rejig on May 31: Adani Transmission, Adani Total to exit; HAL, Max Health to be included",
            "body": "Adani Transmission, Adani Total Gas and Indus Towers are set to leave the MSCI Global Standard Index on May 31, 2023, with Max Healthcare Institute, Hindustan Aeronautics and Sona BLW Precision Forgings entering the index. The move is expected to result in outflows of $189m and $167m for Adani Transmission and Adani Total Gas, respectively, with 18 million shares for each stock being offloaded. Meanwhile, Max Healthcare's addition will result in inflows of $312m, with HAL and Sona BLW's inclusion likely bringing in $196m and $171m.Shares of Adani Transmission, Adani Total Gas and Indus Towers will exit the MSCI Global Standard Index on May 31, 2023, as a part of the May rejig exercise. On the other hand, Max Healthcare Institute, Hindustan Aeronautics (HAL) and Sona BLW Precision Forgings will make an entry into the index.\n\nThe exit of Adani companies from the MSCI Global Standard Index is expected to trigger outflows of $189 million in the case of Adani Transmission and $167 million in the case of Adani Total Gas, according to a Nuvama Alternative & Quantitative Research report.\n\nThe exit will see 18 million shares each of both the Adani Group stocks getting offloaded from the index, the report said further. The stocks carry weights of 0.31 and 0.28, respectively according to the report.\n\nLikewise, the exit of Indus Towers is expected to result in outflows of $84 million. Around 44 million shares will be offloaded as a part of the exercise. The weight of Indus Towers is 0.14.\n\nMeanwhile, Max Healthcare's addition will result in inflows of $312 million while 47 million shares will be added to the index. It will carry a weight of 0.52. HAL and Sona BLW's inclusion in the index will likely bring inflows of $196 million and $171 million. They will carry a weight of 0.33 and 0.29, respectively according to Nuvama.\n\nOn the other hand, 16 stocks will witness an addition to their weights while 21 will see their weights getting slashed.\n\nZomato will see an addition to its weight in the index which will trigger inflows of $63 million and add 77 million shares. The weight will go up by 10 bps taking it to 0.4. The average volume is expected to go up by 0.8 times.\n\nOther stocks that will see their weights in the MSCI Global Standard Index go up include Maruti Suzuki India, Kotak Mahindra Bank, Interglobe Aviation, Samvardhana Motherson International, Cipla, Yes Bank, Bandhan Bank and NTPC among others.\n\nWhile the weights of Reliance Industries, Infosys, ICICI Bank, JSW Steel, Axis Bank, Hindustan Unilever, Tech Mahindra, Dr Reddy's Laboratories and Bharti Airtel will come down.\n\n(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-100581681,width-1070,height-580,imgsize-33504,overlay-etmarkets/photo.jpg",
            "eventUri": "eng-8661615",
            "sentiment": 0.192156862745098,
            "wgt": 423031500,
            "relevance": 1
        },
        {
            "uri": "7567001715",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-29",
            "time": "01:07:00",
            "dateTime": "2023-05-29T01:07:00Z",
            "dateTimePub": "2023-05-29T01:00:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://economictimes.indiatimes.com/wealth/invest/franklin-india-flexi-cap-mutual-fund-review-should-deliver-healthy-returns/articleshow/100543355.cms",
            "title": "Franklin India Flexi Cap mutual fund review: Should deliver healthy returns",
            "body": "The portfolio is well diversified yet retains large positions in its top bets. The fund endured a blip in performance between 2017-2020 but came back strong in 2021 and 2022. The shift in market's preference towards value has helped the fund recover smartly.ET Wealth collaborates with Value Research to analyse top mutual funds. We examine the key fundamentals of the fund, its portfolio and performance to help you make an informed investment decision.\n\nBASIC FACTS\n\nDATE OF LAUNCH\n\n29 SEPTEMBER 1994\n\nCATEGORY\n\nEQUITY\n\nTYPE\n\nFLEXI CAP\n\nAUM*\n\nRs.10,370 Crore\n\nBENCHMARK\n\nNIFTY 500 TOTAL\n\nRETURN INDEX\n\nWHAT IT COSTS\n\nNAV**\n\nGROWTH OPTION\n\nRs.1,018.27\n\nIDCW\n\nRs.46.97\n\nMINIMUM INVESTMENT\n\nRs.5,000\n\nMINIMUM SIP AMOUNT\n\nRs.500\n\nEXPENSE RATIO*** (%)\n\n1.77\n\nEXIT LOAD\n\n1% for redemption\n\nwithin 365 days\n\n*AS ON 30 APRIL 2023\n\n**AS ON 23 MAY 2023\n\n***AS ON 30 APRIL 2023\n\nFUND MANAGERS\n\nR. JANAKIRAMAN /ANAND RADHAKRISHNAN\n\n12 YEARS / 16 YEARS\n\nRecent portfolio changes\n\nNew Entrants\n\nDevyani International, Hindustan Aeronautics (Mar), Crompton Greaves Consumer Electricals (Apr).\n\nComplete Exits\n\nDr. Reddy's Laboratories, Ultratech Cement (Mar), Delhivery, Maruti Suzuki India, One 97 Communications (Apr).\n\nIncreasing allocation\n\nACC, City Union Bank, ICICI Prudential Life Insurance Company, United Breweries, Westlife Foodworld, Whirlpool Of India, Zomato (Apr).\n\nShould you buy?\n\nEarlier known as Franklin India Equity, this fund was shifted to the flexi cap category, allowing it to retain its go-anywhere approach to different market cap segments. It maintains its earlier large cap tilt. The fund managers run a quality and growth centric approach with a value overlay. The portfolio is well diversified yet retains large positions in its top bets. The fund endured a blip in performance between 2017-2020 but came back strong in 2021 and 2022. The shift in market's preference towards value has helped the fund recover smartly. With highly experienced fund managers at the helm, the fund should deliver healthy outcomes over the long term.\n\n(Source: Value Research)",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-100549456,width-1070,height-580,imgsize-340304,overlay-etwealth/photo.jpg",
            "eventUri": null,
            "sentiment": 0.3960784313725489,
            "wgt": 423018420,
            "relevance": 26
        },
        {
            "uri": "7564671162",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-27",
            "time": "05:33:00",
            "dateTime": "2023-05-27T05:33:00Z",
            "dateTimePub": "2023-05-27T05:32:00Z",
            "dataType": "news",
            "sim": 0.5921568870544434,
            "url": "https://zeenews.india.com/companies/indias-sun-pharma-posts-near-30-rise-in-q4-profit-on-lower-input-costs-2614192.html",
            "title": "India's Sun Pharma Posts Near-30% Rise In Q4 Profit On Lower Input Costs",
            "body": "New Delhi: Sun Pharmaceutical Industries Ltd, India's largest drugmaker by revenue, on Friday reported a 29.6 percent rise in fourth-quarter profit, as it benefited from lower expenses and higher sales of specialty drugs.\n\nThe company's consolidated profit before exceptional items and tax rose to 24.11 billion rupees ($291.7 million) for the quarter ended March 31, it said in an exchange filing.\n\nTotal revenue from operations climbed 15.7 percent to 109.31 billion rupees, while input costs declined 13.2 percent. The company, founded in 1983, makes over-the-counter medications, antiretrovirals, and active pharmaceutical ingredients for chronic and acute treatments.\n\nDrug sales in India, which account for over 31 percent of Sun Pharma's total consolidated sales, rose 8.7 percent year-on-year, while U.S. sales climbed 20.9 percent.\n\nThe company said it was impacted by the U.S. Food and Drug Administration's import alert in December at a plant in Gujarat, without elaborating.\n\nDespite the popularity of its generics business, the intense price competition prompted the drugmaker to enter the high-margin specialty segment about seven years ago. Its global specialty drugs sales rose 28 percent.\n\nIn March, Sun Pharma completed acquisition of U.S.-based Concert Pharmaceuticals Inc, giving it access to the company's late-stage drug deuruxolitinib to treat patchy baldness.\n\nIts exceptional item for the March quarter, amounting to 1.71 billion rupees, included Concert Pharma's acquisition-related expenses of 643.9 million rupees.\n\nThe company proposed a final dividend of 4 rupees per share for the year financial year 2023, adding to a previously paid interim dividend of 7.5 rupees per share.\n\nShares of Sun Pharma settled 2.6 percent higher after the results and snapped six weeks of losses with a gain of 4.8 percent for the week.\n\nRivals Dr Reddy's Laboratories Ltd and Cipla Ltd posted higher profits earlier in the month.",
            "source": {
                "uri": "zeenews.india.com",
                "dataType": "news",
                "title": "Zee News"
            },
            "authors": [],
            "image": "https://english.cdn.zeenews.com/sites/default/files/2023/05/27/1208317-untitled-design-2023-05-27t104231.821.jpg",
            "eventUri": "eng-8647902",
            "sentiment": 0.2470588235294118,
            "wgt": 422861580,
            "relevance": 1
        },
        {
            "uri": "7563486753",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-26",
            "time": "10:50:00",
            "dateTime": "2023-05-26T10:50:00Z",
            "dateTimePub": "2023-05-26T10:45:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.marketscreener.com//quote/stock/SUN-PHARMACEUTICAL-INDUST-9058928/news/India-s-Sun-Pharma-posts-near-30-rise-in-Q4-profit-on-lower-input-costs-43955413/",
            "title": "India's Sun Pharma posts near-30% rise in Q4 profit on lower input costs | MarketScreener",
            "body": "BENGALURU (Reuters) -Sun Pharmaceutical Industries Ltd, India's largest drugmaker by revenue, on Friday reported a 29.6% rise in fourth-quarter profit, as it benefited from lower expenses and higher sales of specialty drugs.\n\nThe company's consolidated profit before exceptional items and tax rose to 24.11 billion rupees ($291.7 million) for the quarter ended March 31, it said in an exchange filing.\n\nTotal revenue from operations climbed 15.7% to 109.31 billion rupees, while input costs declined 13.2%.\n\nThe company, founded in 1983, makes over-the-counter medications, anti-retrovirals and active pharmaceutical ingredients for chronic and acute treatments.\n\nDrug sales in India, which account for over 31% of Sun Pharma's total consolidated sales, rose 8.7% year-on-year, while U.S. sales climbed 20.9%.\n\nThe company said it was impacted by the U.S. Food and Drug Administration's import alert in December at a plant in Gujarat, without elaborating.\n\nDespite the popularity of its generics business, the intense price competition prompted the drugmaker to enter the high-margin specialty segment about seven years ago. Its global specialty drugs sales rose 28%.\n\nIn March, Sun Pharma completed acquisition of U.S.-based Concert Pharmaceuticals Inc, giving it access to the company's late-stage drug deuruxolitinib to treat patchy baldness.\n\nIts exceptional item for the March quarter, amounting to 1.71 billion rupees, included Concert Pharma's acquisition-related expenses of 643.9 million rupees.\n\nThe company proposed a final dividend of 4 rupees per share for the year financial year 2023, adding to a previously paid interim dividend of 7.5 rupees per share.\n\nShares of Sun Pharma settled 2.6% higher after the results, and snapped six weeks of losses with a gain of 4.8% for the week.\n\nRivals Dr Reddy's Laboratories Ltd and Cipla Ltd posted higher profits earlier in the month.\n\n($1 = 82.6420 Indian rupees)\n\n(Reporting by Rama Venkat in Bengaluru; Editing by Varun H K)",
            "source": {
                "uri": "marketscreener.com",
                "dataType": "news",
                "title": "Market Screener"
            },
            "authors": [],
            "image": "https://img.zonebourse.com/reuters/2023-05/2023-05-02T042448Z_2_LYNXMPEJ41037_RTROPTP_3_SUN-PHARM-FDA.JPG",
            "eventUri": null,
            "sentiment": 0.2470588235294118,
            "wgt": 422794200,
            "relevance": 1
        },
        {
            "uri": "7563313849",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-26",
            "time": "08:59:00",
            "dateTime": "2023-05-26T08:59:00Z",
            "dateTimePub": "2023-05-26T08:00:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.indiantelevision.com/mam/marketing/mam/msixpartners-wins-integrated-media-mandate-for-dr-reddys-otc-business-230526",
            "title": "mSix&Partners wins integrated media mandate for Dr Reddy's OTC",
            "body": "Mumbai: mSix&Partners, GroupM's youngest outcome-based agency, has added another prestigious client to its roster by winning the integrated media mandate for Dr. Reddy's OTC business, one of India's leading pharmaceutical companies. The account will be managed by the agency's Mumbai office, which will leverage its data and tech-driven approach to drive business growth for the client through targeted and effective media planning and execution.\n\nWith a focus on maximising ROI for the client, mSix&Partners plans to use its vast experience in media planning, execution, and measurement to craft solutions that resonate with Dr. Reddy's regional audience. The mandate will focus on crafting detailed micro-marketing solutions with a clear focus on the regionalisation story for Reblanz ORS brands. The agency's approach for Reblanz ORS brands is to create a smart solution based on certain fixed+fluid moments & data signals that are available to make it more relevant to the audience. mSix&Partners India managing partner Subhamay Mukhopadhyay said, \"We are thrilled to partner with Dr. Reddy's and bring our data-driven approach to the table. As a data and tech-driven agency, we understand the importance of driving business growth through bespoke, dedicated, multi-disciplinary teams that closely partner with our clients. Our data-driven approach is what sets us apart, and we're excited to bring that to the table for Dr. Reddy's. We look forward to adding value through our expertise in media planning and execution to deliver on the client's objectives\".\n\nWith this win, mSix&Partners continues to expand its portfolio of clients and demonstrate its capabilities as a leading outcome-based agency in the industry.\n\nDr. Reddy's, head of marketing OTC GG India Nigel Saldanha said \" We are on a very interesting journey in building an OTC business at Dr. Reddy's GG India, and at this juncture, having the right partners on board is of paramount importance. After rigorous evaluations, we are happy to award the integrated media mandate to mSix&Partners India and look forward to accelerating our ambitions through this partnership\".",
            "source": {
                "uri": "indiantelevision.com",
                "dataType": "news",
                "title": "Indian Television Dot Com"
            },
            "authors": [
                {
                    "uri": "https@indiantelevision.com",
                    "name": "https",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://www.indiantelevision.com/sites/default/files/images/tv-images/2023/05/26/29.jpg",
            "eventUri": null,
            "sentiment": 0.5137254901960784,
            "wgt": 422787540,
            "relevance": 100
        },
        {
            "uri": "7563144602",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-26",
            "time": "07:01:00",
            "dateTime": "2023-05-26T07:01:00Z",
            "dateTimePub": "2023-05-26T07:00:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.businesstelegraph.co.uk/indias-top-100-great-people-manager-list-of-2023-a-study-done-by-great-manager-institute-in-association-with-the-national-hrd-network/",
            "title": "India's Top 100 Great People Manager List of 2023 - A study done by Great Manager InstituteÂ®, in association with the National HRD Network",
            "body": "One of the largest studies on people management the Great People Manager Studyâ„¢ assesses thousands of people managers across the country and recognizes the Top 100 Great People Managers. This research is conducted by Great Manager InstituteÂ® - an organization dedicated to the assessment, development and recognition of people managers.\n\nAll the participating managers and leaders go through a rigorous selection process using a multi-layered evaluation methodology. This finally culminates in a list of the Top 100 Great People Managers.\n\nThe methodology for this study captures team members' feedback through a valid and reliable survey instrument across 3 broad themes of Connect, Develop, and Inspire. In addition to the team feedback managers' day-to-day people management practices are also assessed.\n\nThe list is a diverse mix of CEOsâ€¯ Senior and early-stage managers and emphasizes that the most compelling leaders prioritize human values over mundane corporate metrics by showing compassion and empathy. Because a Great People Manager is someone who builds high-trust relationships to deliver sustained business results\n\nNational HRD Network (NHRDN) is a partner in doing this Study and eligible managers are jointly certified by Great Manager InstituteÂ® and NHRDN.\n\nTop 100 Great People Managers of 2023 (In alphabetical order)\n\nAbhijeet Angane- (Senior Vice President & Relationship Head - West India Factoring & Finance Solutions, FIM Bank Group) Abhradip Ray- (AVP - Delivery, Blazeclan Technologies Pvt. Ltd.) Ajit Inamdar- (Cloud Architect, Blazeclan Technologies Pvt. Ltd.) Ajith Sankaran- (Senior Vice President, Course5 Intelligence Ltd.) Amar Pathak- (Head Learning & Development, Viraj Profiles (P) Limited) Amit Mishra- (Manager - Operations, Nexval Infotech Pvt. Ltd) Anish Anand- (Senior Technical Program Manager, Mastercard Technology Pvt. Ltd.) Anoop Kumar- (Deputy General Manager, PGP Glass Pvt. Ltd.) Atiq Rehman- (Sr. Manager Operations, Nexval Infotech Pvt. Ltd.) Avinash Kajale- (Sr Director Professional Services, e-Emphasys Systems Pvt Ltd) Bhanukumar Parmar- (Sr. Vice President, UltraTech Cement) Biju Velayudhan- (Chief Information Officer, G. Kuppuswamy Naidu Memorial Hospital) Binoy Thomas- (Deputy Vice President, Macrotech Developers Ltd ( Lodha Group) Clint Misquitta- (Senior Vice President, Edelweiss Tokio) Cornelius Lyngdoh- (Associate Manager, Enable India) Deepak Kumar- (Associate Director, Rakuten India Enterprise Private Limited) Deepak Malik- (Senior Manager QA, Iris Software Pvt Ltd) Dilip Kumar R- (Assistant Manager Operations, Nexval InfoTech Pvt Ltd) Dinesh Kumar T K- (Vice President - Human Resources, Aspire Systems (India) Private Limited) Dr. Sarvana Kumar- (Group Unit Head, Dr Mehtas Hospitals Chennai) Dr. Amrita Vohra- (COO and Director Education India region, GEMS Education) Dr. Ankita Singh- (Senior Vice President & Global Head: HR Admin IT Travel, CIGNEX Technologies Private Limited) Dr. C. Jayakumar- (Executive Vice President & Head - Human Resource (CHRO), Larsen & Toubro Ltd Drashti Shah Rajkotwala- (Head - Growth and Development, Unitile) Hari Agrawal- (Director - Digital, M&G Global Services Private Limited) Harsh Monga- (Head - Sales Capability & Coaching Practice, Dr. Reddy's) Hemal Thakor- (Chief Marketing Officer, PGP GLASS PVT LTD) Indranil Sen- (Co-Founder, AlterEgo Accelerators LLP) Jaikrishna B- (President - Group HR, AMARA RAJA GROUP) Jaswinder Saini- (Vice President - Supply Chain Services, Tata Play) Kishore Rajah Rajendran- (Sr. Project Manager, Rakuten India Enterprise Private Limited) Krishna Gautam- (Head of Customer Experience, Urbanic) Krishnan Bangarusamy- (Associate Vice President - Human Resources, Omega Healthcare Management Services Private Limited Krupali Raval- (Senior Manager HR, The Walt Disney Company) Lata Chemudupati- (Head-People&Culture, Netconnectglobal) Manjula Rao- (Sr General Manager, Schneider Electric) Manu Kaushal- (Senior Director, Iris Software Pvt Ltd.) Milan Thakkar- (Vice President - Strategic Alliance, Rishabh Software Pvt Limited) Mohanraj S- (Director Sales & Strategy - South, FabHotels) Neena Chakraborty- (Director Human Resources, GeBBS Healthcare) Nivedita Nanda- (Country Director People and Culture, ISS) Pavan Kumar Maddela, (Senior Recruitment Manager, ADITI TECH CONSULTING PRIVATE LIMITED) Pompayya H M- (Manager - Manufacturing Operations, Eaton Industrial Products Pvt Ltd - Aerospace Division) Pramod Ganji- (Sr. Vice President- Business Development, Infibeam Avenues Limited) Rashmi Priya- (Head HR, IIFL Home Finance Ltd) Ravish Kumar- (Senior Director, Iris Software Pvt Ltd) Renoy Titus- (Project Manager, Infosys Ltd) Rohit Kapur- (Chief of F&A and Company Secretary, Beumer India Private Limited) Sachin Katkar- (Director - Enterprise Solutions and Delivery, Nitor Infotech Pvt Ltd) Sachin Pethkar- (Zonal Sales Manager, ROINET SOLUTION PRIVATE LIMITED) Sachin Raja- (Chief: Operations Engineering, Beumer India Pvt Ltd) Sachin Sharma- (Head - Project Management, Beumer India Pvt Ltd) Samapti Acharjee- (Associate Manager, EnAble India) Sandeep Khar- (Principal Consultant, Infosys Ltd) Sandeep Kumar- (HR Operations Head India, Sodexo India Services Private Limited) Sanjeeb Lahiri- (Chief HR Officer, GRP Limited) Sarvanakumar N- (Unit Head, SHOPPERS STOP) Satish Kumar Krishnamurthy- (Principal Consultant, Infosys Ltd) Shabana Upanal- (Director Global Talent Management APJ, TechData APAC a TD SYNNEX Company) Shadab Ashraf- (Director Global Support & Customer Experience, Udacity) Shalini Sinha- (General Manager- Hospitality and Property Management, Macrotech Developers Ltd ( Lodha Group) Shamanth SN- (Director - New & Emerging Business, Rakuten India Enterprises Private Limited) Sharmilaa Rajesh Kannan- (VP-HR, Kensium) Shashi Singh- (Head Credit Control & Compliances, PERSOLKELLY INDIA PVT. LTD.) Shatabdi Ghosh- (Talent Management | Leadership Readiness Lead, John Deere India Pvt. Ltd.) Shipra Lavania- (Head Human Resources, Wunderman Thompson) Shreepad Kuthyar- (Country Head, SSi People) Shrija Chandak- (Chief of Strategy and Digitization, Amrit Cement Limited) Shrikant Naik- (SVP Global Delivery Head, Quest Global) Srinivas Pindi- (Sr Director Hr & TA, Phenom) Sudha Rajan- (Manager - HR Digital Transformation Lead, Prodapt Solutions) Swaminathan Lakshmanan- (Associate Director - Talent Acquisition, Mindsprint (erstwhile Olam Information Services Pvt Ltd) Vijayakumar M- (Senior Vice President, ADF Data Science Pvt Ltd) Vineet Shukla- (Deputy General Manager-Human Resources, Emcure Pharmaceuticals) Vinod Phadatare- (Corporate Head - HR and OD, Mungi Engineers Pvt Ltd)\n\nA few Business Leaders in the Top 100 list (In alphabetical order)\n\nAmit Ramani- (Founder & CEO, Awfis Space Solutions Pvt Ltd) Anil Kumar Mehrotra-(Managing Director, SBL SPECIALTY COATINGS PVT LTD ( 100% Subsidiary Of Berger Paints) Atul Satija- (Founder 2.0 & CEO, Give.do) Deepak Jain- (CEO, BMW DEUTSCHE MOTOREN Deepak Narayanan- (Founder & CEO, Practus Advisors) Dr. Nalini Prabhushanker- (Founder and Chairperson, SPRING MOUNT PUBLIC SCHOOL) Dr. Prasanna Venkatesh M K- (Managing Director & Sr. Consultant Paediatric Urologist Robotic & Renal Transplant Surgeon, NU Hospitals) Gagan Arora- (Founder & President, Vertex Group) K Narender Reddy- (Chief Executive Officer, NATURAL REMEDIES PVT LTD) Manish Lunia- (Co-Founder, FlexiLoans.com (Epimoney Private Limited) Manoj Chhablani- (VP of India Operations, Webgility Software Technocrats Pvt Ltd) Motilal Oswal- (Founder & CEO, MOTILAL OSWAL FINANCIAL SERVICES LTD) Nilaya Varma- (Co-Founder and CEO, Primus Partners) Rajan Aggarwal- (Executive Director and Chief Executive Officer, AGI Milltec) Sandip Chhettri- (Chief Executive Officer, Infocom Network Private Limited (TradeIndia.com) Saumya Kaushik- (Founder, Growup Technologies) Shailendra Jagtap- (Managing Director & Country Manager, John Deere India Pvt Ltd) Shivaashish Gupta- (Chief Executive Officer, Sanctum Wealth Private Limited) Shrikant Bairagi- (Managing Director, ARGO-HYTOS PVT. LTD) Sumit Raina- (CEO, Shubham Tanks, and Liners Pvt Limited) Sushil Kumar Jain- (Group CEO, ORBIT TECHSOL INDIA PVT LTD) Trishneet Arora- (Founder and CEO, TAC Security) Vaishal Dalal- (Chairman Co-Founder & Director, Excellent Global Endeavors LLP) Vineet Agarwal- (Co-Founder, Carbon Negative Pvt Ltd) Vipul Vij- (COO Cosmetics and Perfumery Division, PGP GLASS PVT LTD)\n\nGreat Manager InstituteÂ® has also published a list of Leadership Factories of India. Click here to view the list.\n\nDisclaimer: Content Produced by Great Manager Institute\n\nREAD SOURCE",
            "source": {
                "uri": "businesstelegraph.co.uk",
                "dataType": "news",
                "title": "Business Telegraph"
            },
            "authors": [],
            "image": "https://usercontent.one/wp/www.businesstelegraph.co.uk/wp-content/uploads/2023/05/Indias-Top-100-Great-People-Manager-List-of-2023.jpg?media=1683224819",
            "eventUri": null,
            "sentiment": 0.5607843137254902,
            "wgt": 422780460,
            "relevance": 26
        },
        {
            "uri": "7562965946",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-26",
            "time": "04:26:00",
            "dateTime": "2023-05-26T04:26:00Z",
            "dateTimePub": "2023-05-26T04:22:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://economictimes.indiatimes.com/markets/stocks/news/value-buys-these-20-nifty-stocks-trading-below-10-year-pes/articleshow/100517945.cms",
            "title": "Value buys? These 20 Nifty stocks trading below 10-year PEs",
            "body": "NEW DELHI: While valuations on Dalal Street have fallen in line with 5-year and 10-year historical averages following a rangebound trade over the last two years, analysts believe they have still not fallen to levels that give investors comfort to put money aggressively. That said, nearly half of index stocks are below their 10-year averages and can offer decent returns to investors.\n\nTrendlyne data suggests these 20 stocks have 5-35% upside scope and hold to strong buy ratings from analysts.\n\nFor UPL, analysts have an average target upside of 35%. Out of 23 calls on the stock, 17 have strong buy ratings, 3 buy ratings, 2 hold calls and one sell call. UPL has a 12-month trailing PE of 14.03 times vs 10-year average PE of 17.32 times.\n\nBrokerage Prabhudas Lilladher recently slashed the FY24E/25E estimates for UPL by 16%/12% and target multiple from 14x earlier to 12x currently, to factor in subdued growth and margin outlook in the near term. It, however, maintained a BUY post the earnings show at a target of Rs 850.\n\nAs for Hindalco, its TTM PE stands at 7.92 times currently against the 10-year average of 12.52 times. The stock, which declared its Q4 earnings on Wednesday, has 14 strong buy out of 20 recommendations and no sell calls. It has an average upside scope of 30%, Trendlyne data further suggests.\n\nHDFC Bank, SBI, Axis Bank and M&M are also below their 10-year average while they have an upside scope of over 20% each in the next 12 months. This is when these stocks have gained 20-37% in the last one year already.\n\nHDFC Bank's counterpart HDFC is also trailing its 10-year average PE of 20.17 times as stock trades at 19.11 times. With the merger between the two entities just 4-5 weeks away, analysts on Thursday said the move would result in a lower net interest margin (NIM) for the lender this year.\n\nThe bank expects NIM - a key profitability measure - to fall to 3.7%-3.8% in 2023-24 from 4.1% a year ago due to the merger, Nomura analysts wrote in a report.\n\nNTPC, Apollo Hospitals, IndusInd Bank, Cipla, Bharti Airtel, Kotak Mahindra Bank, Dr. Reddy's Labs and ONGC are among companies that are trading at a PE multiple of below their historical average. Analysts expect them to give gains in the high to mid-teens.\n\n(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of Economic Times)",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-100517931,width-1070,height-580,imgsize-105922,overlay-etmarkets/photo.jpg",
            "eventUri": null,
            "sentiment": 0.09019607843137245,
            "wgt": 422771160,
            "relevance": 1
        },
        {
            "uri": "7562055710",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-25",
            "time": "14:10:00",
            "dateTime": "2023-05-25T14:10:00Z",
            "dateTimePub": "2023-05-25T14:03:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.thehindu.com/business/granules-hit-by-it-security-incident-drugmaker-isolates-impacted-it-assets/article66893123.ece",
            "title": "Granules hit by IT security incident, drugmaker  isolates impacted IT assets  ",
            "body": "Matter is being investigated with utmost priority, says the company\n\nGranules has been hit by an information-security incident following which the drugmaker said it isolated the impacted IT assets.\n\nThe matter is being investigated with \"utmost priority and appropriate containment and remediation actions are being taken in a controlled manner to address the incident,\" the company said in regulatory filing on Thursday.\n\nIt said \"please be informed that an information-security incident has occurred at the company and the impacted IT assets have been isolated,\" but did not elaborate on the incident. The company's shares closed at 2.10% lower at â‚¹273.05 each on the BSE.\n\nGranules joins Sun Pharmaceutical Industries, which in March had reported an information security incident resulting in breach of certain file systems and the theft of certain company data and personal data, for which a ransomware group had claimed responsibility. In 2020 , Dr. Reddy's faced a ransomware attack and Lupin an information-security incident.",
            "source": {
                "uri": "thehindu.com",
                "dataType": "news",
                "title": "The Hindu"
            },
            "authors": [],
            "image": "https://www.thehindu.com/theme/images/og-image.png",
            "eventUri": null,
            "sentiment": 0.05882352941176472,
            "wgt": 422719800,
            "relevance": 1
        },
        {
            "uri": "7561589031",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-25",
            "time": "09:26:00",
            "dateTime": "2023-05-25T09:26:00Z",
            "dateTimePub": "2023-05-25T09:01:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/granules-india-reports-information-security-incident-isolates-impacted-it-assets/articleshow/100499226.cms",
            "title": "Granules India reports 'information security incident'; isolates impacted IT assets",
            "body": "The appropriate containment and remediation actions are being taken in a controlled manner to address the incident, it added. In March, Sun Pharma also reported an information security incident at the company.Drug firm Granules India on Thursday reported an \"information security incident\" and said the impacted IT assets have been isolated. The company is investigating the matter with utmost priority, it said in a regulatory filing.\n\nThe appropriate containment and remediation actions are being taken in a controlled manner to address the incident, it added.\n\nIn March, Sun Pharma also reported an information security incident at the company.\n\nIn 2020, Dr Reddy's Laboratories and Lupin reported cyber security breaches.",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-100499782,width-1070,height-580,imgsize-89368,overlay-economictimes/photo.jpg",
            "eventUri": null,
            "sentiment": 0.2,
            "wgt": 422702760,
            "relevance": 1
        },
        {
            "uri": "7561537434",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-25",
            "time": "08:55:00",
            "dateTime": "2023-05-25T08:55:00Z",
            "dateTimePub": "2023-05-25T08:52:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.devdiscourse.com/article/technology/2464400-granules-india-reports-information-security-incident-isolates-impacted-it-assets",
            "title": "Granules India reports 'information security incident'; isolates impacted IT assets | Technology",
            "body": "Drug firm Granules India on Thursday reported an information security incident and said the impacted IT assets have been isolated. The company is investigating the matter with utmost priority, it said in a regulatory filing.The appropriate containment and remediation actions are being taken in a controlled manner to address the incident, it added.In March, Sun Pharma also reported an information security incident at the company.\n\nDrug firm Granules India on Thursday reported an ''information security incident'' and said the impacted IT assets have been isolated. The company is investigating the matter with utmost priority, it said in a regulatory filing.\n\nThe appropriate containment and remediation actions are being taken in a controlled manner to address the incident, it added.\n\nIn March, Sun Pharma also reported an information security incident at the company. In 2020, Dr Reddy's Laboratories and Lupin reported cyber security breaches.\n\n(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)",
            "source": {
                "uri": "devdiscourse.com",
                "dataType": "news",
                "title": "Devdiscourse"
            },
            "authors": [],
            "image": "https://www.devdiscourse.com/remote.axd?https://devdiscourse.blob.core.windows.net/imagegallery/29_02_2020_16_59_02_2201424.jpg?width=920&format=jpeg",
            "eventUri": null,
            "sentiment": 0.1843137254901961,
            "wgt": 422700900,
            "relevance": 1
        },
        {
            "uri": "7561087437",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-25",
            "time": "02:44:00",
            "dateTime": "2023-05-25T02:44:00Z",
            "dateTimePub": "2023-05-25T02:40:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://thenelsonpost.ca/news/306794/sapropterin-industry-size-growth-forecast-business-outlook-2023-2030/",
            "title": "Sapropterin Industry: Size, Growth, Forecast, Business Outlook 2023-2030",
            "body": "A new business intelligence report on the global Sapropterin market has recently been added to the Dynamic Report Repository and has been published to provide an exclusive hands-on reference to the various market dynamics that will enable high potential growth in the global Sapropterin Market. The report presents a market summary, sophisticated TOC, a variety of unique research methodologies, and a research database composed of multiple data sources. This report has been prepared to encourage and guide investor investment with a detailed analysis of the five forces SWOT, PESTEL and PORTER. The report has been designed with current and past developments in mind that are critical to utilizing profitable forecast development to ensure stable market growth and uninterrupted survival despite fierce competition in the global Sapropterin Market.\n\nRequest for Sample with Complete TOC and Figures & Graphs @ https://globalmarketvision.com/sample_request/182416\n\nThe report highlights the latest trends in revenue and market progress, and all realistic statistics on ventures. It provides prevention and pre-planned management and highlights a summary of the global Sapropterin Market, along with classification, definition and market chain structure.\n\nMajor Market Players Profiled in the Report include:\n\nBioMarin Pharmaceutical, Par, Dr Reddy's Laboratories\n\nFurthermore, the users of the report will acquire all the vital business facts and figures given by analysing numerous financial statements to regional advancements. The global economic factors play a great role in enhancing the quality of the analysis of the global Sapropterin Market, including many more specific market characteristics. Moreover, various new market features and aspects are well included to make the readers well informed about the entire market.\n\nAs the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.\n\nGeographically, the detailed analysis of consumption, revenue, market share, and growth rate of the following regions:\n\nAnalysis of the market:\n\nOther important factors studied in this report include demand and supply dynamics, industry processes, import & export scenario, R&D development activities, and cost structures. Besides, consumption demand and supply figures, cost of production, gross profit margins, and selling price of products are also estimated in this report.\n\nThe conclusion part of their report focuses on the existing competitive analysis of the market. We have added some useful insights for both industries and clients. All leading manufacturers included in this report take care of expanding operations in regions. Here, we express our acknowledgment for the support and assistance from the Sapropterin industry experts and publicizing engineers as well as the examination group's survey and conventions. Market rate, volume, income, demand and supply data are also examined.\n\nThe following aspects are given with full analysis from the Sapropterin market research reports:\n\nProduction Analysis - The beginning of this Sapropterin is examined based on the most important countries, types, and applications. The pricing analysis of various Sapropterin market main players will be completely covered in this study.\n\nProfit and Sales Analysis - Earnings and sales for key components of the international Sapropterin market are validated. Another important factor, price, which has a significant impact on sales growth, can be evaluated in this section for many regions.\n\nSegments and Benefits -- Continuing with the profits theme, this paper examines the design and ingestion of its Sapropterin market. The differences between usage and supply, export and import data are also highlighted in this research.\n\nMany global Sapropterin industry - leading players have been evaluated in this area based on their company profile, product portfolio, ability, pricing, cost, and revenue.\n\nOther Analysis - In addition to the foregoing data, demand, and supply analysis for the Sapropterin economy, contact information for significant producers, suppliers, and consumers can be assigned.\n\nDirect Purchase this Market Research Report Now @ https://globalmarketvision.com/checkout/?currency=USD&type=single_user_license&report_id=182416\n\nIf you have any special requirements, please let us know and we will offer you the report at a customized price.\n\nThe final report will add the analysis of the Impact of Covid-19 in this report Sapropterin Market.\n\nAdapting to the recent novel COVID-19 pandemic, the impact of the COVID-19 pandemic on the global Sapropterin Market is included in the present report. The influence of the novel coronavirus pandemic on the growth of the Sapropterin Market is analyzed and depicted in the report.\n\nAbout Global Market Vision\n\nGlobal Market Vision consists of an ambitious team of young, experienced people who focus on the details and provide the information as per customer's needs. Information is vital in the business world, and we specialize in disseminating it. Our experts not only have in-depth expertise, but can also create a comprehensive report to help you develop your own business.\n\nWith our reports, you can make important tactical business decisions with the certainty that they are based on accurate and well-founded information. Our experts can dispel any concerns or doubts about our accuracy and help you differentiate between reliable and less reliable reports, reducing the risk of making decisions. We can make your decision-making process more precise and increase the probability of success of your goals.",
            "source": {
                "uri": "thenelsonpost.ca",
                "dataType": "news",
                "title": "Finance BC"
            },
            "authors": [],
            "image": null,
            "eventUri": null,
            "sentiment": 0.5137254901960784,
            "wgt": 422678640,
            "relevance": 51
        },
        {
            "uri": "7559926380",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-24",
            "time": "10:50:00",
            "dateTime": "2023-05-24T10:50:00Z",
            "dateTimePub": "2023-05-24T10:49:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.livemint.com/market/stock-market-news/top-gainers-losers-today-adani-enterprises-adani-ports-hdfc-twins-sun-pharma-indiabulls-real-estate-check-list-11684924867348.html",
            "title": "Top gainers, losers today: Adani Ent, HDFC twins, Sun Pharma, Indiabulls Real Estate; check full list here",
            "body": "Indian markets pulled back in the closing hours of Wednesday on the back of muted global cues, stalled US debt ceiling negotiations, rising bond yields, and Fed's hawkish comments. Also, profit booking in Adani stocks coupled with a decline in HDFC twins, banking, and financial stocks dragged the performance.\n\nSensex moved away from its critical 62,000 mark to end at 61,773.78 down by 208.01 points or 0.34% on Wednesday. Nifty 50 closed at 18,285.40 lower by 62.60 points or 0.34%. Bank Nifty plunged by nearly 277 points to finish at 43,677.85. Also, the financial services index dipped nearly a percent.\n\nIn the broader markets, midcap and smallcap stocks witnessed a slight upside. In terms of sectoral indices, consumer durables stocks outperformed with the index on BSE rising over 511 points followed by the healthcare index which gained by 170 points. Banking and financials were top laggards.\n\nTalking about market performance, Vinod Nair, Head of Research at Geojit Financial Services said, \"The domestic market experienced a short-lived rally that was overshadowed by subdued global market sentiment. US Treasury yields rose due to concerns over stalled US debt ceiling talks and hawkish comments from US Fed officials, which reduced the chances of a rate pause. European markets also declined, triggered by higher-than-expected UK inflation figures that bet on more rate hikes by the BoE.\"\n\nOn May 24th, a total of 1,677 stocks advanced, while 1,796 stocks declined, and the remaining 129 stocks were unchanged. Meanwhile, a total of 116 stocks touched a new 52-week high and 46 stocks struck their new 1-year low.\n\nTop gainers: Sun Pharma (+1.96%), Titan (+1.05%), ITC (+1.01%), IndusInd Bank (+1.01%), and Tech Mahindra (+0.80%).\n\nTop losers: Tata Motors (-1.57%), ICICI Bank (-1.30%), HDFC Bank (-1.29%), HDFC (-1.23%), and Bajaj Finserv (-0.73%).\n\nTop gainers: Sun Pharma (+1.98%), Dr. Reddy's Lab (+1.31%), ITC (+1.13%), IndusInd Bank (+1.06%), and Titan (+0.99%).\n\nTop losers: Adani Enterprises (-6.03%), Adani Ports (-2.21%), Tata Motors (-1.49%), HDFC Bank (-1.36%), and ICICI Bank (-1.29%).\n\nTop gainers: Schneider Electric (+13.46%), Sudarshan Chemical Industries (+11.96%), Optiemus Infracom (+10.70%), Deepak Nitrate (+9.58%), and Indiabulls Real Estate (+8.81%).\n\nTop losers: Polypex Corporation (-8.18%), Adani Enterprises (-5.9%), Cummins India (-5.36%), Sequent Scientific (-5.09%), and Johnson Controls-Hitachi Air Conditioning India (-4.39%).\n\nTop gainers: Schneider Electric (+14.01%), Prime Focus (+13.47%), GTL Infra (+13.33%), Dynamic Cables (+12.63%), and Visesh Infotechnics (+12.50%).\n\nTop losers: Dishman Carbogen (-12.27%), Antony Waste Handling Cell (-11.54%), Orient Bell (-10.09%), Sanghvi Movers (-8.88%), and Polyplex Corp (-8.28%).\n\nBy the end of Wednesday's trading session, BSE-listed firms' market cap stood at over â‚¹279.46 lakh crore.",
            "source": {
                "uri": "livemint.com",
                "dataType": "news",
                "title": "mint"
            },
            "authors": [
                {
                    "uri": "pooja_sitaram_jaiswar@livemint.com",
                    "name": "Pooja Sitaram Jaiswar",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://www.livemint.com/lm-img/img/2023/05/24/600x338/Bull_vs_bear_iStock_1659059910651_1684925070971.JPG",
            "eventUri": null,
            "sentiment": 0.06666666666666665,
            "wgt": 422621400,
            "relevance": 1
        },
        {
            "uri": "7559923726",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-24",
            "time": "10:48:00",
            "dateTime": "2023-05-24T10:48:00Z",
            "dateTimePub": "2023-05-24T10:45:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://economictimes.indiatimes.com/markets/stocks/stock-watch/share-market-update-most-active-stocks-of-the-day-in-terms-of-traded-value/articleshow/100474719.cms",
            "title": "Share market update: Most active stocks of the day in terms of traded value",
            "body": "NEW DELHI: Adani Ent.(Rs. 5993.77 crore), HDFC Bank(Rs. 2728.48 crore), ICICI Bank(Rs. 1711.81 crore), Dixon Tech(Rs. 1271.36 crore), SBI(Rs. 1027.16 crore), Adani Ports SEZ(Rs. 926.23 crore), Mahindra CIE(Rs. 921.04 crore), RIL(Rs. 916.40 crore), Deepak Nitrite(Rs. 836.10 crore) and Adani Green(Rs. 748.41 crore) were among the most traded securities on the National Stock Exchange in Wednesday's session.\n\nThe NSE Nifty index ended the session 62.6 points down at 18285.4, while BSE Sensex fell 208.01 points to 61773.78.\n\nIn the Nifty index, Sun Pharmaceutical Industries Ltd.(up 2.21 per cent), Dr. Reddy's Laboratories Ltd.(up 1.32 per cent), Hero MotoCorp Ltd.(up 1.04 per cent), ITC Ltd.(up 1.01 per cent) and IndusInd Bank Ltd.(up 0.92 per cent) stood among the top gainers.\n\nOn the other hand, Adani Enterprises Ltd.(down 6.00 per cent), Adani Ports & Special Economic Zone Ltd.(down 2.15 per cent), Tata Motors Ltd.(down 1.57 per cent), ICICI Bank Ltd.(down 1.34 per cent) and HDFC Bank Ltd.(down 1.31 per cent) were among the top losers of the day.",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-83725308,width-1070,height-580,imgsize-48184,overlay-etmarkets/photo.jpg",
            "eventUri": null,
            "sentiment": 0.07450980392156858,
            "wgt": 422621280,
            "relevance": 1
        },
        {
            "uri": "7559914341",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-24",
            "time": "10:42:00",
            "dateTime": "2023-05-24T10:42:00Z",
            "dateTimePub": "2023-05-24T10:41:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.rttnews.com/3366086/sensex-nifty-snap-three-day-winning-streak.aspx",
            "title": "Sensex, Nifty Snap Three-day Winning Streak ",
            "body": "Indian shares ended modestly lower on Wednesday to snap a three-day winning streak.\n\nWeak global cues weighed after no new progress was made in talks between the White House and U.S. congressional leaders to raise the federal debt ceiling and avoid a potential default next month.\n\nThe FOMC minutes also remained on investors' radar following recent dovish tones in Fed speeches.\n\nThe minutes from the Federal Reserve's May meeting are slated for release later in the day, with investors awaiting further clarity on the central bank's thinking on interest-rate rises going forward.\n\nThe benchmark S&P BSE Sensex dropped 208.01 points, or 0.34 percent, to 61,773.78 while the broader NSE Nifty index settled down 62.60 points, or 0.34 percent, at 18,285.40.\n\nAdani Group stocks fell on profit taking after recent strong gains. Adani Enterprises lost 6 percent and Adani Ports fell 2.2 percent.\n\nICICI Bank, HDFC Bank and Tata Motors all ended down over 1 percent.\n\nOn the positive side, Titan Company, IndusInd Bank, ITC, Dr Reddy's Laboratories and Sun Pharma rose 1-2 percent.\n\nThe rupee traded slightly higher in the afternoon and gold held steady while oil prices rose about 2 percent to extend gains from the previous session on concerns over tightening supply and after a warning from Saudi Arabia's energy minister that oil prices may not continue to decline.\n\nFor comments and feedback contact: editorial@rttnews.com",
            "source": {
                "uri": "rttnews.com",
                "dataType": "news",
                "title": "RTTNews"
            },
            "authors": [],
            "image": "https://cdn.rttnews.com/images/v4/RTTNews-logo-512x512.png",
            "eventUri": null,
            "sentiment": 0.2078431372549019,
            "wgt": 422620920,
            "relevance": 1
        },
        {
            "uri": "7559897565",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-24",
            "time": "10:31:00",
            "dateTime": "2023-05-24T10:31:00Z",
            "dateTimePub": "2023-05-24T10:28:00Z",
            "dataType": "news",
            "sim": 0.4901960790157318,
            "url": "https://www.rttnews.com/3366086/sensex-nifty-snap-three-day-winning-streak.aspx",
            "title": "Sensex, Nifty Snap Three-day Winning Streak ",
            "body": "Indian shares ended modestly lower on Wednesday to snap a three-day winning streak.\n\nWeak global cues weighed after no new progress was made in talks between the White House and U.S. congressional leaders to raise the federal debt ceiling and avoid a potential default next month.\n\nThe FOMC minutes also remained on investors' radar following recent dovish tones in Fed speeches.\n\nThe minutes from the Federal Reserve's May meeting are slated for release later in the day, with investors awaiting further clarity on the central bank's thinking on interest-rate rises going forward.\n\nThe benchmark S&P BSE Sensex dropped 208.01 points, or 0.34 percent, to 61,773.78 while the broader NSE Nifty index settled down 62.60 points, or 0.34 percent, at 18,285.40.\n\nAdani Group stocks fell on profit taking after recent strong gains. Adani Enterprises lost 6 percent and Adani Ports fell 2.2 percent.\n\nICICI Bank, HDFC Bank and Tata Motors all ended down over 1 percent.\n\nOn the positive side, Titan Company, IndusInd Bank, ITC, Dr Reddy's Laboratories and Sun Pharma rose 1-2 percent.\n\nThe rupee traded slightly higher in the afternoon and gold held steady while oil prices rose about 2 percent to extend gains from the previous session on concerns over tightening supply and after a warning from Saudi Arabia's energy minister that oil prices may not continue to decline.\n\nFor comments and feedback contact: editorial@rttnews.com",
            "source": {
                "uri": "rttnews.com",
                "dataType": "news",
                "title": "RTTNews"
            },
            "authors": [],
            "image": "https://cdn.rttnews.com/images/v4/RTTNews-logo-512x512.png",
            "eventUri": "eng-8644137",
            "sentiment": 0.2078431372549019,
            "wgt": 422620260,
            "relevance": 1
        },
        {
            "uri": "7559878004",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-24",
            "time": "10:20:00",
            "dateTime": "2023-05-24T10:20:00Z",
            "dateTimePub": "2023-05-24T10:19:00Z",
            "dataType": "news",
            "sim": 0.5568627715110779,
            "url": "https://www.moneycontrol.com/news/business/markets/taking-stock-market-snaps-3-day-gains-nifty-below-18300-sensex-falls-208-pts-10652841.html",
            "title": "Taking Stock: Market snaps 3-day gains; Nifty below 18,300, Sensex falls 208 pts",
            "body": "Adani Enterprises, Adani Ports, Tata Motors, HDFC Bank, and ICICI Bank were among the biggest losers on the Nifty.\n\nThe Indian equity market snapped a 3-day winning streak and ended lower in yet another volatile session on May 24. At close, the Sensex was down 208.01 points or 0.34% at 61,773.78, while the Nifty was down 62.60 points or 0.34% at 18,285.40.\n\nOn the back of weak global markets, Indian indices started the day on a negative note, but soon recovered and witnessed rangebound movement in the first half. However, second half selling pressure dragged the benchmark to the day's low.\n\nStocks and Sectors\n\nAdani Enterprises, Adani Ports, Tata Motors, HDFC Bank, and ICICI Bank were among the biggest losers on the Nifty. However, gainers included Sun Pharma, Dr Reddy's Laboratories, ITC, IndusInd Bank, and Hero MotoCorp.\n\nAmong sectors, metal index shed 1 percent, Bank down 0.5 percent, while pharma index added 1 percent and power index up 0.6 percent.\n\nThe BSE midcap and smallcap indices ended on a flat note.",
            "source": {
                "uri": "moneycontrol.com",
                "dataType": "news",
                "title": "MoneyControl"
            },
            "authors": [],
            "image": "https://images.moneycontrol.com/static-mcnews/2023/05/sensex_nifty_sensexdown-2-770x433.jpg",
            "eventUri": "eng-8639858",
            "sentiment": -0.01960784313725494,
            "wgt": 422619600,
            "relevance": 1
        },
        {
            "uri": "7559470492",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-24",
            "time": "05:44:00",
            "dateTime": "2023-05-24T05:44:00Z",
            "dateTimePub": "2023-05-24T05:44:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://economictimes.indiatimes.com/markets/stocks/stock-watch/share-market-update-most-active-stocks-of-the-day-in-terms-of-total-traded-value/articleshow/100465161.cms",
            "title": "Share market update: Most active stocks of the day in terms of total traded value",
            "body": "NEW DELHI: Adani Ent.(Rs. 2641.23 crore), Mahindra CIE(Rs. 776.78 crore), Dixon Tech(Rs. 672.13 crore), HDFC Bank(Rs. 612.55 crore), Max Healthcare(Rs. 576.64 crore), Adani Ports SEZ(Rs. 465.22 crore), ICICI Bank(Rs. 464.60 crore), Adani Green(Rs. 430.65 crore), Adani Wilmar(Rs. 411.94 crore) and Adani Power(Rs. 392.87 crore) were among the most traded securities on the National Stock Exchange at 11:01AM in Wednesday's session.\n\nThe NSE Nifty index traded 37.3 points up at 18385.3, while BSE Sensex was up 152.35 points at 62134.14 as of 11:01AM(IST)on May 24.\n\nIn the Nifty index, Maruti Suzuki India Ltd.(up 1.13 per cent), Power Grid Corporation of India Ltd.(up 1.09 per cent), Dr. Reddy's Laboratories Ltd.(up 1.07 per cent), HDFC Life Insurance Company Ltd.(up 1.07 per cent) and Sun Pharmaceutical Industries Ltd.(up 1.05 per cent) were among the top gainers.\n\nOn the other hand, Adani Enterprises Ltd.(down 1.81 per cent), Adani Ports & Special Economic Zone Ltd.(down 1.27 per cent), Hindalco Industries Ltd.(down 1.12 per cent), Divi's Laboratories Ltd.(down 0.73 per cent) and IndusInd Bank Ltd.(down 0.64 per cent) were among the top losers.",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-83800143,width-1070,height-580,imgsize-287158,overlay-etmarkets/photo.jpg",
            "eventUri": null,
            "sentiment": 0.07450980392156858,
            "wgt": 422603040,
            "relevance": 1
        },
        {
            "uri": "7559395495",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-24",
            "time": "04:37:00",
            "dateTime": "2023-05-24T04:37:00Z",
            "dateTimePub": "2023-05-24T04:36:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://economictimes.indiatimes.com/markets/stocks/stock-watch/share-market-update-most-active-stocks-on-d-street-today-in-terms-of-volume/articleshow/100463623.cms",
            "title": "Share market update: Most active stocks on D-Street today in terms of volume",
            "body": "NEW DELHI: Suzlon Energy(number of shares traded: 8.42 crore), Reliance Power(number of shares traded: 4.85 crore), Indian Railway Fin(number of shares traded: 1.83 crore), Mahindra CIE(number of shares traded: 1.58 crore), TV18 Broadcast(number of shares traded: 1.46 crore), Brightcom Group(number of shares traded: 1.34 crore), Adani Power(number of shares traded: 1.13 crore), Vodafone Idea(number of shares traded: 1.13 crore), JP Power(number of shares traded: 1.06 crore) and Vikas Multicorp(number of shares traded: 0.92 crore) were among the most traded securities on the National Stock Exchange at 09:59AM in Wednesday's session.\n\nThe NSE Nifty index was trading 1.9 points up at 18349.9, while BSE Sensex was up 3.94 points at 61985.73 at the time of writing this report.\n\nIn the Nifty index, Dr. Reddy's Laboratories Ltd.(up 1.40 per cent), Britannia Industries Ltd.(up 0.81 per cent), Apollo Hospitals Enterprise Ltd.(up 0.76 per cent), Maruti Suzuki India Ltd.(up 0.76 per cent) and Tech Mahindra Ltd.(up 0.72 per cent) were among the top gainers.\n\nWhile Hindalco Industries Ltd.(down 0.94 per cent), Adani Ports & Special Economic Zone Ltd.(down 0.61 per cent), ICICI Bank Ltd.(down 0.60 per cent), Housing Development Finance Corporation Ltd.(down 0.56 per cent) and Adani Enterprises Ltd.(down 0.55 per cent) were among the top losers in the index.",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-83769615,width-1070,height-580,imgsize-98874,overlay-etmarkets/photo.jpg",
            "eventUri": null,
            "sentiment": 0.4823529411764707,
            "wgt": 422599020,
            "relevance": 1
        },
        {
            "uri": "7558267719",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-23",
            "time": "12:10:00",
            "dateTime": "2023-05-23T12:10:00Z",
            "dateTimePub": "2023-05-23T10:50:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.indiantelevision.com/mam/marketing/brands/pad-group-launches-its-branded-content-arm-hotcult-230523",
            "title": "PAD Group launches its branded content arm Hotcult",
            "body": "Mumbai: PAD Group, an established & integrated communications agency that is running creative, digital, and production services for brands announces the launch of its branded content venture - Hotcult. Hotcult aims to cultivate culture to produce distinctive human experiences that have a long-lasting influence on behaviour by focusing on culture, consumption, and commerce; its proprietary concept - is 'connecting loculturally'. The company is headquartered in Mumbai with offices in Hyderabad and Bangalore.\n\nHotcult will be positioned as a GLOCUL and LOCUL solutions provider, catering to a diverse country like India, i.e. Bharat, with a deeper understanding and expertise of the cultural landscape. Whether it's through TVCs, short or long-format videos, immersive digital experiences, or authentic influencer collaborations, Hotcult shall enable brands to not just relate but resonate with their target audiences, driving engagement, loyalty, and business growth.\n\nPAD Group CEO and founder Gautam Reddy, commented on the launch, said, \"When it comes to advertising, the one-size-fits-all strategy is slipping to the side-lines. The idea now is to think locally and culturally to ensure that any communication is current and timeless. The changing landscape is a testament to the fact that culture and authentic representation is of utmost importance. Trends and countertrends may come and go, but culture always finds a new shape and form to prevail. Hotcult's expertise lies in bringing out these hidden gems and fusing them with brand strategy in a very symbiotic manner, to create campaigns of great impact.\"\n\nHotcult shall be creatively led by Rupesh Kashyap, known for his culturally nuanced, rooted, and yet contemporary strategies and concepts. He is the writer behind the classic \"Swami-Savithri\" ad film made for Green Plywood in 2005, which became the inspiration for the recently released Malayalam movie \"Nanpakal Nerathu Mayakkam.\" probably the first of its kind where an ad film inspired the plot of a movie. He was instrumental in the launch of Disney Hotstar in South India. In his previous role, he assisted Aha with rebranding and drove the development of the premium service Aha Gold.\n\nElaborating on this, chief content officer Rupesh Kashyap, \"Hotcult, as the name implies, is focused on making brands HOT with culturally nuanced stories. Hotcult will fill a critical gap in the market for creative services of an agency that understands the pulse of Bharat. While the majority of national brands only talk about connecting locally through language, we take a true hyper-local approach with culture, highlighting how 'culture drives consumption' and 'belief drives behaviour'. The idea is to connect with the audience 'loculturally'- whether through retail experiences, product experiences, content, or any other brand experience medium.\"\n\nHotcult, with its extensive expertise, shall combine data-driven insights and innovation with a deep understanding of culture and a relentless focus on delivering exceptional results.\n\nThe agency's commitment to linguistic diversity - Tamil, Telugu, Kannada, Malayalam, Hindi, and English shall ensure that the content reaches and resonates with a wide range of audiences, fostering a sense of belonging and inclusivity.\n\nWith over a decade of experience, PAD has worked with some of the finest national brands across sectors. The agency has serviced over 300 clients, which include Paytm, Dabur, Ecolink by Philips, Dr. Reddy's Laboratories, Shapoorji Pallonji Real Estate, Viacom 18, Mantri, Raheja Mindspace, Holland & Barrett, Grenade India, Ratnadeep Retail, My Home Group, Sri Chaitanya Educational Institutions, Narayana Educational Institutions, Star Maa, Zee Telugu, AHA and many more.",
            "source": {
                "uri": "indiantelevision.com",
                "dataType": "news",
                "title": "Indian Television Dot Com"
            },
            "authors": [
                {
                    "uri": "https@indiantelevision.com",
                    "name": "https",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://www.indiantelevision.com/sites/default/files/images/tv-images/2023/05/23/hotcult-logo.jpg",
            "eventUri": null,
            "sentiment": 0.2627450980392156,
            "wgt": 422539800,
            "relevance": 1
        },
        {
            "uri": "7557837041",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-23",
            "time": "07:42:00",
            "dateTime": "2023-05-23T07:42:00Z",
            "dateTimePub": "2023-05-23T07:35:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.inventiva.co.in/trends/top-biotechnology-companies-in-india/",
            "title": "Top 10 Best Biotechnology Companies In India In 2023 - Inventiva",
            "body": "Biotechnology has become an increasingly important industry in India over the last decade, with a growing number of biotechnology companies now operating in the country. These companies are working to bring innovative products and services to the Indian market, as well as creating jobs and contributing to the nation's economic growth.\n\nIn 2023, the biotechnology industry in India is expected to grow significantly, with a number of new companies entering the market. Many of these companies are focused on developing novel treatments for healthcare-related issues, such as cancer, diabetes, and infectious diseases. Other companies are researching new technologies and products related to agriculture, energy, food, and water.\n\nGovernment initiatives to spur innovation have also helped encourage the growth of the biotechnology industry in India. The startup program 'Startup India' was launched in 2016 to help foster innovation and entrepreneurship in India, providing grants, loans, and other incentives to help startups get off the ground. In addition, the government has offered tax incentives to investors who fund biotechnology companies in the country.\n\nThe biotechnology sector in India is likely to continue to expand in the coming years, with more companies entering the market and existing ones continuing to develop innovative solutions.\n\nIndia is becoming an attractive destination for biotechnology investments due to its large population, highly-skilled talent pool, and favourable government policies. With the right support and resources, India has the potential to become a leader in biotechnology.\n\nIMPORTANCE\n\nBiotechnology is becoming increasingly important in India in 2023. The country has made great strides in biotechnological research and advancements, with a focus on developing new treatments and cures for various diseases.\n\nAdditionally, biotechnological companies are playing an essential role in the development of agricultural technologies to help increase yields and reduce costs for farmers.\n\nFurthermore, biotechnological companies are also exploring ways to use renewable energy sources for generating electricity and providing clean drinking water for people.\n\nThe Indian government has introduced several initiatives in this sector, such as the National Biotech Development Plan, which aims to develop human resources, infrastructure and other aspects of biotechnology.\n\nThis plan has been implemented in many states across India, including Maharashtra, Gujarat, Karnataka, Haryana, Rajasthan and Andhra Pradesh. Moreover, the Government of India has announced that it will invest Rs. 600 billion (US$8.2 billion) during the 12th Five-Year Plan period (2012-2017).\n\nFurthermore, the government has established a number of biotechnology parks in India, which have become hubs for biotechnological research and development. These biotechnology parks have attracted some of the leading biotechnology companies from around the world, including Merck, Pfizer and Biocon.\n\nAdditionally, the government has set up a Biotechnology Industry Research Assistance Council (BIRAC), which provides financial and technical assistance to biotechnology startups and SMEs in India.\n\nAll these steps taken by the government and industry show that biotechnology is becoming a rapidly growing sector in India. Companies can take advantage of the opportunities provided by the Indian market, as well as the availability of funding, infrastructure and skilled manpower.\n\nThis is likely to result in greater investment from foreign companies and further development of biotechnological services in India.\n\nBharat Biotech - Bharat Biotech is an Indian biotechnology company founded in 1996. It is based out of Hyderabad, India and is the largest vaccine manufacturer in the country. It is a public-private partnership between Bharat Biotech International Limited and the Government of India's Department of Biotechnology.\n\nThe company produces vaccines for various diseases such as rotavirus, Japanese encephalitis, cholera, rabies, hepatitis B, influenza, and polio. It has also developed several innovative products such as Typbar Typhoid Conjugate Vaccine (TCV), a world first and the world's first indigenous vaccine for dengue fever - Dengvaxia.\n\nIn addition to vaccines, the company also offers other healthcare products such as diagnostics, drug delivery systems, plasma-derived products, and immunobiological.\n\nBharat Biotech works with several partners around the world in research and development of new products. Through its partnerships, it has developed a number of products, such as the world's first fully human monoclonal antibody and a vaccine for pandemic H1N1 influenza virus.\n\nThrough its manufacturing capabilities, the company serves not only the domestic market but also exports its products to over 80 countries worldwide. It has a state-of-the-art manufacturing facility located at Genome Valley in Hyderabad. The facility follows Good Manufacturing Practices (GMP) and adheres to international regulatory standards.\n\nBharat Biotech has been recognized globally for its innovation and technology leadership. The company has won numerous awards, including the World Health Organization's Award for Selfless Dedication to Global Health, the Prime Minister's Award for Excellence in Public Administration, and the National Entrepreneurship Award. It is also one of the few companies in India to be ISO certified.\n\nReliance Life Sciences - Reliance Life Sciences is a research, development and manufacturing company based in India. Founded in 2002, the company focuses on drug discovery, biotechnology, and active pharmaceutical ingredients.\n\nThe company has a team of experts in fields such as biology, chemistry and engineering. Their offerings include monoclonal antibody technologies, stem cell therapies, gene therapy, vaccine and therapeutic peptide development, and customized drug delivery systems.\n\nReliance Life Sciences covers a wide range of services, from basic research to product development and commercialization. They have the expertise and resources to manage projects through all stages of development efficiently. The company also provides value-added services such as regulatory compliance and marketing.\n\nReliance Life Sciences is committed to providing innovative and cost-effective solutions for their clients. Their goal is to increase access to healthcare services by developing high-quality products that are affordable and accessible to everyone. They strive to make healthcare more accessible and affordable by leveraging their scientific knowledge and cutting-edge technologies.\n\nThe company's research facility is equipped with advanced instruments and equipment, which enables them to develop high-quality products at competitive prices. Reliance Life Sciences has a strong presence in the pharma market, having collaborations and partnerships with renowned institutions across the globe. The company has an impressive portfolio of products that serve both the Indian and global markets.\n\nReliance Life Sciences is dedicated to delivering quality products and making a meaningful impact on people's lives. For this reason, they are committed to ensuring that their products are safe, effective and affordable. They invest in research and development in order to remain at the forefront of the industry and to continue offering innovative solutions.\n\nBiocon - Biocon is a leading biopharmaceutical company based in India. Founded in 1978, the company has grown to become one of Asia's largest and most successful companies in the healthcare sector.\n\nBiocon's core focus is on the development and production of novel biologics, small molecule APIs, and biosimilars for global markets. The company has a strong presence across India, with operations in over 25 countries globally.\n\nIts product portfolio includes therapeutics, insulin, generic API, and biopharmaceuticals for infectious diseases, cancer, diabetes, autoimmunity, and cardiovascular diseases. Biocon employs a wide range of experts in research and development, manufacturing, quality control, sales & marketing, regulatory compliance, and customer service.\n\nThe company is also actively engaged in the fields of contract research and manufacturing services (CRAMS), bio-agriculture, and bio-industrial products. Biocon has a strong commitment to sustainability and environmental responsibility and is committed to making healthcare more accessible and affordable.\n\nAurobindo Pharma - Aurobindo Pharma is an Indian multinational pharmaceutical company headquartered in Hyderabad, Telangana, India. Established in 1986, it manufactures generic drugs and active pharmaceutical ingredients (API).\n\nIt has a presence in over 125 countries and exports to over 200 countries worldwide. The company's product portfolio includes generic formulations, ointments, creams, capsules and tablets. Aurobindo Pharma also has a strong presence in the manufacturing of high-end injectable products and speciality products.\n\nIt is one of the world's leading suppliers of APIs and finished dosage forms. The company has nearly 50 manufacturing facilities, including 5 USFDA-approved and 4 EU GMP-approved plants located in India, the United Kingdom, Ireland, the United States and Brazil.\n\nAurobindo Pharma has a strong research and development infrastructure with a focus on advanced drug delivery systems, new drug entities, complex generics and biosimilars. Its R&D operations are centred around discovering and developing novel molecules, process optimization of existing molecules, formulation development, and analytical method development.\n\nIts innovation agenda focuses on partnering with universities, other institutions, and industry peers to identify sources of new chemical compounds and develop the most effective and efficient means of producing them.\n\nAurobindo Pharma is committed to improving patient care through its products and services while placing great emphasis on its ethical business principles. Its mission is to become a global pharma leader by providing affordable and innovative medicines for healthier lives.\n\nCipla - Cipla is a global pharmaceutical and biotechnology company headquartered in Mumbai, India. Founded in 1935 by Dr. K.A. Hamied, Cipla has become one of the largest pharmaceutical companies in the world, with a presence in over 170 countries worldwide.\n\nCipla produces over 2,500 products, including drugs for cancer, HIV/AIDS, heart disease, diabetes, and other chronic diseases. The company focuses on providing affordable and quality medicines to people around the world. In addition, Cipla also produces over-the-counter (OTC) products, nutraceuticals, and medical devices.\n\nCipla has a strong commitment to research and development and invests heavily in new technologies to ensure that its products are safe and effective. They also strive to provide access to healthcare services to all sectors of society and are committed to both sustainability and social responsibility.\n\nCipla's mission is: \"To bring high-quality and affordable medicines to people across the globe.\"\n\nDr. Reddy's Laboratories - Dr. Reddy's Laboratories is a leading global pharmaceutical company based in India. Founded in 1984 by Dr. Anji Reddy, the company has grown to become one of the largest research-based drug manufacturers in the world.\n\nDr. Reddy's Laboratories specializes in generic drugs and produces over 60 million prescriptions a year for patients around the globe. The company's products are available in over 190 countries, and its portfolio includes medicines for various therapeutic areas such as cardiovascular, diabetes, oncology, dermatology, and gastroenterology.\n\nDr. Reddy's Laboratories has a strong commitment to innovation, investing heavily in R&D with a focus on discovering new molecules. In addition, the company engages in contract manufacturing, biotechnology, and clinical research in order to foster growth and development.\n\nThe company has a large presence in emerging markets, such as India, Russia, and China, as well as operations in Europe, North America, and Japan. Dr. Reddy's Laboratories is committed to providing quality healthcare solutions and making a difference in people's lives through the power of medicine.\n\nPanacea Biotec - Panacea Biotec is a leading biotechnology company based in India. Founded in 1984, the company has grown to become one of the largest healthcare companies in the world.\n\nPanacea specializes in developing and manufacturing innovative pharmaceuticals and biologics for human and animal health. Their product portfolio includes everything from vaccines to generics and diagnostics. They also offer services such as drug discovery, contract research and development, and clinical trials.\n\nPanacea's mission is to improve the quality of life and health of people around the world through pioneering innovation in medical science. To this end, they have consistently invested in state-of-the-art technology, infrastructure and capabilities to meet these goals.\n\nThe company has several research and development centres located across India, as well as overseas in the US, Europe, Latin America, China and Southeast Asia. They employ a highly educated and experienced team of researchers and scientists who are continuously pushing the boundaries of medical science to expand their portfolio of products.\n\nApart from pharmaceuticals, Panacea also provides diagnostic kits, veterinary products and nutraceuticals. The company has also diversified into other areas, such as bioinformatics and biopharmaceuticals. Their efforts have resulted in over 50 products approved by the FDA since its inception.\n\nPanacea continues to focus on improving the quality of healthcare worldwide with an emphasis on developing new therapies and medications to treat disease. In addition to their innovative products, they are also committed to providing educational and community programs to promote health and well-being among communities.\n\nThey strive to build relationships with customers and partners across the globe to ensure that their products reach those in need.\n\nIntas Pharmaceuticals - Intas Pharmaceuticals is a leading global pharmaceutical company based in Ahmedabad, India. Founded in 1973, Intas has grown to become one of the largest players in the global generic pharmaceuticals market, with operations spanning multiple countries.\n\nThe company offers a broad range of quality and affordable medicines and diagnostics across therapeutic areas, including cardiovascular, central nervous system (CNS), metabolic disorders, oncology, pain management, respiratory, skincare, and women's health.\n\nIntas has more than 40 manufacturing facilities across India, Europe, the US, Canada, and Australia that produce over 300 APIs and many generic formulations. In addition, Intas also produces active pharmaceutical ingredients (APIs) for major multinational pharmaceutical companies.\n\nThe main focus of Intas' business model is to manufacture high-quality products at competitive prices and to deliver them on time. To this end, the company employs strict quality control standards for its products and partners with world-class suppliers to ensure the quality and safety of its products.\n\nIntas has consistently invested in R&D to develop new products, technologies, and processes, which allows it to remain at the cutting edge of the industry. Additionally, Intas has an efficient distribution network that enables the company to meet customer demand quickly and reliably.\n\nIntas is focused on providing access to affordable medicines to the public and is actively involved in public health initiatives across the globe. The company works with governments and NGOs to improve access to healthcare for underserved populations.\n\nIntas has also launched several initiatives to support social and economic development, such as educational programs, poverty alleviation programs, and rural healthcare initiatives.\n\nOverall, Intas is committed to improving healthcare access globally by delivering innovative, reliable, and affordable medicines. With its strong commitment to innovation, research, and development, Intas has established itself as a leader in providing quality and affordable medicines to patients around the world.\n\nWockhardt - Wockhardt is a global pharmaceutical and biotechnology company based in India. Founded in 1960 by Habil Khorakiwala, the company operates in more than 30 countries and has a presence in over 5 continents.\n\nWockhardt's portfolio includes therapeutic areas such as cardiovascular, diabetes, gastroenterology, orthopaedics, critical care, ophthalmology and vaccines.\n\nThe company is also engaged in research and development of new drugs and currently has over 50 molecules in its pipeline. Wockhardt's mission is to provide quality healthcare across the globe. The company has manufacturing facilities in India, the UK, Ireland, the USA, France, and Germany.\n\nWockhardt follows stringent standards of quality and safety and is compliant with international standards such as Good Manufacturing Practices (GMP) and Current Good Manufacturing Practices (cGMP). The company has invested heavily in technology and modern equipment to ensure that all its products meet the highest standards of quality.\n\nWockhardt also focuses on sustainability initiatives and actively works towards reducing carbon footprint and promoting green energy. In addition, the company also invests in healthcare infrastructure and education in underserved communities. Wockhardt is committed to providing affordable and accessible healthcare to everyone across the globe.\n\nCONCLUSION\n\nBy 2023, biotechnology companies in India are expected to become leading players in the global market due to the increasing number of investments and collaborations with foreign firms.\n\nThis will be facilitated by the government's initiatives, such as Atmanirbhar Bharat and Make in India, which will focus on promoting innovation and research in this sector. The Indian biotechnology sector is expected to benefit from the growing demand for new and innovative products from the medical, pharmaceutical, agriculture and food industries.\n\nFurthermore, the number of patents related to biotechnology is expected to grow as the government works to protect the intellectual property rights of innovators. As a result, the biotechnology industry in India is set to expand significantly over the next few years.",
            "source": {
                "uri": "inventiva.co.in",
                "dataType": "news",
                "title": "Inventiva"
            },
            "authors": [],
            "image": "https://www.inventiva.co.in/wp-content/uploads/2023/05/biotechnology-examples-types.jpg",
            "eventUri": null,
            "sentiment": 0.4901960784313726,
            "wgt": 422523720,
            "relevance": 75
        },
        {
            "uri": "7557707110",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-23",
            "time": "06:08:00",
            "dateTime": "2023-05-23T06:08:00Z",
            "dateTimePub": "2023-05-23T06:01:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://thenelsonpost.ca/news/265494/biosimilars-industry-see-incredible-growth-2023-2030/",
            "title": "Biosimilars Industry See Incredible Growth 2023-2030",
            "body": "Global Market Vision added an innovative statistical data of 'Global Biosimilars market Recent Trends, In-depth Analysis, Size and Forecast To 2030'. To discover the different aspects of the business, this report uses exploratory techniques, such as primary and secondary research. It provides a valuable source of data, which helps to take complicated decisions in business. The research analyst provides an elaborated description of different verticals of businesses.\n\nSample Report of Biosimilars Market @: https://globalmarketvision.com/sample_request/170422\n\nThe report has analyzed several players in the market, some of which include:\n\nNovartis AG (Switzerland), Pfizer, Inc. (US), Dr. Reddy's Laboratories Ltd. (India), Amgen, Inc. (US), Eli Lilly and Company (US), Teva Pharmaceutical Industries Ltd. (Israel), Fresenius SE & Co. KGaA (Germany), STADA Arzneimittel AG (Germany), Boehringer Ingelheim (Germany), Gedeon Richter PLC (Hungary), Celltrion (South Korea), Samsung Biologics (South Korea), Coherus BioSciences (US), Biocon Limited (India), Viatris, Inc. (US), Amega Biotech (Argentina), Apotex, Inc. (Canada), Biocad (Russia), mAbxience (Spain), Probiomed S.A. De C.V. (Mexico), Fujifilm Kyowa Kirin Biologics Co., Ltd. (Japan), Intas Pharmaceuticals Ltd. (India), Thermex (UK), Reliance Life Sciences (India), Kashiv Biosciences (US)\n\nThe report presents a thorough overview of the competitive landscape of the global Biosimilars Market and the detailed business profiles of the market's notable players. Threats and weaknesses of leading companies are measured by the analysts in the report by using industry-standard tools such as Porter's five force analysis and SWOT analysis. The Biosimilars Market report covers all key parameters such as product innovation, market strategy for leading companies, Biosimilars market share, revenue generation, the latest research and development and market expert perspectives.\n\nBy Product, Monoclonal Antibodies, * Infliximab, * Trastuzumab, * Rituximab, * Adalimumab, * Other monoclonal antibodies (bevacizumab, cetuximab, ranibizumab, denosumab, and eculizumab), Insulin, Granulocyte Colony-Stimulating Factor, Erythropoietin, Recombinant Human Growth Hormone, Etanercept, Follitropin, Teriparatide, Interferons, Enoxaparin Sodium, Glucagon, Calcitonin\n\nBy Application\n\nBy Indication, Oncology, Inflammatory & Autoimmune Disorders, Chronic Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, Other Indications (infertility, hypoglycemia, postmenopausal osteoporosis, chronic kidney failure, and ophthalmic diseases)\n\nBy Geography\n\n{North America (U.S., Canada and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia Pacific (India, China, Japan, South Korea, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest of South America), and Middle East & Africa (GCC, South Africa and Rest of MEA)}\n\nThis report especially focuses on the dynamic view of the Biosimilars market, that can help to manage the outline of the industries. Several analysis tools and standard procedures help to demonstrate the role of different domains in Biosimilars market. The study estimates the factors that are boosting the development of companies.\n\nCOVID-19 put an immediate halt to many business activities across the globe, as several countries had shut down their ports, The industry was affected in several ways due to the pandemic leading to low-scale operations, and eventually, a negative impact on business activities. Over a period, this adversely affected the turnover and revenue.\n\nThis Report Addresses:\n\nThe report provides insights on the following pointers:\n\nMarket Penetration: Comprehensive information on the product portfolios of the top players in the Biosimilars market.\n\nProduct Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.\n\nCompetitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.\n\nMarket Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.\n\nMarket Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Biosimilars market.\n\nAccess Full Report (Access to complete regional report + Data Packs (factbook)+ 6 months analyst support + Downloadable and Printable pdf): https://globalmarketvision.com/checkout/?currency=USD&type=single_user_license&report_id=170422\n\nThe report's conclusion leads into the overall scope of the global market with respect to feasibility of investments in various segments of the market, along with a descriptive passage that outlines the feasibility of new projects that might succeed in the global Biosimilars market in the near future. The report will assist understand the requirements of customers, discover problem areas and possibility to get higher, and help in the basic leadership manner of any organization. It can guarantee the success of your promoting attempt, enables to reveal the client's competition empowering them to be one level ahead and restriction losses.\n\nIf you have any special requirements, please let us know and we will offer you the report at a customized price.\n\nAbout Global Market Vision\n\nGlobal Market Vision consists of an ambitious team of young, experienced people who focus on the details and provide the information as per customer's needs. Information is vital in the business world, and we specialize in disseminating it. Our experts not only have in-depth expertise, but can also create a comprehensive report to help you develop your own business.\n\nWith our reports, you can make important tactical business decisions with the certainty that they are based on accurate and well-founded information. Our experts can dispel any concerns or doubts about our accuracy and help you differentiate between reliable and less reliable reports, reducing the risk of making decisions. We can make your decision-making process more precise and increase the probability of success of your goals.",
            "source": {
                "uri": "thenelsonpost.ca",
                "dataType": "news",
                "title": "Finance BC"
            },
            "authors": [],
            "image": null,
            "eventUri": null,
            "sentiment": 0.1529411764705881,
            "wgt": 422518080,
            "relevance": 51
        },
        {
            "uri": "7555929288",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-22",
            "time": "05:30:00",
            "dateTime": "2023-05-22T05:30:00Z",
            "dateTimePub": "2023-05-22T05:25:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://economictimes.indiatimes.com/markets/stocks/stock-watch/share-market-update-most-active-stocks-on-d-street-today-in-terms-of-volume/articleshow/100410353.cms",
            "title": "Share market update: Most active stocks on D-Street today in terms of volume",
            "body": "NEW DELHI: Zomato(number of shares traded: 4.18 crore), PNB(number of shares traded: 3.59 crore), Suzlon Energy(number of shares traded: 3.01 crore), Brightcom Group(number of shares traded: 3.00 crore), Indian Railway Fin(number of shares traded: 1.67 crore), YES Bank(number of shares traded: 1.55 crore), Vodafone Idea(number of shares traded: 1.41 crore), BEL(number of shares traded: 1.36 crore), Future Consumer (number of shares traded: 1.32 crore) and Adani Ports SEZ(number of shares traded: 1.25 crore) were among the most traded securities on the National Stock Exchange at 10:55AM in Monday's session.\n\nThe NSE Nifty index was trading 82.45 points up at 18285.85, while BSE Sensex was up 191.88 points at 61921.56 at the time of writing this report.\n\nIn the Nifty index, Adani Enterprises Ltd.(up 10.00 per cent), Adani Ports & Special Economic Zone Ltd.(up 8.69 per cent), Divi's Laboratories Ltd.(up 2.48 per cent), Sun Pharmaceutical Industries Ltd.(up 1.73 per cent) and Dr. Reddy's Laboratories Ltd.(up 1.64 per cent) were among the top gainers.\n\nWhile UPL Ltd.(down 0.66 per cent), Eicher Motors Ltd.(down 0.63 per cent), Hindalco Industries Ltd.(down 0.53 per cent), Nestle India Ltd.(down 0.53 per cent) and Tata Consumer Products Ltd.(down 0.50 per cent) were among the top losers in the index.",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-78620279,width-1070,height-580,imgsize-275381,overlay-etmarkets/photo.jpg",
            "eventUri": null,
            "sentiment": 0.4352941176470588,
            "wgt": 422429400,
            "relevance": 1
        },
        {
            "uri": "7553711316",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-20",
            "time": "11:13:00",
            "dateTime": "2023-05-20T11:13:00Z",
            "dateTimePub": "2023-05-20T09:42:00Z",
            "dataType": "news",
            "sim": 0.7411764860153198,
            "url": "https://www.businessworld.in/article/Glenmark-Pharma-Registers-Lower-Q4-Profit-On-Account-Of-One-Off-Expense-/20-05-2023-477340/",
            "title": "Glenmark Pharma Registers Lower Q4 Profit On Account Of One-Off Expense ",
            "body": "Glenmark Pharmaceuticals reported a 12.3 per cent decline in fourth-quarter profit on Friday, hurt by higher input costs and lower demand in its domestic drugs business. Consolidated profit before exceptional items and tax fell to Rs 309 crores for the three months ended March 31, from Rs 352 crores billion a year earlier, the cetirizine maker said in a stock exchange filing.\n\nFor the quarter, the company had reported a one-time expense of Rs 800 crores in settlements of antitrust claims and consumer protection lawsuits in the United States. Glenmark, which caters to therapeutic areas such as diabetes, cardiovascular and oral contraceptives, reported an 11.5 per cent rise in quarterly net sales.\n\nIt included a 6.4 per cent decline in sales from its India drugs segment, which accounted for 31 per cent of total sales, while sales in its North American business, which had a 24 per cent contribution, grew 15.3 per cent.\n\nInput costs for the quarter rose 11 per cent to Rs 877 crores from a year earlier. Shares of the Mumbai-based company settled 3.3 per cent higher at 624.30 rupees ahead of its results on Friday. Glenmark Pharma shares had climbed 9.6 per cent in the March quarter, comfortably outperforming the Nifty Pharma index which fell 4.6 per cent.\n\nGlenmark's consolidated revenue was at Rs. 3,3,73 crore as against Rs 3,019 crore recorded an increase of 11.7 per cent YoY. EBITDA was Rs 605 crores in the quarter ended March 31, 2023, as compared to Rs 463 crores in the previous corresponding quarter, registering growth of 30.5 per cent. EBITDA margin for Q4 FY 2022-23 was 17.9 per cent.\n\nThe company reported a net loss of Rs 403 crores for the quarter ended March 31, 2023, on account of an exceptional loss of Rs 799 crores, primarily on account of settlement of the litigation related to generic Zetia in the U.S.\n\nGlenmark Life Sciences Ltd, the company's unit that spun off in 2019 to focus on the active pharma ingredients business, reported last month a 48 per cent rise in fourth-quarter profit, helped by growth in its core business of making APIs for drugs.\n\nGlenmark's rivals Dr Reddy's Laboratories Ltd and Cipla Ltd earlier in the month had posted higher profits for their fourth quarter.",
            "source": {
                "uri": "businessworld.in",
                "dataType": "news",
                "title": "BW Businessworld"
            },
            "authors": [],
            "image": "https://static.businessworld.in/article/article_extra_large_image/1680012718_dx60WB_wallpaperflare_com_wallpaper.jpg",
            "eventUri": "eng-8637960",
            "sentiment": 0.1607843137254903,
            "wgt": 422277180,
            "relevance": 1
        },
        {
            "uri": "7553461164",
            "lang": "eng",
            "isDuplicate": true,
            "date": "2023-05-20",
            "time": "07:20:00",
            "dateTime": "2023-05-20T07:20:00Z",
            "dateTimePub": "2023-05-20T07:19:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.zawya.com/en/markets/equities/indias-glenmark-pharma-reports-lower-q4-profit-as-domestic-sales-weaken-gyfjiz79",
            "title": "India's Glenmark Pharma reports lower Q4 profit as domestic sales weaken",
            "body": "BENGALURU - India's Glenmark Pharmaceuticals Ltd reported a 12.3% decline in fourth-quarter profit on Friday, hurt by higher input costs and lower demand in its domestic drugs business.\n\nConsolidated profit before exceptional items and tax fell to 3.09 billion rupees ($37.78 million) for the three months ended March 31, from 3.52 billion rupees a year earlier, the cetirizine maker said in a stock exchange filing.\n\nFor the quarter, the company had reported a one-time expense of 8 billion rupees in settlements of antitrust claims and consumer protection lawsuits in the United States.\n\nGlenmark, which caters to the therapeutic areas such as diabetes, cardiovascular and oral contraceptives, reported a 11.5% rise in quarterly net sales.\n\nIt included a 6.4% decline in sales from its India drugs segment, which accounted for 31% of total sales, while sales in its North America business, which had a 24% contribution, grew 15.3%.\n\nInput costs for the quarter rose 11% to 8.77 billion rupees from a year earlier.\n\nShares of the Mumbai-based company settled 3.3% higher at 624.30 rupees ahead of its results on Friday. Glenmark Pharma shares had climbed 9.6% in the March quarter, comfortably outperforming the Nifty Pharma index that fell 4.6%.\n\nGlenmark Life Sciences Ltd, the company's unit that spun off in 2019 to focus on the active pharma ingredients business, reported last month a 48% rise in fourth-quarter profit, helped by growth in its core business of making APIs for drugs.\n\nGlenmark's rivals Dr Reddy's Laboratories Ltd and Cipla Ltd earlier in the month had posted higher profits for their fourth quarter.\n\n($1 = 82.4680 Indian rupees)\n\n(Reporting by Rama Venkat in Bengaluru; Editing by Shweta Agarwal)",
            "source": {
                "uri": "zawya.com",
                "dataType": "news",
                "title": "Zawya.com"
            },
            "authors": [],
            "image": "https://static.zawya.com/view/acePublic/alias/contentid/MjI1Y2NhYTItZTU4OS00/25/210904161711jqss-jpg.jpeg?f=3%3A2",
            "eventUri": null,
            "sentiment": 0.2078431372549019,
            "wgt": 422263200,
            "relevance": 1
        },
        {
            "uri": "7552695836",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-19",
            "time": "16:40:00",
            "dateTime": "2023-05-19T16:40:00Z",
            "dateTimePub": "2023-05-19T16:40:00Z",
            "dataType": "news",
            "sim": 0.545098066329956,
            "url": "https://economictimes.indiatimes.com/markets/stocks/earnings/glenmark-pharma-q4-results-profit-declines-12-3-on-higher-input-costs-and-lower-demand/articleshow/100363040.cms",
            "title": "Glenmark Pharma Q4 Results: Profit declines 12.3% on higher input costs and lower demand",
            "body": "Glenmark Pharmaceuticals' Q4 consolidated profit before exceptional items and tax was INR3.09bn ($37.78m) for the quarter ended 31 March, down 12.3% compared to a year earlier, due to increased input costs and lower demand in the Indian drugs market. The firm posted one-time costs of INR8bn due to settlements over lawsuits in the US related to antitrust issues and consumer protection. While its sales rose 11.5%, the Indian drugs segment reported a 6.4% sales decline, accounting for 31% of its total, while North American sales grew by 15.3%.India's Glenmark Pharmaceuticals Ltd reported a 12.3% decline in fourth-quarter profit on Friday, hurt by higher input costs and lower demand in its domestic drugs business.\n\nConsolidated profit before exceptional items and tax fell to 3.09 billion rupees ($37.78 million) for the three months ended March 31, from 3.52 billion rupees a year earlier, the cetirizine maker said in a stock exchange filing.\n\nFor the quarter, the company had reported a one-time expense of 8 billion rupees in settlements of antitrust claims and consumer protection lawsuits in the United States.\n\nGlenmark, which caters to the therapeutic areas such as diabetes, cardiovascular and oral contraceptives, reported a 11.5% rise in quarterly net sales.\n\nIt included a 6.4% decline in sales from its India drugs segment, which accounted for 31% of total sales, while sales in its North America business, which had a 24% contribution, grew 15.3%.\n\nInput costs for the quarter rose 11% to 8.77 billion rupees from a year earlier.\n\nShares of the Mumbai-based company settled 3.3% higher at 624.30 rupees ahead of its results on Friday. Glenmark Pharma shares had climbed 9.6% in the March quarter, comfortably outperforming the Nifty Pharma index that fell 4.6%.\n\nGlenmark Life Sciences Ltd, the company's unit that spun off in 2019 to focus on the active pharma ingredients business, reported last month a 48% rise in fourth-quarter profit, helped by growth in its core business of making APIs for drugs.\n\nGlenmark's rivals Dr Reddy's Laboratories Ltd and Cipla Ltd earlier in the month had posted higher profits for their fourth quarter",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-100363052,width-1070,height-580,imgsize-40958,overlay-etmarkets/photo.jpg",
            "eventUri": "eng-8629547",
            "sentiment": 0.05098039215686279,
            "wgt": 422210400,
            "relevance": 1
        },
        {
            "uri": "7552573227",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-19",
            "time": "15:11:00",
            "dateTime": "2023-05-19T15:11:00Z",
            "dateTimePub": "2023-05-19T15:06:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.finanznachrichten.de/nachrichten-2023-05/59135626-fnf-research-usd-306-2-billion-growth-in-active-pharmaceutical-ingredients-market-size-industry-analysis-market-trends-market-growth-opportuniti-008.htm",
            "title": "FnF Research: USD 306.2 Billion Growth in Active Pharmaceutical Ingredients Market Size - Industry Analysis, Market Trends, Market Growth, Opportunities",
            "body": "NEW YORK, May 19, 2023 /PRNewswire/ -- As per Facts and Factors study, the global active pharmaceutical ingredients market size was worth around USD 191.3 billion in 2022 and is predicted to grow to around USD 306.2 billion by 2030 with a compound annual growth rate (CAGR) of roughly 4.7% between 2023 and 2030.\n\nReport Link with All Related Graphs & Charts: https://www.fnfresearch.com/active-pharmaceutical-ingredient-market\n\nActive Pharmaceutical Ingredients Market: Overview\n\nThe market, also known as the API market, refers to the activities surrounding the production and sales of chemical compounds that are used in the process of pharmaceutical drug production. The ingredients are medication components used to produce desired therapeutic results and are biologically active. The industry is one of the crucial segments of the larger pharmaceutical sector as these ingredients form integral components during the process of safe and effective drug production.\n\nGet a Free Sample Report with All Related Graphs & Charts (with COVID 19 Impact Analysis): https://www.fnfresearch.com/sample/active-pharmaceutical-ingredient-market\n\nKey Insights:\n\nAs per the analysis shared by our research analyst, the global active pharmaceutical ingredients market is estimated to grow annually at a CAGR of around 4.7% over the forecast period (2022-2030)In terms of revenue, the global active pharmaceutical ingredients market size was valued at around USD 191.3 billion in 2022 and is projected to reach USD 306.2 billion, by 2030.The market is projected to grow at a significant rate due to the growing demand for effective drugsBased on the type of manufacturer segmentation, the capital was predicted to show maximum market share in the year 2022Based on type segmentation, generic active pharmaceutical ingredients was the leading type in 2022On the basis of region, Asia-Pacific was the leading revenue generator in 2022\n\nFacts and Factors published the latest report titled \"Active Pharmaceutical Ingredients Market Size, Share, Growth Analysis Report By Type (Generic Active Pharmaceutical Ingredients and Innovative Active Pharmaceutical Ingredients), By Molecule (Large and Small), By Type of Manufacturer (Merchant and Capital), By Indications (Saxagliptin, Enoxaparin Sodium, Tamoxifen, Acetaminophen, Artemisinin, Ibuprofen Losartan Potassium, Naproxen, Sodium Chloride, Rufinamide, and Others), and By Region - Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2023 - 2030\" into their research database.\n\nIndustry Dynamics:\n\nGlobal Active Pharmaceutical Ingredients Market: Growth Drivers\n\nGrowing demand for effective drugs to propel market demand.\n\nThe global active pharmaceutical ingredients market is projected to grow owing to the increasing demand for effective drugs due to several factors. One of the crucial reasons is the increasing number of people suffering from a range of medical conditions. The population is prone to suffering from generic conditions like cold, fever, headache, and others while there is a growing segment that suffers from more serious medical conditions like cancer, arthritis, cardiovascular diseases, and diabetes to name a few. Furthermore, with an increasing diagnosis of people contracting mental health conditions like anxiety and depression due to several socio-economic-political factors increasing at a rapid rate.\n\nGlobal Active Pharmaceutical Ingredients Market: Restraints\n\nCost pressure to restrict the market growth.\n\nOne of the key growth restraints in the global industry is the cost pressure that is associated with the production of APIs and their distribution. The rising price of raw materials impacted by changing political tension and dynamics along with the significant cost attributed to the requirement of intense research and study to develop effective APIs and meet regulatory compliances are factors that can potentially limit the growth trajectory of the industry.\n\nDirectly Purchase a Copy of the Report @ https://www.fnfresearch.com/buynow/su/active-pharmaceutical-ingredient-market\n\nActive Pharmaceutical Ingredients Market: Opportunities\n\nGrowing demand for personalized medicines to provide growth opportunities.\n\nThe global industry players can benefit from the rising demand for personalized medicines across the globe. Factors that are contributing to the customization of medicines include the increasing prevalence of complex diseases, advancements in molecular biology and genomics, the cost-effectiveness of personalized medicines, the increasing availability of health data, and patient empowerment.\n\nActive Pharmaceutical Ingredients Market: Challenges\n\nConcerns over intellectual property rights to challenge market growth.\n\nThe market struggles with maintaining momentum in terms of innovation and competition due to the protection of intellectual rights undertaken by industry players. This can potentially limit the availability of affordable APIs in the pharmaceutical industry leading to a large segment of the population outside the consumer group.\n\nFurthermore, growing concerns over the availability of poor-quality products due to the absence of laws for reinforcing regulatory procedures could impact the trust of the stakeholders which can create multiple challenges during the projection period.\n\nGlobal Active Pharmaceutical Ingredients Market: Segmentation\n\nThe global active pharmaceutical ingredients market is segmented based on type, molecule, type of manufacturer, indications, and region.\n\nBased on type, the global market segments are generic active pharmaceutical ingredients and innovative active pharmaceutical ingredients\n\nAlthough both segments are crucial for overall market growth, the revenue size for generic APIs is more than innovative segmentThe major factors driving the segmental growth are increasing demand for affordable healthcare and the generally low prices of generic medicines as compared to the counterpartsInnovative APIs are new biologics or drugs and are developed through extensive research and development programs. These APIs are protected against infringement with the help of patents causing the producer to charge higher pricesAs per a 2019 study by the IQVIA Institute for Human Data Science, generic medicines in the US were recorded to be 94% less in cost as compared to innovative medicines\n\nBased on the molecule, the global market divisions are large and small.\n\nBased on the type of manufacturer, the global market segments are merchant and capital.\n\nBoth capital and merchant segments can lead the market depending on several factorsHowever, in 2022, the industry was dominated by the capital segmentIn most cases, APIs are developed by capital-intensive players like Teva Pharmaceuticals, Pfizer, and otherSince research & development of APIs is expensive and required advanced resources, it is generally the large companies that play an extensive role in the development of new APIsIn 2020, Teva Pharmaceuticals generated over USD 16.5 billion in revenue\n\nBased on indications, the global market is divided into saxagliptin, enoxaparin sodium, tamoxifen, acetaminophen, artemisinin, ibuprofen, losartan potassium, naproxen, sodium chloride, rufinamide, and others.\n\nGet More Insight before Buying@: https://www.fnfresearch.com/inquiry/active-pharmaceutical-ingredient-market\n\nList of Key Players in Active Pharmaceutical Ingredients Market:\n\nÂ· F. Hoffmann-La Roche Ltd.\n\nTeva Pharmaceutical Industries LtdBoehringer IngelheimSanofiMylan N.V.Pfizer Inc.Bristol-Myers SquibbNovartis International AGSun Pharmaceutical Industries Ltd.Aurobindo PharmaCambrex CorporationDr. Reddy's LaboratoriesAbbVie Inc.Cipla LimitedBASF SEGlaxoSmithKline plcMerch & CoLonza GroupDaiichi Sankyo Company Limited.\n\nKey questions answered in this report:\n\nWhat are the growth rate forecast and market size for Active Pharmaceutical Ingredients Market?What are the key driving factors propelling the Active Pharmaceutical Ingredients Market forward?What are the most important companies in the Active Pharmaceutical Ingredients Market Industry?What segments does the Active Pharmaceutical Ingredients Market cover?How can I receive a free copy of the Active Pharmaceutical Ingredients Market sample report and company profiles?\n\nReport Scope:\n\nReport Attribute\n\nDetails\n\nMarket size value in 2022\n\nUSD 191.3 Billion\n\nRevenue forecast in 2030\n\nUSD 306.2 Billion n\n\nGrowth Rate\n\nCAGR of almost 4.7% 2023-2030\n\nBase Year\n\n2022\n\nHistoric Years\n\n2016 - 2021\n\nForecast Years\n\n2023-2030\n\nSegments Covered\n\nBy Type, Molecule, Type of Manufacturer, Indications, and Region\n\nForecast Units\n\nValue (USD Billion), and Volume (Units)\n\nQuantitative Units\n\nRevenue in USD million/billion and CAGR from 2023 to 2030\n\nRegions Covered\n\nNorth America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World\n\nCountries Covered\n\nU.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others\n\nCompanies Covered\n\nF. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim, Sanofi, Mylan N.V., Pfizer Inc., Bristol-Myers Squibb, Novartis International AG, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Cambrex Corporation, Dr. Reddy's Laboratories, AbbVie Inc., Cipla Limited, BASF SE, GlaxoSmithKline plc, Merch & Co, Lonza Group, Daiichi Sankyo Company Limited, and others.\n\nReport Coverage\n\nMarket growth drivers, restraints, opportunities, Porter's five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.\n\nCustomization Scope\n\nAvail of customized purchase options to meet your exact research needs.\n\nhttps://www.fnfresearch.com/customization/active-pharmaceutical-ingredient-market\n\nFree Brochure: https://www.fnfresearch.com/ask-to-analyst/active-pharmaceutical-ingredient-market\n\nRegional Dominance:\n\nAsia-Pacific to witness the highest growth.\n\nThe global active pharmaceutical ingredients market is projected to witness the highest growth in Asia-Pacific during the projection period as it is currently the most dominant region in the industry. The growth is led by countries like China and India which are witnessing tremendous growth in the production of APIs due to several factors. The countries boast of a well-established pharmaceutical sector especially in the manufacturing wing since they are home to large-scale production sites with a client base from across the globe.\n\nFurthermore, the regional governments have amped up their efforts to promote the industry even higher and reduce import dependence on medicines from international countries. Additionally, India and China have a large pool of skilled professionals along with supportive governmental regulations for the production of APIs. Europe and North America are also important contributors due to the growing research and product innovation activities.\n\nGlobal Active Pharmaceutical Ingredients Market is segmented as follows:\n\nActive Pharmaceutical Ingredients Market: By Type Outlook (2023-2030)\n\nGeneric Active Pharmaceutical IngredientsInnovative Active Pharmaceutical Ingredients\n\nActive Pharmaceutical Ingredients Market: By Molecule Outlook (2023-2030)\n\nLargeSmall\n\nActive Pharmaceutical Ingredients Market: By Type of Manufacturer Outlook (2023-2030)\n\nMerchantCapital\n\nActive Pharmaceutical Ingredients Market: By Indications Outlook (2023-2030)\n\nSaxagliptinEnoxaparin SodiumTamoxifenAcetaminophenArtemisininIbuprofen Losartan PotassiumNaproxenSodium ChlorideRufinamideOthers\n\nActive Pharmaceutical Ingredients Market: By Region Outlook (2023-2030)\n\nNorth America\n\nThe U.S.Canada\n\nEurope\n\nFranceThe UKSpainGermanyItalyRest of Europe\n\nAsia Pacific\n\nChinaJapanIndiaSouth KoreaSoutheast AsiaRest of Asia Pacific\n\nLatin America\n\nBrazilMexicoRest of Latin America\n\nMiddle East & Africa\n\nGCCSouth AfricaRest of Middle East & Africa\n\nPress Release: https://www.fnfresearch.com/news/global-active-pharmaceutical-ingredients-market\n\nBrowse Other Related Research Reports from Facts and Factors\n\nRheumatoid Arthritis Drugs Market: According to the report published by Facts and Factors, the global rheumatoid arthritis drugs market size was worth around USD 60.1 billion in 2021 and is predicted to grow to around USD 70.1 billion by 2030 with a compound annual growth rate (CAGR) of roughly 1.75% between 2022 and 2030.Pneumococcal Vaccine Market: According to the report published by Facts Factors, the global pneumococcal vaccine market size was worth around USD 8.57 billion in 2021 and is predicted to grow to around USD 12 billion by 2030 with a compound annual growth rate (CAGR) of roughly 5.34% between 2022 and 2030.Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: According to the report published by Facts Factors, the global chimeric antigen receptor (CAR) T-Cell therapy market size was worth around USD 1.69 billion in 2021 and is predicted to grow to around USD 6 billion by 2030 with a compound annual growth rate (CAGR) of roughly 13.49% between 2022 and 2030.Anticoagulant Drugs Market: According to the report published by Facts Factors, the global Anticoagulant Drugs market size was worth around USD 36.5 billion in 2021 and is predicted to grow to around USD 68.9 billion by 2028 with a compound annual growth rate (CAGR) of roughly 9.5% between 2022 and 2028.Spirulina Market: According to the report published by Facts Factors, the global spirulina market size was worth around USD 410.2 million in 2021 and is predicted to grow to around USD 989.6 million by 2028 with a compound annual growth rate (CAGR) of roughly 11.1% between 2022 and 2028.\n\nBrowse through Facts and Factors's coverage of the Global Pharmaceuticals Industry\n\nFollow Us on: LinkedIn | Twitter | Facebook\n\nAbout Us\n\nFacts and Factors is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, and company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client's needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us-after all-if you do well, a little of the light shines on us.\n\nContact Us:\n\nFacts and Factors\n\nTel: +1 347 690-0211\n\nUSA/Canada Toll-Free No. +44 2032 894158\n\nEmail: sales@fnfresearch.com\n\nWebsite: https://www.fnfresearch.com/\n\nLogo: https://mma.prnewswire.com/media/1981423/FnF_Research_Logo.jpg\n\nView original content:https://www.prnewswire.co.uk/news-releases/usd-306-2-billion-growth-in-active-pharmaceutical-ingredients-market-size---industry-analysis-market-trends-market-growth-opportunities-301829516.html\n\nKostenloser Report: +40% Gewinn nur mit Aktien!+39,93% Rendite seit Januar -- so lautet die Erfolgsbilanz der Aktie der Woche. Damit wurden sowohl der DAX als auch der S&P 500 deutlich outperformt. Wie das genau funktioniert, erklÃ¤rt Chefradakteur Lars WiÃŸler in seiner Zwischenbilanz.Hier klicken",
            "source": {
                "uri": "finanznachrichten.de",
                "dataType": "news",
                "title": "FinanzNachrichten.de"
            },
            "authors": [],
            "image": "https://rt.prnewswire.com/rt.gif?NewsItemId=EN05748&Transmission_Id=202305191100PR_NEWS_EURO_ND__EN05748&DateId=20230519",
            "eventUri": null,
            "sentiment": 0.6705882352941177,
            "wgt": 422205060,
            "relevance": 1
        },
        {
            "uri": "7552545078",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-19",
            "time": "14:51:00",
            "dateTime": "2023-05-19T14:51:00Z",
            "dateTimePub": "2023-05-19T14:47:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.marketscreener.com//quote/stock/GLENMARK-PHARMACEUTICALS-9058934/news/India-s-Glenmark-Pharma-reports-lower-Q4-profit-as-domestic-sales-weaken-43903641/",
            "title": "India's Glenmark Pharma reports lower Q4 profit as domestic sales weaken | MarketScreener",
            "body": "BENGALURU (Reuters) - India's Glenmark Pharmaceuticals Ltd reported a 12.3% decline in fourth-quarter profit on Friday, hurt by higher input costs and lower demand in its domestic drugs business.\n\nConsolidated profit before exceptional items and tax fell to 3.09 billion rupees ($37.78 million) for the three months ended March 31, from 3.52 billion rupees a year earlier, the cetirizine maker said in a stock exchange filing.\n\nFor the quarter, the company had reported a one-time expense of 8 billion rupees in settlements of antitrust claims and consumer protection lawsuits in the United States.\n\nGlenmark, which caters to the therapeutic areas such as diabetes, cardiovascular and oral contraceptives, reported a 11.5% rise in quarterly net sales.\n\nIt included a 6.4% decline in sales from its India drugs segment, which accounted for 31% of total sales, while sales in its North America business, which had a 24% contribution, grew 15.3%.\n\nInput costs for the quarter rose 11% to 8.77 billion rupees from a year earlier.\n\nShares of the Mumbai-based company settled 3.3% higher at 624.30 rupees ahead of its results on Friday. Glenmark Pharma shares had climbed 9.6% in the March quarter, comfortably outperforming the Nifty Pharma index that fell 4.6%.\n\nGlenmark Life Sciences Ltd, the company's unit that spun off in 2019 to focus on the active pharma ingredients business, reported last month a 48% rise in fourth-quarter profit, helped by growth in its core business of making APIs for drugs.\n\nGlenmark's rivals Dr Reddy's Laboratories Ltd and Cipla Ltd earlier in the month had posted higher profits for their fourth quarter.\n\n($1 = 82.4680 Indian rupees)\n\n(Reporting by Rama Venkat in Bengaluru; Editing by Shweta Agarwal)",
            "source": {
                "uri": "marketscreener.com",
                "dataType": "news",
                "title": "Market Screener"
            },
            "authors": [],
            "image": null,
            "eventUri": null,
            "sentiment": 0.2078431372549019,
            "wgt": 422203860,
            "relevance": 1
        },
        {
            "uri": "7551989417",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-19",
            "time": "08:51:00",
            "dateTime": "2023-05-19T08:51:00Z",
            "dateTimePub": "2023-05-19T08:28:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://economictimes.indiatimes.com/markets/stocks/recos/hold-dr-reddys-laboratories-target-price-rs-5100-sharekhan-by-bnp-paribas/articleshow/100351716.cms",
            "title": "Hold Dr. Reddy's Laboratories, target price Rs 5100:  Sharekhan by BNP Paribas ",
            "body": "Dr. Reddy's Laboratories, incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 73305.57 Crore) operating in Pharmaceuticals sector.Sharekhan by BNP Paribas has hold call on Dr. Reddy's Laboratories with a target price of Rs 5100. The current market price of Dr. Reddy's Laboratories is Rs 4387.85.\n\nDr. Reddy's Laboratories, incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 73305.57 Crore) operating in Pharmaceuticals sector.\n\nDr. Reddy's Laboratories key Products/Revenue Segments include Pharmaceuticals, Licence Fees, Other Operating Revenue, Spent Chemicals, Service Income and Scrap for the year ending 31-Mar-2022.\n\nFinancials\n\nFor the quarter ended 31-03-2023, the company has reported a Consolidated Total Income of Rs 6453.70 Crore, down -5.76 % from last quarter Total Income of Rs 6848.50 Crore and up 15.31 % from last year same quarter Total Income of Rs 5596.80 Crore. Company has reported net profit after tax of Rs 952.50 Crore in latest quarter.\n\nThe company's top management includes Mr.K Satish Reddy, Mr.G V Prasad, Mr.Leo Puri, Mr.Prasad R Menon, Ms.Shikha Sharma, Mr.Allan Oberman, Ms.Kalpana Morparia, Mr.Sridar Iyengar, Mr.Arun Madhavan Kumar. Company has S R Batliboi & Associates LLP as its auditors. As on 31-03-2023, the company has a total of 17 Crore shares outstanding.\n\nInvestment Rationale\n\nThe brokerage expects it to clock in ~ 6.3% and ~9.1% CAGR rise in revenue and net income, respectively, over FY23-FY25E. At CMP, the stock trades at ~15.3x/14.3x it's FY24E/FY25E.\n\nFurthermore, Sharekhan downgrades it to HOLD with a revised PT of Rs. 5,100 though. The brokerage values it at a lower multiple than before and downgrade it to HOLD to factor in the uncertainty surrounding impact of gRevlimid on its profitability, going forward, given loss of exclusivity on 2.5 and 20.0 mg strengths of it by the end of Q4FY23.\n\nPromoter/FII Holdings\n\nPromoters held 26.7 per cent stake in the company as of 31-Mar-2023, while FIIs owned 27.25 per cent, DIIs 23.03 per cent.",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-100351783,width-1070,height-580,imgsize-921756,overlay-etmarkets/photo.jpg",
            "eventUri": null,
            "sentiment": 0.1686274509803922,
            "wgt": 422182260,
            "relevance": 100
        },
        {
            "uri": "7551484745",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-19",
            "time": "01:17:00",
            "dateTime": "2023-05-19T01:17:00Z",
            "dateTimePub": "2023-05-19T01:15:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.moneycontrol.com/news/business/stocks/buy-eris-lifesciences-target-of-rs-720-motilal-oswal-10615941.html",
            "title": "Buy Eris Lifesciences; target of Rs 720: Motilal Oswal",
            "body": "Eris Lifesciences (ERIS) delivered in-line 4QFY23, led by steady growth in base business and improved performance of Oaknet as well as insulin franchise. Besides, addition of complimentary brands in medical/cosmetic dermatology from Glenmark Pharma and Dr. Reddy's Lab is expected to enhance derma offerings going forward. We retain our earnings estimates for FY24/FY25 and value ERIS at 19x 12M forward earnings to arrive at our TP of INR720. We remain positive on ERIS aided by its: a) robust portfolio offerings in antidiabetes, cardiovascular and dermatology segments through organic as well as inorganic route, b) field force addition, which would expand coverage of specialist/consulting physicians, and c) improving operating leverage. Reiterate BUY.\n\nOutlook\n\nWe retain our earnings estimates for FY24/FY25 and value ERIS at 19x 12M forward earnings to arrive at our TP of INR720.\n\nFor all recommendations report, click here\n\nDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.",
            "source": {
                "uri": "moneycontrol.com",
                "dataType": "news",
                "title": "MoneyControl"
            },
            "authors": [],
            "image": "https://images.moneycontrol.com/static-mcnews/2022/10/Buy-378x213.png",
            "eventUri": null,
            "sentiment": 0.3490196078431373,
            "wgt": 422155020,
            "relevance": 51
        },
        {
            "uri": "7551091133",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-18",
            "time": "18:12:00",
            "dateTime": "2023-05-18T18:12:00Z",
            "dateTimePub": "2023-05-18T18:08:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.goodreturns.in/personal-finance/investment/motilal-oswal-initiates-buy-on-midcap-pharma-stock-sees-15-potential-upside-1283809.html",
            "title": "Motilal Oswal Initiates Buy On Midcap Pharma Stock, Sees 15% Potential Upside",
            "body": "For Quick Alerts Subscribe Now Stay updated with all the happenings around the globe. Click here View Sample For Quick Alerts ALLOW NOTIFICATIONS For Daily Alerts Just In 26 min ago Midcap Chemicals Stock With 355% Return In 3 Yrs Recommends Rs 30/Share Dividend, Check Details 31 min ago Zydus Lifesciences Q4: Consolidated Net Profit Falls 25%, Recommends Dividend 36 min ago IndiGo Soars With Record-Breaking Fourth-Quarter Net Profit Of Rs 919 Crore 43 min ago 4 Stocks From Discretionary Consumption Space That Can Jump Upto 31% Don't Miss Sports Virat Kohli Smashes Sixth Hundred, Goes Level With Chris Gayle For Most Centuries in IPL History News PM Modi To Inaugurate New Parliament Building On May 28 Movies Cannes 2023 Diary Day 3: Aishwarya Rai's Jalwa At Cannes Red Carpet! Woos Fans With Oversize White Cape Automobiles 2023 Volkswagen Tiguan Launched At Rs 34.69 Lakh Lifestyle Benefits Of Drinking Garlic Water On An Empty Stomach; Is It Good For Cholesterol? Travel Couples Call Kodaikanal An Exotic Destination But, Is It Worth Visiting? Find Out Here! Technology Samsung Galaxy F54 5G Specifications and Indian Price Tipped: Not A Threat To Redmi Note 12 And Others? Education NID MDes Mains Result 2023 Declared; Check Out for more Details Home Personal finance Investment Motilal Oswal Initiates Buy On Midcap Pharma Stock, Sees 15% Potential Upside Investment oi-Shubham Kumar By Shubham Kumar | Published: Thursday, May 18, 2023, 23:38 [IST]\n\nLeading broking firm Motilal Oswal reiterate Buy on Eris Lifesciences Ltd., a midcap Pharma sector firm. The brokerage assigns a target price of Rs. 720/share on the stock, claiming an upside of 15% from its current level. The company is engaged in the business of manufacturing and marketing of pharmaceutical products. It has a market capitalisation of Rs. 8,555.86 crore.\n\nOn track to improve profitability of inorganic opportunities\n\nAccording to Motilal Oswal, Eris Lifesciences (ERIS) delivered in-line 4QFY23, led by steady growth in base business and improved performance of Oaknet as well as insulin franchise. Besides, addition of complimentary brands in medical/cosmetic dermatology from Glenmark Pharma and Dr. Reddy's Lab is expected to enhance derma offerings going forward.\n\nBuy for a atrget price of Rs. 720/share\n\nMotilal Oswa, said, \"We retain our earnings estimates for FY24/FY25 and value ERIS at 19x 12M forward earnings to arrive at our TP of INR720. We remain positive on ERIS aided by its: a) robust portfolio offerings in antidiabetes, cardiovascular and dermatology segments through organic as well as inorganic route, b) field force addition, which would expand coverage of specialist/consulting physicians, and c) improving operating leverage. Reiterate BUY.\"\n\nStock Overview\n\nThe stock's last traded share price on NSE is Rs. 629.15/share, down 1.18% from its previous close. The stock traded its 52 week high at Rs. 749.80/share and 52 week low at Rs. 551.30/share, respectively.\n\nIn the past week, it declined 1.55%, whereas it jumped 1,.36% in 1 month. It declined 10.36% in 1 year. In 3 years it jumped 31.79%. It has fallen 19.37% in 5 years.\n\nDisclaimer - The stock has been picked from the brokerage report of Motilal Oswal. Greynium Information Technologies, the Author, and the respective Brokerage house are not liable for any losses caused as a result of decisions based on the article. Goodreturns.in advises users to consult with certified experts before making any investment decision.\n\nMORE ERIS LIFESCIENCES NEWS Midcap Pharma Stock Hits New 52-Week Low, Shares Can Surge 38%, Buy, Says Prabhudas Lilladher Motilal Oswal Picks 2 Stocks To Buy For Higher Return, Both Hit 52-Week Low Today 3 Stocks That Can Rally Up To 63%: Motilal Oswal Recommends Best Stocks To Buy Motilal Oswal Assigns Buy On 11 Stocks From Healthcare Sector, Sees Robust Gains In 2023 Motilal Oswal Tuesday Stock Ideas: Buy 5 Mid Cap, Small Cap Stocks To Get Up To 46% Return Buy This Small Cap Pharma Stock, Revenue Grew 28% YoY, Shares Can Surge 17%: Prabhudas Lilladher Buy This Pharma Stock For A Target Price Of Rs 870 Offering 735% Dividend; Turning Ex-Dividend Soon 'Buy' This Pharma Stock For 18% Gains In Short Term Suggests ICICI Direct Midcap Chemicals Stock With 355% Return In 3 Yrs Recommends Rs 30/Share Dividend, Check Details HDFC Securities Places Buy Call On Midcap Real Estate Stock, Sees 32% Robust Upside Auto Ancillary Stock Hits 52-Week High, Board Recommends Dividend, Gets Buy Rating For 25% Gains Oil Sector PSU Stock To Buy, Likely To Give Up To 22% Return, Says ICICI Securities For investment related articles, business news and mutual fund advise Allow Notifications You have already subscribed Story first published: Thursday, May 18, 2023, 23:38 [IST] Other articles published on May 18, 2023",
            "source": {
                "uri": "goodreturns.in",
                "dataType": "news",
                "title": "https://www.goodreturns.in/"
            },
            "authors": [
                {
                    "uri": "shubham_kumar@goodreturns.in",
                    "name": "Shubham Kumar",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://www.goodreturns.in/img/2021/09/stocks-word-from-wooden-blocks-with-letters-sorry-concept-yellow-background-384017-185-1631086111.jpg?18052023234208",
            "eventUri": null,
            "sentiment": 0.1764705882352942,
            "wgt": 422129520,
            "relevance": 26
        },
        {
            "uri": "7551070835",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-18",
            "time": "17:55:00",
            "dateTime": "2023-05-18T17:55:00Z",
            "dateTimePub": "2023-05-18T17:55:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.moneycontrol.com/news/business/stocks/hold-dr-reddys-laboratories-target-of-rs-5100-sharekhan-10617671.html",
            "title": "Hold Dr. Reddy's Laboratories; target of Rs 5100: Sharekhan",
            "body": "For Q4FY23, Dr. Reddy's Laboratories' (DRL's) profitability was augmented by proceeds from divestment of a few non-core brands amounting to Rs. 494.1 crore; this was included in reported revenue. Normalized net income rose ~27.9% y-o-y to ~ Rs. 550 crore, excluding brand divestment-related income, while reported net profits increased ~ 889.8% y-o-y to Rs. 960.1 crore in Q4FY23. Core EBITDA margins excluding other non-operating income and unusual gains and impairment costs fell by ~ 165 bps y-o-y to ~ 18.8% in Q4FY23. Reported EBITDA margins rose ~ 156 bps y-o-y to 25.1%.\n\nOutlook\n\nStock trades at ~ 15.3x/14.3x its FY2024E/25E EPS estimates. We downgrade it to Hold from Buy with a revised PT of Rs. 5,100, using lower multiples than before to factor in uncertainty on impact of loss of exclusivity for gRevlimid's 2.5 and 20.0 mg strengths on the profitability, going forward.\n\nFor all recommendations report, click here\n\nDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.",
            "source": {
                "uri": "moneycontrol.com",
                "dataType": "news",
                "title": "MoneyControl"
            },
            "authors": [],
            "image": "https://images.moneycontrol.com/static-mcnews/2022/10/hold-2.jpg",
            "eventUri": null,
            "sentiment": 0.0980392156862746,
            "wgt": 422128500,
            "relevance": 51
        },
        {
            "uri": "7549863912",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-18",
            "time": "03:27:00",
            "dateTime": "2023-05-18T03:27:00Z",
            "dateTimePub": "2023-05-18T03:24:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://thenelsonpost.ca/news/297701/nateglinide-industry-2023-scope-of-current-and-future-market-2030/",
            "title": "Nateglinide Industry 2023 | Scope of Current and Future Market 2030",
            "body": "Nateglinide Market Status, Trends and COVID-19 Impact Report 2023, Covid 19 Outbreak Impact research report added by Global Market Vision, is an in-depth analysis of market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends, and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider Nateglinide Market, and compares it with other markets., market definition, regional market opportunity, sales and revenue by region, manufacturing cost analysis, Industrial Chain, market effect factors analysis, Nateglinide market size forecast, market data & Graphs and Statistics, Tables, Bar &Pie Charts, and many more for business intelligence.\n\nGet a Sample Copy of this report with the latest Industry trends and COVID-19 Impact @ https://globalmarketvision.com/sample_request/252282\n\nThe major players covered in Nateglinide Market:\n\nAvKARE, Inc., Dr. Reddy's Laboratories Limited, Wilshire Pharmaceuticals, Inc., American Health Packaging, Actavis Pharma, Inc., Avera McKennan Hospital, Nivagen Pharmaceuticals, Inc., Caremark L.L.C., Novartis Europharm Limited, Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc., Par Pharmaceutical, Inc.\n\nDecreased Blood GlucoseDiabetesHyperglycemiaType 2 Diabetes MellitusDecreased Weight\n\nMarket Segmentation: By Application\n\nOnline PharmaciesHospital PharmaciesRetail Pharmacies\n\nThe regional analysis section of the report allows players to concentrate on high-growth regions and countries that could help them to expand their presence in the Nateglinide market. Apart from extending their footprint in the Nateglinide market, the regional analysis helps players to increase their sales while having a better understanding of customer behavior in specific regions and countries. The report provides CAGR, revenue, production, consumption, and other important statistics and figures related to the global as well as regional markets. It shows how different type, application, and regional segments are progressing in the Nateglinide market in terms of growth.\n\nOur report contains current and latest market trends, market shares of companies, market forecasts, competition benchmarking, competition mapping and an in-depth analysis of the most important sustainability tactics and their impact on market growth and competition. To estimate quantitative aspects and segment the global Nateglinide market, we used a recommended combination of top-down and bottom-up approaches. We examined the global Nateglinide market from three key perspectives through data triangulation. Our iterative and comprehensive research methodology helps us to provide the most accurate market forecasts and estimates with minimal errors.\n\nReport covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Nateglinide Market in 2023.\n\nThe outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.\n\nKey Insights That Study Is Going to Provide:\n\nThe following aspects are given with full analysis from the Nateglinide market research reports:\n\nProduction Analysis - The beginning of this Nateglinide is examined based on the most important countries, types, and applications. The pricing analysis of various Nateglinide market main players will be completely covered in this study.\n\nProfit and Sales Analysis - Earnings and sales for key components of the international Nateglinide market are validated. Another important factor, price, which has a significant impact on sales growth, can be evaluated in this section for many regions.\n\nSegments and Benefits -- Continuing with the profits theme, this paper examines the design and ingestion of its Nateglinide market. The differences between usage and supply, export and import data are also highlighted in this research.\n\nMany global Nateglinide industry - leading players have been evaluated in this area based on their company profile, product portfolio, ability, pricing, cost, and revenue.\n\nOther Analysis - In addition to the foregoing data, demand, and supply analysis for the Nateglinide economy, contact information for significant producers, suppliers, and consumers can be assigned.\n\nBuy Exclusive Report @ https://globalmarketvision.com/checkout/?currency=USD&type=single_user_license&report_id=252282\n\nIf you have any special requirements, please let us know and we will offer you the report at a customized price.\n\nAbout Global Market Vision\n\nGlobal Market Vision consists of an ambitious team of young, experienced people who focus on the details and provide the information as per customer's needs. Information is vital in the business world, and we specialize in disseminating it. Our experts not only have in-depth expertise, but can also create a comprehensive report to help you develop your own business.\n\nWith our reports, you can make important tactical business decisions with the certainty that they are based on accurate and well-founded information. Our experts can dispel any concerns or doubts about our accuracy and help you differentiate between reliable and less reliable reports, reducing the risk of making decisions. We can make your decision-making process more precise and increase the probability of success of your goals.",
            "source": {
                "uri": "thenelsonpost.ca",
                "dataType": "news",
                "title": "Finance BC"
            },
            "authors": [],
            "image": null,
            "eventUri": null,
            "sentiment": 0.2627450980392156,
            "wgt": 422076420,
            "relevance": 51
        },
        {
            "uri": "7549318891",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-17",
            "time": "17:48:00",
            "dateTime": "2023-05-17T17:48:00Z",
            "dateTimePub": "2023-05-17T17:13:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://telanganatoday.com/warangal-delegation-of-45-uttarakhand-students-visit-ramappa-temple",
            "title": "Warangal: Delegation of 45 Uttarakhand students visit Ramappa temple",
            "body": "The delegation, accompanied by four faculty members, will be staying in Warangal until May 22, engaging in a range of activities designed to foster understanding and collaboration between the two states\n\nWarangal: A group of 45 students representing various educational institutions in Uttarakhand, including IIT Roorkee, visited the UNESCO heritage site Ramappa temple, located at Palampet in Mulugu district, near here on Wednesday. They arrived at NIT Warangal as a part of the second phase of the government's 'Ek Bharat Shreshtha Bharat YuvaSangam' initiative, aimed at promoting cultural and educational exchange.\n\nThe delegation, accompanied by four faculty members, will be staying in Warangal until May 22, engaging in a range of activities designed to foster understanding and collaboration between the two states. NIT Warangal serves as the nodal institute for Telangana, while IIT Roorkee represents Uttarakhand in this programme.\n\nThey are also scheduled to visit the Bhadrakali temple, the Kaleshwaram Lift Irrigation Project, and Dr. Reddy's Labs, gaining insights into various aspects of technology, culture, and innovation.",
            "source": {
                "uri": "telanganatoday.com",
                "dataType": "news",
                "title": "Telangana Today"
            },
            "authors": [
                {
                    "uri": "telangana_today@telanganatoday.com",
                    "name": "Telangana Today",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://cdn.telanganatoday.com/wp-content/uploads/2022/02/cropped-android-chrome-512x512-1-267x267-2.png",
            "eventUri": null,
            "sentiment": 0.3411764705882352,
            "wgt": 422041680,
            "relevance": 1
        },
        {
            "uri": "7547806706",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-16",
            "time": "22:38:00",
            "dateTime": "2023-05-16T22:38:00Z",
            "dateTimePub": "2023-05-16T22:15:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.benzinga.com/pressreleases/23/05/n32435873/global-small-molecule-api-market-report-2023-growing-demand-for-small-molecule-drugs-fuels-the-sec",
            "title": "Global Small Molecule API Market Report 2023: Growing Demand for Small Molecule Drugs Fuels the Sector ",
            "body": "This report provides strategists, marketers and senior management with the critical information they need to assess the market.\n\nThe global small molecule API market is expected to grow from $180.67 billion in 2022 to $193.62 billion in 2023 at a compound annual growth rate (CAGR) of 7.2%. The small molecule API market is expected to grow to $246.18 billion in 2027 at a CAGR of 6.2%.\n\nMajor players in the small molecule api market are Merck & Co., Inc., AbbVie, Inc., Bristol-Myers Squibb Company, Albemarle Corporation, Boehringer Ingelheim International GmbH, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Aurobindo Pharma, Cambrex Corporation, Lonza, Siegfried AG, AstraZeneca, Hoffmann-La Roche Ltd., AND Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.\n\nReasons to Purchase\n\nSmall molecules API (active pharmaceutical ingredient) refers to organic components that have a low molecular weight of less than 1 nm and are typically made up of 20-100 atoms. These are active ingredients found in a wide range of biological and pharmaceutical procedures. Small molecules can be used as research tools to investigate biological function and to help develop new therapeutic agents. The small molecule API are used in pharmaceuticals and biological procedures.\n\nThe main types of small molecule API include Synthetic and biotech. Synthetic refers to a molecule that has been synthesised in a laboratory using various chemical processes. The different small molecule API manufacturing include in-house and outsourced, used for applications in cardiology, oncology, CNS and neurology, orthopaedic, endocrinology and other applications.\n\nStrategic partnership is a key trend in the small-molecule API market. Many companies operating in the small-molecule API market are undergoing partnerships to strengthen their position in the small-molecule API market and advance the development of various drugs and therapies.\n\nIn March 2022, GHO Capital, a European specialist investor in healthcare companies, acquired a majority stake in Sterling Pharma Solutions. With this acquisition, GHO Capital will facilitate the extensive sectoral pharmaceutical expertise in Europe and expand its market share in the U.S. Sterling Pharma Solutions is a US-based manufacturer of active pharmaceutical ingredients (APIs).\n\nNorth America was the largest region in the small molecule API market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the small molecule API market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.\n\nThe countries covered in the Small Molecule API market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.\n\nThe growing demand for small-molecule drugs is expected to propel the growth of the small-molecule API market. Small-molecule drugs refer to low-molecular-weight compounds that can modulate biochemical processes to diagnose, treat, or prevent disease. Aspirin, diphenhydramine, and other molecules commonly found in medicine cabinets are examples of small-molecule drugs. These molecule drug products come under the category of small molecule API products, which help in preventing disease.\n\nAccording to the National Center for Biotechnology Information (NCBI), in 2021, 75% of the drugs accepted by the Food and Drug Administration (FDA) were small molecules, with the dominant therapeutic area being oncology. Over 50% of these approvals were from small and mid-sized companies, which require support from CDMOs for the commercialization of products that contribute to the growth of CDMOs. Therefore, the growing demand for small-molecule drugs is driving the growth of the small-molecule API market.\n\nThe small molecules API market consists of sales of contract and captive small molecules API. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.\n\nThe market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).\n\nThe revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.\n\n1. Executive Summary\n\n2. Small Molecule API Market Characteristics\n\n3. Small Molecule API Market Trends And Strategies\n\n4. Small Molecule API Market - Macro Economic Scenario\n\n4.1. COVID-19 Impact On Small Molecule API Market\n\n4.2. Ukraine-Russia War Impact On Small Molecule API Market\n\n4.3. Impact Of High Inflation On Small Molecule API Market\n\n5. Small Molecule API Market Size And Growth\n\n5.1. Global Small Molecule API Historic Market, 2017-2022, $ Billion\n\n5.1.1. Drivers Of The Market\n\n5.1.2. Restraints On The Market\n\n5.2. Global Small Molecule API Forecast Market, 2022-2027F, 2032F, $ Billion\n\n5.2.1. Drivers Of The Market\n\n5.2.2. Restraints On the Market\n\n6. Small Molecule API Market Segmentation\n\n6.1. Global Small Molecule API Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion\n\n6.2. Global Small Molecule API Market, Segmentation By Manufacturer, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion\n\n6.3. Global Small Molecule API Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion\n\n7. Small Molecule API Market Regional And Country Analysis\n\n7.1. Global Small Molecule API Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion\n\n7.2. Global Small Molecule API Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion\n\nFor more information about this report visit https://www.researchandmarkets.com/r/jd2vvk\n\nAbout ResearchAndMarkets.com\n\nResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.",
            "source": {
                "uri": "benzinga.com",
                "dataType": "news",
                "title": "Benzinga"
            },
            "authors": [],
            "image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "eventUri": null,
            "sentiment": 0.06666666666666665,
            "wgt": 421972680,
            "relevance": 51
        },
        {
            "uri": "7547788275",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-16",
            "time": "22:14:00",
            "dateTime": "2023-05-16T22:14:00Z",
            "dateTimePub": "2023-05-16T21:25:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.rnz.co.nz/national/programmes/ninetonoon/audio/2018890503/new-zealand-developed-cancer-treatment-one-step-closer-to",
            "title": "New Zealand developed cancer treatment: one step closer to",
            "body": "A breakthrough cancer treatment developed in here New Zealand which uses a patient's own immune system to find and destroys the disease is a step closer to market.\n\nWellington Zhaotai Therapies, which is a joint venture between the Malaghan Institute and China's Hunan Zhaotai Medical, has signed a multi-milllon dollar deal with Indian pharmaceutical giant Dr Reddy's Laboratories.\n\nThe agreement will see trials of a new generation of CAR T-cell therapy, where a patient's own immune or T-cells are genetically modified to recognise and destroy their cancer.\n\nKathryn talks to Dr Rob Weinkove the clinical director at Malagan about the clinical trials and his ambition to see this become a mainstream treatment.",
            "source": {
                "uri": "rnz.co.nz",
                "dataType": "news",
                "title": "RNZ"
            },
            "authors": [],
            "image": "https://rnz-ressh.cloudinary.com/image/upload/s--XpGb7V5C--/t_tohu-badge-twitter/v1684266989/4NUNX2K_Dr_Robert_Weinkove_png",
            "eventUri": null,
            "sentiment": -0.4666666666666667,
            "wgt": 421971240,
            "relevance": 26
        },
        {
            "uri": "7547323030",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-16",
            "time": "15:39:00",
            "dateTime": "2023-05-16T15:39:00Z",
            "dateTimePub": "2023-05-16T15:38:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://finance.yahoo.com/research/reports/MS_0P000001RS_AnalystReport_1684246931000/",
            "title": "Dr. Reddy's Laboratories Ltd (RDY) Stock Forecasts",
            "body": "Headquartered in India, Dr. Reddy's Laboratories develops and manufactures generic pharmaceutical products sold across the world. The company specializes in low-cost, easy-to-produce small-molecule generic drugs and active pharmaceutical ingredients. Its drug portfolio in recent years has included biosimilar drug launches in select emerging markets and has shifted toward injectables and more complex generic products. Geographically, the company's sales are well dispersed across North America, India, and other emerging markets.",
            "source": {
                "uri": "finance.yahoo.com",
                "dataType": "news",
                "title": "Yahoo! Finance"
            },
            "authors": [],
            "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo.png",
            "eventUri": null,
            "sentiment": 0.1686274509803922,
            "wgt": 421947540,
            "relevance": 51
        },
        {
            "uri": "7546815622",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-16",
            "time": "10:29:00",
            "dateTime": "2023-05-16T10:29:00Z",
            "dateTimePub": "2023-05-16T10:23:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.marketscreener.com//quote/stock/DR-REDDY-S-LABORATORIES-6492671/news/Sub-Transcript-of-the-Earnings-call-conducted-on-May-10-2023-Form-6-K-43864279/",
            "title": "Sub: Transcript of the Earnings call conducted on May 10, 2023 - Form 6-K | MarketScreener",
            "body": "Sub: Transcript of the Earnings call conducted on May 10, 2023\n\nPursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the transcript of the Earnings call for the quarter and financial year ended March 31, 2023, conducted on May 10, 2023. Also please note that this transcript of the call has been uploaded on our website.\n\nThe weblink to access it:\n\nhttps://www.drreddys.com/investor#investor-meet\n\nThis is for your information.\n\nThanking you\n\nYours faithfully,\n\nFor Dr. Reddy's Laboratories Limited\n\n/s/ K Randhir Singh K Randhir Singh Company Secretary, Compliance Officer & Head-CSR\n\n\"Dr. Reddy's Laboratories Limited\n\nQ4 FY '23 Earnings Conference Call\"\n\nMay 10, 2023\n\nPage 1 of 17\n\nDr. Reddy's Laboratories Limited\n\nMay 10, 2023\n\nModerator: Ladies and gentlemen, good day, and welcome to the Dr. Reddy's Q4 FY23 Earnings Conference Call. As a reminder, all participants' lines will be in a listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance, during the conference, please signal an operator by pressing star then zero on your touch tone phone. Please note that this conference is being recorded. I now hand the conference over to Ms. Richa Periwal. Thank you, and over to you, ma'am. Richa Periwal: Thank you. A very good morning and good evening to all of you and thank you for joining us today for the Dr. Reddy's Earnings Conference Call for the quarter and full year ended March 31, 2023. Earlier during the day, we released our results and the same are also posted on our website. This call is being recorded, and the playback and transcript shall be made available on our website soon. All the discussions and analysis of this call will be based on the IFRS consolidated financial statements. The discussion today contains certain non-GAAP financial measures. For the reconciliation of GAAP to non-GAAP measures, please refer to our press release. To discuss the business performance and outlook, we have the leadership team of Dr. Reddy's comprising Mr. G V Prasad, our Co-Chairman and Managing Director; Mr. Erez Israeli, our CEO; Mr. Parag Agarwal, our CFO; and the entire Investor Relations team. Please note that today's call is a copyrighted material of Dr. Reddy's and cannot be rebroadcasted or attributed in press or media outlet without the company's express written consent. Before I proceed with the call, I would like to remind everyone that the safe harbour contained in today's press release also pertains to this conference call. Now I hand over the call to Mr. G V Prasad. Over to you, sir. G.V. Prasad: Thank you. Thank you very much. Good evening, and good morning to all of you. Welcome to the annual earnings call. My best wishes to you. I'm delighted to be here today along with the members of the executive team. As you may have seen in our published results, this year has been an outstanding year for the company, a year in which we set all-time highs in our reported sales, profits and generated a healthy cash flow. And we continue to strengthen our core businesses while investing in building businesses of the future. Our sustained investments are being made to drive manufacturing excellence, strengthen our pipeline, and we continue to build efficiency and productivity in our R&D as well as operations and continue to augment reaching customers by opening new markets and new channels. Looking beyond the financial performance. During the year, we made great progress on multiple fronts, and were recognized for these achievements. Noteworthy among these are the recognition by CNBC TV18 under the 'Master of Risk -Healthcare and Pharma' segment, and we secured leadership band scores from the CDP for the action on climate change and supplier engagement. We also featured in the Bloomberg Gender Equality Index, the S&P Global Sustainability Yearbook, the DGSI Sustainability Index in the Emerging Markets category, and were also awarded by the Economic Times as being among the best organizations for women in the year 2023. Our largest finished dosages factory was recognized by the World Economic Forum as part of its Global Lighthouse Network. These recognitions are an endorsement of our commitment to building a sustainable, high-performance organization focused on the needs of patients as well as society. I am excited about how far we have come in the past few years and by the opportunities we have for the future, as we continue to make efforts to bring to life our credo of 'Good Health Can't Wait'. With this, I'd like to hand over the call to Parag for taking you through the financial performance of the company. Page 2 of 17\n\nDr. Reddy's Laboratories Limited\n\nMay 10, 2023\n\nParag Agarwal: Thank you, Prasad. Greetings to all of you and I hope all of you are doing well. I am delighted to take you through our results for the quarter 4 and full year of fiscal 2023. FY23 has been a year of strong financial performance with the highest ever sales, record profitability and robust cash flow generation from operations. Let me provide you with a quick rundown of our Q4 and FY23 financials. For this section, all the amounts are translated into U.S. dollar at a convenience translation rate of INR82.19, which is the rate as of 31st March 2023. Consolidated revenues for the quarter stood at INR6,297 crores, that is U.S. $766 million and grew by 16% on year-on-year basis and declined by 7% on a sequential quarter basis. Year-on-year growth was driven by growth in both generics and PSAI businesses. This was further augmented with income from divestment of a few non-core brands in India. Quarter-on-quarter decline was primarily due to sales volatility in the NAG business. The revenues for the financial year 2023 stood at INR24,588 crores, that is U.S. $2.99 billion and grew by 15%. The growth was mainly driven by new product launches, partly offset with price erosion. Consolidated gross profit margin for this quarter has been 57.2%, an increase of approximately 430 bps over previous year and decline of 210 bps on quarter-on-quarter basis. Year-on-year increase was driven by new product sales with higher gross margins and favourable foreign exchange. Quarter-on-quarter decline was primarily due to product mix and lower operating leverage, although partly offset by divestment income. Gross margins for the global generics and PSAI were at 61.7% and 25.2% for the quarter. Gross margin for FY23 has been 56.7%, which is an increase of 360 bps over FY22. The increase was driven by new product sales with higher gross margins, higher government incentives and favourable foreign exchange, partly offset with the impact of price erosion. Gross margins for the global generics and PSAI were at 62.1% and 16.2% for the year. The SG&A spend for the quarter is INR1,799 crores, that is U.S. $219 million and increased by 15% YoY, while it remained flat quarter-on-quarter. The year-on-year increase is largely on account of sales and marketing investments and adverse impact of forex translation. The SG&A spend for the year is INR6,803 crores, that is U.S. $828 million and has grown by 10%. The SG&A cost as a percentage to sales was 27.7% and is lower by 130 bps over previous year due to better operating leverage. The R&D spend for the quarter is INR5,37 crores, that is U.S. $65 million and is at 8.5% of sales. Our R&D efforts are focused towards building a healthy pipeline of new products across our markets, including biosimilars. The R&D spent for FY23 is INR1,938 crores, that is U.S. $236 million. R&D percentage to sales for the year stood at 7.9%. The EBITDA for the quarter is INR1,631 crores, that is U.S. $198 million and the EBITDA margin is 25.9%. The EBITDA for the year is INR7,308 crores, that is U.S. $889 million. Page 3 of 17\n\nDr. Reddy's Laboratories Limited\n\nMay 10, 2023\n\nEBITDA margin for the year is at 29.7%, which is ahead of our aspirational target of 25%. Our profit before tax for the quarter stood at INR1,326 crores, that is U.S. $161 million and that for the year stood at INR6,037 crores, that is U.S. $734 million. Our profit before tax for the quarter grew by 434% year on year and for the year it grew by 87%. Effective tax rate has been at 27.6% for the quarter and at 25.3% for the year. The effective tax rate was lower in FY23 largely due to changes in the company's jurisdictional mix of earnings. We expect our normal ETR to be in the range of 24% to 25%. Profit after tax for the quarter stood at INR959 crores, that is U.S. $117 million and that for the year stood at INR4,507 crores, that is U.S. $548 million. Reported EPS for the quarter is INR57.62 and that for the year is INR270.85. Operating working capital reduced by INR364 crores, which is U.S. $44 million, against that on December 31st, 2022, mainly supported by an improvement in receivables. Our capital investment stood at INR258 crores, which is U.S. $31 million in this quarter and INR1,132 crores, which is U.S. $138 million during the year. The free cash flow generated during this quarter was at INR1,596 crores, which is U.S. $194 million. The free cash flow generated during this year was at INR4,009 crores, which is U.S. $488 million. Consequently, we now have a net surplus cash of INR5,046 crores, that is U.S. $614 million as on March 31st, 2023. Foreign currency cash flow hedges in the form of derivatives for the U.S. dollar are approximately U.S. $774 million, largely hedged around the range of INR82.4 to INR84.5 for the dollar, RUB 7,380 million at the rate of INR1.045 to the ruble, and Australian dollar 4.2 million at the rate of INR57.8 Australian dollar, maturing in the next 12 months. With this, I now request Erez to take you through the key business highlights. Erez Israeli: Thank you Parag. Good morning and good evening to everyone. As Prasad highlighted, we have delivered strong financial performance in FY23. We closed the financial year with double-digit top line and bottom line growth, with EBITDA and ROCE margin exceeding the 25% levels. This impressive performance was reflected in our cash flow, and we continue to have a strong balance sheet. We progressed well on our strategic priorities and were able to invest in our organic capabilities and business development opportunities to thrive and deliver on our purpose over the long term. Let me take you through some of the key highlights of the year. 1. We witnessed underlying growth momentum in FY23 across all businesses, adjusted for COVID products' contribution during last year. 2. Revenue in North America Generics and in Branded markets of India and EM crossed the $1 billion mark for the second consecutive year. 3. We divested certain non-core brands in India to focus on strengthening the core. 4. Our EBITDA is at 30%, and our ROCE is at 35%. 5. We generated a strong free cash flow, leading to a net cash surplus of $614 million. 6. We also see positive momentum on BD/M&As with acquisition of Novartis Cardiovascular brand in India, Mayne Pharma's U.S. generic prescription product portfolio, and Eton's branded and generic injectable products in the United States. Page 4 of 17\n\nDr. Reddy's Laboratories Limited\n\nMay 10, 2023\n\n7. Significant progress also made in our biosimilar businesses. We see a launch of biosimilar Stimufend which is Pegfilgrastim by Fresenius KABI in the U.S. We completed and we saw the completion of clinical studies of Rituximab biosimilars, and we already filed in U.S., Europe, and the UK MHRA. We saw the completions of phase one study of biosimilar tocilizumab, and global phase three study was initiated. 8. Recently we received approvals for three products in China, namely Sevelamer, Sitagliptin, and Carboprost, and our partners got GEA approval for Nicergoline tablets. 9. We are also progressing well in our digitalization, as well as our ESG journey. 10. Our diversified global presence, capability, and strong balance sheet make us a partner of choice. We continue to work towards strengthening our position as a partner of choice, including in horizon two spaces. From a horizon two perspective, we signed some strategic licensing deals in April 23, including the below a. With Cardiacare for their wearable for atrial fibrillation treatment b. With Theranica for the wearable in management of migraine c. With the New Zealand based WZTL to bring the third generation CAR T asset for clinical trials in India d. With Junshi Bioscience to bring Toripalimab to India and other markets. We are investing in development and trials of these DTX, CAR T, biosimilar assets in keeping with our stated horizon two strategy. We see them as a future growth drivers. Now let me take you through the key business highlights for the Q4 and FY23. Please note that all the reference to the numbers in this section are in respective local currencies. Our North America generic business recorded sales of $312 million for the quarter, with a strong growth of 18% year over year and 17% decline on sequential basis. On a full year basis, we recorded sales of $1,268 million, with a growth of 26% over the previous year. This growth was largely led by new product launches such as Lenalidomide, Sorafenib tablets and Timolol gel, and growing market share in certain key existing products, which more than offset increased price erosion. We launched 6 products during the quarter and overall 25 products during the year. We expect the launch momentum to further improve in FY24. Our Europe business recorded sales of Euro 56 million this quarter, with year over year growth of 7% and sequential quarter growth of 9%. On a full year basis, the sales are Euro 210 million and has grown by 9%, driven by base business volume and new product launches. We launched 5 new products during the quarter and 35 for the full year in Europe across all markets. We expect this launch momentum to continue in FY 24. Our Emerging Market business recorded sales of Rs 1,114 crores, with year over year decline of 7% and sequential quarter decline of 15%. On a full year basis, Emerging Market sales have been roughly flat at Rs 4,553 crores. However, the sales have grown by 13%, adjusted for the COVID-related products and divestment income in FY22. We launched 10 new products during the quarter and 94 new products during the year across various countries of the Emerging Markets. Within the EM segments, the Russia business in Q4 declined by 34% on a year to year basis and 17% on a QoQ basis in constant currency. In FY23, Russia business declined by 9% in constant currency. The decline is attributable to divestment of few non-core brands during the previous year. During the year, there has been normalization in the channel/customer stocking level after the uptick seen in Q4 FY22.We have been navigating the evolving geopolitical uncertainties and have managed the ruble currency fluctuation with effective hedging. Page 5 of 17\n\nDr. Reddy's Laboratories Limited\n\nMay 10, 2023\n\nOur India business recorded Q4 sales of INR1,283 crores with a year over year growth of 32% and sequential increase of 14%. On a full year basis, our sales were INR4,893 crores with a growth of 17%. Excluding the benefits of the divestment income and adjusted for COVID-19 related products, the year over year sales growth for the quarter has been 11% and for the full year has been 13%. As per the IQVIA report, we are ranked number 10 at MAT March'23 level. India remains our priority market and we are committed to continue to grow this business at a healthy rate. Our PSAI business recorded sales of $95 million with a year over year decline of 4% and flat sequentially. On a full year basis, the sales were $362 million with a decline of 12%. The decline was primarily due to high base effect of COVID related products. We expect this business to grow during FY24. Our R&D efforts are focused on developing value, accretive products including several generic injectables and biosimilars where there is a patient need. We have done 195 global generic filings including 12 ANDAs filed in the U.S. and 130 drug master files filed globally including 12 drug master files in the U.S, during FY23 and are on track to accelerate on this in FY24. We are progressing well in development of our biosimilar products and working on some niche opportunities in our Horizon 2 initiatives. Our strong balance sheets provide financial flexibility to support future growth, invest in business development opportunities, and we will continue to maintain a disciplined approach to cash management and acquisitions. We continue to focus on optimizing workplace efficiency and productivity. We remain focused on strengthening our core generics and API business and delivering more from strong foundation. We are building a pipeline of products to meet the evolving needs of patients and healthcare professionals through investments in internal R&D as well as strategic acquisitions. With this, I would like to open the floor for questions-and-answers. Moderator: The first question is from the line of Balaji Prasad from Barclays. Balaji Prasad: Thanks for taking my questions. Just wondering if you could provide a bit more detail around your deals with just discussing what the responsibilities will look like on both ends. And just what really convinced you about their asset and its potential? Thanks. Parag Agarwal: Balaji, we were not able to hear you well. I'm afraid you will have to repeat the question. Erez Israeli: Can you repeat, please? Balaji Prasad: Sure. Is this better? Can you hear me better now? Erez Israeli: Yes, please. Page 6 of 17\n\nDr. Reddy's Laboratories Limited\n\nMay 10, 2023\n\nBalaji Prasad: This is Michella on behalf of Balaji. I was just wondering if you could provide a bit more detail around your deal with Junshi just discussing what responsibilities will look like on both ends. And also, just wondering what convinced you about just their asset and its potential. Erez Israeli: So strategically, we are looking for unmet need, especially in India. And we believe and we are in a great dialogue with the innovation industry in China, and we are trying to bring products that we believe that we can bring value and we believe that this product showed very, very nice results and can be absolutely considered standard for sale and where we can bring it to India in a very affordable prices versus the alternatives. And this is our purpose. We are trying to bring a great help in the affordability terms. And that was the main incentive behind this deal. Moderator: The next question is from the line of Surya Patra from PhilipCapital. Surya Patra: Congratulations for the great set of numbers, sir. Sir, my first question is on the U.S. business front. So, is it possible to share that what is the sequential growth in the U.S. that we would have seen of ex of Revlimid in the current quarter? Erez Israeli: So, we cannot give guidance per product with or without, you know very well. What I can say is that we are very consistent. So likely we are going to continue to see growth in all of our spaces including the United States with and without the product. And it will be driven primarily for the organic activities, specifically for the United States, besides the Revlimid, we are going to launch somewhere between 25 to 30 products as well as the contribution of our recent acquisitions and likely that we will see also additional activity through the year. Surya Patra: Sir, is it possible to give some extra colour on the launch momentum that you have mentioned in your opening remarks for the U.S. market, which you believe that to be strong in the current financial year? Erez Israeli: Yes, I think that the investment in R&D and especially on products that hopefully or likely to have less competition than the others is paying off. And as well as the type of patent fleet that we will see in FY '24 as well as the years after. So right now, that's the numbers that I mentioned, 25 to 30 products can be meaningful launches with a lesser of a competition. And we will continue to accumulate this kind of products also in the years after. So, it's absolutely our strategy in the U.S., and we will continue to focus on that. Surya Patra: Sir, my second question is on the composite question, let's say. We are seeing a strong cash accumulation and simultaneously, we are seeing multiple M&A activities by us to improve our focus on the domestic formulation business, which has now achieved around 20% of the total revenue base. And we are mentioning that this is going to be one of the focus market for us? So, could you share your thought process, sir, on the kind of capital allocation to build this business in the near future? And ultimately, what is the kind of a business mix that you want to make, achieve it for domestic formulation considering the potential sales growth and all that, if you can share. Erez Israeli: Yes, absolutely. So, in India, our primary growth will come from, one, focusing on our brands. We identified focus therapeutic areas as well as the focus brands. And we have doubled down on that by increasing our footprint by going to more cities, etcetera. So, this is one growth, specifically to your question. The second one is that we are collaborating with the innovation industry in the United States, in Israel, in China and other places as well, of course, with companies and institutes in India to bring innovation to India. We are doing it as both with our own internal R&D as well as with external R&D. Page 7 of 17\n\nDr. Reddy's Laboratories Limited\n\nMay 10, 2023\n\nSome of the deals, I mentioned in my script and more to come. We are doing it both on Horizon 1 as well as Horizon 2. And our path of growth is people see us as a very attractive partner being compliant with all the international norms, given our reputation in the marketplace, and we are leveraging it to bring more and more innovation into India. And that's also part of the capital allocation will go to a deals like this. In addition, we are always looking for opportunity also for acquisitions. There is nothing that we can report at this stage. But it's absolutely something that we are open to do all the time. For the initial part of the capital allocation, all of our spaces, including U.S., Europe, India, etcetera, our B2B business, we are looking for potential complementary deals. The type of deals that we are looking for is complementary. We are looking for products that we don't have or capabilities that we don't have. Unlikely that you are going to see megadeals or this kind of stuff. This is not our comfort zone. We are looking for primarily unmet needs or complementary products that will fit our portfolio in that way. Surya Patra: So that is really great to know. And just lastly, any colour that you can add to the Pegfilgrastim expectations in the progress post launch? Erez Israeli: Sorry yes, the product, as you know, is marketed by Fresenius. I don't have any expectation of anything like that, we as a partner, have a certain arrangement with them and if they will be successful, we will be successful as well. Moderator: The next question is from the line of Damayanti Kerai from HSBC. Please go ahead. Damayanti Kerai: My first question is on the U.S. business; you have been obviously very consistent in terms of new launches. But can you talk a bit more about the kind of price erosion, which we are seeing in your existing product? And my second part of the question is compared to oral solids in injectables, what kind of price erosion you are witnessing? Erez Israeli: So, the nature of the U.S. did not change in the last quarter. It's a similar structure of the market and similar behaviour of players. Specifically for the quarter, the mix of products that we had, we saw less of a price erosion that will be quarters before, but the fundamental structure of the market did not change. So likely that when we will face competition in certain products, then we'll see an erosion that's the nature. But specifically, we saw a better mix this time. Comparing injectables to oral solid, both are very competitive. It's more of a function of how many players are attracting the customers and so both injectable as well as oral solids can see a high level of erosion, but also from time-to-time product with less competition and therefore better pricing situation. Page 8 of 17\n\nDr. Reddy's Laboratories Limited\n\nMay 10, 2023\n\nDamayanti Kerai: My second question is, as you continue to invest in your business and long-term growth drivers, how do you see R&D and SG&A costs moving from here on? And you obviously have done better than your aspirational EBITDA margin for this year. But on a more sustained basis, how do you see this like margin trajectory moving? Erez Israeli: So, we are maintaining the 25-25 as a long term, and we discussed it in previous meetings, and there will be years and quarters that we will exceed it. There will be maybe also year that it will be below, which has happened also in the past. But we are very much there. What we are doing is that we are allocating the extra results that we invest. And especially in R&D, the R&D likely to be somewhere between 8% to 9% also going forward. And it's naturally nominal will grow because we are growing the sales, and this is allowing us to invest in the biologics, it allows us to invest in products that we are partners with other and we need to do some clinical trials. And of course, very important on the generic R&D, especially focusing on products that are likely to have less competition. Moderator: We have the next question from the line of Neha Manpuria from Bank of America. Please go ahead. Neha Manpuria: On the ROW markets, historically, if I exclude the last year because of COVID impact, we have grown that market north of 20% or 25%. As we go forward, should we see the ROW market going back to those levels of growth. And this is the excluding Russia. That's my first question. And second, on the India business, could you quantify the divestment income in the current quarter? And excluding that, how should we look at growth? Is there more divestment that we see from the India perspective? Or do you think this is based on which we should grow? And do you think you can grow in line with the market in India? Erez Israeli: On the ROW question yes, the answer is yes. We are aiming for our traditional growth and also give or take without guidance, that range of growth that we saw. And indeed, when you are taking out all the one-offs and the fluctuation of currency, we are growing very, very nicely. This is primarily as we are accelerating the development and the filings of products in all these markets and also focusing on the footprint, especially on the hospital business. So yes, the answer is that we will see growth and some of those markets with an accelerated growth versus the past. As for India, the divestment was INR264 crores, and that's the value we've got. And specifically, we see more, yes, from time to time, but nothing significant that we are going and what we are also very busy with is actually to bring more and more products, and we are enhancing the collaboration discussions and the BD deals that will be for India. So, it's a kind of organic plus inorganic. But most of the inorganic will come from collaboration rather than kind of M&A acquisitions of other companies. Neha Manpuria: And just to extend the India question, do you think we can grow in line with the market, keeping aside the collaborations, etcetera, because that would take time to reflect the numbers just from the effort that we have been putting in the business over the last few years. Could we see Reddy's go back to or at least try to get in line with IPM growth? Page 9 of 17\n\nDr. Reddy's Laboratories Limited\n\nMay 10, 2023\n\nErez Israeli: We believe that we should be better than the IPM growth. Neha Manpuria: In FY24, itself? Erez Israeli: In FY24 and after. Neha Manpuria: And one last question, if I may. On the Russia business, I didn't quite catch what you mentioned in the quarter. Was there any specific impact from channel inventory being cleared in the quarter? I'm not sure what you mentioned. Parag Agawwal: So, Neha, the impact is actually in the base, if you remember when the conflict started at that time, we have said that yes, there was up stocking. And to that extent, in Q4, same time last year, the base was high, and that's impacting the year-on-year growth. Neha Manpuria: There's nothing specifically in this quarter? Erez Israeli: Yes. So, nothing specific happened in this quarter. And most of the sequential decline stuff primarily timing of product. There is a specific timing of tenders of the biologic products and stuff like that. So, we can sell that in Russia business as usual. Moderator: The next question is from the line of Ankush Mahajan from Axis Securities. Ankush Mahajan: So, my question is related to the gRevlimid that has an incremental revenue for U.S. business. So, could you throw some light on it? What is the sustainability run rate for this molecule in upcoming quarters? And excluding this gRevlimid, how do you see the EBITDA margins for the U.S. business? Erez Israeli: So, on the product, we want it to continue to be meaningful product and may fluctuate from quarter-to-quarter, but - it is going to be there probably for the entire agreement timelines. The fluctuation is primarily patterns of ordering, but we as you know, it's a limited volume arrangement, and we believe that it will serve us well to the entirety of the agreement. As for the activities outside of it, it's going to continue to grow. I mentioned in your previous discussion, all the time we have products that have less competition than others. Naturally this product is bigger than the other, but likely, because in the future, we are going to see products like that. And that's what we are also focusing on so the profitability as well as the growth of our U.S. markets will continue to be in the same range also in the years to come and quarters to come. Ankush Mahajan: And sir, what are the EBITDA margins that we - sustainable EBITDA margins? Erez Israeli: Like I mentioned, we are going to sustain the 25-25 on a long-term basis. We are not guiding for EBITDA per market, as you know. And from time to time, it will be more than that and it will be maybe times about it in terms of a function of how much we want to put into the R&D, likely that there will be higher through the time that we will have Revlimid and the combination of other low competitive products. Page 10 of 17\n\nDr. Reddy's Laboratories Limited\n\nMay 10, 2023\n\nAnkush Mahajan: So, if I do my calculations and we're excluding Revlimid, base business is still on the lower side in terms of growth. So, any strategy for the base business? Erez Israeli: I don't share that observation. Ankush Mahajan: Thank you, sir. Thanks. Moderator: Thank you. The next question is from the line of Kunal Dhamesha from Macquarie. Please go ahead. Kunal Dhamesha: Yes. Thank you for taking my question. So, the first question on strategy to leverage our U.S.-generic portfolio for Europe and other markets. And we have seen significant growth in Europe geography over the last two, three years. But in your view, how far along we are in that journey? Let's say in U.S., we have roughly around 140 products, 150 products. How many products we would have already launched in Europe? How many in pipeline? And if you can throw some light there, it would be helpful? Erez Israeli: Yes, we decided to focus on Europe when we took the decision on the diversification. This is working well for us. And in terms of where are we in the journey, somewhere in the beginning. So I do see that most of the growth in Europe are ahead of us. We are planning to launch many products in Europe in the next coming years, as well as to make other moves, including inorganic. So, we see Europe as a focus market, especially around Germany. So, Germany will be the focal market. And of course, the rest of the big countries in Europe, we believe that we have to offer, including biosimilars. So likely that you continue to see growth in Europe also in the next coming years, including next year. Kunal Dhamesha: And this leveraging of portfolio when you launch same product, does it become highly ROIC-accretive in your view, even beyond what our aspirational target is, or it helps us achieve that 25% ROIC target? On a portfolio level, product portfolio. Erez Israeli: Yes, absolutely. Because it's primarily leverage. And obviously, it's a piece in the puzzle. Europe is still relatively small compared to the other spaces. But over the time, it's getting more-and-more positive impact on the overall average. But it's a good thing. Kunal Dhamesha: Sure. And the second question on the CTO-1 observation. What's the kind of nature of observation? And have we submitted the response to U.S. FDA? Or are we in the process of submitting a response? Erez Isreali: It's a minor observation. We will address it. And we did not submit it yet. We just got it. I think we have 15 days, if I'm not mistaken. So, we will submit it on time. I believe that this will be helpful. Kunal Dhamesha: Sure. Thank you, and all the best. Erez Israeli: Thank you. Moderator: Thank you. The next question is from the line of Madhav Marda from FIL Industries. Please go ahead. Page 11 of 17\n\nDr. Reddy's Laboratories Limited\n\nMay 10, 2023\n\nMadhav Marda: Hi, good evening. Thank you so much for your time. Just had one question. Basically, we've accumulated a lot of free cash flow in recent times. And I think have been doing some M&A activity already. Just wanted to understand, given I think in general, a lot of the peers have good free cash flows and net cash balance sheets in the industry. So, when we're looking at M&A, aren't good assets very aggressively bid? We've seen that in the past as well in the industry. I just want to understand that for a good asset, is it easy to get it at a good IRR, or how should we think about M&A opportunities, given we have a good cash balance available today? Erez Israeli: Yes, so if you recall, it was part of our strategy to close the debt and accumulate cash, anticipating this situation, anticipating at the time, the increase in the interest rate and inflation. So, we are now looking for opportunities that one, will of course fit us strategically, and second, will be in good valuation. So now I think there are certain areas and certain type of products that potentially can get a good multiples. And that's what we are looking for. In addition to that, we are looking for, we are using this money for the type of licensing and type of boosting the portfolio also for the future. And the money will be used also for that. We are not the type of company that is seeking what you call transformational acquisitions that are unlikely that you'll see in our case. But we will see, hopefully, more deals than we saw in the past. Madhav Marda: So basically, our M&A will be more bolt-on, the kind that we've done in recent times as well. That's the idea? Erez Israeli: Let's call it business development, which is including licensing and we'll include the product acquisitions, collaboration with companies, and also M&A. Madhav Marda: Got it. Okay, thank you. Moderator: Thank you. The next question is from the line of Cyndrella Thomas Carvalho from JM Financial. Please go ahead. Cyndrella Carvalho: Thanks for the opportunity. So, I just wanted to clarify this. Sorry for asking on generic Revlimid again. But is the higher volume share reflected in this quarter, or will it be reflected next quarter? Erez Israeli: If you're talking about the Lenalidomide, we cannot share quantity numbers. And what I said is it continues to be meaningful to us and in accordance to the agreement terms that we have. Cyndrella Carvalho: Okay, thank you. And in your opening remarks, you highlighted about the Chinese product approvals that you have received. When and where should we start reflecting these into earnings? And what is our outlook here, if you can help us understand? Erez Israeli: Yes, this is a reflection of the efforts that we had through the years by submitting more products. And China focusing on those products since we can get GEA status and be one of the early entry for the market. So, I think getting product approvals in less than a couple of weeks is a big achievement for a company like us. What we see, we see pick-up all the time as a significant impact on our results. Page 12 of 17\n\nDr. Reddy's Laboratories Limited\n\nMay 10, 2023\n\nWe will see more about, let's say, from starting in FY24, but more likely we'll see bigger numbers in FY25 and FY26 fiscal as the submissions and the approvals and the timing of those GPOs will take place. That's what we anticipate. And right now, we are in the pace of 15 product to 20 product submissions per year. And naturally, with the cycle of approvals that happened in China and the timing of the GPOs, it will be more meaningful. But let's say the strategy so far is working well because it's a leveraged strategy in which we have an outlet for the very, very important markets. We are very pleased from this approval. Cyndrella Carvalho: Thanks. This is helpful. And coming to the PSAI business, compared to your peers, we have not seen the top line growth. However, the gross margins have definitely improved Q-on-Q. So how should we see the outlook for this business? We've been positive on growing this business. But does anything change here at this point in time, or is it some seasonal impact that we have seen in this quarter, and we should start seeing growth from next fiscal onwards? How should we read this? Erez Israeli: We will see both. We will see growth and we will see improvement of profitability. For us, this market also in the past, and I'm excluding also in this segment, we used to record also COVID sales. So, if I'm excluding the COVID, what we saw is at that time, it was a decrease in prices of some of portfolio as well as increase in some of the raw material. Now we see the reverse. What we see that we are launching new products and most of the sales are to more territories, especially in Asia. And we see also a better mix of products. And we see an ease on the supply chain and to a certain extent procurement. So actually, now I see a positive momentum that is building on both growth as well as profitability. Cyndrella Carvalho: But we should see this gross margin level sustaining? Erez Israeli: I hope that it will be even enhanced, not just sustained for sure, but we are aiming for enhancing it. Cyndrella Carvalho: And the top line, any number that you would like to share, like only double digits, a mix double digits, anything, any color that can be helpful? Erez Israeli: No, we are aiming for double digits. We are not guiding, but we are aiming for double digits for all of our markets, including our PSAI. Cyndrella Carvalho: Thank you so much. I'll join back the queue. Moderator: Thank you. The next question is from the line of Tushar Manudhane from Motilal Oswal Financial Services. Please go ahead. Tushar Manudhane: Yes, thanks for the opportunity. So again, on North America's sales, given that FY23 had a certain strength-related exclusivity as well for generic Revlimid and competition to some extent kicking in the coming quarters. So, considering these aspects, I just would like to understand, will we still grow in FY24 in U.S. sales, North America sales? Page 13 of 17\n\nDr. Reddy's Laboratories Limited\n\nMay 10, 2023\n\nErez Israeli: I believe that we will grow not just because of the product. We will grow because we are also launching 25 to 30 products. And the combination of all that mix should grow up in the United States. Tushar Manudhane: Okay, sir. Thank you. Moderator: Thank you. The next question is from the line of Ashish S Thavkar from IIFL Asset Management. Please go ahead. Ashish Thavkar: Yes, thanks for the opportunity. So, I have this question since we have been maintaining this 25% EBITDA margin guidance. But if we just try to strip off one-time big opportunities and say some one-off non-recurring items, the EBITDA margins on the core business seem to be lower versus what we were earlier guiding for. So, if you could help us understand for FY24, as we're going to FY '24, would you like to provide some color as to directionally of what we as investors can expect? Erez Israeli: Yes, first, I don't share the observation that it's less than what we guide. So that's a starting point. And we may need to clarify it. We will be maintaining the 25-25 message on the long-term basis, in which we will allow us both to grow, give great return to the shareholder, as well as to finance the future. And what you see is that we are building a bigger and better portfolio as time goes by. And plus, the balance sheet is probably the best ever in terms of both cash flow, as well as no additional substantial risk that exists in the balance sheet. So, this is, of course, allowing us - much better, also, utilization of the working capital. So, this will allow us a better ROCE, also, in the future. Ashish Thavkar: Yes, fair enough. So lastly, on this India business, you did mention that FY24, you expect to beat the IPM growth. And we have been acquiring assets, trying to strengthen our portfolio. What gives you the confidence that FY24, we can beat the industry growth? We just wanted to have some understanding on that. Erez Israeli: I'm confident that we'll do it. And we need to recall that, for me, I know that we are looking at external sources, like IQVIA, et cetera. But the most important for me is what is our bottom-line growth. And that should be very healthy. So, the answer is that I am confident. And I believe that we will grow the bottom line even faster than we'll grow the top line. Ashish Thavkar: Okay. Fair enough. Thanks, all the best. Moderator: Thank you. The next question is from the line of Nitin Agarwal from DAM Capital Advisors. Please go ahead. Nitin Agarwal: Thanks for taking my question. It is on the Mayne portfolio that we acquired in the U.S. Can you give us some more color on what opportunities you see in that portfolio, in terms of to grow the portfolio from the current side? Erez Israeli: Yes, it's a portfolio that has a certain lower level of competition, especially in women health. It's allowed us to get back to women health, something that was missing for us, as you know, through the years. And it's also, there were many products in the pipeline that Mayne did not launch. And something that we'll be able to do in the future. So, if you wish, we have a triple impact. One, we believe that we can do well with this product. Second, we will be able to launch more products. And third, we can launch some of these products in other markets. And relatively, the economy of the deal is relatively attractive for us. So, we are very pleased so far with the progress of the main acquisition. Page 14 of 17\n\nDr. Reddy's Laboratories Limited\n\nMay 10, 2023\n\nNitin Agarwal: So, I think it's fair to assume, given the new product launches that you have opportunities that you have, we see possibilities for growing the business from where we acquired it? Erez Israeli: That's what we are aiming to, yes. Nitin Agarwal: And from a profitability perspective, is this a business which is higher than our corporate profitability right now? Erez Israeli: I cannot share information about the specific profitability of products. But we believe that the nature of the products and the mix of the product that have less competition is always favorable versus those with a high level of competition. This is the nature of the business. Nitin Agarwal: And besides the acquisition that you made, the part of this investment that you made in the U.S. generics, do we still are open to investing more money in U.S. generics by way of acquisition? Or this is more of a special case transaction which came our way? Erez Israeli: We will continue to look for opportunity in the U.S. market, including generics, if it will fit the financials and if it will be complementary to what we do. So, we will continue to look for opportunities, both organic and inorganic, in the U.S., not just now also in the future. It is a very important market for us. Nitin Agarwal: Okay, sir, thank you. Moderator: Thank you. The next question is from the line of Prakash Agarwal from Axis Capital. Please go ahead. Prakash Agarwal: Yes, hi, good evening. Thanks for the opportunity. If I heard that right, I just wanted to reconfirm that you mentioned that you expect double digit growth from across markets, including the U.S. Would that be correct? Erez Israeli: I do. Not necessarily every quarter and not necessarily all the time. But absolutely, this is the long-term aspiration for us. Absolutely, that's what we are aiming for in the short term. But I cannot promise you that it will happen every quarter and every product and every situation, obviously. Prakash Agarwal: So, asking for fiscal '24 specifically, sir? Erez Israeli: Specifically, that's what we are aiming. We are aiming for double digit growth. Prakash Agarwal: And excluding the acquisition with the base portfolio and some one-offs, it is possible, as what you see? Page 15 of 17\n\nDr. Reddy's Laboratories Limited\n\nMay 10, 2023\n\nErez Israeli: I believe that it's possible. Prakash Agarwal: Okay. That is helpful. And just to follow-up on this, the U.S. generic market, I mean, many companies have been talking about while price erosion remains more or less similar, there is a lot of volume opportunities that is coming, new business opportunities, etcetera, so would you say that we would have also brought these in the last three, six months, given there's some U.S. FDA issues with the PSAI? Erez Israeli: I'm not sure I understand the FDA comment. Can you clarify that? Prakash Agarwal: Yes, so what we hear from some of the peers is that they are getting some volume opportunities, like new business opportunities, NBOs, where they need to supply a few of the products where earlier they were not contracted, largely due to the U.S. FDA issues by the peers. So, are we getting some volume-based opportunities to supply in the U.S. market? Erez Israeli: We do from time-to-time. I'm not considering it as a strategic issue, but we do from time-to-time have a situation. So, give or take, if I saw correctly, about 10% to 15% of the SKU in the United States in some sort of a shortage for all kinds of reasons, not just the FDA, but all kinds of reasons. And in those situations, you have always an opportunity for one-time buy and stuff like that. Prakash Agarwal: And have you seen anything incremental in the last quarter is what I'm trying to get some color on? I mean, given we have seen some large companies having some issues. Erez Israeli: Yes, so nothing that I see as strategic. In general, we are not building ourselves on the failures of others. We are trying to build ourselves with our own capabilities. Prakash Agarwal: Fair enough. And lastly, on the run rate that we see in the past, it was $225 million, and then it came back, the base business side to $250 million, and then we saw some big jumps. And now things are normalizing, and you still maintain it is going to be volatile, but material. And I also understand that market share of these Revlimid are, it changes, right? It increases every six, 12 months or maybe calendar year. So would it be fair to say that, with the new launches that you spoke about and Revlimid continuing, this is an addition to the first question. So that is the key to grow double digit. Would that be a fair assessment that on that Revlimid base also you will grow? Erez Israeli: The growth in the United States will be from new products, as well as volume from other products, as well as better costing. All of that will contribute, absolutely. But I cannot guide you on with and without or this kind of stuff. I will not be able to do that. Prakash Agarwal: Okay, lovely. And lastly, while you spoke about growth across markets, would you say with this kind of launch and product visibility across markets, these kind of margins could be sustainable? Erez Israeli: Yes, I believe so. I believe that that's why we are guiding for the 25-25, which will enable us even to finance Horizon 2. So, if you recall, we said that about 50 to 100 basis points on Horizon 2, and we are able to cater that within the margins. So, we are strategically positioned well that we are able to finance our future and at the same time to provide these margins and ROCE to the shareholders. Page 16 of 17\n\nDr. Reddy's Laboratories Limited\n\nMay 10, 2023\n\nPrakash Agarwal: But we are doing better than what we are guiding, right? That's what I'm asking. Will we be able to continue with this kind of performance? Erez Israeli: Now we are doing better and maybe there will be also a period of time that will be not better, but right now we are doing better, yes. Prakash Agarwal: Okay, lovely. Thank you and all the best. Erez Israeli: Thank you. Moderator: Thank you. We will take that as our last question for today, ladies and gentlemen. I would now like to hand the conference over to Ms. Richa Periwal for closing comments. Over to you, ma'am. Richa Periwal: Thank you. Thank you everyone for joining us today for the earnings call. For any further queries, please reach out to the investor relations team. Thank you, have a great day. Moderator: Thank you. On behalf of Dr. Reddy's Laboratories Limited, that concludes this conference. Thank you for joining us. You may now disconnect your lines. Page 17 of 17\n\nAttachments\n\nOriginal Link Original Document Permalink\n\nDisclaimer\n\nDr. Reddy's Laboratories Limited published this content on 16 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 May 2023 10:22:39 UTC.",
            "source": {
                "uri": "marketscreener.com",
                "dataType": "news",
                "title": "Market Screener"
            },
            "authors": [],
            "image": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "eventUri": null,
            "sentiment": 0.3725490196078431,
            "wgt": 421928940,
            "relevance": 100
        },
        {
            "uri": "7546810859",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-16",
            "time": "10:25:00",
            "dateTime": "2023-05-16T10:25:00Z",
            "dateTimePub": "2023-05-16T10:16:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.benzinga.com/pressreleases/23/05/g32416515/aspergillosis-treatment-market-is-to-reach-usd-3569-72-mn-by-2029-at-a-growth-rate-of-5-4-percent-",
            "title": "Aspergillosis Treatment Market is to reach USD 3569.72 Mn by 2029 at a growth rate of 5.4 percent over the forecast period ",
            "body": "Pune, May 16, 2023 (GLOBE NEWSWIRE) -- Maximize Market Research, a global Healthcare market research firm has published a competitive intelligence and market research report on the \"Aspergillosis Treatment Market\". The Aspergillosis Treatment Market size was valued at USD 2470.30 Mn in 2022. The total Aspergillosis Treatment Market revenue is expected to grow at a CAGR of 5.4 percent from 2023 to 2029, reaching USD 3569.72 Mn during the forecast period.\n\nRequest For Free Sample Report : https://www.maximizemarketresearch.com/request-sample/187451\n\nAspergillosis Treatment Market Scope and Research Methodology\n\nThe objective of the report is to present a comprehensive analysis of the Aspergillosis Treatment Market. The Aspergillosis Treatment Market is segmented By Type, Drug Class, Route of Administration, and Distribution Channel. The Aspergillosis Treatment Market report is a guide for investors that provides a comprehensive analysis of the competitive benchmarking of major market players in the market by revenue, financial status, portfolio, growth strategies, and geographical presence. The report is a detailed analysis of the Aspergillosis Treatment Market by country, regional and global presence. The Aspergillosis Treatment Market size was estimated through a bottom-up approach. The new entrants in Aspergillosis Treatment Market were researched for growth prospects and future business outlooks. Restraints, drivers, challenges, and opportunities are provided in detail in the Aspergillosis Treatment Market report.\n\nThe Aspergillosis Treatment Market refers to the market for pharmaceutical products and therapies used in the management and treatment of Aspergillosis, a fungal infection caused by the Aspergillus fungus. It includes antifungal drugs, immunotherapy, and supportive care medications aimed at controlling the infection, relieving symptoms, preventing complications, and improving patient outcomes.\n\nHigh treatment costs and lack of awareness about aspergillosis among individuals\n\nMajor factors boosting the market are rising demand for advanced aspergillosis treatment, install-industry competition, and increasing new entrants. The aspergillosis treatment market is consolidated thanks to increasing inorganic growth activities such as mergers and acquisitions. High treatment costs and a lack of knowledge about aspergillosis are important obstacles. The cost of therapy, which includes costly antifungal drugs and specialized care, places financial strain on patients and healthcare systems, limiting access to timely and adequate care. Raising awareness about aspergillosis, its prevention, and the necessity of early detection through educational campaigns, public health initiatives, and medical conferences is critical. Efforts to academiclower treatment costs, such as the availability of generic drugs and reimbursement programs, are underway.\n\nGet a Sample Copy of the Report : https://www.maximizemarketresearch.com/request-sample/187451\n\nNorth America is expected to hold a significant share of the Aspergillosis Treatment Market by 2029\n\nNorth America is expected to hold a significant share of the aspergillosis treatment market by 2029. Firstly, North America has a high prevalence of conditions that increase the risk of aspergillosis, such as lung diseases, HIV/AIDS, and organ transplantation. This contributes to a larger patient pool requiring treatment. The region has a robust pipeline of innovative antifungal drugs and therapies, creating opportunities for advancement in aspergillosis treatment Collaborations between institutions, research organizations, and pharmaceutical companies contribute to the development of novel treatment options. Favorable reimbursement policies and insurance coverage in North America facilitate patient access to expensive antifungal medications and treatments.\n\nAspergillosis Treatment Market Segmentation\n\nBy Type, allergic aspergillosis held the highest market share of 4.5% in terms of revenue in 2022 in the global aspergillosis treatment market. The segment is expected to grow at a significant CAGR during the forecast period and maintain its dominance by 2029. The prevalence of allergic bronchopulmonary aspergillosis (ABPA) changes according to the population (child/adult), geographic region, or diagnostic criteria that have been used.\n\nBy Drug Class, Corticosteroids are anti-inflammatory drugs used in aspergillosis treatment. Antifungal drugs, including Azoles (voriconazole, itraconazole), Echinocandins (caspofungin, micafungin), and others (amphotericin B), target fungal growth. It is challenging to determine the largest revenue share and market dominance without specific data. Market dynamics vary by region and time.\n\nGet Customization on this Report for Specific Research Solutions: https://www.maximizemarketresearch.com/request-customization/187451\n\nBy Route of Administration:\n\n* Oral\n\n* Injectable\n\n* Others\n\nBy Distribution Channel:\n\n* Hospital Pharmacies\n\n* Retail Pharmacies\n\n* Online Pharmacies\n\n* Others\n\nAspergillosis Treatment Market Key Players include\n\n* Pfizer Inc. (United States)\n\n* Merck & Co., Inc. (United States)\n\n* Novartis AG (Switzerland)\n\n* Gilead Sciences, Inc. (United States)\n\n* Johnson & Johnson (United States)\n\n* AbbVie Inc. (United States)\n\n* AstraZeneca PLC (United Kingdom)\n\n* Astellas Pharma Inc. (Japan)\n\n* GlaxoSmithKline PLC (United Kingdom)\n\n* Sanofi S.A. (France)\n\n* Bristol Myers Squibb Company (United States)\n\n* Roche Holding AG (Switzerland)\n\n* Eli Lilly and Company (United States)\n\n* Takeda Pharmaceutical Company Limited (Japan)\n\n* Bayer AG (Germany)\n\n* Boehringer Ingelheim International GmbH (Germany)\n\n* Mylan N.V. (United States)\n\n* Teva Pharmaceutical Industries Ltd. (Israel)\n\n* Daiichi Sankyo Company, Limited (Japan)\n\n* Cipla Ltd. (India)\n\n* Lupin Limited (India)\n\n* Dr. Reddy's Laboratories Ltd. (India)\n\n* Sun Pharmaceutical Industries Ltd. (India)\n\nGet the Sample PDF of Report: https://www.maximizemarketresearch.com/request-sample/187451\n\nKey questions answered in the Aspergillosis Treatment Market are:\n\nKey Offerings:\n\nMaximize Market Research is leading Healthcare research firm, has also published the following reports:\n\nCaspofungin Market: The total market size was valued at USD 496.36 Mn in 2021 and the total revenue is expected to grow at 1.8 percent through 2022 to 2029, reaching USD 572.50 Mn. Steady demand for the Caspofungin Market from end-user industries is expected to boost market growth.\n\nAntifungal Agents Market: The total market size was valued at USD 13.86 Bn in 2021 and the total revenue is expected to grow at 4.06 % percent from 2022 to 2029, reaching USD 19.05 Bn. Steady demand for Antifungal Agents from end-user industries is expected to boost market growth.\n\nNatural Fatty Acids Market: The total market size was valued at USD 15.15 Bn in 2021 and the total revenue is expected to grow at 5.85 percent through 2022 to 2029, reaching USD 23.87 Bn. Steady demand for Natural Fatty Acids Market from end-user industries is expected to boost market growth.\n\nChitosan Market: The total market size was valued at USD 5.48 Bn. in 2021 and the total revenue is expected to grow at 18 percent through 2022 to 2029, reaching USD 20.60 Bn. Steady demand for Chitosan market from end-user industries is expected to boost market growth.\n\nCuprous Chloride Market: The total market size was valued at USD 0.78 Bn in 2021 and the total revenue is expected to grow at 3.8 percent through 2022 to 2029, reaching USD 1.05 Bn. Steady demand for Cuprous Chloride from end-user industries is expected to boost market growth.\n\nAbout Maximize Market Research:\n\nMaximize Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology, and communication, cars, and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.",
            "source": {
                "uri": "benzinga.com",
                "dataType": "news",
                "title": "Benzinga"
            },
            "authors": [],
            "image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "eventUri": null,
            "sentiment": 0.3568627450980393,
            "wgt": 421928700,
            "relevance": 1
        },
        {
            "uri": "7546703385",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-16",
            "time": "09:22:00",
            "dateTime": "2023-05-16T09:22:00Z",
            "dateTimePub": "2023-05-16T09:22:00Z",
            "dataType": "news",
            "sim": 0.4980392158031464,
            "url": "https://www.livemint.com/market/stock-market-news/zomato-nykaa-adani-ent-among-top-largecap-stocks-that-mutual-funds-bought-in-april-check-out-full-list-here-11684223126547.html",
            "title": "Zomato, Nykaa, Adani Ent among top largecap stocks that mutual funds bought in April: Check out full list here",
            "body": "Inflows into equity mutual funds witnessed a sharp drop in the month of April. As per the latest data released by industry body the Association of Mutual Funds in India (AMFI), the net flows into equity mutual funds fell to â‚¹6,480 crore in April from â‚¹20,534 crore in March.\n\nIt was the category of large cap funds that took the biggest beating. Inflows into large cap funds plunged to a meager â‚¹53 crore during the month from â‚¹911 crore in March.\n\nAmong large caps, Zomato, Nykaa, Adani Enterprises, Cipla, among others wer the top stocks that witnessed mutual funds's buying, while Wipro, Hero, Dr Reddy's, among others witnessed selling.\n\nMeanwhile, the Indian equity market underperformed global peers in the first three months of 2023. However, domestic markets recovered in April led by the return of foreign capital inflows and improved prospects of the Indian economy amid easing domestic inflation and macro conditions.\n\nHere are the top 10 large cap stocks that mutual funds bought the most in the month of April, as per ICICI Direct report.\n\nHindustan Zinc: Mutual funds bought around 40 lakh shares of Hindustan Zinc worth â‚¹125 crore in April as compared to around 24 lakh shares worth â‚¹69 crore bought in March.\n\nFSN E-Commerce Ventures Ltd: The shares of FSN E-Commerce Ventures, the parent company of Nykaa - the e-retailer of beauty and personal care solutions - were also on the radar of the fund houses in April. Mutual funds bought 20.37 crore Nykaa shares worth â‚¹2,498 crore as against 14.96 shares worth â‚¹1,859 crore bought in March.\n\nAdani Enterprises: Around 11.7 lakh shares of Adani Enterprises were bought by mutual funds for â‚¹2,243 crore in April. This is as against around 98 lakh shares bought for â‚¹1,707 crore in the previous month.\n\nZomato: Fund houses bought Zomato shares worth â‚¹4,043 crore in April as compared to â‚¹2,820 crore-worth shares bought in March.\n\nIndus Towers: Mutual funds bought Indus Towers shares worth â‚¹203 crore in April as against shares worth â‚¹168 crore bought, MoM.\n\nBerger Paints India: The total buying of mutual funds in Berger Paints India shares stood at â‚¹675 crore in April versus â‚¹592 crore in March.\n\nGodrej Consumer Products: The company received mutual funds inflow of â‚¹3,915 crore, up from â‚¹3,851 crore, MoM.\n\nCipla Ltd: Mutual funds purchased 12.71 crore shares of drugmaker Cipla worth â‚¹11,540 crore as against 12.08 crore shares worth â‚¹10,876 crore purchased in March.\n\nSiemens Ltd: AMCs bought Siemens shares worth â‚¹4,246 during the month against â‚¹3,904 crore in the previous month.\n\nSamvardhana Motherson International: Mutual fund houses purchased the company's shares worth â‚¹5,982 crore as against â‚¹5,218 worth shares, MoM.\n\nOn the other hand, as per the ICICI Direct report, these are the top 10 large cap stocks that mutual funds sold the most during the month of April:\n\nVedanta Ltd: Mutual fund houses sold 1.37 crore Vedanta shares aggregating up to â‚¹383 crore in April as compared to around 2.03 crore shares worth â‚¹558 crore sold in March.\n\nAdani Total Gas: Shares of Adani Total Gas witnessed mutual funds selling worth â‚¹97 crore in April as against â‚¹115 crore in March.\n\nHDFC Life Insurance Company: Fund houses sold HDFC Life Insurance Company's shares aggregating to â‚¹4,126 crore during the month. This is down from â‚¹4,434 crore worth of shares sold in March\n\nSRF: Fund houses sold SRF shares worth â‚¹5,717 crore as against â‚¹5,955 crore, MoM.\n\nLife Insurance Corporation of India: The shares of state-run insurance behemoth also witnessed mutual fund outflow in April. Mutual funds sold around 3.7 crore LIC shares worth â‚¹2,034 crore during the month. This comes after they sold 3.97 crore LIC shares worth â‚¹2,121 crore in March.\n\nEicher Motors: In April, AMCs sold Eicher Motors shares aggregating to â‚¹6,023 crore as against â‚¹5,722 crore, MoM.\n\nWipro: Shares of IT major Wipro also saw mutual fund selling. They sold Wipro 14.60 crore shares worth â‚¹5,620 crore in April.\n\nJSW Steel: Mutual funds sold JSW Steel shares worth â‚¹2,942 crore during the month.\n\nHero MotoCorp: Around 2.34 crore shares aggregating to â‚¹5,984 crore of Hero MotoCorp were sold by mutual funds in April. This is against 2.45 crore shares worth â‚¹5,746 crore sold in the previous month.\n\nDr Reddy's Laboratories: Fund houses sold Dr Reddy's shares worth â‚¹7,771 crore in April.",
            "source": {
                "uri": "livemint.com",
                "dataType": "news",
                "title": "mint"
            },
            "authors": [],
            "image": "https://www.livemint.com/lm-img/img/2023/05/16/600x338/mf2_kNeD_621x414LiveMint_1684223391870_1684223392023.jpg",
            "eventUri": "eng-8620322",
            "sentiment": 0.2470588235294118,
            "wgt": 421924920,
            "relevance": 1
        },
        {
            "uri": "7546567979",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-16",
            "time": "07:55:00",
            "dateTime": "2023-05-16T07:55:00Z",
            "dateTimePub": "2023-05-16T02:07:00Z",
            "dataType": "news",
            "sim": 0.4196078479290009,
            "url": "http://tehelka.com/curbing-water-usage-in-agriculture/",
            "title": "Curbing water usage in agriculture",
            "body": "A set of smart practices and technological interventions introduced as part of regenerative agriculture are ensuring that farmers not only reduce water usage but also get access to it. A report by Deepanwita Gita Niyogi\n\nFarmer Ramakrishna Mandala has three acres of land on which he cultivates paddy and maize. While paddy occupies two acres, maize is grown on the rest in both Kharif and Rabi seasons.\n\nMandala, who is in his forties, resides in Tirupati Palem village of Srikakulam, a coastal district in Andhra Pradesh, highly impacted by extreme weather events like cyclones. To add to problems, in the past 10 years, the rainfall pattern has changed in the region which has made farmers dependent on borewells for irrigation. The farmer has two borewells for watering his land.\n\nAs borewells draw out groundwater from aquifers, it is important to conserve and replenish this precious source in a changing climate when more droughts have been predicted. Smart farming practices can help reduce water usage in agriculture.\n\nPrior to 2017, Mandala used to follow traditional farming methods which did not focus on water conservation efforts. A few others, who thought about conserving water, also had no idea about how to go about it.\n\nSince 2017 onwards, thanks to technological interventions introduced by Hyderabad-based non-profit Dr. Reddy's Foundation, as part of regenerative agriculture, a change took place. By following water-saving techniques, Mandala was able to cover his entire land area of three acres as well as share water with other farmers in his village.\n\nSmart water use\n\nLast year, during a seminar at ICRISAT, which focuses mainly on dryland agriculture, experts discussed the benefits of regenerative farming in view of a changing climate.\n\nOne of the most important interventions under regenerative agriculture has been the introduction of direct seeded rice (DSR) which ensures throwing seeds in the field with the multi-crop planter machine. This replaced nursery preparation of growing seedlings and then transplanting them in flooded fields traditionally followed across India.\n\nAs DSR does not need standing water in fields, a lot of water is saved. In coastal Andhra Pradesh, paddy is the dominant crop along with maize. Sometimes a third crop such as oilseed is also grown in April. For maize too, direct seed sowing replaced ploughing, thus conserving water. This is being done with the double wheel marker.\n\nUnder regenerative agriculture, water usage is an important component, said Suman Reddy, associate director-operations, Dr. Reddy's Foundation.\"Apart from reducing water use in agriculture, no ploughing by tractors also saves fuel.\"\n\nCurrently, regenerative agriculture is on in 24 blocks of Srikakulam and adjoining Vizianagaram districts covering 1560 villages. As part of this, 1200 lead farmers and 21000 fellow farmers have been identified. Lead farmers selected in every village spread the good word and encourage others to follow suit.\n\nApart from DSR rice, soil moisture conservation in agroforestry set ups is also one of the smartest ways to reduce water usage. As part of it, farmers have introduced fruit trees in traditional coconut orchards. \"The aim is to cover the soil and not leave it barren. Farmers also start getting yields from the second year itself and do not have to wait for five years for coconut trees to bear fruits,\" said Lakshmi Narasimha Murthy, who works for the non-profit in Srikakulam.\n\nCover crops in agroforestry improve soil fertility. In Tirupati Palem village of Ranasthalam block, horse gram has been planted as a cover crop in the coconut orchard of farmer Venugopal Velichetti. The farmer has mango, lemon and guava trees in his orchard. Venugopal has 122 plants on 1.4 acres.\n\nSaving a precious resource\n\nFarmer Sathyam Sarika of Neliwada could not cover his entire three acres of land before due to the lack of adequate water. Now, the water level in his borewell has increased within 10 months. This has been possible through borewell recharge which harvests rainwater and sends it back to aquifers through natural filtration. It is another way to reduce water usage. Many farmers who failed to irrigate their lands before due to water shortage now find it easy with this method. This was introduced after due consultation with scientists from the Krishi Vigyan Kendra.\n\nIn Neliwada village, lead farmer Simhachalam Pandranki owns about five acres of land. \"Farmers try to conserve as much water as possible. DSR rice, borewell recharge and zero tillage in maize conserve water and it can be used for other purposes. Then there is the rain hose technology which irrigates lands quickly, thus saving water.\" Rain hose sprays water like rain and helps cover two acres in about two hours.\n\nAcross Srikakulam, many farmers have adopted water conservation measures in the face of a changing climate and cyclonic disturbances. They are reaping benefits too. Sanyasirao Reddy, who has three acres of land, does not need to water his fields daily now. In a week, five days are adequate. He is a resident of Venkateshwara Colony village.\n\n\"Regenerative agriculture is all about focusing on soil health and water conservation. While water use is reducing, access to water is increasing with rain hose technology and borewell recharge,\" Suman Reddy added. According to Murthy, much water used to be wasted in paddy transplantation. But DSR has managed to save water and give increased yields, even in some cases by five quintals more.",
            "source": {
                "uri": "tehelka.com",
                "dataType": "news",
                "title": "Tehelka"
            },
            "authors": [
                {
                    "uri": "deepanwita_gita_niyogi@tehelka.com",
                    "name": "Deepanwita Gita Niyogi",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "http://tehelka.com/media/2023/05/Deepanwita-RA-1-scaled.jpg",
            "eventUri": "eng-8620105",
            "sentiment": 0.1372549019607843,
            "wgt": 421919700,
            "relevance": 51
        },
        {
            "uri": "7545090997",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-15",
            "time": "10:49:00",
            "dateTime": "2023-05-15T10:49:00Z",
            "dateTimePub": "2023-05-15T10:43:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.marketscreener.com//quote/stock/DR-REDDY-S-LABORATORIES-6492671/news/Sub-Intimation-Form-6-K-43852808/",
            "title": "Sub: Intimation - Form 6-K | MarketScreener",
            "body": "Sub: Intimation\n\nThis is to inform you that the United States Food & Drug Administration (USFDA) today completed a product-specific Pre-Approval Inspection (PAI) and a routine GMP inspection at our formulations manufacturing facility in Srikakulam (FTO SEZ PU2). The inspection was conducted from 8th May, 2023 to 12th May, 2023. We have been issued a Form 483 with four observations, which we will address within the stipulated timeline.\n\nKindly take the above on your record.\n\nThanking you.\n\nYours faithfully,\n\nFor Dr. Reddy's Laboratories Limited\n\n/s/ K Randhir Singh K Randhir Singh Company Secretary, Compliance Officer & Head-CSR Cc: New York Stock Exchange Inc. (Stock Code: RDY) NSE IFSC Ltd. (Stock Code: DRREDDY)\n\nAttachments\n\nOriginal Link Original Document Permalink\n\nDisclaimer\n\nDr. Reddy's Laboratories Limited published this content on 15 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 May 2023 10:42:25 UTC.",
            "source": {
                "uri": "marketscreener.com",
                "dataType": "news",
                "title": "Market Screener"
            },
            "authors": [],
            "image": "https://www.marketscreener.com/images/twitter_MS_fdgris.png",
            "eventUri": null,
            "sentiment": 0.2470588235294118,
            "wgt": 421843740,
            "relevance": 26
        },
        {
            "uri": "7545003410",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-15",
            "time": "09:53:00",
            "dateTime": "2023-05-15T09:53:00Z",
            "dateTimePub": "2023-05-15T09:53:00Z",
            "dataType": "news",
            "sim": 0.8627451062202454,
            "url": "https://zeenews.india.com/india/amitoje-india-gets-2nd-patent-a-game-changer-in-retail-display-industry-2608315.html",
            "title": "Amitoje India Gets 2nd Patent: A Game-Changer In Retail Display Industry",
            "body": "Horoscope Today, May 15 By Astro Sundeep Kochar: Taurus, Emotional Day For You\n\nThe company recently received a patent that is set to change the dynamics of the POS display industry, making it a game-changer in the field. The patent, awarded in 2023, pertains to Amitoje India's innovative foldable display mechanisms. What makes this patent remarkable is its material independence, meaning it applies to the foldability of units made of diverse materials such as wood, metal, plastic, and paper. This patent marks a significant advancement in the POS display industry, heralding a new era of innovation and convenience.\n\nUnder the dynamic leadership of Maniraj Singh Juneja, an alumnus of IIT Delhi and MIT, Amitoje India has consistently pushed the boundaries of innovation. The foldable display mechanisms offer a plethora of benefits over traditional display stands. They are more compact, easy to transport, take up less storage space, and are simpler to assemble and disassemble, offering increased durability.\n\nMoreover, these foldable displays provide significant cost savings and ecological benefits. The units ship flat, significantly reducing carbon footprint and logistical costs. There's a reduced risk of damage during transit, and the automatic and foolproof assembly process greatly simplifies the setup. The significant reduction in packaging and shipping costs is a major draw for companies looking to maximize their return on investment.\n\nAmitoje India's client base has rapidly expanded to over 700, including industry giants like Coca-Cola, PepsiCo, ITC, Parle, Kellogg's, Mars, Patanjali, Wow Cosmetics, Bombay Shaving Co., Pidilite, Dabur, Wipro, Himalaya, Dr. Reddy's, and SC Johnson. The company's recent patent has been a major factor in attracting such high-profile clients, reinforcing Amitoje India's position as an industry leader in innovation.\n\nThere are even more reasons to switch to foldable displays. You can learn more in detail through this link on their website: Benefits of foldable display stands and shop racks\n\nJuneja's vision for Amitoje India is clear and ambitious: \"Our company aims to completely revolutionize the retail display and fixture industry by providing simple, yet effective solutions such as this one, thereby eliminating the hassles associated with traditional retail promotion and event setups.\"\n\nWith offices in Delhi, Mumbai, Bengaluru, and Kolkata, Amitoje India is ideally positioned to serve clients across the nation. The company's innovative products have not only disrupted the POS display industry but also set new standards for quality and innovation.\n\nThe recent patent awarded to Amitoje India is a testament to the company's commitment to innovation and customer satisfaction. It's clear that Amitoje India is poised to continue leading the way in the POS display industry, reshaping it with its game-changing foldable display mechanisms. This patent is indeed a significant milestone in Amitoje India's journey, solidifying its position as a true innovator in the POS display industry.\n\nTo learn more about Amitoje India and its game-changing patented foldable display mechanisms, visit their official website at Amitoje India - Best Retail Display Stands in India.",
            "source": {
                "uri": "zeenews.india.com",
                "dataType": "news",
                "title": "Zee News"
            },
            "authors": [],
            "image": "https://english.cdn.zeenews.com/sites/default/files/2023/05/15/1200480-amitoje-india.png",
            "eventUri": "eng-8625954",
            "sentiment": 0.3960784313725489,
            "wgt": 421840380,
            "relevance": 26
        },
        {
            "uri": "7544756825",
            "lang": "eng",
            "isDuplicate": true,
            "date": "2023-05-15",
            "time": "07:31:00",
            "dateTime": "2023-05-15T07:31:00Z",
            "dateTimePub": "2023-05-15T07:07:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://tradebrains.in/features/large-cap-pharma-stock-falls-more-than-7-in-two-days-check-here-to-know-why/",
            "title": "Large cap Pharma stock falls more than 7% in two days; Check here to know why",
            "body": "The shares of Dr. Reddy's Laboratories Ltd opened at the price of â‚¹4,543.30 on Friday, logging over a 7.60 percent downfall from two trading sessions from a price of â‚¹ 4,869 on Wednesday. One of the probable reasons for the low stock price movement is the company's recent announcement of Q4 FY 22-23 earnings.\n\nThe company posted positive Q4 FY23 results on Wednesday but missed shy of the street's estimated profit of â‚¹1,093.6 crore (As per Elara Securities Pvt Ltd).\n\nAs per Consolidated financials of the previous quarter, their operating revenues have declined from â‚¹ 6,789 crores in Q3 to â‚¹ 6,315 crores in Q4. Similarly, for YoY comparison, the revenues significantly increased from â‚¹ 21,545 crores during FY 21-22 to â‚¹ 24,669 crores in FY 22-23.\n\nThe net profit of the company has declined from â‚¹ 1,237 crores in Q3 to â‚¹ 952 crores in Q4, Similarly, for YoY comparison the net profit significantly increased from â‚¹ 2,122 crores during FY 21-22 to â‚¹ 4,470 crores in FY 22-23.\n\nDr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company that offers a portfolio of products and services, including Active Pharmaceutical Ingredients, Custom Pharmaceutical services generics, biosimilars, and differentiated formulations, catering to both domestic and international clients.\n\nThe company declared a final dividend of â‚¹40 (800% of the face value of Rs 5 ) per equity share for FY23.\n\nOver the previous fiscal year, the company introduced new products and benefitted from favourable currency moves, resulting in a 27% year-on-year (YoY) growth in US business to â‚¹ 2,532 crore, and an 11.6% YoY gain in European sales to 496 crores.\n\nIn India, the company released nine new items, which led to an increase in revenue growth of 32.5% year on year to â‚¹ 1283.4 crores And the company reported a Net cash surplus of â‚¹ 50.5 billion and a free cash flow of â‚¹ 40.1 billion as of March FY23.\n\nThe basic profitability ratios exhibiting operational efficiencies such as return on equity (ROE) and return on capital employed (ROCE) showed an upward trend in the past couple of financial years. ROE moved from 11.35 percent during FY 21-22 to 19.35 percent in FY 22-23 and ROCE, keeping the time frame the same, took a shift from 15.44 percent to 25.95 percent and The debt-to-equity ratio stands at 0.06.\n\nOn a last year-to-date basis, the stock gained 6.22 percent ranging from â‚¹ 4,238.35 to the current price level. In the previous three years, the stock has gained around 19.28 percent ranging from â‚¹ 3,735 to the current price level.\n\nAccording to the latest data pertaining to the shareholding pattern, the promoters hold a 26.69 percent stake, and Foreign Institutional Investors (FIIs) hold a 27.25 percent stake in the company for FY 22-23.",
            "source": {
                "uri": "tradebrains.in",
                "dataType": "news",
                "title": "Trade Brains"
            },
            "authors": [
                {
                    "uri": "trade_brains@tradebrains.in",
                    "name": "Trade Brains",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://tradebrains.in/features/wp-content/uploads/2023/04/pharma-cover-image.jpg",
            "eventUri": null,
            "sentiment": 0.3333333333333333,
            "wgt": 421831860,
            "relevance": 75
        },
        {
            "uri": "7544627501",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-15",
            "time": "05:19:00",
            "dateTime": "2023-05-15T05:19:00Z",
            "dateTimePub": "2023-05-15T05:17:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.marketscreener.com//quote/stock/DR-REDDY-S-LABORATORIES-6492671/news/Dr-Reddy-Laboratories-Earnings-Conference-Call-Q4-FY-23-43850390/",
            "title": "Dr Reddy Laboratories : Earnings Conference Call - Q4 FY 23 | MarketScreener",
            "body": "\"Dr. Reddy's Laboratories Limited\n\nQ4 FY '23 Earnings Conference Call\"\n\nMay 10, 2023\n\nPage 1 of 17\n\nDr. Reddy's Laboratories Limited\n\nMay 10, 2023\n\nModerator:\n\nLadies and gentlemen, good day, and welcome to the Dr. Reddy's Q4 FY23 Earnings Conference\n\nCall. As a reminder, all participants' lines will be in a listen-only mode, and there will be an\n\nopportunity for you to ask questions after the presentation concludes. Should you need\n\nassistance, during the conference, please signal an operator by pressing star then zero on your\n\ntouch tone phone. Please note that this conference is being recorded. I now hand the conference\n\nover to Ms. Richa Periwal. Thank you, and over to you, ma'am.\n\nRicha Periwal:\n\nThank you. A very good morning and good evening to all of you and thank you for joining us\n\ntoday for the Dr. Reddy's Earnings Conference Call for the quarter and full year ended March\n\n31, 2023. Earlier during the day, we released our results and the same are also posted on our\n\nwebsite. This call is being recorded, and the playback and transcript shall be made available on\n\nour website soon.\n\nAll the discussions and analysis of this call will be based on the IFRS consolidated financial\n\nstatements. The discussion today contains certain non-GAAP financial measures. For the\n\nreconciliation of GAAP to non-GAAP measures, please refer to our press release. To discuss the\n\nbusiness performance and outlook, we have the leadership team of Dr. Reddy's comprising Mr.\n\nG V Prasad, our Co-Chairman and Managing Director; Mr. Erez Israeli, our CEO; Mr. Parag\n\nAgarwal, our CFO; and the entire Investor Relations team.\n\nPlease note that today's call is a copyrighted material of Dr. Reddy's and cannot be rebroadcasted\n\nor attributed in press or media outlet without the company's express written consent. Before I\n\nproceed with the call, I would like to remind everyone that the safe harbour contained in today's\n\npress release also pertains to this conference call.\n\nNow I hand over the call to Mr. G V Prasad. Over to you, sir.\n\nG.V. Prasad:\n\nThank you. Thank you very much. Good evening, and good morning to all of you. Welcome to\n\nthe annual earnings call. My best wishes to you. I'm delighted to be here today along with the\n\nmembers of the executive team. As you may have seen in our published results, this year has\n\nbeen an outstanding year for the company, a year in which we set all-time highs in our reported\n\nsales, profits and generated a healthy cash flow. And we continue to strengthen our core\n\nbusinesses while investing in building businesses of the future.\n\nOur sustained investments are being made to drive manufacturing excellence, strengthen our\n\npipeline, and we continue to build efficiency and productivity in our R&D as well as operations\n\nand continue to augment reaching customers by opening new markets and new channels.\n\nLooking beyond the financial performance. During the year, we made great progress on multiple\n\nfronts, and were recognized for these achievements.\n\nNoteworthy among these are the recognition by CNBC TV18 under the 'Master of Risk -\n\nHealthcare and Pharma' segment, and we secured leadership band scores from the CDP for the\n\naction on climate change and supplier engagement. We also featured in the Bloomberg Gender\n\nEquality Index, the S&P Global Sustainability Yearbook, the DGSI Sustainability Index in the\n\nEmerging Markets category, and were also awarded by the Economic Times as being among the\n\nbest organizations for women in the year 2023. Our largest finished dosages factory was\n\nPage 2 of 17\n\nDr. Reddy's Laboratories Limited\n\nMay 10, 2023\n\nrecognized by the World Economic Forum as part of its Global Lighthouse Network. These recognitions are an endorsement of our commitment to building a sustainable, high-performance organization focused on the needs of patients as well as society. I am excited about how far we have come in the past few years and by the opportunities we have for the future, as we continue to make efforts to bring to life our credo of 'Good Health Can't Wait'. With this, I'd like to hand over the call to Parag for taking you through the financial performance of the company.\n\nParag Agarwal:Thank you, Prasad. Greetings to all of you and I hope all of you are doing well. I am delighted to take you through our results for the quarter 4 and full year of fiscal 2023. FY23 has been a year of strong financial performance with the highest ever sales, record profitability and robust cash flow generation from operations. Let me provide you with a quick rundown of our Q4 and FY23 financials. For this section, all the amounts are translated into U.S. dollar at a convenience translation rate of INR82.19, which is the rate as of 31st March 2023. Consolidated revenues for the quarter stood at INR6,297 crores, that is U.S. $766 million and grew by 16% on year-on- year basis and declined by 7% on a sequential quarter basis. Year-on-year growth was driven by growth in both generics and PSAI businesses.\n\nThis was further augmented with income from divestment of a few non-core brands in India. Quarter-on-quarter decline was primarily due to sales volatility in the NAG business. The revenues for the financial year 2023 stood at INR24,588 crores, that is U.S. $2.99 billion and grew by 15%. The growth was mainly driven by new product launches, partly offset with price erosion. Consolidated gross profit margin for this quarter has been 57.2%, an increase of approximately 430 bps over previous year and decline of 210 bps on quarter-on-quarter basis. Year-on-year increase was driven by new product sales with higher gross margins and favourable foreign exchange.\n\nQuarter-on-quarter decline was primarily due to product mix and lower operating leverage, although partly offset by divestment income. Gross margins for the global generics and PSAI were at 61.7% and 25.2% for the quarter. Gross margin for FY23 has been 56.7%, which is an increase of 360 bps over FY22. The increase was driven by new product sales with higher gross margins, higher government incentives and favourable foreign exchange, partly offset with the impact of price erosion.\n\nGross margins for the global generics and PSAI were at 62.1% and 16.2% for the year. The SG&A spend for the quarter is INR1,799 crores, that is U.S. $219 million and increased by 15% YoY, while it remained flat quarter-on-quarter. The year-on-year increase is largely on account of sales and marketing investments and adverse impact of forex translation.\n\nThe SG&A spend for the year is INR6,803 crores, that is U.S. $828 million and has grown by 10%. The SG&A cost as a percentage to sales was 27.7% and is lower by 130 bps over previous year due to better operating leverage. The R&D spend for the quarter is INR5,37 crores, that is U.S. $65 million and is at 8.5% of sales. Our R&D efforts are focused towards building a healthy pipeline of new products across our markets, including biosimilars. The R&D spent for FY23 is INR1,938 crores, that is U.S. $236 million. R&D percentage to sales for the year stood at 7.9%. The EBITDA for the quarter is INR1,631 crores, that is U.S. $198 million and the EBITDA margin is 25.9%. The EBITDA for the year is INR7,308 crores, that is U.S. $889 million.\n\nPage 3 of 17\n\nDr. Reddy's Laboratories Limited\n\nMay 10, 2023\n\nEBITDA margin for the year is at 29.7%, which is ahead of our aspirational target of 25%. Our\n\nprofit before tax for the quarter stood at INR1,326 crores, that is U.S. $161 million and that for\n\nthe year stood at INR6,037 crores, that is U.S. $734 million. Our profit before tax for the quarter\n\ngrew by 434% year on year and for the year it grew by 87%.\n\nEffective tax rate has been at 27.6% for the quarter and at 25.3% for the year. The effective tax\n\nrate was lower in FY23 largely due to changes in the company's jurisdictional mix of earnings.\n\nWe expect our normal ETR to be in the range of 24% to 25%. Profit after tax for the quarter\n\nstood at INR959 crores, that is U.S. $117 million and that for the year stood at INR4,507 crores,\n\nthat is U.S. $548 million.\n\nReported EPS for the quarter is INR57.62 and that for the year is INR270.85. Operating working\n\ncapital reduced by INR364 crores, which is U.S. $44 million, against that on December 31st,\n\n2022, mainly supported by an improvement in receivables. Our capital investment stood at\n\nINR258 crores, which is U.S. $31 million in this quarter and INR1,132 crores, which is U.S.\n\n$138 million during the year. The free cash flow generated during this quarter was at INR1,596\n\ncrores, which is U.S. $194 million. The free cash flow generated during this year was at\n\nINR4,009 crores, which is U.S. $488 million. Consequently, we now have a net surplus cash of\n\nINR5,046 crores, that is U.S. $614 million as on March 31st, 2023.\n\nForeign currency cash flow hedges in the form of derivatives for the U.S. dollar are\n\napproximately U.S. $774 million, largely hedged around the range of INR82.4 to INR84.5 for\n\nthe dollar, RUB 7,380 million at the rate of INR1.045 to the ruble, and Australian dollar 4.2\n\nmillion at the rate of INR57.8 Australian dollar, maturing in the next 12 months. With this, I\n\nnow request Erez to take you through the key business highlights.\n\nErez Israeli:\n\nThank you Parag. Good morning and good evening to everyone. As Prasad highlighted, we have\n\ndelivered strong financial performance in FY23. We closed the financial year with double-digit\n\ntop line and bottom line growth, with EBITDA and ROCE margin exceeding the 25% levels.\n\nThis impressive performance was reflected in our cash flow, and we continue to have a strong\n\nbalance sheet. We progressed well on our strategic priorities and were able to invest in our\n\norganic capabilities and business development opportunities to thrive and deliver on our purpose\n\nover the long term.\n\nLet me take you through some of the key highlights of the year.\n\n1. We witnessed underlying growth momentum in FY23 across all businesses, adjusted for\n\nCOVID products' contribution during last year.\n\n2.\n\nRevenue in North America Generics and in Branded markets of India and EM crossed the\n\n$1 billion mark for the second consecutive year.\n\n3.\n\nWe divested certain non-core brands in India to focus on strengthening the core.\n\n4.\n\nOur EBITDA is at 30%, and our ROCE is at 35%.\n\n5.\n\nWe generated a strong free cash flow, leading to a net cash surplus of $614 million.\n\n6.\n\nWe also see positive momentum on BD/M&As with acquisition of Novartis Cardiovascular\n\nbrand in India, Mayne Pharma's U.S. generic prescription product portfolio, and Eton's\n\nbranded and generic injectable products in the United States.\n\nPage 4 of 17\n\nDr. Reddy's Laboratories Limited\n\nMay 10, 2023\n\nSignificant progress also made in our biosimilar businesses. We see a launch of biosimilar Stimufend which is Pegfilgrastim by Fresenius KABI in the U.S. We completed and we saw the completion of clinical studies of Rituximab biosimilars, and we already filed in U.S., Europe, and the UK MHRA. We saw the completions of phase one study of biosimilar tocilizumab, and global phase three study was initiated. Recently we received approvals for three products in China, namely Sevelamer, Sitagliptin, and Carboprost, and our partners got GEA approval for Nicergoline tablets. We are also progressing well in our digitalization, as well as our ESG journey. Our diversified global presence, capability, and strong balance sheet make us a partner of choice. We continue to work towards strengthening our position as a partner of choice, including in horizon two spaces. From a horizon two perspective, we signed some strategic licensing deals in April 23, including the below With Cardiacare for their wearable for atrial fibrillation treatment With Theranica for the wearable in management of migraine With the New Zealand based WZTL to bring the third generation CAR T asset for clinical trials in India With Junshi Bioscience to bring Toripalimab to India and other markets.\n\nWe are investing in development and trials of these DTX, CAR T, biosimilar assets in keeping with our stated horizon two strategy. We see them as a future growth drivers.\n\nNow let me take you through the key business highlights for the Q4 and FY23. Please note that all the reference to the numbers in this section are in respective local currencies. Our North America generic business recorded sales of $312 million for the quarter, with a strong growth of 18% year over year and 17% decline on sequential basis.\n\nOn a full year basis, we recorded sales of $1,268 million, with a growth of 26% over the previous year. This growth was largely led by new product launches such as Lenalidomide, Sorafenib tablets and Timolol gel, and growing market share in certain key existing products, which more than offset increased price erosion. We launched 6 products during the quarter and overall 25 products during the year. We expect the launch momentum to further improve in FY24.\n\nOur Europe business recorded sales of Euro 56 million this quarter, with year over year growth of 7% and sequential quarter growth of 9%. On a full year basis, the sales are Euro 210 million and has grown by 9%, driven by base business volume and new product launches. We launched 5 new products during the quarter and 35 for the full year in Europe across all markets. We expect this launch momentum to continue in FY 24.\n\nOur Emerging Market business recorded sales of Rs 1,114 crores, with year over year decline of 7% and sequential quarter decline of 15%. On a full year basis, Emerging Market sales have been roughly flat at Rs 4,553 crores. However, the sales have grown by 13%, adjusted for the COVID-related products and divestment income in FY22. We launched 10 new products during the quarter and 94 new products during the year across various countries of the Emerging Markets. Within the EM segments, the Russia business in Q4 declined by 34% on a year to year basis and 17% on a QoQ basis in constant currency. In FY23, Russia business declined by 9% in constant currency. The decline is attributable to divestment of few non-core brands during the\n\nPage 5 of 17\n\nAttachments\n\nOriginal Link Original Document Permalink\n\nDisclaimer\n\nDr. Reddy's Laboratories Limited published this content on 15 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 May 2023 05:16:02 UTC.",
            "source": {
                "uri": "marketscreener.com",
                "dataType": "news",
                "title": "Market Screener"
            },
            "authors": [],
            "image": "https://www.marketscreener.com/images/twitter_MS_fdgris.png",
            "eventUri": null,
            "sentiment": 0.3568627450980393,
            "wgt": 421823940,
            "relevance": 100
        },
        {
            "uri": "7544524469",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-15",
            "time": "03:32:00",
            "dateTime": "2023-05-15T03:32:00Z",
            "dateTimePub": "2023-05-15T03:27:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.thehindubusinessline.com/markets/stocks-to-watch-on-may-15-2023/article66852255.ece",
            "title": "Stocks to watch on May 15, 2023",
            "body": "The board of directors of Adani Enterprises Ltd has approved a proposal for raising funds by way of issuance of such number of equity shares and/or other eligible securities or any combination thereof for an aggregate amount not exceeding â‚¹12,500 crore or an equivalent amount thereof by way of qualified institutional placement or other permissible mode.\n\nHero MotoCorp has announced a partnership with Motosport SA in Costa Rica to boost its presence in Central America. As an exclusive distributor for the sale and service of Hero MotoCorp motorcycles and scooters in the country, Motosport SA will play a key role in the rapid expansion of Hero's network there.\n\nAlso read: Nifty may see a 100-point gap-down opening\n\nRCCPL, subsidiary of Birla Corporation, has acquired the mining rights for 889.760 hectares at Katni, Madhya Pradesh pursuant to a Tripartite Agreement executed with the Government of Madhya Pradesh and Sanghi Infrastructure MP Limited. RCCPL has acquired 100 per cent equity shares of Sanghi Infrastructure. Accordingly, Sanghi has become a wholly owned subsidiary of RCCPL and a step down wholly owned subsidiary of Birla Corporation.\n\nThe Board of Sonata Software has accorded in principle approval for the merger of Gapbuster Ltd and its subsidiaries with group entities of Sonata Software Limited. The board also approved the merger of Gapbuster Limited and Gapbuster Europe Limited with Sonata Europe Limited; Gapbuster Worldwide Pty. Ltd. with Sonata Australia Pty. Ltd; Gapbuster Inc. with Sonata Software North America Inc; and Kabushiki Kaisha Gapbuster Japan, Gapbuster China Co. Ltd., and Gapbuster Worldwide Malaysia SDN BHD to be merged with their parent companies.\n\nAlso read: FPIs invest â‚¹23,152-crore in Indian equities in May so far\n\nGI Engineering Solutions has announced the receipt of first-ever confirmed order for supplying Structural Steel with a single order valued at an amount exceeding â‚¹16 crore. The company received the order from a reputed Infrastructure development company paving its way into project sales business for infrastructure and construction materials. The company has targeted to enter the Project Sales Segment alongside the distribution network for infrastructural steel and eying a sales target to achieve â‚¹2,000 million sales from its infrastructural materials business segment during FY 2023-24.\n\nMedico Remedies Ltd. has completed its trial production rounds at the newly established ointment manufacturing plant at Palghar. The new facility measuring 15,000 sq ft. has been constructed adjacent to the existing plant which manufactures tablets and other medicines. The facility will have the capacity to manufacture up to three million tubes monthly.\n\nBisleri International Private Limited, the Principal of the Company, has increased the territory in which the company has been authorised to do business in packaged drinking water under the trademark soda and their other soft drink products from May 16. The business territory of the company has been increased from existing rights in part of West Bengal to the entire state of West Bengal and also the entire state of Sikkim. Besides, the company also has franchise rights for Jharkhand.\n\nCrosslay Remedies Limited, a wholly-owned subsidiary of Max Healthcare Institute Limited, has entered into an agreement to sell for acquisition of land and building admeasuring 4,000 square meters situated in Uttar Pradesh subject to fulfilment of certain conditions precedents post which CRL shall enter into definitive agreements.\n\nThe board of Adani Transmission Ltd has approved a proposal for raising funds by way of issuance of such number of equity shares having and/or other eligible securities or any combination thereof for an aggregate amount not exceeding â‚¹8,500 crore by way of Qualified Institutional Placement or other permissible mode.\n\nDr Reddy's Laboratories has said that the United States Food & Drug Administration (USFDA) has completed a product-specific Pre-Approval Inspection (PAI) and a routine GMP inspection at our formulations manufacturing facility in Srikakulam (FTO SEZ PU2). The inspection was conducted from May 8 to May 12. We have been issued a Form 483 with four observations, which we will address within the stipulated timeline.\n\nThe board of IL&FS Transportation Networks Limited has approved the transfer of the entire shareholding in Pune Sholapur Road Development Company Limited (PSRDCL): 16 crore shares representing 90.91 per cent of the paid-up capital of PSRDCL to Roadstar Infra Investment Trust for a consideration of â‚¹1. Further, the company has also assigned its Receivables owed by PSRDCL amounting to â‚¹477 crore to Roadstar Infra Investment Trust to the Deed of Assignment executed with Axis Trustee Services Limited (as the Trustees) paid in the form of 4,74,33,603 units of the Trust aggregating to a value of â‚¹474.33 crore.\n\nAlso read: Investors toolbox: What, how and when of stock analytics websites\n\nRainbow Children's Medicare Limited (RCML) is expanding its bed capacity in NCR (National Capital Region) by adding two hospitals with a capacity of about 400 beds in Gurugram. The proposed expansion will strengthen the company's existing footprint in the NCR and enable it to cater to the growing healthcare needs of the residents of Gurugram and northern states. The addition of these two hospitals will provide increased access to specialised pediatric and perinatal care services in the geography.\n\nResults Calendar: Asahi India Glass, Astral, Century Plyboards, Coromandel International, Emkay Global Financial Services, Kalyan Jewellers India, Patel Engineering, PCBL, Pfizer, Procter & Gamble Health, PVR Inox, Skipper, Suryoday Small Finance Bank, Tube Investments of India, Ugro Capital, and Vascon Engineers.\n\nSHARE Copy linkEmailFacebookTwitterTelegramLinkedInWhatsAppRedditPublished on May 15, 2023",
            "source": {
                "uri": "thehindubusinessline.com",
                "dataType": "news",
                "title": "@businessline"
            },
            "authors": [],
            "image": "https://bl-i.thgim.com/public/news/hclrgc/article66830255.ece/alternates/LANDSCAPE_1200/stock%20market%202546.jpg",
            "eventUri": null,
            "sentiment": 0.3254901960784313,
            "wgt": 421817520,
            "relevance": 1
        },
        {
            "uri": "7544478320",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-15",
            "time": "02:37:00",
            "dateTime": "2023-05-15T02:37:00Z",
            "dateTimePub": "2023-05-15T02:36:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://economictimes.indiatimes.com/markets/stocks/news/beaten-down-realty-pharma-top-mutual-fund-buys-in-april/articleshow/100237716.cms",
            "title": "Beaten-down realty, pharma top mutual fund buys in April",
            "body": "Money managers at leading fund houses took fresh exposures to real estate and pharmaceutical stocks in April, a month when the Sensex and Nifty rose 3.59% and 4.06%, respectively. Peaking out of interest rates and recent stock price underperformance are the major reasons fund managers bought into prominent realty companies such as DLF, Prestige Estates, and Godrej Properties.\n\nIn the pharmaceutical sector, fewer incidents of regulatory breaches and attractive valuations drove fund managers to add stocks such as Alkem Laboratories, Ajanta Pharma, and Dr Reddy's Laboratories. Mutual funds continued to shuffl e their holdings in IT and banking sectors in April, while at least two large AMCs -- ICICI Prudential and Nippon -- trimmed their stakes in ITC -- one of the top performers in recent months. ET takes a look at some of the top holdings changes of leading mutual funds.",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-100237698,width-1070,height-580,imgsize-13674,overlay-etmarkets/photo.jpg",
            "eventUri": null,
            "sentiment": 0.4509803921568627,
            "wgt": 421814220,
            "relevance": 1
        },
        {
            "uri": "7544408527",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-15",
            "time": "01:01:00",
            "dateTime": "2023-05-15T01:01:00Z",
            "dateTimePub": "2023-05-15T00:59:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.bqprime.com/business/revlimid-the-star-drug-in-us-for-indian-pharma-companies-bq-exclusive",
            "title": "Revlimid: The Star Drug In U.S. For Indian Pharma Companies  --  BQ Exclusive",
            "body": "Indian pharmaceutical companies are betting on the copycat version of a cancer drug in the U.S. to shore up their fortunes even as they face price erosion and heightened competition.Sun Pharmaceutical Industries Ltd. became the eighth entrant in the U.S. and fifth Indian drugmaker to launch generic Revlimid (lenalidomide) capsules. Other domestic companies that have already entered this market are Natco Pharma Ltd. along with its mar...\n\nIndian pharmaceutical companies are betting on the copycat version of a cancer drug in the U.S. to shore up their fortunes even as they face price erosion and heightened competition.\n\nSun Pharmaceutical Industries Ltd. became the eighth entrant in the U.S. and fifth Indian drugmaker to launch generic Revlimid (lenalidomide) capsules. Other domestic companies that have already entered this market are Natco Pharma Ltd. along with its marketing partner Teva Pharmaceutical Industries, followed by Dr Reddy's Laboratories Ltd., Zydus Lifesciences Ltd. and Cipla Ltd. in 2022.\n\nSun Pharma reported a negligible market share of the generic version of Bristol Myers Squibb's Revlimid in March, the first month of its launch in the U.S., according to IIFL Securities.\n\nBut the drug, which treats blood cancer, has been the star performer for companies like Natco Pharma and Dr Reddy's, which launched the drug exclusively and early on.\n\nSales of generic drugmakers, however, are only expected to get better in the next two years even as more competition enters until January 2026, when it will be an open market for all players.",
            "source": {
                "uri": "bqprime.com",
                "dataType": "news",
                "title": "BQ"
            },
            "authors": [
                {
                    "uri": "monal_sanghvi@bqprime.com",
                    "name": "Monal Sanghvi",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://gumlet.assettype.com/bloombergquint%2F2023-05%2F1d704c93-6267-4c91-acda-2bde88a97647%2Fistockphoto_1358625659_170667a.jpg?rect=0%2C3%2C553%2C290&w=1200&auto=format%2Ccompress&ogImage=true",
            "eventUri": null,
            "sentiment": -0.0980392156862745,
            "wgt": 421808460,
            "relevance": 1
        },
        {
            "uri": "7543862444",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-14",
            "time": "14:10:00",
            "dateTime": "2023-05-14T14:10:00Z",
            "dateTimePub": "2023-05-14T14:02:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://thenelsonpost.ca/news/291553/targeted-drugs-for-multiple-myeloma-industry-2023-growth-prospects-outlook-and-product-development-to-2030/",
            "title": "Targeted Drugs for Multiple Myeloma Industry 2023 Growth Prospects, Outlook and Product Development to 2030",
            "body": "The Targeted Drugs for Multiple Myeloma market report considers the major factors accountable for driving the growth of the Targeted Drugs for Multiple Myeloma Industry, in addition to the key hindrances and challenges. In the initial segment of the report, the market definition, market overview, product description, product scope, product characterization, and product specification has been discussed. The information presented in this report provides an overview of the latest trends and development plans, patterns, and policies observed in the global market. Moreover, the study offers an analysis of the latest events such as the technological advancements and the product launches and their consequences on the global Targeted Drugs for Multiple Myeloma market. The global market also comprises the data accumulated from numerous primary and secondary sources.\n\nClick to get Targeted Drugs for Multiple Myeloma Research Sample PDF Copy Here: https://globalmarketvision.com/sample_request/166331\n\nThe report highlights the latest trends in revenue and market progress, and all realistic statistics on ventures. It provides prevention and pre-planned management and highlights a summary of the global Targeted Drugs for Multiple Myeloma Market, along with classification, definition and market chain structure.\n\nMajor Market Players Profiled in the Report include:\n\nCelgene, SL Pharma, Natco Pharma, Intas Pharmaceuticals, Indiabulls Pharmaceutical, Cipla, Glenmark Pharmaceuticals, Dr Reddy's Laboratories, Qilu Pharmaceutical, Chia Tai-Tianqing, Hanson Pharm, Meidakang Huakang Pharmaceutical, Shandong Kongfu Pharmaceutical, J&J, Takeda, Amgen, Bristol Myers Squibb, Abbvie, Seattle Genetics, Karyopharm Therapeutics, PDL BioPharma, Roche, Sumitomo, Merck, Biogen, Schering-Plough, Glaxo, Chiron.\n\nImmunomodulator, Proteasome Inhibitors, Histone Deacetylase Inhibitors HDACI, Monoclonal Antibody\n\nFurthermore, the users of the report will acquire all the vital business facts and figures given by analysing numerous financial statements to regional advancements. The global economic factors play a great role in enhancing the quality of the analysis of the global Targeted Drugs for Multiple Myeloma Market, including many more specific market characteristics. Moreover, various new market features and aspects are well included to make the readers well informed about the entire market.\n\nAs the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.\n\nGeographically, the detailed analysis of consumption, revenue, market share, and growth rate of the following regions:\n\nAnalysis of the market:\n\nOther important factors studied in this report include demand and supply dynamics, industry processes, import & export scenario, R&D development activities, and cost structures. Besides, consumption demand and supply figures, cost of production, gross profit margins, and selling price of products are also estimated in this report.\n\nThe conclusion part of their report focuses on the existing competitive analysis of the market. We have added some useful insights for both industries and clients. All leading manufacturers included in this report take care of expanding operations in regions. Here, we express our acknowledgment for the support and assistance from the Targeted Drugs for Multiple Myeloma industry experts and publicizing engineers as well as the examination group's survey and conventions. Market rate, volume, income, demand and supply data are also examined.\n\nSome Points from Table of Content\n\nGlobal Targeted Drugs for Multiple Myeloma Market Research Report with Opportunities and Strategies to Boost Growth- COVID-19 Impact and Recovery\n\nChapter 6 Market Analysis and Forecast, By Product Types\n\nChapter 7 Market Analysis and Forecast, By Applications\n\nChapter 8 Market Analysis and Forecast, By Regions\n\nChapter 9 North America Targeted Drugs for Multiple Myeloma Market Analysis\n\nChapter 10 Europe Targeted Drugs for Multiple Myeloma Market Analysis\n\nChapter 11 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Analysis\n\nChapter 12 South America Targeted Drugs for Multiple Myeloma Market Analysis\n\nChapter 13 Middle East and Africa Targeted Drugs for Multiple Myeloma Market Analysis\n\nDirect Purchase this Market Research Report Now @ https://globalmarketvision.com/checkout/?currency=USD&type=single_user_license&report_id=166331\n\nIf you have any special requirements, please let us know and we will offer you the report at a customized price.\n\nThe final report will add the analysis of the Impact of Covid-19 in this report Targeted Drugs for Multiple Myeloma Market.\n\nAdapting to the recent novel COVID-19 pandemic, the impact of the COVID-19 pandemic on the global Targeted Drugs for Multiple Myeloma Market is included in the present report. The influence of the novel coronavirus pandemic on the growth of the Targeted Drugs for Multiple Myeloma Market is analyzed and depicted in the report.\n\nAbout Global Market Vision\n\nGlobal Market Vision consists of an ambitious team of young, experienced people who focus on the details and provide the information as per customer's needs. Information is vital in the business world, and we specialize in disseminating it. Our experts not only have in-depth expertise, but can also create a comprehensive report to help you develop your own business.\n\nWith our reports, you can make important tactical business decisions with the certainty that they are based on accurate and well-founded information. Our experts can dispel any concerns or doubts about our accuracy and help you differentiate between reliable and less reliable reports, reducing the risk of making decisions. We can make your decision-making process more precise and increase the probability of success of your goals.",
            "source": {
                "uri": "thenelsonpost.ca",
                "dataType": "news",
                "title": "Finance BC"
            },
            "authors": [],
            "image": null,
            "eventUri": null,
            "sentiment": 0.1058823529411765,
            "wgt": 421769400,
            "relevance": 51
        },
        {
            "uri": "7542774001",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-13",
            "time": "16:37:00",
            "dateTime": "2023-05-13T16:37:00Z",
            "dateTimePub": "2023-05-13T16:33:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.thehindu.com/business/us-fda-issues-observations-for-dr-reddys-unit/article66847628.ece",
            "title": "U.S. FDA issues observations for Dr. Reddy's unit",
            "body": "The United States Food and Drug Administration (U.S. FDA) has issued a Form 483 with four observations to a formulations manufacturing facility of pharma major Dr. Reddy's Laboratories in Srikakulam, Andhra Pradesh. The observations followed an inspection of the facility (FTO SEZ PU2). It was a product-specific pre-approval inspection and a routine GMP inspection and conducted from May 8-12. \"We have been issued a Form 483 with four observations, which we will address within the stipulated timeline,\" Dr. Reddy's said in an intimation to the stock exchange.",
            "source": {
                "uri": "thehindu.com",
                "dataType": "news",
                "title": "The Hindu"
            },
            "authors": [],
            "image": "https://www.thehindu.com/theme/images/og-image.png",
            "eventUri": null,
            "sentiment": 0.1058823529411765,
            "wgt": 421691820,
            "relevance": 26
        },
        {
            "uri": "7542332673",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-13",
            "time": "09:46:00",
            "dateTime": "2023-05-13T09:46:00Z",
            "dateTimePub": "2023-05-13T09:37:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.moneycontrol.com/news/business/stocks/reduce-dr-reddys-laboratories-target-of-rs-4500-prabhudas-lilladher-10575801.html",
            "title": "Reduce Dr. Reddy's Laboratories; target of Rs 4500: Prabhudas Lilladher",
            "body": "Dr. Reddy's (DRRD) Q4FY23 reported profitability was in line with our estimate. Adjusted for one-time divestment income (Rs2.65bn), EBITDA was 20% below our estimates impacted by lower GMs and higher overheads. Our FY24E and FY25E EPS stands reduced by 10% and 6% as we factor in lower margins ex of gRevlimid.\n\nOutlook\n\nWe downgrade stock to Reduce from Buy with revised TP of Rs4,500/share (Rs4,900 earlier). At CMP, DRRD is trading at expensive valuations of 24x P/E on FY25E adjusted for gRevlimid. Any big ticket ANDA approvals and sharp recovery in base business margins are key risks to our call.\n\nFor all recommendations report, click here\n\nDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.",
            "source": {
                "uri": "moneycontrol.com",
                "dataType": "news",
                "title": "MoneyControl"
            },
            "authors": [],
            "image": "https://images.moneycontrol.com/static-mcnews/2020/10/reduced-770x433.jpg",
            "eventUri": null,
            "sentiment": -0.07450980392156858,
            "wgt": 421667160,
            "relevance": 51
        },
        {
            "uri": "7542040319",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-13",
            "time": "04:58:00",
            "dateTime": "2023-05-13T04:58:00Z",
            "dateTimePub": "2023-05-13T04:52:00Z",
            "dataType": "news",
            "sim": 0.7450980544090271,
            "url": "https://www.inventiva.co.in/trends/dr-reddys-laboratories-one-of-the-best-pharma-companies-in-india-declines-and-becomes-nifty-50s-top-loser/",
            "title": "Great Pharma Firm Dr Reddy's Laboratories Becomes Nifty 50's Top Loser.",
            "body": "Dr Reddy's Laboratories Ltd's stock was the worst performer in the Nifty 50 recently, falling roughly 7% in response to the announcement of poor March quarter (Q4 FY23) earnings. Its revenue fell owing to reduced sales from gRevlimid and the US generics portfolio, resulting in a 530 bps sequential decline in its projected Ebitda margin to 25.1% for the March quarter.\n\nSome experts believed that early prices accounted for most of the benefits for Dr Reddy's. Before the presentation of the Q4 results, Dr Reddy's stock had risen 15% so far this calendar year. Adjusting for numerous divestments, the core Ebitda margins came in at around 21.9%, according to Antique Stock Broking analysts. It should be noted that Dr Reddy's introduced gRevlimid in the United States in Q2FY23, with a 180-day sales exclusivity for the 2.5 mg and 20 mg dosages. Lower revenues in the fourth quarter weighed on profits in the previous quarter.\n\nIn the US market, generic gRevlimid sales have been the most important contributors to revenue for Dr Reddy's. However, this category suffered a setback in the current quarter, falling by half to 17% compared to Q3 and Q2 sales. The EBITDA margin was 21.7% in the March 2023 quarter, down around 8% from the previous quarter. This demonstrates the abnormally large influence of gRevlimid. According to industry pundits, the dimming of gRevlimid's disproportionately large contribution owing to decreasing demand in the future spells pain for the corporation.\n\nThe road ahead is difficult for Dr Reddy's, with profit growth projected to slow in FY24 following a robust performance in FY23. Analysts are concerned that Dr Reddy's earnings will be dragged down by the high base of FY23 and the lack of visibility of possible products over the next two years.\n\nIn fiscal year 23, it introduced 25 new goods in the United States. It has a healthy pipeline of 81 abbreviated new drug applications or ANDAs. While gRevlimid represents a huge opportunity, sales may fluctuate once the exclusive period expires. Furthermore, without gRevlimid, substantial growth might be difficult.\n\nIn the future, the business wants to commercialise 25-30 molecules in the fiscal year 2024, including peptides and gPentasa, gCopaxone, and gVenofer. It plans to increase its presence in gAmitiza, gNuvaring, gRemodulin, and gLexiscan. Furthermore, with China's supply limits and the world embracing the 'China plus one policy, Dr Reddy is poised to gain from this long-term megatrend.\n\nJM Financial Institutional Securities Analysts predict the Mayne Pharma deal to be earnings accretive in FY24. The brokerage has accounted for the purchase in its projections. Dr Reddy's wants to be one of India's top five pharmaceutical corporations. Its domestic company may outperform industry growth as it follows inorganic expansion on the strength of robust cash flows. Price erosion, on the other pointer, remains a problem. In India, competition is fierce, with everyone vying for a piece of the chronic market. According to Unnati Jadhav, research analyst at Sharekhan by BNP Paribas, it may eventually lower Dr Reddy's market share.\n\nThe company's management anticipates dual-digit growth in all important markets in FY24. As a result, all focus will be on new product releases that generate money, sell existing commodities, and maintain quality at its facilities.\n\nHowever, margin performance may be tracked. The firm believes that the competitive intensity in the US business remains high. The lack of niche-limited competition products is likely to cap its core Ebitda margins at 22-23%. Furthermore, government efforts like the product-linked incentive (PLI) plan and the creation of bulk medication parks benefit Indian pharma enterprises.\n\nWe will have to wait and watch how the stocks perform in the markets going forward.\n\nProofread, Edited & Published By Naveenika Chauhan",
            "source": {
                "uri": "inventiva.co.in",
                "dataType": "news",
                "title": "Inventiva"
            },
            "authors": [],
            "image": "https://www.inventiva.co.in/wp-content/uploads/2023/05/Dr.-Reddys.jpg",
            "eventUri": "eng-8614427",
            "sentiment": -0.003921568627450966,
            "wgt": 421649880,
            "relevance": 51
        },
        {
            "uri": "7541450305",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-12",
            "time": "17:16:00",
            "dateTime": "2023-05-12T17:16:00Z",
            "dateTimePub": "2023-05-12T17:04:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.moneycontrol.com/news/business/stocks/neutral-dr-reddys-labs-target-of-rs-4500-motilal-oswal-10575031.html",
            "title": "Neutral Dr Reddy's Labs; target of Rs 4500: Motilal Oswal",
            "body": "Adj. for divestment of brands in the domestic formulation (DF) segment, Dr. Reddy's Labs (DRRD) recorded in-line sales in 4QFY23. However, it posted lower-than-expected EBITDA/PAT due to higher opex. DRRD delivered the highest-ever annual earnings in FY23, led by strong traction in g-Revlimid.\n\nOutlook\n\nWe reduce our earnings estimates for FY24/FY25 by 7%/7.5%, factoring in 1) higher SGA expenses, 2) prolonged slowdown in the CIS business, and 3) some price erosion in export markets. We continue to value DRRD's base business at 22x 12M forward earnings and add INR170 as NPV of g-Revlimid to arrive at a TP of INR4,500.\n\nFor all recommendations report, click here\n\nDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.",
            "source": {
                "uri": "moneycontrol.com",
                "dataType": "news",
                "title": "MoneyControl"
            },
            "authors": [],
            "image": "https://images.moneycontrol.com/static-mcnews/2020/06/neutral2-770x433.jpg",
            "eventUri": null,
            "sentiment": 0.1058823529411765,
            "wgt": 421607760,
            "relevance": 51
        },
        {
            "uri": "7540943078",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-12",
            "time": "11:35:00",
            "dateTime": "2023-05-12T11:35:00Z",
            "dateTimePub": "2023-05-12T10:55:00Z",
            "dataType": "news",
            "sim": 0.7098039388656616,
            "url": "https://finance.yahoo.com/news/indias-cipla-posts-45-jump-105542382.html",
            "title": "India's Cipla posts 45% jump in Q4 profit on domestic drugs business boost",
            "body": "BENGALURU (Reuters) - Cipla Ltd, India's third-largest drugmaker by sales, reported a 45.2% increase in fourth-quarter profit on Friday, driven by strength in its key domestic and North American drugs business.\n\nShares of the company, which manufactures generic versions of respiratory drugs Advair and Albuterol, were flat after the results but closed 0.7% lower in their second straight session of losses.\n\nCipla's consolidated net profit jumped to 5.26 billion rupees in the quarter ended March 31 from 3.62 billion rupees a year earlier.\n\nRevenue from sale of products rose 8.5% to 56.66 billion rupees. Revenue from its mainstay pharmaceutical business climbed nearly 7% to 55.36 billion rupees, while revenue from new ventures more than doubled to 2.34 billion rupees.\n\nCipla, which also makes anti-allergic drug Cetirizine, said revenue from its drugs business in India rose 3.5%, while revenue from its North American market surged 39%.\n\nCipla's profit growth had outpaced its revenue growth in the second and third quarters, helped by a smaller rise in operating expenses.\n\nThe company's EBITDA margins for the quarter expanded to 20.5% from 14.5% from a year earlier.\n\nThe Mumbai-based company expects to achieve adjusted EBITDA margin between 23%-24% in the financial year 2024, Cipla's Global Chief Executive Officer Umang Vohra said in a post-earnings call.\n\nCipla's peer Dr Reddy's Laboratories posted a jump in fourth-quarter profit on Wednesday, while Lupin Ltd swung to a profit from a loss last year.\n\n($1 = 81.7800 Indian rupees)\n\n(Reporting by Rama Venkat in Bengaluru; Editing by Sohini Goswami)",
            "source": {
                "uri": "finance.yahoo.com",
                "dataType": "news",
                "title": "Yahoo! Finance"
            },
            "authors": [],
            "image": "https://media.zenfs.com/en/reuters.com/4895431c1b7f99f3f8a8b5a78c2e4621",
            "eventUri": "eng-8612623",
            "sentiment": 0.2078431372549019,
            "wgt": 421587300,
            "relevance": 1
        },
        {
            "uri": "7540926520",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-12",
            "time": "11:23:00",
            "dateTime": "2023-05-12T11:23:00Z",
            "dateTimePub": "2023-05-12T11:14:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.wsj.com/articles/health-care-roundup-market-talk-ecb4df6",
            "title": "Health Care Roundup: Market Talk",
            "body": "The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.\n\n0545 GMT - Dr. Reddy's 4Q results disappointed Nomura analysts, but they maintain a buy rating on the stock, viewing its valuation as supported by investment in non-U.S. businesses and a strong balance sheet. They like the visibility of ramp-up in sales in China, Europe and other emerging markets, as well as value-accretive M&A. Dr. Reddy's expects its India business -- a bright spot in 4Q -- to grow further, and guides for double-digit growth in most EMs like China, where it makes up to 20 product filings a year. Dr. Reddy's expects strong growth in Europe to persist as it expands its product basket there, and its pipeline to boost sales in North America generics. Nomura has a INR5,161 target price on the stock, which was last at INR4,478. (fabiana.negrinochoa@wsj.com)",
            "source": {
                "uri": "wsj.com",
                "dataType": "news",
                "title": "The Wall Street Journal"
            },
            "authors": [],
            "image": "https://images.wsj.net/im-696832/social",
            "eventUri": null,
            "sentiment": 0.3490196078431373,
            "wgt": 421586580,
            "relevance": 75
        },
        {
            "uri": "7540906275",
            "lang": "eng",
            "isDuplicate": true,
            "date": "2023-05-12",
            "time": "11:11:00",
            "dateTime": "2023-05-12T11:11:00Z",
            "dateTimePub": "2023-05-12T11:10:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.zawya.com/en/world/indian-sub-continent/indias-cipla-posts-45-jump-in-q4-profit-on-domestic-drugs-business-boost-opjg2erw",
            "title": "India's Cipla posts 45% jump in Q4 profit on domestic drugs business boost",
            "body": "Cipla's peer Dr Reddy's Laboratories posted a jump in fourth-quarter profit on Wednesday\n\nCipla Ltd, India's third-largest drugmaker by sales, reported a 45.2% increase in fourth-quarter profit on Friday, driven by strength in its key domestic and North American drugs business.\n\nShares of the company, which manufactures generic versions of respiratory drugs Advair and Albuterol, were flat after the results but closed 0.7% lower in their second straight session of losses.\n\nCipla's consolidated net profit jumped to 5.26 billion rupees in the quarter ended March 31 from 3.62 billion rupees a year earlier.\n\nRevenue from sale of products rose 8.5% to 56.66 billion rupees. Revenue from its mainstay pharmaceutical business climbed nearly 7% to 55.36 billion rupees, while revenue from new ventures more than doubled to 2.34 billion rupees.\n\nCipla, which also makes anti-allergic drug Cetirizine, said revenue from its drugs business in India rose 3.5%, while revenue from its North American market surged 39%.\n\nCipla's profit growth had outpaced its revenue growth in the second and third quarters, helped by a smaller rise in operating expenses.\n\nThe company's EBITDA margins for the quarter expanded to 20.5% from 14.5% from a year earlier.\n\nThe Mumbai-based company expects to achieve adjusted EBITDA margin between 23%-24% in the financial year 2024, Cipla's Global Chief Executive Officer Umang Vohra said in a post-earnings call.\n\nCipla's peer Dr Reddy's Laboratories posted a jump in fourth-quarter profit on Wednesday, while Lupin Ltd swung to a profit from a loss last year. ($1 = 81.7800 Indian rupees) (Reporting by Rama Venkat in Bengaluru; Editing by Sohini Goswami)",
            "source": {
                "uri": "zawya.com",
                "dataType": "news",
                "title": "Zawya.com"
            },
            "authors": [],
            "image": "https://static.zawya.com/view/acePublic/alias/contentid/M2ZiMGIwMGEtMTBkZS00/1/200725064217aopa-jpeg.jpeg?f=3%3A2",
            "eventUri": null,
            "sentiment": 0.1607843137254903,
            "wgt": 421585860,
            "relevance": 51
        },
        {
            "uri": "7540883885",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-12",
            "time": "11:01:00",
            "dateTime": "2023-05-12T11:01:00Z",
            "dateTimePub": "2023-05-12T10:55:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.marketscreener.com//quote/stock/CIPLA-LIMITED-9058821/news/India-s-Cipla-posts-45-jump-in-Q4-profit-on-domestic-drugs-business-boost-43831503/",
            "title": "India's Cipla posts 45% jump in Q4 profit on domestic drugs business boost | MarketScreener",
            "body": "BENGALURU (Reuters) - Cipla Ltd, India's third-largest drugmaker by sales, reported a 45.2% increase in fourth-quarter profit on Friday, driven by strength in its key domestic and North American drugs business.\n\nShares of the company, which manufactures generic versions of respiratory drugs Advair and Albuterol, were flat after the results but closed 0.7% lower in their second straight session of losses.\n\nCipla's consolidated net profit jumped to 5.26 billion rupees in the quarter ended March 31 from 3.62 billion rupees a year earlier.\n\nRevenue from sale of products rose 8.5% to 56.66 billion rupees. Revenue from its mainstay pharmaceutical business climbed nearly 7% to 55.36 billion rupees, while revenue from new ventures more than doubled to 2.34 billion rupees.\n\nCipla, which also makes anti-allergic drug Cetirizine, said revenue from its drugs business in India rose 3.5%, while revenue from its North American market surged 39%.\n\nCipla's profit growth had outpaced its revenue growth in the second and third quarters, helped by a smaller rise in operating expenses.\n\nThe company's EBITDA margins for the quarter expanded to 20.5% from 14.5% from a year earlier.\n\nThe Mumbai-based company expects to achieve adjusted EBITDA margin between 23%-24% in the financial year 2024, Cipla's Global Chief Executive Officer Umang Vohra said in a post-earnings call.\n\nCipla's peer Dr Reddy's Laboratories posted a jump in fourth-quarter profit on Wednesday, while Lupin Ltd swung to a profit from a loss last year.\n\n($1 = 81.7800 Indian rupees)\n\n(Reporting by Rama Venkat in Bengaluru; Editing by Sohini Goswami)\n\nBy Rama Venkat",
            "source": {
                "uri": "marketscreener.com",
                "dataType": "news",
                "title": "Market Screener"
            },
            "authors": [],
            "image": "https://img.zonebourse.com/reuters/2023-05/2023-05-12T105542Z_1_LYNXMPEJ4B0D4_RTROPTP_3_CIPLA-RESULTS.JPG",
            "eventUri": null,
            "sentiment": 0.2078431372549019,
            "wgt": 421585260,
            "relevance": 1
        },
        {
            "uri": "7540851362",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-12",
            "time": "10:36:00",
            "dateTime": "2023-05-12T10:36:00Z",
            "dateTimePub": "2023-05-12T10:31:00Z",
            "dataType": "news",
            "sim": 0.6745098233222961,
            "url": "https://www.goodreturns.in/news/msci-reduces-weights-of-these-15-nifty-stocks-including-infosys-reliance-hdfc-1283278.html",
            "title": "MSCI Reduces Weights Of These 15 Nifty Stocks, Including Infosys, Reliance, HDFC",
            "body": "For Quick Alerts Subscribe Now Billionaire Gautam Adani's Firms Consider Raising Up To $5 Billion View Sample For Quick Alerts ALLOW NOTIFICATIONS For Daily Alerts Just In 1 hr ago Maruti Suzuki To Invest $5.5 Billion To Increase Production Capacity By 2030 1 hr ago Hindustan Aeronautics Q4 Results: Consolidated Net Profit Declines, Share Fall 2 hrs ago Billionaire Gautam Adani's Firms Consider Raising Up To $5 Billion 5 hrs ago 2 Adani Group Stocks To Be Dropped From MSCI Global Standard Index Don't Miss Sports DC vs PBKS: Ishant Sharma to Shikhar Dhawan - Players Who Can Cross Milestones In IPL 2023 Match 59 News A trip down memory lane: Karnataka's tryst with rocky coalition governments Movies Good Night Box Office Collection Day 1 Prediction: Manikandan Starrer Gets Amazing Response Lifestyle Mothers Day 2023: How To Be A Responsible And Caring Mother Inspite Of Being A Single Mom Education MHT CET Admit Card 2023 Issued for PCB Exams; Check Details Here Automobiles Maruti Suzuki Jimny Production Commences - Launch Details Inside Technology Tinder Updates Community Guidelines for Authenticity, Respect, and Inclusivity Travel Gjirokastra, Albania- Known for its Ottoman-era architecture Home News MSCI Reduces Weights Of These 15 Nifty Stocks, Including Infosys, Reliance, HDFC News oi-Aditi Murkute By Aditi Murkute | Published: Friday, May 12, 2023, 16:01 [IST]\n\nThe weights of total fifteen Nifty50 stocks were reduced by the MSCI Global Standard Index on Thursday as part of its May Global Index. MSCI decided to offload two of Adani Group stocks as well.\n\nApart from Adani Total Gas and Adani Transmission, MSCI reduced the weights of Infosys, Tata Consultancy Services, Tech Mahindra, and Mphasis, according to The Economic Times report. The weights of Reliance Industries, Bajaj Finance, Hindalco Industries, Bharat Petroleum Corp, JSW Steel, Divi's Laboratories, ICICI Bank, HDFC Ltd, Dr Reddy's Laboratories, Hindustan Unilever, Shree Cement, and Axis Bank were also cut.\n\nMSCI reduced Infosys' weight by 22 basis points which will result in net outflows of $134 million. RIL's weight has been reduced by 26 basis points, which will see net outflows of about $155 million, BPCL's weight has been cut by just 6 bps, which may trigger outflows of about $38 million.\n\nThe exit of Adani Transmission and Adani Total Gas from the MSCI Global will result in an outflow of $201million and $186 million. While the cut in weights of ICICI Bank, Axis Bank, and HDFC will lead to cumulative outflows of a little over $200 million, as per the Nuvama Alternative Quantitative Research estimates. The resultant total net outflow will likely be around $1 billion.\n\nHowever to replace the 15 stocks whose weights were reduced, MSCI increased the weightage of eight index stocks namely, Kotak Mahindra Bank, Mahindra & Mahindra, Maruti Suzuki India, Cipla, Oil and Natural Gas Corp, UltraTech Cement, NTPC, and Power Grid Corp of India.\n\nKotak Bank was increased by 135 bps in terms of the weightage, which alone will bring net inflows of over $800 million.The increase in the weight of other index stocks will result in net inflows of around $400 million.\n\nApart from the index stocks, Zomato, YES Bank, Samvardhana Motherson, and TVS Motor also saw an increase in their weights. Zomato's weight has been increased by 10 bps, which may see FII inflows of around $60 million.\n\nMORE MSCI NEWS Top Adani Energy Stocks To Buy With Bearish Market, Given Upto 168% Soaring Return In 1 Year MSCI Rejig: 7 Stocks Including Tata Power To Find Place In Sensex, Zomato To Be A Large-Cap Stock MSCI World Index: HDFC MF Launches First International Fund MSCI Semi-Annual Index Review: Adds 6 Stocks To India Index, 33 To Small Cap Index-Complete List Adani's 3 Companies May Be Included In MSCI India Index In May Bharti Airtel Up 5% On Possible Weightage Increase In MSCI Index MSCI Global Standard Index Rejig Effective Today 2 Indian Stocks Removed From MSCI Index In Semi-Annual Review, 12 Stocks Added MSCI to Tweak FOL In Indian Stocks; Huge Foreign Funds Expected Muthoot Finance Shares May Be Included In MSCI India Index After 70% Jump This Year MSCI India Index Revision Becomes Effective; 8 Stocks Added Why Do Changes In MSCI Index Matter To Indian Stocks? For investment related articles, business news and mutual fund advise Allow Notifications You have already subscribed Story first published: Friday, May 12, 2023, 16:01 [IST] Other articles published on May 12, 2023",
            "source": {
                "uri": "goodreturns.in",
                "dataType": "news",
                "title": "https://www.goodreturns.in/"
            },
            "authors": [
                {
                    "uri": "aditi_murkute@goodreturns.in",
                    "name": "Aditi Murkute",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://www.goodreturns.in/img/2015/09/16-1442375879-stock-market.jpg?12052023160555",
            "eventUri": "eng-8614335",
            "sentiment": 0.9843137254901961,
            "wgt": 421583760,
            "relevance": 26
        },
        {
            "uri": "7540810087",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-12",
            "time": "10:11:00",
            "dateTime": "2023-05-12T10:11:00Z",
            "dateTimePub": "2023-05-12T10:09:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://thenelsonpost.ca/news/291692/buspirone-market-to-flourish-with-an-impressive-cagr-by-2030-bristol-myers-squibb-apotex-dr-reddys-laboratories/",
            "title": "Buspirone Market to Flourish with an Impressive CAGR by 2030 | Bristol Myers Squibb, Apotex, Dr. Reddy's Laboratories",
            "body": "A2Z Market Research has published a report that represents the process of collecting, analyzing, and interpreting data about a Buspirone market. This is a crucial step in developing a business strategy or launching a new product, as it helps companies to gain a deeper understanding of the Buspirone market, identify customer needs and preferences, and assess competition in the industry.\n\nBuspirone, sold under the brand name Buspar among others, is a medication primarily used to treat anxiety disorders, particularly generalized anxiety disorder. Benefits support its short term use. It has not been found to be effective in treating psychosis. It is taken by mouth, and it may take up to four weeks for an effect.\n\nThis Buspirone research report highlights the key market players who are succeeding in the market. It tracks their business strategies, financial status, and upcoming products.\n\nSome of the top companies influencing this market are:\n\nBristol Myers Squibb\n\nApotex\n\nDr. Reddy's Laboratories\n\nLaboratoires Servier\n\nTeva\n\nAMAG Pharmaceuticals\n\nMylan\n\nNovartis\n\nWatson Laboratories\n\nHikma\n\nWockhardt\n\nCadila Healthcare\n\nOrion Corporation.\n\nThis Buspirone research report introduces the market by providing an overview that includes definitions, applications, product introductions, developments, challenges, and regions.\n\nBuspirone Market research is also conducted using various methods including surveys, focus groups, interviews and observations. The data collected is both qualitative (e.g. opinions, attitudes) and quantitative (e.g. statistics, numbers). The Buspirone market research results are then analyzed to draw conclusions and make informed decisions.\n\nThe regional coverage of the Buspirone market is mentioned in the report, with the main focus being on regions such as North America, South America, the Asia Pacific region, the Middle East and Africa, and Europe.\n\nGet Special pricing with up to 30% Discount on the first purchase of this report @: https://a2zmarketresearch.com/discount/1057847\n\nSegmentation: The Buspirone market is segmented by type, product, end-users, etc. Segmentation helps to provide an accurate explanation of the market.\n\nConclusion: Buspirone Market research also helps companies identify potential opportunities and threats in the industry, assess demand for a product or service, and determine the optimal strategy. It's an ongoing process that requires companies to stay up to date with the latest trends and changes in the Buspirone market in order to remain competitive.",
            "source": {
                "uri": "thenelsonpost.ca",
                "dataType": "news",
                "title": "Finance BC"
            },
            "authors": [],
            "image": null,
            "eventUri": null,
            "sentiment": 0.2705882352941176,
            "wgt": 421582260,
            "relevance": 26
        },
        {
            "uri": "7540695977",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-12",
            "time": "08:59:00",
            "dateTime": "2023-05-12T08:59:00Z",
            "dateTimePub": "2023-05-12T08:56:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://seekingalpha.com/news/3970652-gsk-says-canadian-court-dismisses-potential-zantac-class-suit",
            "title": "GSK says Canadian court dismisses potential Zantac class suit",
            "body": "GSK (NYSE:GSK) said it welcomed a Canadian court's decision to dismiss a proposed class action suit on behalf of a class of ranitidine users in Canada.\n\nThe British pharma giant said that the decision recognizes that after more than three years of study, the scientific consensus is that there is no reliable evidence that ranitidine increases the risk for any type of cancer.\n\nThe company added that since 2019 there have been 13 peer-reviewed epidemiological studies conducted looking at human data related to the use of ranitidine, sold as Zantac for heartburn.\n\n\"Given the uncontroverted evidence that neither ranitidine nor NDMA are reliably associated with increased cancer risk, and the absence of evidence that ranitidine or NDMA cause cancer in humans, the plaintiff has failed to raise a bona fide triable issue regarding injury due to the ingestion and/or purchase of ranitidine,\" said the British Columbia Supreme Court in Dussiaume v. Sandoz Canada Inc. 2023 BCSC 795, according to the company.\n\nGSK noted that it will continue to defend proposed class actions by ranitidine users which have been filed in Ontario and Quebec and individual actions by users of the drug in Canada.\n\nZantac (ranitidine) was pulled from the U.S. market in 2020 amid concerns over the unacceptable levels of potential human carcinogen, N-nitrosodimethylamine (NDMA).\n\nZantac lawsuits have been a cause of concern for not only GSK, but also Sanofi (SNY), GSK consumer spinoff Haleon (HLN), Pfizer (PFE), Teva Pharmaceutical (TEVA), Perrigo (PRGO), Dr. Reddy's Laboratories (RDY), and Boehringer Ingelheim.\n\nThe companies have faced thousands of lawsuits for alleged failure to adequately warn health risks of the antacid. A report from Bloomberg Businessweek in February, claimed that GSK chose to keep quiet on the cancer risks of Zantac.\n\nIn March, GSK said it disagreed with a California state court ruling in respect to the Goetz case related to Zantac. In December 2022, Sanofi and Pfizer had reached an agreement in a Zantac case in California that was set to go to trial, while GSK remained a defendant in the case.\n\nAlso last year, a federal judge in Florida ruled that GSK and Sanofi would not have to face thousands of lawsuits related to claims that Zantac allegedly cause cancer. GSK had noted that the court dismissed all Multi-District Litigation (MDL) cases alleging the five remaining cancers in the MDL.",
            "source": {
                "uri": "seekingalpha.com",
                "dataType": "news",
                "title": "Seeking Alpha"
            },
            "authors": [],
            "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1442119524/image_1442119524.jpg?io=getty-c-w750",
            "eventUri": null,
            "sentiment": -0.2784313725490196,
            "wgt": 421577940,
            "relevance": 1
        },
        {
            "uri": "7540614786",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-12",
            "time": "08:04:00",
            "dateTime": "2023-05-12T08:04:00Z",
            "dateTimePub": "2023-05-12T08:04:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://in.investing.com/news/large-cap-pharma-stock-falls-more-than-7-in-two-days-check-here-to-know-why-3641683",
            "title": "Large cap Pharma stock falls more than 7% in two days; Check here to know why",
            "body": "The shares of Dr. Reddy's Laboratories Ltd opened at the price of â‚¹4,543.30 on Friday, logging over a 7.60 percent downfall from two trading sessions from a price of â‚¹ 4,869 on Wednesday. One of the probable reasons for the low stock price movement is the company's recent announcement of Q4 FY 22-23 earnings.\n\nThe company posted positive Q4 FY23 results on Wednesday but missed shy of the street's estimated profit of â‚¹1,093.6 crore (As per Elara Securities Pvt Ltd).\n\nAs per Consolidated financials of the previous quarter, their operating revenues have declined from â‚¹ 6,789 crores in Q3 to â‚¹ 6,315 crores in Q4. Similarly, for YoY comparison, the revenues significantly increased from â‚¹ 21,545 crores during FY 21-22 to â‚¹ 24,669 crores in FY 22-23.\n\nThe net profit of the company has declined from â‚¹ 1,237 crores in Q3 to â‚¹ 952 crores in Q4, Similarly, for YoY comparison the net profit significantly increased from â‚¹ 2,122 crores during FY 21-22 to â‚¹ 4,470 crores in FY 22-23.\n\nDr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company that offers a portfolio of products and services, including Active Pharmaceutical Ingredients, Custom Pharmaceutical services generics, biosimilars, and differentiated formulations, catering to both domestic and international clients.\n\nThe company declared a final dividend of â‚¹40 (800% of the face value of Rs 5 ) per equity share for FY23.\n\nOver the previous fiscal year, the company introduced new products and benefitted from favourable currency moves, resulting in a 27% year-on-year (YoY) growth in US business to â‚¹ 2,532 crore, and an 11.6% YoY gain in European sales to 496 crores.\n\nIn India, the company released nine new items, which led to an increase in revenue growth of 32.5% year on year to â‚¹ 1283.4 crores And the company reported a Net cash surplus of â‚¹ 50.5 billion and a free cash flow of â‚¹ 40.1 billion as of March FY23.\n\nThe basic profitability ratios exhibiting operational efficiencies such as return on equity (ROE) and return on capital employed (ROCE) showed an upward trend in the past couple of financial years. ROE moved from 11.35 percent during FY 21-22 to 19.35 percent in FY 22-23 and ROCE, keeping the time frame the same, took a shift from 15.44 percent to 25.95 percent and The debt-to-equity ratio stands at 0.06.\n\nOn a last year-to-date basis, the stock gained 6.22 percent ranging from â‚¹ 4,238.35 to the current price level. In the previous three years, the stock has gained around 19.28 percent ranging from â‚¹ 3,735 to the current price level.\n\nAccording to the latest data pertaining to the shareholding pattern, the promoters hold a 26.69 percent stake, and Foreign Institutional Investors (FIIs) hold a 27.25 percent stake in the company for FY 22-23.\n\nWritten by Omkar\n\nThe post Large cap Pharma stock falls more than 7% in two days; Check here to know why appeared first on Trade Brains.",
            "source": {
                "uri": "in.investing.com",
                "dataType": "news",
                "title": "Investing.com India"
            },
            "authors": [],
            "image": "https://i-invdn-com.investing.com/news/https://i-invdn-com.investing.com/akapi-images/800x450/edc80cb895dc4560db26183b67cbbbbb_w_800_h_450.jpg",
            "eventUri": null,
            "sentiment": 0.3333333333333333,
            "wgt": 421574640,
            "relevance": 75
        },
        {
            "uri": "7540491840",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-12",
            "time": "06:36:00",
            "dateTime": "2023-05-12T06:36:00Z",
            "dateTimePub": "2023-05-12T06:35:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://economictimes.indiatimes.com/markets/stocks/news/nearly-1-billion-outflow-msci-reduces-weights-of-these-15-nifty-stocks/articleshow/100178576.cms",
            "title": "Nearly $1 billion outflow! MSCI reduces weights of these 15 Nifty stocks",
            "body": "MSCI Inc has reduced the weightage of 15 Nifty50 stocks as part of its May global index review. The downgrades will cause net outflows of nearly $1bn. Weights of Tech Mahindra, Tata Consultancy Services, Infosys and Mphasis have been cut. Weights for Axis Bank, Bajaj Finance, Divi's Laboratories, ICICI Bank, HDFC, Hindalco Industries, Bharat Petroleum Corp and JSW Steel have also been reduced. The weights of eight index stocks, including Kotak Mahindra Bank, NTPC and UltraTech Cement have been increased, resulting in net inflows of approximately $400m.MSCI Inc on Thursday, reduced the weightage of 15 Nifty50 stocks as part of its May global index review, and this is likely to result in net outflows of nearly $1 billion, according to estimates by Nuvama Alternative Quantitative Research.\n\nIn the information technology pack alone, the weights of four stocks namely Infosys, Tata Consultancy Services, Tech Mahindra, and Mphasis, have been cut.\n\nApart from these, weights have been reduced for Reliance Industries, Bajaj Finance, Hindalco Industries, Bharat Petroleum Corp, JSW Steel, Divi's Laboratories, ICICI Bank, HDFC Ltd, Dr Reddy's Laboratories, Hindustan Unilever, Shree Cement, and Axis Bank.\n\nRIL's weight has been reduced by 26 basis points, which will see net outflows of about $155 million, Nuvama said. Shares of the conglomerate were trading about 1% down at Rs 2,462.85.\n\nMSCI has reduced Infosys' weight by 22 basis points which will result in net outflows of $134 million. This saw the stock drop by around 1% in trade today.\n\nThe weight of TCS has been reduced by 10 basis points which is expected to result in net outflows of about $61 million.\n\nIn banks and financials, the cut in weights of ICICI Bank, Axis Bank, and HDFC will lead to cumulative outflows of a little over $200 million, Nuvama said.\n\nBPCL's weight has been cut by just 6 bps, which may trigger outflows of about $38 million. The stock was the worst hit in Nifty50 pack, down 2.6% at Rs 362.95.\n\nWEIGHTS INCREASED\n\nWhile on one hand, the weights of 15 Nifty stocks were reduced, MSCI increased the weightage of eight index stocks namely, Kotak Mahindra Bank, Mahindra & Mahindra, Maruti Suzuki India, Cipla, Oil and Natural Gas Corp, UltraTech Cement, NTPC, and Power Grid Corp of India.\n\nKotak Bank saw a whopping 135 bps increase in the weightage, which alone will bring net inflows of over $800 million.\n\nThe increase in the weight of other index stocks will result in net inflows of around $400 million.\n\nApart from the index stocks, Zomato, YES Bank, Samvardhana Motherson, and TVS Motor also saw an increase in their weights.\n\nZomato's weight has been increased by 10 bps, which may see FII inflows of around $60 million. However, the news failed to move the stock, which was down 0.6%.\n\n(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-100178576,width-1070,height-580,imgsize-14458,overlay-etmarkets/photo.jpg",
            "eventUri": null,
            "sentiment": -0.01960784313725494,
            "wgt": 421569360,
            "relevance": 26
        },
        {
            "uri": "7540351387",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-12",
            "time": "04:29:00",
            "dateTime": "2023-05-12T04:29:00Z",
            "dateTimePub": "2023-05-12T04:28:00Z",
            "dataType": "news",
            "sim": 0.6117647290229797,
            "url": "https://www.rttnews.com/3363641/sensex-nifty-open-lower-as-pharma-and-metal-stocks-drag.aspx",
            "title": "Sensex, Nifty Open Lower As Pharma And Metal Stocks Drag ",
            "body": "Indian shares opened lower on Friday, with uncertainty over the U.S. debt ceiling and jitters over the health of U.S. regional banks keeping investors nervous.\n\nTraders also looked ahead to the release of domestic CPI data later in the day for directional cues.\n\nThe benchmark S&P BSE Sensex was down 280 points, or half a percent, at 61,625 in early trade, while the broader NSE Nifty index was down 86 points, or half a percent at 18,210.\n\nDivis Laboratories led losses to fall about 4 percent while Dr Reddy's Laboratories, JSW Steel, Hindalco and BPCL were down 2-3 percent.\n\nAdani Enterprises fell about 1 percent ahead of a board meet on Saturday to consider fund raising.\n\nAsian Paints dropped 1 percent despite reporting a 45 percent jump in Q4 net profit.\n\nEicher Motors soared 6.6 percent on posting robust quarterly earnings.\n\nUjjivan Small Finance Bank jumped 4.4 percent on reporting a two-fold rise in March quarter net profit.\n\nAdani Transmission slumped 4.5 percent, Adani Total Gas lost 5 percent and Indus Towers declined 1.7 percent after they have been removed from the MSCI India Index.\n\nTata Motors gained half a percent ahead of its earnings release.\n\nONGC rose half a percent on news it has discovered oil and gas reserves in Mumbai offshore fields located in the Arabian Sea.\n\nReliance Industries shed 0.7 percent after German retailer METRO AG completed sale of its Indian cash and carry business to Reliance Retail.\n\nFor comments and feedback contact: editorial@rttnews.com",
            "source": {
                "uri": "rttnews.com",
                "dataType": "news",
                "title": "RTTNews"
            },
            "authors": [],
            "image": "https://cdn.rttnews.com/images/v4/RTTNews-logo-512x512.png",
            "eventUri": "eng-8612128",
            "sentiment": 0.01960784313725483,
            "wgt": 421561740,
            "relevance": 26
        },
        {
            "uri": "7540263575",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-12",
            "time": "02:55:00",
            "dateTime": "2023-05-12T02:55:00Z",
            "dateTimePub": "2023-05-12T02:46:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://economictimes.indiatimes.com/markets/stocks/news/big-movers-on-d-st-what-should-investors-do-with-ratnamani-metal-dr-reddys-laboratories-and-fsl/articleshow/100173230.cms",
            "title": "Big Movers on D-St: What should investors do with Ratnamani Metal, DR Reddy's Laboratories and FSL?",
            "body": "The S&P BSE Sensex and Nifty50 in India closed flat with a negative bias. Stocks in capital goods, healthcare, metals, and energy sectors experienced selling pressure, while consumer durables, FMCG, power, and utilities saw some buying. Ratnamani Metals rose over 6%, Dr Reddy's Laboratories fell nearly 7%, and Firstsource Solutions closed near its 52-week high on Thursday. Technically, Amol Athawale, Deputy Vice President of Technical Research at Kotak Securities, suggests that Ratnamani Metals could experience pricing issues below 2325, Dr Reddy's Laboratories has weak momentum, and FSL could encounter profit booking.Indian market pared gains and closed negative on Thursday. The S&P BSE Sensex and Nifty50 closet flat with a negative bias.\n\nSectorally, selling was seen in capital goods, metals, healthcare, and energy stocks while some buying was visible in power, utilities, consumer durables, and FMCG stocks.\n\nStocks that were in focus include names like Ratnamani Metals which rose more than 6%, Dr Reddy's Laboratories which fell nearly 7% and Firstsource Solutions which closed near its 52-week high on Thursday.\n\nHere's what Amol Athawale, Deputy Vice President - Technical Research, Kotak Securities Ltd recommends investors should do with these stocks when the market resumes trading today:\n\nRatnamani Metal: Below 2325 uptrend would be vulnerable\n\nThe stock has rallied over 20% so far in this quarter. Last Thursday, it opened on a gap-up note and registered a fresh all-time high of 2528.\n\nHowever, due to profit booking at higher levels, it trimmed some intraday gains. We are of the view that the short-term texture of the stock is bullish but mildly overbought.\n\nHence, we could expect rangebound activity in the near term. Technically, 2350-2325 would be the immediate support level while on the upside, 2525 -2550 could be the immediate hurdle for the bulls.\n\nOn the flip side, below 2325, the uptrend would be vulnerable.\n\nDr. Reddy's Laboratories: Weak momentum is likely to continue\n\nAfter a promising uptrend rally, the stock corrected sharply. This week, it has corrected by over 8%. A sharp reversal formation and long bearish candle on weekly charts indicate further weakness from the current levels.\n\nTechnically, as long as the stock is trading below the 50-Day SMA (Simple Moving Average) or 4650, weak momentum is likely to continue.\n\nBelow the same, the stock could slip towards Rs 4500-4425. On the other side, a minor pullback rally is possible if the stock succeeds to trade above 4570.\n\nA close above the same could move the stock higher towards Rs 4600-4620.\n\nFSL: Profit booking at higher levels\n\nThe stock has rallied nearly 25% so far in this quarter. After reversal formation, the stock successfully cleared the medium-term resistance of 125, and post the breakout, it intensified the positive momentum.\n\nOn the daily and weekly charts, the stock has formed a breakout continuation formation. We are of the view that the short-term texture of the market is bullish but due to temporarily overbought conditions we could see some profit booking at higher levels.\n\nFor trend-following traders, buying on dips and selling on rallies would be the ideal strategy. Technically, 127-125 would be the key support zones while 137-143 could be the immediate profit booking area for the bulls.\n\nOn the flip side, below 125, traders may prefer to exit from the trading long positions\n\n(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-100173216,width-1070,height-580,imgsize-54240,overlay-etmarkets/photo.jpg",
            "eventUri": null,
            "sentiment": 0.02745098039215677,
            "wgt": 421556100,
            "relevance": 100
        },
        {
            "uri": "7540244991",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-12",
            "time": "02:35:00",
            "dateTime": "2023-05-12T02:35:00Z",
            "dateTimePub": "2023-05-12T02:30:00Z",
            "dataType": "news",
            "sim": 0.6235294342041016,
            "url": "https://www.thehindubusinessline.com/portfolio/news-analysis/dr-reddys-q4-results-why-the-stock-fell-7-and-what-it-means-for-investors/article66839094.ece",
            "title": "Dr Reddy's Q4 results: Why the stock fell 7% and what it means for investors",
            "body": "Dr. Reddy reported revenue growth of 20 per cent YoY to â‚¹6,297 crore and an EBITDA margin of 25 per cent in Q4FY23 results. But adjusted for divestment proceeds in the current quarter and the base quarter, the revenue growth was at 16 per cent YoY, which was in line with consensus estimates. The adjusted EBITDA margin on the other hand, without divestment income, is closer to around 22 per cent, missing the consensus expectation of a 25 per cent EBITDA margin. Despite the reported quarter being backed by a strong margin US portfolio and favourable forex movement, margins missed expectations. The stock declined by 7 per cent on the day following the results, driven by miss versus consensus and the sequential dip in gRevlimid sales.\n\ngRevlimid uncertainty\n\nDr. Reddy's US sales at $312 million was up 17 per cent YoY. But sequentially was $50 million lower than the last two quarters' average run rate, when gRevlimid contributions started. This could be tied to volume-limited launch contracts for gRevlimid or channel destocking. Management expects stable contribution from the product in FY24.\n\nThe quarter also witnessed 16 launches in the US, and the company reported 25 launches in the year. Dr Reddy expects to sustain a similar launch momentum in FY24 as well, with stable contribution from gRevlimid driving strong growth in US markets. But the investor focus may be centred on dip in sales post FY26 when gRevlimid opportunity may sharply decline and margin performance following the dip.\n\nAlso read: Dr Reddy's launches generic Treprostinil injection\n\nIndia and pipeline\n\nIndia accounts for 20 per cent of Q4FY23 revenues with US/Emerging markets/Europe accounting for 40/18/8 per cent of revenues. Dr. Reddy has been divesting non-core brands in India and in-licensing brands to restructure its India portfolio, which it considers its key market. India, excluding divestment income and Covid sales, reported 11 per cent growth YoY in the quarter. Apart from in-licensing to complement its domestic portfolio, the company plans to increase its footprint, which should gain from the focussed portfolio.\n\nThe international biosimilar portfolio is progressing as per Dr Reddy's quarterly update. Pegfilgrastim launch by Dr Reddy's commercial partner, Fresenius Kabi, in developed markets, filing for Rituximab in the US, Europe, and the UK and global phase-III trials for tocilizumab are in progress. The company has also in-licensed or got into a strategic partnership with others, including medical devices and CAR-T assets for trials in India in the long run.\n\nAlso read: About 25% of Dr Reddy's products to be first-to-market by 2027: Co-chairman GV Prasad\n\nValuation\n\nPost the 7 per cent dip, Dr. Reddy is trading at 18 times one year forward earnings . The valuation takes into account contribution from gRevlimid earnings in FY24 which are largely one time lumpsum gains. With the strong cash flows from US portfolio, focussed India portfolio, a start from Biosimilar revenue stream in developed markets and commercialisation of current pipeline in development, Dr. Reddy should sustain earnings even beyond gRevlimid earnings cliff in FY26. The cost of development will be reflected in muted margin growth in the meanwhile, despite strong product mix. We reiterate our accumulate rating on Dr. Reddy stock considering the strong product mix and product development underway. .\n\nSHARE Copy linkEmailFacebookTwitterTelegramLinkedInWhatsAppRedditPublished on May 12, 2023",
            "source": {
                "uri": "thehindubusinessline.com",
                "dataType": "news",
                "title": "@businessline"
            },
            "authors": [],
            "image": "https://bl-i.thgim.com/public/news/qyh01x/article65702251.ece/alternates/LANDSCAPE_1200/dr%20reddys.jpg",
            "eventUri": "eng-8614427",
            "sentiment": 0.08235294117647052,
            "wgt": 421554900,
            "relevance": 51
        },
        {
            "uri": "7540158717",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-12",
            "time": "00:46:00",
            "dateTime": "2023-05-12T00:46:00Z",
            "dateTimePub": "2023-05-12T00:38:00Z",
            "dataType": "news",
            "sim": 0.6117647290229797,
            "url": "https://economictimes.indiatimes.com/markets/stocks/news/analysts-fret-about-drls-prospects-slash-targets/articleshow/100171613.cms",
            "title": "Analysts fret about DRL's prospects, slash targets",
            "body": "Mumbai: Shares of Dr Reddy's Laboratories tanked nearly 7% Thursday, its biggest single-day fall in two-and-a-half months, as analysts flagged concerns over future growth prospects despite a 10-fold growth in fourth quarter consolidated net profit and dividend to shareholders.\n\nThe Hyderabad-based pharma major was the biggest loser on the bourses with trading volume rising nearly 10 times after a majority of the analysts slashed their price targets. The stock made an intraday low of â‚¹4,524.05 apiece in Thursday's trading before closing at â‚¹4,532, down 6.9%.\n\n\"Revlimid sales drop leads to miss on estimates,\" said Jefferies in a client note. \"The US sales could remain volatile but the new product launch momentum remains strong across geographies.\"\n\nThe US brokerage sees a 23% upside potential from current levels and remains the most optimistic on the stock even after lowering FY24 EPS by 5% owing to lower margins.\n\nOn Thursday, Dr Reddy's reported an 890% year-on-year growth in consolidated net profit for the fourth quarter at â‚¹960.1 crore, while revenue (from operations) grew 15.28% to â‚¹5,843 crore.\n\nJP Morgan sees the likelihood of a 17% downside with the brokerage too cutting its price target. Brokerage Nuvama downgraded the stock with a revised target price that translates into a potential 8% decline from current levels.\n\nOf the 23 analysts who reviewed Dr Reddy's fourth-quarter earnings, eight have a 'buy' or 'outperform' rating and 13 had 'hold' or 'reduce'.",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-100171628,width-1070,height-580,imgsize-921756,overlay-etmarkets/photo.jpg",
            "eventUri": "eng-8614427",
            "sentiment": 0.07450980392156858,
            "wgt": 421548360,
            "relevance": 51
        },
        {
            "uri": "7540033803",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "22:08:00",
            "dateTime": "2023-05-11T22:08:00Z",
            "dateTimePub": "2023-05-11T21:59:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://thenelsonpost.ca/news/280218/medication-assisted-treatment-mat-industry-projected-to-be-resilient-during-2023-2030/",
            "title": "Medication-Assisted Treatment (MAT) Industry Projected to be Resilient During 2023-2030",
            "body": "Global Market Vision has recently added a new informative report, titled \"Global Medication-Assisted Treatment (MAT) market\" to its ever-expanding database. The Medication-Assisted Treatment (MAT) market is analyzed with an aim to provide assistance to the readers to gain maximum returns on the investment and to enable an informed decision-making process. The report is furnished with the latest updates about the current market scenario with regards to the COVID-19 pandemic. It covers all the essential features of the Medication-Assisted Treatment (MAT) market, with key statistical data represented in the form of tables, charts, diagrams, figures, and graphs. Medication-Assisted Treatment (MAT) market report provides study with in-depth overview, describing about the Product/Industry Scope and elaborates market outlook and status (2023-2030). The research study gives a near look at the market scenario and dynamics impacting its growth. This report highlights the crucial developments along with other events happening in the market which are marking on the growth and opening doors for future growth in the coming years. Additionally, the report is built on the basis of the macro- and micro-economic factors and historical data that can influence the growth.\n\nGet PDF Sample Copy Of This Report (Including Full TOC, Table & Figures) @ https://globalmarketvision.com/sample_request/254813\n\nThis report focuses on Medication-Assisted Treatment (MAT) volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Medication-Assisted Treatment (MAT) market size by analysing historical data and future prospect.\n\nSome of the key players in the Global Medication-Assisted Treatment (MAT) Market are Company Coverage (Company Profile, Sales Revenue, Price, Gross Margin, Main Products, etc.):\n\nIndivior PLC, Recovery Centers of America, Orexo US Inc (a subsidiary of Orexo AB), Alkermes. Sun Pharmaceutical Industries Ltd., Taj Pharmaceuticals Limited, Purdue Pharma L.P., Lannett, Pfizer Inc., Hikma Pharmaceuticals PLC, Pinnacle Treatment Center, Adamis Pharmaceuticals Corporation, American Addiction Centers, Glenmark Pharmaceutical Inc. Viatris Inc., Alvogen, Mallinckrodt, Accord Healthcare, Teva Pharmaceutical Industries Ltd. Dr. Reddy's Laboratories Ltd. Amneal Pharmaceuticals LLC. Titan Pharmaceuticals, VistaPharm\n\nThe report provides an in-depth examination of all the market risks and opportunities. It contains all the vital information regarding the latest technologies and trends being adopted or followed by the vendors in this market. The report an in-depth examination of all the market risks and opportunities. The analysis covered in the report helps manufacturers in the global Medication-Assisted Treatment (MAT) industry in eliminating the risks offered by the global market. The market research report also offers readers with full documentation of past market valuation, present dynamics and future projections regarding market volume and size.\n\nGlobal Medication-Assisted Treatment (MAT) Market Segmentation:\n\nHospital PharmacyDirect TenderRetail PharmacyOnline Pharmacy and Others\n\nIn this report, the pre- and post-COVID impact on the market growth and development is well depicted for better understanding of the Medication-Assisted Treatment (MAT) Market based on the financial and industrial analysis. The COVID-19 pandemic has affected a number of market and Global Medication-Assisted Treatment (MAT) Market is no exception. However, the dominating players of the Global Medication-Assisted Treatment (MAT) Market are adamant to adopt new strategies and look for new funding resources to overcome the rising obstacles in the market growth.\n\nMedication-Assisted Treatment (MAT) market report provides answer for following question:\n\nStudy objectives of Medication-Assisted Treatment (MAT) Market Report:\n\nAccess Full Report @ https://globalmarketvision.com/checkout/?currency=USD&type=single_user_license&report_id=254813\n\nIf you have any special requirements, please let us know and we will offer you the report at a customized price.\n\nAbout Global Market Vision\n\nGlobal Market Vision consists of an ambitious team of young, experienced people who focus on the details and provide the information as per customer's needs. Information is vital in the business world, and we specialize in disseminating it. Our experts not only have in-depth expertise, but can also create a comprehensive report to help you develop your own business.\n\nWith our reports, you can make important tactical business decisions with the certainty that they are based on accurate and well-founded information. Our experts can dispel any concerns or doubts about our accuracy and help you differentiate between reliable and less reliable reports, reducing the risk of making decisions. We can make your decision-making process more precise and increase the probability of success of your goals.",
            "source": {
                "uri": "thenelsonpost.ca",
                "dataType": "news",
                "title": "Finance BC"
            },
            "authors": [],
            "image": null,
            "eventUri": null,
            "sentiment": 0.3019607843137255,
            "wgt": 421538880,
            "relevance": 26
        },
        {
            "uri": "7539873914",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "19:34:00",
            "dateTime": "2023-05-11T19:34:00Z",
            "dateTimePub": "2023-05-11T19:34:00Z",
            "dataType": "news",
            "sim": 0.6392157077789307,
            "url": "https://www.livemint.com/market/mark-to-market/after-a-weak-quarter-dr-reddy-s-stares-at-a-gradual-recovery-11683833169772.html",
            "title": "After a weak quarter, Dr Reddy's stares at a gradual recovery",
            "body": "Dr Reddy's Laboratories Ltd's stock emerged as the top loser among the Nifty 50 companies on Thursday, dropping nearly 7% following the release of disappointing March quarter (Q4 FY23) earnings. Its revenue took a hit due to lower sales from gRevlimid and the US generics portfolio, which resulted in a sequential decline of 530 basis point in its calculated Ebitda margin to 25.1% for the March quarter.\n\nSome analysts reckoned that the valuations were factoring in most of the positives initially. So far this calendar year, the stock gained 15% before its Q4 result announcement.\"Adjusting for various divestments, the core Ebitda margins as per our estimates came in at about 21.9%,\" said Antique Stock Broking analysts. Note, the company had launched gRevlimid in US in Q2FY23 with sales exclusivity of 180 days for 2.5 mg and 20 mg strengths. Its lower sales in Q4 weighed on the last quarter's profitability.\n\nThe path ahead seems tough with profit growth expected to moderate in FY24 after a strong performance in FY23. Analysts worry that the high base of FY23 and limited visibility of potential products over the next two years may drag Dr Reddy's earnings.\n\nIn FY23, it launched 25 new products in the US. Further, it has a robust pipeline of 81 abbreviated new drug applications, or ANDAs. While gRevlimid offers significant opportunity, its sales may fluctuate as the exclusivity period is over. Moreover, substantial growth, excluding gRevlimid, could be challenging.\n\nAmong positives, JM Financial Institutional Securities' analysts expect the Mayne Pharma acquisition to be earning accretive in FY24 itself. The brokerage has factored the acquisition into their estimates. Dr Reddy's aspires to be one of the top five pharma companies in India. Its domestic business may beat industry growth, as it explores inorganic growth on the back of strong cash -flows. However, price erosion remains a concern. \"Competition is high in India with everyone wanting a share of the chronic segment. It may eventually reduce market share for Dr Reddy's,\" Unnati Jadhav, research analyst at Sharekhan by BNP Paribas, said.\n\nThe company's management expects all key markets to grow in double digits in FY24. Thus, all eyes will be on new launches, which can fetch revenues, sales of existing products and maintaining quality at its facilities.\n\nMargin performance is monitorable, though. \"We continue to believe the competitive intensity remains high in the US business and lack of niche limited competition products is likely to cap its core Ebitda margins at 22-23%,\" said Antique's analysts.",
            "source": {
                "uri": "livemint.com",
                "dataType": "news",
                "title": "mint"
            },
            "authors": [
                {
                    "uri": "aprajita_sharma@livemint.com",
                    "name": "Aprajita Sharma",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://www.livemint.com/lm-img/img/2023/05/11/600x338/DrReddys_1683833219162_1683833219394.jpg",
            "eventUri": "eng-8614427",
            "sentiment": 0.09019607843137245,
            "wgt": 421529640,
            "relevance": 51
        },
        {
            "uri": "7539863851",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "19:25:00",
            "dateTime": "2023-05-11T19:25:00Z",
            "dateTimePub": "2023-05-11T19:14:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://newsdaemon.com/2023/05/11/dr-reddys-laboratories-limited-rdy-plunge-4-13-in-a-week-will-this-be-a-lucky-break-through/",
            "title": "Dr. Reddy's Laboratories Limited (RDY) plunge -4.13% in a week: will this be a lucky break through? - News Daemon",
            "body": "Dr. Reddy's Laboratories Limited (NYSE: RDY) flaunted slowness of -3.01% at $58.55, as the Stock market unbolted on May 10, 2023. During the day, the stock rose to $58.69 and sunk to $56.50 before settling in for the price of $60.37 at the close. Taking a more long-term approach, RDY posted a 52-week range of $49.59-$61.40.\n\nThe Healthcare sector firm's twelve-monthly sales growth has been 8.80% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 14.50%. Nevertheless, stock's Earnings Per Share (EPS) this year is 36.70%. This publicly-traded company's shares outstanding now amounts to $166.08 million, simultaneously with a float of $166.00 million. The organization now has a market capitalization sitting at $9.73 billion. At the time of writing, stock's 50-day Moving Average stood at $57.36, while the 200-day Moving Average is $54.36.\n\nIt is quite necessary to find out the efficiency of the corporate organization, which has 24795 number of employees on its payroll. It has generated 8,646,542 per worker during the last fiscal year. Meanwhile, its income per employee was 950,514. The stock had 3.02 Receivables turnover and 0.77 Total Asset turnover. For the Profitability, stocks gross margin was +50.21, operating margin was +16.08 and Pretax Margin of +14.74.\n\nSometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Dr. Reddy's Laboratories Limited industry. Dr. Reddy's Laboratories Limited's current insider ownership accounts for 27.70%, in contrast to 10.30% institutional ownership.\n\nGoing through the last 3-months fiscal report unveiled on the 12/30/2022, it has been observed that the corporation posted $0.91 earnings per share (EPS) during the time that was better the consensus figure (set at $0.58) by $0.33. This company achieved a net margin of +10.99 while generating a return on equity of 12.96. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.\n\nDr. Reddy's Laboratories Limited's EPS increase for this current 12-month fiscal period is 36.70% and is forecasted to reach 3.67 in the upcoming year. Considering the longer run, market analysts have predicted that Company's EPS will increase by 34.70% through the next 5 years, which can be compared against the 14.50% growth it accomplished over the previous five years trading on the market.\n\nLet's observe the current performance indicators for Dr. Reddy's Laboratories Limited (RDY). It's Quick Ratio in the last reported quarter now stands at 1.70. The Stock has managed to achieve an average true range (ATR) of 0.86. Alongside those numbers, its PE Ratio stands at $21.90, and its Beta score is 0.50. Another valuable indicator worth pondering is a publicly-traded company's price to sales ratio for trailing twelve months, which is currently 3.35. Similarly, its price to free cash flow for trailing twelve months is now 22.18.\n\nIn the same vein, RDY's Diluted EPS (Earnings per Share) trailing twelve months is recorded 2.67, a figure that is expected to reach 0.64 in the next quarter, and analysts are predicting that it will be 3.67 at the market close of one year from today.\n\nNow, what If we examine the latest scores posted by [Dr. Reddy's Laboratories Limited, RDY]. During the last 5-days, its volume was better the volume of 0.21 million it reported in year-ago period. During the previous 9 days, stock's Stochastic %D was recorded 37.15% While, its Average True Range was 0.96.\n\nRaw Stochastic average of Dr. Reddy's Laboratories Limited (RDY) in the period of the previous 100 days is set at 72.30%, which indicates a major rise in contrast to 41.84% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company's historic volatility was 19.28% that was higher than 17.22% volatility it exhibited in the past 100-days period.",
            "source": {
                "uri": "newsdaemon.com",
                "dataType": "news",
                "title": "newsdaemon.com"
            },
            "authors": [],
            "image": null,
            "eventUri": null,
            "sentiment": 0.192156862745098,
            "wgt": 421529100,
            "relevance": 100
        },
        {
            "uri": "7539723089",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "17:24:00",
            "dateTime": "2023-05-11T17:24:00Z",
            "dateTimePub": "2023-05-11T17:24:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.moneycontrol.com/news/business/markets/trade-setup-for-friday-top-15-things-to-know-before-the-opening-bell-34-10570541.html",
            "title": "Trade setup for Friday: Top 15 things to know before the opening bell",
            "body": "Based on the OI percentage, 63 stocks, including Siemens, Delta Corp, Gujarat Gas, ACC, and Adani Enterprises saw long build-ups.\n\nThe market closed moderately lower after volatile and rangebound trade on May 11, dented by selling in final hour of the session, the weekly expiry day. Traders may be waiting for the CPI inflation data for the month of April scheduled after market hours on May 12.\n\nThe BSE Sensex fell 36 points to 61,905, while the Nifty50 declined 18 points to 18,297 and formed bearish candlestick pattern on the daily charts as the closing was lower than opening levels, but there was higher high higher low formation.\n\n\"Though Nifty is placed at the crucial overhead resistance of 18,300 levels, still there is no indication of any strength required for decisive upside breakout. The formations of Doji/Spinning Top or High Wave candle patterns back-to-back at the hurdle signal possibility of reasonable downward correction ahead,\" said Nagaraj Shetti, Technical Research Analyst, HDFC Securities.\n\nHowever, he feels a decisive move above 18,400 levels is likely to change the short term negative sentiment on the positive side. Immediate support is placed at 18,150 levels, he said.\n\nThe broader markets outperformed frontliners, with the Nifty Midcap 100 and Smallcap 100 indices rising third of a percent and half a percent, respectively, on positive breadth, while India VIX sustained uptrend for fifth straight session, increasing by 1.01 percent to 13.22 levels, from 13.08 levels.\n\nWe have collated 15 data points to help you spot profitable trades:\n\nNote: The open interest (OI) and volume data of stocks in this article are the aggregates of three-month data and not just the current month.\n\nKey support and resistance levels on Nifty\n\nThe pivot charts indicate that the Nifty may get support at 18,273, followed by 18,245 and 18,200. If the index advances, 18,365 is the initial key resistance level to watch out for, followed by 18,393 and 18,438.\n\nNifty Bank\n\nThe Bank Nifty extended gains for yet another session, rising 144 points to 43,475 and formed Doji kind of pattern on the daily timeframe, suggesting indecisiveness among traders.\n\nOverall, Bank Nifty had a rangebound trading session during the expiry period. \"The 43,000 levels served as a strong support area with the highest open interest built up on the Put side. On the other hand, the 44,000 levels acted as resistance with fresh Call writing,\" said Kunal Shah, Senior Technical & Derivatives Analyst at LKP Securities.\n\nOverall, the market showed uncertainty, with traders closely monitoring these support and resistance levels for potential market movements, he said.\n\nAs per the pivot point calculator, the Bank Nifty may take support at 43,383, followed by 43,287 and 43,132. Key resistance levels are expected to be 43,694 along with 43,790 and 43,946.\n\nCall options data\n\nOn the weekly options front, we have seen the maximum Call open interest (OI) at 18,300 strike, with 1.34 crore contracts, which is expected to be a crucial resistance level for the Nifty in the coming sessions.\n\nThis was followed by 18,400 strike, comprising 87.75 lakh contracts, and 18,500 strike, with more than 83.99 lakh contracts.\n\nCall writing was seen at 18,300 strike, which added 59.23 lakh contracts.\n\nCall unwinding was at 18,500 strike, which shed 34.29 lakh contracts, followed by 18,200 strike, which shed 29.06 lakh contracts, and 18,600 strike, which shed 21.84 lakh contracts.\n\nThe maximum Put open interest was at 18,200 strike with 72.72 lakh contracts, which is expected to act as an important support level in the coming sessions.\n\nThis was followed by the 18,300 strike, comprising 60.62 lakh contracts, and the 18,100 strike where we have 52.88 lakh contracts.\n\nPut writing was seen at 17,300 strike, which added 4.76 lakh contracts, followed by 17,400 strike, which added 2.31 lakh contracts.\n\nWe have seen Put unwinding at 18,200 strike, which shed 42.89 lakh contracts, followed by 18,100 strike, which shed 32.13 lakh contracts, and 18,000 strike, which shed 31.11 lakh contracts.\n\nA high delivery percentage suggests that investors are showing interest in the stock. The highest delivery was seen in Atul, Bajaj Auto, Titan Company, Crompton Greaves Consumer Electricals, and ICICI Prudential Life Insurance Company, among others.\n\nAn increase in open interest (OI) and price typically indicates a build-up of long positions. Based on the OI percentage, 63 stocks, including Siemens, Delta Corp, Gujarat Gas, ACC, and Adani Enterprises saw long build-ups.\n\nA decline in OI and price generally indicates a long unwinding. Based on the OI percentage, 19 stocks including Mahanagar Gas, Aurobindo Pharma, Laurus Labs, Alkem Laboratories, and Canara Bank saw a long unwinding.\n\nAn increase in OI along with a price decrease indicates a build-up of short positions. Based on the OI percentage, 47 stocks, including Larsen & Toubro, Dr Reddy's Laboratories, Hindalco Industries, Navin Fluorine International, and Indraprastha Gas saw a short build-up.\n\nA decrease in OI along with a price increase is an indication of short-covering. Based on the OI percentage, 60 stocks were on the short-covering list. These included Oracle Financial, GNFC, Syngene International, Aarti Industries, and Pidilite Industries.\n\nTata Motors, Cipla, Vedanta, Colgate-Palmolive, DLF, Hindustan Petroleum Corporation, APL Apollo Tubes, Butterfly Gandhimathi Appliances, Cholamandalam Financial Holdings, Ethos, Great Eastern Shipping Company, Greaves Cotton, Hindustan Aeronautics, Indraprastha Gas, Indian Overseas Bank, Laxmi Organic Industries, Manappuram Finance, Max Financial Services, Polycab India, Shree Renuka Sugars, Sapphire Foods India will be in focus ahead of quarterly earnings on May 12.\n\nAvenue Supermarts, Advanced Enzyme Technologies, Affle (India), Data Patterns (India), Navin Fluorine International, Neogen Chemicals, Sonata Software, and Vikas EcoTech will be in focus ahead of quarterly earnings on May 13.\n\nStocks in the news\n\nOil & Natural Gas Corporation: The company has discovered crude oil and natural gas in two blocks in Mumbai offshore, reported PTI. The discoveries, which have been named 'Amrit' and 'Moonga', were made in the blocks that the company won in recent open acreage licensing rounds.\n\nMahindra & Mahindra: The utility vehicle maker announced 18.5 percent year-on-year growth in production at 58,644 units for the month of April, while sales grew 40.9 percent YoY to Rs 60,481 units. However, exports dropped 32.9 percent at 1,813 units compared to year-ago period.\n\nJay Bharat Maruti: The joint venture company owned by JBM Group and Maruti Suzuki India, will be setting up two new manufacturing plants in Haryana and Gujarat to cater to the requirements of its key customer Maruti Suzuki in both the regions. These plants will be commissioned at Kharkhoda, Sonipat in Haryana and SMG Suppliers' Park in Gujarat. The company will invest Rs 300-350 crore in a phased manner.\n\nEicher Motors: The motorcycle maker reported a 48.5 percent year-on-year growth in consolidated profit at Rs 905.6 crore for quarter ended March FY23, driven by better topline and operating performance. Revenue from operations in Q4 grew by 19.1 percent to Rs 3,804.3 crore compared to year-ago period. The board has recommended a final dividend of Rs 37 per share, and approved cash outlay towards capex of more than Rs 1,000 crore for FY24.\n\nSiemens: The company recorded 38.8 percent year-on-year growth in consolidated profit at Rs 471.8 crore for quarter ended March FY23, driven by healthy growth in operating numbers and topline. Consolidated revenue from operations grew 27.8 percent to Rs 4,858 crore compared to year-ago period. The company booked new orders of Rs 31,151 crore in Q2FY23, including order of Rs 25,455 crore for the 9000 HP locomotive project.\n\nDCW: The chemical manufacturing company said its board has re-appointed Pramodkumar Shriyansprasad Jain as Chairman and Managing Director for three years, with effect from November 1, 2023. The board also re-appointed Krishnamoorthy Krishnan as an Independent Director for five years with effect from May 22.\n\nForeign institutional investors (FII) bought shares worth Rs 837.21 crore, whereas domestic institutional investors (DII) sold shares worth Rs 200.09 crore on May 11, provisional data from the National Stock Exchange showed.\n\nStocks under F&O ban on NSE\n\nThe National Stock Exchange added Punjab National Bank, and retained Canara Bank, BHEL and Manappuram Finance on its F&O ban list for May 12. Securities in the ban period under the F&O segment include companies in which the security has crossed 95 percent of the market-wide position limit.",
            "source": {
                "uri": "moneycontrol.com",
                "dataType": "news",
                "title": "MoneyControl"
            },
            "authors": [],
            "image": "https://images.moneycontrol.com/static-mcnews/2023/05/Collage-Maker-01-May-2023-12-01-PM-8961-770x433.jpg",
            "eventUri": null,
            "sentiment": 0.2,
            "wgt": 421521840,
            "relevance": 1
        },
        {
            "uri": "7539667992",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "16:43:00",
            "dateTime": "2023-05-11T16:43:00Z",
            "dateTimePub": "2023-05-11T16:42:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.morningstar.com/news/dow-jones/2023051112892/dr-reddys-laboratories-on-pace-for-largest-percent-decrease-since-july-2021-data-talk",
            "title": "Dr. Reddy's Laboratories on Pace for Largest Percent Decrease Since July 2021  --  Data Talk",
            "body": "Dr. Reddy's Laboratories Ltd. Sponsored ADR (RDY) is currently at $55.04, down $3.51 or 5.99%\n\n--Would be lowest close since March 24, 2023, when it closed at $54.78\n\n--On pace for largest percent decrease since July 27, 2021, when it fell 12.38%\n\n--Currently down seven consecutive days; down 9.89% over this period\n\n--Longest losing streak since June 27, 2018, when it fell for eight straight trading days\n\n--Worst seven day stretch since the seven days ending March 7, 2022, when it fell 11.12%\n\n--Traded as low as $54.87; lowest intraday level since March 24, 2023, when it hit $54.35",
            "source": {
                "uri": "morningstar.com",
                "dataType": "news",
                "title": "Morningstar"
            },
            "authors": [],
            "image": "https://www.morningstar.com/assets/img/dow-jones.51166f0.png",
            "eventUri": null,
            "sentiment": -0.3960784313725491,
            "wgt": 421519380,
            "relevance": 51
        },
        {
            "uri": "7539655096",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "16:34:00",
            "dateTime": "2023-05-11T16:34:00Z",
            "dateTimePub": "2023-05-11T16:27:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.marketscreener.com//quote/stock/DR-REDDY-S-LABORATORIES-6492671/news/Dr-Reddy-s-Laboratories-on-Pace-for-Largest-Percent-Decrease-Since-July-2021-Data-Talk-43821886/",
            "title": "Dr. Reddy's Laboratories on Pace for Largest Percent Decrease Since July 2021 -- Data Talk | MarketScreener",
            "body": "Dr. Reddy's Laboratories Ltd. Sponsored ADR (RDY) is currently at $55.04, down $3.51 or 5.99%\n\n--Would be lowest close since March 24, 2023, when it closed at $54.78\n\n--On pace for largest percent decrease since July 27, 2021, when it fell 12.38%\n\n--Currently down seven consecutive days; down 9.89% over this period\n\n--Longest losing streak since June 27, 2018, when it fell for eight straight trading days\n\n--Worst seven day stretch since the seven days ending March 7, 2022, when it fell 11.12%\n\n--Down 8.96% month-to-date\n\n--Up 6.36% year-to-date\n\n--Down 26.9% from its all-time closing high of $75.29 on July 2, 2021\n\n--Up 9.53% from 52 weeks ago (May 12, 2022), when it closed at $50.25\n\n--Down 9.89% from its 52-week closing high of $61.08 on May 2, 2023\n\n--Up 10.3% from its 52-week closing low of $49.90 on Sept. 26, 2022\n\n--Traded as low as $54.87; lowest intraday level since March 24, 2023, when it hit $54.35\n\n--Down 6.29% at today's intraday low\n\nAll data as of 12:08:07 PM ET\n\nSource: Dow Jones Market Data, FactSet\n\n(END) Dow Jones Newswires\n\n05-11-23 1226ET",
            "source": {
                "uri": "marketscreener.com",
                "dataType": "news",
                "title": "Market Screener"
            },
            "authors": [],
            "image": "https://www.marketscreener.com/images/twitter_MS_fdgris.png",
            "eventUri": null,
            "sentiment": -0.4431372549019608,
            "wgt": 421518840,
            "relevance": 51
        },
        {
            "uri": "7539562825",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "15:31:00",
            "dateTime": "2023-05-11T15:31:00Z",
            "dateTimePub": "2023-05-11T15:31:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://economictimes.indiatimes.com/markets/stocks/news/ahead-of-market-10-things-that-will-decide-d-street-action-on-friday/articleshow/100166894.cms",
            "title": "Ahead of Market: 10 things that will decide D-Street action on Friday",
            "body": "Indian shares closed lower on Thursday due to weak quarterly earnings reports, despite positive inflation data from the US. The Nifty 50 index fell 0.10% to 18,297, while the S&P BSE Sensex decreased 0.06% to 61,904.52. The upswing in the market has been influenced by consistent FII inflows and the weakness of the US dollar. The weak earnings data from heavyweight companies dampened investor sentiment.Indian shares reversed intraday gains and logged losses on Thursday, as a handful of downbeat quarterly earnings reports overshadowed optimism from favourable U.S. inflation data.The Nifty 50 closed 0.10% lower at 18,297, while the S&P BSE Sensex fell 0.06% to 61,904.52.\n\n\"The current market rally has been largely influenced by consistent FII inflows, driven by lower treasury yields and the weakness of the US Dollar. However, the gains in the domestic market were tempered by weak earnings reported by a few heavyweight companies. On the global front, markets remained positive as US inflation eased below 5%, providing reassurance to investors that the Fed's rate hike measures have been effective in managing inflation levels,\" Vinod Nair, Head of Research at Geojit Financial Services, said.\"The short-term uptrend formation is still positive, and the index is consistently forming a higher bottom formation which is also supportive for bulls. We are of the view that as long as the index is trading above 18200, the uptrend formation Is likely to continue. Above this, the index could move up till 18400-18475. On the flip side, below 18200, the market could slip till 18125-18100,\" Shrikant Chouhan, Head of Equity Research (Retail), Kotak Securities, said.\n\nThat said, here's a look at what some key indicators are suggesting for Friday's action:\n\nWall Street Watch\n\nWall Street is slipping Thursday, weighed down by a sharp drop for The Walt Disney Co. and flaring fears about the health of some U.S. banks.\n\nThe S&P 500 was 0.3% lower in early trading. The Dow Jones Industrial Average was down 287 points, or 0.8%, at 33,243, as of 9:45 a.m. Eastern time, while the Nasdaq composite was virtually unchanged.\n\nEuropean Shares\n\nEurope's stock markets, the dollar and oil all had a spring back in their step on Thursday as a deflationary jolt from China made way for broader optimism ahead of what was set to be the Bank of England's 12th straight rate rise later.\n\nHopes that the U.S. The Federal Reserve's aggressive hiking cycle may be over at least it was still feeding through following inflation data there on Wednesday, with the pan-European STOXX 600 index up 0.5% and key borrowing costs inching down.\n\nTech View: Small negative candle\n\nA small negative candle was formed on the daily chart with minor upper and lower shadows. Technically, this pattern indicates a formation of high wave type candle formation, but not a classical one.\n\nStocks showing bullish bias\n\nMomentum indicator Moving Average Convergence Divergence (MACD) showed bullish trade on the counters of Zee Entertainment, GCPL, Quess Corp, HG Infra and Sanofi India, among others.The MACD is known for signalling trend reversals in traded securities or indices. When the MACD crosses above the signal line, it gives a bullish signal, indicating that the price of the security may see an upward movement and vice versa.\n\nStocks signaling weakness ahead\n\nThe MACD showed bearish signs on the counters of ITC, Hindalco, L&T, NHPC and Aditya Birla Capital among others.\n\nMost active stocks in value terms\n\nHDFC Bank (Rs 2959 crore), L&T (Rs 2136 crore) ICICI Bank (Rs 1884 crore), Adani Enterprises (Rs 1744 crore) and Dr. Reddy's Laboratories (Rs 1274 crore) were among the most active stocks on NSE in value terms. Higher activity on a counter in value terms can help identify the counters with highest trading turnovers in the day.\n\nMost active stocks in volume terms\n\nVodafone Idea (Shares traded: 20.25 crore), IRFC (Shares traded: 13.77 crore), Zomato (Shares traded: 7.5 crore), RVNL (Shares traded: 5.14 crore), and YES Bank (Shares traded: 4.9 crore) among the most traded stocks in the session on NSE.\n\nStocks showing buying interest\n\nShares of Ratnamani Metals Cyient, KEI Industries, HG Infra, Siemens and Glenmark Pharma, among others, witnessed strong buying interest from market participants as they scaled their fresh 52-week highs, signalling bullish sentiment.\n\nStocks seeing selling pressure\n\nShares of Vikas Multicorp, Paisalo Digital and BEML Land Assets, among others, hit their 52-week lows, signalling bearish sentiment on the counters.\n\nSentiment meter favours bulls\n\nOverall, market breadth favoured bulls as 1,942 stocks ended in the green, while 1,553 names settled with losses.\n\n(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-100166931,width-1070,height-580,imgsize-88698,overlay-etmarkets/photo.jpg",
            "eventUri": null,
            "sentiment": 0.06666666666666665,
            "wgt": 421515060,
            "relevance": 1
        },
        {
            "uri": "7539422502",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "14:04:00",
            "dateTime": "2023-05-11T14:04:00Z",
            "dateTimePub": "2023-05-11T13:46:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.benzinga.com/pressreleases/23/05/g32341873/non-muscle-invasive-bladder-cancer-therapeutics-market-size-to-surpass-us-9-8-billion-at-a-cagr-of",
            "title": "Non-muscle Invasive Bladder Cancer Therapeutics Market Size to Surpass US$ 9.8 billion at a CAGR of 14.8% between 2023 to 2033| Persistence Market Research ",
            "body": "New York, May 11, 2023 (GLOBE NEWSWIRE) -- Several cutting-edge cancer treatments available all over the world and a rising need for innovation in cancer treatments led the global non-muscle invasive bladder cancer therapeutics market to reach a value of US$ 2.2 billion in 2022, and the market is projected to expand rapidly at a CAGR of 14.8% over the forecast period (2023 to 2033). Non-muscle Invasive Bladder Cancer Therapeutics Market is forecasted to reach US$ 9.8 billion by the end of 2033.\n\nInnovation in cancer treatment modalities is being monitored by academic institutions, biopharmaceutical firms, and various healthcare system stakeholders globally. The efficiency of novel cancer treatments depends on the difficulty and length of each regulatory process, as well as manufacturers' filing of registration applications in each country. 62 novel cancer medications have been introduced in the United States over the past five years, some of which have received approval for several indications.\n\nThe idea of switching to molecularly targeted medications or immunotherapies instead of conventional chemotherapy--which has historically been the basis of first-line treatment for advanced malignancies--has a lot of appeal because they promise improved efficacy and enhanced quality of life. Emerging from the research and development pipeline are several creative medicines that are frequently used in conjunction with brand-new or current cancer medications. Many pharmaceutical corporations are funding oncology research initiatives to provide cutting-edge cancer treatments. This, together with consumers' increasing preference for biologics and biosimilars, is anticipated to fuel market expansion.\n\nClick Here to Get Free Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/32011\n\nThe number of projects has increased as a result of increased financing for cancer research and investments in anticancer medications. Governments, the private sector, and businesses are the main sources of research and development spending. All these factors will boost global demand for non-muscle invasive bladder cancer therapeutics over the coming years.\n\n\"During the projected period, the market for therapeutics for non-muscle invasive bladder cancer is expected to be positively impacted by an increase in contract research and contract manufacturing activities aimed at producing new cancer treatments,\" says an analyst at Persistence Market Research.\n\nGet Full Access of this Report@ https://www.persistencemarketresearch.com/checkout/32011\n\nMarket Competition\n\nImportant Key Players are Pfizer Inc., Merck KGaA, AstraZeneca PLC, Roche Holding AG (Genentech), Astellas Pharma Inc., J&J (Janssen Biotech), Cipla Inc., Amneal Pharma, Bristol Myers Squibb Co., Dr. Reddy's Laboratories, Inc., Gilead Sciences Inc., Endo Pharma, UroGen Pharma, Inc., Teva Pharmaceuticals (Actavis), Hikma Pharmaceuticals, Incyte and more\n\nManufacturers of cancer therapeutic drugs are taking steps to develop cost-effective products in response to growing competition and increasing expectations from consumers. These initiatives include increasing research and development expenses through clinical partnerships.\n\nWhat Does the Report Cover?\n\nPersistence Market Research offers a unique perspective and actionable insights on the non-muscle invasive bladder cancer therapeutics market in its latest study, presenting a historical demand assessment for 2012 to 2022 and projections for 2023 to 2033.\n\nThe research study is based on\n\nFor additional insights on how the growth of the non-muscle invasive bladder cancer therapeutics market will unfold over the decade, write to the analyst atâ€¯media@persistencemarketresearch.com\n\nYou Can Customize this Report As per Your Requirement Click Here@ https://www.persistencemarketresearch.com/request-customization/32011\n\nPersistence Market Research's Expertise in Life Sciences and Transformational Health\n\nOur expert team of industry analysts comprising management graduates, medical professionals, engineers, and project managers provides insights on emerging therapy areas, diagnostic tools, medical devices and components, reimbursement and market access, biotechnology, and life science research products and services to equip decision-makers with sound inputs and strategic recommendations.\n\nBusiness intelligence is the foundation of every business model employed by Persistence Market Research. Multi-dimensional sources are being put to work, which include big data, customer experience analytics, and real-time data collection. Thus, working on \"micros\" by Persistence Market Research helps companies overcome their \"macro\" business challenges.\n\nPersistence Market Research is always way ahead of its time. In other words, it tables market solutions by stepping into the companies'/clients' shoes much before they themselves have a sneak pick into the market. The pro-active approach followed by experts at Persistence Market Research helps companies/clients lay their hands on techno-commercial insights beforehand, so that the subsequent course of action could be simplified on their part.",
            "source": {
                "uri": "benzinga.com",
                "dataType": "news",
                "title": "Benzinga"
            },
            "authors": [],
            "image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "eventUri": null,
            "sentiment": -0.1607843137254902,
            "wgt": 421509840,
            "relevance": 26
        },
        {
            "uri": "7539416137",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "14:00:00",
            "dateTime": "2023-05-11T14:00:00Z",
            "dateTimePub": "2023-05-11T13:46:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://forextv.com/top-news/non-muscle-invasive-bladder-cancer-therapeutics-market-size-to-surpass-us-9-8-billion-at-a-cagr-of-14-8-between-2023-to-2033-persistence-market-research/",
            "title": "Non-muscle Invasive Bladder Cancer Therapeutics Market Size to Surpass US$ 9.8 billion at a CAGR of 14.8% between 2023 to 2033| Persistence Market Research",
            "body": "Growing Cancer Patient Pool and Increased Accessibility to Advanced Therapies Driving Non-muscle Invasive Bladder Cancer Therapeutics Market Growth\n\nNew York, May 11, 2023 (GLOBE NEWSWIRE) -- Several cutting-edge cancer treatments available all over the world and a rising need for innovation in cancer treatments led the global non-muscle invasive bladder cancer therapeutics market to reach a value of US$ 2.2 billion in 2022, and the market is projected to expand rapidly at a CAGR of 14.8% over the forecast period (2023 to 2033). Non-muscle Invasive Bladder Cancer Therapeutics Market is forecasted to reach US$ 9.8 billion by the end of 2033.\n\nInnovation in cancer treatment modalities is being monitored by academic institutions, biopharmaceutical firms, and various healthcare system stakeholders globally. The efficiency of novel cancer treatments depends on the difficulty and length of each regulatory process, as well as manufacturers' filing of registration applications in each country. 62 novel cancer medications have been introduced in the United States over the past five years, some of which have received approval for several indications.\n\nThe idea of switching to molecularly targeted medications or immunotherapies instead of conventional chemotherapy-which has historically been the basis of first-line treatment for advanced malignancies-has a lot of appeal because they promise improved efficacy and enhanced quality of life. Emerging from the research and development pipeline are several creative medicines that are frequently used in conjunction with brand-new or current cancer medications. Many pharmaceutical corporations are funding oncology research initiatives to provide cutting-edge cancer treatments. This, together with consumers' increasing preference for biologics and biosimilars, is anticipated to fuel market expansion.\n\nClick Here to Get Free Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/32011\n\nThe number of projects has increased as a result of increased financing for cancer research and investments in anticancer medications. Governments, the private sector, and businesses are the main sources of research and development spending. All these factors will boost global demand for non-muscle invasive bladder cancer therapeutics over the coming years.\n\nKey Takeaways from Market Study\n\n\"During the projected period, the market for therapeutics for non-muscle invasive bladder cancer is expected to be positively impacted by an increase in contract research and contract manufacturing activities aimed at producing new cancer treatments,\" says an analyst at Persistence Market Research.\n\nGet Full Access of this Report@ https://www.persistencemarketresearch.com/checkout/32011\n\nMarket Competition\n\nImportant Key Players are Pfizer Inc., Merck KGaA, AstraZeneca PLC, Roche Holding AG (Genentech), Astellas Pharma Inc., J&J (Janssen Biotech), Cipla Inc., Amneal Pharma, Bristol Myers Squibb Co., Dr. Reddy's Laboratories, Inc., Gilead Sciences Inc., Endo Pharma, UroGen Pharma, Inc., Teva Pharmaceuticals (Actavis), Hikma Pharmaceuticals, Incyte and more\n\nManufacturers of cancer therapeutic drugs are taking steps to develop cost-effective products in response to growing competition and increasing expectations from consumers. These initiatives include increasing research and development expenses through clinical partnerships.\n\nWhat Does the Report Cover?\n\nPersistence Market Research offers a unique perspective and actionable insights on the non-muscle invasive bladder cancer therapeutics market in its latest study, presenting a historical demand assessment for 2012 to 2022 and projections for 2023 to 2033.\n\nThe research study is based on\n\nFor additional insights on how the growth of the non-muscle invasive bladder cancer therapeutics market will unfold over the decade, write to the analyst atâ€¯media@persistencemarketresearch.com\n\nYou Can Customize this Report As per Your Requirement Click Here@ https://www.persistencemarketresearch.com/request-customization/32011\n\nPersistence Market Research's Expertise in Life Sciences and Transformational Health\n\nOur expert team of industry analysts comprising management graduates, medical professionals, engineers, and project managers provides insights on emerging therapy areas, diagnostic tools, medical devices and components, reimbursement and market access, biotechnology, and life science research products and services to equip decision-makers with sound inputs and strategic recommendations.\n\nBusiness intelligence is the foundation of every business model employed by Persistence Market Research. Multi-dimensional sources are being put to work, which include big data, customer experience analytics, and real-time data collection. Thus, working on \"micros\" by Persistence Market Research helps companies overcome their \"macro\" business challenges.\n\nPersistence Market Research is always way ahead of its time. In other words, it tables market solutions by stepping into the companies'/clients' shoes much before they themselves have a sneak pick into the market. The pro-active approach followed by experts at Persistence Market Research helps companies/clients lay their hands on techno-commercial insights beforehand, so that the subsequent course of action could be simplified on their part.",
            "source": {
                "uri": "forextv.com",
                "dataType": "news",
                "title": "ForexTV"
            },
            "authors": [],
            "image": "https://ml.globenewswire.com/media/Y2MyZDFmZTUtYmQ1MC00MjY4LThhY2MtOTdkM2Q3N2JkYzZiLTUwMDAyNzE4Mg==/tiny/Persistence-Market-Research.png",
            "eventUri": null,
            "sentiment": -0.1450980392156863,
            "wgt": 421509600,
            "relevance": 1
        },
        {
            "uri": "7539381021",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "13:37:00",
            "dateTime": "2023-05-11T13:37:00Z",
            "dateTimePub": "2023-05-11T13:27:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.business-standard.com/companies/news/weak-us-sales-weighs-on-dr-reddy-s-sequential-performance-in-march-quarter-123051100854_1.html",
            "title": "Dr Reddy's Laboratories QoQ showing catches a cold on weak US sales",
            "body": "The stock of Dr Reddy's Laboratories (DRL's) fell 6.9 per cent on Thursday on weak 2022-23 (FY23) January-March quarter (fourth quarter, or Q4) results. The Hyderabad-headquartered company delivered an operating miss in Q4FY23 due to lower sales across markets, except for Europe, as well as higher marketing and research and development (R&D) costs.",
            "source": {
                "uri": "business-standard.com",
                "dataType": "news",
                "title": "Business Standard"
            },
            "authors": [],
            "image": "https://bsmedia.business-standard.com/_media/bs/img/article/2022-05/22/full/1653236018-1419.jpg",
            "eventUri": null,
            "sentiment": -0.3098039215686275,
            "wgt": 421508220,
            "relevance": 51
        },
        {
            "uri": "7539251009",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "12:20:00",
            "dateTime": "2023-05-11T12:20:00Z",
            "dateTimePub": "2023-05-11T12:19:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.business-standard.com/companies/results/south-indian-bank-q4-results-net-profit-rises-22-4-to-rs-333-crore-123051100833_1.html",
            "title": "South Indian Bank Q4 results: Net profit rises 22.4% to Rs 333 crore",
            "body": "Dr Reddy's Laboratories Q4 PAT grows nine-fold riding on US, India biz \"The strategy of the business by the bank had contributed to the above performance. During the period, bank could register growth in all the desired segments with focus on building quality asset across all verticals like Corporate, SME, Auto Loan, Credit Card, Personal Loan Gold Loan etc.,\" said Murali Ramakrishnan, MD & CEO South Indian Bank.",
            "source": {
                "uri": "business-standard.com",
                "dataType": "news",
                "title": "Business Standard"
            },
            "authors": [],
            "image": "https://bsmedia.business-standard.com/_media/bs/img/article/2016-07/08/full/1467990708-3228.jpg",
            "eventUri": null,
            "sentiment": 0.4431372549019608,
            "wgt": 421503600,
            "relevance": 51
        },
        {
            "uri": "7539238972",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "12:12:00",
            "dateTime": "2023-05-11T12:12:00Z",
            "dateTimePub": "2023-05-11T11:58:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://economictimes.indiatimes.com/markets/stocks/stock-watch/share-market-update-most-active-stocks-in-todays-market-in-terms-of-volume/articleshow/100162484.cms",
            "title": "Share market update: Most active stocks in today's market in terms of volume",
            "body": "NEW DELHI: Vodafone Idea(numbers of share traded: 20.26 crore), Indian Railway Finance Corporation Ltd.(numbers of share traded: 13.77 crore), GTL Infra(numbers of share traded: 9.78 crore), Zomato Ltd.(numbers of share traded: 7.51 crore), Rail Vikas Nigam(numbers of share traded: 5.14 crore), YES Bank(numbers of share traded: 4.95 crore), Ircon Intl.(numbers of share traded: 4.86 crore), PNB(numbers of share traded: 4.46 crore), Suzlon Energy(numbers of share traded: 3.59 crore) and Vakrangee (numbers of share traded: 3.48 crore) emerged top gainers in Thursday's market in terms of trading volume.\n\nThe NSE Nifty index closed 18.1 points down at 18297.0, while BSE Sensex ended down 35.68 points at 61904.52.\n\nOn the other hand, Dr. Reddy's Laboratories Ltd.(down 6.89 per cent), Larsen & Toubro Ltd.(down 5.17 per cent), Hindalco Industries Ltd.(down 3.57 per cent), Divi's Laboratories Ltd.(down 2.80 per cent) and JSW Steel Ltd.(down 1.90 per cent) were among the top losers of the day.",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-77646325,width-1070,height-580,imgsize-71505,overlay-etmarkets/photo.jpg",
            "eventUri": null,
            "sentiment": 0.5764705882352941,
            "wgt": 421503120,
            "relevance": 1
        },
        {
            "uri": "7539182778",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "11:39:00",
            "dateTime": "2023-05-11T11:39:00Z",
            "dateTimePub": "2023-05-11T11:38:00Z",
            "dataType": "news",
            "sim": 0.6549019813537598,
            "url": "https://economictimes.indiatimes.com/markets/stocks/stock-watch/share-market-update-most-active-stocks-of-the-day-in-terms-of-traded-value/articleshow/100161553.cms",
            "title": "Share market update: Most active stocks of the day in terms of traded value",
            "body": "NEW DELHI: Rail Vikas Nigam(Rs. 97.09 crore), Adani Ent.(Rs. 86.60 crore), Varun Beverages(Rs. 67.63 crore), L&T(Rs. 56.87 crore), Vodafone Idea(Rs. 50.46 crore), Adani Ports SEZ(Rs. 44.44 crore), P&G(Rs. 37.19 crore), Dr. Reddys(Rs. 36.50 crore), Titan Company (Rs. 35.68 crore) and Gujarat Gas(Rs. 34.63 crore) were among the most traded securities on the National Stock Exchange in Thursday's session.\n\nThe NSE Nifty index ended the session 18.1 points down at 18297.0, while BSE Sensex fell 35.68 points to 61904.52.\n\nIn the Nifty index, Adani Enterprises Ltd.(up 4.89 per cent), Asian Paints Ltd.(up 3.23 per cent), Hindustan Unilever Ltd.(up 2.76 per cent), Adani Ports & Special Economic Zone Ltd.(up 2.58 per cent) and NTPC Ltd.(up 1.41 per cent) stood among the top gainers.\n\nOn the other hand, Dr. Reddy's Laboratories Ltd.(down 6.89 per cent), Larsen & Toubro Ltd.(down 5.17 per cent), Hindalco Industries Ltd.(down 3.57 per cent), Divi's Laboratories Ltd.(down 2.80 per cent) and JSW Steel Ltd.(down 1.90 per cent) were among the top losers of the day.",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-82267819,width-1070,height-580,imgsize-142669,overlay-etmarkets/photo.jpg",
            "eventUri": "eng-8612295",
            "sentiment": 0.07450980392156858,
            "wgt": 421501140,
            "relevance": 1
        },
        {
            "uri": "7539114448",
            "lang": "eng",
            "isDuplicate": true,
            "date": "2023-05-11",
            "time": "10:58:00",
            "dateTime": "2023-05-11T10:58:00Z",
            "dateTimePub": "2023-05-11T10:58:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.indiatoday.in/business/story/stock-market-closing-sensex-nifty-dull-earnings-upbeat-us-cpi-data-2377804-2023-05-11",
            "title": "Sensex, Nifty end lower as dull earnings offset upbeat US CPI data ",
            "body": "By Reuters: Indian shares reversed intraday gains and logged losses on Thursday, as a handful of downbeat quarterly earnings reports overshadowed optimism from favourable US inflation data.\n\nThe Nifty 50 was closed 0.10% lower at 18,297, while the S&P BSE Sensex fell 0.06% to 61,904.52.\n\nEleven of the 13 major sectoral indexes advanced, with high-weightage financials gaining 0.33%.\n\nWhile the markets closed lower on Thursday, the benchmark Nifty 50 has added over 1% so far this week, gaining 5.5% since March 31, 2023.\n\nShares of Adani Enterprises rose nearly 5% after the company's board said it will consider a fundraise.\n\nMeanwhile, foreign institutional investors (FIIs) have purchased shares worth 176.41 billion rupees ($2.16 billion) over the last ten sessions, according to provisional data from the National Stock Exchange.\n\n\"The appreciating rupee is one of the reasons why FIIs have turned buyers. Also, FIIs have changed their strategy of 'sell India, buy China' which they pursued in January and February,\" Vijayakumar added.\n\nPharma lost over 1%, dragged by Dr. Reddy's Laboratories Ltd, which lost nearly 7% after reporting a less-than-expected rise in March-quarter consolidated profit on Wednesday.\n\nLarsen & Toubro Ltd fell over 5% after analysts flagged weak core profit margins in the March quarter.\n\nBoth Larsen & Toubro and Dr. Reddy's were among the top Nifty 50 losers.\n\nGlobal equities advanced after data showed that U.S. consumer price inflation slowed to its lowest in two years in April, signalling that the Federal Reserve's rate hikes have managed to tackle high inflation.\n\nThe probability of a rate hike at the next Fed meeting in June slid to 9.6% as of 8:00 a.m. IST from 21.9% ahead of the data release.",
            "source": {
                "uri": "indiatoday.in",
                "dataType": "news",
                "title": "India Today"
            },
            "authors": [],
            "image": "https://akm-img-a-in.tosshub.com/indiatoday/images/story/202305/stock-market-opening-bell-2-sixteen_nine.png?VersionId=tvTxZflnaoV9nPyZw04P0F7A3Oi1LvZy",
            "eventUri": null,
            "sentiment": 0.2862745098039217,
            "wgt": 421498680,
            "relevance": 26
        },
        {
            "uri": "7539079589",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "10:36:00",
            "dateTime": "2023-05-11T10:36:00Z",
            "dateTimePub": "2023-05-11T10:36:00Z",
            "dataType": "news",
            "sim": 0.5098039507865906,
            "url": "https://www.rttnews.com/3363406/sensex-nifty-end-choppy-session-marginally-lower.aspx",
            "title": "Sensex, Nifty End Choppy Session Marginally Lower ",
            "body": "Indian shares fluctuated before ending marginally lower on Thursday as downbeat earnings updates from prominent companies offset signs of slowing inflationary pressures in the United States.\n\nThe benchmark S&P BSE Sensex ended the session down 35.68 points at 61,904.52 while the broader NSE Nifty index settled down 18.10 points at 18,297.\n\nBroader indexes outperformed, with the BSE mid-cap and small-cap indexes closing up 0.4 percent and 0.7 percent, respectively.\n\nAdani Group stocks were in focus after reports that Adani Ports would prepay USD 130 million of debt ahead of schedule.\n\nAdani Enterprises jumped 5.1 percent, Adani Ports rallied 2.5 percent, Adani Transmission added 3.1 percent and Adani Power rose 1.9 percent.\n\nAsian Paints jumped 3.3 percent after its fourth-quarter numbers beat Street estimates almost on all fronts.\n\nDr Reddy's Laboratories plunged 6.9 percent after its fourth-quarter profit lagged Street's estimates.\n\nLarsen & Toubro slumped 5.1 percent after veteran industrialist AM Naik decided to step down as Non-Executive Chairman of the construction giant.\n\nThe dollar traded higher in international markets, weighing on rupee.\n\nGold was marginally lower in European trade while oil prices rose about 1 percent on signs of strong fuel demand in the United States.\n\nFor comments and feedback contact: editorial@rttnews.com",
            "source": {
                "uri": "rttnews.com",
                "dataType": "news",
                "title": "RTTNews"
            },
            "authors": [],
            "image": "https://cdn.rttnews.com/images/v4/RTTNews-logo-512x512.png",
            "eventUri": "eng-8613936",
            "sentiment": 0.1607843137254903,
            "wgt": 421497360,
            "relevance": 1
        },
        {
            "uri": "7539069854",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "10:31:00",
            "dateTime": "2023-05-11T10:31:00Z",
            "dateTimePub": "2023-05-11T10:26:00Z",
            "dataType": "news",
            "sim": 0.7372549176216125,
            "url": "https://www.thehindubusinessline.com/markets/sensex-nifty-edge-lower-as-dull-earnings-offset-upbeat-us-cpi-data/article66838437.ece",
            "title": "Sensex, Nifty edge lower as dull earnings offset upbeat US CPI data",
            "body": "Indian shares reversed intraday gains and logged losses on Thursday, as a handful of downbeat quarterly earnings reports overshadowed optimism from favourable US inflation data.\n\nThe Nifty 50 was closed 0.10 per cent lower at 18,297, while the S&P BSE Sensex fell 0.06 per cent to 61,904.52.\n\nEleven of the 13 major sectoral indexes advanced, with high weightage financials gaining 0.33 per cent.\n\nWhile the markets closed lower on Thursday, the benchmark Nifty 50 has added over 1 per cent so far this week, gaining 5.5 per cent since March 31, 2023.\n\nShares of Adani Enterprises rose nearly 5 per cent after the company's board said it will consider a fundraise.\n\nMeanwhile, foreign institutional investors (FIIs) have purchased shares worth â‚¹17,641 crore over the last ten sessions, according to provisional data from the National Stock Exchange.\n\n\"The appreciating rupee is one of the reasons why FIIs have turned buyers. Also, FIIs have changed their strategy of 'sell India, buy China' which they pursued in January and February,\" Vijayakumar added.\n\nPharma lost over 1 per cent, dragged by Dr Reddy's Laboratories Ltd., which lost nearly 7 per cent after reporting a less-than-expected rise in March-quarter consolidated profit on Wednesday.\n\nLarsen & Toubro Ltd fell over 5 per cent after analysts flagged weak core profit margins in the March quarter.\n\nBoth Larsen & Toubro and Dr Reddy's were among the top Nifty 50 losers.\n\nGlobal equities advanced after data showed that US consumer price inflation slowed to its lowest in two years in April, signalling that the Federal Reserve's rate hikes have managed to tackle high inflation.\n\nThe probability of a rate hike at the next Fed meeting in June slid to 9.6 per cent as of 8:00 a.m. IST from 21.9 per cent ahead of the data release.\n\nSHARE Copy linkEmailFacebookTwitterTelegramLinkedInWhatsAppRedditPublished on May 11, 2023",
            "source": {
                "uri": "thehindubusinessline.com",
                "dataType": "news",
                "title": "@businessline"
            },
            "authors": [],
            "image": "https://bl-i.thgim.com/public/news/axbmtg/article66838439.ece/alternates/LANDSCAPE_1200/stock%20market%2002159.jpg",
            "eventUri": "eng-8622367",
            "sentiment": 0.2862745098039217,
            "wgt": 421497060,
            "relevance": 1
        },
        {
            "uri": "7539064809",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "10:28:00",
            "dateTime": "2023-05-11T10:28:00Z",
            "dateTimePub": "2023-05-11T10:22:00Z",
            "dataType": "news",
            "sim": 0.8078431487083435,
            "url": "https://timesofindia.indiatimes.com/business/markets/sensex/indian-shares-edge-lower-as-dull-earnings-offset-upbeat-us-cpi-data/articleshow/100159431.cms",
            "title": "Indian shares edge lower as dull earnings offset upbeat US CPI data - Times of India",
            "body": "BENGALURU: Indian shares reversed intraday gains and logged losses on Thursday, as a handful of downbeat quarterly earnings reports overshadowed optimism from favourable US inflation data.\n\nThe Nifty 50 was closed 0.10% lower at 18,297, while the S&P BSE Sensex fell 0.06% to 61,904.52.\n\nEleven of the 13 major sectoral indexes advanced, with high weightage financials gaining 0.33%.\n\nWhile the markets closed lower on Thursday, the benchmark Nifty 50 has added over 1% so far this week, gaining 5.5% since March 31, 2023.\n\nShares of Adani Enterprises rose nearly 5% after the company's board said it will consider a fundraise.\n\nMeanwhile, foreign institutional investors (FIIs) have purchased shares worth 176.41 billion rupees ($2.16 billion) over the last ten sessions, according to provisional data from the National Stock Exchange.\n\n\"The appreciating rupee is one of the reasons why FIIs have turned buyers. Also, FIIs have changed their strategy of 'sell India, buy China' which they pursued in January and February,\" Vijayakumar added.\n\nPharma lost over 1%, dragged by Dr. Reddy's Laboratories Ltd., which lost nearly 7% after reporting a less-than-expected rise in March-quarter consolidated profit on Wednesday.\n\nLarsen & Toubro Ltd fell over 5% after analysts flagged weak core profit margins in the March quarter.\n\nBoth Larsen & Toubro and Dr Reddy's were among the top Nifty 50 losers.\n\nGlobal equities advanced after data showed that U.S. consumer price inflation slowed to its lowest in two years in April, signalling that the Federal Reserve's rate hikes have managed to tackle high inflation.\n\nThe probability of a rate hike at the next Fed meeting in June slid to 9.6% as of 8:00 a.m. IST from 21.9% ahead of the data release.",
            "source": {
                "uri": "timesofindia.indiatimes.com",
                "dataType": "news",
                "title": "The Times of India"
            },
            "authors": [
                {
                    "uri": "reuters@timesofindia.indiatimes.com",
                    "name": "Reuters",
                    "type": "author",
                    "isAgency": true
                },
                {
                    "uri": "may@timesofindia.indiatimes.com",
                    "name": "May",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://static.toiimg.com/thumb/msid-100159401,width-1070,height-580,imgsize-2076984,resizemode-75,overlay-toi_sw,pt-32,y_pad-40/photo.jpg",
            "eventUri": "eng-8622367",
            "sentiment": 0.2862745098039217,
            "wgt": 421496880,
            "relevance": 1
        },
        {
            "uri": "7538847733",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "08:17:00",
            "dateTime": "2023-05-11T08:17:00Z",
            "dateTimePub": "2023-05-11T08:11:00Z",
            "dataType": "news",
            "sim": 0.8666666746139526,
            "url": "https://www.news18.com/business/markets/dr-reddys-dips-7-even-as-q4-net-profit-jumps-10-fold-should-you-buy-sell-or-hold-7782451.html",
            "title": "Dr Reddy's Dips 7% Even as Q4 Net Profit Jumps 10-Fold; Should you Buy, Sell or Hold?",
            "body": "Shares of Dr Reddy's slipped 7 per cent in early trade on May 11, a day after the company posted its Q4 results\n\nShares of Dr Reddy's Laboratories slipped 7 per cent in early trade on May 11, a day after the company posted its Q4 results. The drugmaker's net profit for the quarter jumped 10-fold to Rs 959.2 crore from Rs 87.5 crore in the same period last year but still lagged the Street's estimate of Rs 1,093.6 crore.\n\nIts revenue from operations stood at Rs 5,843 crore in Q4 FY23, up 15.28% YoY as against Rs 5,068.4 crore in Q4 FY22. Meanwhile, total expenses were down 4 per cent at Rs 5,132.2 crore against Rs 5,348.4 crore in Q4FY22.\n\nRevenue came in at Rs 6,296.8 crore, 15.81 per cent up from Rs 5,436.8 crore in the year-ago quarter. The topline beat the Street's expectation of Rs 6,090.5 crore for the quarter under review.\n\nEBIDTA margin also expanded to 25.9 percent in January-March from 23.9 per cent in the same quarter last year.\n\n\"Dr Reddys' reported an all round miss vs our expectation as US revenues declined 17% QoQ and margin stood at 25 per cent. Management commentary reaffirmed growth in US business though we sense it may be difficult to grow on a Revlimid base in FY25 and beyond,\" YES Securities said.\n\nWhat Should Investors Do Now?\n\nBrokerages, however, don't seem too impressed with the numbers as subdued performance of the core business and waning of gRevlimid's disproportionately high contribution points towards pain.\n\nEven though the management expects gRevlimid to continue contributing to its revenue in the coming quarters, brokerages do not share the optimism.\n\nNuvama Institutional Equities, said that given the contribution from gRevlimid was cut in half, Q4FY23 was a stronger reflection of the company's main business than Q2/Q3. The pipeline for the company is strong, but the brokerage points out difficulties with important items like gCiprodex, where market share has dropped by roughly 1200 bp, and gVascepa, gKuvan, and gNuvaring, which have plateaued.\n\nIt predicted single digit organic growth despite successful launches like gRemodulin and gLexsican, at roughly USD950mn ex gRevlimid base.\n\nThe brokerage has downgraded the stock to 'Reduce' despite gRevlimid strength.\n\n\"We keep FY24/25E consolidated EPS unchanged, but cut core EPS (ex- gRevlimid) by about 12% given core business challenges. Our 300bp Q4FY23-FY25 core margin expansion captures upside potential. Our â‚¹4,200 target price (vs â‚¹4,675) is based on unchanged 22x FY25E EPS and â‚¹435 from gRevlimid; downgrade to 'REDUCE/SU',\" said the brokerage in its report.\n\nPrabhudas Lilladher downgraded Dr Reddy's to Reduce from Buy with a revised target price of Rs 4,500 from Rs 4,900.\n\n\"Dr Reddy's Q4FY23 reported profitability was in line with our estimate. Adjusted for one-time divestment income (Rs 2.65 billion), EBITDA was 20% below our estimates impacted by lower GMs and higher overheads. Our FY24E and FY25E EPS stands reduced by 10% and 6% as we factor in lower margins ex of gRevlimid,\" it said.\n\nYES Securities downgraded Dr Reddy's to Neutral with a target price of Rs 5,150.\n\n\"Dr Reddys' reported an all round miss vs our expectation as US revenues declined 17% QoQ and margin stood at 25%. Management commentary reaffirmed growth in US business though we sense it may be difficult to grow on a Revlimid base in FY25 and beyond,\" YES Securities said.",
            "source": {
                "uri": "news18.com",
                "dataType": "news",
                "title": "News18"
            },
            "authors": [],
            "image": "https://images.news18.com/ibnlive/uploads/2023/05/mankind-pharma-to-acquire-combihale-and-daffy-brands-from-dr-reddys-laboratories-168351927216x9.jpg",
            "eventUri": "eng-8614427",
            "sentiment": 0.08235294117647052,
            "wgt": 421489020,
            "relevance": 51
        },
        {
            "uri": "7538811072",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "07:54:00",
            "dateTime": "2023-05-11T07:54:00Z",
            "dateTimePub": "2023-05-11T07:53:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://economictimes.indiatimes.com/markets/stocks/recos/motilal-oswal-neutralnbsp-on-dr-reddys-laboratories-target-price-rs-4500/articleshow/100154541.cms",
            "title": "Motilal Oswal neutral  on Dr. Reddy's Laboratories, target price: Rs 4500",
            "body": "Dr. Reddy's Laboratories, incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 75969.18 Crore) operating in Pharmaceuticals sector.Motilal Oswal Financial Services has neutral call on Dr. Reddy's Laboratories with a target price of Rs 4500. The current market price of Dr. Reddy's Laboratories is Rs 4550.\n\nDr. Reddy's Laboratories, incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 75969.18 Crore) operating in Pharmaceuticals sector.\n\nDr. Reddy's Laboratories key Products/Revenue Segments include Pharmaceuticals, Licence Fees, Other Operating Revenue, Spent Chemicals, Service Income and Scrap for the year ending 31-Mar-2022.\n\nFinancials\n\nFor the quarter ended 31-03-2023, the company has reported a Consolidated Total Income of Rs 6453.70 Crore, down -5.76 % from last quarter Total Income of Rs 6848.50 Crore and up 15.31 % from last year same quarter Total Income of Rs 5596.80 Crore. Company has reported net profit after tax of Rs 952.50 Crore in latest quarter.\n\nThe company's top management includes Mr.K Satish Reddy, Mr.G V Prasad, Mr.Leo Puri, Mr.Prasad R Menon, Ms.Shikha Sharma, Mr.Allan Oberman, Ms.Kalpana Morparia, Mr.Sridar Iyengar, Mr.Arun Madhavan Kumar. Company has S R Batliboi & Associates LLP as its auditors. As on 31-03-2023, the company has a total of 17 Crore shares outstanding.\n\nInvestment Rationale\n\nWhile the company delivered 39% YoY earnings growth in FY23, the brokerage expects moderation in the earnings CAGR to 3.6% over FY23-25 due to a high base ofFY23 and limited visibility of potential products to deliver growth over the next two years.\n\nFurther, Motilal Oswal believes the valuation already factors in the earnings upside, hence it maintains its Neutral rating on the stock.\n\nPromoter/FII Holdings\n\nPromoters held 26.7 per cent stake in the company as of 31-Mar-2023, while FIIs owned 27.25 per cent, DIIs 23.03 per cent.",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-100154635,width-1070,height-580,imgsize-921756,overlay-etmarkets/photo.jpg",
            "eventUri": null,
            "sentiment": 0.1764705882352942,
            "wgt": 421487640,
            "relevance": 100
        },
        {
            "uri": "7538807345",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "07:51:00",
            "dateTime": "2023-05-11T07:51:00Z",
            "dateTimePub": "2023-05-11T07:33:00Z",
            "dataType": "news",
            "sim": 0.4470588266849518,
            "url": "https://timesofindia.indiatimes.com/city/hyderabad/dr-reddys-labs-q4-profit-jumps-a-record-890/articleshow/100153478.cms",
            "title": "Dr Reddy's Labs Q4 profit jumps a record 890% | Hyderabad News - Times of India",
            "body": "HYDERABAD: Pharmaceutical giant Dr Reddy's Laboratories reported a staggering 890% increase in its net profit during the fourth quarter that ended in March 2023, when compared to the corresponding period last year. It's profit touched 960.1 crore - a massive jump from the 97 crore registered in 2022.\n\nThe Q4 results, released by the company on Wednesday, showed that pharma major hit a record growth as its total revenue from operations stood at 5,843 crore which is a 15.28% Y-o-Y growth compared to 5,068.4 crore recorded in Q4 of FY22.\n\nAddressing a virtual press conference, chief financial officer, Parag Agarwal, attributed a substantial part of the profits to earnings from their new product line launched in the last financial year. Also, this growth, company officials added, was particularly driven by their business in North America, Europe and India while the emerging markets stood flat.\n\nOverall, around 40% of Dr Reddy's consolidated revenue came from North America and 20% from the domestic market. During Q4, the consolidated operating profit, calculated as earnings before interest, taxes, depreciation and amortization (EBITDA) increased by 26% Y-o-Y to 1,631 crore. Gross margins expanded sharply by 430 basis points to 57.2%.\n\n\"Sales in the domestic market registered 17% growth primarily attributable to increase in prices of our existing products, along with additional revenues from the launch of new products,\" said Agarwal adding, \"The momentum from the new launches shall continue and will be more in the next financial year as more product launches are in the pipeline.\"\n\nNot surprisingly, the expenditure on research and development (R&D) increased by 24% Y-o-Y to 537 crore. The Q4 results put out by the company noted that other the revenue generated from the Global Generic segment stood at 213.8 billion which is 19% higher compared to FY22.",
            "source": {
                "uri": "timesofindia.indiatimes.com",
                "dataType": "news",
                "title": "The Times of India"
            },
            "authors": [
                {
                    "uri": "tnn@timesofindia.indiatimes.com",
                    "name": "tnn",
                    "type": "author",
                    "isAgency": false
                },
                {
                    "uri": "updated_may@timesofindia.indiatimes.com",
                    "name": "Updated May",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://static.toiimg.com/thumb/msid-47529300,width-1070,height-580,imgsize-110164,resizemode-75,overlay-toi_sw,pt-32,y_pad-40/photo.jpg",
            "eventUri": "eng-8612295",
            "sentiment": 0.411764705882353,
            "wgt": 421487460,
            "relevance": 51
        },
        {
            "uri": "7538648337",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "05:57:00",
            "dateTime": "2023-05-11T05:57:00Z",
            "dateTimePub": "2023-05-11T05:57:00Z",
            "dataType": "news",
            "sim": 0.8274509906768799,
            "url": "https://www.zawya.com/en/world/indian-sub-continent/indian-shares-flat-as-dull-earnings-offset-upbeat-us-cpi-data-ub1sb3j0",
            "title": "Indian shares flat as dull earnings offset upbeat US CPI data",
            "body": "Indian shares pared early gains to trade flat on Thursday, as a handful of downbeat earnings from key corporates offset optimism from favourable U.S. inflation data and persistent foreign buying in Indian equities.\n\nThe Nifty 50 was up 0.01% at 18,316.20 as of 10:10 a.m. IST, while the S&P BSE Sensex rose 0.04% to 61,965.94. Both indexes had opened higher.\n\nTen of the 13 major sectoral indexes advanced, with high weightage financials and information technology (IT) gaining 0.4% and 0.5%, respectively.\n\nIndia's benchmark Nifty 50 has added over 1.3% so far this week, gaining 5.5% since March 31, 2023.\n\nShares of Adani Enterprises rose 4.38% after the company's board said it will consider a fundraise.\n\n\"The main driver of the ongoing rally is the sustained FII inflows,\" said VK Vijayakumar, chief investment strategist at Geojit Financial Services.\n\nForeign institutional investors (FIIs) have purchased shares worth 176.41 billion Indian rupees ($2.16 billion) over the last ten sessions, according to provisional data from the National Stock Exchange.\n\n\"The appreciating rupee is one of the reasons why FIIs have turned buyers. Also, FIIs have changed their strategy of 'sell India, buy China' which they pursued in January and February,\" Vijayakumar added.\n\nPharma lost over 1%, dragged by Dr. Reddy's Laboratories Ltd., which lost over 5% after reporting a less-than-expected rise in March-quarter consolidated profit on Wednesday.\n\nLarsen & Toubro Ltd fell over 5% after analysts flagged weak core profit margins in the March quarter.\n\nBoth Larsen & Toubro and Dr Reddy's were among the top Nifty 50 losers.\n\nGlobal equities advanced after data showed that U.S. consumer price inflation slowed to its lowest in two years in April, signalling that the Federal Reserve's rate hikes have managed to tackle high inflation.\n\nThe probability of a rate hike at the next Fed meeting in June slid to 9.6% as of 8:00 a.m. IST from 21.9% ahead of the data release. (Reporting by Bharath Rajeswaran in Bengaluru; Editing by Nivedita Bhattacharjee, Varun H K, and Janane Venkatraman)",
            "source": {
                "uri": "zawya.com",
                "dataType": "news",
                "title": "Zawya.com"
            },
            "authors": [],
            "image": "https://static.zawya.com/view/acePublic/alias/contentid/NjRjYWRiYmItZmM5Ny00/42/140122065540ccim-jpg.jpeg?f=3%3A2",
            "eventUri": "eng-8622367",
            "sentiment": 0.3803921568627451,
            "wgt": 421480620,
            "relevance": 1
        },
        {
            "uri": "7538647816",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "05:56:00",
            "dateTime": "2023-05-11T05:56:00Z",
            "dateTimePub": "2023-05-11T05:55:00Z",
            "dataType": "news",
            "sim": 0.8039215803146362,
            "url": "https://economictimes.indiatimes.com/markets/stocks/news/dr-reddys-tumbles-7-post-q4-results-heres-what-brokerages-recommend/articleshow/100151601.cms",
            "title": "Dr Reddy's tumbles 7% post Q4 results! Here's what brokerages recommend",
            "body": "Dr Reddy's Laboratories reported an 890% YoY surge in March quarter profit at Rs 960.1 crore but shares tumbled nearly 7% to Rs 4,545 in Thursday's trade. While its revenue from operations increased by 15.28% YoY to Rs 5,843 crore, total expenses were down 4% at Rs 5,132.2 crore. US revenues fell 17% QoQ. Jefferies maintained its Buy rating on Dr Reddy's Laboratories with a target price of Rs 5,650, while Prabhudas Lilladher downgraded the stock to Reduce with a revised target price of Rs 4,500 from Rs 4,900.Shares of Dr Redyy's Laboratories (DRL) tumbled nearly 7% to Rs 4,545 in Thursday's trade even after the firm reported an 890% YoY increase in the March quarter profit at Rs 960.1 crore as against Rs 97 crore clocked in the corresponding quarter of last year.\n\nIts revenue from operations stood at Rs 5,843 crore in Q4 FY23, up 15.28% YoY as against Rs 5,068.4 crore in Q4 FY22. Meanwhile, total expenses were down 4% at Rs 5,132.2 crore against Rs 5,348.4 crore in Q4FY22.\n\n\"Dr Reddys' reported an all round miss vs our expectation as US revenues declined 17% QoQ and margin stood at 25%. Management commentary reaffirmed growth in US business though we sense it may be difficult to grow on a Revlimid base in FY25 and beyond,\" YES Securities said.\n\nAt 10.07 am, the stock was trading 6.4% lower at Rs 4,558 on BSE. However, the stock has surged over 17% in the last one year.\n\nShould you buy, sell or hold Dr Reddy's stock? Here's what analysts say:\n\nJefferies | Buy\n\nJefferies maintained its Buy rating on Dr Reddy's Laboratories with a target price of Rs 5,650. Revlimid sales drop leads to miss on estimates.\n\nThe US sales could remain volatile but the new product launch momentum remains strong across geographies. The global investment bank lowered FY24 EPS by 5% on lower margins.\n\nPrabhudas Lilladher\n\nPrabhudas Lilladher downgraded Dr Reddy's to Reduce from Buy with a revised target price of Rs 4,500 from Rs 4,900.\n\n\"Dr Reddy's Q4FY23 reported profitability was in line with our estimate. Adjusted for one-time divestment income (Rs 2.65 billion), EBITDA was 20% below our estimates impacted by lower GMs and higher overheads. Our FY24E and FY25E EPS stands reduced by 10% and 6% as we factor in lower margins ex of gRevlimid,\" it said.\n\nJM Financial\n\nJM Financial maintained its Buy rating on Dr Reddys with a target price of Rs 5,980.\n\n\"DRRD's 4Q earnings were below our estimates on account of lower gRevlimid sales which reflected in EBITDA and PAT misses. We have factored in Mayne Pharma acquisition into our estimates and expect it to be earnings accretive in FY24 itself. The US base business ex-Revlimid is around USD 250mn, in our view, which should see some improvement from upcoming launches (25-30 in FY24),\" it said.\n\nYES Securities\n\nYES Securities downgraded Dr Reddy's to Neutral with a target price of Rs 5,150.\n\n\"Dr Reddys' reported an all round miss vs our expectation as US revenues declined 17% QoQ and margin stood at 25%. Management commentary reaffirmed growth in US business though we sense it may be difficult to grow on a Revlimid base in FY25 and beyond,\" YES Securities said.\n\nMotilal Oswal\n\nMotilal maintained its Neutral rating on Dr Reddy's with a target price of Rs 4,500.\n\nWhile DRRD delivered 39% YoY earnings growth in FY23, we expect moderation in the earnings CAGR to 3.6% over FY23-25 due to a high base of FY23 and limited visibility of potential products to deliver growth over the next two years.\n\n(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-100151572,width-1070,height-580,imgsize-921756,overlay-etmarkets/photo.jpg",
            "eventUri": "eng-8614427",
            "sentiment": 0.1764705882352942,
            "wgt": 421480560,
            "relevance": 100
        },
        {
            "uri": "7538639466",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "05:50:00",
            "dateTime": "2023-05-11T05:50:00Z",
            "dateTimePub": "2023-05-11T05:49:00Z",
            "dataType": "news",
            "sim": 0.8274509906768799,
            "url": "https://www.zawya.com/en/world/indian-sub-continent/indian-shares-set-to-open-higher-on-cooling-us-inflation-steady-fii-inflows-jiuvy6nh",
            "title": "Indian shares set to open higher on cooling U.S. inflation, steady FII inflows",
            "body": "The probability of a rate hike at the next Fed meeting in June slid to 9.6%\n\nIndian shares were set to open higher on Thursday, tracking Asian peers, after cooling U.S. consumer price inflation raised hopes of a Fed policy rate pause, while persistent foreign buying in domestic equities gave further support.\n\nIndia's NSE stock futures listed on the Singapore exchange were up 0.20% at 18,395, as of 8:00 a.m. IST.\n\nMost Wall Street equities advanced after data showed that U.S. consumer price inflation slowed to its lowest in two years in April, signalling that the U.S. Federal Reserve's rate hikes have managed to tackle high inflation. Asian equities edged edger.\n\nThe probability of a rate hike at the next Fed meeting in June slid to 9.6%, as of 8:00 a.m. IST from 21.9% ahead of the release of the U.S. inflation data.\n\nIndian shares have risen for three sessions in a row, with the Nifty 50 adding 1.36% so far this week. The benchmark has gained 5.5% since March 31, 2023.\n\n\"The main driver of the ongoing rally is the sustained FII inflows,\" said VK Vijayakumar, chief investment strategist at Geojit Financial Services.\n\nForeign institutional investors extended their buying streak in Indian equities for the tenth session in a row on Wednesday, adding equities worth 18.33 billion Indian rupees ($224.14 million). FIIs have purchased shares worth 176.41 billion Indian rupees ($2.16 billion) over the period, according to provisional data from the National Stock Exchange.\n\n\"Appreciating rupee is one of the reasons why FIIs have turned buyers. Also, FIIs have changed their strategy of 'sell India, buy China' which they pursued in January and February\".\n\nInvestors also await quarterly results of major firms such as Asian Paints Ltd, Eicher Motors Ltd, Deepak Nitrite Ltd, Siemens Ltd among others on Thursday.\n\nStocks to Watch:\n\n** Larsen & Toubro Ltd: Co beats Q4 profit view on higher project execution.\n\n** Dr Reddy's Laboratories: Co posts 11-fold jump in Q4 profit.\n\n** Hindalco Ltd: Subsidiary Novelis said its net income in March quarter was down 27% Y/Y.\n\n** Godrej Consumer Products: Co reports 25% jump in fourth-quarter profit on strong demand. ($1 = 81.7800 Indian rupees) (Reporting by Bharath Rajeswaran in Bengaluru; Editing by Nivedita Bhattacharjee)",
            "source": {
                "uri": "zawya.com",
                "dataType": "news",
                "title": "Zawya.com"
            },
            "authors": [],
            "image": null,
            "eventUri": "eng-8622367",
            "sentiment": 0.2313725490196079,
            "wgt": 421480200,
            "relevance": 1
        },
        {
            "uri": "7538625285",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "05:38:00",
            "dateTime": "2023-05-11T05:38:00Z",
            "dateTimePub": "2023-05-11T05:31:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.bqprime.com/research-reports/dr-reddys-q4-review-weaker-performance-in-base-business-long-term-growth-strategy-intact-axis-securities",
            "title": "Dr. Reddy's Q4 Review - Weaker Performance In Base Business; Long-Term Growth Strategy Intact: Axis Securities",
            "body": "BQ Prime's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BQ Prime's subscribers an opportunity to expand their understanding of companies, sectors and the economy.\n\nDr. Reddy's Laboratories Ltd.'s core business performance in Q4 FY23 seems to be on the lower side - excluding assumed business from gRevlimid sales of $65 million-70 million. Ebitda margin would have been ~20%, which in our view, shows deterioration over the previous years.\n\nFurthermore, we exclude the Eris Lifesciences Ltd. brand sale (~Rs 250 crore) from the India business. Ebitda margins have further deteriorated as compared to the previous quarters. The Eris reports ~32% Ebitda margins for its business.\n\nU.S. at ~$310 million would have included ~$65-70 million of gRevlimid. We believe Ciprodex's market share loss and stagnation in other key products could have led to a modest Q4 revenue and margins.\n\nThe reported gross margin was 69.9% and the Ebitda margin was ~25.1%. However, excluding gRevlimid and Eris brand sales, Dr. Reddy's gross margins stood at 65% and Ebitda margin at 20%.\n\nOutlook:\n\nQ4FY22 results were week. However, we believe the company's strategy of investing in various businesses may provide growth in the long term. Dr. Reddy's is proactively building a global pipeline of biosimilars, developing new chemical entity for immunooncology, and building up a Neutraceuticals portfolio, vaccines, contract development and manufacturing organisation, and digital healthcare platforms.\n\nDr. Reddy's is planning to launch at least 30 products in the U.S. in FY24E. There are complex drugs in the pipeline that could drive revenue growth over the next four-five years as per the management.",
            "source": {
                "uri": "bqprime.com",
                "dataType": "news",
                "title": "BQ"
            },
            "authors": [
                {
                    "uri": "axis_securities@bqprime.com",
                    "name": "Axis Securities",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://gumlet.assettype.com/bloombergquint%2F2022-06%2F1c5f72a9-1d62-4d6d-9c6e-5cd7c276bd31%2FDr__Reddys_Laboratories_Ltd___Source_Company_website_.png?rect=0%2C34%2C359%2C188&w=1200&auto=format%2Ccompress&ogImage=true",
            "eventUri": null,
            "sentiment": 0.03529411764705892,
            "wgt": 421479480,
            "relevance": 51
        },
        {
            "uri": "7538624470",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "05:37:00",
            "dateTime": "2023-05-11T05:37:00Z",
            "dateTimePub": "2023-05-11T05:23:00Z",
            "dataType": "news",
            "sim": 0.4588235318660736,
            "url": "https://www.business-standard.com/markets/news/dr-reddy-s-labs-sinks-7-on-disappointing-q4-operating-performance-123051100257_1.html",
            "title": "Dr Reddy's Labs sinks 7% on disappointing Q4 operating performance",
            "body": "Shares of Dr Reddy's Laboratories plunged 7 per cent to Rs 4,545 on the BSE in Thursday's intra-day after the company delivered an operating miss in January-March quarter (Q4FY23) due to lower sales across markets, barring Europe, as well as higher marketing and R&D costs. In Q4FY23, the company's revenue grew 18 per cent year-on-year (YoY) and was down 8 per cent quarter-on-quarter (QoQ) at Rs 5,430 crore. The company said QoQ decline in revenue was mainly due to decline in North America and Emerging Markets, partially offset by growth in Europe and India. In Q4, the company's North America's revenue declined 17 per cent QoQ to Rs 2,530 crore, due to fluctuations in demand for new launches. EBITDA (earnings before interest, taxes, depreciation, and amortization) margins grew 1,605 bps YoY to 24.3 per cent. However, adjusted for non-core brands sales, the margins were at 21 per cent. Adjusted profit after tax increased 192.6 per cent YoY to Rs 952.5 crore. US business grew 26.8 per cent YoY to Rs 2,532 crore, driven by new products launches and favourable forex movement, which was partly offset by price erosion. While US growth was far ahead of estimates, adjusted India growth was in line. Europe revenues were also higher than estimates. Pharmaceutical services and active Ingredients witnessed growth due to favourable currency movements but were below estimates. Quarterly fluctuations notwithstanding, the company continue to deliver within its determined framework, ICICI Securities said in its note. The brokerage firm remains positive on the company's growth story based on simultaneous launches across major geographies and persistent recalibration of the existing portfolio. Dr Reddy's reported sales in line with our estimates, with a 5 per cent miss on our's EBITDA estimates due to higher SG&A (up 15 per cent YoY) and R&D (up 24 per cent YoY) costs, analysts at Kotak Securities said. The miss would have been higher at 21 per cent as the company not reported income of Rs 264 crore from the divestment of a few brands in India to Eris, the brokerage firm added. The company has maintained its 25 per cent medium-term EBITDA margin guidance, but the company's quarterly core margins have fluctuated widely in the 17-23 per cent range in the past two years. Going forward, apart from the peptides, we build in key launches, including gPentasa, gCopaxone and gVenofer as well as factor in sales rampup in gAmitiza, gNuvaring, gRemodulin and gLexiscan, into our estimates. However, on an elevated US base, given the slow pace of complex launches, we remain concerned about DRRD's ex-gRevlimid US growth outlook, analysts said. Analysts at Prabhudas Lilladher downgrade stock to Reduce from Buy with revised target price of Rs 4,500/share (Rs 4,900 earlier). At CMP, DR Redy is trading at expensive valuations of 24x P/E on FY25E adjusted for gRevlimid. Any big ticket ANDA approvals and sharp recovery in base business margins are key risks to our call, the brokerage firm said.",
            "source": {
                "uri": "business-standard.com",
                "dataType": "news",
                "title": "Business Standard"
            },
            "authors": [],
            "image": "https://bsmedia.business-standard.com/_media/bs/img/article/2014-01/15/full/1389775886-3642.jpg",
            "eventUri": "eng-8609368",
            "sentiment": 0.2078431372549019,
            "wgt": 421479420,
            "relevance": 51
        },
        {
            "uri": "7538612056",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "05:27:00",
            "dateTime": "2023-05-11T05:27:00Z",
            "dateTimePub": "2023-05-11T05:24:00Z",
            "dataType": "news",
            "sim": 0.5843137502670288,
            "url": "https://in.investing.com/news/dr-reddys-stock-tanks-7-worst-performer-on-nifty50-nifty-pharma-packs-3639389",
            "title": "Dr Reddy's Stock Tanks 7%, Worst Performer on Nifty50, Nifty Pharma Packs",
            "body": "Investing.com -- Shares of the pharmaceutical giant Dr Reddy's Laboratories (NS: REDY ) plunged 6.6% in Thursday's session and hit an intraday low of Rs 4,545 apiece on May 11 despite a multifold jump in bottomline figure for the quarter ended March 31, 2023.\n\nDr Reddy's Labs' stock fell almost 7% in Thursday's trade and was the worst performer on the benchmark index Nifty50 as well as Nifty Pharma . It is not listed on Sensex .\n\nEven though the pharma company posted good results for the March-ended quarter on a year-on-year basis, it posted feeble figures on a sequential basis and failed to meet some of the Street's estimates.\n\nDr Reddy's Labs recorded a whopping 996% rally in consolidated net profit at Rs 959.2 crore on YoY basis in the March quarter from Rs 87.5 crore in the same period last year, however, missing Bloomberg's consensus estimate of Rs 1,034 crore.\n\nThe company's total revenue rose 16% YoY to Rs 6,297 crore from Rs 5,436 crore in the same quarter last year.\n\nOn a sequential basis, both PAT and revenue declined by 23% and 7% in the March quarter when compared to December 2022 quarterly numbers.\n\nThe pharma giant posted an EBITDA of Rs 1,631 crore, which accounted for 25.9% of revenue. The figure surged 26% on a YoY basis but dropped 17% QoQ.\n\nThe Hyderabad-based company's Gross Margin expanded to 57.2% in Q4 FY23 from 52.9% in Q4 FY22, while contracting from 59.2% in the preceding quarter.",
            "source": {
                "uri": "in.investing.com",
                "dataType": "news",
                "title": "Investing.com India"
            },
            "authors": [],
            "image": "https://i-invdn-com.investing.com/news/https://i-invdn-com.investing.com/akapi-images/800x450/7987dd10517de002a7580ae84c61db3b_w_800_h_450.jpg",
            "eventUri": "eng-8609368",
            "sentiment": -0.07450980392156858,
            "wgt": 421478820,
            "relevance": 51
        },
        {
            "uri": "7538610957",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "05:26:00",
            "dateTime": "2023-05-11T05:26:00Z",
            "dateTimePub": "2023-05-11T05:18:00Z",
            "dataType": "news",
            "sim": 0.6235294342041016,
            "url": "https://www.fortuneindia.com/investing/dr-reddys-shares-plunge-over-5-despite-nine-fold-profit-in-march-quarter/112635",
            "title": "Dr. Reddy's shares plunge over 5% despite nine-fold profit in March quarter",
            "body": "Shares of pharmaceutical major Dr. Reddy's Laboratories plunged as much as 5.7% in early trade to â‚¹4,589 apiece on the BSE on Thursday, a day after the company reported a nine-fold jump in its profit to â‚¹959.2 crore in March quarter of FY23, as against â‚¹87.5 crore in the same period last year.\n\nThe scrip opened lower on Thursday at â‚¹4,688 crore as against the closing price of the previous session at â‚¹4,868. The company's stock surged as much as 3.4% to hit an intraday high of â‚¹4,704 in the early hours of the trading session. At 9:33 am, the stock was trading 5.24% lower at â‚¹4,613. In contrast to this, the broader BSE Sensex opened higher at 62,158. In the early hours of the trading session, the company's market capitalisation stood at â‚¹76,931.30 crore as 7,285 shares were exchanging hands on the BSE as against the two-week average of 7,472 shares. At present, the share price of Dr. Reddy's is trading 7.6% lower than the 52-week high of â‚¹4,987 whereas the shares are trading 21.6% lower than the 52-week low of â‚¹3,787.55.\n\nIn the January to March period, the company's revenue from operations surged double-digit by 16% year-on-year (YoY) to â‚¹6,296.8.2 crore, up from â‚¹5,436.8 crore in the same period last year, driven by growth in North America, Europe and India markets; however, partially impacted due to a decline in revenues in emerging markets. The company's EBITDA (earnings before interest, taxes, depreciation and amortisation) surged 25.6% YoY to â‚¹1,631.2 crore, during the quarter under review as against â‚¹1,298 crore in the same period last year.\n\nOn a sequential basis, the company's profit surged 23% QoQ as against â‚¹1,247.1 crore, whereas its revenue from operations was up 7% QoQ as against â‚¹6,770 crore in the December quarter. In FY23, the company's revenue stood at â‚¹24,588 crore, whereas profit after tax stood at â‚¹4,507 crore. For the year under review, the company's EBITDA stood at â‚¹7,308 crore. In FY23, the revenue of the global generics segment stood at â‚¹2,138 crore, higher by 19% as compared to FY22 owing to the growth in North America, Europe, and India, while emerging markets remained flat.\n\n\"FY23 has been a year of record sales, profits and cash flow, driven by our performance in US Generics. We progressed well in our productivity and sustainability agenda. We will continue to deliver on our purpose, invest in growth drivers and promote a culture that is innovative and collaborative ensuring the future of our business,\" said G V Prasad, MD, Dr. Reddy's Laboratories.\n\nThe company's board has recommended payment of a dividend of â‚¹40 per equity share of face value â‚¹5/- each (800% of face value) for the year ended March 31, 2023.",
            "source": {
                "uri": "fortuneindia.com",
                "dataType": "news",
                "title": "FortuneIndia"
            },
            "authors": [],
            "image": "https://gumlet.assettype.com/fortuneindia/2022-07/445f5edc-c897-4020-88bd-6145712f49a6/COVID_drug.jpg?w=700",
            "eventUri": "eng-8612295",
            "sentiment": 0.1215686274509804,
            "wgt": 421478760,
            "relevance": 75
        },
        {
            "uri": "7538609239",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "05:25:00",
            "dateTime": "2023-05-11T05:25:00Z",
            "dateTimePub": "2023-05-11T05:19:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.bqprime.com/research-reports/dr-reddys-q4-results-review-focus-on-ex-revlimid-us-outlook-yes-securities",
            "title": "Dr. Reddy's Q4 Results Review - Focus On ex-Revlimid U.S. Outlook: Yes Securities",
            "body": "BQ Prime's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BQ Prime's subscribers an opportunity to expand their understanding of companies, sectors and the economy.\n\nDr. Reddy's Laboratories Ltd. reported an all round miss versus our expectation as U.S. revenues declined 17% QoQ and margin stood at 25%.\n\nDr. Reddy's management commentary reaffirmed growth in U.S. business though we sense it may be difficult to grow on a Revlimid base in FY25 and beyond.\n\nAssessment of core U.S. growth stripping out currency and Revlimid tailwind in FY23 implies base business may not have grown much per our working - such an outcome would be largely mirroring peers as H1 FY23 particularly saw sharp price erosion.\n\nLooking forward., we budget in $330 million of Revlimid sales and ~5-6% growth in base business; we also add acquired Mayne Pharma business which results in sharp increase in FY24 estimates (more due to higher Revlimid sales assumption than Mayne).\n\nReckon Revlimid is creating a base akin to what happened with others in the past (Lupin Ltd. and Glumetza, Sun and Gleevec) which would create an elevated peak for U.S. sales that may take some time to surpass.\n\nHence, we perceive performance of base business ex-Revlimid becomes important as Revlimid sales might hit a peak some time in FY24.",
            "source": {
                "uri": "bqprime.com",
                "dataType": "news",
                "title": "BQ"
            },
            "authors": [
                {
                    "uri": "yes_securities@bqprime.com",
                    "name": "Yes Securities",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://gumlet.assettype.com/bloombergquint%2F2022-05%2F1c851d21-9b2e-46fb-9540-22bbc51cf383%2FA_technician_performing_an_experiment_at_Dr__Reddy_s_Labs_API_unit___Source_Company_website_.png?rect=0%2C23%2C347%2C182&w=1200&auto=format%2Ccompress&ogImage=true",
            "eventUri": null,
            "sentiment": 0.3647058823529412,
            "wgt": 421478700,
            "relevance": 75
        },
        {
            "uri": "7538608208",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "05:24:00",
            "dateTime": "2023-05-11T05:24:00Z",
            "dateTimePub": "2023-05-11T05:23:00Z",
            "dataType": "news",
            "sim": 0.686274528503418,
            "url": "https://economictimes.indiatimes.com/markets/stocks/stock-watch/share-market-update-most-active-stocks-of-the-day-in-terms-of-total-traded-value/articleshow/100150686.cms",
            "title": "Share market update: Most active stocks of the day in terms of total traded value",
            "body": "NEW DELHI: L&T(Rs. 1259.17 crore), HDFC Bank(Rs. 819.67 crore), Dr. Reddys(Rs. 672.13 crore), Adani Ent.(Rs. 624.67 crore), ICICI Bank(Rs. 568.12 crore), Axis Bank(Rs. 407.25 crore), Mankind Pharma(Rs. 393.91 crore), RIL(Rs. 383.07 crore), SBI(Rs. 333.58 crore) and IndusInd Bank(Rs. 298.72 crore) were among the most traded securities on the National Stock Exchange at 10:50AM in Thursday's session.\n\nThe NSE Nifty index traded 29.5 points up at 18344.6, while BSE Sensex was up 122.06 points at 62062.26 as of 10:50AM(IST)on May 11.\n\nIn the Nifty index, Adani Enterprises Ltd.(up 3.46 per cent), IndusInd Bank Ltd.(up 2.08 per cent), Adani Ports & Special Economic Zone Ltd.(up 1.45 per cent), NTPC Ltd.(up 1.33 per cent) and HCL Technologies Ltd.(up 1.13 per cent) were among the top gainers.\n\nOn the other hand, Dr. Reddy's Laboratories Ltd.(down 6.40 per cent), Larsen & Toubro Ltd.(down 4.42 per cent), Hindalco Industries Ltd.(down 3.32 per cent), Bharti Airtel Ltd.(down 0.83 per cent) and Eicher Motors Ltd.(down 0.44 per cent) were among the top losers.",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-77646325,width-1070,height-580,imgsize-71505,overlay-etmarkets/photo.jpg",
            "eventUri": "eng-8609368",
            "sentiment": 0.07450980392156858,
            "wgt": 421478640,
            "relevance": 1
        },
        {
            "uri": "7538589961",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "05:09:00",
            "dateTime": "2023-05-11T05:09:00Z",
            "dateTimePub": "2023-05-11T04:54:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://economictimes.indiatimes.com/markets/stocks/stock-watch/share-market-update-most-active-stocks-on-d-street-today-in-terms-of-volume/articleshow/100150089.cms",
            "title": "Share market update: Most active stocks on D-Street today in terms of volume",
            "body": "NEW DELHI: GTL Infra(number of shares traded: 4.72 crore), Atreya Petro(number of shares traded: 0.69 crore), Vodafone Idea(number of shares traded: 0.64 crore), MPS Infotecnics (number of shares traded: 0.56 crore), Suzlon Energy(number of shares traded: 0.49 crore), Indian Railway Finance Corporation Ltd.(number of shares traded: 0.45 crore), Alstone Textiles(number of shares traded: 0.39 crore), Excel Realty N Infr(number of shares traded: 0.38 crore), YES Bank(number of shares traded: 0.36 crore) and Rail Vikas Nigam(number of shares traded: 0.31 crore) were among the most traded securities on the National Stock Exchange at 10:24AM in Thursday's session.\n\nThe NSE Nifty index was trading 16.8 points up at 18331.9, while BSE Sensex was up 67.27 points at 62007.47 at the time of writing this report.\n\nIn the Nifty index, Adani Enterprises Ltd.(up 3.34 per cent), IndusInd Bank Ltd.(up 2.06 per cent), Adani Ports & Special Economic Zone Ltd.(up 1.40 per cent), NTPC Ltd.(up 1.19 per cent) and HDFC Life Insurance Company Ltd.(up 1.10 per cent) were among the top gainers.\n\nWhile Dr. Reddy's Laboratories Ltd.(down 6.49 per cent), Larsen & Toubro Ltd.(down 4.42 per cent), Hindalco Industries Ltd.(down 3.16 per cent), Bharti Airtel Ltd.(down 1.04 per cent) and ITC Ltd.(down 0.59 per cent) were among the top losers in the index.",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-77646325,width-1070,height-580,imgsize-71505,overlay-etmarkets/photo.jpg",
            "eventUri": null,
            "sentiment": 0.4352941176470588,
            "wgt": 421477740,
            "relevance": 1
        },
        {
            "uri": "7538570365",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "04:49:00",
            "dateTime": "2023-05-11T04:49:00Z",
            "dateTimePub": "2023-05-11T04:43:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.bqprime.com/research-reports/dr-reddys-q4-results-review-weak-base-business-profitability-prabhudas-lilladher",
            "title": "Dr. Reddy's Q4 Results Review - Weak Base Business Profitability: Prabhudas Lilladher",
            "body": "BQ Prime's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BQ Prime's subscribers an opportunity to expand their understanding of companies, sectors and the economy.\n\nDr. Reddy's Laboratories Ltd.'s Q4 FY23 reported profitability was in line with our estimate.\n\nDr. Reddy's sales grew by 16% YoY at Rs 63 billion. Adjusted for one-time divestment income (Rs 2.64 billion), revenues were down 11% QoQ and below our estimate. The miss was largely on account lower pharma services and active ingredients and U.S. sales.\n\nU.S. revenue came in at $308 million ($372 million in Q3 FY23) versus our estimate of $322 million.\n\nDomestic business adjusted for divestment of certain brands grew 5% YoY. PSAI sales increased by mere 3% YoY; below our estimate. Europe increased 12% YoY, while Russia sales declined by 25% YoY.\n\nAt current market price, Dr. Reddy's is trading at expensive valuations of 24 times price/earnings on FY25E adjusted for gRevlimid.",
            "source": {
                "uri": "bqprime.com",
                "dataType": "news",
                "title": "BQ"
            },
            "authors": [
                {
                    "uri": "prabhudas_lilladher@bqprime.com",
                    "name": "Prabhudas Lilladher",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://gumlet.assettype.com/bloombergquint%2F2022-06%2Fa9c509a2-e63e-41a7-ad40-2d6bd820a542%2FDr__Reddys_Laboratories_R_D_fcility__image_Company_website__png_3png.png?rect=0%2C0%2C1078%2C566&w=1200&auto=format%2Ccompress&ogImage=true",
            "eventUri": null,
            "sentiment": 0.2392156862745098,
            "wgt": 421476540,
            "relevance": 51
        },
        {
            "uri": "7538559767",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "04:39:00",
            "dateTime": "2023-05-11T04:39:00Z",
            "dateTimePub": "2023-05-11T04:38:00Z",
            "dataType": "news",
            "sim": 0.7058823704719543,
            "url": "https://www.indiatoday.in/business/story/stock-market-opening-sensex-nifty-global-cues-improve-adani-stocks-rise-2377611-2023-05-11",
            "title": "Sensex, Nifty open higher as global cues improve; Adani stocks rise ",
            "body": "By Koustav Das: Benchmark stock market indices opened higher on Thursday as global cues improved, following a drop in US inflation that raised the possibility of a pause in rate tightening by the Federal Reserve.\n\nThe S&P BSE Sensex was up 0.17 per cent at 62,057.73 at around 9:15 am, while the NSE Nifty 50 inched 0.14 per cent higher to trade at 18,339.10. Broader markets were also trading in positive territory in the wake of positive global sentiments.\n\nSome of the top sectoral indices were Nifty Bank, Nifty Financial Services, Nifty IT and Nifty Oil and Gas. Nifty Pharma was down almost 1 per cent.\n\nThe top gainers on the Nifty 50 were Adani Enterprises, Adani Ports and Special Economic Zone, NTPC, HDFC Life and Tech Mahindra.\n\nAdani Enterprises and Adani Ports were the top two gainers on the index, following a report that indicated that the conglomerate's flagship firm is considering a stock sale.\n\nOn the other hand, Dr Reddy's Laboratories was the biggest drag on the index, losing over 5 per cent in early trade. L&T also lost nearly 5 per cent, while Hindalco was down over 3 per cent. Bharti Airtel and ITC also lost nearly 1 per cent each.\n\nWhile domestic markets seem to be on a winning streak, volatility seems to be on the rise on Dalal Street as investors are now awaiting India's April inflation data, due on May 12.\n\nThe mood, however, remains fairly positive in the wake of strong Q4 results, improvement in US consumer inflation prices, and strong foreign buying in domestic equities.",
            "source": {
                "uri": "indiatoday.in",
                "dataType": "news",
                "title": "India Today"
            },
            "authors": [],
            "image": "https://akm-img-a-in.tosshub.com/indiatoday/images/story/202305/stock-market-closing-bell-2_4-sixteen_nine.png?VersionId=5.Vgy7ZnTQ8e4VETziHVRJY0mGw_xvjB",
            "eventUri": "eng-8612261",
            "sentiment": 0.3098039215686275,
            "wgt": 421475940,
            "relevance": 1
        },
        {
            "uri": "7538559234",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "04:38:00",
            "dateTime": "2023-05-11T04:38:00Z",
            "dateTimePub": "2023-05-11T04:36:00Z",
            "dataType": "news",
            "sim": 0.5921568870544434,
            "url": "https://www.bqprime.com/business/dr-reddys-q4-results-review-shares-fall-on-profit-miss-analyst-downgrades",
            "title": "Dr. Reddy's Q4 Results Review: Shares Fall On Profit Miss, Analyst Downgrades",
            "body": "Shares of Dr. Reddy's Laboratories Ltd. declined after most analysts cut ratings and estimates after the company's fourth-quarter profit missed analysts' estimates. There is also limited visibility of potential products to deliver growth over the next two years, according to the analysts.The Hyderabad-based drugmaker's net profit rose to Rs 960 crore in the three months ended March, according to its exchange filing. That compares wit...\n\nShares of Dr. Reddy's Laboratories Ltd. declined after most analysts cut ratings and estimates after the company's fourth-quarter profit missed analysts' estimates. There is also limited visibility of potential products to deliver growth over the next two years, according to the analysts.\n\nThe Hyderabad-based drugmaker's net profit rose to Rs 960 crore in the three months ended March, according to its exchange filing. That compares with the Rs 1,034 crore consensus estimate of analysts tracked by Bloomberg.\n\nDr. Reddy's Laboratories Q4 FY23 Highlights (YoY)\n\nShares of the drugmaker fell 5.59% to Rs 4,595.30 apiece as of 9:30 a.m. on Thursday, while the benchmark Nifty 50 was trading flat.\n\nOf the 41 analysts tracking the drugmaker, 25 recommend a 'buy,' eight suggest a 'hold,' and eight suggest 'sell,' according to Bloomberg data. The average of the 12-month consensus price target implies an upside of 8.6%.",
            "source": {
                "uri": "bqprime.com",
                "dataType": "news",
                "title": "BQ"
            },
            "authors": [
                {
                    "uri": "monal_sanghvi@bqprime.com",
                    "name": "Monal Sanghvi",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://gumlet.assettype.com/bloombergquint%2F2023-05%2F4b2d9fed-9d6c-463e-b80e-a460d78705d7%2Fistockphoto_618192458_170667a.jpg?w=1200&auto=format%2Ccompress&ogImage=true",
            "eventUri": "eng-8614427",
            "sentiment": 0.2705882352941176,
            "wgt": 421475880,
            "relevance": 75
        },
        {
            "uri": "7538549880",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "04:29:00",
            "dateTime": "2023-05-11T04:29:00Z",
            "dateTimePub": "2023-05-11T04:18:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.bqprime.com/research-reports/dr-reddys-q4-results-review-benefitted-from-one-off-brand-divestments-systematix",
            "title": "Dr. Reddy's Q4 Results Review - Benefitted From One-Off Brand Divestments: Systematix",
            "body": "BQ Prime's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BQ Prime's subscribers an opportunity to expand their understanding of companies, sectors and the economy.\n\nDr. Reddy's Laboratories Ltd.'s Q4 FY23 revenue was in-line with our/consensus expectations. We had anticipated a QoQ decline in revenue led by slowdown in gRevlimid sales in the U.S. Net earnings at Rs 9,592 million were 4.8%/6.4% below our/consensus estimates as there was steep increase in research and development costs and one off impairment charge.\n\nThe production linked incentive incentive contribution was also weak during the quarter. One off gain from brand divestments in the Indian market helped offset these pressures.\n\nDr. Reddy's has been aggressively filing products in the Chinese market; the company has received approval for three products and expects incremental revenue contribution to start in FY24.\n\nDr. Reddy's North America business declined by ~17% QoQ due to lower gRevlimid sales in the U.S. due to fluctuating volume share in this market. While we expect Dr. Reddy's to be permitted a higher volume share in gRevlimid in FY24, price erosion in the market will need to be monitored given multiple generic entrants in FY24.\n\nDr. Reddy's has maintained its Ebitda margin guidance of ~25% for the next two years. The company is also aiming to grow in double digits across business segments.",
            "source": {
                "uri": "bqprime.com",
                "dataType": "news",
                "title": "BQ"
            },
            "authors": [
                {
                    "uri": "systematix_institutional_equities@bqprime.com",
                    "name": "Systematix Institutional Equities",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://gumlet.assettype.com/bloombergquint%2F2022-05%2Fcb546329-63c6-4067-a8d8-c50b6d98b5da%2FDr__Reddy_s_Laboratories_Ltd__s_UK_facility.png?rect=0%2C38%2C276%2C145&w=1200&auto=format%2Ccompress&ogImage=true",
            "eventUri": null,
            "sentiment": 0.2705882352941176,
            "wgt": 421475340,
            "relevance": 75
        },
        {
            "uri": "7538541518",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "04:20:00",
            "dateTime": "2023-05-11T04:20:00Z",
            "dateTimePub": "2023-05-11T04:20:00Z",
            "dataType": "news",
            "sim": 0.4666666686534882,
            "url": "https://www.rttnews.com/3363232/sensex-nifty-lackluster-in-early-trade-it-and-adani-group-stocks-gain.aspx",
            "title": "Sensex, Nifty Lackluster In Early Trade; IT And Adani Group Stocks Gain ",
            "body": "Indian shares struggled for direction in early trade on Thursday as investors reacted to mixed earnings updates and overnight data showing U.S. inflation slowed slightly more than expected in April.\n\nThe benchmark S&P BSE Sensex was up 48 points at 61,988 while the broader NSE Nifty index was up 7 points at 18,322.\n\nAdani Ports advanced 1.6 percent after reports that would prepay USD 130 million of debt ahead of schedule. Adani Enterprises jumped 3.6 percent, Adani Transmission added 1.4 percent and Adani Power climbed 2.2 percent.\n\nIT stocks were moving higher, with HCL Technologies and Asian Paints rising around 1 percent each.\n\nLarsen &Toubro tumbled more than 4 percent after veteran industrialist AM Naik decided to step down as Non-Executive Chairman of the company.\n\nGodrej Consumer Products rallied 2.3 percent on reporting decent earnings growth.\n\nDr Reddy's Laboratories plunged 5.6 percent after its fourth-quarter profit lagged Street's estimates.\n\nVodafone Idea edged up slightly on reports that it may unveil a revival plan within a month.\n\nFor comments and feedback contact: editorial@rttnews.com",
            "source": {
                "uri": "rttnews.com",
                "dataType": "news",
                "title": "RTTNews"
            },
            "authors": [],
            "image": "https://cdn.rttnews.com/images/v4/RTTNews-logo-512x512.png",
            "eventUri": "eng-8612128",
            "sentiment": 0.07450980392156858,
            "wgt": 421474800,
            "relevance": 1
        },
        {
            "uri": "7538521156",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "04:03:00",
            "dateTime": "2023-05-11T04:03:00Z",
            "dateTimePub": "2023-05-11T02:37:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.marketscreener.com/quote/currency/AUSTRALIAN-DOLLAR-US-DO-2373531/news/Indian-shares-set-to-open-higher-on-cooling-U-S-inflation-steady-FII-inflows-43810598/",
            "title": "Indian shares set to open higher on cooling U.S. inflation, steady FII inflows",
            "body": "India's NSE stock futures listed on the Singapore exchange were up 0.20% at 18,395, as of 8:00 a.m. IST.\n\nMost Wall Street equities advanced after data showed that U.S. consumer price inflation slowed to its lowest in two years in April, signalling that the U.S. Federal Reserve's rate hikes have managed to tackle high inflation. Asian equities edged edger. [MKTS/GLOB]\n\nThe probability of a rate hike at the next Fed meeting in June slid to 9.6%, as of 8:00 a.m. IST from 21.9% ahead of the release of the U.S. inflation data. [FEDWATCH]\n\nIndian shares have risen for three sessions in a row, with the Nifty 50 adding 1.36% so far this week. The benchmark has gained 5.5% since March 31, 2023.\n\n\"The main driver of the ongoing rally is the sustained FII inflows,\" said VK Vijayakumar, chief investment strategist at Geojit Financial Services.\n\nForeign institutional investors extended their buying streak in Indian equities for the tenth session in a row on Wednesday, adding equities worth 18.33 billion Indian rupees ($224.14 million). FIIs have purchased shares worth 176.41 billion Indian rupees ($2.16 billion) over the period, according to provisional data from the National Stock Exchange.\n\n\"Appreciating rupee is one of the reasons why FIIs have turned buyers. Also, FIIs have changed their strategy of 'sell India, buy China' which they pursued in January and February\".\n\nInvestors also await quarterly results of major firms such as Asian Paints Ltd, Eicher Motors Ltd, Deepak Nitrite Ltd, Siemens Ltd among others on Thursday.\n\nStocks to Watch:\n\n** Larsen & Toubro Ltd: Co beats Q4 profit view on higher project execution.\n\n** Dr Reddy's Laboratories: Co posts 11-fold jump in Q4 profit.\n\n** Hindalco Ltd: Subsidiary Novelis said its net income in March quarter was down 27% Y/Y.\n\n** Godrej Consumer Products: Co reports 25% jump in fourth-quarter profit on strong demand.\n\n(Reporting by Bharath Rajeswaran in Bengaluru; Editing by Nivedita Bhattacharjee)",
            "source": {
                "uri": "marketscreener.com",
                "dataType": "news",
                "title": "Market Screener"
            },
            "authors": [],
            "image": "https://img.zonebourse.com/reuters/2021-05/2021-05-24T042224Z_1_LYNXNPEH4N04F_RTROPTP_3_INDIA-STOCKS.JPG",
            "eventUri": null,
            "sentiment": 0.2,
            "wgt": 421473780,
            "relevance": 1
        },
        {
            "uri": "7538515793",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "03:56:00",
            "dateTime": "2023-05-11T03:56:00Z",
            "dateTimePub": "2023-05-11T03:56:00Z",
            "dataType": "news",
            "sim": 0.8392156958580017,
            "url": "https://www.moneycontrol.com/news/business/markets/dr-reddys-q4-net-profit-jumps-10-fold-but-brokerages-still-neutral-heres-why-10565051.html",
            "title": "Dr Reddy's Q4 net profit jumps 10-fold but brokerages still neutral. Here's why",
            "body": "Dr Reddy's net profit for the fourth quarter lagged the Street's estimate despite the meteoric jump.\n\nShares of Dr Reddy's Laboratories will remain in focus on May 11, a day after the pharmaceutical company reported a 10-fold year-on-year jump in net profit at Rs 959.2 crore from Rs 87.5 crore.\n\nThe net profit in the base quarter was hit by impairment charges while this quarter was aided by largely aided by a favourable base, brand deals and strong traction in the developed markets. Despite the big jump, net profit lagged the Street's estimate of Rs 1,093.6 crore.\n\nRevenue came in at Rs 6,296.8 crore, 15.81 percent up from Rs 5,436.8 crore in the year-ago quarter. The topline beat the Street's expectation of Rs 6,090.5 crore for the quarter under review.\n\nEBIDTA margin also expanded to 25.9 percent in January-March from 23.9 percent in the same quarter last year.\n\nAlso Read: Dr Reddy's Q4 net profit jumps to Rs 959 crore on favourable base, US launches, brand deals\n\nBrokerages' view\n\nBrokerages, however, don't seem too impressed with the numbers as subdued performance of the core business and waning of gRevlimid's disproportionately high contribution points towards pain.\n\nEven though the management expects gRevlimid to continue contributing to its revenue in the coming quarters, brokerages do not share the optimism.\n\nWith the contribution from gRevlimid being halved in Q4 from Q3 and Q2, Nuvama notes plateauing of gVascepa, gKuvan and gNuvaring sales as other challenges for Dr Reddy's.\n\nFactoring that in, the brokerage has forecast single-digit organic growth at best for the Hyderabad-based drugmaker despite solid launches like gRemodulin and gLexsican.\n\nAlso Read: US sales, brand deals to seal the fortune for Dr Reddy's in Q4\n\nNuvama downgraded Dr Reddy's to \"reduce\", while slashing its target price by 10 percent to Rs 4,200.\n\nPrabhudas Lilladher, too, reduced its FY24E and FY25E earnings-per-stock estimates by 10 percent and 6 percent, respectively, as it factored in lower\n\nmargins ex of gRevlimid.\n\nThe brokerage has downgraded the stock to \"reduce\", with an 8 percent cut in its target price to Rs 4,500.\n\nMotilal Oswal Financial Services also expects growth to moderate in FY24, largely due to a high base of FY23 and limited visibility of potential products to deliver over the next two years.\n\nThe brokerages said valuation already factored in the earnings upside and it retained its \"neutral\" rating on the stock, with a target price of Rs 4,500.\n\nGoldman Sachs also has a \"neutral\" call with a price target of Rs 4,750. The broking firm believes Q4 adjusted EBITDA margin for Dr Reddy's grew primarily on account of its higher gross margin.",
            "source": {
                "uri": "moneycontrol.com",
                "dataType": "news",
                "title": "MoneyControl"
            },
            "authors": [],
            "image": "https://images.moneycontrol.com/static-mcnews/2023/05/Dr.-Reddys-building-756x435.jpg",
            "eventUri": "eng-8614427",
            "sentiment": 0.06666666666666665,
            "wgt": 421473360,
            "relevance": 51
        },
        {
            "uri": "7538506597",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "03:46:00",
            "dateTime": "2023-05-11T03:46:00Z",
            "dateTimePub": "2023-05-11T03:45:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.bqprime.com/research-reports/dr-reddys-q4-results-review-earnings-growth-to-moderate-after-superior-show-in-fy23-motilal-oswal",
            "title": "Dr. Reddy's Q4 Results Review - Earnings Growth To Moderate After Superior Show In FY23: Motilal Oswal",
            "body": "BQ Prime's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BQ Prime's subscribers an opportunity to expand their understanding of companies, sectors and the economy.\n\nAdjusted for divestment of brands in the domestic formulation segment, Dr. Reddy's Laboratories Ltd. recorded in-line sales in Q4 FY23. However, it posted lower-than-expected Ebitda/profit after tax due to higher opex.\n\nDr. Reddy's delivered the highest-ever annual earnings in FY23, led by strong traction in g-Revlimid.\n\nWhile Dr. Reddy's delivered 39% YoY earnings growth in FY23, we expect moderation in the earnings compound annual growth rate to 3.6% over FY23-25 due to a high base of FY23 and limited visibility of potential products to deliver growth over the next two years.",
            "source": {
                "uri": "bqprime.com",
                "dataType": "news",
                "title": "BQ"
            },
            "authors": [],
            "image": "https://gumlet.assettype.com/bloombergquint%2F2023-05%2Fe5d5daac-523f-4f69-a6ad-2245b56b9e9a%2FDr__Reddy_s_2__1___1_.png?w=1200&auto=format%2Ccompress&ogImage=true",
            "eventUri": null,
            "sentiment": 0.4274509803921569,
            "wgt": 421472760,
            "relevance": 51
        },
        {
            "uri": "7538489186",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "03:28:00",
            "dateTime": "2023-05-11T03:28:00Z",
            "dateTimePub": "2023-05-11T03:12:00Z",
            "dataType": "news",
            "sim": 0.658823549747467,
            "url": "https://www.latestly.com/agency-news/business-news-dr-reddys-profit-grows-ninefold-in-march-quarter-5118272.html",
            "title": "Business News | Dr Reddy's Profit Grows Ninefold in March Quarter | LatestLY",
            "body": "Hyderabad (Telangana) [India], May 11 (ANI): Pharma giant Dr Reddy's Laboratories has posted a ninefold jump in its profit after tax to Rs 959 crore for the quarter that ended March 31, 2023, driven by its performance in US generics.\n\nThe company had Rs 87-crore net profit in the year-ago period.\n\nAlso Read | Uttar Pradesh Fire: Seven Members of Family Burnt to Death After Massive Blaze Engulfs Entire House in Kushinagar District (Watch Video).\n\nThe pharma's revenue went up 16 per cent to Rs 6,297 crore during the quarter reviewed, over the figure in the corresponding period the previous year. Its Ebitda went up 25.9 per cent to Rs. 1,631 crore while its gross margin was at 57.2 per cent in Q4 FY23.\n\nThe company incurred Rs 537 crore in research and development.\n\nAlso Read | Punjab Blast: Another Low-Intensity Explosion Reported Near Golden Temple in Amritsar, Third in Less Than A Week (Watch Video).\n\nCommenting on the results, Co-Chairman and Managing Director, G V Prasad said: \"FY23 has been a year of record sales, profits and cash flow, driven by our performance in US Generics. We progressed well in our productivity and sustainability agenda. We will continue to deliver on our purpose, invest in growth drivers and promote a culture that is innovative and collaborative ensuring the future of our business.\"\n\nIn FY23, the firm's net profit went up 91 per cent to Rs 4,507 crore in the quarter under review over the figure in the year-ago period. Revenue in FY23 went up 15 per cent year-on-year to Rs 24,588 crore.\n\nEarnings before interest, taxes, depreciation and amortization (Ebitda) rose 42 per cent in FY23 to Rs 7,308 crore.\n\nIn FY23, revenue from India was at Rs 48.9 billion. \"Year-on-year growth of 17 per cent was primarily attributable to the increase in prices of our existing products,\" the pharma giant said. The growth was also aided by the divestment of a few non-core brands during the year.\n\n\"During the year, we launched nine brands in India,\" the company said. (ANI)\n\n(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)",
            "source": {
                "uri": "latestly.com",
                "dataType": "news",
                "title": "LatestLY"
            },
            "authors": [],
            "image": "https://st1.latestly.com/wp-content/uploads/2020/10/news-default-img-784x441.jpg",
            "eventUri": "eng-8609368",
            "sentiment": 0.03529411764705892,
            "wgt": 421471680,
            "relevance": 51
        },
        {
            "uri": "7538472215",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "03:10:00",
            "dateTime": "2023-05-11T03:10:00Z",
            "dateTimePub": "2023-05-11T02:56:00Z",
            "dataType": "news",
            "sim": 0.6196078658103943,
            "url": "https://www.goodreturns.in/news/fm-sitharaman-leaves-for-japan-to-attend-g-7-meeting-1283154.html",
            "title": "Finance Minister Sitharaman Leaves For Japan To Attend G 7 Meeting",
            "body": "For Quick Alerts Subscribe Now Stay updated with all the happenings around the globe. Click here View Sample For Quick Alerts ALLOW NOTIFICATIONS For Daily Alerts Just In 8 hrs ago Microsoft Cuts Salary Raises And Bonuses For Employees As Focus Shifts To Generative AI 9 hrs ago SEBI Allows Foreign Portfolio Investors DMA to Exchange Traded Commodity Derivatives 10 hrs ago SMBC Aviation Capital Files Appeal Against NCLT's Decision Granting Go First's Voluntary Insolvency Plea 11 hrs ago Dr Reddy's Laboratories Q4 Results: Profit Surges By 996%, Dividend Of Rs 40 Per Share Declared Don't Miss News Uddhav vs Shinde: SC verdict on Maharashtra crisis today Lifestyle Things Women Do When They Truly Love Their Partner Movies Khatron Ke Khiladi 13: THIS Female Celeb BEATS Shiv Thakare, Becomes Highest-Paid Contestant? Sports KKR vs RR Playing 11 IPL 2023: Probable Lineup of Kolkata Knight Riders and Rajasthan Royals Technology Google makes its entry into the foldable market with Pixel Fold: All you need to know Travel Mocha Cyclone: Bengaluru On High Risk Of Urban Flooding, Know The Reason Why? Automobiles 2023 Bajaj Avenger 220 Street Motorcycle Launched At Rs 1.42 Lakh - Powertrain Updated Education NCHM JEE 2023 Admit Card Released: Download Now from nchmjee.nta.nic.in Home News Business Finance Minister Sitharaman Leaves For Japan To Attend G 7 Meeting Business oi-PTI By Pti | Published: Thursday, May 11, 2023, 8:26 [IST]\n\nFinance Minister Nirmala Sitharaman on Wednesday embarked on an official two-day visit to Niigata, Japan, to attend a G7 meeting. India is an invitee to G 7 Finance Ministers and Central Bank Governors meeting. \"During her visit, FM [email protected] will also have multilateral and bilateral engagements with her counterparts, besides a roundtable meeting with business leaders and investors,\" a finance ministry tweet said. During her trip, she will address investors and business leaders in Tokyo.\n\nBesides, she will address a seminar on 'Economic Policy in Pursuit of Welfare' at the Finance Ministers and Central Bank Governors (FMCBG) meeting while two other sessions--Tackling Immediate Challenges Facing Developing Countries and Strengthening International Cooperation for Sustainable and Inclusive Growth. The G7 is a forum of leading industrialised nations--Canada, France, Germany, Italy, Japan, the United Kingdom and the United States. Representatives of the European Union are always present at the annual meeting of the heads of state and government of the G 7.\n\n(PTI)\n\nMORE NIRMALA SITHARAMAN NEWS Finance Minister Sitharaman To Review State Of Economy At FSDC Meeting Today India Working To Rein In Inflation: Nirmala Sitharaman FM Sitharaman Asks CBIC To Introduce Automated GST Return Scrutiny System No Proposal Before Finance Minister To Regulate Financial Influencers: Sitharaman 'Crypto' Issue Requires Immediate Attention, Says FM Sitharaman FinMin Plans Rs 3,000 Cr Additional Capital Infusion In PSU 'General Insurance' Cos In FY24 Nirmala Sitharaman To Host G20 Meeting, Attend IMF, World Bank Meetings In US Inflation Kept At 6 % Or Below Despite Adverse Circumstances: Nirmala Sitharaman PSU Banks Recover 14 Per Cent Of Written-Off Loans In Last 5 Years: FM FM Proposes Panel To Look Into Issues Related To Government Employees' Pension Sitharaman Presents Rs 1.18 Lakh Cr Budget For J-K In Lok Sabha E-rupee Worth Over Rs 130 Cr In Circulation: Sitharaman For investment related articles, business news and mutual fund advise Allow Notifications You have already subscribed Story first published: Thursday, May 11, 2023, 8:26 [IST] Other articles published on May 11, 2023",
            "source": {
                "uri": "goodreturns.in",
                "dataType": "news",
                "title": "https://www.goodreturns.in/"
            },
            "authors": [],
            "image": "https://www.goodreturns.in/img/2023/05/fm-1683773731.jpg?11052023083410",
            "eventUri": "eng-8614018",
            "sentiment": 0.2941176470588236,
            "wgt": 421470600,
            "relevance": 51
        },
        {
            "uri": "7538472288",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "03:10:00",
            "dateTime": "2023-05-11T03:10:00Z",
            "dateTimePub": "2023-05-11T03:09:00Z",
            "dataType": "news",
            "sim": 0.6980392336845398,
            "url": "https://www.aninews.in/news/business/business/dr-reddys-profit-grows-ninefold-in-march-quarter20230511083522/",
            "title": "Dr Reddy's profit grows ninefold in March quarter",
            "body": "Hyderabad (Telangana) [India], May 11 (ANI): Pharma giant Dr Reddy's Laboratories has posted a ninefold jump in its profit after tax to Rs 959 crore for the quarter that ended March 31, 2023, driven by its performance in US generics.\n\nThe company had Rs 87-crore net profit in the year-ago period.\n\nThe pharma's revenue went up 16 per cent to Rs 6,297 crore during the quarter reviewed, over the figure in the corresponding period the previous year. Its Ebitda went up 25.9 per cent to Rs. 1,631 crore while its gross margin was at 57.2 per cent in Q4 FY23.\n\nThe company incurred Rs 537 crore in research and development.\n\nCommenting on the results, Co-Chairman and Managing Director, G V Prasad said: \"FY23 has been a year of record sales, profits and cash flow, driven by our performance in US Generics. We progressed well in our productivity and sustainability agenda. We will continue to deliver on our purpose, invest in growth drivers and promote a culture that is innovative and collaborative ensuring the future of our business.\"\n\nIn FY23, the firm's net profit went up 91 per cent to Rs 4,507 crore in the quarter under review over the figure in the year-ago period. Revenue in FY23 went up 15 per cent year-on-year to Rs 24,588 crore.\n\nEarnings before interest, taxes, depreciation and amortization (Ebitda) rose 42 per cent in FY23 to Rs 7,308 crore.\n\nIn FY23, revenue from India was at Rs 48.9 billion. \"Year-on-year growth of 17 per cent was primarily attributable to the increase in prices of our existing products,\" the pharma giant said. The growth was also aided by the divestment of a few non-core brands during the year.\n\n\"During the year, we launched nine brands in India,\" the company said. (ANI)",
            "source": {
                "uri": "aninews.in",
                "dataType": "news",
                "title": "Asian News International (ANI)"
            },
            "authors": [],
            "image": "https://d65zu7a5alzko.cloudfront.net/media/details/ANI-20230511030512.jpg",
            "eventUri": "eng-8609368",
            "sentiment": 0.2392156862745098,
            "wgt": 421470600,
            "relevance": 51
        },
        {
            "uri": "7538463078",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "03:01:00",
            "dateTime": "2023-05-11T03:01:00Z",
            "dateTimePub": "2023-05-11T03:01:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.marketscreener.com/quote/currency/AUSTRALIAN-DOLLAR-US-DO-2373531/news/Indian-shares-set-to-open-higher-on-cooling-U-S-inflation-steady-FII-inflows-43810598/",
            "title": "Indian shares set to open higher on cooling U.S. inflation, steady FII inflows",
            "body": "India's NSE stock futures listed on the Singapore exchange were up 0.20% at 18,395, as of 8:00 a.m. IST.\n\nMost Wall Street equities advanced after data showed that U.S. consumer price inflation slowed to its lowest in two years in April, signalling that the U.S. Federal Reserve's rate hikes have managed to tackle high inflation. Asian equities edged edger. [MKTS/GLOB]\n\nThe probability of a rate hike at the next Fed meeting in June slid to 9.6%, as of 8:00 a.m. IST from 21.9% ahead of the release of the U.S. inflation data. [FEDWATCH]\n\nIndian shares have risen for three sessions in a row, with the Nifty 50 adding 1.36% so far this week. The benchmark has gained 5.5% since March 31, 2023.\n\n\"The main driver of the ongoing rally is the sustained FII inflows,\" said VK Vijayakumar, chief investment strategist at Geojit Financial Services.\n\nForeign institutional investors extended their buying streak in Indian equities for the tenth session in a row on Wednesday, adding equities worth 18.33 billion Indian rupees ($224.14 million). FIIs have purchased shares worth 176.41 billion Indian rupees ($2.16 billion) over the period, according to provisional data from the National Stock Exchange.\n\n\"Appreciating rupee is one of the reasons why FIIs have turned buyers. Also, FIIs have changed their strategy of 'sell India, buy China' which they pursued in January and February\".\n\nInvestors also await quarterly results of major firms such as Asian Paints Ltd, Eicher Motors Ltd, Deepak Nitrite Ltd, Siemens Ltd among others on Thursday.\n\nStocks to Watch:\n\n** Larsen & Toubro Ltd: Co beats Q4 profit view on higher project execution.\n\n** Dr Reddy's Laboratories: Co posts 11-fold jump in Q4 profit.\n\n** Hindalco Ltd: Subsidiary Novelis said its net income in March quarter was down 27% Y/Y.\n\n** Godrej Consumer Products: Co reports 25% jump in fourth-quarter profit on strong demand.\n\n(Reporting by Bharath Rajeswaran in Bengaluru; Editing by Nivedita Bhattacharjee)",
            "source": {
                "uri": "marketscreener.com",
                "dataType": "news",
                "title": "Market Screener"
            },
            "authors": [],
            "image": "https://img.zonebourse.com/reuters/2021-05/2021-05-24T042224Z_1_LYNXNPEH4N04F_RTROPTP_3_INDIA-STOCKS.JPG",
            "eventUri": null,
            "sentiment": 0.2,
            "wgt": 421470060,
            "relevance": 1
        },
        {
            "uri": "7538456957",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "02:55:00",
            "dateTime": "2023-05-11T02:55:00Z",
            "dateTimePub": "2023-05-11T02:40:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.bqprime.com/research-reports/dr-reddys-q4-results-review-sharp-miss-on-base-business-margin-dolat-capital",
            "title": "Dr. Reddy's Q4 Results Review - Sharp Miss On Base Business Margin: Dolat Capital",
            "body": "BQ Prime's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BQ Prime's subscribers an opportunity to expand their understanding of companies, sectors and the economy.\n\nDr. Reddy's Laboratories Ltd.'s earnings were below our estimates on account of lower than expected gRevlimid sales and base business margin in our view.\n\nRevenues, ex divestment of non-core brands, grew at 15.6% YoY but declined 10.9% QoQ in Q4 to Rs 60.3 billion. Ebitda stood at Rs 13.2 billion grew 24.3% YoY but declined 35.9% QoQ and Ebitda margin at 21.9% expanded by 153 basis points YoY.\n\nEx Revlimid, base business sales was in line while base business margin was lower than estimated. We believe gRevlimid might have contributed $71 million/$323 million to sales in Q4 FY23/FY23.\n\nWe downgrade our earnings per share estimates by 2%/5% in FY24E/FY25E assuming lower than expected Ebitda margin.",
            "source": {
                "uri": "bqprime.com",
                "dataType": "news",
                "title": "BQ"
            },
            "authors": [],
            "image": "https://gumlet.assettype.com/bloombergquint%2F2023-01%2F567aab4c-2524-4c9a-be3f-a879ad78268b%2FDr__Reddys_Labs_R_D_centre___Source_Company_website_.png?rect=0%2C41%2C286%2C150&w=1200&auto=format%2Ccompress&ogImage=true",
            "eventUri": null,
            "sentiment": 0.09019607843137245,
            "wgt": 421469700,
            "relevance": 26
        },
        {
            "uri": "7538446448",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "02:43:00",
            "dateTime": "2023-05-11T02:43:00Z",
            "dateTimePub": "2023-05-11T02:42:00Z",
            "dataType": "news",
            "sim": 0.5254902243614197,
            "url": "https://www.rttnews.com/3363223/sensex-nifty-seen-opening-up-as-us-inflation-eases.aspx",
            "title": "Sensex, Nifty Seen Opening Up As US Inflation Eases ",
            "body": "Indian shares may open a tad higher on Thursday after data showed U.S. inflation slowed slightly more than expected in April.\n\nDomestic earnings prove to be a mixed bag, with L&T's Q4 net profit missing Street estimates while Godrej Consumer Products reported decent earnings growth and Dr Reddy's Laboratories saw quarterly profit climbing nine-fold.\n\nAdani Group stocks could be in focus today after reports that Adani Ports would prepay USD 130 million of debt ahead of schedule.\n\nBenchmark indexes Sensex and Nifty recovered from an early slide to end modestly higher on Wednesday. The rupee gained 6 paise to close at 82 against the dollar.\n\nAsian markets traded mixed this morning as data showed China's consumer price inflation eased further in April and producer prices remained in deflation.\n\nGold and oil prices were slightly higher as the dollar sank for a second day against the yen after a drop in Treasury yields.\n\nU.S. stocks ended mixed overnight as data showed consumer inflation fell below 5 percent for the first time in two years. So-called core inflation also eased, giving the Federal Reserve room to pause interest-rate increases soon.\n\nThe S&P 500 rose half a percent and the tech-heavy Nasdaq Composite rallied 1 percent while the Dow slid 0.1 percent as regional banks extended declines on concerns about the health of the banking sector.\n\nEuropean stocks ended Wednesday's session broadly lower after leaders in Washington failed to make progress on a debt ceiling deal.\n\nThe pan European STOXX 600 gave up 0.4 percent. The German DAX slipped 0.4 percent, France's CAC 40 shed half a percent and the U.K.'s FTSE 100 eased 0.3 percent.\n\nFor comments and feedback contact: editorial@rttnews.com",
            "source": {
                "uri": "rttnews.com",
                "dataType": "news",
                "title": "RTTNews"
            },
            "authors": [],
            "image": "https://cdn.rttnews.com/images/v4/RTTNews-logo-512x512.png",
            "eventUri": "eng-8612128",
            "sentiment": 0.223529411764706,
            "wgt": 421468980,
            "relevance": 51
        },
        {
            "uri": "7538421108",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "02:11:00",
            "dateTime": "2023-05-11T02:11:00Z",
            "dateTimePub": "2023-05-11T02:05:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.bqprime.com/markets/lt-shines-godrej-consumer-meets-dr-reddys-misses-estimates-earnings-wrap",
            "title": "L&T Shines, Godrej Consumer Meets, Dr Reddy's Misses Estimates  -- Earnings Wrap",
            "body": "Pharmaceutical major Dr. Reddy's Laboratories saw its net profit for the quarter under review rise 9.9 times in annual terms during the March quarter of financial year 2022-23. This significant growth, however, was not enough to meet the estimated Rs 1,034 crore for the period.Meanwhile, engineering major Larsen & Toubro reported over 10% growth in both its top line and bottom line figures.",
            "source": {
                "uri": "bqprime.com",
                "dataType": "news",
                "title": "BQ"
            },
            "authors": [
                {
                    "uri": "vivek_punj@bqprime.com",
                    "name": "Vivek Punj",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://gumlet.assettype.com/bloombergquint%2F2023-01%2F567aab4c-2524-4c9a-be3f-a879ad78268b%2FDr__Reddys_Labs_R_D_centre___Source_Company_website_.png?rect=0%2C41%2C286%2C150&w=1200&auto=format%2Ccompress&ogImage=true",
            "eventUri": null,
            "sentiment": 0.607843137254902,
            "wgt": 421467060,
            "relevance": 51
        },
        {
            "uri": "7538410307",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "01:59:00",
            "dateTime": "2023-05-11T01:59:00Z",
            "dateTimePub": "2023-05-11T01:58:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.bqprime.com/business/dr-reddys-q4-results-profit-down-1-misses-estimates",
            "title": "Dr. Reddy's Q4 Results: Profit Rises, Misses Estimates",
            "body": "Dr. Reddy's Laboratories Ltd. saw its net profit rise 9.9 times during the fourth quarter of fiscal 2023, missing analyst estimates.The Hyderabad-based drugmaker's profit stood at Rs 960 crore in the quarter ended March, according to its exchange filing. That compares with the Rs 1,034 crore consensus estimate of analysts tracked by Bloomberg.Sequentially, the profit fell 23%.Dr. Reddy's Q4 FY23 Highlights (YoY)Revenue rose 15% to Rs...\n\nDr. Reddy's Laboratories Ltd. saw its net profit rise 9.9 times during the fourth quarter of fiscal 2023, missing analyst estimates.\n\nThe Hyderabad-based drugmaker's profit stood at Rs 960 crore in the quarter ended March, according to its exchange filing. That compares with the Rs 1,034 crore consensus estimate of analysts tracked by Bloomberg.\n\nThe board has recommended a dividend of Rs 40 per share.\n\n\"FY23 has been a year of record sales, profits and cash flow, driven by our performance in U.S. generics. We will continue to deliver on our purpose, invest in growth drivers and promote a culture that is innovative and collaborative, ensuring the future of our business,\" said GV Prasad, co-chairman and managing director at Dr. Reddy's, in the exchange filing.",
            "source": {
                "uri": "bqprime.com",
                "dataType": "news",
                "title": "BQ"
            },
            "authors": [
                {
                    "uri": "monal_sanghvi@bqprime.com",
                    "name": "Monal Sanghvi",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://gumlet.assettype.com/bloombergquint%2F2023-05%2Fe5d5daac-523f-4f69-a6ad-2245b56b9e9a%2FDr__Reddy_s_2__1___1_.png?w=1200&auto=format%2Ccompress&ogImage=true",
            "eventUri": null,
            "sentiment": 0.419607843137255,
            "wgt": 421466340,
            "relevance": 100
        },
        {
            "uri": "7538398626",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "01:43:00",
            "dateTime": "2023-05-11T01:43:00Z",
            "dateTimePub": "2023-05-11T01:43:00Z",
            "dataType": "news",
            "sim": 0.5686274766921997,
            "url": "https://www.moneycontrol.com/news/business/markets/stock-market-today-top-10-things-to-know-before-the-market-opens-42-10563921.html",
            "title": "Stock Market Today: Top 10 things to know before the market opens",
            "body": "Foreign institutional investors (FII) bought shares worth Rs 1,833.13 crore, whereas domestic institutional investors (DII) sold shares worth Rs 789.67 crore on May 10, provisional data from the National Stock Exchange showed.\n\nThe market is likely to open marginally higher on Thursday as the SGX Nifty indicates a positive start for the broader index with a gain of 35 points after opening the session at 18,350. SGX futures touched a high of 18,410 in early trade today.\n\nThe BSE Sensex gained 178 points to close at 61,940 in the previous session, while the Nifty 50 closed 49 points higher at 18,315. The Nifty50 traded comfortably higher than its 200-day moving average of 17,804 and is expected to build on the recent momentum.\n\nThe pivot charts indicate that the Nifty may get support at 18,241, followed by 18,214 and 18,170. If the index advances, 18.,328 is the initial key resistance level to watch out for followed by 18,356 and 18,400.\n\nStay tuned to Moneycontrol to find out what happens in the currency and equity markets today. We have collated a list of important headlines across news platforms which could impact Indian as well as international markets.\n\nSGX Nifty\n\nThe SGX Nifty indicates a positive start for the broader index with a gain of 35 points on Thursday. SGX futures stood at 18,395.\n\nThe Nasdaq Composite closed higher Wednesday as investors fled to tech stocks after a tamer-than-expected inflation report. The tech-heavy index added 1.04 percent, closing at 12,306.44. The S&P 500 added 0.45 percent to close at 4,137.64. Finally, the Dow Jones Industrial Average inched downward by 0.09 percent, or 30.48 points, to end the day at 33,531.33.\n\nApril consumer prices climbed 4.9 percent from a year ago, which was less than the 5 percent gain anticipated by economists polled by Dow Jones. Month-over-month inflation matched expectations with a 0.4 percent increase in April.\n\nEuropean Markets\n\nEuropean markets closed lower on Wednesday as investors digested the latest U.S. inflation data and how it could affect the U.S. Federal Reserve's monetary policy.\n\nThe pan-European Stoxx 600 index provisionally ended down 0.5 percent, with major bourses and most sectors in negative territory. Food and beverages stocks led the losses, down 1.4 percent. FTSE closed 0.29 percent lower at 7741. DAX closed 0.37 percent lower at 15896. CAC 40 Index closed 0.49 percent lower at 7361.\n\nAsian markets\n\nAsia-Pacific markets traded mixed after Wall Street saw a tech rally as U.S. consumer price index rose less than expected for April. The consumer price index showed a reading of 4.9 percent, slightly less than the 5 percent gain anticipated by economists polled by Dow Jones. Month-over-month, inflation matched expectations with a 0.4 percent increase. Investors in Asia will be closely watching the inflation print from China for April as well later Thursday, forecasted to come in at 0.3 percent, according to a Reuters poll of economists.\n\nSouth Korea's Kospi rose 0.46 percent and the Kosdaq saw a larger gain of 0.74 percent. In Australia, the S&P/ASX 200 opened 0.12 percent higher. In Japan, the Nikkei 225 traded close to the flatline, while the Topix saw a marginal loss. Futures tied to Hong Kong's Hang Seng index stood at 19,725, lower than the HSI's last close of 19,762.\n\nL&T Q4 net profit spikes 10% to Rs 3,987 crore, misses estimates\n\nEngineering and construction major Larsen and Toubro (L&T) on May 10 reported a consolidated net profit for the quarter ended March 2023 at Rs 3,987 crore, up 10 percent compared to Rs 3,621 crore in the same quarter last year.\n\nIts revenue from operations for the quarter stood at Rs 58,335 crore, registering a growth of 10 percent from Rs 52,851 crore, the company said in an exchange filing. The share of international revenues during the quarter was 39 percent.\n\nDr Reddy's Q4 net profit jumps to Rs 959 crore on favorable base, US launches, brand deals\n\nPharmaceutical major Dr Reddy's Laboratories recorded a manifold rise in its net profit to Rs 959.2 crore for the fourth quarter that ended March 31, from Rs 87.5 crore in the same period last year.\n\nThe net profit in the base quarter was hit by impairment charges, price erosion and increased competition in the US market, Dr Reddy's Laboratories said in an exchange filing. In addition, the company also benefitted from the sale of nine dermatology brands to Eris Lifesciences for Rs 275 crore, which incrementally boosted its headline numbers for Q4.\n\nOil prices\n\nOil prices fell on Wednesday, ending a three-day rally as an unexpected rise in U.S. oil inventories sparked demand concerns and investors awaited inflation data for a steer on U.S. interest rates. Brent crude dropped 98 cents, or 1.27 percent, to $76.46 a barrel while U.S. West Texas Intermediate (WTI) crude fell $1.02, or 1.4 percent, to $72.68.\n\nDollar\n\nThe Dollar index traded 0.03 percent higher in futures at 101.58, whereas the value of one dollar hovered near Rs 81.98\n\nGold\n\nGold prices edged lower on Wednesday as optimism over the Federal Reserve cutting interest rates this year faded after U.S. inflation report, triggering profit-taking among some investors. Spot gold was last down 0.19 percent to $2,030.59 per ounce and U.S. gold futures settled 0.3 percent lower at $2,037.10.\n\nFII and DII\n\nForeign institutional investors (FII) bought shares worth Rs 1,833.13 crore, whereas domestic institutional investors (DII) sold shares worth Rs 789.67 crore on May 10, provisional data from the National Stock Exchange showed.",
            "source": {
                "uri": "moneycontrol.com",
                "dataType": "news",
                "title": "MoneyControl"
            },
            "authors": [],
            "image": "https://images.moneycontrol.com/static-mcnews/2020/04/BSE-building-coronavirus-1-770x433.jpg",
            "eventUri": "eng-8612128",
            "sentiment": 0.4666666666666666,
            "wgt": 421465380,
            "relevance": 1
        },
        {
            "uri": "7538398627",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-11",
            "time": "01:43:00",
            "dateTime": "2023-05-11T01:43:00Z",
            "dateTimePub": "2023-05-11T01:43:00Z",
            "dataType": "news",
            "sim": 0.7019608020782471,
            "url": "https://www.moneycontrol.com/news/business/markets/buzzing-stocks-asian-paints-lt-godrej-consumer-gujarat-gas-others-in-focus-today-10564551.html",
            "title": "Buzzing Stocks: Asian Paints, L&T, Godrej Consumer, Gujarat Gas, others in focus today",
            "body": "Results on May 11: Asian Paints, Eicher Motors, Siemens, Aditya Birla Capital, Balrampur Chini Mills, BLS International Services, CARE Ratings, Deepak Nitrite, Gillette India, Gujarat State Petronet, Intellect Design Arena, Dr Lal PathLabs, PTC India Financial Services, Shankara Building Products, South Indian Bank, Ujjivan Small Finance Bank, and Zensar Technologies will be in focus ahead of quarterly earnings on May 11.\n\nLarsen & Toubro: The engineering and infrastructure major has recorded a 10% year-on-year growth in consolidated profit at Rs 3,987 crore in the quarter ended March FY23 despite a drop in operating margin. Revenue from operations grew by 10% to Rs 58,335 crore compared to the year-ago period. The board has recommended a final dividend of Rs 24 per share. The order inflow for FY23 crossed Rs 2 lakh crore, coming in higher by 19% YoY at Rs 2.3 lakh crore. The board has also decided to confer the status of Chairman Emeritus on A M Naik after he decided to step down as Non-Executive Chairman of the L&T Group at the end of his tenure on September 30, 2023, and appointed S N Subrahmanyan as Chairman and Managing Director of L&T with effect from October 1, 2023.\n\nDr Reddy's Laboratories: The pharma major has registered an 11-fold year-on-year increase in profit at Rs 959 crore for the March FY23 quarter as profit in Q4FY22 was impacted by impairment of non-current assets, but supported by healthy operating performance. Revenue for the quarter increased by 16% to Rs 6,297 crore compared to the year-ago period, with North America business growing 27%, Europe 12%, and India business showing a 32% growth YoY. The board recommended a final dividend of Rs 40 per share for FY23.\n\nHindalco Industries: Subsidiary Novelis said its net income attributable to the common shareholder in Q4FY23 was $156 million, down 27% compared to the year-ago period. Net income from continuing operations excluding special items was $175 million, down 7% YoY, while adjusted EBITDA of $403 million fell 6% YoY.\n\nGodrej Consumer Products: The FMCG company has reported a 24.5% year-on-year growth in consolidated profit at Rs 452.1 crore for quarter ended March FY23, backed by better-than-expected operating numbers. Consolidated revenue grew by 10% YoY to Rs 3,200.2 crore in Q4FY23 with volume growth of 6%. India business sales increased by 12% year-on-year led by volume growth of 11%, Indonesia sales grew by 8%; Africa, USA and Middle East sales rose by 6%, but Latin America & SAARC sales declined by 3%.\n\nHDFC: The company has received final approval from the Securities and Exchange Board of India (SEBI) for a change in control of HDFC Asset Management Company, investment manager of HDFC AMC AIF II on account of the proposed composite scheme of amalgamation for the amalgamation of HDFC Investments and HDFC Holdings with HDFC, and HDFC with HDFC Bank.\n\nRattanIndia Enterprises: The company has received board approval for raising of funds up to Rs 1,000 crore through the issue of securities, either by way of qualified institutions placement (QIP) or any other permissible mode of fundraising.\n\nGujarat Gas: The leading city gas distribution company has reported a half-a percent sequential decline in profit at Rs 369.22 crore for the quarter ended March FY23, impacted by weak operating performance. Revenue from operations (net of excise duty) in Q4FY23 grew by 6.6% to Rs 3,928.6 crore compared to the previous quarter.\n\nKPI Green Energy: The Gujarat-based solar company has received a new order for a 35 MW capacity solar power plant under the captive power producer (CPP) segment. The project is scheduled to be completed in FY24, in various tranches as per the terms of the order. The said order is in lieu of the previous order of a 33 MW capacity solar power plant under the CPP segment received in December 2022.\n\nHG Infra Engineering: The company has recorded a massive 64.4% year-on-year growth in profit at Rs 170.9 crore for the March FY23 quarter, supported by healthy operating numbers and topline. Revenue from operations in Q4FY23 increased by 44.2% to Rs 1,535.4 crore compared to year-ago period.\n\nSagar Cements: The cement company has reported a consolidated profit of Rs 100.5 crore for the quarter ended March FY23, against a loss of Rs 115.1 crore in the same period last year, supported by higher other income. Revenue grew by 24% to Rs 621.5 crore compared to the year-ago.\n\nProcter & Gamble Hygiene & Health Care: The FMCG company has registered a 60.44% year-on-year growth in profit at Rs 165.02 crore for quarter ended March FY23, driven by tax write-back and higher other income. Revenue from operations in Q3 fell 9.3% to Rs 883.09 crore compared to year-ago period.\n\nRatnamani Metals and Tubes: The company has recorded a massive 71.6% year-on-year growth in profit at Rs 191.5 crore, while revenue from operations grew by 54% to Rs 1,449 crore compared to year-ago period. The board has approved the re-appointment of Prakash M Sanghvi as the Managing Director, Jayanti M Sanghvi as the Joint Managing Director and Shanti M Sanghvi as the Whole Time Director of the company for 5 years with effect from November 1, 2023. The company also announced a dividend of Rs 12.00 per share for FY23.\n\nPricol: The automotive components and precision engineered products manufacturer has reported a 127% year-on-year increase in profit at Rs 29.8 crore for March FY23 quarter despite weak operating margin. Revenue from operations for the quarter at Rs 523.5 crore grew by 26.4% over a year-ago period.\n\nNovartis India: The healthcare company has recorded a profit of Rs 25 crore for the quarter ended March FY23 quarter, against a loss of Rs 23.4 crore in the same period last year. Revenue from operations fell 22.6% YoY to Rs 76.1 crore during the quarter. The company has announced a final dividend of Rs 10 per share and a one-time special dividend of Rs 37.50 per share.",
            "source": {
                "uri": "moneycontrol.com",
                "dataType": "news",
                "title": "MoneyControl"
            },
            "authors": [],
            "image": "https://images.moneycontrol.com/static-mcnews/2023/04/stocks_sensex_nifty_stockmarket1-2-770x433.jpg",
            "eventUri": "eng-8609368",
            "sentiment": 0.3960784313725489,
            "wgt": 421465380,
            "relevance": 51
        },
        {
            "uri": "7535450968",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "23:51:00",
            "dateTime": "2023-05-10T23:51:00Z",
            "dateTimePub": "2023-05-09T07:06:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.finanznachrichten.de/nachrichten-2023-05/59029821-cardiacare-names-ken-nelson-chairman-of-its-board-of-directors-008.htm",
            "title": "CardiaCare Names Ken Nelson Chairman of its Board of Directors",
            "body": "Digital health and medtech leader brings 20 years of cardiac innovation and commercialization experience to startup developing AI powered neuromodulation wearable for non-invasive atrial fibrillation treatment\n\nREHOVOT, Israel, May 9, 2023 /PRNewswire/ -- CardiaCare, a clinical stage digital therapeutic company developing the world's first non-invasive, neuromodulation wearable for atrial fibrillation treatment, announced today that Ken Nelson has been appointed Chairman of the Board. Mr. Nelson is a 20-year digital health, medical device, and remote patient monitoring executive with a stellar track record of building successful sales, marketing and commercialization teams at Fortune 500 companies as well as startups.\n\n\"We are privileged and excited to welcome Ken Nelson to CardiaCare as Chairman of the Board of Directors,\" said Ofer Halbreich, CEO of CardiaCare. \"Ken brings a wealth of market development, commercialization and sales experience in the cardiac monitoring and cardiac rhythm management space. Ken joins CardiaCare as the company ramps up multiple clinical trials of our revolutionary wearable for atrial fibrillation treatment. Ken's prior experience and success scaling cardiac device companies will be invaluable to us as we create global awareness of CardiaCare's disruptive innovation and build out the infrastructure towards successful commercialization of our technology.\"\n\nMr. Nelson spent just under 10 years in sales and commercial operations leadership roles at Boston Scientific (formerly Guidant) in the Cardiac Rhythm Management division. Then, over the past 12 years, he has led commercial sales and marketing efforts and has launched disruptive wearable technologies in cardiac digital health and remote patient monitoring. He played a significant role in building the teams, cultures, and infrastructures for what have become three of the top four market share players in cardiac digital health and remote patient monitoring (iRhythm; Biotelemetry, acquired by Philips; Bardy Diagnostics, acquired by HillRom). Most recently, he served as Head of Digital Health, Diagnostics, and Monitoring at BIOTRONIK, a global leader in the treatment of cardiac and vascular disease.\n\nAmos Ziv, founder and CSO, of CardiaCare adds, \"CardiaCare is committed to disrupting the atrial fibrillation treatment paradigm, enabling effective, non-invasive, side-effect free therapy for AFib with our first of its kind home-care wearable technology. We've made important strides in the development of our technology, including the recent licensing and distribution agreement with Dr. Reddy's Laboratories in India and multiple clinical trials now underway. We look forward to Ken's leadership contribution to continue building on this momentum.\"\n\n\"I am pleased to join CardiaCare and look forward to working with the management team and the Board, to commercialize the first ever wearable device for closed loop, personalized, atrial fibrillation treatment, powered by artificial intelligence, that can both detect and treat atrial fibrillation non-invasively,\" said Ken Nelson, Chairman of the Board, CardiaCare. \"I'm impressed with the company's revolutionary technology and the successful engagement with key opinion leaders including Mount Sinai electrophysiologist Dr. Vivek Reddy. I believe CardiaCare's innovative solution is poised to advance patient care for the treatment of atrial fibrillation.\"\n\nAbout CardiaCare\n\nCardiaCare is a clinical stage digital therapeutic company developing the world's first closed-loop neuromodulation wearable for non-invasive, AI-based arrythmia care. CardiaCare was a Medtech Innovator 2022 cohort member. For more information, visit our website and follow us on LinkedIn.\n\nMedia Contact:\n\nOfer Halbreich\n\nCEO, CardiaCare\n\ninfo@my-cardiacare.com\n\nView original content:https://www.prnewswire.co.uk/news-releases/cardiacare-names-ken-nelson-chairman-of-its-board-of-directors-301818194.html\n\nKostenloser Report: Gefallene Big-Techs - Hier winken jetzt bis zu 200%!Marktexperte ist Ã¼berzeugt: Diese groÃŸen Tech-Aktien sind zu stark gefallen und kommen jetzt zurÃ¼ck!Hier klicken",
            "source": {
                "uri": "finanznachrichten.de",
                "dataType": "news",
                "title": "FinanzNachrichten.de"
            },
            "authors": [],
            "image": "https://rt.prnewswire.com/rt.gif?NewsItemId=EN89288&Transmission_Id=202305090300PR_NEWS_EURO_ND__EN89288&DateId=20230509",
            "eventUri": null,
            "sentiment": 0.4666666666666666,
            "wgt": 421458660,
            "relevance": 1
        },
        {
            "uri": "7534815425",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "23:43:00",
            "dateTime": "2023-05-10T23:43:00Z",
            "dateTimePub": "2023-05-08T17:28:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://finance.yahoo.com/news/dr-reddys-profitable-predictable-margin-172842347.html",
            "title": "Dr. Reddy's: A Profitable, Predictable Margin Expander",
            "body": "The Profitable Predictable Margin Expanders screener on GuruFocus has been a helpful one for me when searching for quality stocks that show solid growth. It does what the name suggests - it sorts through the thousands of stocks in the GuruFocus database and selects those that are currently profitable, have a business predictability ranking of at least 3 out of 5 stars and have expanding operating margins. There are no criteria for valuation or other considerations.\n\nDr. Reddy's Laboratories Ltd (NYSE:RDY) is one of only 42 stocks that make it through the screener. While it may not be undervalued, it is at least fairly valued according to the GF Value chart.\n\nAbout Dr. Reddys\n\nDr. Reddy's develops and manufactures pharmaceutical products and specializes in low-cost, easy-to-produce generic drugs and pharmaceutical ingredients. This illustration of its income statement shows where it gets its revenues and what becomes of them:\n\nBased in Hyderabad, India and traded on the New York Stock Exchange, it sells its products globally. It has a market cap of $10.18 billion and had trailing 12-month revenue of just under $3 billion.\n\nNote that it has industry-leading results for the drug manufacturers industry in all but one category. Most importantly for the screener, it enjoys a higher operating margin than 89.50% of peers.\n\nIt's worth noting, too, that its return on equity is among the best in the industry at 18.04%, which means it should double in value over four years by my estimates.\n\nGrowth\n\nWhile there are lots of dark green bars on the profitability table, the picture doesnt look as positive for its growth based on the earnings per share without non-recurring items. As this 10-year chart shows, there have been only three \"up\" years in the past decade.\n\nTurning to predictability, Dr. Reddys scores 3 out of 5 on its GuruFocus business predictability rank, which meets the screener's minimum. Behind the predictability rank is the ability to consistently generate increased revenues and Ebitda, while keeping costs in line.\n\nTo grow its revenue relatively consistently, a company must have a tried and tested marketing strategy and new products that not only maintain current sales levels but also expand its market each year.\n\nIn addition, it also must keep its fixed and variable costs under control. That can be particularly difficult when inflation rises, but Dr. Reddys has a continuous improvement initiative.\n\nMargins\n\nGrowing margins are the third major criterion for the screener. In this case, expansion means growth of net margin (a minimum of 10% per year) and the operating margin (a minimum of 5% per year).\n\nHeres a chart showing the operating margin in green and the operating margin in red:\n\nRDY Data by GuruFocus\n\nObviously, there has been some improvement over the past five years, but over the past 10 years there has been a decline in these two margins.\n\nNormally, I would take that as bad news, but we have to consider that both margins are still industry-leading, so perhaps they can be seen as normalizing rather than being in trouble.\n\nTaking a closer look, I see that the industrys operating margin median is 5.16%, while the net margin median is 3.29%. Dr. Reddys is a high-flyer compared to most of the industry.\n\nThe margins are greater than they were five years ago, so I would grudgingly say they are expanding, but it's something to keep an eye on.\n\nAnnual report\n\nHow likely is the company to remain profitable, predictable and margin expansive? To assess this, I have taken a look at the company's latest 10K for 2022.\n\nIn its annual report for 2022, management reported, In FY22, we filed 10 Drug Master Files and seven ANDAs in the U.S., and launched 157 products across markets. As we can see, the company is growing its pipeline.\n\nIt also noted it is ready to grow through acquisitions:\n\nAll of this is part of a consistent strategic orientation:\n\nI always like to see continuous improvement initiatives, because they mean a company is focused on its costs, but not necessarily to the exclusion of everything else.\n\nDr. Reddys also cites continuing growth industry-wide:\n\nLooking forward, analysts at Morningstar Inc. (NASDAQ:MORN) expect EPS without NRI to increase from $2.67 per share last year to $2.88 per share for the current year, then $3.17 per share for the two subsequent years.\n\nOverall, I believe Dr. Reddys Laboratories deserves its place on the screener. It appears to offer slow but steady growth potential for patient investors.",
            "source": {
                "uri": "finance.yahoo.com",
                "dataType": "news",
                "title": "Yahoo! Finance"
            },
            "authors": [],
            "image": "https://media.zenfs.com/en/us.finance.gurufocus/0e96c137b45aa37f9896c19ce8f76424",
            "eventUri": null,
            "sentiment": 0.2313725490196079,
            "wgt": 421458180,
            "relevance": 75
        },
        {
            "uri": "7535824184",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "22:49:00",
            "dateTime": "2023-05-10T22:49:00Z",
            "dateTimePub": "2023-05-09T10:54:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.finanznachrichten.de/nachrichten-2023-05/59034020-eagle-pharmaceuticals-inc-eagle-pharmaceuticals-reports-first-quarter-2023-results-399.htm",
            "title": "Eagle Pharmaceuticals, Inc.: Eagle Pharmaceuticals Reports First Quarter 2023 Results",
            "body": "Total revenue for Q1 2023 was $66.3 million, compared to $115.9 million in Q1 2022Q1 2023 net income was $0.44 per basic and diluted share and adjusted non-GAAP net income1 was $1.27 per basic and $1.26 per diluted shareQ1 2023 adjusted non-GAAP EBITDA of $22.3 millionQ1 2023 net sales of PEMFEXYÂ® totaled $22.9 million; Eagle estimates that it has an approximate 15% share in commercial (non-340B) pemetrexed market for the second quarter of 2023 to date2BENDEKAÂ®3 and BELRAPZOÂ®4 - both ready-to-dilute (\"RTD\") products - combined maintained approximately 89% share of the bendamustine U.S. market for the first quarter of 2023 compared to approximately 90% historically5Company reaffirms full year guidance; adjusted EBITDA1 of $74.0 - $80.0 million and adjusted non-GAAP earnings per share1 of $4.20 - $4.53The Company is also currently working with lenders to secure financing to support a potential accretive acquisition.\n\nWOODCLIFF LAKE, N.J., May 09, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (\"Eagle\" or the \"Company\") today announced financial results for the three months ended March 31, 2023.\n\nBusiness and Recent Highlights:\n\nNet product sales of PEMFEXY totaled $22.9 million in the first quarter 2023. Based on internal data and customer feedback, the Company estimates that as of the second quarter to date, its U.S. share of commercial (non-340B) pemetrexed usage has grown to 15% up from 6% exiting the fourth quarter of 2022.Centers for Medicare & Medicaid Services (\"CMS\") established a unique, product-specific billing code for ByfavoÂ® (remimazolam for injection)6, a short-acting sedative for procedures lasting 30 minutes or less. This new Healthcare Common Procedure Coding System (HCPCS) Level II code (\"J-code\") is J2249 \"Injection, remimazolam, 1 mg.\" The J-code will be effective on July 1, 2023.Reached a settlement agreement with Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. (collectively, \"Dr. Reddy's\"). Eagle had asserted its Orange Book-listed patents against Dr. Reddy's related to its new drug application referencing BENDEKA. Under the settlement agreement, Dr. Reddy's has the right to market its product beginning November 17, 2027, or earlier based on certain circumstances. The settlement with Dr. Reddy's follows Eagle's previously announced settlements with Hospira, Inc. (\"Hospira\") and Accord Healthcare, Inc. (\"Accord\") related to their new drug applications referencing BENDEKA. With the Dr. Reddy's settlement, all the existing challenges, except for one, which is for a proposed powder, not liquid, formulation have been settled. The Company expects bendamustine to be a significant contributor for several more years. Reaffirms full-year Company guidance.The Company is also currently working with lenders to secure financing to support a potential accretive acquisition.\n\nFinancial Highlights\n\nFirst Quarter 2023\n\nTotal revenue for Q1 2023 was $66.3 million, compared to $115.9 million in Q1 2022.Q1 2023 net income was $5.8 million, or $0.44 per basic and diluted share, compared to net income of $44.1 million, or $3.47 per basic and $3.41 per diluted share, in Q1 2022.Q1 2023 adjusted non-GAAP net income was $16.5 million, or $1.27 per basic and $1.26 per diluted share, compared to adjusted non-GAAP net income of $52.2 million, or $4.10 per basic and $4.04 per diluted share, in Q1 2022.Cash and cash equivalents were $21.9 million, net accounts receivable was $115.0 million, and total debt was $77.5 million, as of March 31, 2023.\n\n\"Following on from our outstanding performance in 2022, we believe Eagle remains well positioned for another strong year, and therefore we are reiterating our 2023 guidance. Our products continue to track well, and we are on pace to surpass our 2022 net product sales for the full year 2023 for PEMFEXY, which continues to gain share in commercial (non-340B) pemetrexed usage in the U.S.,\" stated Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals.\n\n\"To be clear, the investments we are making for the future account for much of the expected difference of our earnings in 2023 versus 2022. We are investing to support our products and advance our pipeline, notably CAL02, which bridges much of the year-over-year gap. We believe the expansion of our commercial team will enable us to capture synergies with an acquisition target and are currently working with lenders to secure financing to support a potentially accretive transaction,\" concluded Tarriff.\n\nFirst Quarter 2023 Financial Results\n\nTotal revenue for the three months ended March 31, 2023 was $66.3 million, as compared to $115.9 million for the three months ended March 31, 2022.\n\nQ1 2023 RYANODEXÂ® net product sales were $8.8 million, compared to $6.6 million in the first quarter of 2022.\n\nQ1 2023 BELRAPZO net product sales were $6.4 million, compared to $5.9 million in the first quarter of 2022.\n\nQ1 2023 PEMFEXY net product sales were $22.9 million, compared to $37.2 million in the first quarter of 2022.\n\nQ1 2023 vasopressin net product sales were $3.5 million, compared to $34.3 million in the first quarter of 2022. During the first quarter of 2023, the Company gave notice to customers and the FDA that it was withdrawing from the vasopressin market. Inventory on hand is expected to be depleted by the end of the second quarter of 2023.\n\nQ1 2023 royalty revenue was $20.1 million, compared to $25.8 million in the prior year quarter.\n\nA summary of total revenue is outlined below:\n\nThree Months Ended March 31, 2023 2022 (unaudited) (unaudited) Revenue (in thousands): Product sales, net$46,221 $90,088 Royalty revenue 20,084 25,786 Total revenue$66,305 $115,874\n\nGross margin was 74% during the first quarter of 2023, compared to 76% in the first quarter of 2022. The decrease in gross margin was primarily the result of the inclusion of amortization of intangible assets related to the newly acquired products, which we expect to continue going forward.\n\nR&D expense was $9.3 million for the first quarter of 2023, compared to $6.1 million for the first quarter of 2022. The increase was primarily due to higher spend of $2.0 million on CAL02 and $1.0 million on Byfavo and Barhemsys pediatric studies.\n\nSG&A expenses in the first quarter of 2023 were $28.0 million compared to $22.2 million in the first quarter of 2022. This increase was driven by $3.3 million in salary and other personnel-related costs, $2.0 million in external sales and marketing spend, partially offset by $2.0 million in lower legal-related costs.\n\nNet income for the first quarter of 2023 was $5.8 million, or $0.44 per basic and diluted share, compared to net income of $44.1 million, or $3.47 per basic and $3.41 per diluted share, in the first quarter of 2022, primarily as a result of the factors discussed above.\n\nAdjusted non-GAAP net income for the first quarter of 2023 was $16.5 million, or $1.27 per basic and $1.26 per diluted share, compared to adjusted non-GAAP net income of $52.2 million, or $4.10 per basic and $4.04 per diluted share, in the first quarter of 2022.\n\nAdjusted non-GAAP EBITDA for the first quarter of 2023 was $22.3 million, compared to adjusted non-GAAP EBITDA of $66.9 million in the first quarter of 2022.\n\n2023 Full-Year Guidance\n\nThe Company continues to expect:\n\nAdjusted EBITDA of $74.0-$80.0 millionAdjusted non-GAAP earnings per share of $4.20-$4.53Adjusted non-GAAP R&D expense of $41.0-$45.0 millionAdjusted non-GAAP SG&A expense of $86.0-$90.0 million\n\nLiquidity\n\nAs of March 31, 2023, Eagle had $21.9 million in cash and cash equivalents, $115.0 million in accounts receivable, net, and $77.5 million in outstanding debt on the Company's $150 million credit facility with JPMorgan. As of March 31, 2023, Eagle had a working capital surplus of $94.7 million.\n\nConference Call\n\nAs previously announced, Eagle management will host its first quarter 2023 conference call as follows:\n\nDate May 9, 2023Time 8:30 A.M. ETToll free (U.S.) 800-274-8461International 203-518-9814Webcast (live and replay) www.eagleus.com, under the \"Investor + News\" section\n\nA replay of the conference call will be available for two weeks after the call's completion by dialing 888-566-0151 (U.S.) or 402-220-9181 (International) and entering conference call ID EGRXQ123. The webcast will be archived for 30 days at the aforementioned URL.\n\nAbout Eagle Pharmaceuticals, Inc.\n\nEagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients' lives. Eagle's commercialized products include vasopressin, PEMFEXYÂ®, RYANODEXÂ®, BENDEKAÂ®, BELRAPZOÂ®, TREAKISYMÂ® (Japan), and ByfavoÂ® and BarhemsysÂ® through its wholly owned subsidiary Acacia Pharma Inc. Eagle's oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle's website at www.eagleus.com.\n\nForward-Looking Statements\n\nThis press release contains \"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities law. Forward-looking statements are statements that are not historical facts. Words and phrases such as \"anticipated,\" \"forward,\" \"will,\" \"would,\" \"could,\" \"should,\" \"may,\" \"remain,\" \"potential,\" \"prepare,\" \"expect,\" \"anticipate,\" \"believe,\" \"plan,\" \"future,\" \"believe,\" \"guidance,\" \"project,\" \"estimate,\" \"intend,\" \"advance,\" \"continue\" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements with respect to: the effectiveness date of the J-code and potential benefits thereof; the Company's ability to manage its bendamustine franchise; the potential further investment by the Company in its development programs, products and pipeline the ability of the Company's products and product candidates to address unmet clinical needs; the Company's financial projections and guidance, including anticipated financial performance for 2023, including expected adjusted EBITDA, adjusted non-GAAP earnings per share, adjusted non-GAAP R&D and adjusted non-GAAP SG&A expense; the potential benefits and commercial opportunity of Enalare's product candidates; expected continued earnings growth and anticipated deployment of cash to fund clinical development and potential strategic transactions; the potential for the Company to transition into a diversified pharmaceutical company with a portfolio of branded, first-in-class assets and to utilize legacy products; the Company's ability to pursue additional potential transactions to further diversify its product portfolio and pipeline and broaden its footprint on favorable terms or at all and expectations that the Company's cash and balance sheet will be used for any such transaction and that any such transaction will be accretive; the Company's ability to obtain and maintain regulatory approval of its products and product candidates; the Company's clinical development plan for its product candidates, including the number and timing of development initiatives or new indications for the Company's product candidates; the timing, scope or likelihood and timing of regulatory filings and approvals from the FDA for the Company's or its partner's product candidates; the progress and success of the Company's launch of any products; the addressable market size for, and the ability of the Company to successfully commercialize, its products and product candidates, and expectations with respect to growth of market share; the period of marketing exclusivity for any of the Company's products or product candidates; the resolution of patent litigation and related settlement terms, including the date of market entry and the potential for earlier market entry under certain circumstances and submission of settlement agreements to the U.S. Federal Trade Commission and the U.S. Department of Justice for review; the strength of the Company's intellectual property rights; the expected expansion, defense and enforcement of intellectual property rights; the ability of the Company to obtain and maintain coverage and adequate reimbursement for its products; the success of the Company's collaborations with its strategic partners and the timing and results of these partners' preclinical studies and clinical trials, and the Company's potential earnings potential through such collaborations; the ability of the Company's executive team to execute on the Company's strategy and to utilize its cash and other assets to increase shareholder value; and the ability of the Company's product candidates to deliver value to stockholders; the Company's ability to deliver value in 2023 and over the long term; the Company's ability to sustain and further its growth; the Company's ability to effectively manage and control expenses in line with its budget; the sufficiency of the Company's cash flows and capital resources; and the Company's ability to achieve expected future financial performance and results. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the Company's control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks and uncertainties include, but are not limited to: the risk that the anticipated benefits of the Company's acquisition of Acacia are not realized; the ability of Enalare to achieve milestones and deliverables and achieve successful results in the development of ENA-001 and the Company's ability to exercise its option to acquire the remaining outstanding share capital of Enalare; the impacts of the continuing effects of the COVID-19 pandemic and geopolitical events such as the conflict in Ukraine, including disruption or impact in the sales of the Company's marketed products, interruptions or other adverse effects to clinical trials, delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems, disruption in the operations of the Company's third party partners and disruption of the global economy or other events on the Company's business, financial condition and results of operations; macroeconomic conditions, including rising inflation and interest rates, uncertain credit and financial markets and recent and potential disruptions in banking systems; whether the Company will incur unforeseen expenses or liabilities or other market factors; whether the Company will successfully implement its development plan for its product candidates; delay in or failure to obtain regulatory approval of the Company's or its partners' product candidates; whether the Company can successfully market and commercialize its product candidates; the success of the Company's relationships with its partners; the availability and pricing of third party sourced products and materials; the outcome of litigation involving any of its products or that may have an impact on any of our products; successful compliance with the FDA and other governmental regulations applicable to product approvals, manufacturing facilities, products and/or businesses; general economic conditions, including the potential adverse effects of public health issues, including the COVID-19 pandemic and geopolitical events, on economic activity and the performance of the financial markets generally; the strength and enforceability of the Company's intellectual property rights or the rights of third parties; competition from other pharmaceutical and biotechnology companies and the potential for competition from generic entrants into the market; the risks inherent in the early stages of drug development and in conducting clinical trials; and any unanticipated factors in addition to the foregoing that may impact the Company's financial and business projections and guidance and may cause the Company's actual results and outcomes to materially differ from its projections and guidance; and those risks and uncertainties identified in the \"Risk Factors\" sections of the Company's Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (the \"SEC\") on March 23, 2023, and its other subsequent filings with the SEC, including the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2023. Readers are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.\n\nNon-GAAP Financial Performance Measures\n\nIn addition to financial information prepared in accordance with U.S. GAAP, this press release also contains adjusted non-GAAP net income, adjusted non-GAAP earnings per share, adjusted non-GAAP R&D expense and adjusted non-GAAP SG&A expense and projected adjusted non-GAAP R&D expense, adjusted EBITDA, adjusted non-GAAP earnings per share and adjusted non-GAAP SG&A expense. The Company believes these measures provide investors and management with supplemental information relating to operating performance and trends that facilitate comparisons between periods and with respect to projected information.\n\nAdjusted non-GAAP net income and related earnings per share information excludes amortization expense, stock-based compensation expense, depreciation expense, severance, acquisition related costs, legal settlement, non-cash interest expense, fair value adjustments on equity investment, convertible promissory note related adjustments, fair value adjustments related to derivative instruments, foreign currency exchange gain, inventory step-up, and the tax effect of these adjustments.\n\nAdjusted EBITDA excludes interest expense net of interest income, income tax provision, depreciation and amortization expense, stock-based compensation expense, fair value adjustments on equity investment, convertible promissory note related adjustments, fair value adjustments related to derivative instruments, foreign currency exchange gain, gain on euro debt, legal settlement, acquisition related costs, inventory step-up, debt issuance cost and severance.\n\nAdjusted non-GAAP R&D expense excludes stock-based compensation expense and depreciation expense.\n\nAdjusted non-GAAP SG&A expense excludes stock-based compensation expense, depreciation expense, severance, acquisition related costs and legal settlement.\n\nThe Company believes the use of non-GAAP financial measures helps indicate underlying trends in the Company's business and are important in comparing current results with prior period results and understanding projected operating performance. Non-GAAP financial measures provide the Company and its investors with an indication of the Company's baseline performance before items that are considered by the Company not to be reflective of the Company's ongoing results. See the attached reconciliation tables for details of the amounts excluded and included to arrive at certain of the non-GAAP financial measures.\n\nInvestors should note that reconciliations of the forward-looking or projected non-GAAP financial measures included in this press release to their most comparable GAAP financial measures cannot be provided because the Company cannot do so without unreasonable efforts due to the unavailability of information needed to calculate the reconciling items and the variability, complexity, and limited visibility of comparable GAAP measures, and the reconciling items that would be excluded from the non-GAAP financial measures in the future. Likewise, the Company is unable to provide projected GAAP financial measures. GAAP projections and reconciliations of the components of projected adjusted EBITDA, adjusted non-GAAP R&D expenses, adjusted non-GAAP SG&A expense, and adjusted non-GAAP earning per share to their most comparable GAAP financial measures are not provided because the quantification of projected GAAP R&D expenses, adjusted non-GAAP SG&A expense, net income and earnings per share and the reconciling items between projected GAAP to adjusted EBITDA, adjusted non-GAAP R&D expenses, adjusted non-GAAP SG&A expense and adjusted non-GAAP earnings per share cannot be reasonably calculated or predicted at this time without unreasonable efforts. For example, with respect to GAAP net income, R&D expenses and SG&A expenses, the Company is not able to calculate the favorable or unfavorable expenses related to the fair value adjustments on equity investments and derivative instruments primarily due to nature of these items. Such unavailable information could be significant such that actual GAAP net income, R&D expenses, SG&A expenses and earnings per share would vary significantly from projected adjusted EBITDA, adjusted non-GAAP R&D expenses, adjusted non-GAAP SG&A expense and adjusted non-GAAP earnings per share.\n\nThese non-GAAP financial measures should be considered in addition to, but not as a substitute for, the information prepared in accordance with U.S. GAAP. In addition, from time to time in the future there may be other items that the Company may exclude for purposes of its non-GAAP financial measures; and the Company has ceased, and may in the future cease, to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. For example, beginning in the fourth quarter of 2022, the Company no longer excludes expense of acquired in-process research & development from the Company's adjusted non-GAAP net income or adjusted EBITDA, their line item components, and non-GAAP earnings per share. For purposes of comparability, non-GAAP adjusted financial measures for the three ended March 31, 2022 have been updated to reflect this change. Accordingly, such expenses are not excluded from its non-GAAP financial measures for the three months ended March 31, 2023 and 2022, as detailed in the reconciliation tables that follow, or from 2023 non-GAAP adjusted net income and adjusted non-GAAP earnings per share guidance. Likewise, the Company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. The Company strongly encourages investors to review its consolidated financial statements and publicly-filed reports in their entirety and cautions investors that the non-GAAP financial measures used by the Company may differ from similar measures used by other companies, even when similar terms are used to identify such measures.\n\nInvestor Relations for Eagle Pharmaceuticals, Inc.:\n\nLisa M. Wilson\n\nIn-Site Communications, Inc.\n\nT: 212-452-2793\n\nE: lwilson@insitecony.com\n\n-- Financial tables follow --\n\nEAGLE PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (In thousands, except share amounts) March 31, 2023 December 31, 2022 ASSETS Current assets: Cash and cash equivalents$21,897 $55,321 Accounts receivable, net 114,953 72,439 Inventories 44,140 47,794 Prepaid expenses and other current assets 11,501 13,200 Total current assets 192,491 188,754 Property and equipment, net 1,116 1,168 Intangible assets, net 112,875 118,327 Goodwill 45,033 45,033 Deferred tax asset, net 29,150 27,146 Other assets 33,510 25,732 Total assets$414,175 $406,160 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable$17,108 $18,993 Accrued expenses and other liabilities 73,201 85,844 Short-term debt 7,500 6,250 Total current liabilities 97,809 111,087 Long-term debt 68,829 56,216 Other long-term liabilities 4,692 5,297 Total liabilities 171,330 172,600 Commitments and Contingencies Stockholders' equity: Preferred stock, 1,500,000 shares authorized and no shares issued or outstanding as of March 31, 2023 and December 31, 2022 - - Common stock, $0.001 par value; 50,000,000 shares authorized; 17,636,973 and 17,569,375 shares issued as of March 31, 2023 and December 31, 2022, respectively 18 18 Additional paid in capital 369,800 366,265 Accumulated other comprehensive loss (1,112) (1,112) Retained earnings 117,254 111,504 Treasury stock, at cost, 4,552,730 and 4,552,730 shares as of March 31, 2023 and December 31, 2022, respectively (243,115) (243,115) Total stockholders' equity 242,845 233,560 Total liabilities and stockholders' equity$414,175 $406,160 EAGLE PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (In thousands, except share and per share amounts) Three Months Ended March 31, 2023 2022 Revenue: Product sales, net$46,221 $90,088 Royalty revenue 20,084 25,786 Total revenue 66,305 115,874 Operating expenses: Cost of product sales 17,300 25,176 Cost of royalty revenue - 2,579 Research and development 9,272 6,108 Selling, general and administrative 27,960 22,182 Total operating expenses 54,532 56,045 Income from operations 11,773 59,829 Interest income 212 154 Interest expense (1,516) (366) Other expense (238) (1,957) Total other expense, net (1,542) (2,169) Income before income tax provision 10,231 57,660 Income tax provision (4,481) (13,602) Net income$5,750 $44,058 Earnings per share: Basic$0.44 $3.47 Diluted$0.44 $3.41 Weighted average number of common shares outstanding: Basic 13,059,153 12,710,646 Diluted 13,153,271 12,906,811 EAGLE PHARMACEUTICALS, INC. RECONCILIATION OF GAAP NET INCOME TO ADJUSTED NON-GAAP NET INCOME AND GAAP EARNINGS PER SHARE TO ADJUSTED NON-GAAP EARNINGS PER SHARE (UNAUDITED) (In thousands, except share and per share amounts) Three Months Ended March 31, 2023 2022 Net income - GAAP$5,750 $44,058 Adjustments: Cost of product revenues: Amortization expense 5,442 731 Research and development: Stock-based compensation expense 687 643 Depreciation expense 30 48 Selling, general and administrative: Stock-based compensation expense 3,952 3,652 Depreciation expense 80 129 Severance 43 49 Acquisition related costs - 1,490 Legal settlement - 300 Other: Non-cash interest expense 122 118 Fair value adjustments on equity investment 403 2,530 Convertible promissory note related adjustments - (9) Fair value adjustments related to derivative instruments (77) (608) Foreign currency exchange gain (90) - Inventory step-up 320 - Tax effect of the non-GAAP adjustments (126) (979) Adjusted non-GAAP net income$16,536 $52,152 Earnings per share: Basic$0.44 $3.47 Diluted$0.44 $3.41 Weighted average number of common shares outstanding: Basic 13,059,153 12,710,646 Diluted 13,153,271 12,906,811 Adjusted non-GAAP earnings per share: Basic$1.27 $4.10 Diluted$1.26 $4.04 Weighted average number of common shares outstanding: Basic 13,059,153 12,710,646 Diluted 13,153,271 12,906,811 EAGLE PHARMACEUTICALS, INC. RECONCILIATION OF GAAP NET INCOME (LOSS) TO ADJUSTED NON-GAAP EBITDA (UNAUDITED) (In thousands) Three Months Ended March 31, Twelve Months Ended March 31, Twelve Months Ended December 31, 2023 2022 2023 2022 Net income (loss) - GAAP$5,750 $44,058 $(2,666) $35,642 Add back: Interest expense, net of interest income 1,304 212 4,866 3,774 Income tax provision 4,481 13,602 16,670 25,791 Depreciation and amortization expense 5,552 908 16,668 12,024 Add back: Stock-based compensation expense 4,639 4,295 16,795 16,451 Fair value adjustments on equity investment 403 2,530 2,330 4,457 Convertible promissory note related adjustments - 36 4,206 4,242 Fair value adjustments related to derivative instruments (77) (608) 8,496 7,965 Foreign currency exchange gain (90) - (737) (647) Gain on euro debt - - (264) (264) Legal Settlement - 300 - 300 Acquisition related costs - 1,490 11,632 13,122 Inventory step-up 320 - 866 546 Debt issuance cost - - 258 258 Severance 43 49 8,445 8,451 Adjusted Non-GAAP EBITDA$22,325 $66,872 $87,565 $132,112 EAGLE PHARMACEUTICALS, INC. RECONCILIATION OF GAAP RESEARCH AND DEVELOPMENT AND SELLING, GENERAL AND ADMINISTRATIVE TO ADJUSTED NON-GAAP RESEARCH AND DEVELOPMENT AND SELLING, GENERAL AND ADMINISTRATIVE (UNAUDITED) (In thousands) Three Months Ended March 31, 2023 2022 Research and development - GAAP$9,272 $6,108 Add back: Stock-based compensation expense 687 643 Depreciation expense 30 48 Research and development - Non-GAAP$8,555 $5,417 Three Months Ended March 31, 2023 2022 Selling, general and administrative - GAAP$27,960 $22,182 Add back: Stock-based compensation expense 3,952 3,652 Depreciation expense 80 129 Severance 43 49 Acquisition related costs - 1,490 Legal settlement - 300 Selling, general and administrative - Non-GAAP$23,885 $16,562\n\nImportant Safety Information for BARHEMSYSÂ® (amisulpride)7 Injection\n\nContraindication\n\nBARHEMSYS is contraindicated in patients with known hypersensitivity to amisulpride.\n\nQT Prolongation\n\nBARHEMSYS causes dose- and concentration-dependent prolongation of the QT interval. The recommended dosage is 5 mg or 10 mg as a single intravenous (IV) dose infused over 1 to 2 minutes.\n\nAvoid BARHEMSYS in patients with congenital long QT syndrome and in patients taking droperidol.\n\nElectrocardiogram (ECG) monitoring is recommended in patients with pre-existing arrhythmias/cardiac conduction disorders, electrolyte abnormalities (e.g., hypokalemia or hypomagnesemia), congestive heart failure, and in patients taking other medicinal products (e.g., ondansetron) or with other medical conditions known to prolong the QT interval.\n\nAdverse Reactions\n\nCommon adverse reactions reported in = 2% of adult patients who received BARHEMSYS 5 mg (n=748) and at a higher rate than placebo (n=741) in clinical trials for the prevention of PONV were: chills (4% vs. 3%), hypokalemia (4% vs. 2%), procedural hypotension (3% vs. 2%), and abdominal distention (2% vs. 1%).\n\nSerum prolactin concentrations were measured in one prophylaxis study where 5% (9/176) of BARHEMSYS-treated patients had increased blood prolactin reported as an adverse reaction compared with 1% (1/166) of placebo-treated patients.\n\nThe most common adverse reaction, reported in = 2% of adult patients who received BARHEMSYS 10 mg (n=418) and at a higher rate than placebo (n=416), in clinical trials for the treatment of PONV was infusion site pain (6% vs. 4%).\n\nUse in Specific Populations\n\nLactation\n\nAmisulpride is present in human milk. There are no reports of adverse effects on the breastfed child and no information on the effects of amisulpride on milk production.\n\nBARHEMSYS may result in an increase in serum prolactin levels, which may lead to a reversible increase in maternal milk production. In a clinical trial, serum prolactin concentrations in females (n=112) increased from a mean of 10 ng/mL at baseline to 32 ng/mL after BARHEMSYS treatment and from 10 ng/mL to 19 ng/mL in males (n=61). No clinical consequences due to elevated prolactin levels were reported.\n\nTo minimize exposure to a breastfed infant, lactating women may consider interrupting breastfeeding and pumping and discarding breast milk for 48 hours after receiving a dose of BARHEMSYS.\n\nPediatric Use\n\nSafety and effectiveness in pediatric patients have not been established.\n\nGeriatric Use\n\nNo overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.\n\nRenal Impairment\n\nAvoid BARHEMSYS in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m2). The pharmacokinetics of amisulpride in patients with severe renal impairment have not been adequately studied in clinical trials. Amisulpride is known to be substantially excreted by the kidneys, and patients with severe renal impairment may have increased systemic exposure and an increased risk of adverse reactions.\n\nNo dosage adjustment is necessary in patients with mild to moderate renal impairment\n\n(eGFR = 30 mL/min/1.73 m2).\n\nDrug Interactions\n\nBARHEMSYS causes dose- and concentration-dependent QT prolongation. To avoid potential additive effects, avoid use of BARHEMSYS in patients taking droperidol.ECG monitoring is recommended in patients taking other drugs known to prolong the QT interval (e.g., ondansetron).Reciprocal antagonism of effects occurs between dopamine agonists (e.g., levodopa) and BARHEMSYS. Avoid using levodopa with BARHEMSYS.\n\nImportant Safety Information for BYFAVO (remimazolam)8 Injection\n\nIndications\n\nBYFAVO is a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less.\n\nImportant Safety Information\n\nWARNING: PERSONNEL AND EQUIPMENT FOR MONITORING AND RESUSCITATION AND RISKS FROM CONCOMITANT USE WITH OPIOID ANALGESICS\n\nPersonnel and Equipment for Monitoring and Resuscitation\n\nOnly personnel trained in the administration of procedural sedation, and not involved in the conduct of the diagnostic or therapeutic procedure, should administer BYFAVO. Administering personnel must be trained in the detection and management of airway obstruction, hypoventilation, and apnea, including the maintenance of a patent airway, supportive ventilation, and cardiovascular resuscitation. BYFAVO has been associated with hypoxia, bradycardia, and hypotension. Continuously monitor vital signs during sedation and during the recovery period.Resuscitative drugs, and age- and size-appropriate equipment for bag-valve-mask-assisted ventilation must be immediately available during administration of BYFAVO.\n\nRisks From Concomitant Use With Opioid Analgesics and Other Sedative-Hypnotics\n\nConcomitant use of benzodiazepines, including BYFAVO, and opioid analgesics may result in profound sedation, respiratory depression, coma, and death. The sedative effect of intravenous BYFAVO can be accentuated by concomitantly administered CNS depressant medications, including other benzodiazepines and propofol. Continuously monitor patients for respiratory depression and depth of sedation.\n\nContraindication\n\nBYFAVO is contraindicated in patients with a history of severe hypersensitivity reaction to dextran 40 or products containing dextran 40.\n\nPersonnel and Equipment for Monitoring and Resuscitation\n\nClinically notable hypoxia, bradycardia, and hypotension were observed in Phase 3 studies of BYFAVO. Continuously monitor vital signs during sedation and through the recovery period. Only personnel trained in the administration of procedural sedation, and not involved in the conduct of the diagnostic or therapeutic procedure, should administer BYFAVO. Administering personnel must be trained in the detection and management of airway obstruction, hypoventilation, and apnea, including the maintenance of a patent airway, supportive ventilation, and cardiovascular resuscitation. Resuscitative drugs, and age- and size-appropriate equipment for bag-valve-mask-assisted ventilation must be immediately available during administration of BYFAVO. Consider the potential for worsened cardiorespiratory depression prior to using BYFAVO concomitantly with other drugs that have the same potential (e.g., opioid analgesics or other sedative-hypnotics). Administer supplemental oxygen to sedated patients through the recovery period. A benzodiazepine reversal agent (flumazenil) should be immediately available during administration of BYFAVO.\n\nRisks From Concomitant Use With Opioid Analgesics and Other Sedative-Hypnotics\n\nConcomitant use of BYFAVO and opioid analgesics may result in profound sedation, respiratory depression, coma, and death. The sedative effect of IV BYFAVO can be accentuated when administered with other CNS depressant medications (eg, other benzodiazepines and propofol). Titrate the dose of BYFAVO when administered with opioid analgesics and sedative-hypnotics to the desired clinical response. Continuously monitor sedated patients for hypotension, airway obstruction, hypoventilation, apnea, and oxygen desaturation. These cardiorespiratory effects may be more likely to occur in patients with obstructive sleep apnea, the elderly, and ASA-PS class III or IV patients.\n\nHypersensitivity Reactions\n\nBYFAVO contains dextran 40, which can cause hypersensitivity reactions, including rash, urticaria, pruritus, and anaphylaxis. BYFAVO is contraindicated in patients with a history of severe hypersensitivity reaction to dextran 40 or products containing dextran 40.\n\nNeonatal Sedation\n\nUse of benzodiazepines during the later stages of pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) in the neonate. Observe newborns for signs of sedation and manage accordingly.\n\nPediatric Neurotoxicity\n\nPublished animal studies demonstrate that anesthetic and sedation drugs that block NMDA receptors and/or potentiate GABA activity increase neuronal apoptosis in the developing brain and result in long-term cognitive deficits when used for longer than 3 hours. The clinical significance of this is not clear. However, the window of vulnerability to these changes is believed to correlate with exposures in the third trimester of gestation through the first several months of life but may extend out to approximately 3 years of age in humans.\n\nAnesthetic and sedation drugs are a necessary part of the care of children needing surgery, other procedures, or tests that cannot be delayed, and no specific medications have been shown to be safer than any other. Decisions regarding the timing of any elective procedures requiring anesthesia should take into consideration the benefits of the procedure weighed against the potential risks.\n\nAdverse Reactions\n\nThe most common adverse reactions reported in >10% of patients (N=630) receiving BYFAVO 5-30 mg (total dose) and undergoing colonoscopy (two studies) or bronchoscopy (one study) were: hypotension, hypertension, diastolic hypertension, systolic hypertension, hypoxia, and diastolic hypotension.\n\nUse in Specific Populations\n\nPregnancy\n\nThere are no data on the specific effects of BYFAVO on pregnancy. Benzodiazepines cross the placenta and may produce respiratory depression and sedation in neonates. Monitor neonates exposed to benzodiazepines during pregnancy and labor for signs of sedation and respiratory depression.\n\nLactation\n\nMonitor infants exposed to BYFAVO through breast milk for sedation, respiratory depression, and feeding problems. A lactating woman may consider interrupting breastfeeding and pumping and discarding breast milk during treatment and for 5 hours after BYFAVO administration.\n\nPediatric Use\n\nSafety and effectiveness in pediatric patients have not been established. BYFAVO should not be used in patients less than 18 years of age.\n\nGeriatric Use\n\nNo overall differences in safety or effectiveness were observed between these subjects and younger subjects. However, there is a potential for greater sensitivity (eg, faster onset, oversedation, confusion) in some older individuals. Administer supplemental doses of BYFAVO slowly to achieve the level of sedation required and monitor all patients closely for cardiorespiratory complications.\n\nHepatic Impairment\n\nIn patients with severe hepatic impairment, the dose of BYFAVO should be carefully titrated to effect. Depending on the overall status of the patient, lower frequency of supplemental doses may be needed to achieve the level of sedation required for the procedure. All patients should be monitored for sedation-related cardiorespiratory complications.\n\nAbuse and Dependence\n\nBYFAVO is a federally controlled substance (CIV) because it contains remimazolam which has the potential for abuse and physical dependence.\n\n1 Adjusted non-GAAP net income, adjusted non-GAAP earnings per share, adjusted non-GAAP EBITDA, adjusted non-GAAP R&D expense and adjusted non-GAAP SG&A expense are non-GAAP financial measures. For descriptions and reconciliations of these non-GAAP financial measures to their most comparable GAAP financial measures, please see below and the tables at the end of this press release.\n\n2 Based on IQVIA SMART-US weekly volume data and internal data.\n\n3 https://www.bendekahcp.com/globalassets/bendeka-hcp/prescribinginformation.pdf\n\n4 https://belrapzo.com/prescribing-information.pdf\n\n5 IQVIA SMART-US weekly volume data for the first quarter of 2023 and 2022 historic IQVIA data.\n\n6 https://bynder.acaciapharma.com/m/5d7c2cd0d58865f7/original/Barhemsys-Prescribing-Information.pdf\n\n7 https://bynder.acaciapharma.com/m/5d7c2cd0d58865f7/original/Barhemsys-Prescribing-Information.pdf\n\n8 https://bynder.acaciapharma.com/m/403e8c343b2922de/original/Byfavo-PI.pdf\n\nKostenloser Report: Gefallene Big-Techs - Hier winken jetzt bis zu 200%!Marktexperte ist Ã¼berzeugt: Diese groÃŸen Tech-Aktien sind zu stark gefallen und kommen jetzt zurÃ¼ck!Hier klicken",
            "source": {
                "uri": "finanznachrichten.de",
                "dataType": "news",
                "title": "FinanzNachrichten.de"
            },
            "authors": [],
            "image": "https://www.finanznachrichten.de/chart-eagle-pharmaceuticals-inc-aktie-intraklein-tradegate.png",
            "eventUri": null,
            "sentiment": 0.388235294117647,
            "wgt": 421454940,
            "relevance": 100
        },
        {
            "uri": "7536274533",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "22:31:00",
            "dateTime": "2023-05-10T22:31:00Z",
            "dateTimePub": "2023-05-09T16:59:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://seekingalpha.com/article/4602020-eagle-pharmaceuticals-inc-egrx-q1-2023-earnings-call-transcript",
            "title": "Eagle Pharmaceuticals, Inc. (EGRX) Q1 2023 Earnings Call Transcript",
            "body": "Scott Tarriff - President and Chief Executive Officer\n\nBrian Cahill - Chief Financial Officer\n\nMike Greenberg - Vice President of Medical Affairs\n\nGood morning, everyone. My name is Todd and I'll be your conference operator. At this time, I'd like to welcome everyone to Eagle Pharmaceuticals First Quarter 2023 Financial Results. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer period. [Operator Instructions] As a reminder, this conference call is being recorded today. May 9, 2023.\n\nIt is now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. Please go ahead.\n\nLisa Wilson\n\nThank you, Carl. Welcome to Eagle Pharmaceuticals first quarter 2023 earnings call. This is Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. With me on today's call are Eagle's President and Chief Executive Officer, Scott Tarriff; Chief Financial Officer, Brian Cahill; and Vice President of Medical Affairs, Dr. Mike Greenberg.\n\nThis morning Eagle issued a press release detailing its financial results for the three months ended March 31, 2023. This press release and a webcast of this call can be accessed through the investor section of the Eagle website at eagle.us.com.\n\nBefore we get started, I would like to remind everyone that any statements made on today's conference call that express a belief, expectations, projection, forecasts, anticipation or intent regarding future events and the company's future performance may be considered forward-looking statements as defined by the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to Eagle Pharmaceuticals management as of today, and involve risks and uncertainties including those noted in this morning's press release and our filings with the SEC.\n\nSuch forward-looking statements are not guarantees of future performance. Actual results may differ materially from those projected in the forward-looking statements. Eagle Pharmaceuticals specifically disclaims any intent or obligation to update these forward-looking statements, except as required by law. A telephone replay will be available shortly after completion of this call. You'll find the dial-in information in today's press release. The archived webcast will be available for 30 days on our website at eagle.us.com.\n\nFor the benefit of those who may be listening to the replay or archive webcast, this call was held recorded on May 9, 2023. Since then, Eagle may have made announcements related to the topics discussed, so please refer to the company's most recent press releases and SEC filings. In addition, we will be discussing non-GAAP financial measures during this conference call in addition to financial information prepared in accordance with U.S. GAAP. These non-GAAP financial measures should be considered in addition to but not as a substitute for the information prepared in accordance with GAAP.\n\nA description of these non-GAAP financial measures and reconciliations of these non-GAAP financial measures to their most comparable GAAP measures are set forth in our earnings press release available on our website at eagle.us.com.\n\nAnd with that, I'll turn the call over to Eagle's President and CEO, Scott Tarriff.\n\nScott Tarriff\n\nWell, thank you, Lisa. Good morning, everyone. And thank you for joining our call today.\n\nFollowing on from the outstanding year Eagle had in 2022, we remain well-positioned for another strong year in 2023. Our products continue to do well as you can see from the strong earnings we announced this morning. We expect this momentum to continue and our longer-term growth come from our pipeline of potential acquisitions.\n\nFor the first quarter of 2023, our net income was $5.8 million, or $0.44 per basic and diluted share and adjusted non-GAAP earnings was 16.5 million or $1.27 per basic and $1.26 per diluted share. Our adjusted non-GAAP EBITDA was 22.3 million for the first quarter. This positions us well to achieve our full year '23 guidance, which we reaffirmed. To be clear investments we are making for the future account for much of the expected difference of our earnings in 2023 versus 2022. We are investing to support our products and advance our pipeline, notably CAL02, which bridges much of the year-over-year gap.\n\nWith the commercial infrastructure already in place, we believe we will be able to capture synergies through a potential acquisition target.\n\nLet's look at the products. During the first quarter of '23, PEMFEXY net product sales totaled $22.9 million. And we believe we are well on our way to surpassing the $67 million recorded for the full year of 2022.\n\nAs you recall, we exited the fourth quarter of last year with a 6% share of commercial, non-340B pemetrexed usage in community oncology in the United States. Based on the internal data and customer feedback, we estimate that as of the second quarter to-date, that our share has now grown to 15%. We expect growth to continue throughout the year and believe that the market share at the end of Q2 could be greater than the current 15%. PEMFEXY remains an important asset for us as you recall, we eliminated the royalty on the first $85 million of profit on PEMFEXY beginning October 1, '22 and a reduced royalty thereafter in exchange for a one-time payment of $15 million. So far that is looking like a great decision.\n\nMoving on to our Bendamustine franchise. As we have discussed in the past our bendamustine franchise face new competition for the first time beginning on December 7, 2022. Since that time, we continued to be pleased with the strong performance of BENDEKA and BELRAPZO in the marketplace. It is our belief that BENDEKA is a beneficial product for patients and healthcare providers. Together, BENDEKA and BELRAPZO maintained approximately 89% share of the bendamustine U.S. market for the first quarter of '23 compared to approximately 90% historically.\n\nIn the first quarter, we reached the settlement agreement with Dr. Reddy's, Eagle's asserted its orange book listed patents against Dr. Reddy's related to its new drug application referencing BENDEKA. The settlement follows our previously announced settlements with Hospira and Accord Healthcare related to their new drug applications referencing BENDEKA.\n\nOther than one recent challenger, which is for a proposed powder not liquid formulation all existing cases have now been settled. We remain confident in exclusivity into November of '27, which we believe positions bendamustine to be a significant contributor for several more years.\n\nTurning now to the Acacia products, BARHEMSYS and BYFAVO combined net sales of the two products totaled just shy of $1 million in the first quarter. Our BARHEMSYS and BYFAVO product sales are up 32% sequentially versus Q4 of '22. Although this is a small base, it is a very solid showing, and we expect their shares to continue to grow nicely.\n\nJust last week, we announced that CMS established a unique product specific billing code for BYFAVO, which as you may recall, is a short acting sedative for procedures lasting 30 minutes or less. This new J-Code is effective on July 1 of '23. We believe the establishment of a unique J-Code for BYFAVO is an important step in facilitating reimbursement and broadening access to this innovative sedation drug.\n\nOur go-forward business development plans remain intact. As we've stated in the past, we intend to use our strong balance sheet and financial flexibility to potentially make an accretive acquisition, with the aim to broaden our footprint within the acute care or oncology space and solidify our foundation for future growth.\n\nWe are also currently working with lenders to secure financing to support a potential accretive acquisition.\n\nLet me make a few comments on the pipeline. First, a global Phase 2 studies underway for CAL02, a novel first-in-class agent for the treatment of severe community acquired bacterial pneumonia used in addition to standard of care, including antibiotic treatment. We expect to enroll 276 patients in 120 centers in 22 countries.\n\nSecond, ENA-001 an investigational one-of-a-kind new chemical entity is an agnostic respiratory stimulant being developed by Enalare for the potential treatment of post-operative respiratory depression, community drug overdose and apnea of prematurity. As a reminder, we acquired approximately 17% equity stake in Enalare in exchange for two upfront investments paid in August of '22 and February of '23, and we have an option to purchase the rest of Enalare in the events specified milestones are achieved.\n\nThird, Landiolol NDA is under review at FDA, the filing seeks approval for Landiolol for the short-term reduction of ventricular rate in patients with super ventricular tachycardia, including atrial fibrillation and atrial flutter. To recap, as you can see, we had another impressive quarter. Our plan is to accelerate long-term growth through potential acquisitions and our pipeline. We believe that we are in a good position to execute on all three aspects of our business, namely, strength from our existing product line, potential future accretive acquisitions, and the development of our pipeline\n\nWith that, I'll turn the call over to Brian Cahill to discuss our first quarter financials. Brian?\n\nIn the first quarter of 2023, total revenue was $66.3 million, compared to $115.9 million in the prior year. Net product sales during the first quarter of 2023 were $46.2 million, compared to $90.1 million in Q1 2022, our launch quarter for both PEMFEXY and vasopressin. PEMFEXY, net product sales were $22.9 million in the first quarter of 2023, compared to 37.2 million in the first quarter of 2022. We recorded revenue on delivery of our product to our direct customers, primarily wholesalers, which estimates the current and near-term needs of the wholesaler channel for our growing product. As we continue to capture more share of the pemetrexed market, customer inventory levels may be higher than for similar established product. Vasopressin, net product sales were $3.5 million in the first quarter of 2023, as previously announced during the first quarter of 2023, we notified customers and the FDA, and our decision to withdraw from the vasopressin market.\n\nOur inventory on hand has been depleted at this time. BELRAPZO, net product sales increased to $6.4 million in the first quarter of 2023, compared to $5.9 million in Q1 of 2022. And first quarter 2023, RYANODEX net product sales were $8.8 million, compared to 6.6 million in Q1 of 2022.\n\nQ1 2023 royalty revenue was $20.1 million compared to $25.8 million in the prior year quarter. Royalty revenues included royalties earned on sales of BENDEKA in the U.S. and TREAKISYM in Japan. Gross margin was 74% in Q1 2023, compared to 76% in the prior year quarter. The decrease was primarily the result of the inclusion of amortization of intangible assets related to the newly acquired products, BARHEMSYS and BYFAVO, which we expect will continue going forward.\n\nOn the expense front, R&D expenses were $9.3 million for the first quarter of 2023, compared to $6.1 million in Q1 of 2022. This increase is largely attributable to continuing CMC and clinical trial spend on CAL02 program and BARHEMSYS and BYFAVO pediatric studies. Excluding stock-based compensation and other non-cash and non-recurring items, first quarter 2023 non-GAAP R&D expense was $8.6 million.\n\nSG&A expenses in the first quarter of 2023 were $28 million, compared to $22.2 million in the first quarter of 2022. This increase was driven by $3.3 million in salary and other personnel related costs, $2 million in external sales and marketing spend partially offset by $2 million in lower legal related costs. Excluding stock-based compensation and other non-cash and non-recurring items, first quarter 2023 non-GAAP SG&A expense was $23.9 million.\n\nNet income for the first quarter of 2023 was $5.8 million or 0.44 per basic and diluted share compared to net income of $44.1 million or $3.47 per basic and $3.41 per diluted share in the prior year quarter. Adjusted non-GAAP net income for the first quarter of 2023 was $16.5 million or $1.27 per basic and $1.26 per diluted share compared to adjusted non-GAAP net income of $52.2 million or $4.10 per basic and $4.04 per diluted share in the prior year quarter. Our adjusted non-GAAP EBITDA was $22.3 million for the first quarter of 2023.\n\nFor a full reconciliation of non-GAAP measures to the most comparable GAAP measures, please see the table at the end of our earnings press release. As of March 31, 2023, the company had $21.9 million in cash and cash equivalents, $150 million in net accounts receivable and $77.5 million in outstanding debt.\n\nWith that, I'll ask the operator to please open the call for questions. Operator, please go ahead.\n\nThank you. At this time, we will open the floor for questions. [Operator Instructions]. Our first question comes from Tim Lugo with William Blair.\n\nLachlan Hanbury-Brown\n\nHey guys, is Lachlan on for Tim. Thanks for taking the question and congratulations on the strong quarter. On the announcement for securing the financing for the deal and where you are in that stage, just curious on the rationale for announcing that now rather than wait until everything is fully signed, sealed and delivered. And then, Brian on that, just wanted to check if the guidance you guys provided earlier in the year included any consideration for [indiscernible]?\n\nScott Tarriff\n\nAll right. Thanks for the question. Let me pick up the whitespace something now. It's just simple. We're working hard at it. We've been speaking about the potential of an acquisition for a number of quarters now. We're just very deliberate in our actions and very selective about what we do. But we are moving forward as aggressively as we can to find the right opportunity. And this was just a sign that we take the business development and the M&A actions seriously. And we are lining up lenders. So we're in a position to transact as soon as practicable.\n\nIn terms of the guidance, Brian, do you have anything to add?\n\nBrian Cahill\n\nSure. Our guidance does not contemplate the completion and integration of any M&A. But those have a sliver of investigational work in our G&A naturally, since we've been doing that for over a year.\n\nLachlan Hanbury-Brown\n\nThanks. Yes. That's helpful. And I guess, ahead of land deal PDUFA. Scott, curious about the sort of what we should be expecting for the launch timing. Are you planning to sort of let the sales team loose with that immediately? Or will you be spending a couple of quarters trying to gain access before they sort of take it out into the field?\n\nScott Tarriff\n\nYes. That's a great point. Depending on the timing of the approval, we wind up with an approval that could be happening going into the summer months, and probably launching a drug into the summer isn't the most effective way to handle it, especially considering that we're so pleased with the traction we're starting to get with the two Acacia products.\n\nAgain, small base, but this was only the really the first quarter. It's the last two quarters that we've had the full territories and everybody in full strength. And we picked up the 32% growth in the Acacia products, you don't want anything to get in the way, launching landiolol. So we're probably better off waiting a little bit, get through a couple more quarters with the Acacia products and not trying to launch something in the middle of summertime.\n\nThank you. Our next question comes from Brandon Folkes with Cantor Fitzgerald.\n\nBrandon Folkes\n\nHi, thanks for taking my questions and congratulations on the very strong quarter. Let me firstly, on PEMFEXY. Can you talk about any sort of benefits in 1Q '23 that may not be here for the rest of the year, any one time as well? How should we think about the cadence of quarters in 2023? And then along those lines, seems like the generic arbitrage is pretty well behind us here. So just is that fair thinking? [Indiscernible] add-ons?\n\nScott Tarriff\n\nYes, Brandon. So PEMFEXY is really shaping up to be really wonderful for us going from the 6% share in Q4 to where we are right now at 15% is really very encouraging. My guess is, as we stated today based on how we see the trends running, speaking to our customers and just watching this all unfold that 15% is going to just continue throughout the year to grow. How high it goes, it's just too difficult to predict right now. But with the -- just shy of $23 million we had in Q1, relative to the $67 million that we sold in all of last year, our forecast that will sell more than last year's numbers, and '23 is probably looking pretty good. There's always ins and outs you can't predict in pricing and inventory levels. But we would expect, what we're seeing now is that $67 million number for the year is looking pretty darn good. We're pretty pleased about the $15 million, we spent to buy back that first $85 million of profit. So our expectation is that the shares just going to continue to grow. And we're pretty good place for the year as it relates to PEMFEXY, and couldn't be more pleased with the way launch is going.\n\nBrandon Folkes\n\nGreat. Thanks very much. I may just changing speed to BARHEMSYS and BYFAVO. Can you just provide any feedback you're getting from the field? How should we think about these going forward, just sort of a normal kind of hospital type launch where just sort of takes a bit of time? Or kind of any color you can provide there in terms of how should we think about maybe the sales?\n\nScott Tarriff\n\nBrandon, I'm thrilled you asked that question. I would tell you from our standpoint, here, internally, we're more excited about these two products than we were when we made the acquisition a year ago. The feedback that we're getting has really been tremendous from the users of the product, the nurses and the physicians and the feedback we're getting from those two groups, by the way, the patients feel about the products.\n\nAs we all know, there's a ramp process that goes through to be able to establish these products in the hospital. And we're really, I mean, we're extremely pleased with the trajectory so far, 32% growth in a quarter, we expect that market share that growth to just continue. The feedback has been really just wonderful. We're doing a lot the J-Code helps. I think we're just going to have a nice steady ramp out through time and remember, these products are both protected into the early 30, so we have plenty of time and it's going well.\n\nWe have Dr. Greenberg, with us who's much closer with the physicians and the nurses that we speak to. Mike maybe want to say a couple of short comments about what you're hearing about the two products.\n\nMike Greenberg\n\nSure, Scott. Thank you. I just like to reiterate the feedback that you shared. On the medical affairs side, we've been hearing exactly the same, exactly the same thing. So regarding BARHEMSYS, we're starting to see some real-world evidence percolate into meetings and being published, that data echoes what we've seen in our pivotal trials. And in fact, in some cases surpasses it. So this is a drug that really seemed to be over delivering at this point, at least to a certain extent, on the BYFAVO side, was a great increase in accounts that are using BYFAVO as well. And again, the feedback has been extraordinary, helping patient throughput, patients are being sedated for their procedures more rapidly, waking up alert and moving on to the very high level of satisfaction in both the health care providers. And for the patient's medical affairs team was really excited about these products, and some of the sales team.\n\nScott Tarriff\n\nSo conclusion, Brandon, I would say that we're just expecting nice steady growth over the next several years and many quarters and it compounds. And if you just keep having really nice solid growth like this quarter after quarter after quarter after quarter, you can see where these two products build in a relatively short period of time. And what we've been stating, as we project where the company is going. Fortunately, the products that we sell today are doing rather well, right, another strong quarter. We've had several strong quarters of performance now with the products that we sell, '23 is probably going to be another very strong year for the company that gives us time to build the foundation of BARHEMSYS and BYFAVO. And you can just see if this growth continues by the time you get to '24, '25 and '26. These products can start to be a very significant portion of our earnings and our growth. So far, less than a year into the acquisition, recently having all the territories at full strength we're pretty excited and pleased about where we are so far and where we're going.\n\nBrandon Folkes\n\nRight Thanks. One more for me just a clarifying question on the prior question. I mean, talk about the fact that you're working with lenders for an acquisition, does this imply you have a target that you're ready to move on right now? Or are you subject to the financing? Or are you just trying to line up the financing, so you can move quickly, when you do find a suitable target? That's it for me. Thank you.\n\nScott Tarriff\n\nYes. There's not much more Brandon, we can say about that, other than the fact that we've been talking about it for a while, and this is just trying to convey to everybody that we are working diligently and we're very focused. We believe we're in a very unique situation, right? As the industry starts to unfold, if we just take a step back, when we acquired Acacia, there were 70 people in that organization and we were able to just run that business with 20, not the full 70 that they had. And the way we've built our infrastructure here at Eagle and the way we've prudently managed our cash and our balance sheet, we believe that we can make a very significant acquisition relative to our size and have similar reduction in cost. And so we can probably take in another large product, probably more in the oncology space than the hospital space right now, and probably bring in a really tremendous amount of synergy when we bring -- if we bring a company into the organization. And it's a unique situation that we find ourselves in, one, having the infrastructure to be able to take advantage of the synergy. And two, having the financial wherewithal to make a rather large accretive situation. And so based on the historical, positive situation we find ourselves in right now, having those factors come together, we have to be aggressive, we need to take advantage of it. It's an opportunity, we can't pass for our shareholders. And so we're very focused, we'll just have to see how things unfold over time here. But the message is, we do take this seriously and we are trying our best to be able to bring a company into Eagle and take advantage of all of this.\n\nThank you. [Operator Instructions] Our next question will come from David Amsellem with Piper Sandler.\n\nDavid Amsellem\n\nThanks. So just a couple. Can you size up the opportunity for landiolol, and more interested in particular how you think about the initial ramp here? So that's number one. Number two is, I know, there's a lot you can't say. But can you about the acquisition or what you're contemplating. But I guess the question here is just thinking more broadly, are you still very much wedded to the hospital space given just the financial pressures that we're seeing in the space? Do you want to think more expansively about the business? Or is this mainly just hospital focused? Thank you.\n\nScott Tarriff\n\nDavid, thank you, for all of that. Let's take the second question first and talk a little bit more about the acquisition. We just spent a lot of time speaking about the BARHEMSYS and BYFAVO situation. And it does, it takes a lot of effort. And we're very pleased with the ramp. And we have the hospital business that I would call more saturated right now because we do have the two products that we're in launch mode for. And then as you bring up in your first question, we have the landiolol situation coming up once it's approved.\n\nAnd so I would say it's probably more likely that an acquisition that we make in the short-term, would fall more in the oncology space, then it would in the hospital space. Mostly, the oncology business right now is just a wonderful place to be in the country. We think we can help a number of patients and at the same time, help our shareholders, but it's the oncology side of our business where we have so much room from an infrastructure standpoint.\n\nI think, if I can try to explain this, the clearest way I can, we can probably bring a significant oncology product into our company right now, without needing a heck of a lot of additional expense. I don't mean direct marketing from that standpoint, but the infrastructure that we have could probably support a large oncology product with a minimal amount of additional spending. And so that's the situation we need to take advantage of.\n\nSo if we're able to do what we're hoping to do, it's likely -- it's more likely to be on the oncology side and the hospital side right now. And that goes into your landiolol question, right? We will launch it, it will ramp that's the way these products work. And it'll be the same type of ramp that you normally see in the hospital space. It'll just fortify what we have, we'll see how that goes. But we are very concentrated right now in oncology.\n\nThank you. We have no further questions in queue at this time. I will now turn the call back over to Scott Tarriff for any additional or closing remarks.\n\nScott Tarriff\n\nWell, thank you, everyone for joining the call today. Clearly, obviously, we believe we're poised for another solid year in '23. We look forward to updating you as we advance our business plans. We think we have really a very strong vision of the future. Let's see how it unfolds. And as always, we appreciate your ongoing support for Eagle. Thank you, everybody and stay well.\n\nThis concludes today's call. Thank you for your participation. You may disconnect at any time.",
            "source": {
                "uri": "seekingalpha.com",
                "dataType": "news",
                "title": "Seeking Alpha"
            },
            "authors": [
                {
                    "uri": "sa_transcripts@seekingalpha.com",
                    "name": "Sa Transcripts",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "eventUri": null,
            "sentiment": 0.2392156862745098,
            "wgt": 421453860,
            "relevance": 75
        },
        {
            "uri": "7536290249",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "22:30:00",
            "dateTime": "2023-05-10T22:30:00Z",
            "dateTimePub": "2023-05-09T16:59:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://seekingalpha.com/article/4602020-eagle-pharmaceuticals-inc-egrx-q1-2023-earnings-call-transcript",
            "title": "Eagle Pharmaceuticals, Inc. (EGRX) Q1 2023 Earnings Call Transcript",
            "body": "Scott Tarriff - President and Chief Executive Officer\n\nBrian Cahill - Chief Financial Officer\n\nMike Greenberg - Vice President of Medical Affairs\n\nGood morning, everyone. My name is Todd and I'll be your conference operator. At this time, I'd like to welcome everyone to Eagle Pharmaceuticals First Quarter 2023 Financial Results. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer period. [Operator Instructions] As a reminder, this conference call is being recorded today. May 9, 2023.\n\nIt is now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. Please go ahead.\n\nLisa Wilson\n\nThank you, Carl. Welcome to Eagle Pharmaceuticals first quarter 2023 earnings call. This is Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. With me on today's call are Eagle's President and Chief Executive Officer, Scott Tarriff; Chief Financial Officer, Brian Cahill; and Vice President of Medical Affairs, Dr. Mike Greenberg.\n\nThis morning Eagle issued a press release detailing its financial results for the three months ended March 31, 2023. This press release and a webcast of this call can be accessed through the investor section of the Eagle website at eagle.us.com.\n\nBefore we get started, I would like to remind everyone that any statements made on today's conference call that express a belief, expectations, projection, forecasts, anticipation or intent regarding future events and the company's future performance may be considered forward-looking statements as defined by the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to Eagle Pharmaceuticals management as of today, and involve risks and uncertainties including those noted in this morning's press release and our filings with the SEC.\n\nSuch forward-looking statements are not guarantees of future performance. Actual results may differ materially from those projected in the forward-looking statements. Eagle Pharmaceuticals specifically disclaims any intent or obligation to update these forward-looking statements, except as required by law. A telephone replay will be available shortly after completion of this call. You'll find the dial-in information in today's press release. The archived webcast will be available for 30 days on our website at eagle.us.com.\n\nFor the benefit of those who may be listening to the replay or archive webcast, this call was held recorded on May 9, 2023. Since then, Eagle may have made announcements related to the topics discussed, so please refer to the company's most recent press releases and SEC filings. In addition, we will be discussing non-GAAP financial measures during this conference call in addition to financial information prepared in accordance with U.S. GAAP. These non-GAAP financial measures should be considered in addition to but not as a substitute for the information prepared in accordance with GAAP.\n\nA description of these non-GAAP financial measures and reconciliations of these non-GAAP financial measures to their most comparable GAAP measures are set forth in our earnings press release available on our website at eagle.us.com.\n\nAnd with that, I'll turn the call over to Eagle's President and CEO, Scott Tarriff.\n\nScott Tarriff\n\nWell, thank you, Lisa. Good morning, everyone. And thank you for joining our call today.\n\nFollowing on from the outstanding year Eagle had in 2022, we remain well-positioned for another strong year in 2023. Our products continue to do well as you can see from the strong earnings we announced this morning. We expect this momentum to continue and our longer-term growth come from our pipeline of potential acquisitions.\n\nFor the first quarter of 2023, our net income was $5.8 million, or $0.44 per basic and diluted share and adjusted non-GAAP earnings was 16.5 million or $1.27 per basic and $1.26 per diluted share. Our adjusted non-GAAP EBITDA was 22.3 million for the first quarter. This positions us well to achieve our full year '23 guidance, which we reaffirmed. To be clear investments we are making for the future account for much of the expected difference of our earnings in 2023 versus 2022. We are investing to support our products and advance our pipeline, notably CAL02, which bridges much of the year-over-year gap.\n\nWith the commercial infrastructure already in place, we believe we will be able to capture synergies through a potential acquisition target.\n\nLet's look at the products. During the first quarter of '23, PEMFEXY net product sales totaled $22.9 million. And we believe we are well on our way to surpassing the $67 million recorded for the full year of 2022.\n\nAs you recall, we exited the fourth quarter of last year with a 6% share of commercial, non-340B pemetrexed usage in community oncology in the United States. Based on the internal data and customer feedback, we estimate that as of the second quarter to-date, that our share has now grown to 15%. We expect growth to continue throughout the year and believe that the market share at the end of Q2 could be greater than the current 15%. PEMFEXY remains an important asset for us as you recall, we eliminated the royalty on the first $85 million of profit on PEMFEXY beginning October 1, '22 and a reduced royalty thereafter in exchange for a one-time payment of $15 million. So far that is looking like a great decision.\n\nMoving on to our Bendamustine franchise. As we have discussed in the past our bendamustine franchise face new competition for the first time beginning on December 7, 2022. Since that time, we continued to be pleased with the strong performance of BENDEKA and BELRAPZO in the marketplace. It is our belief that BENDEKA is a beneficial product for patients and healthcare providers. Together, BENDEKA and BELRAPZO maintained approximately 89% share of the bendamustine U.S. market for the first quarter of '23 compared to approximately 90% historically.\n\nIn the first quarter, we reached the settlement agreement with Dr. Reddy's, Eagle's asserted its orange book listed patents against Dr. Reddy's related to its new drug application referencing BENDEKA. The settlement follows our previously announced settlements with Hospira and Accord Healthcare related to their new drug applications referencing BENDEKA.\n\nOther than one recent challenger, which is for a proposed powder not liquid formulation all existing cases have now been settled. We remain confident in exclusivity into November of '27, which we believe positions bendamustine to be a significant contributor for several more years.\n\nTurning now to the Acacia products, BARHEMSYS and BYFAVO combined net sales of the two products totaled just shy of $1 million in the first quarter. Our BARHEMSYS and BYFAVO product sales are up 32% sequentially versus Q4 of '22. Although this is a small base, it is a very solid showing, and we expect their shares to continue to grow nicely.\n\nJust last week, we announced that CMS established a unique product specific billing code for BYFAVO, which as you may recall, is a short acting sedative for procedures lasting 30 minutes or less. This new J-Code is effective on July 1 of '23. We believe the establishment of a unique J-Code for BYFAVO is an important step in facilitating reimbursement and broadening access to this innovative sedation drug.\n\nOur go-forward business development plans remain intact. As we've stated in the past, we intend to use our strong balance sheet and financial flexibility to potentially make an accretive acquisition, with the aim to broaden our footprint within the acute care or oncology space and solidify our foundation for future growth.\n\nWe are also currently working with lenders to secure financing to support a potential accretive acquisition.\n\nLet me make a few comments on the pipeline. First, a global Phase 2 studies underway for CAL02, a novel first-in-class agent for the treatment of severe community acquired bacterial pneumonia used in addition to standard of care, including antibiotic treatment. We expect to enroll 276 patients in 120 centers in 22 countries.\n\nSecond, ENA-001 an investigational one-of-a-kind new chemical entity is an agnostic respiratory stimulant being developed by Enalare for the potential treatment of post-operative respiratory depression, community drug overdose and apnea of prematurity. As a reminder, we acquired approximately 17% equity stake in Enalare in exchange for two upfront investments paid in August of '22 and February of '23, and we have an option to purchase the rest of Enalare in the events specified milestones are achieved.\n\nThird, Landiolol NDA is under review at FDA, the filing seeks approval for Landiolol for the short-term reduction of ventricular rate in patients with super ventricular tachycardia, including atrial fibrillation and atrial flutter. To recap, as you can see, we had another impressive quarter. Our plan is to accelerate long-term growth through potential acquisitions and our pipeline. We believe that we are in a good position to execute on all three aspects of our business, namely, strength from our existing product line, potential future accretive acquisitions, and the development of our pipeline\n\nWith that, I'll turn the call over to Brian Cahill to discuss our first quarter financials. Brian?\n\nIn the first quarter of 2023, total revenue was $66.3 million, compared to $115.9 million in the prior year. Net product sales during the first quarter of 2023 were $46.2 million, compared to $90.1 million in Q1 2022, our launch quarter for both PEMFEXY and vasopressin. PEMFEXY, net product sales were $22.9 million in the first quarter of 2023, compared to 37.2 million in the first quarter of 2022. We recorded revenue on delivery of our product to our direct customers, primarily wholesalers, which estimates the current and near-term needs of the wholesaler channel for our growing product. As we continue to capture more share of the pemetrexed market, customer inventory levels may be higher than for similar established product. Vasopressin, net product sales were $3.5 million in the first quarter of 2023, as previously announced during the first quarter of 2023, we notified customers and the FDA, and our decision to withdraw from the vasopressin market.\n\nOur inventory on hand has been depleted at this time. BELRAPZO, net product sales increased to $6.4 million in the first quarter of 2023, compared to $5.9 million in Q1 of 2022. And first quarter 2023, RYANODEX net product sales were $8.8 million, compared to 6.6 million in Q1 of 2022.\n\nQ1 2023 royalty revenue was $20.1 million compared to $25.8 million in the prior year quarter. Royalty revenues included royalties earned on sales of BENDEKA in the U.S. and TREAKISYM in Japan. Gross margin was 74% in Q1 2023, compared to 76% in the prior year quarter. The decrease was primarily the result of the inclusion of amortization of intangible assets related to the newly acquired products, BARHEMSYS and BYFAVO, which we expect will continue going forward.\n\nOn the expense front, R&D expenses were $9.3 million for the first quarter of 2023, compared to $6.1 million in Q1 of 2022. This increase is largely attributable to continuing CMC and clinical trial spend on CAL02 program and BARHEMSYS and BYFAVO pediatric studies. Excluding stock-based compensation and other non-cash and non-recurring items, first quarter 2023 non-GAAP R&D expense was $8.6 million.\n\nSG&A expenses in the first quarter of 2023 were $28 million, compared to $22.2 million in the first quarter of 2022. This increase was driven by $3.3 million in salary and other personnel related costs, $2 million in external sales and marketing spend partially offset by $2 million in lower legal related costs. Excluding stock-based compensation and other non-cash and non-recurring items, first quarter 2023 non-GAAP SG&A expense was $23.9 million.\n\nNet income for the first quarter of 2023 was $5.8 million or 0.44 per basic and diluted share compared to net income of $44.1 million or $3.47 per basic and $3.41 per diluted share in the prior year quarter. Adjusted non-GAAP net income for the first quarter of 2023 was $16.5 million or $1.27 per basic and $1.26 per diluted share compared to adjusted non-GAAP net income of $52.2 million or $4.10 per basic and $4.04 per diluted share in the prior year quarter. Our adjusted non-GAAP EBITDA was $22.3 million for the first quarter of 2023.\n\nFor a full reconciliation of non-GAAP measures to the most comparable GAAP measures, please see the table at the end of our earnings press release. As of March 31, 2023, the company had $21.9 million in cash and cash equivalents, $150 million in net accounts receivable and $77.5 million in outstanding debt.\n\nWith that, I'll ask the operator to please open the call for questions. Operator, please go ahead.\n\nThank you. At this time, we will open the floor for questions. [Operator Instructions]. Our first question comes from Tim Lugo with William Blair.\n\nLachlan Hanbury-Brown\n\nHey guys, is Lachlan on for Tim. Thanks for taking the question and congratulations on the strong quarter. On the announcement for securing the financing for the deal and where you are in that stage, just curious on the rationale for announcing that now rather than wait until everything is fully signed, sealed and delivered. And then, Brian on that, just wanted to check if the guidance you guys provided earlier in the year included any consideration for [indiscernible]?\n\nScott Tarriff\n\nAll right. Thanks for the question. Let me pick up the whitespace something now. It's just simple. We're working hard at it. We've been speaking about the potential of an acquisition for a number of quarters now. We're just very deliberate in our actions and very selective about what we do. But we are moving forward as aggressively as we can to find the right opportunity. And this was just a sign that we take the business development and the M&A actions seriously. And we are lining up lenders. So we're in a position to transact as soon as practicable.\n\nIn terms of the guidance, Brian, do you have anything to add?\n\nBrian Cahill\n\nSure. Our guidance does not contemplate the completion and integration of any M&A. But those have a sliver of investigational work in our G&A naturally, since we've been doing that for over a year.\n\nLachlan Hanbury-Brown\n\nThanks. Yes. That's helpful. And I guess, ahead of land deal PDUFA. Scott, curious about the sort of what we should be expecting for the launch timing. Are you planning to sort of let the sales team loose with that immediately? Or will you be spending a couple of quarters trying to gain access before they sort of take it out into the field?\n\nScott Tarriff\n\nYes. That's a great point. Depending on the timing of the approval, we wind up with an approval that could be happening going into the summer months, and probably launching a drug into the summer isn't the most effective way to handle it, especially considering that we're so pleased with the traction we're starting to get with the two Acacia products.\n\nAgain, small base, but this was only the really the first quarter. It's the last two quarters that we've had the full territories and everybody in full strength. And we picked up the 32% growth in the Acacia products, you don't want anything to get in the way, launching landiolol. So we're probably better off waiting a little bit, get through a couple more quarters with the Acacia products and not trying to launch something in the middle of summertime.\n\nThank you. Our next question comes from Brandon Folkes with Cantor Fitzgerald.\n\nBrandon Folkes\n\nHi, thanks for taking my questions and congratulations on the very strong quarter. Let me firstly, on PEMFEXY. Can you talk about any sort of benefits in 1Q '23 that may not be here for the rest of the year, any one time as well? How should we think about the cadence of quarters in 2023? And then along those lines, seems like the generic arbitrage is pretty well behind us here. So just is that fair thinking? [Indiscernible] add-ons?\n\nScott Tarriff\n\nYes, Brandon. So PEMFEXY is really shaping up to be really wonderful for us going from the 6% share in Q4 to where we are right now at 15% is really very encouraging. My guess is, as we stated today based on how we see the trends running, speaking to our customers and just watching this all unfold that 15% is going to just continue throughout the year to grow. How high it goes, it's just too difficult to predict right now. But with the -- just shy of $23 million we had in Q1, relative to the $67 million that we sold in all of last year, our forecast that will sell more than last year's numbers, and '23 is probably looking pretty good. There's always ins and outs you can't predict in pricing and inventory levels. But we would expect, what we're seeing now is that $67 million number for the year is looking pretty darn good. We're pretty pleased about the $15 million, we spent to buy back that first $85 million of profit. So our expectation is that the shares just going to continue to grow. And we're pretty good place for the year as it relates to PEMFEXY, and couldn't be more pleased with the way launch is going.\n\nBrandon Folkes\n\nGreat. Thanks very much. I may just changing speed to BARHEMSYS and BYFAVO. Can you just provide any feedback you're getting from the field? How should we think about these going forward, just sort of a normal kind of hospital type launch where just sort of takes a bit of time? Or kind of any color you can provide there in terms of how should we think about maybe the sales?\n\nScott Tarriff\n\nBrandon, I'm thrilled you asked that question. I would tell you from our standpoint, here, internally, we're more excited about these two products than we were when we made the acquisition a year ago. The feedback that we're getting has really been tremendous from the users of the product, the nurses and the physicians and the feedback we're getting from those two groups, by the way, the patients feel about the products.\n\nAs we all know, there's a ramp process that goes through to be able to establish these products in the hospital. And we're really, I mean, we're extremely pleased with the trajectory so far, 32% growth in a quarter, we expect that market share that growth to just continue. The feedback has been really just wonderful. We're doing a lot the J-Code helps. I think we're just going to have a nice steady ramp out through time and remember, these products are both protected into the early 30, so we have plenty of time and it's going well.\n\nWe have Dr. Greenberg, with us who's much closer with the physicians and the nurses that we speak to. Mike maybe want to say a couple of short comments about what you're hearing about the two products.\n\nMike Greenberg\n\nSure, Scott. Thank you. I just like to reiterate the feedback that you shared. On the medical affairs side, we've been hearing exactly the same, exactly the same thing. So regarding BARHEMSYS, we're starting to see some real-world evidence percolate into meetings and being published, that data echoes what we've seen in our pivotal trials. And in fact, in some cases surpasses it. So this is a drug that really seemed to be over delivering at this point, at least to a certain extent, on the BYFAVO side, was a great increase in accounts that are using BYFAVO as well. And again, the feedback has been extraordinary, helping patient throughput, patients are being sedated for their procedures more rapidly, waking up alert and moving on to the very high level of satisfaction in both the health care providers. And for the patient's medical affairs team was really excited about these products, and some of the sales team.\n\nScott Tarriff\n\nSo conclusion, Brandon, I would say that we're just expecting nice steady growth over the next several years and many quarters and it compounds. And if you just keep having really nice solid growth like this quarter after quarter after quarter after quarter, you can see where these two products build in a relatively short period of time. And what we've been stating, as we project where the company is going. Fortunately, the products that we sell today are doing rather well, right, another strong quarter. We've had several strong quarters of performance now with the products that we sell, '23 is probably going to be another very strong year for the company that gives us time to build the foundation of BARHEMSYS and BYFAVO. And you can just see if this growth continues by the time you get to '24, '25 and '26. These products can start to be a very significant portion of our earnings and our growth. So far, less than a year into the acquisition, recently having all the territories at full strength we're pretty excited and pleased about where we are so far and where we're going.\n\nBrandon Folkes\n\nRight Thanks. One more for me just a clarifying question on the prior question. I mean, talk about the fact that you're working with lenders for an acquisition, does this imply you have a target that you're ready to move on right now? Or are you subject to the financing? Or are you just trying to line up the financing, so you can move quickly, when you do find a suitable target? That's it for me. Thank you.\n\nScott Tarriff\n\nYes. There's not much more Brandon, we can say about that, other than the fact that we've been talking about it for a while, and this is just trying to convey to everybody that we are working diligently and we're very focused. We believe we're in a very unique situation, right? As the industry starts to unfold, if we just take a step back, when we acquired Acacia, there were 70 people in that organization and we were able to just run that business with 20, not the full 70 that they had. And the way we've built our infrastructure here at Eagle and the way we've prudently managed our cash and our balance sheet, we believe that we can make a very significant acquisition relative to our size and have similar reduction in cost. And so we can probably take in another large product, probably more in the oncology space than the hospital space right now, and probably bring in a really tremendous amount of synergy when we bring -- if we bring a company into the organization. And it's a unique situation that we find ourselves in, one, having the infrastructure to be able to take advantage of the synergy. And two, having the financial wherewithal to make a rather large accretive situation. And so based on the historical, positive situation we find ourselves in right now, having those factors come together, we have to be aggressive, we need to take advantage of it. It's an opportunity, we can't pass for our shareholders. And so we're very focused, we'll just have to see how things unfold over time here. But the message is, we do take this seriously and we are trying our best to be able to bring a company into Eagle and take advantage of all of this.\n\nThank you. [Operator Instructions] Our next question will come from David Amsellem with Piper Sandler.\n\nDavid Amsellem\n\nThanks. So just a couple. Can you size up the opportunity for landiolol, and more interested in particular how you think about the initial ramp here? So that's number one. Number two is, I know, there's a lot you can't say. But can you about the acquisition or what you're contemplating. But I guess the question here is just thinking more broadly, are you still very much wedded to the hospital space given just the financial pressures that we're seeing in the space? Do you want to think more expansively about the business? Or is this mainly just hospital focused? Thank you.\n\nScott Tarriff\n\nDavid, thank you, for all of that. Let's take the second question first and talk a little bit more about the acquisition. We just spent a lot of time speaking about the BARHEMSYS and BYFAVO situation. And it does, it takes a lot of effort. And we're very pleased with the ramp. And we have the hospital business that I would call more saturated right now because we do have the two products that we're in launch mode for. And then as you bring up in your first question, we have the landiolol situation coming up once it's approved.\n\nAnd so I would say it's probably more likely that an acquisition that we make in the short-term, would fall more in the oncology space, then it would in the hospital space. Mostly, the oncology business right now is just a wonderful place to be in the country. We think we can help a number of patients and at the same time, help our shareholders, but it's the oncology side of our business where we have so much room from an infrastructure standpoint.\n\nI think, if I can try to explain this, the clearest way I can, we can probably bring a significant oncology product into our company right now, without needing a heck of a lot of additional expense. I don't mean direct marketing from that standpoint, but the infrastructure that we have could probably support a large oncology product with a minimal amount of additional spending. And so that's the situation we need to take advantage of.\n\nSo if we're able to do what we're hoping to do, it's likely -- it's more likely to be on the oncology side and the hospital side right now. And that goes into your landiolol question, right? We will launch it, it will ramp that's the way these products work. And it'll be the same type of ramp that you normally see in the hospital space. It'll just fortify what we have, we'll see how that goes. But we are very concentrated right now in oncology.\n\nThank you. We have no further questions in queue at this time. I will now turn the call back over to Scott Tarriff for any additional or closing remarks.\n\nScott Tarriff\n\nWell, thank you, everyone for joining the call today. Clearly, obviously, we believe we're poised for another solid year in '23. We look forward to updating you as we advance our business plans. We think we have really a very strong vision of the future. Let's see how it unfolds. And as always, we appreciate your ongoing support for Eagle. Thank you, everybody and stay well.\n\nThis concludes today's call. Thank you for your participation. You may disconnect at any time.",
            "source": {
                "uri": "seekingalpha.com",
                "dataType": "news",
                "title": "Seeking Alpha"
            },
            "authors": [
                {
                    "uri": "sa_transcripts@seekingalpha.com",
                    "name": "Sa Transcripts",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "eventUri": null,
            "sentiment": 0.2392156862745098,
            "wgt": 421453800,
            "relevance": 75
        },
        {
            "uri": "7536770539",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "21:40:00",
            "dateTime": "2023-05-10T21:40:00Z",
            "dateTimePub": "2023-05-10T03:27:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.marketscreener.com//quote/stock/APOLLO-TYRES-LIMITED-9058904/news/Indian-shares-set-to-open-higher-ahead-of-key-macro-data-earnings-43795820/",
            "title": "Indian shares set to open higher ahead of key macro data, earnings | MarketScreener",
            "body": "BENGALURU (Reuters) - Indian shares are set to open higher on Wednesday amid caution in global markets ahead of key macroeconomic data from the U.S. and corporate earnings for top domestic firms.\n\nIndia's NSE stock futures listed on the Singapore exchange were up 0.19% at 18,345, as of 8:18 a.m. IST.\n\nWall Street equities declined ahead of U.S. consumer prices data and on disappointing forecasts from several companies. Investors are awaiting the inflation data for potential cues into the future rate-hike trajectory of the U.S. Federal Reserve. Asian markets were subdued. [MKTS/GLOB]\n\nIndian shares were little changed on Tuesday amid a slew of earnings. The benchmark Nifty 50 has risen over 5% in the 2024 fiscal so far, aided by a relatively stable results season.\n\n\"The earnings season has been decent with 77% of the companies in our coverage either meeting or exceeding profit expectations,\" analysts at Motilal Oswal said in a note. The brokerage identified financials and autos as top sectoral performers in the March-quarter season.\n\nLarsen & Toubro Ltd, Dr Reddy's Laboratories Ltd, Bosch Ltd, Godrej Consumer Products Ltd, Cera Sanitaryware Ltd, and Escorts Kubota Ltd are among the companies reporting their quarterly earnings on Wednesday.\n\nMeanwhile, foreign institutional investors extended their buying streak in Indian equities for the ninth session in a row on Tuesday, adding equities worth 19.42 billion rupees ($237.5 million).\n\nStocks to Watch:\n\n** Nazara Technologies Ltd: Co reports rise in consolidated net profit in March quarter.\n\n** SRF Ltd: Co posts fall in March-quarter profit, increases capex to set up an aluminium foil manufacturing facility to 5.30 bln rupees from 4.25 bln rupees.\n\n** Apollo Tyres Ltd: Co reports rise in consolidated profit in Q4; recommends final dividend of 4 rupees per share.\n\n** Greaves Cotton Ltd: Co enters definitive agreement for acquisition of Excel Controlinkage.\n\n($1 = 81.7800 Indian rupees)\n\n(Reporting by Bharath Rajeswaran in Bengaluru; Editing by Sonia Cheema)",
            "source": {
                "uri": "marketscreener.com",
                "dataType": "news",
                "title": "Market Screener"
            },
            "authors": [],
            "image": "https://img.zonebourse.com/reuters/2023-02/2023-02-08T023540Z_1_LYNXMPEJ1703P_RTROPTP_3_INDIA-BUDGET.JPG",
            "eventUri": null,
            "sentiment": 0.1529411764705881,
            "wgt": 421450800,
            "relevance": 26
        },
        {
            "uri": "7536853465",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "21:22:00",
            "dateTime": "2023-05-10T21:22:00Z",
            "dateTimePub": "2023-05-10T04:56:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.marketscreener.com/quote/index/NIFTY-50-9743680/news/INDIA-STOCKS-Financials-weigh-on-Indian-shares-ahead-of-key-macro-data-43796127/",
            "title": "INDIA STOCKS-Financials weigh on Indian shares ahead of key macro data",
            "body": "Indian shares reversed gains on Wednesday, weighed by financials, amid a slide in global equities ahead of key U.S. macroeconomic data and corporate earnings for top domestic firms.\n\nThe Nifty 50 was down 0.14% at 18,239.35, as of 10:23 a.m. IST, while the S&P BSE Sensex fell 0.14% to 61,677.23. The benchmarks had risen 0.3% earlier in the session.\n\nEight of the 13 major sectoral indexes declined, with high-weightage financials losing 0.6%. The bank index fell 0.8%, while public sector banks declined over 2.3%.\n\n\"Investors have resorted to selective profit-taking after a sharp spike in the recent sessions,\" said Shrikant Chouhan, head of equity research (retail) at Kotak Securities.\n\n\"The Nifty 50 has formed a small bearish candle in the daily charts, which indicates indecisiveness.\"\n\nWall Street equities declined overnight, ahead of U.S. consumer prices data and on disappointing company forecasts.\n\nInvestors will be focusing on U.S. inflation data for potential cues into the Federal Reserve's future rate-hike path. Asian markets were subdued.\n\nAmong individual stocks, shares of Shipping Corporation of India Ltd jumped over 7% in a weak market after\n\nPrivate lender IndusInd Bank Ltd rose over 2% and was the top Nifty 50 gainer after global brokerage UBS\n\nupgraded\n\nthe stock to \"buy\" from \"neutral\", citing stable operating metrics.\n\nAgri-business firm Godrej Agrovet Ltd lost nearly 5% after\n\nShares of PTC India Ltd <PTCI.NS. and PTC India Financial Services Ltd lost 1% and 5%, respectively, after Reuters reported that the market regulator\n\nissued\n\nlegal notices to the firms, demanding explanations of alleged lapses in corporate governance.\n\nOn the earnings front, companies including Larsen & Toubro Ltd, Dr Reddy's Laboratories Ltd, Bosch Ltd, Godrej Consumer Products Ltd and Escorts Kubota Ltd are scheduled to report their quarterly results on Wednesday.\n\n(Reporting by Bharath Rajeswaran in Bengaluru; Editing by Sonia Cheema and Dhanya Ann Thoppil)",
            "source": {
                "uri": "marketscreener.com",
                "dataType": "news",
                "title": "Market Screener"
            },
            "authors": [],
            "image": "https://www.marketscreener.com/images/twitter_ZB_fdnoir.png",
            "eventUri": null,
            "sentiment": 0.09019607843137245,
            "wgt": 421449720,
            "relevance": 1
        },
        {
            "uri": "7538169839",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "21:09:00",
            "dateTime": "2023-05-10T21:09:00Z",
            "dateTimePub": "2023-05-10T21:07:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.marketscreener.com/news/latest/Health-Care-Lags-Market-Amid-Cyclical-Bias-Health-Care-Roundup--43808806/",
            "title": "Health Care Lags Market Amid Cyclical Bias - Health Care Roundup",
            "body": "Health-care companies rose, but not by as much as the broad market, as traders rotated into cyclical sectors in the wake of weakening inflation data.\n\nShares of Indian drugmaker Dr. Reddy's Laboratories fell after it posted quarterly sales shy of some investors' expectations.\n\nAdvisers to the Food and Drug Administration recommended making an oral contraceptive available without a prescription for the first time, potentially widening access to birth control for women across the country.",
            "source": {
                "uri": "marketscreener.com",
                "dataType": "news",
                "title": "Market Screener"
            },
            "authors": [],
            "image": "https://www.marketscreener.com/images/twitter_ZB_fdblanc.png",
            "eventUri": null,
            "sentiment": -0.06666666666666665,
            "wgt": 421448940,
            "relevance": 26
        },
        {
            "uri": "7536644608",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "20:17:00",
            "dateTime": "2023-05-10T20:17:00Z",
            "dateTimePub": "2023-05-10T00:09:00Z",
            "dataType": "news",
            "sim": 0.7019608020782471,
            "url": "https://economictimes.indiatimes.com/markets/ipos/fpos/mankind-pharma-rallies-32-on-day-1/articleshow/100114821.cms",
            "title": "Mankind Pharma rallies 32% on day 1",
            "body": "Mumbai: Mankind Pharma made a strong stock market debut on Tuesday with the stock listing 20% above its initial public offering price of â‚¹1,080. The stock, which listed at â‚¹1,300 apiece, ended at â‚¹1,424, nearly 32% higher than the offer price. Analysts remain bullish about the stock's prospects but recommend traders locking in profits for now.\n\nAt Tuesday's closing price, Mankind Pharma was valued at a price-to-earnings ratio of 43 times its FY22 earnings. Mankind is now India's fifth largest pharma company by market value of â‚¹57,046 crore. Sun Pharma, Divi's Lab, Dr. Reddy's Lab, and Cipla are currently valued between â‚¹75,284 crore and â‚¹2.31 lakh crore.\n\nThe â‚¹4,326-crore public issue of Mankind Pharma - the biggest IPO in 2023 so far- was subscribed 15.32 times. It was an offer for sale (OFS) by existing shareholders.\n\nThe IPO was the largest ever by a domestic drug maker since Gland Pharma came up with its â‚¹6,480 crore public issue in November 2020.\n\n\"The healthcare sector was a laggard over the last one year but started seeing traction over the last two months as the monthly pharma data showed improvement. Mankind received a good response from its anchor clients given its domestic-focused business with strong brand recall in chronic and consumer healthcare segments,\" said Hemang Jani, head of equity strategy at Motilal Oswal Financial Services.",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-100114828,width-1070,height-580,imgsize-804767,overlay-etmarkets/photo.jpg",
            "eventUri": "eng-8612160",
            "sentiment": 0.3176470588235294,
            "wgt": 421445820,
            "relevance": 26
        },
        {
            "uri": "7536870371",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "19:58:00",
            "dateTime": "2023-05-10T19:58:00Z",
            "dateTimePub": "2023-05-10T05:10:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://economictimes.indiatimes.com/markets/stocks/stock-watch/share-market-update-most-active-stocks-on-d-street-today-in-terms-of-volume/articleshow/100120836.cms",
            "title": "Share market update: Most active stocks on D-Street today in terms of volume",
            "body": "NEW DELHI: Indian Railway Finance Corporation Ltd.(number of shares traded: 4.83 crore), PNB(number of shares traded: 3.96 crore), Brightcom Group(number of shares traded: 3.77 crore), YES Bank(number of shares traded: 3.52 crore), Zomato Ltd.(number of shares traded: 3.05 crore), Suzlon Energy(number of shares traded: 1.84 crore), Ircon Intl.(number of shares traded: 1.76 crore), Ibull Real Estate(number of shares traded: 1.70 crore), Vodafone Idea(number of shares traded: 1.40 crore) and JP Power(number of shares traded: 1.39 crore) were among the most traded securities on the National Stock Exchange at 10:40AM in Wednesday's session.\n\nThe NSE Nifty index was trading 3.4 points down at 18262.55, while BSE Sensex was down 1.5 points at 61759.83 at the time of writing this report.\n\nIn the Nifty index, HDFC Life Insurance Company Ltd.(up 1.69 per cent), IndusInd Bank Ltd.(up 1.68 per cent), Britannia Industries Ltd.(up 1.10 per cent), Adani Enterprises Ltd.(up 0.90 per cent) and Power Grid Corporation of India Ltd.(up 0.88 per cent) were among the top gainers.\n\nWhile UPL Ltd.(down 1.69 per cent), Dr. Reddy's Laboratories Ltd.(down 1.20 per cent), State Bank of India(down 1.08 per cent), Divi's Laboratories Ltd.(down 0.77 per cent) and Mahindra & Mahindra Ltd.(down 0.76 per cent) were among the top losers in the index.",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-83769615,width-1070,height-580,imgsize-98874,overlay-etmarkets/photo.jpg",
            "eventUri": null,
            "sentiment": 0.4745098039215687,
            "wgt": 421444680,
            "relevance": 1
        },
        {
            "uri": "7537532076",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "19:50:00",
            "dateTime": "2023-05-10T19:50:00Z",
            "dateTimePub": "2023-05-10T13:21:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.marketscreener.com//quote/stock/ALEMBIC-LIMITED-6498517/news/India-s-Dr-Reddy-s-Labs-posts-11-fold-jump-in-Q4-profit-43804336/",
            "title": "India's Dr Reddy's Labs posts 11-fold jump in Q4 profit | MarketScreener",
            "body": "BENGALURU (Reuters) - Indian drugmaker Dr Reddy's Laboratories Ltd reported nearly an eleven-fold surge in fourth-quarter profit on Wednesday, driven by higher sales from its mainstay generic drugs business in North America.\n\nThe Hyderabad-based company's consolidated profit rose to 9.59 billion rupees in the three months ended March 31, compared with 875 million rupees a year earlier.\n\nThe profit, however, missed analysts' expectations of 9.74 billion rupees, according to Refinitiv IBES data.\n\nRevenue from its generic business in North America, the company's biggest market accounting for almost half of its total sales, jumped 27% to 25.32 billion rupees, on the back of new launches and scaling up of existing products. In India, its revenue from generic drugs business climbed 32%.\n\nDr Reddy's consolidated revenue jumped 15.8% to 62.97 billion rupees, while total operating expenses fell 13.3%.\n\nThe company also recommended a final dividend of 40 rupees per share for the financial year 2023.\n\nShares of the company settled 1.3% down at 4,867 rupees on Wednesday ahead of the earnings. They have advanced 14.9% so far this year, outperforming the Nifty pharma index which was up 0.95%.\n\nIts peers Lupin Ltd swung to a profit in fourth quarter from a loss last year, while Alembic Pharmaceuticals Ltd posted a near-seven-fold increase in quarterly profit. Cipla Ltd is scheduled to report its results later this week.\n\n(Reporting by Rama Venkat in Bengaluru; Editing by Sohini Goswami)",
            "source": {
                "uri": "marketscreener.com",
                "dataType": "news",
                "title": "Market Screener"
            },
            "authors": [],
            "image": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "eventUri": null,
            "sentiment": 0.3098039215686275,
            "wgt": 421444200,
            "relevance": 51
        },
        {
            "uri": "7536837663",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "19:44:00",
            "dateTime": "2023-05-10T19:44:00Z",
            "dateTimePub": "2023-05-10T04:42:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.latestly.com/agency-news/business-news-sensex-loses-71-points-amid-weak-global-cues-in-morning-trade-5115687.html",
            "title": "Business News | Sensex Loses 71 Points Amid Weak Global Cues in Morning Trade | LatestLY",
            "body": "Mumbai (Maharashtra) [India], May 10 (ANI): The key benchmark of the equity domestic markets opened with losses on Wednesday morning, tracking weak global cues. Better-than-expected corporate earnings haven't still lifted the investors' moods. Data on US inflation is expected later in the day which would impact the future course of interest rates across the world. Meanwhile, investors are in a \"wait-and-watch\" mode.\n\nBSE Sensex went down 71 points to 61,689.38 and NSE Nifty lost 21 points to 18,244.35 in morning trade. The top gainers on Nifty 50 were IndusInd Bank, Tata Motors, Power Grid, Bajaj Auto and HCL Tech while the losers were UPL, Dr Reddy, SBIN, Grasim and Adani Ports.\n\nAlso Read | Poco F5 With 64MP Cameras, Android 13 OS Launched in India - Check Price, Specs, Features, and Other Key Details Here.\n\nIn Asian markets, Hong Kong's Hang Seng went down 133 points, Japan's Nikkei lost 129 points, China's Shanghai went down 46 points and Thailand SET dropped 1 point as domestic markets opened on Wednesday.\n\nIn the US markets, Dow Jones lost 56 points, S-P 500 went down 18 points, Nasdaq dropped 77 points and NYSE declined 38 points.\n\nAlso Read | Air Movie Review: Ben Affleck's Energetic Direction and Matt Damon's Impressive Performance Fuel This Engaging Biopic (LatestLY Exclusive).\n\nIn European markets, Amsterdam Exchange, BEL, CAC and Deutsche Borse were trading in the positive territory, FTSE lost 14 points and Madrid was also in the positive territory.\n\nRupee rose 5 paise to 82.01 against the US dollar in early trade on Wednesday. On Tuesday, On May 9, the Reserve Bank of India (RBI) said fees and charges payable in India on forex prepaid cards, store value cards, and travel cards must be denominated and settled in local currency.\n\nLarsen and Toubro, Dr Reddy's Laboratories, Godrej Consumer Products, Bosch, Procter & Gamble Hygiene, Escorts Kubota, Sanofi India, and Max Financial Services, and several others are scheduled to release their March quarter earnings on Wednesday. (ANI)\n\n(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)",
            "source": {
                "uri": "latestly.com",
                "dataType": "news",
                "title": "LatestLY"
            },
            "authors": [],
            "image": "https://st1.latestly.com/wp-content/uploads/2018/03/default-img-01.jpg",
            "eventUri": null,
            "sentiment": 0.01960784313725483,
            "wgt": 421443840,
            "relevance": 1
        },
        {
            "uri": "7537772781",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "19:26:00",
            "dateTime": "2023-05-10T19:26:00Z",
            "dateTimePub": "2023-05-10T15:43:00Z",
            "dataType": "news",
            "sim": 0.4745098054409027,
            "url": "https://www.wallstreet-online.de/nachricht/16915300-dr-reddy-s-q4-fy23-financial-results",
            "title": "Dr. Reddy's Q4 & FY23 Financial Results",
            "body": "* Excluding impairments in current & previous periods, Q4 FY 23 PBT is Rs. 1,380 Cr (growth of 38% YoY) and FY 23 PBT is Rs. 6,107 Cr (growth of 53% YoY)\n\nCommenting on the results, Co-Chairman & MD, G V Prasad said: \"FY 23 has been a year of record sales, profits and cash flow, driven by our performance in US Generics. We progressed well in our productivity and sustainability agenda. We will continue to deliver on our purpose, invest in growth drivers and promote a culture that is innovative and collaborative ensuring the future of our business.\"\n\nAll amounts in millions, except EPS. All US dollar amounts based on convenience translation rate of 1 USD = Rs. 82.19\n\nAll amounts in millions, except EPS. All US dollar amounts based on convenience translation rate of 1 USD = Rs. 82.19\n\nAll amounts in millions, except EPS. All US dollar amounts based on convenience translation rate of 1 USD = Rs. 82.19\n\nAll amounts in millions, except EPS. All US dollar amounts based on convenience translation rate of 1 USD = Rs. 82.19\n\nPharmaceutical Services and Active Ingredients (PSAI)\n\nAbout key metrics and non-GAAP Financial Measures\n\nThis press release contains non-GAAP financial measures within the meaning of Regulation G and Item 10(e) of Regulation S-K. Such non-GAAP financial measures are measures of our historical performance, financial position or cash flows that are adjusted to exclude or include amounts, as the case may be, from the most directly comparable financial measure calculated and presented in accordance with IFRS.\n\nThe presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with IFRS. Our non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. These measures may be different from non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes.\n\nWe believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and allow for greater transparency with respect to key metrics used by management in operating our business.\n\nFor more information on our non-GAAP financial measures and a reconciliation of GAAP to non-GAAP measures, please refer to \"Reconciliation of GAAP to Non-GAAP Results\" table in this press release.\n\nThe management of the Company will host an earnings call to discuss the Company's financial performance and answer any questions from the participants.\n\nPre-register with the below link and join without waiting for the operator.\n\nhttps://services.choruscall.in/DiamondPassRegistration/register?confir ...\n\nNo password/pin number is necessary to dial in to any of the above numbers. The operator will provide instructions on asking questions before and during the call.\n\nPlay Back: The play back will be available after the earnings call, till May 17, 2023. For play back dial in phone No: +91 22 7194 5757, and Playback Code is 65827.\n\nTranscript: Transcript of the Earnings call will be available on the Company's website: www.drreddys.com\n\nAbout Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its businesses, Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy's operates in markets across the globe. Our Major markets include - USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com\n\nDisclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words \"may\", \"will\", \"should\", \"expects\", \"plans\", \"intends\", \"anticipates\", \"believes\", \"estimates\", \"predicts\", \"potential\", or \"continue\" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the \"Risk Factors\" and \"Forward-Looking Statements\" sections of our Annual Report on Form 20-F for the year ended March 31, 2022. The company assumes no obligation to update any information contained herein.\"",
            "source": {
                "uri": "wallstreet-online.de",
                "dataType": "news",
                "title": "wallstreet:online"
            },
            "authors": [],
            "image": "https://assets.wallstreet-online.de/_media/6/source1280/size_645/businesswire-1280.png",
            "eventUri": "eng-8612994",
            "sentiment": 0.1529411764705881,
            "wgt": 421442760,
            "relevance": 51
        },
        {
            "uri": "7535828203",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "19:19:00",
            "dateTime": "2023-05-10T19:19:00Z",
            "dateTimePub": "2023-05-09T11:47:00Z",
            "dataType": "news",
            "sim": 0.7176470756530762,
            "url": "https://www.moneycontrol.com/news/business/earnings/us-sales-brand-deals-to-seal-the-fortune-for-dr-reddys-in-q4-10554141.html",
            "title": "US sales, brand deals to seal the fortune for Dr Reddy's in Q4",
            "body": "Dr Reddy's is poised to reap the benefits of brand sales of Rs 275 crore, which will incrementally boost its headline numbers for Q4.\n\nDr Reddy's Laboratories is scheduled to report its earnings for the fourth quarter on May 10. According to a poll of brokerages conducted by Moneycontrol, revenue is expected to come in at Rs 6,090.5 crore, translating to a 12 percent year-on-year increase.\n\nConsolidated net profit for the drugmaker is seen at Rs 1,093.6 crore, a significant jump from Rs 87. 5 crore in the corresponding quarter last year. The company is also poised to benefit from brand sales of Rs 275 crore, which will incrementally boost its headline numbers for Q4. During the quarter, Dr Reddy's sold nine dermatology brands to Eris Lifesciences.\n\nPrabhudas Lilladher expects a healthy rise in US sales year-on-year, aided by gRevlimid and other new launches to support the drugmaker's earnings growth for the fourth quarter.\n\nAccording to BNP Paribas, the domestic formulation may also support, amid expectations of double-digit revenue growth in the segment.\n\nA slew of brokerages, including Axis Securities, ShareKhan, and JM Financial Services, also anticipate Dr Reddy's to be an earnings leader within the entire pharma pack.\n\n\"We expect companies like Dr Reddy's Laboratories to surpass the industry growth due to their superior product portfolio and strong product pipeline for the future,\" Axis Securities stated in its report.\n\nOn the operational front, margins may soften sequentially with lowering gRevlimid sales but are still likely to remain firm on a year-on-year basis, led by an improved product mix, as per Philip Capital.\n\nIn sync with this view, the EBIDTA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) margin for Q4 is seen at 24.9 percent, showing an expansion of 333 basis points year-on-year but declining 552 bps sequentially.\n\nHowever, Sharekhan also highlights that increased scrutiny from the US Food and Drug Administration, leading to production delays, and rising guidance around research and development and promotion and marketing costs in the near term, could act as headwinds against a potentially strong operating performance for the drugmaker.\n\nAdditionally, Prabhudas Lilladher believes the management's commentary on margins and US sales, excluding the generic Revlimid, will remain key monitorable.",
            "source": {
                "uri": "moneycontrol.com",
                "dataType": "news",
                "title": "MoneyControl"
            },
            "authors": [],
            "image": "https://images.moneycontrol.com/static-mcnews/2021/07/shutterstock_1308720301-4-770x433.jpg",
            "eventUri": "eng-8614427",
            "sentiment": 0.411764705882353,
            "wgt": 421442340,
            "relevance": 75
        },
        {
            "uri": "7537993065",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "18:36:00",
            "dateTime": "2023-05-10T18:36:00Z",
            "dateTimePub": "2023-05-10T18:22:00Z",
            "dataType": "news",
            "sim": 0.4901960790157318,
            "url": "https://www.goodreturns.in/news/microsoft-cuts-salary-raises-and-bonuses-for-employees-as-focus-shifts-to-generative-ai-1283152.html",
            "title": "Microsoft Cuts Salary Raises And Bonuses For Employees As Focus Shifts To Generative AI",
            "body": "For Quick Alerts Subscribe Now Stay updated with all the happenings around the globe. Click here View Sample For Quick Alerts ALLOW NOTIFICATIONS For Daily Alerts Just In 33 min ago SEBI Allows Foreign Portfolio Investors DMA to Exchange Traded Commodity Derivatives 1 hr ago SMBC Aviation Capital Files Appeal Against NCLT's Decision Granting Go First's Voluntary Insolvency Plea 2 hrs ago Dr Reddy's Laboratories Q4 Results: Profit Surges By 996%, Dividend Of Rs 40 Per Share Declared 3 hrs ago L&T Q4 Results: Reports 10% YoY Growth In Net Profit For March Quarter Don't Miss News Karnataka may record highest voter turnout in 34 years Sports CSK vs DC IPL 2023: Full List of Award Winners, Man of The Match, Post-Match Presentation, Stats and Records Lifestyle Enchanting Temple Of Goddess Renuka And Renuka Tal Far Above The Sea Level In Himachal Movies Cannes Film Festival 2023: Dress Code, Ticket Prices, Jury Members & All Other Details You Need To Know Travel Mocha Cyclone: Bengaluru On High Risk Of Urban Flooding, Know The Reason Why? Technology Asus ROG Zephyrus Duo 16 2023 Review: Worth the Price? Automobiles 2023 Bajaj Avenger 220 Street Motorcycle Launched At Rs 1.42 Lakh - Powertrain Updated Education NCHM JEE 2023 Admit Card Released: Download Now from nchmjee.nta.nic.in Home News Microsoft Cuts Salary Raises And Bonuses For Employees As Focus Shifts To Generative AI News oi-Ajeeta Bhatia By Ajeeta Bhatia | Published: Wednesday, May 10, 2023, 23:52 [IST]\n\nMicrosoft Corp has reportedly informed its full-time employees that they will not receive salary raises this year, and the company will also reduce its budget for bonuses and stock awards. The news was first reported by Insider, which cited an internal email sent by CEO Satya Nadella.\n\nMicrosoft has yet to respond to a Reuters request for comment.\n\n\"Last year, we made a significant investment in compensation driven by market conditions and company performance, nearly doubling our global merit budget...this year the economic conditions are very different across many dimensions\" the report quoted Nadella saying.\n\nMicrosoft stated in January that it would lay off 10,000 employees, adding to the tens of thousands of layoffs that had already been reported throughout the IT sector as it struggles with sluggish growth in a volatile market.\n\nMicrosoft has now devoted its whole attention to generative AI, an area that the business community considers to be a strength.\n\nMicrosoft has been integrating artificial intelligence technology into its Office products as well as its Bing search engine in partnership with OpenAI, the company that created ChatGPT and has also gotten billions of dollars in funding from Microsoft.\n\nMORE MICROSOFT NEWS Microsoft Inks 10-Year Deal With Nware In Spain, After UK Blocks Activision Bid UK Blocked Microsoft $69 Bn Activision Blizzard Acquisition Deal Microsoft Net Income Up 9% In 3rd Quarter Driven By Cloud Strength Alphabet Merges AI Units Google Brain And DeepMind To Take On Rival Reddit To Charge OpenAI, Google Soon Elon Musk To Launch TruthGPT, To Take On Microsoft And Google Microsoft Hosted Sting Concert In Davos An Night Before Announcement To Cut 10,000 Jobs: Report Microsoft To Axe 10,000 Jobs, Nearly 5 Per Cent, Of Global Workforce This Bluechip Mutual Fund Has Holdings In Facebook, Google & Amazon, Outperformed Benchmark BPCL Teams Up With Microsoft, To Leverage Cloud, AI Technologies 'Microsoft' CEO Satya Nadella's Son Dies Zuddl Raises USD 13.35 Million Funding From Alpha Wave Incubation, Qualcomm Ventures, others For investment related articles, business news and mutual fund advise Allow Notifications You have already subscribed Story first published: Wednesday, May 10, 2023, 23:52 [IST] Other articles published on May 10, 2023",
            "source": {
                "uri": "goodreturns.in",
                "dataType": "news",
                "title": "https://www.goodreturns.in/"
            },
            "authors": [
                {
                    "uri": "ajeeta_bhatia@goodreturns.in",
                    "name": "Ajeeta Bhatia",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://www.goodreturns.in/img/2023/04/im-702425-1682499793.jpg?10052023235906",
            "eventUri": "eng-8612609",
            "sentiment": 0.4431372549019608,
            "wgt": 421439760,
            "relevance": 51
        },
        {
            "uri": "7537443782",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "17:59:00",
            "dateTime": "2023-05-10T17:59:00Z",
            "dateTimePub": "2023-05-10T11:58:00Z",
            "dataType": "news",
            "sim": 0.8078431487083435,
            "url": "https://economictimes.indiatimes.com/markets/stocks/earnings/dr-reddys-labs-q4-results-profit-zooms-890-yoy-to-rs-960-crore-dividend-declared-at-rs-40/share/articleshow/100133004.cms",
            "title": "Dr Reddy's Labs Q4 Results: PAT sees nine-fold jump to Rs 960 crore, dividend declared at Rs 40/share",
            "body": "Indian pharmaceutical major Dr Reddy's Laboratories reports a whopping 890% YoY growth in net profit. Revenue from operations stood at Rs 5,843 crore, up 15.28% YoY, while total expenses fell by 4% to Rs 5,132.2 crore. Company recommends a final dividend of Rs 40 per share for the financial year 2022-23Dr Reddy's Laboratories has reported a consolidated net profit of Rs 960.1 crore for the fourth quarter ended March 2023. This is an increase of 890% from Rs 97 crore clocked in the corresponding quarter of last year.\n\nIts revenue from operations stood at Rs 5,843 crore in Q4 FY23, up 15.28% YoY as compared to Rs 5,068.4 crore in Q4FY22. Meanwhile, total expenses were down by 4% at Rs 5,132.2 crore against Rs 5,348.4 crore in Q4FY22.\n\nThe company recommended a final dividend of Rs 40 (800%) per equity share of Rs 5 each for the financial year 2022-23. The dividend will be paid on or after five days from the date of declaration of the final dividend by the shareholders at the 39th Annual General Meeting (AGM), the company said in an exchange filing.\n\nOther income during the quarter increased to Rs 138.5 crore as against Rs 121.9 crore in the previous-year period. The company's total income rose 15.3% YoY to Rs 6,453.7 crore for the March quarter. The same was Rs 5,596.8 crore in the same quarter of last year.\n\nIn Wednesday's trade, shares of Dr Reddy's Labs ended 1.3% lower at Rs 4,868 on the BSE. On a year-to-date basis, the stock has surged 15%, while it has risen 25% in the last one year.\n\nCommenting on the results, Co-Chairman & MD G V Prasad said, \"FY 23 has been a year of record sales, profits and cash flow, driven by our performance in US Generics.\"\n\nFor FY23, revenue for the Global Generic segment stood at Rs 213.8 billion, higher by 19% over FY22. This growth was driven by North America, Europe and India while emerging markets remained flat.\n\nFor the March quarter, consolidated operating profit, calculated as earnings before interest, taxes, depreciation and amortization (EBITDA), rose 26% YoY to Rs 1,631 crore, but was down 17% sequentially. Gross margins expanded sharply by 430 basis points to 57.2%. The spend on research and development (R&D) rose 24% YoY to Rs 537 crore.\n\nThe global generics business reported an 18% YoY growth in revenue to Rs 5,426 crore, with North America witnessing 27% growth. Europe saw 12% growth and India 32% growth in the quarter.\n\nAbout 40% of the consolidated revenue for Dr Reddy's came from North America, and 20% from India.",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-100133852,width-1070,height-580,imgsize-99004,overlay-etmarkets/photo.jpg",
            "eventUri": "eng-8609368",
            "sentiment": 0.2470588235294118,
            "wgt": 421437540,
            "relevance": 51
        },
        {
            "uri": "7537443783",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "17:56:00",
            "dateTime": "2023-05-10T17:56:00Z",
            "dateTimePub": "2023-05-10T11:53:00Z",
            "dataType": "news",
            "sim": 0.686274528503418,
            "url": "https://economictimes.indiatimes.com/markets/stocks/stock-watch/share-market-update-most-active-stocks-of-the-day-in-terms-of-traded-value/articleshow/100133176.cms",
            "title": "Share market update: Most active stocks of the day in terms of traded value",
            "body": "NEW DELHI: HDFC Bank(Rs. 3810.33 crore), ICICI Bank(Rs. 2419.41 crore), RIL(Rs. 1251.20 crore), SBI(Rs. 1055.90 crore), Axis Bank(Rs. 1055.30 crore), Infosys(Rs. 823.71 crore), Mankind Pharma(Rs. 783.02 crore), Kotak Bank(Rs. 763.60 crore), IndusInd Bank(Rs. 753.11 crore) and PayTM(Rs. 655.98 crore) were among the most traded securities on the National Stock Exchange in Wednesday's session.\n\nThe NSE Nifty index ended the session 49.15 points up at 18315.1, while BSE Sensex rose 178.87 points to 61940.2.\n\nIn the Nifty index, IndusInd Bank Ltd.(up 2.80 per cent), HDFC Life Insurance Company Ltd.(up 1.92 per cent), Power Grid Corporation of India Ltd.(up 1.75 per cent), Bharat Petroleum Corporation Ltd.(up 1.39 per cent) and Divi's Laboratories Ltd.(up 1.24 per cent) stood among the top gainers.\n\nOn the other hand, UPL Ltd.(down 2.12 per cent), Dr. Reddy's Laboratories Ltd.(down 1.34 per cent), Hindalco Industries Ltd.(down 0.89 per cent), Infosys Ltd.(down 0.59 per cent) and Larsen & Toubro Ltd.(down 0.42 per cent) were among the top losers of the day.",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-82267819,width-1070,height-580,imgsize-142669,overlay-etmarkets/photo.jpg",
            "eventUri": "eng-8609368",
            "sentiment": 0.07450980392156858,
            "wgt": 421437360,
            "relevance": 1
        },
        {
            "uri": "7536786652",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "17:50:00",
            "dateTime": "2023-05-10T17:50:00Z",
            "dateTimePub": "2023-05-10T03:48:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.freepressjournal.in/business/opening-bell-markets-trade-in-green-sensex-at-6186874-nifty-at-1829895-2",
            "title": "Opening bell: Markets trade in green; Sensex at 61,868.74, Nifty at 18,298.95",
            "body": "The markets on Wednesday opened in green with Sensex at 61,876.15, up by 114.82 points and Nifty rose by 35.45 points at 18,301.40. Power Grid, IndusInd Bank, Tata Motors, Bajaj Finserv and Bajaj Finance were the top gainers whereas HDFC Bank, Sun Pharma, Asian Paints, ITC and HDFC were the top losers.\n\nThe stocks of Larsen & Toubro, Dr Reddy's Laboratories, Bosch, Godrej Consumer Products, BASF India, Gujarat Gas, Orchid Pharma, Novartis India and Escorts Kubota will be in focus as the companies are announcing the results for the last quarter today.\n\nMarkets on Tuesday\n\nThe markets on Tuesday erased its early gains in late sell-off with Sensex closing at 61,761.33 down by 2.92 points and Nifty closing at 18,265.95 with a gain of 1.55 points. IndusInd Bank, TCS, Axis Bank, Tata Motors and Mahindra and Mahindra were among the gainers whereas HDFC Bank, Bharti Airtel, Titan, Kotak Bank, Sun Pharma and ICICI Bank were among the losers for the day.\n\nGlobal markets\n\nThe US stock indexes on Tuesday closed lower as investors prepare for the Labor Department's consumer price index that is expected to be released on Wednesday. The investors are also waiting for an update on the plans for the debt ceiling from a meeting between US president Joe Biden, Republican House Speaker Kevin McCarthy and other congressional leaders at the White House. The Dow Jones Industrial Average slipped 56.88 points to 33,561.81, the S&P 500 fell 18.95 points to 4,119.17 and the Nasdaq Composite lost 77.36 points to 12,179.55.\n\nAsian markets on Wednesday were also on the lower end with Japan's Nikkei 225 down by 119.84 points at 29,122.98, Hong Kong's Hang Seng fell 117.34 points to 19,750.24 and South Korea's KOSPI slipped 3.04 points to 2,507.02. On the other hand Singapore's SGX Nifty was up by 36 points at 18,347.\n\nOil prices\n\nOil prices on Wednesday were lower after data showed a build in US crude stocks and as investors wait for US inflation data for the month of April that would indicate the direction of the Federal Reserve's next rate decision. Brent crude futures were down 54 cents at $76.90 and US Texas Intermediate was down by 57 cents at $73.14.\n\nRupee\n\nRupee on Tuesday falls to 82.06 per dollar against Tuesday's close of 82.04 per dollar.",
            "source": {
                "uri": "freepressjournal.in",
                "dataType": "news",
                "title": "Free Press Journal"
            },
            "authors": [],
            "image": "https://gumlet.assettype.com/freepressjournal/2023-02/45ea0ee5-0933-4bfd-a4ee-042c7e864540/stocks_hero.jpg?rect=0%2C0%2C3900%2C2194&w=1200&auto=format%2Ccompress&ogImage=true",
            "eventUri": null,
            "sentiment": -0.05882352941176472,
            "wgt": 421437000,
            "relevance": 51
        },
        {
            "uri": "7537064783",
            "lang": "eng",
            "isDuplicate": true,
            "date": "2023-05-10",
            "time": "17:40:00",
            "dateTime": "2023-05-10T17:40:00Z",
            "dateTimePub": "2023-05-10T08:09:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.aninews.in/news/business/sensex-loses-71-points-amid-weak-global-cues-in-morning-trade20230510100335/",
            "title": "Sensex loses 71 points amid weak global cues in morning trade",
            "body": "Mumbai (Maharashtra) [India], May 10 (ANI): The key benchmark of the equity domestic markets opened with losses on Wednesday morning, tracking weak global cues. Better-than-expected corporate earnings haven't still lifted the investors' moods. Data on US inflation is expected later in the day which would impact the future course of interest rates across the world. Meanwhile, investors are in a \"wait-and-watch\" mode.\n\nBSE Sensex went down 71 points to 61,689.38 and NSE Nifty lost 21 points to 18,244.35 in morning trade. The top gainers on Nifty 50 were IndusInd Bank, Tata Motors, Power Grid, Bajaj Auto and HCL Tech while the losers were UPL, Dr Reddy, SBIN, Grasim and Adani Ports.\n\nIn Asian markets, Hong Kong's Hang Seng went down 133 points, Japan's Nikkei lost 129 points, China's Shanghai went down 46 points and Thailand SET dropped 1 point as domestic markets opened on Wednesday.\n\nIn the US markets, Dow Jones lost 56 points, S-P 500 went down 18 points, Nasdaq dropped 77 points and NYSE declined 38 points.\n\nIn European markets, Amsterdam Exchange, BEL, CAC and Deutsche Borse were trading in the positive territory, FTSE lost 14 points and Madrid was also in the positive territory.\n\nRupee rose 5 paise to 82.01 against the US dollar in early trade on Wednesday. On Tuesday, On May 9, the Reserve Bank of India (RBI) said fees and charges payable in India on forex prepaid cards, store value cards, and travel cards must be denominated and settled in local currency.\n\nLarsen and Toubro, Dr Reddy's Laboratories, Godrej Consumer Products, Bosch, Procter & Gamble Hygiene, Escorts Kubota, Sanofi India, and Max Financial Services, and several others are scheduled to release their March quarter earnings on Wednesday. (ANI)",
            "source": {
                "uri": "aninews.in",
                "dataType": "news",
                "title": "Asian News International (ANI)"
            },
            "authors": [],
            "image": "https://aniportalimages.s3.amazonaws.com/media/details/ANI-20230510042253.jfif",
            "eventUri": null,
            "sentiment": -0.003921568627450966,
            "wgt": 421436400,
            "relevance": 1
        },
        {
            "uri": "7536844770",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "17:36:00",
            "dateTime": "2023-05-10T17:36:00Z",
            "dateTimePub": "2023-05-10T04:55:00Z",
            "dataType": "news",
            "sim": 0.7176470756530762,
            "url": "https://www.indiatoday.in/business/story/stock-market-opening-sensex-nifty-fall-flat-global-cues-weaken-us-india-key-macro-data-2377115-2023-05-10",
            "title": "Sensex, Nifty slip after opening flat as global cues weaken ",
            "body": "By Koustav Das: Benchmark stock market indices fell after rising marginally on Wednesday after a broad-based decline in domestic shares, triggered by weak global cues.\n\nThe S&P BSE Sensex fell 51.69 points at 61,709.64 at 9:44 am, while the NSE Nifty 50 declined 5.95 per cent to 18,260. Broader markets were also under pressure due to cautiousness among investors.\n\nMost of the major sectoral indices declined in early trade, including heavyweight Nifty Financial Services and Nifty Bank.\n\nSome of the top gainers on the Nifty 50 were IndusInd Bank, Power Grid Corporation, Britannia, Tata Motors and HDFC Life. On the other hand, the top losers were UPL, SBI Axis Bank, Dr Reddy's Laboratories and Bajaj Finserv.\n\nAlso Read | Sensex, Nifty end flat as investors await key macro data; bank stocks fall\n\nThe decline in domestic markets comes after both benchmark indices gained for several trading sessions, which analysts had attributed to improvement in global cues and a strong Q4 earnings season led by financials and auto sector companies.\n\nHowever, analysts had also highlighted several headwinds that could hurt sentiments in the medium term. This included high interest rates, the inflation trajectory and the fears of a possible recession in the US.\n\nDomestic investors seem to be taking a cautious approach as they wait for key macroeconomic data from the US (consumer prices data) and India (April inflation data). Apart from this, several companies will report their Q4 results later in the day and these are also expected to have an impact on market movement.",
            "source": {
                "uri": "indiatoday.in",
                "dataType": "news",
                "title": "India Today"
            },
            "authors": [],
            "image": "https://akm-img-a-in.tosshub.com/indiatoday/images/story/202305/stock-market-closing-bell-2_3-sixteen_nine.png?VersionId=ByVcHyL8U6EZiD7xmcIl33v1pPvIrM9R",
            "eventUri": "eng-8612261",
            "sentiment": 0.1137254901960785,
            "wgt": 421436160,
            "relevance": 26
        },
        {
            "uri": "7537863555",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "16:59:00",
            "dateTime": "2023-05-10T16:59:00Z",
            "dateTimePub": "2023-05-10T16:50:00Z",
            "dataType": "news",
            "sim": 0.3960784375667572,
            "url": "https://www.livemint.com/market/stock-market-news/lt-dr-reddys-lab-q4-results-what-should-investors-know-before-trading-in-share-prices-11683736430062.html",
            "title": "L&T, Dr Reddy's Lab Q4 results: What should investors know before trading in share prices?",
            "body": "Stock prices of Larsen & Toubro (L&T) and Dr Reddy's Laboratories will be in focus on Thursday after their Q4 numbers. In the fourth quarter of FY23, L&T missed expectations in terms of revenue, while operation performance stood healthy amidst challenges. In case of Dr Reddy's, the drug maker witnessed a mixed bag with multi-fold rise in PAT on year-on-year but sequentially the performance was bitter. Among the common factors is that both L&T and Dr Reddy's have declared a hefty dividend for shareholders.\n\nBoth the share prices tumbled on Wednesday. On BSE, L&T stock ended marginally lower to â‚¹2366.75 apiece, while Dr Reddy's share price closed at â‚¹4868 apiece down by 1.3%.\n\nL&T Q4 results:\n\nIn Q4FY23, the infrastructure major earned a consolidated PAT and revenue of â‚¹3,987 crore and â‚¹58,335 crore respectively --- registering a growth 10% YoY each. EBITDA came in at â‚¹6,833 crore, up by 5% YoY, while EBITDA margin contracted to 11.7% in the quarter.\n\nAlso, in the quarter, L&T's order book stood at â‚¹76,099 crore, registering a growth of 3% YoY, while international orders came in at â‚¹36,046 crore constituting 47% of the total.\n\nFor shareholders, the company's board of directors on Wednesday recommended a final dividend of â‚¹24 per equity share subject to approval of shareholders. In FY22, the company paid a dividend of 1100% aggregating to â‚¹18 per share to the shareholders from its net profit.\n\nRead here: L&T Q4 results: Consolidated PAT rises 10% YoY to â‚¹3,987 cr, declares dividend of â‚¹24 per share\n\nOn the performance, Khadija Mantri, Associate VP Research Analyst at Sharekhan by BNP Paribas said, \"L&T's Q4FY23 consolidated numbers were below our estimates. Revenue/OPM/ PAT fell short of expectations by 3.3%/~30 bps/~6%. Consolidated revenues grew by ~10% y-o-y to â‚¹58,335 crore. Revenue growth was driven by energy and hi-tech manufacturing segments, while its largest- infrastructure segment grew at a moderate pace of 5% y-o-y.\"\n\nMantri also said, \"Operating profit increased at a slower pace by ~5% y-o-y to â‚¹6,833 crore. OPM, thus, came in lower by 60 bps y-o-y to 11.7%. Net profit grew by ~10% y-o-y to â‚¹3,986 crore aided by higher other income. The company reported 19% y-o-y growth in order inflows surpassing its guidance of 12-15% growth. The order inflow for the quarter and year stands at Rs76,072 crore/ â‚¹2,30,528 crore respectively. Order book grew by 12% y-o-y to â‚¹3,99,526 crore.\"\n\nMoreover, Amit Anwani - Research Analyst, Prabhudas Lilladher said, L&T's saw a healthy operational performance amidst challenges. He highlighted that L&T's consolidated sales grew 10.4% YoY to ~Rs583.4 billion (up 17.3% YoY; PL estimate/ consensus estimate of ~Rs590 billion/Rs589 billion), driven by revenue growth in segments such as Infrastructure (up ~4.3% YoY; Rs315.5 billion), IT & Technology services (up 21.9% YoY; Rs107bn), Energy Projects (up 17% YoY; Rs79.3 billion), Hi-Tech Manufacturing (up 24.6% YoY; Rs23.2 billion), Development Projects (up 12.4% YoY; Rs12.3 billion) and Financial Services (up 5.2% YoY; Rs31.2 billion).\n\nAnwani also mentioned that margins declined YoY in infrastructure (6.6% vs 8.4% in Q4FY22), Hi-Tech Manufacturing (16.2% vs 20.4% in Q4FY22) and IT &Tech (16.8% vs 20% in Q4FY22). While energy segment margin expanded to 9.7% vs 8.4% in Q4FY22.\n\nNevertheless, Prabhudas Lilladher's analyst has set a Buy rating on L&T stock with a target price of â‚¹2,479. He said, At the CMP, the stock is currently trading at PE of 26.9x/22.5xFY24/25E.\"\n\nDrug maker, Dr Reddy's Lab saw a strong growth in Q4 consolidated net profit to â‚¹959.2 crore rising by 10-folds year-on-year, while revenue jumped by 16% YoY to â‚¹6,296.8 crore. However, performance was feeble on quarter-on-quarter basis with PAT and revenue down by 23% and 7% respectively.\n\nYear-on-year revenue growth in Q4FY23 was driven by growth in North America (27% YoY), Europe (12% YoY) and India (32% YoY) markets. However, partially impacted due to a decline of 7% YoY in revenues in Emerging Markets. Sequentially, the revenue dipped due to fall in North America (-17% QoQ), and Emerging Markets (-15% QoQ), partially offset by growth in Europe (15% QoQ growth) and India (14% QoQ growth).\n\nOn Dr Reddy's performance, Prathamesh Masdekar, Research Analyst, Stoxbox said, \"the company reported healthy performance on the back of new launches during the quarter. On the revenue side, the North American business (41% of sales) saw robust growth, led by new product launches, increase in volumes and a favorable forex movement, which was partly offset by price erosion.\"\n\nFurther, he said, \"the company added six products in the US during the quarter which will lead to strong growth in US sales in future. The growth trajectory in India (20% of sales) was driven by favorable price variance, new product launches and non-core brand divestment of non-core brands, partly offset by decline in volumes for certain products. Europe (12% of sales) and emerging market (19% of sales) grew by new product launches and increased volumes.\"\n\nGoing ahead, Masdekar added, \"the company will actively look for other new investment avenues for growth across all the business segments.\"",
            "source": {
                "uri": "livemint.com",
                "dataType": "news",
                "title": "mint"
            },
            "authors": [
                {
                    "uri": "pooja_sitaram_jaiswar@livemint.com",
                    "name": "Pooja Sitaram Jaiswar",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://www.livemint.com/lm-img/img/2023/05/10/600x338/PTI02_01_2021_000109B_1614148644666_1614148663709_1683737197913.jpg",
            "eventUri": "eng-8612295",
            "sentiment": 0.1686274509803922,
            "wgt": 421433940,
            "relevance": 51
        },
        {
            "uri": "7537842549",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "16:55:00",
            "dateTime": "2023-05-10T16:55:00Z",
            "dateTimePub": "2023-05-10T16:21:00Z",
            "dataType": "news",
            "sim": 0.7529411911964417,
            "url": "https://wtop.com/news/2023/05/doctor-reddys-fiscal-q4-earnings-snapshot/",
            "title": "Doctor Reddy's: Fiscal Q4 Earnings Snapshot - WTOP News",
            "body": "HYDERABAD, India (AP) -- HYDERABAD, India (AP) -- Dr. Reddy's Laboratories Ltd. (RDY) on Wednesday reported net income of $117 million in its fiscal fourth quarter.\n\nOn a per-share basis, the Hyderabad, India-based company said it had profit of 70 cents.\n\nThe pharmaceutical posted revenue of $766 million in the period.\n\nFor the year, the company reported profit of $548 million, or $3.30 per share. Revenue was reported as $2.99 billion.\n\n_____\n\nThis story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RDY at https://www.zacks.com/ap/RDY\n\nCopyright Â© 2023 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.",
            "source": {
                "uri": "wtop.com",
                "dataType": "news",
                "title": "WTOP"
            },
            "authors": [],
            "image": null,
            "eventUri": "eng-8609598",
            "sentiment": 0.1215686274509804,
            "wgt": 421433700,
            "relevance": 51
        },
        {
            "uri": "7537844513",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "16:43:00",
            "dateTime": "2023-05-10T16:43:00Z",
            "dateTimePub": "2023-05-10T16:34:00Z",
            "dataType": "news",
            "sim": 0.5529412031173706,
            "url": "https://www.goodreturns.in/news/smbc-aviation-capital-files-appeal-against-nclt-s-decision-granting-go-first-s-voluntary-insolvency-1283144.html",
            "title": "SMBC Aviation Capital Files Appeal Against NCLT's Decision Granting Go First's Voluntary Insolvency Plea",
            "body": "For Quick Alerts Subscribe Now Stay updated with all the happenings around the globe. Click here View Sample For Quick Alerts ALLOW NOTIFICATIONS For Daily Alerts Just In 40 min ago Dr Reddy's Laboratories Q4 Results: Profit Surges By 996%, Dividend Of Rs 40 Per Share Declared 1 hr ago L&T Q4 Results: Reports 10% YoY Growth In Net Profit For March Quarter 1 hr ago Nexus Select Trust REIT IPO Receives 57% Subscription On Day 2 1 hr ago Cisco To Invest In Manufacturing In India, Targeting $1 Billion In Sales Don't Miss Movies Top Bollywood News: The Kerala Story Team Meets UP CM Yogi Adityanath, Karan Deol Spotted With Fiance News Karnataka elections: With 54.53% of voting, Bengalureans disappoint again Sports IPL 2023: Sport would be 'dull' without conflict - Swann on Kohli-Gambhir bust-up Lifestyle Chokkanathaswamy Temple At Domlur: The Vishnu Temple Which Is A Pranic Energy Point Travel Mocha Cyclone: Bengaluru On High Risk Of Urban Flooding, Know The Reason Why? Technology Asus ROG Zephyrus Duo 16 2023 Review: Worth the Price? Automobiles 2023 Bajaj Avenger 220 Street Motorcycle Launched At Rs 1.42 Lakh - Powertrain Updated Education NCHM JEE 2023 Admit Card Released: Download Now from nchmjee.nta.nic.in Home News SMBC Aviation Capital Files Appeal Against NCLT's Decision Granting Go First's Voluntary Insolvency Plea News oi-Ajeeta Bhatia By Ajeeta Bhatia | Published: Wednesday, May 10, 2023, 22:04 [IST]\n\nSMBC Aviation Capital Ltd, a leading aircraft leasing firm on wednesday lodged a challenge with the National Company Law Appellate Tribunal (NCLAT) against the decision made earlier in the day by the National Company Law Tribunal (NCLT) that granted Go First's request to begin insolvency proceedings voluntarily.\n\nThe legal counsel of SMBC Aviation Capital quickly approached the NCLAT after the NCLT granted Go First's plea and presented the request before a bench presided by Chairman Justice Ashok Bhushan.\n\nThe action was taken in response to the NCLT's prohibition on lessors returning their aircraft to Go First, which prompted legal action by a number of the airline's lessors, notably SMBC Aviation Capital.\n\nThe NCLAT Chairman instructed to list the matter for hearing on Thursday after listening to the aircraft lessor. The hearing for SMBC Aviation Capital's appeal is scheduled for Thursday before the two-member bench made up of Justice Ashok Bhushan and Barun Mitra, according to the cause list.\n\nSeveral aircraft lessors have contacted the DGCA, the aviation authority, in the last week to request the deregistration and repossession of 45 Go First aircraft. These actions come after several lessors, including SMBC Aviation Capital Ltd, Narmada Aviation Leasing, Yamuna Aviation Leasing, GAL MSN, and GY Aviation Lease, expressed their opposition to Go First's petition during a hearing at the NCLT last week.\n\nThe lessors also indicated their intent to file an application under Section 65 of the Insolvency and Bankruptcy Code (IBC) in response to what they deemed as fraudulent or malicious initiation of proceedings.\n\nAccording to a statement made by the NCLT on Wednesday, there is \"no bar in entertaining/ considering/ adjudicating\" a Section 65 application following the start of the insolvency resolution process. \"Keeping in mind the urgency of the instant case, to protect and maximise the value of the assets in line with the objectives of the IBC, employment involved, and the larger public interest, the judicial propriety demands, it will not be apt to wait for the filing of the Section 65 application,\" the NCLT said.\n\nGo First halted operating as of May 3, and the aviation watchdog DGCA on Monday ordered the airline to halt ticket sales pending further instructions. Earlier in the day, the NCLT's Delhi-based principal bench suspended the board of Go First and assigned an interim resolution specialist to handle its business.\n\nMORE NCLT NEWS NCLT Grants Go First's Request For Moratorium And Insolvency Proceedings Indiabulls Real Estate Shares Decline 20% As NCLT Rejects Merger With Embassy Group Spicejet Lessors Seek Deregistration Of Four Aircraft: Report Go First Crisis: Wadia Group May Push For One-Time Settlement Lessors Oppose Go First's Plea And Request DGCA To Deregister 20 Aircraft Go First Insolvency: What Has Transpired So Far? DGCA Orders Go First To Refund Passengers Go First Seeks Out NCLT For Directions To Deal With The Crisis Go First Suspends Flights To File For Voluntary Insolvency With NCLT NCLT Grants 90 Days Extension For Concluding Insolvency To Future Retail NCLT Extends Insolvency Resolution Process, For Srei Infra Till Jan 5 NCLT Says It Did Not Issue Notification, On Hearing Urgent Matters For investment related articles, business news and mutual fund advise Allow Notifications You have already subscribed Story first published: Wednesday, May 10, 2023, 22:04 [IST] Other articles published on May 10, 2023",
            "source": {
                "uri": "goodreturns.in",
                "dataType": "news",
                "title": "https://www.goodreturns.in/"
            },
            "authors": [
                {
                    "uri": "ajeeta_bhatia@goodreturns.in",
                    "name": "Ajeeta Bhatia",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://www.goodreturns.in/img/2023/05/gofirst-1683632752.jpg?10052023220748",
            "eventUri": "eng-8609091",
            "sentiment": 0.4274509803921569,
            "wgt": 421432980,
            "relevance": 51
        },
        {
            "uri": "7537305311",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "15:59:00",
            "dateTime": "2023-05-10T15:59:00Z",
            "dateTimePub": "2023-05-10T10:56:00Z",
            "dataType": "news",
            "sim": 0.7803921699523926,
            "url": "https://www.indiatoday.in/business/story/stock-market-closing-sensex-nifty-gain-financial-stocks-recover-investors-inflation-data-2377317-2023-05-10",
            "title": "Sensex, Nifty gain as financial stocks rebound; investors await key inflation data",
            "body": "By Koustav Das: Benchmark stock market indices ended Wednesday's trading session with gains as financial stocks rebounded. While investors are waiting for key inflation data due on Friday, it seems the mood remains upbeat in the wake of strong Q4 earnings.\n\nThe S&P BSE Sensex closed 178.87 points higher at 61,940.20, while the NSE Nifty ended 49.15 points higher to settle at 18,315.10. Broader market indices also witnessed a strong recovery, led by an improvement in sentiments.\n\nMost sectoral indices recovered after falling in early trade, with a strong rebound in Nifty Bank and Nifty Financial Services stock. Nifty Realty, Nifty Auto, Nifty FMCG and Nifty Oil & Gas also gained.\n\nThe top five gainers on the Nifty 50 were IndusInd Bank, HDFC Life, Power Grid Corporation, Tata Motors and BPCL. On the other hand, the top drags were UPL, Dr Reddy's Laboratories, Infosys, Hindalco and Sun Pharma.\n\nSome analysts attributed the volatility in the domestic market to profit booking after both benchmarks witnessed strong gains in recent sessions, supported by robust Q4 earnings.\n\nAt the same time, investors have turned cautious as global markets declined in the wake of US consumer prices and domestic retail inflation data.\n\nA poll of economists conducted by news agency Reuters indicated that retail inflation in April could fall below 5 per cent, thus remaining within the RBI's upper tolerance limit for the second consecutive month.\n\nThe consumer price index-based inflation data for April will be released on Friday.",
            "source": {
                "uri": "indiatoday.in",
                "dataType": "news",
                "title": "India Today"
            },
            "authors": [],
            "image": "https://akm-img-a-in.tosshub.com/indiatoday/images/story/202305/stock-market-closing-bell_0-sixteen_nine.png?VersionId=1FkwixKqxzqs9sugGn62h0JLsb_oJJtl",
            "eventUri": "eng-8612261",
            "sentiment": 0.5529411764705883,
            "wgt": 421430340,
            "relevance": 1
        },
        {
            "uri": "7537367264",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "15:45:00",
            "dateTime": "2023-05-10T15:45:00Z",
            "dateTimePub": "2023-05-10T11:38:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.rttnews.com/3362985/sensex-nifty-shrug-off-weak-global-cues-to-end-higher.aspx",
            "title": "Sensex, Nifty Shrug Off Weak Global Cues To End Higher ",
            "body": "Indian shares recovered from an early slide to end modestly higher on Wednesday.\n\nA cautious undertone prevailed as investors positioned for the April U.S. consumer price inflation data due out later in the day that could determine the Federal Reserve's next interest rate decision.\n\nMarkets were also monitoring the developments of the U.S. debt ceiling after a high stakes meeting between U.S. President Joe Biden and key lawmakers from both parties on Tuesday yielded no breakthrough.\n\nThe U.S. government could start to run out of money if Congress does not act in three weeks.\n\nThe benchmark S&P BSE Sensex ended the session up 178.87 points, or 0.29 percent, at 61,940.20, with gains in rupee and a reversal in oil prices offering some support.\n\nOil prices fell more than 1 percent in European trade to snap a three-day rally after industry data showed a surprise build in U.S. crude and gasoline stockpiles.\n\nThe broader NSE Nifty index settled 49.15 points, or 0.27 percent, higher at 18,315.10, led by financials.\n\nIndusInd Bank topped the gainers list to close 2.8 percent higher while BPCL, Tata Motors, Power Grid Corp and HDFC Life added 1-2 percent.\n\nOn the losing side, UPL lost 2 percent and Dr Reddy's Laboratories gave up 1.3 percent.\n\nFor comments and feedback contact: editorial@rttnews.com",
            "source": {
                "uri": "rttnews.com",
                "dataType": "news",
                "title": "RTTNews"
            },
            "authors": [],
            "image": "https://cdn.rttnews.com/images/v4/RTTNews-logo-512x512.png",
            "eventUri": null,
            "sentiment": 0.05098039215686279,
            "wgt": 421429500,
            "relevance": 1
        },
        {
            "uri": "7536910906",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "15:38:00",
            "dateTime": "2023-05-10T15:38:00Z",
            "dateTimePub": "2023-05-10T05:59:00Z",
            "dataType": "news",
            "sim": 0.5372549295425415,
            "url": "https://www.thehindubusinessline.com/news/dr-reddys-likely-to-post-20-22-growth-in-q4-net/article66833459.ece",
            "title": "Dr Reddy's likely to post 20-22% growth in Q4 net ",
            "body": "Pharma major Dr Reddy's Laboratories will declare the numbers for the fourth quarter ended March 2023 and for the full year FY23 today.\n\nAnalysts expect the Hyderabad-based company to post a year-on-year growth of 20-22 per cent and 10-12 per cent in net profit and revenue, respectively, for the fourth quarter of FY23.\n\nDr Reddy's scrip opened to trade at â‚¹4,900 on the BSE on Wednesday after a previous close at â‚¹4,390.55.\n\nAlso read:How are healthcare companies faring as Covid-19 ebbs?\n\nDr Reddy's Laboratories' consolidated net profit declined 76 per cent at â‚¹88 crore in the fourth quarter ended March 31, 2022, compared with â‚¹362 crore in the corresponding quarter of previous financial year on a 15 per cent revenue growth at â‚¹5,437 crore, as per IFRS\n\nFor the full year ended March 31, 2022, Dr Reddy's posted a 37 per cent increase in net profit at â‚¹2,357 crore on a revenue of â‚¹21,439 crore, which increased by 13 per cent over the previous year's revenue of â‚¹18,972 crore.\n\nIn the fourth quarter of FY23, the company was not impacted in Russia despite the Russia-Ukraine war, but saw some impact overall.\n\nAlso read:Russia woos Indian pharma companies in effort to give its economy a boost\n\nThe impact of geopolitical challenges, which lasted the whole of FY23, needs to be seen on the company's performance in the emerging markets.\n\nSHARE Copy linkEmailFacebookTwitterTelegramLinkedInWhatsAppRedditPublished on May 10, 2023",
            "source": {
                "uri": "thehindubusinessline.com",
                "dataType": "news",
                "title": "@businessline"
            },
            "authors": [],
            "image": "https://bl-i.thgim.com/public/incoming/8815p3/article66833684.ece/alternates/LANDSCAPE_1200/IMG_iStock-1160000507_2_1_M39AQI3K.jpg",
            "eventUri": "eng-8612295",
            "sentiment": 0.3568627450980393,
            "wgt": 421429080,
            "relevance": 75
        },
        {
            "uri": "7536900064",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "15:29:00",
            "dateTime": "2023-05-10T15:29:00Z",
            "dateTimePub": "2023-05-10T05:51:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "http://risingkashmir.com/sensex-loses-71-points-amid-weak-global-cues-in-morning-trade-cb479c06-9a73-4c47-8522-54574182351a",
            "title": "Sensex loses 71 points amid weak global cues in morning trade ",
            "body": "The key benchmark of the equity domestic markets opened with losses on Wednesday morning, tracking weak global cues. Better-than-expected corporate earnings haven't still lifted the investors' moods. Data on US inflation is expected later in the day which would impact the future course of interest rates across the world. Meanwhile, investors are in a \"wait-and-watch\" mode.\n\nBSE Sensex went down 71 points to 61,689.38 and NSE Nifty lost 21 points to 18,244.35 in morning trade.\n\nThe top gainers on Nifty 50 were IndusInd Bank, Tata Motors, Power Grid, Bajaj Auto and HCL Tech while the losers were UPL, Dr Reddy, SBIN, Grasim and Adani Ports. In Asian markets, Hong Kong's Hang Seng went down 133 points, Japan's Nikkei lost 129 points, China's Shanghai went down 46 points and Thailand SET dropped 1 point as domestic markets opened on Wednesday.\n\nIn the US markets, Dow Jones lost 56 points, S-P 500 went down 18 points, Nasdaq dropped 77 points and NYSE declined 38 points.\n\nIn European markets, Amsterdam Exchange, BEL, CAC and Deutsche Borse were trading in the positive territory, FTSE lost 14 points and Madrid was also in the positive territory.\n\nRupee rose 5 paise to 82.01 against the US dollar in early trade on Wednesday. On Tuesday, On May 9, the Reserve Bank of India (RBI) said fees and charges payable in India on forex prepaid cards, store value cards, and travel cards must be denominated and settled in local currency.\n\nLarsen and Toubro, Dr Reddy's Laboratories, Godrej Consumer Products, Bosch, Procter & Gamble Hygiene, Escorts Kubota, Sanofi India, and Max Financial Services, and several others are scheduled to release their March quarter earnings on Wednesday. (ANI)",
            "source": {
                "uri": "risingkashmir.com",
                "dataType": "news",
                "title": "Rising Kashmir"
            },
            "authors": [],
            "image": "http://admin.risingkashmir.com/Source/News/2e5024ea-abe0-4185-b5e0-fad1df3e2fa8.jpg",
            "eventUri": null,
            "sentiment": -0.003921568627450966,
            "wgt": 421428540,
            "relevance": 1
        },
        {
            "uri": "7536900061",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "14:52:00",
            "dateTime": "2023-05-10T14:52:00Z",
            "dateTimePub": "2023-05-10T05:51:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "http://risingkashmir.com/sensex-loses-71-points-amid-weak-global-cues-in-morning-trade-cb479c06-9a73-4c47-8522-54574182351a",
            "title": "Sensex loses 71 points amid weak global cues in morning trade ",
            "body": "The key benchmark of the equity domestic markets opened with losses on Wednesday morning, tracking weak global cues. Better-than-expected corporate earnings haven't still lifted the investors' moods. Data on US inflation is expected later in the day which would impact the future course of interest rates across the world. Meanwhile, investors are in a \"wait-and-watch\" mode.\n\nBSE Sensex went down 71 points to 61,689.38 and NSE Nifty lost 21 points to 18,244.35 in morning trade.\n\nThe top gainers on Nifty 50 were IndusInd Bank, Tata Motors, Power Grid, Bajaj Auto and HCL Tech while the losers were UPL, Dr Reddy, SBIN, Grasim and Adani Ports. In Asian markets, Hong Kong's Hang Seng went down 133 points, Japan's Nikkei lost 129 points, China's Shanghai went down 46 points and Thailand SET dropped 1 point as domestic markets opened on Wednesday.\n\nIn the US markets, Dow Jones lost 56 points, S-P 500 went down 18 points, Nasdaq dropped 77 points and NYSE declined 38 points.\n\nIn European markets, Amsterdam Exchange, BEL, CAC and Deutsche Borse were trading in the positive territory, FTSE lost 14 points and Madrid was also in the positive territory.\n\nRupee rose 5 paise to 82.01 against the US dollar in early trade on Wednesday. On Tuesday, On May 9, the Reserve Bank of India (RBI) said fees and charges payable in India on forex prepaid cards, store value cards, and travel cards must be denominated and settled in local currency.\n\nLarsen and Toubro, Dr Reddy's Laboratories, Godrej Consumer Products, Bosch, Procter & Gamble Hygiene, Escorts Kubota, Sanofi India, and Max Financial Services, and several others are scheduled to release their March quarter earnings on Wednesday. (ANI)",
            "source": {
                "uri": "risingkashmir.com",
                "dataType": "news",
                "title": "Rising Kashmir"
            },
            "authors": [],
            "image": "http://admin.risingkashmir.com/Source/News/2e5024ea-abe0-4185-b5e0-fad1df3e2fa8.jpg",
            "eventUri": null,
            "sentiment": -0.003921568627450966,
            "wgt": 421426320,
            "relevance": 1
        },
        {
            "uri": "7537457889",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "14:52:00",
            "dateTime": "2023-05-10T14:52:00Z",
            "dateTimePub": "2023-05-10T12:37:00Z",
            "dataType": "news",
            "sim": 0.6039215922355652,
            "url": "https://www.livemint.com/companies/news/dr-reddys-q4-firm-declares-dividend-of-rs-40-check-details-here-11683720865233.html",
            "title": "Dr Reddy's Q4: Firm declares dividend of  â‚¹40, check details here",
            "body": "The final dividend will be paid on or after five days from the date of declaration of the final dividend by the shareholders at the annual general meeting.\n\n\"Recommended a final dividend of Rs. 40/- (800%) per equity share of Rs. 5/- each for the financial year 2022-23. The dividend will be paid on or after five days from the date of declaration of the final dividend by the shareholders at the 39th Annual General Meeting (AGM),\" said Dr Reddy's in its regulatory filing.\n\nIn the last one year, Dr Reddy's Laboratories has declared an equity dividend of 600 per cent amounting to â‚¹30 per share. At the current share price this results in a dividend yield of 0.62 per cent.\n\nDr Reddy's Laboratories recorded a manifold rise in its net profit to â‚¹959.2 crore for the quarter ended March 31, from â‚¹87.5 crore in the same period last year.\n\nHowever, sequentially, the PAT witnessed a decline as against â‚¹1,243.9 crore in Q3FY23.\n\nThe revenue from operations rose 15.81 percent year-on-year to â‚¹6296.8 crore, up from â‚¹5,436.8 crore in Q4 of FY22.\n\nSales from the generic of Revlimid and new launches were the key contributors to the strong traction in the US market. The domestic formulations business also aided revenues as it posted double-digit growth.",
            "source": {
                "uri": "livemint.com",
                "dataType": "news",
                "title": "mint"
            },
            "authors": [
                {
                    "uri": "jyoti_banthia@livemint.com",
                    "name": "Jyoti Banthia",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://www.livemint.com/lm-img/img/2023/05/10/600x338/2-0-111908453-Reddys-lab1-4C-0_1681807251897_1683721888280.jpg",
            "eventUri": "eng-8610380",
            "sentiment": 0.1529411764705881,
            "wgt": 421426320,
            "relevance": 51
        },
        {
            "uri": "7537543603",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "14:50:00",
            "dateTime": "2023-05-10T14:50:00Z",
            "dateTimePub": "2023-05-10T13:34:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.kitco.com/news/2023-05-10/Indian-shares-edge-higher-amid-earnings-rush-eye-on-key-US-data.html",
            "title": "Indian shares edge higher amid earnings rush; eye on key US data",
            "body": "BENGALURU, May 10 (Reuters) - Indian shares advanced on Wednesday as investors parsed through a slate of major corporate earnings and looked ahead to U.S. inflation data.\n\nThe Nifty 50 (.NSEI) closed 0.27% higher at 18,315.10, while the S&P BSE Sensex (.BSESN) gained 0.29% to 61,940.20. The benchmarks swung between gains of 0.3% and losses of 0.3% during the session.\n\nHigh-weightage financials (.NIFTYFIN) led gains in the Nifty, reversing intraday losses to end 0.32% higher. Fast-moving consumer goods (.NIFTYFMCG) index gained over 0.5%.\n\n\"Investors have resorted to selective profit-taking after a sharp spike in the recent sessions,\" said Shrikant Chouhan, head of equity research (retail) at Kotak Securities.\n\n\"The Nifty 50 has formed a small bearish candle in the daily charts, which indicates indecisiveness.\"\n\nMeanwhile, global equities declined ahead of U.S. consumer prices data and on disappointing company forecasts. Investors will focus on U.S. inflation data for potential cues into the Federal Reserve's future rate-hike path. Asian markets were subdued.\n\nAmong individual stocks, private lender IndusInd Bank Ltd (ICBK.NS) rose nearly 3% and was the top Nifty 50 gainer after global brokerage UBS upgraded the stock to \"buy\" from \"neutral\", citing stable operating metrics.\n\nShares of Shipping Corporation of India Ltd (SCI.NS) jumped over 5% after the company reported a rise in quarterly profit.\n\nAgri-business firm Godrej Agrovet Ltd (GODE.NS) lost 3.57% after posting a 75% slide in net profit.\n\nShares of PTC India Ltd (PTCI.NS) and PTC India Financial Services Ltd (PTCN.NS) lost 0.16% and 4.50%, respectively, after Reuters reported that the market regulator issued legal notices to the firms, demanding explanations for alleged lapses in corporate governance.\n\nOn the earnings front, Larsen & Toubro Ltd (LART.NS), Dr Reddy's Laboratories Ltd (REDY.NS), Bosch Ltd (BOSH.NS), Godrej Consumer Products Ltd (GOCP.NS) are among companies scheduled to report their quarterly results post market hours on Wednesday.\n\nReporting by Bharath Rajeswaran in Bengaluru; Editing by Sonia Cheema",
            "source": {
                "uri": "kitco.com",
                "dataType": "news",
                "title": "Kitco.com"
            },
            "authors": [],
            "image": "https://www.kitco.com/news/images/reuters/Reuters_235x147_V4.jpg",
            "eventUri": null,
            "sentiment": 0.2,
            "wgt": 421426200,
            "relevance": 1
        },
        {
            "uri": "7537614154",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "14:49:00",
            "dateTime": "2023-05-10T14:49:00Z",
            "dateTimePub": "2023-05-10T13:58:00Z",
            "dataType": "news",
            "sim": 0.7568627595901489,
            "url": "https://www.latestly.com/agency-news/latest-news-low-base-effect-dr-reddys-pat-zooms-nine-fold-to-959-cr-in-q4-5117355.html",
            "title": "Latest News | Low Base Effect: Dr Reddy's PAT Zooms Nine Fold to 959 Cr in Q4 | LatestLY",
            "body": "Hyderabad, May 10 (PTI): Dr Reddy's Laboratories Ltd on Wednesday reported multifold growth (996 per cent) in its consolidated profit after tax to Rs 959.2 crore due to low base during the same quarter previous year.\n\nAlso Read | The Kerala Story: Is Adah Sharma's Film Inspired by 'Caliphate'? All You Need to Know About Netflix Swedish Series That is Going Viral With This Claim.\n\nIt was 87.5 crore in the January-March period of FY22.\n\nAlso Read | Cyclone Mocha Latest Update: Depression Over Southeast Bay of Bengal Likely To Intensify Into Cyclonic Storm, Says IMD.\n\nParag Agarwal, Chief Financial Officer of Dr Reddy's, said Revenues for the quarter under discussion was up by 25 per cent to Rs 6,297 crore on the back of strong growth from North America, Europe and Indian markets, against Rs 5,437 crore in Q4 of last fiscal.\n\nFor the full financial year PAT stood at Rs 4507 crore against Rs 2357 crore, a growth of 91 per cent while revenues during the last fiscal was up by 15 per cent to Rs 24, 588 crore against Rs 21439 crore\n\nin FY22.\n\n\"This (FY23) has been a record year for us with a double digit growth in revenues as well as profits. Our revenue growth has been supported by new product launches and we have seen strong underlying growth momentum in all our businesses,\" Agarwal told reporters in a press conference.\n\nHe further said the strong financial performance reflected in strong cash flows. The drug maker currently has over Rs 5000 crore cash surplus in the Balance Sheet.\n\nThe Board has recommended payment of a dividend of Rs. 40 per equity share of face value Rs 5 each (800 per cent of face value) for the year ended March 31, 2023 subject to approval of the shareholders of the company.\n\nThe revenues from global generics during the fourth quarter stood at Rs. 2530 crore a YoY growth of 27 per cent. Dr Reddy's during the quarter, launched six new products taking the total launches of the year to 25 products.\n\nSales from India witnessed 17 per cent growth at Rs 1,280 crore attributable to increase in prices of the existing products, along with additional revenues from the launch of new products.\n\nEurope revenues in Q4 stood at Rs 500 crore with 15 per cent growth while emerging markets contributed Rs 1,110 crore in the fourth quarter up seven per cent compared to the same period in FY22.\n\nThe Pharmaceutical Services and Active Ingredients (PSAI) segment revenues were up three per cent to Rs 778 crore against Rs 756 crore in Q4 of FY22.\n\nThe company spent Rs 1940 crore on Research and Development expenses in FY23 and is expected to spend 8-9 per cent on total sales in the current fiscal, Agarwal said.\n\nThe official said during the last fiscal Dr Reddy's made a significant progress on Rituximab with filings done in USA, Europe and UK and as far as Tocilizumab is concerned Phase-3 studies began.",
            "source": {
                "uri": "latestly.com",
                "dataType": "news",
                "title": "LatestLY"
            },
            "authors": [],
            "image": "https://st1.latestly.com/wp-content/uploads/2018/03/default-img-01-781x441.jpg",
            "eventUri": "eng-8609368",
            "sentiment": 0.3960784313725489,
            "wgt": 421426140,
            "relevance": 51
        },
        {
            "uri": "7537609964",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "14:34:00",
            "dateTime": "2023-05-10T14:34:00Z",
            "dateTimePub": "2023-05-10T14:12:00Z",
            "dataType": "news",
            "sim": 0.7215686440467834,
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/indias-dr-reddys-labs-posts-11-fold-jump-q4-profit-2023-05-10/",
            "title": "India's Dr Reddy's Labs posts 11-fold jump in Q4 profit",
            "body": "BENGALURU, May 10 (Reuters) - Indian drugmaker Dr Reddy's Laboratories Ltd (REDY.NS) reported nearly an eleven-fold surge in fourth-quarter profit on Wednesday, driven by higher sales from its mainstay generic drugs business in North America.\n\nThe Hyderabad-based company's consolidated profit rose to 9.59 billion rupees in the three months ended March 31, compared with 875 million rupees a year earlier.\n\nThe profit, however, missed analysts' expectations of 9.74 billion rupees, according to Refinitiv IBES data.\n\nRevenue from its generic business in North America, the company's biggest market accounting for almost half of its total sales, jumped 27% to 25.32 billion rupees, on the back of new launches and scaling up of existing products. In India, its revenue from generic drugs business climbed 32%.\n\nDr Reddy's consolidated revenue jumped 15.8% to 62.97 billion rupees, while total operating expenses fell 13.3%.\n\nThe company also recommended a final dividend of 40 rupees per share for the financial year 2023.\n\nShares of the company settled 1.3% down at 4,867 rupees on Wednesday ahead of the earnings. They have advanced 14.9% so far this year, outperforming the Nifty pharma index (.NIPHARM) which was up 0.95%.",
            "source": {
                "uri": "reuters.com",
                "dataType": "news",
                "title": "Reuters"
            },
            "authors": [
                {
                    "uri": "reuters@reuters.com",
                    "name": "Reuters",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://www.reuters.com/pf/resources/images/reuters/reuters-default.webp?d=141",
            "eventUri": "eng-8612623",
            "sentiment": 0.2627450980392156,
            "wgt": 421425240,
            "relevance": 51
        },
        {
            "uri": "7537594841",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "14:16:00",
            "dateTime": "2023-05-10T14:16:00Z",
            "dateTimePub": "2023-05-10T14:02:00Z",
            "dataType": "news",
            "sim": 0.47843137383461,
            "url": "https://www.thehindubusinessline.com/companies/dr-reddys-q4-net-profit-soars-to-959-crore/article66835131.ece",
            "title": "Dr Reddy's Q4 net profit soars to â‚¹959 crore",
            "body": "Pharma major Dr Reddy's Laboratories' net profit increased manifold to â‚¹959 crore in the fourth quarter ended March 31, 2023 as against â‚¹88 crore in the same period last year.\n\nThe total revenue of the Hyderabad-based company grew 16 per cent at â‚¹6,297 crore as against â‚¹5,436 crore. For the full year, the company's net profit increased 18.3 per cent to â‚¹4,507 crore as against â‚¹2,356 crore while the revenue increased 15 per cent at â‚¹24,588 crore (â‚¹21,438 crore).\n\n\"This year (FY23) has been a record year for us in terms of sales and profit driven by new product launches and good performance by all business segments,'' Parag Agarwal, Chief Financial Officer, Dr Reddy's told newspersons on Wednesday.\n\nGlobal growth\n\nDuring the year under review, revenue for the global generics segment grew 19 per cent over previous year driven by North America, Europe and India, while emerging markets remained flat.\n\nThe North America Generics business recorded YoY growth of 36 per cent. \"The growth was contributed by new launches, scale up of existing products and favorable forex rates movement, which was partially offset by price erosion,'' the CFO said. Revenue from Europe grew by 6%.\n\n\"The sales in the domestic market registered 17 per cent growth primarily attributable to increase in prices of our existing products, along with additional revenues from the launch of new products,'' he said. The growth was also aided by divestment of a few non-core brands during the year. The drug maker launched 9 new brands in India.\n\nFY23 revenue from Emerging Markets remained flat over the previous year. Revenue from Russia for the year at â‚¹21.2 billion, YoY growth of 2 per cent impacted due to higher\n\nRobust product pipeline\n\nDuring the year, the company filed 12 new Abbreviated New Drug Applications (ANDAs) with the US Food and Drug Administration (USFDA). As of March 31, 2023, cumulatively 86 generic filings are pending approval with the USFDA (81 ANDAs and 5 NDAs under 505(b)(2) route). Out of the pending 86 ANDAs, 45 are Para IVs, and 18 are believed to have 'First to File' status.\n\n\"The R&D expenditure was at 9 per cent of sales during FY23 and we expect it to be in the same range for the current financial year too,'' Agarwal said.\n\nAccording to the Erez Israel, CEO, the company would continue its focus on building a robust product pipeline of biosimilars and generics besides driving productivity, among others.\n\nThe board recommended a final dividend of â‚¹40 (800 per cent) per equity share of â‚¹5 each for the financial year 2022-23. Dr Reddy's scrip lost 1.27 per cent on the Bombay Stock Exchange (BSE) on Wednesday to end at â‚¹4,868.\n\nSHARE Copy linkEmailFacebookTwitterTelegramLinkedInWhatsAppRedditPublished on May 10, 2023",
            "source": {
                "uri": "thehindubusinessline.com",
                "dataType": "news",
                "title": "@businessline"
            },
            "authors": [],
            "image": "https://bl-i.thgim.com/public/portfolio/news-analysis/kb3zj9/article32970216.ece/alternates/LANDSCAPE_1200/BL30DRL",
            "eventUri": "eng-8612295",
            "sentiment": 0.4509803921568627,
            "wgt": 421424160,
            "relevance": 51
        },
        {
            "uri": "7537439889",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-10",
            "time": "14:15:00",
            "dateTime": "2023-05-10T14:15:00Z",
            "dateTimePub": "2023-05-10T12:26:00Z",
            "dataType": "news",
            "sim": 0.4823529422283173,
            "url": "https://www.bqprime.com/business/dr-reddys-q4-results-profit-down-1-misses-estimates",
            "title": "Dr. Reddy's Q4 Results: Profit Flat, Misses Estimates",
            "body": "Dr. Reddy's Laboratories Ltd. reported a 1% fall in its net profit during the fourth quarter of fiscal 2023, missing analyst estimates.The Hyderabad-based drugmaker's profit stood at Rs 960 crore in the quarter ended March, 1% lower than the previous year, according to its exchange filing. That compares with the Rs 1,034 crore consensus estimate of analysts tracked by Bloomberg.Sequentially, the profit fell 23%.Dr. Reddy's Q4 FY23 Hi...\n\nDr. Reddy's Laboratories Ltd. reported a 1% fall in its net profit during the fourth quarter of fiscal 2023, missing analyst estimates.\n\nThe Hyderabad-based drugmaker's profit stood at Rs 960 crore in the quarter ended March, 1% lower than the previous year, according to its exchange filing. That compares with the Rs 1,034 crore consensus estimate of analysts tracked by Bloomberg.\n\nThe board has recommended a dividend of Rs 40 per share.\n\n\"FY23 has been a year of record sales, profits and cash flow, driven by our performance in US Generics. We will continue to deliver on our purpose, invest in growth drivers and promote a culture that is innovative and collaborative, ensuring the future of our business,\" said GV Prasad, co-chairman and managing director at Dr. Reddy's, in the exchange filing.",
            "source": {
                "uri": "bqprime.com",
                "dataType": "news",
                "title": "BQ"
            },
            "authors": [
                {
                    "uri": "monal_sanghvi@bqprime.com",
                    "name": "Monal Sanghvi",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://gumlet.assettype.com/bloombergquint%2F2023-05%2Fe5d5daac-523f-4f69-a6ad-2245b56b9e9a%2FDr__Reddy_s_2__1___1_.png?w=1200&auto=format%2Ccompress&ogImage=true",
            "eventUri": "eng-8609368",
            "sentiment": 0.3568627450980393,
            "wgt": 421424100,
            "relevance": 100
        },
        {
            "uri": "7536686427",
            "lang": "eng",
            "isDuplicate": true,
            "date": "2023-05-10",
            "time": "06:20:00",
            "dateTime": "2023-05-10T06:20:00Z",
            "dateTimePub": "2023-05-10T01:24:00Z",
            "dataType": "news",
            "sim": 0.7098039388656616,
            "url": "https://www.businesstelegraph.co.uk/mankind-pharma-rallies-32-on-day-1/",
            "title": "Mankind Pharma rallies 32% on day 1",
            "body": "Mumbai: Mankind Pharma made a strong stock market debut on Tuesday with the stock listing 20% above its initial public offering price of â‚¹1,080. The stock, which listed at â‚¹1,300 apiece, ended at â‚¹1,424, nearly 32% higher than the offer price. Analysts remain bullish about the stock's prospects but recommend traders locking in profits for now.\n\nAt Tuesday's closing price, Mankind Pharma was valued at a price-to-earnings ratio of 43 times its FY22 earnings. Mankind is now India's fifth largest pharma company by market value of â‚¹57,046 crore. Sun Pharma, Divi's Lab, Dr. Reddy's Lab, and Cipla are currently valued between â‚¹75,284 crore and â‚¹2.31 lakh crore.\n\nThe â‚¹4,326-crore public issue of Mankind Pharma - the biggest IPO in 2023 so far- was subscribed 15.32 times. It was an offer for sale (OFS) by existing shareholders.\n\nThe IPO was the largest ever by a domestic drug maker since Gland Pharma came up with its â‚¹6,480 crore public issue in November 2020.\n\n\"The healthcare sector was a laggard over the last one year but started seeing traction over the last two months as the monthly pharma data showed improvement. Mankind received a good response from its anchor clients given its domestic-focused business with strong brand recall in chronic and consumer healthcare segments,\" said Hemang Jani, head of equity strategy at Motilal Oswal Financial Services.\n\nREAD SOURCE",
            "source": {
                "uri": "businesstelegraph.co.uk",
                "dataType": "news",
                "title": "Business Telegraph"
            },
            "authors": [],
            "image": "https://usercontent.one/wp/www.businesstelegraph.co.uk/wp-content/uploads/2023/05/Mankind-Pharma-rallies-32-on-day-1.jpg?media=1683224819",
            "eventUri": null,
            "sentiment": 0.3176470588235294,
            "wgt": 421395600,
            "relevance": 26
        },
        {
            "uri": "7535393730",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-09",
            "time": "20:25:00",
            "dateTime": "2023-05-09T20:25:00Z",
            "dateTimePub": "2023-05-09T06:14:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.inventiva.co.in/trends/biotechnology-companies-in-india-2023/",
            "title": "Top 10 Best Biotechnology Companies In India In 2023 - Inventiva",
            "body": "Biotechnology is a rapidly growing field in India, with the government investing heavily in research and development. In 2023, there are a number of biotechnology companies doing business in India. Some of the leading players in this field include Bharat Biotech, Genotypic Technologies, Panacea Biotec, Biological E, Biocon, Intas Pharmaceuticals, Aurobindo Pharma, Cipla, Dr Reddy's Laboratories, and Wockhardt.\n\nThese companies are engaged in various activities such as drug discovery, biopharmaceutical manufacturing, diagnostics, clinical trials, and healthcare services. These companies have strong research capabilities, which have enabled them to develop products that can tackle some of the most pressing public health issues.\n\nThey also strive to offer cutting-edge technologies and innovative drug delivery systems. Additionally, many of these companies are now focusing on patenting their new drugs and launching them in the market in an efficient and cost-effective manner.\n\nIMPORTANCE\n\nBiotechnology companies in India have become increasingly important in 2023 due to the rapid advances in science and technology. This has led to a surge of biotechnology companies sprouting up in India, creating numerous jobs and opportunities for growth. India's biotechnology industry has become an important part of the country's economy and is expected to grow significantly in the coming years.\n\nThe biotechnology sector in India is heavily focused on research and development, as well as finding innovative solutions to global health problems. Many Indian biotechnology companies are dedicated to creating cutting-edge treatments for diseases such as cancer and HIV/AIDS, which have been significant public health challenges for decades.\n\nAdditionally, biotechnology companies in India are developing novel approaches to tackle climate change and environmental degradation by researching ways to create sustainable and renewable energy sources.\n\nBiotechnology is also gaining attention in the agricultural sector, with many biotechnology companies working to develop improved varieties of crops, livestock, and other plant and animal products.\n\nThese efforts have already yielded successful results in terms of improving crop yields, reducing the use of chemical fertilizers, and increasing food security in India. Furthermore, biotechnology companies in India are exploring ways to introduce more efficient and cost-effective methods of food production.\n\nIn addition to their innovative contributions to agriculture and healthcare, biotechnology companies in India are also playing a major role in the industrial sector. By investing in research, development, and manufacturing, biotech firms in India are helping to drive the growth of the country's economy.\n\nThis is especially true in the pharmaceutical industry, where biotechnological advancements are being used to create new, effective medicines.\n\nOverall, biotechnology companies in India have become a vital component of the country's economy in 2023, contributing to numerous areas, including health, agriculture, industrial development, and environmental protection.\n\nBiocon - Biocon is a leading biopharmaceutical company headquartered in Bengaluru, India. Founded in 1978 by Kiran Mazumdar-Shaw, it has grown to become one of the world's most respected companies, with more than 10,000 employees in India, the United States, Europe and Asia Pacific.\n\nThe company is focused on developing and commercializing innovative biologics, drugs, and insulin delivery systems, as well as providing contract research services to the pharmaceutical, nutraceutical and biotechnology industries.\n\nBiocon is focused on discovering, developing and delivering affordable, high-quality biopharmaceuticals to patients around the world. It invests heavily in research and development and has an extensive portfolio of approved and investigational drugs across different therapeutic areas. The company also has proprietary technologies in glycoprotein engineering, monoclonal antibodies and peptide chemistry.\n\nBiocon's products are used in the treatment of cancer, immunological and metabolic diseases, women's health and cardiovascular diseases. It has strategic collaborations with some of the leading global pharma companies like Mylan, Eli Lilly, and Teva Pharma, among others, for the development and commercialization of its products. In addition, Biocon also provides contract research services to the global healthcare industry.\n\nThe company has a presence in over 75 countries and has more than 100 manufacturing facilities across the world. It also has several subsidiaries, such as Syngene International Ltd, Biocon Biologics Ltd and Clinigene International Ltd. Biocon was listed on the National Stock Exchange of India in 2004.\n\nCipla - Cipla is a global pharmaceutical company based in India. Founded in 1935, Cipla has grown to become one of the world's leading generics and biosimilar manufacturers. The company has over 200 manufacturing sites in more than 100 countries, with an extensive product portfolio that spans over 1,500 products.\n\nCipla is committed to providing quality, affordable medicines to consumers around the world. Its mission is to make healthcare accessible by making essential medicines accessible at an affordable price. Cipla prides itself on its ability to combine innovation and technology to bring affordable, high-quality healthcare to people everywhere.\n\nThe company is also involved in research activities, such as drug discovery, development and formulation, and production processes to ensure the highest quality of medicines. Cipla also takes social responsibility for the communities it serves and invests in health awareness campaigns and health education programs.\n\nAurobindo Pharma - Aurobindo Pharma is one of India's leading pharmaceutical companies. Founded in 1986, Aurobindo manufactures and markets a wide range of generic pharmaceuticals and active pharmaceutical ingredients (APIs). The company also has a strong presence in the United States, Europe and other markets.\n\nAurobindo has a vast product portfolio that spans seven therapeutic areas - oncology, central nervous system disorder, gastroenterology, HIV/AIDS, cardiovascular, diabetes and respiratory disorders. Its products include tablets, capsules, injectables, powders, liquids, semi-solids, topicals and inhalation. It has over 15,000 employees and offers over 3,000 products in more than 140 countries globally.\n\nThe company also focuses on research and development activities to bring new drugs to market. It has more than 200 scientists employed in its R&D teams, working on innovative formulations, novel drug delivery systems and advanced technology platforms.\n\nIn addition, Aurobindo has a presence in the contract manufacturing space, providing customers with customised solutions for their APIs and intermediates. It works closely with leading global pharmaceutical companies to develop and manufacture their products.\n\nThe company also understands the importance of sustainability and invests heavily in corporate social responsibility initiatives. This includes programs such as providing access to healthcare, promoting education, improving infrastructure and supporting environmental protection.\n\nOverall, Aurobindo Pharma is a leading Indian pharmaceutical company that produces quality medicines, invests heavily in research and development and plays an important role in the global healthcare landscape.\n\nSun Pharmaceuticals - Sun Pharmaceuticals is one of India's leading pharmaceutical companies, engaged in the manufacture, marketing and distribution of pharmaceuticals. Founded by Dilip Shanghvi in 1983, Sun Pharma has grown to become the world's fifth-largest speciality generic pharmaceutical company, with a presence in over 150 countries.\n\nSun Pharma focuses on providing high-quality, affordable products across various therapeutic categories, including dermatology, ophthalmology, neurology, cardiology, diabetes, gastrointestinal, nephrology and women's health. The company has a strong presence in India, the US, Europe, South America, Africa and Asia Pacific.\n\nSun Pharma also has a number of research and development facilities spread across India, the US, Italy, Hungary and Canada. Sun Pharma's extensive range of products is designed to meet the requirements of patients, physicians, hospitals and other healthcare providers.\n\nThe company also offers advanced services such as patient assistance programs, disease management solutions, patient education, clinical trials and drug safety monitoring. Sun Pharma focuses on responsible manufacturing practices and strives to create a positive impact on society and the environment.\n\nDr. Reddy's Laboratories - Dr. Reddy's Laboratories is a global pharmaceutical company based in India. Founded in 1984 by entrepreneur Anji Reddy, the company has grown to become one of the largest manufacturers and marketers of generic drugs in the world.\n\nDr. Reddy focuses on developing, manufacturing and marketing pharmaceuticals, biotechnology products and active pharmaceutical ingredients. The company operates across three business segments: Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products.\n\nThe company's mission is to bring innovative healthcare products to market that make a difference in people's lives while creating value for stakeholders. Dr. Reddy has more than 50 years of experience in delivering high-quality, affordable medicines to customers in more than 100 countries. It has built a strong reputation as a reliable supplier of quality medicines at competitive prices.\n\nDr. Reddy also takes pride in its commitment to corporate social responsibility and sustainability. The company works with various partners to help provide access to medicine for underserved communities. It also engages in environmental and social initiatives that reduce its carbon footprint and promote sustainable development.\n\nDr. Reddy has a wide range of products, including generics, biosimilars, over-the-counter (OTC) and prescription products. It has an extensive research and development pipeline and is actively involved in the development of new drug delivery systems and formulations. The company is also making strides in personalized medicine and molecular diagnostics.\n\nDr. Reddy is focused on creating long-term value for its shareholders through sound business practices and a customer-centric approach. It has consistently delivered strong financial performance and has achieved significant growth in recent years. The company is committed to innovation and intends to continue leveraging its capabilities and resources to remain competitive.\n\nLupin - Lupin Company is an international pharmaceutical company based in Mumbai, India. Founded in 1968 by Mr Desh Bandhu Gupta, Lupin is a leader in branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) across the world.\n\nThe company has a presence in more than 65 countries, including the United States, Europe, Japan, Canada, Australia, South Africa and several other Asian countries.\n\nLupin offers a wide range of products, from generics to speciality medicines, ranging from antibiotics, anti-diabetics, cardiovascular, anti-asthmatics, gastroenterology, urology, neurology, psychiatry and various other therapeutic areas.\n\nIt has an established manufacturing base with four state-of-the-art integrated plants in India and a further 11 manufacturing facilities spread over the globe for APIs, intermediates, and finished dosage forms.\n\nThe company has expanded its footprint across markets through strategic investments, acquisitions, and alliances. One of its key acquisitions was Gavis Pharmaceuticals LLC in 2015 which helped Lupin gain greater access to the US market.\n\nFurthermore, it has entered into strategic partnerships with large players like Pfizer, Sanofi, Merck, and Wockhardt, as well as venture capital firms, to increase its global presence.\n\nLupin also has strong research programs focused on discovering new molecules and improving existing ones. It has invested substantially over the years in building up a strong R&D portfolio and recently acquired Symbiomix Therapeutics, a women's health company.\n\nThe company has aggressively pursued drug discovery and development initiatives in areas such as diabetes, cardiovascular diseases, and CNS disorders, among others.\n\nIn addition, Lupin has developed a strong network of partners and distributors to ensure the effective reach and availability of its products across different markets. Through continuous reinvestment in building brand equity, leveraging organic and inorganic opportunities, and pursuing innovative R&D initiatives, Lupin has created a strong platform for sustained growth.\n\nCadila Healthcare Ltd. - Cadila Healthcare is a leading pharmaceutical company in India. Founded in 1952, the company has a strong presence in over 25 countries, with products ranging from generic drugs and biopharmaceuticals to diagnostic services and speciality formulations.\n\nThe company has a strong research and development setup and has achieved several breakthroughs in the field of drug discovery, development and delivery systems.\n\nCadila is focused on developing innovative medicines to treat complex diseases like cancer, cardiovascular diseases, diabetes, etc. They are also actively involved in initiatives to make healthcare more accessible, especially for underserved populations in rural areas.\n\nIn terms of production, Cadila operates an extensive network of state-of-the-art manufacturing sites, which adhere to global standards of quality and safety. The company focuses on producing high-quality, cost-effective products, always with the customer in mind. Their portfolio includes several well-known brands for the Indian market, such as Deca, Amikind, Parzec, and Epitron.\n\nThe company has introduced several initiatives that have made life easier for patients. For instance, they provide free health checkups and camps in remote areas, provide helplines and online consultations, and offer generic versions of expensive drugs. They have also set up a 100 crore Rupee fund to help poor families cope with medical expenses.\n\nCadila Healthcare is dedicated to expanding access to quality healthcare and delivering lifesaving treatments. Their commitment to innovation and improving patient outcomes makes them a leader in healthcare.\n\nGlenmark Pharmaceuticals - Glenmark Pharmaceuticals is a leading global pharmaceutical company based in Mumbai, India. Founded in 1977, the company has grown to become one of the largest generics manufacturers in the world, with operations in over 70 countries.\n\nThe company focuses on developing and manufacturing branded and generic pharmaceuticals, active pharmaceutical ingredients (APIs) and intermediates for the global market.\n\nGlenmark's product portfolio includes over 500 products in formulations and over 250 APIs across various therapeutic categories. It offers a range of products in areas such as dermatology, respiratory, diabetology and cardiovascular markets. The company also has a growing presence in the biosimilars segment.\n\nGlenmark has a strong network of marketing offices, sales depots, warehouses and distribution centres, enabling it to reach customer needs globally. Its global manufacturing capabilities span multiple continents and include plants in India, South Africa and Brazil, as well as in-licensing arrangements in other countries.\n\nThe company is focused on innovating new medicines through its R&D centres and investments. Glenmark's investment in research and development, particularly in the fields of biotechnology and nanotechnology, has enabled the company to develop several innovative products.\n\nThe company has also been investing in drug discovery and development, building a pipeline of promising drugs for various therapeutic areas such as oncology, autoimmunity, infectious diseases and metabolic disorders.\n\nGlenmark Pharmaceuticals is committed to delivering quality products, making sure that all of its products meet international standards of safety and efficacy. The company works closely with regulatory agencies to ensure compliance with international regulations relating to pharmaceuticals and healthcare products.\n\nIn addition to its main operations, Glenmark also engages in corporate social responsibility activities, engaging in community projects that promote health and wellbeing, provide access to education and improve living standards.\n\nTorrent Pharmaceuticals - Torrent Pharmaceuticals is a leading Indian pharmaceutical and healthcare company headquartered in Ahmedabad, India. It is one of the largest pharma companies in India, with a presence in over 100 countries across the globe.\n\nThe company was established in 1959 and currently produces over 600 formulations ranging from generic medicines to speciality medicines. It has more than 20 manufacturing facilities, 5 research and development centres, and 7 API units located in India, Europe, and the United States.\n\nTorrent Pharmaceuticals is committed to providing world-class products that meet stringent international standards. Its focus is on developing innovative therapies, delivering quality products, and providing superior customer service.\n\nThe company has established strong relationships with medical professionals, hospitals, and other healthcare providers. It also has established strategic partnerships with global pharmaceutical companies and universities to enhance its scientific capabilities.\n\nTorrent Pharmaceuticals is dedicated to improving the health and well-being of its customers. Its portfolio includes a wide range of products for almost all therapeutic areas, including cardiovascular, diabetes, dermatology, gastroenterology, infectious diseases, oncology, respiratory, and others.\n\nThe company also has a strong presence in nutritional products, diagnostics, and consumer healthcare. Torrent Pharmaceuticals' commitment to research and development has led to the development of several first-in-class medicines, making it one of the leading innovators in the pharma industry.\n\nThe company is very conscious of its environmental impact and strives to adhere to stringent green measures at all its manufacturing locations. It is committed to ethical business practices and corporate social responsibility initiatives. As part of its corporate social responsibility, the company focuses on education, health, and environmental sustainability.\n\nOverall, Torrent Pharmaceuticals is an industry leader in the Indian pharma market and offers world-class products and services. Through its cutting-edge technology, innovative and quality products, and dedication to ethical principles, Torrent Pharmaceuticals continually strives to improve and sustain its position as an industry leader.\n\nCONCLUSION\n\nIn 2023, biotechnology companies in India have continued to grow rapidly and make an important contribution to the country's economy. Indian biotechnology companies are involved in the research and development of innovative solutions for various industries such as health care, agriculture, and food processing.\n\nThe sector offers many opportunities for talented scientists and entrepreneurs to develop new technologies that can improve the lives of people around the world. Many of these companies have also opened up new markets for their products, making them competitive on the global stage.\n\nAs a result, the biotechnology industry in India is projected to continue its growth trajectory going forward.",
            "source": {
                "uri": "inventiva.co.in",
                "dataType": "news",
                "title": "Inventiva"
            },
            "authors": [],
            "image": "https://www.inventiva.co.in/wp-content/uploads/2023/05/Biotechnology-Subjects-jpg.webp",
            "eventUri": null,
            "sentiment": 0.3568627450980393,
            "wgt": 421359900,
            "relevance": 100
        },
        {
            "uri": "7535282897",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-09",
            "time": "05:34:00",
            "dateTime": "2023-05-09T05:34:00Z",
            "dateTimePub": "2023-05-09T03:58:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.dnaindia.com/business/report-murali-divi-failed-in-class-12-went-to-us-with-rs-500-net-worth-rs-47000-crore-divi-s-laboratories-3041073",
            "title": "Meet Murali Divi, failed in Class 12, went to US with Rs 500, his net worth is Rs 47000 crore, know about his business",
            "body": "Divi's Labs founder Murali Divi is one of the richest scientists in the world with a net worth of USD 5.8 billion. Divi's Labs is one of the top three manufacturers of active pharmaceutical ingredients (API) and it has a market capitalisation of nearly Rs 1.3 lakh crore (over $17 billion).\n\nWho is Murali Divi?\n\nMurali Divi hails from a small town in Andhra Pradesh and his father was agovernment employee. There was a time when Murali Divi's father used to run his family on a monthly pension of Rs 10,000.\n\nMurali Divi's career\n\nMurali Divi went to the US in 1976 and started working as a pharmacist. Interestingly, Murali Divi failed his intermediate exams twice but he did not give up his dreams. Murali Divi left for the US when he was just 25 and had only Rs 500 in his hands, reported Forbes India.\n\nMurali Divi tasted success in the US and earned USD 65,000 a year while working at companies like Trinity Chemical and Fike Chemical.\n\nMurali Divi, however, returned to India after few years with USD 40,000 but no future plans. In 1984, Divi joined hands with Kallam Anji Reddy to build Cheminor, which was merged with Dr. Reddy's Laboratories in 2000.\n\nAfter working at Dr Reddy's Labs for 6 years, Murali Divi launched Divi's Laboratories in 1990 and started developing commercial processes for the manufacturing of APIs and intermediates. In 1995, Murali Divi set up its first Manufacturing facility at Choutuppal, Telangana. In 2002, he launched the company's second manufacturing utility near Visakhapatnam. Hyderabad-based Divi's Laboratories reported revenue of Rs 88 billion in March 2022.\n\nMurali Divi studied PUC in Machilipatnam and then went to MIT, Manipal Academy of Higher Education for his graduation. Murali Divi completed Bachelor of Pharmacy course at the College of Pharmaceutical Sciences.",
            "source": {
                "uri": "dnaindia.com",
                "dataType": "news",
                "title": "Daily News and Analysis (DNA) India"
            },
            "authors": [],
            "image": "https://cdn.dnaindia.com/sites/default/files/styles/half/public/2023/05/09/2588772-murali.jpeg",
            "eventUri": null,
            "sentiment": 0.2,
            "wgt": 421306440,
            "relevance": 1
        },
        {
            "uri": "7534725787",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-08",
            "time": "23:51:00",
            "dateTime": "2023-05-08T23:51:00Z",
            "dateTimePub": "2023-05-08T16:47:00Z",
            "dataType": "news",
            "sim": 0.545098066329956,
            "url": "https://www.moneycontrol.com/news/business/markets/trade-setup-for-tuesday-top-15-things-to-know-before-the-opening-bell-32-10549871.html",
            "title": "Trade setup for Tuesday: Top 15 things to know before the opening bell",
            "body": "Based on the OI percentage, 79 stocks were on the short-covering list. These included Escorts, Shriram Finance, National Aluminium Company, Bharat Forge, and Vedanta.\n\nThe market started off the week on a strong note as the benchmark indices recovered all the previous day's losses and posted more than one percent gains on May 8. Most of the key sectors including banking & financial services and auto traded higher.\n\nThe BSE Sensex rallied 710 points to 61,764, while the Nifty50 jumped 195 points to 18,264.40, the highest closing level since December 20 last year, and formed a bullish candlestick pattern on the daily charts by making a higher high and higher low formation.\n\n\"A long bull candle was formed on the daily chart, that has covered the decline of the previous session on the upside and filled the opening downside gap of Friday and closed higher. This is a positive indication and one may expect further upside in the short term,\" Nagaraj Shetti, Technical Research Analyst at HDFC Securities said.\n\nHe feels the short-term trend of Nifty remains positive. \"A sustainable move above 18,300 levels is expected to pull Nifty towards the next upper area of 18,600-18,700 levels in the near term. Any failure to surpass the hurdle is likely to result in further consolidation with minor weakness,\" he said.\n\nImmediate support is at 18,100-18,050 levels, he added.\n\nThe Nifty Midcap 100 and Smallcap 100 indices also participated in the run, rising 1 percent each on positive breadth, while the volatility inched up for yet another session with the India VIX rising to 12.64 levels from 11.72 levels.\n\nWe have collated 15 data points to help you spot profitable trades:\n\nNote: The open interest (OI) and volume data of stocks in this article are the aggregates of three-month data and not just the current month.\n\nKey support and resistance levels on Nifty\n\nThe pivot charts indicate that the Nifty may get support at 18,146 followed by 18,102 and 18,031. If the index advances, 18,288 is the initial key resistance level to watch out for followed by 18,333 and 18,404.\n\nNifty Bank\n\nThe Bank Nifty gained more than 600 points to close at 43,284, and formed a bullish candlestick pattern on the daily scale, but traded within the previous day's range.\n\n\"The Bank Nifty bulls after Friday's sell-off once again witnessed buying momentum and the index surpassed the level of 43,000 which will now act as support on the downside,\" Kunal Shah, Senior Technical and Derivative analyst at LKP Securities said.\n\nThe immediate hurdle on the upside is placed at 43,500 and once taken out on a closing basis will witness a sharp short covering towards all-time high levels, he added.\n\nAs per the pivot point calculator, the Bank Nifty may take support at 42,917 followed by 42,766 and 42,523. Key resistance levels are expected to be 43,405 along with 43,555 and 43,799.\n\nCall options data\n\nOn the weekly options front, we have seen the maximum Call open interest (OI) at 18,500 strike, with 86.06 lakh contracts, which is expected to be a crucial resistance level for the Nifty in the coming sessions.\n\nThis was followed by 18,300 strike, comprising 81.89 lakh contracts, and 18,200 strike, with more than 72.1 lakh contracts.\n\nCall writing was seen at 18,500 strike, which added 28.78 lakh contracts, followed by 18,400 strike, which added 11.44 lakh contracts, and 19,000 strike which added 5.85 lakh contracts.\n\nCall unwinding was at 18,100 strike, which shed 46.04 lakh contracts, followed by 18,200 strike, which shed 45.08 lakh contracts, and 19,100 strike, which shed 34.97 lakh contracts.\n\nPut option data\n\nThe maximum Put open interest was at 18,200 strike with 1.09 crore contracts, which is expected to act as an important support level in the coming sessions.\n\nThis was followed by the 18,100 strike, comprising 78.26 lakh contracts, and the 18,000 strike where we have 72.26 lakh contracts.\n\nPut writing was seen at 18,200 strike, which added 47.64 lakh contracts, followed by 18,300 strike, which added 26.98 lakh contracts, and 18,000 strike, which added 26.88 lakh contracts.\n\nWe have seen Put unwinding at 17,800 strike, which shed 7.79 lakh contracts, followed by 17,900 strike, which shed 4.56 lakh contracts, and 17,300 strike, which shed 1.48 lakh contracts.\n\nA high delivery percentage suggests that investors are showing interest in the stock. The highest delivery was seen in SRF, Grasim Industries, Sun Pharmaceutical Industries, Tata Communications and Infosys among others.\n\nAn increase in open interest (OI) and price typically indicates a build-up of long positions. Based on the OI percentage, 84 stocks, including Oracle Financial, Marico, BHEL, ONGC and Federal Bank saw long build-ups.\n\n5 stocks see long unwinding\n\nA decline in OI and price generally indicates a long unwinding. Based on the OI percentage, 5 stocks - United Breweries, Havells India, MRF, Larsen & Toubro and Dr Reddy's Laboratories - saw a long unwinding.\n\nAn increase in OI along with a price decrease indicates a build-up of short positions. Based on the OI percentage, 22 stocks, including Aditya Birla Fashion & Retail, Dr Lal PathLabs, Polycab India, Canara Bank and Tata Communications saw a short build-up.\n\nA decrease in OI along with a price increase is an indication of short-covering. Based on the OI percentage, 79 stocks were on the short-covering list. These included Escorts, Shriram Finance, National Aluminium Company, Bharat Forge and Vedanta.\n\nLupin, Raymond, Reliance Infrastructure, Apollo Tyres, Birla Corporation, Castrol India, Chalet Hotels, Eveready Industries India, Godrej Agrovet, Hatsun Agro Product, Indraprastha Gas, JM Financial, KSB, Latent View Analytics, Matrimony.com, Nazara Technologies, Nuvoco Vistas Corporation, Rain Industries, Shipping Corporation of India, SRF, Suven Life Sciences and Westlife Foodworld will be in focus ahead of quarterly earnings on May 9.\n\nStocks in the news\n\nMahanagar Gas: The natural gas distribution company has recorded a 56.2 percent quarter-on-quarter growth in profit at Rs 268.81 crore for the March FY23 quarter, driven by healthy operating performance. Revenue fell 3.6 percent sequentially to Rs 1,610.5 crore, with volumes declining 1.16 percent QoQ. Numbers, barring topline, were above estimates. The company announced a final dividend of Rs 16 per equity share.\n\nAndhra Paper: The paper and pulp manufacturer has clocked a 168 percent year-on-year growth in profit at Rs 153.9 crore for the quarter ended March FY23, driven by healthy topline and operating numbers. Revenue from operations grew by 38.55 percent to Rs 590 crore compared to the year-ago period.\n\nCarborundum Universal: The Murugappa Group company has recorded a 140.4 percent year-on-year growth in consolidated profit at Rs 137.1 crore for March FY23 quarter on strong operating and topline numbers. Revenue increased by 38 percent to Rs 1,199.6 crore compared to the same period last year with good growth in all segments including abrasives, ceramics and electro minerals. The company announced a final dividend of Rs 2 per share for FY23.\n\nVIP Industries: The luggage and bags manufacturer has posted a net loss of Rs 4.3 crore in the March FY23 quarter, against a profit of Rs 12.4 crore in the same period last year. The company had an exceptional loss of Rs 47.21 crore relating to a loss of property, plant and equipment and inventories that were destroyed due to a major fire at a plant of a Bangladesh subsidiary in Q4FY23. Revenue grew by 27 percent YoY to Rs 450.6 crore.\n\nGodrej Consumer Products: Godrej Consumer has completed the acquisition of the FMCG business of Raymond Consumer Care. On April 27, the company announced the proposed acquisition of the FMCG business of Raymond Consumer Care by way of a slump sale. RCCL is a leading player in the deodorants and sexual wellness categories in India.\n\nPidilite Industries: The adhesive manufacturing company has recorded an 11.3 percent year-on-year growth in consolidated profit at Rs 283.03 crore for the quarter ended March FY23 on good operating numbers, Revenue from operations rose 7.3 percent to Rs 2,689.25 crore in the same period.\n\nForeign institutional investors (FII) bought shares worth Rs 2,123.76 crore, while domestic institutional investors (DII) purchased shares worth Rs 245.27 crore on May 8, provisional data from the National Stock Exchange showed.\n\nStocks under F&O ban on NSE\n\nThe National Stock Exchange added BHEL and retained GNFC and Manappuram Finance to its F&O ban list for May 9. Securities in the ban period under the F&O segment include companies in which the security has crossed 95 percent of the market-wide position limit.",
            "source": {
                "uri": "moneycontrol.com",
                "dataType": "news",
                "title": "MoneyControl"
            },
            "authors": [],
            "image": "https://images.moneycontrol.com/static-mcnews/2023/04/Stock-2-770x433.jpg",
            "eventUri": "eng-8606662",
            "sentiment": 0.1294117647058823,
            "wgt": 421285860,
            "relevance": 1
        },
        {
            "uri": "7534472025",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-08",
            "time": "14:39:00",
            "dateTime": "2023-05-08T14:39:00Z",
            "dateTimePub": "2023-05-08T13:22:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.livemint.com/market/stock-market-news/best-worst-performing-sectors-and-stocks-in-fy23-11683551397888.html",
            "title": "Best & worst performing sectors and stocks in FY23",
            "body": "The domestic market experienced an adrenaline rush in FY23 due to strong monetary policy stances by global central banks, soaring inflation, and the Russia-Ukraine war. For two fiscal years, FPIs sold equities in amounts of â‚¹140010 crores in FY22 and â‚¹37632 crores in FY 23. The Nifty FMCG, Auto, and Bank indices among domestic sectors indices experienced the best performances, while the Nifty Pharma, Energy, Metals, Realty, and IT indices saw the poorest performances in FY23. The NIFTY 50 saw a 2% negative return for the fiscal year while the NIFTY 500 experienced a 3.5% shrink. Unexpectedly, the NIFTY Midcap 100 index had a flat return for the year while NIFTY Next 50 index fell by 9.5% followed by NIFTY Small Cap 250, with a reported decrease of 9% witnessed during FY23.\n\nBanking and financial services, particularly PSU Banks stocks like UCO Bank, Karur Vysya, and Karnataka Bank, ought to be considered among the companies that have fared very well over the past 12 months. In the most recent quarter, these companies' revenues grew by double digits while their earnings more than doubled. This is mostly owing to the drastic reduction in provision that the majority of these banks have made as compared to the same period last year, when it was higher than typical due to the consequences of COVID-19. Also, these banks have experienced a significant improvement in their asset quality, while it is still elevated when compared to banks in the private sector. Stocks from the private sector like South Indian Bank and DCB have performed comparatively better than other private sector banks.\n\nUnexpectedly, the FMCG industry has also performed quite well, despite being the one most negatively affected by the significant inflation we all saw over the last year. Mrs. Bector Foods and Speciality, a company from this sector, got listed at the end of 2020. For the last six months, the company's earnings increased by about 50%, owing to the festive season and the introduction of new items and capacity additions. In the 9M FY23 period, the company has already surpassed its FY22 profitability, and there is still one more quarter to go. Throughout the past year, the stock has had a positive return of almost 90%.\n\nSpeaking about the sector that has struggled this year, it would be IT, which was inevitable given the stellar returns the industry has produced since COVID began and through FY22. There have however been a few exceptions; firms like Cigniti Tech and KPIT Tech have had outstanding financial results. While KPIT increased its profits by more than 30% in a very difficult climate for the sector, Cigniti saw virtually a doubling of its earnings during the past several quarters. In the 9M FY23 timeframe, both of these businesses have already surpassed their FY22 earnings.\n\nNifty IT & Nifty Metals have been two of the worst performing sectors as expected due to economic headwinds being faced by global markets over the past 1 year. With rising interest rate hike cycle now almost at the end of the cycle, investors should buy quality IT & metal stocks like Infosys, TCS & Tata Steel which are now available at very attractive valuations. As US & European markets eventually settle down, FY24 should be much better for these two sectors this year.\"\n\nNifty PSU bank & Nifty FMCG have been the two stellar performers in FY23. A rising interest rate cycle has benefitted banks and especially PSU banks in general which has led to an excellent performance driven by stronger margins. However, FY24 could be tougher for PSU banks as a halt in interest rate hikes and investors moving on to banks with superior asset quality like ICICI, Kotak & HDFC bank could spell a below average year for PSU banks in FY24. In the FMCG space, ITC returns could be much lower this year as compared to FY23 as a gradual pick up in the consumption cycle especially in the second half of FY24 should lead to stronger buying in HUL, Nestle, Marico than ITC.\n\nAs of 2023, India's economy is expected to continue to grow, and the stock market is likely to reflect this growth. However, the performance of individual sectors and stocks can vary depending on various factors. This article will discuss the best and worst-performing sectors/stocks in India for the financial years 2023/24.\n\nTechnology: The technology sector in India has been performing exceptionally well in recent years, and this trend is likely to continue in 2023/24. The sector includes companies that are involved in software development, IT services, and hardware manufacturing. Some of the top-performing companies in this sector include Infosys, Tata Consultancy Services (TCS), Wipro, and HCL Technologies. The sector's growth is driven by the increasing adoption of digital technology and the shift toward cloud computing.\n\nHealthcare: The healthcare sector in India is also expected to perform well in the financial years 2023/24. This sector includes companies involved in pharmaceuticals, medical devices, hospitals, and healthcare services. Some top-performing companies in this sector include Sun Pharmaceuticals, Dr. Reddy's Laboratories, Apollo Hospitals, and Fortis Healthcare. Due to an aging population, the sector will likely benefit from increased government spending on healthcare and rising demand for healthcare services.\n\nConsumer Goods: The consumer goods sector in India is also expected to perform well in 2023/24. This sector includes companies that produce and distribute fast-moving consumer goods (FMCG), such as food, beverages, personal care products, and household items. Some of the top-performing companies in this sector include Hindustan Unilever, Nestle India, ITC, and Britannia Industries. The sector will likelybenefit from rising consumer demand, especially in rural areas.\n\nReal Estate: The real estate sector in India has been struggling in recent years, and this trend is likely to continue in 2023/24. The sector includes companies involved in developing, selling, and leasing residential and commercial properties. Some of the top companies in this sector include DLF, Sobha, Godrej Properties, and Oberoi Realty. The sector faceschallenges such as oversupply, rising interest rates, and sluggish demand due to rise in interest rates.\n\nInfrastructure: The infrastructure sector in India is also expected to face challenges in 2023/24. The sector includes companies developing roads, highways, airports, and other infrastructure projects. Some of the top companies in this sector include Larsen & Toubro, IRB Infrastructure, AdaniPorts, and SEZ. The sector is facing challenges such as delays in project execution, funding issues, and regulatory hurdles.\n\nBanking: The banking sector in India has faced challenges in recent years, and this trend is likely to continue in 2023/24. The sector includes public and private banks providingbanking and financial services. Some of the top banks in India include the State Bank of India, HDFC Bank, ICICI Bank, and Axis Bank. The sector faces rising non-performing assets (NPAs), increased competition, and regulatory challenges.\n\nIn conclusion, the performance of sectors and stocks in the Indian stock market can vary depending on various factors. While some sectors and stocks will likely perform well in the financial years 2023/24, others may face challenges. Investors should carefully analyze the performance of individual sectors and stocks before making investment decisions.\n\nSome of the best performing stocks are TVS Motors, ITC, M&M, Cummins India and Bank of Baroda and the worst performing stocks are Adani Green, Heritage Foods, MphasiS, Lux Industries and Thyrocare Technologies.\n\nThe Best sectors are FMCG, Auto, Banks and the worst Performing Sectors are IT and Pharma.\n\nThough broader markets are flat and for smaller caps it has declined, there is a large deviation among stocks which explains why Indian stock market is still a stock pickers market. For example, stocks like Brightcom Group, which is held by many mutual funds, lost 85% of its value in last 12 months. Similarly, stocks like Tanla solution which powers Airtel's digital ledger technology to approve sms headers lost 63% of its value and a popular company like 8K miles lost almost 57% of the value. Sectorally specialized IT services seems to be one of the most impacted while some of the top performing stocks like Goldstart which manufactures durables is up more than 450% and food or consumer staples like edible oils given constraints of food supply chain has performed upto 800%.\n\nDespite the challenges faced by the markets in the recent quarter, there have been notable performances from defensive sectors, including food & beverages, tobacco, healthcare equipment, and consumer durables. These sectors have benefited from stable consumer spending, leading to positive returns. The general industrial sector has also seen positive returns, buoyed by the central government's capex push.\n\nTo capitalize on these top-performing sectors, our outperforming screener identifies high-growth stocks such as ITC, Siemens, Varun Beverages, Polycab India, and KEI Industries. However, sectors such as commercial services, utilities, media, and retailing have underperformed, with the utilities sector facing significant corporate governance issues related to the Adani group. Consequently, our underperforming screener includes stocks such as Adani Total Gas and Adani Transmission, which have underperformed the Nifty 500 by more than 50 percentage points.\n\nIn light of these trends, it is essential to appreciate the significance of sectoral analysis and company-specific issues when investing in the stock market. By keeping an eye on the best and worst-performing sectors and stocks, investors can make informed decisions that align with their investment objectives.\n\nThere are business cycles and there are market cycles. I believe that one should focus on the former as the latter can generally whiplash you. Some of sectors that I believe have fundamental tailwinds are those such as infra given the government's focus, energy transition given the inflationary pressures caused by conflict, and sectors that should be gaining traction due to the China +1 story.",
            "source": {
                "uri": "livemint.com",
                "dataType": "news",
                "title": "mint"
            },
            "authors": [
                {
                    "uri": "vipul_das@livemint.com",
                    "name": "Vipul Das",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://www.livemint.com/lm-img/img/2023/05/08/600x338/2-0-1244114454-iStock-839214100-0_1679615828655_1683551435951.jpg",
            "eventUri": null,
            "sentiment": 0.3333333333333333,
            "wgt": 421252740,
            "relevance": 26
        },
        {
            "uri": "7533927695",
            "lang": "eng",
            "isDuplicate": true,
            "date": "2023-05-08",
            "time": "05:50:00",
            "dateTime": "2023-05-08T05:50:00Z",
            "dateTimePub": "2023-05-07T14:12:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://dailyfrontierstar.com/junshi-biosciences-announces-collaboration-with-dr-reddys-to-develop-and-commercialize-toripalimab-in-21-countries/",
            "title": "Junshi Biosciences Announces Collaboration with Dr. Reddy's to Develop and Commercialize Toripalimab in 21 Countries",
            "body": "SHANGHAI, China, May 07, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\"Junshi Biosciences\", HKEX: 1877; SSE: 688180) announced a collaboration with Dr. Reddy's Laboratories Limited (\"Dr. Reddy's\") to develop and commercialize toripalimab, the anti-PD-1 monoclonal antibody in Latin America, India, South Africa, and at the election of Dr. Reddy's, also in Australia, New Zealand and other countries.\n\n\"We are thrilled to have established a partnership with Dr. Reddy's while toripalimab's global commercial network has been steadily expanding, reaching more than 50 countries and advancing our mission of being 'In China, For Global,'\" said Dr. Ning LI, Chief Executive Officer of Junshi Biosciences. \"Dr. Reddy's is a well-respected global pharmaceutical company and extends its business over nearly 70 countries worldwide, achieving impressive commerical presence across the globe. We hope that in the near future, leveraging Dr. Reddy's partnership and strong presence, our innovative medicines can accelerate access to new geographies and deliver better and more affordable treatment options to even more patients.\"\n\nM.V. Ramana, CEO - Branded Markets (India & Emerging Markets), Dr. Reddy's said, \"We are pleased to partner with Junshi Biosciences to take this important product to more patients. Oncology is a focus area for Dr. Reddy's. This partnership is a further step towards increasing our offerings to patients in oncology as we aim to build a robust and comprehensive portfolio in the segment. We are committed to facilitating access to innovative products as we pursue our goal of serving over 1.5 billion patients by 2030.\"\n\nUnder the license and commercialization agreement, Junshi Biosciences will grant a licence to Dr. Reddy's to develop and exclusively commercialize toripalimab in Brazil, Mexico, Colombia, Argentina, Peru, Chile, Panama, Uruguay, India and South Africa. Dr. Reddy's may elect to expand the scope of the license to cover Australia, New Zealand and nine other countries.\n\nUnder the terms of the agreement, Junshi Biosciences also grants Dr. Reddy's the exclusive right of first negotiation for commercialization, in the event that Junshi Biosciences determines to grant any third party the rights to commercialize two other products as agreed in the agreement in one or more countries within the total 21 countries of Dr. Reddy's Territory.\n\nJunshi Biosciences may receive up to an aggregate of US$728.3 million for upfront payment, potential expansion of Dr. Reddy's Territory and milestone payment, plus double-digit percentage of royalties on the net sales of products containing toripalimab.\n\nAbout Toripalimab\n\nToripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system's ability to attack and kill tumor cells.\n\nMore than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.\n\nIn China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI). Currently, there are six approved indications for toripalimab in China:\n\nThe first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma.\n\nIn the United States, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine/cisplatin, for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (FDA). The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (SCLC).\n\nIn Europe, marketing authorization applications (MAA) were accepted by the European Medicines Agency (EMA) and the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic ESCC, in December 2022 and February 2023.\n\nAbout Dr. Reddy's\n\nDr. Reddy's is a global pharmaceutical company headquartered in Hyderabad, India and listed on the New York Stock Exchange (stock code: RDY), the National Stock Exchange of India (stock code: DRREDDY), and the Bombay Stock Exchange (stock code: 500124). Established in 1984, Dr. Reddy's is committed to providing access to affordable and innovative medicines. Driven by its purpose of 'Good Health Can't Wait', Dr. Reddy's offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Dr. Reddy's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its major markets include - the United States, India, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, Dr. Reddy's continues to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, Dr. Reddy's released its first Sustainability Report in 2004. Its current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.\n\nAbout Junshi Biosciences\n\nFounded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.\n\nIn the face of the pandemic, Junshi Biosciences' response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. In 2021, JS016 (etesevimab), China's first neutralizing fully human monoclonal antibody against SARS-CoV-2 administered with bamlanivimab, was granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116 (deuremidevir hydrobromide), a novel oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, has been approved for marketing in China and Uzbekistan. The JS016 and VV116 programs are a part of the company's continuous efforts towards innovation for disease control and prevention of the global pandemic.\n\nJunshi Biosciences has about 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.\n\nCollectively, \"Dr. Reddy's Territory 1\" Collectively, \"Dr. Reddy's Territory 2\"\n\nBoth \"Dr. Reddy's Territory 1\" and \"Dr. Reddy's Territory 2\" are collectively known as \"Dr. Reddy's Territory\", totalling 21 countries.",
            "source": {
                "uri": "dailyfrontierstar.com",
                "dataType": "news",
                "title": "dailyfrontierstar.com"
            },
            "authors": [],
            "image": null,
            "eventUri": null,
            "sentiment": 0.2941176470588236,
            "wgt": 421221000,
            "relevance": 100
        },
        {
            "uri": "7533915215",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-08",
            "time": "05:42:00",
            "dateTime": "2023-05-08T05:42:00Z",
            "dateTimePub": "2023-05-08T05:39:00Z",
            "dataType": "news",
            "sim": 0.6901960968971252,
            "url": "https://economictimes.indiatimes.com/markets/stocks/stock-watch/share-market-update-most-active-stocks-of-the-day-in-terms-of-total-traded-value/articleshow/100064677.cms",
            "title": "Share market update: Most active stocks of the day in terms of total traded value",
            "body": "NEW DELHI: HDFC Bank(Rs. 894.00 crore), PayTM(Rs. 530.75 crore), HDFC(Rs. 510.87 crore), Rail Vikas Nigam(Rs. 444.37 crore), IndusInd Bank(Rs. 423.92 crore), Bajaj Finance(Rs. 413.84 crore), ICICI Bank(Rs. 340.94 crore), Indian Railway Finance Corporation Ltd.(Rs. 312.31 crore), Marico(Rs. 303.14 crore) and Aditya Birla Retail(Rs. 275.30 crore) were among the most traded securities on the National Stock Exchange at 10:51AM in Monday's session.\n\nThe NSE Nifty index traded 177.2 points up at 18246.2, while BSE Sensex was up 634.97 points at 61689.26 as of 10:51AM(IST)on May 08.\n\nIn the Nifty index, IndusInd Bank Ltd.(up 5.29 per cent), Bajaj Finance Ltd.(up 3.17 per cent), Tata Motors Ltd.(up 2.43 per cent), Bajaj Finserv Ltd.(up 2.25 per cent) and Oil And Natural Gas Corporation Ltd.(up 2.03 per cent) were among the top gainers.\n\nOn the other hand, Coal India Ltd.(down 2.61 per cent), Adani Enterprises Ltd.(down 1.32 per cent), Dr. Reddy's Laboratories Ltd.(down 0.66 per cent), Larsen & Toubro Ltd.(down 0.48 per cent) and Sun Pharmaceutical Industries Ltd.(down 0.46 per cent) were among the top losers.",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-83769615,width-1070,height-580,imgsize-98874,overlay-etmarkets/photo.jpg",
            "eventUri": "eng-8603227",
            "sentiment": 0.07450980392156858,
            "wgt": 421220520,
            "relevance": 1
        },
        {
            "uri": "7533766497",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-08",
            "time": "03:02:00",
            "dateTime": "2023-05-08T03:02:00Z",
            "dateTimePub": "2023-05-08T03:00:00Z",
            "dataType": "news",
            "sim": 0.7803921699523926,
            "url": "https://www.news18.com/business/markets/stocks-to-watch-coal-india-paytm-dr-reddys-britannia-amara-raja-and-others-7747927.html",
            "title": "Stocks to Watch: Coal India, Paytm, Dr Reddy's, Britannia, Amara Raja, and Others",
            "body": "Stocks To Watch: The Nifty futures contract traded on the Singapore Exchange indicates a positive start to domestic equities. The contract was trading at 18,148.50, up 24.5 points or 0.14% from the previous close.\n\nEarnings today: Aarti Industries, Apar Industries, Apollo Pipes, Avadh Sugar and Energy, Balkrishna Industries, Birlasoft, Canara Bank, Craftsman Automation, Exide Industires, Pidilite, UPL, and VIP Industries are among the top companies due to report their Q4FY23 earnings on Monday, May 8.\n\nAditya Birla Fashion, TCNS: Aditya Birla Fashion and Retail (ABFRL) has entered into a definitive agreement to acquire controlling stake (51 per cent) in TCNS Clothing for Rs 1,650 crore.\n\nDr Reddy's Labs: Dr Reddy's Laboratories Ltd, on Friday, announced the launch of Regadenoson injection, used as an agent in the imaging of heart muscle to check blood flow, in the US market.\n\nPNC Infratech: The company has won an EPC project worth Rs 771.46 crore from Haryana Orbital Rail Corporation Limited.\n\nAmara Raja Batteries: The company has bwegun work on 'Amara Raja Giga Corridor' that aims to produce Lithium Cell and Battery Packs with an ultimate capacity of up to 16GWh, and up to 5GWh, respectively\n\nPaytm: The company, on Friday, posted a consolidated revenue of Rs 2,334 crore for the March quarter of FY23, up 51 per cent rise from Rs 1,540 crore posted in the March quarter of FY22. The company's loss narrowed to Rs 168 crore from Rs 763 crore in the year-ago period.\n\nCoal India: Coal India Ltd, the world's largest coal miner, on Sunday reported 17.7 per cent drop in its March quarter net profit to Rs 5,527.62 crore, on higher provision made for wage revision of employees. Coal production rose 7 per cent to 224.16 million tonne in the quarter ended March 31.\n\nBank of India: Public sector lender Bank of India's (BoI) net profit more than doubled year-on-year (YoY) to Rs 1,350 crore for the quarter ended March 2023 (Q4FY23) on improvement in net interest income (NII). The board of directors declared a dividend of Rs 2.0 per share (Rs 10 each) for FY23, subject to shareholders' approval, the bank informed BSE.\n\nAdani Power: The Adani Group company has posted around 13 per cent jump in consolidated net profit at Rs 5,242 crore for March quarter 2022-23. Total income however fell to Rs 10,795 crore from Rs 13,307 crore in the year-ago quarter. Total expenses were higher at Rs 9,897 crore as against Rs 7,174 crore a year ago.\n\nBritannia: Britannia Industries' net earnings in the January-March quarter of FY23 jumped 47.1 per cent to Rs 558.7 crore as its profit before interest, depreciation and tax (PBIDT) went up 42.7 per cent. This came on the back of softening input costs helping operating margin. The Nusli Wadia group firm's revenue from operations in the quarter increased 13.3 per cent to Rs 4,023.2 crore amid significant distribution gains.",
            "source": {
                "uri": "news18.com",
                "dataType": "news",
                "title": "News18"
            },
            "authors": [],
            "image": "https://images.news18.com/ibnlive/uploads/2023/05/stocks-to-buy-168299536816x9.gif",
            "eventUri": "eng-8603227",
            "sentiment": 0.2941176470588236,
            "wgt": 421210920,
            "relevance": 51
        },
        {
            "uri": "7533749032",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-08",
            "time": "02:37:00",
            "dateTime": "2023-05-08T02:37:00Z",
            "dateTimePub": "2023-05-08T02:31:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.thehindubusinessline.com/portfolio/nifty-at-18000-how-different-is-the-market-now-versus-october-2021/article66815474.ece",
            "title": "Nifty at 18,000: How different is the market now versus October 2021?",
            "body": "Indian equities finally managed to reverse their three-month-long losing streak, with bellwether Nifty50 breaking 18,000 levels for the second time this year. Its attempt to scale beyond 18000 levels since October 2021, when it scaled this milestone the first time, did not meet much success except for the second half of 2022. Since the beginning of 2023, the index has been on a slippery path.\n\nWhile the rally's sustainability remains to be seen, the Nifty 50 has recovered by over 7 per cent from its March 2023 low level of 16,950. Interestingly every time the market has tried to move past 18,000 levels, it has been quite a struggle for the market, given the global recessionary concerns, inflation worries, rate hikes and other adverse geopolitical developments.\n\nBut what has changed between October 2021, when Nifty first breached 18,000? Which stocks have aided the rally this time and then?\n\nThe October 2021 rally was largely led by banking stocks such as HDFC Bank, HDFC, ICICI Bank and Reliance Industries, ruling at new highs then. Banking stocks got a boost from the hopes of economic recovery and credit growth improvement, post easing of covid related curbs.\n\nStocks such as ITC and auto majors such as Maruti failed to participate in the 2021 rally, thanks to the post covid impact and high raw material prices as food and other industrial commodity prices hit the roof in 2021-22.\n\nInterestingly, the Nifty's journey this time has been driven by the stocks that did not participate in the 2021 rally. To understand the contributors to this rally, we have considered the prices of Nifty stocks now (as of 3 May 2023), their 52-week high price and price as on 13 October 2021.\n\nOur analysis reveals that of the 50 stocks that are part of the Nifty 50, 17 stocks, constituting about a third of the index, are trading close to their 52-week high price, with the deviation being under 5 per cent. Topping the list is the stock of drug maker Dr Reddy's Laboratories and ITC Limited. Other stocks include Nestle India, Bajaj Auto, HDFC twins, and Tata Motors. PSU stocks have contributed to the rally this time, including ONGC, Bharat Petroleum Corporation, Power Grid Corporation and NTPC. In terms of themes that have led the rally this time, it is FMCG, Oil and Gas, PSU stocks and in other sectors such as pharmaceuticals and banking, it is specific stocks that have aided the rally, instead of a broad-based rally, covering all stocks in the sector. For instance, While Dr Reddy's is trading close to its 52-week high price, Cipla is about 22 per cent off its one-year high price. Likewise, in banking while ICICI Bank and HDFC Bank have done well, Axis Bank is about 11 per cent off its year high. IT, a significant contributor to the Nifty rally in October 2021, has been a laggard this time. Infosys and Wipro are trading at a steep 24 per cent discount to their one-year high price, while TCS has managed to contain the downside relatively well trading 11 per cent lower than its 52-week high levels.\n\nAdani Enterprise is at the bottom, trading 56 per cent below its year-high price. Others include Adani Ports (32 per cent lower), Divi's Laboratories (29 per cent), Bajaj Finserv (27 per cent) and Infosys (24 per cent).\n\nRally not broad-based\n\nWhile Nifty is the key index the country tracks, what is the broad market trend? To understand this better, we have analysed the data of the top 500 listed stocks.\n\nOf the top 500 stocks, about 88 of them are trading about 5 per cent off their year highs. Dr Reddy's Laboratories, Bajaj Auto and Bosch Limited are topping this list. Others in the top 10 stocks close to their 52-week highs include, Alkem Laboratories, HDFC Ltd, Oracle Financial Services, ITC, and Power Finance Corporation. Besides PSUs, several oil and gas companies, including city gas distributors such as Indraprastha Gas, are featured in the list, with the current price close to about 5 per cent off its peak. Besides large banks, small finance banks - AU Small Finance Bank also features in the list. While large IT has underperformed market, mid and small IT companies have still managed to do well and buck the weakness, with several of them still trading close to their year highs, including names such as KPIT Technologies, Cyient Ltd and Sonata Software.\n\nAbout 72 stocks are trading 5-10 per cent lower than their year-high prices, while 133 stocks are trading 10-20 per cent lower than their 52-week high prices. About 208 stocks are trading at a 20-88 per cent discount to their 52-week highs.\n\nAmong those trading off their year highs, top on the list is Brightcom Group (88 per cent), Adani Total Gas (76 per cent), Adani Transmission (76 per cent), Adani Green (67 per cent), Tata Tele services (59 per cent) and Gland Pharma (58 per cent) among others. About 13 stocks are trading at over half their October 2021 prices.\n\nOf the 500 stocks, 17 stocks were listed after October 2021. Out of the balance 483 stocks, 213 stocks are trading at prices higher than the October 2021 levels; of these, about 19 stocks have doubled since October 2021. Stocks that have delivered the most since October 2021 include RVNL, Lloyds Metals, Raymond, and several defence stocks such as Mazagon Dock, Bharat Dynamics, and Hindustan Aeronautics. About 20 stocks are trading at half the prices seen in October 2021. About 270 stocks are trading at levels below the October 2021 levels. This points to the fact that the market rally is not broad-based but driven by select themes such as PSU, Oil and gas and FMCG.\n\nSHARE Copy linkEmailFacebookTwitterTelegramLinkedInWhatsAppRedditPublished on May 8, 2023",
            "source": {
                "uri": "thehindubusinessline.com",
                "dataType": "news",
                "title": "@businessline"
            },
            "authors": [],
            "image": "https://bl-i.thgim.com/public/incoming/aiipc2/article66816846.ece/alternates/LANDSCAPE_1200/PO07_Analyse_2.jpg",
            "eventUri": null,
            "sentiment": -0.0117647058823529,
            "wgt": 421209420,
            "relevance": 51
        },
        {
            "uri": "7533663557",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-08",
            "time": "00:39:00",
            "dateTime": "2023-05-08T00:39:00Z",
            "dateTimePub": "2023-05-07T14:10:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.messenger-inquirer.com/ap/elections/junshi-biosciences-announces-collaboration-with-dr-reddy-s-to-develop-and-commercialize/article_0b45bb1a-57f8-5ac8-ba67-b445ccdfec05.html",
            "title": "Junshi Biosciences Announces Collaboration with Dr. Reddy's to Develop and Commercialize ...",
            "body": "SHANGHAI, China, May 07, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\"Junshi Biosciences\", HKEX: 1877; SSE: 688180) announced a collaboration with Dr. Reddy's Laboratories Limited (\"Dr. Reddy's\") to develop and commercialize toripalimab, the anti-PD-1 monoclonal antibody in Latin America, India, South Africa, and at the election of Dr. Reddy's, also in Australia, New Zealand and other countries.\n\n\"We are thrilled to have established a partnership with Dr. Reddy's while toripalimab's global commercial network has been steadily expanding, reaching more than 50 countries and advancing our mission of being 'In China, For Global,'\" said Dr. Ning LI, Chief Executive Officer of Junshi Biosciences. \"Dr. Reddy's is a well-respected global pharmaceutical company and extends its business over nearly 70 countries worldwide, achieving impressive commerical presence across the globe. We hope that in the near future, leveraging Dr. Reddy's partnership and strong presence, our innovative medicines can accelerate access to new geographies and deliver better and more affordable treatment options to even more patients.\"\n\nM.V. Ramana, CEO - Branded Markets (India & Emerging Markets), Dr. Reddy's said, \"We are pleased to partner with Junshi Biosciences to take this important product to more patients. Oncology is a focus area for Dr. Reddy's. This partnership is a further step towards increasing our offerings to patients in oncology as we aim to build a robust and comprehensive portfolio in the segment. We are committed to facilitating access to innovative products as we pursue our goal of serving over 1.5 billion patients by 2030.\"\n\nUnder the license and commercialization agreement, Junshi Biosciences will grant a licence to Dr. Reddy's to develop and exclusively commercialize toripalimab in Brazil, Mexico, Colombia, Argentina, Peru, Chile, Panama, Uruguay, India and South Africa1. Dr. Reddy's may elect to expand the scope of the license to cover Australia, New Zealand and nine other countries2.\n\nUnder the terms of the agreement, Junshi Biosciences also grants Dr. Reddy's the exclusive right of first negotiation for commercialization, in the event that Junshi Biosciences determines to grant any third party the rights to commercialize two other products as agreed in the agreement in one or more countries within the total 21 countries of Dr. Reddy's Territory3.\n\nJunshi Biosciences may receive up to an aggregate of US$728.3 million for upfront payment, potential expansion of Dr. Reddy's Territory and milestone payment, plus double-digit percentage of royalties on the net sales of products containing toripalimab.\n\nAbout Toripalimab\n\nToripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system's ability to attack and kill tumor cells.\n\nMore than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.\n\nIn China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYIÂ®). Currently, there are six approved indications for toripalimab in China:\n\nunresectable or metastatic melanoma after failure of standard systemic therapy;recurrent or metastatic NPC after failure of at least two lines of prior systemic therapy;locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma (\"ESCC\");in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (\"NSCLC\").\n\nThe first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma.\n\nIn the United States, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine/cisplatin, for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (FDA). The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (SCLC).\n\nIn Europe, marketing authorization applications (MAA) were accepted by the European Medicines Agency (EMA) and the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic ESCC, in December 2022 and February 2023.\n\nAbout Dr. Reddy's\n\nDr. Reddy's is a global pharmaceutical company headquartered in Hyderabad, India and listed on the New York Stock Exchange (stock code: RDY), the National Stock Exchange of India (stock code: DRREDDY), and the Bombay Stock Exchange (stock code: 500124). Established in 1984, Dr. Reddy's is committed to providing access to affordable and innovative medicines. Driven by its purpose of 'Good Health Can't Wait', Dr. Reddy's offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Dr. Reddy's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its major markets include - the United States, India, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, Dr. Reddy's continues to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, Dr. Reddy's released its first Sustainability Report in 2004. Its current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.\n\nAbout Junshi Biosciences\n\nFounded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.\n\nIn the face of the pandemic, Junshi Biosciences' response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. In 2021, JS016 (etesevimab), China's first neutralizing fully human monoclonal antibody against SARS-CoV-2 administered with bamlanivimab, was granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116 (deuremidevir hydrobromide), a novel oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, has been approved for marketing in China and Uzbekistan. The JS016 and VV116 programs are a part of the company's continuous efforts towards innovation for disease control and prevention of the global pandemic.\n\nJunshi Biosciences has about 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.\n\nJunshi Biosciences Contact Information\n\nIR Team:\n\nJunshi Biosciences\n\ninfo@junshipharma.com\n\n+ 86 021-6105 8800\n\nPR Team:\n\nJunshi Biosciences\n\nZhi Li\n\nzhi_li@junshipharma.com\n\n+ 86 021-6105 8800\n\n1 Collectively, \"Dr. Reddy's Territory 1\"\n\n2 Collectively, \"Dr. Reddy's Territory 2\"\n\n3 Both \"Dr. Reddy's Territory 1\" and \"Dr. Reddy's Territory 2\" are collectively known as \"Dr. Reddy's Territory\", totalling 21 countries.",
            "source": {
                "uri": "messenger-inquirer.com",
                "dataType": "news",
                "title": "Owensboro Messenger-Inquirer"
            },
            "authors": [],
            "image": "https://bloximages.chicago2.vip.townnews.com/messenger-inquirer.com/content/tncms/custom/image/c52fb608-0a01-11e5-9c50-bbf37a41334d.jpg?resize=600%2C315",
            "eventUri": null,
            "sentiment": 0.2941176470588236,
            "wgt": 421202340,
            "relevance": 100
        },
        {
            "uri": "7533659228",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-08",
            "time": "00:31:00",
            "dateTime": "2023-05-08T00:31:00Z",
            "dateTimePub": "2023-05-08T00:30:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.livemint.com/news/india/q4-earnings-canara-bank-indian-bank-and-birlasoftn-set-to-release-today-11683504496589.html",
            "title": "Q4 earnings: Canara Bank, Indian Bank, and Birlasoftn set to release today",
            "body": "The earnings season for the March quarter has been a combination of good and bad news, with the prominent IT companies failing to meet expectations, while the banking and financial sector performed well and reported strong numbers.\n\nThe stock market experienced a significant decline last week after an impressive rally.\n\nThe following companies are also expected to release their financial results for the March quarter: Pidilite Industries, Canara Bank, UPL, CG Power and Industrial Solutions, Indian Bank, Kansai Nerolac Paints, Carborundum Universal, Aarti Industries, Exide Industries, Happiest Minds Technologies, Apar Industries, Mahanagar Gas, HFCL, VIP Industries, Kalpataru Power Transmissions, Birlasoft, Craftsman Automation, IRB InvIT Fund, Shriram Pistons & Rings, Apollo Pipes, Andhra Paper, and Hindustan Motors.\n\nThis week, a number of well-known companies including Tata Motors, L&T, Dr Reddy's Laboratories, Asian Paints, Eicher Motors, Vedanta, Hindustan Aeronautics, DLF, and Avenue Supermarts are scheduled to release their financial results for the March quarter.\n\nThe performance of companies such as Tata Motors, DLF, Vedanta, Apollo Pipes, Eveready Industries India Ltd, and Matrimony.com in the stock market will be greatly influenced by their quarterly financial results.\n\nOn Friday, the Sensex index dropped by 694.96 points, closing at 61,054.29, while the Nifty index fell by 186.80 points to reach 18,069. As a result, the market capitalization of all companies listed on the BSE also decreased by Rs. 1.43 lakh crore, reaching Rs. 273.77 lakh crore.",
            "source": {
                "uri": "livemint.com",
                "dataType": "news",
                "title": "mint"
            },
            "authors": [],
            "image": "https://www.livemint.com/lm-img/img/2023/05/08/600x338/2019-03-19T1045_1683505227115_1683505227350.JPG",
            "eventUri": null,
            "sentiment": 0.3490196078431373,
            "wgt": 421201860,
            "relevance": 1
        },
        {
            "uri": "7533562519",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-07",
            "time": "22:08:00",
            "dateTime": "2023-05-07T22:08:00Z",
            "dateTimePub": "2023-05-07T14:07:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.marketscreener.com//quote/stock/SHANGHAI-JUNSHI-BIOSCIENC-55886669/news/Junshi-Biosciences-Announces-Collaboration-with-Dr-Reddy-s-to-Develop-and-Commercialize-Toripalimab-43773096/",
            "title": "Junshi Biosciences Announces Collaboration with Dr. Reddy's to Develop and Commercialize Toripalimab in 21 Countries | MarketScreener",
            "body": "SHANGHAI, China, May 07, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\"Junshi Biosciences\", HKEX: 1877; SSE: 688180) announced a collaboration with Dr. Reddy's Laboratories Limited (\"Dr. Reddy's\") to develop and commercialize toripalimab, the anti-PD-1 monoclonal antibody in Latin America, India, South Africa, and at the election of Dr. Reddy's, also in Australia, New Zealand and other countries.\n\n\"We are thrilled to have established a partnership with Dr. Reddy's while toripalimab's global commercial network has been steadily expanding, reaching more than 50 countries and advancing our mission of being 'In China, For Global,'\" said Dr. Ning LI, Chief Executive Officer of Junshi Biosciences. \"Dr. Reddy's is a well-respected global pharmaceutical company and extends its business over nearly 70 countries worldwide, achieving impressive commerical presence across the globe. We hope that in the near future, leveraging Dr. Reddy's partnership and strong presence, our innovative medicines can accelerate access to new geographies and deliver better and more affordable treatment options to even more patients.\"\n\nM.V. Ramana, CEO - Branded Markets (India & Emerging Markets), Dr. Reddy's said, \"We are pleased to partner with Junshi Biosciences to take this important product to more patients. Oncology is a focus area for Dr. Reddy's. This partnership is a further step towards increasing our offerings to patients in oncology as we aim to build a robust and comprehensive portfolio in the segment. We are committed to facilitating access to innovative products as we pursue our goal of serving over 1.5 billion patients by 2030.\"\n\nUnder the license and commercialization agreement, Junshi Biosciences will grant a licence to Dr. Reddy's to develop and exclusively commercialize toripalimab in Brazil, Mexico, Colombia, Argentina, Peru, Chile, Panama, Uruguay, India and South Africa1. Dr. Reddy's may elect to expand the scope of the license to cover Australia, New Zealand and nine other countries2.\n\nUnder the terms of the agreement, Junshi Biosciences also grants Dr. Reddy's the exclusive right of first negotiation for commercialization, in the event that Junshi Biosciences determines to grant any third party the rights to commercialize two other products as agreed in the agreement in one or more countries within the total 21 countries of Dr. Reddy's Territory3.\n\nJunshi Biosciences may receive up to an aggregate of US$728.3 million for upfront payment, potential expansion of Dr. Reddy's Territory and milestone payment, plus double-digit percentage of royalties on the net sales of products containing toripalimab.\n\nAbout Toripalimab\n\nToripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system's ability to attack and kill tumor cells.\n\nMore than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.\n\nIn China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYIÂ®). Currently, there are six approved indications for toripalimab in China:\n\nunresectable or metastatic melanoma after failure of standard systemic therapy;recurrent or metastatic NPC after failure of at least two lines of prior systemic therapy;locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma (\"ESCC\");in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (\"NSCLC\").\n\nThe first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma.\n\nIn the United States, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine/cisplatin, for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (FDA). The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (SCLC).\n\nIn Europe, marketing authorization applications (MAA) were accepted by the European Medicines Agency (EMA) and the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic ESCC, in December 2022 and February 2023.\n\nAbout Dr. Reddy's\n\nDr. Reddy's is a global pharmaceutical company headquartered in Hyderabad, India and listed on the New York Stock Exchange (stock code: RDY), the National Stock Exchange of India (stock code: DRREDDY), and the Bombay Stock Exchange (stock code: 500124). Established in 1984, Dr. Reddy's is committed to providing access to affordable and innovative medicines. Driven by its purpose of 'Good Health Can't Wait', Dr. Reddy's offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Dr. Reddy's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its major markets include - the United States, India, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, Dr. Reddy's continues to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, Dr. Reddy's released its first Sustainability Report in 2004. Its current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.\n\nAbout Junshi Biosciences\n\nFounded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.\n\nIn the face of the pandemic, Junshi Biosciences' response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. In 2021, JS016 (etesevimab), China's first neutralizing fully human monoclonal antibody against SARS-CoV-2 administered with bamlanivimab, was granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116 (deuremidevir hydrobromide), a novel oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, has been approved for marketing in China and Uzbekistan. The JS016 and VV116 programs are a part of the company's continuous efforts towards innovation for disease control and prevention of the global pandemic.\n\nJunshi Biosciences has about 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.\n\nJunshi Biosciences Contact Information\n\nIR Team:\n\nJunshi Biosciences\n\ninfo@junshipharma.com\n\n+ 86 021-6105 8800\n\nPR Team:\n\nJunshi Biosciences\n\nZhi Li\n\nzhi_li@junshipharma.com\n\n+ 86 021-6105 8800\n\n1 Collectively, \"Dr. Reddy's Territory 1\"\n\n2 Collectively, \"Dr. Reddy's Territory 2\"\n\n3 Both \"Dr. Reddy's Territory 1\" and \"Dr. Reddy's Territory 2\" are collectively known as \"Dr. Reddy's Territory\", totalling 21 countries.",
            "source": {
                "uri": "marketscreener.com",
                "dataType": "news",
                "title": "Market Screener"
            },
            "authors": [],
            "image": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "eventUri": null,
            "sentiment": 0.2941176470588236,
            "wgt": 421193280,
            "relevance": 100
        },
        {
            "uri": "7533189561",
            "lang": "eng",
            "isDuplicate": true,
            "date": "2023-05-07",
            "time": "15:05:00",
            "dateTime": "2023-05-07T15:05:00Z",
            "dateTimePub": "2023-05-07T14:07:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.asiaone.com/business/junshi-biosciences-announces-collaboration-dr-reddy-s-develop-and-commercialize",
            "title": "AsiaOne",
            "body": "SHANGHAI, China, May 07, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\"Junshi Biosciences\", HKEX: 1877; SSE: 688180) announced a collaboration with Dr. Reddy's Laboratories Limited (\"Dr. Reddy's\") to develop and commercialize toripalimab, the anti-PD-1 monoclonal antibody in Latin America, India, South Africa, and at the election of Dr. Reddy's, also in Australia, New Zealand and other countries.\n\n\"We are thrilled to have established a partnership with Dr. Reddy's while toripalimab's global commercial network has been steadily expanding, reaching more than 50 countries and advancing our mission of being 'In China, For Global,'\" said Dr. Ning LI, Chief Executive Officer of Junshi Biosciences. \"Dr. Reddy's is a well-respected global pharmaceutical company and extends its business over nearly 70 countries worldwide, achieving impressive commerical presence across the globe. We hope that in the near future, leveraging Dr. Reddy's partnership and strong presence, our innovative medicines can accelerate access to new geographies and deliver better and more affordable treatment options to even more patients.\"\n\nM.V. Ramana, CEO - Branded Markets (India & Emerging Markets), Dr. Reddy's said, \"We are pleased to partner with Junshi Biosciences to take this important product to more patients. Oncology is a focus area for Dr. Reddy's. This partnership is a further step towards increasing our offerings to patients in oncology as we aim to build a robust and comprehensive portfolio in the segment. We are committed to facilitating access to innovative products as we pursue our goal of serving over 1.5 billion patients by 2030.\"\n\nUnder the license and commercialization agreement, Junshi Biosciences will grant a licence to Dr. Reddy's to develop and exclusively commercialize toripalimab in Brazil, Mexico, Colombia, Argentina, Peru, Chile, Panama, Uruguay, India and South Africa. Dr. Reddy's may elect to expand the scope of the license to cover Australia, New Zealand and nine other countries.\n\nUnder the terms of the agreement, Junshi Biosciences also grants Dr. Reddy's the exclusive right of first negotiation for commercialization, in the event that Junshi Biosciences determines to grant any third party the rights to commercialize two other products as agreed in the agreement in one or more countries within the total 21 countries of Dr. Reddy's Territory.\n\nJunshi Biosciences may receive up to an aggregate of US$728.3 million for upfront payment, potential expansion of Dr. Reddy's Territory and milestone payment, plus double-digit percentage of royalties on the net sales of products containing toripalimab.\n\nAbout Toripalimab\n\nToripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system's ability to attack and kill tumor cells.\n\nMore than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.\n\nIn China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI). Currently, there are six approved indications for toripalimab in China:\n\nThe first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma.\n\nIn the United States, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine/cisplatin, for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (FDA). The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (SCLC).\n\nIn Europe, marketing authorization applications (MAA) were accepted by the European Medicines Agency (EMA) and the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic ESCC, in December 2022 and February 2023.\n\nAbout Dr. Reddy's\n\nDr. Reddy's is a global pharmaceutical company headquartered in Hyderabad, India and listed on the New York Stock Exchange (stock code: RDY), the National Stock Exchange of India (stock code: DRREDDY), and the Bombay Stock Exchange (stock code: 500124). Established in 1984, Dr. Reddy's is committed to providing access to affordable and innovative medicines. Driven by its purpose of 'Good Health Can't Wait', Dr. Reddy's offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Dr. Reddy's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its major markets include - the United States, India, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, Dr. Reddy's continues to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, Dr. Reddy's released its first Sustainability Report in 2004. Its current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.\n\nAbout Junshi Biosciences\n\nFounded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.\n\nIn the face of the pandemic, Junshi Biosciences' response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. In 2021, JS016 (etesevimab), China's first neutralizing fully human monoclonal antibody against SARS-CoV-2 administered with bamlanivimab, was granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116 (deuremidevir hydrobromide), a novel oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, has been approved for marketing in China and Uzbekistan. The JS016 and VV116 programs are a part of the company's continuous efforts towards innovation for disease control and prevention of the global pandemic.\n\nJunshi Biosciences has about 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.\n\nCollectively, \"Dr. Reddy's Territory 1\"\n\nCollectively, \"Dr. Reddy's Territory 2\"\n\nBoth \"Dr. Reddy's Territory 1\" and \"Dr. Reddy's Territory 2\" are collectively known as \"Dr. Reddy's Territory\", totalling 21 countries.",
            "source": {
                "uri": "asiaone.com",
                "dataType": "news",
                "title": "AsiaOne"
            },
            "authors": [],
            "image": "https://media.asiaone.com/sites/default/files/styles/a1_600x316/public/original_images/May2023/Notified-GlobeNewswire-Color-Large_133.jpg?h=10d202d3&itok=_ge0ZVYH",
            "eventUri": null,
            "sentiment": 0.2941176470588236,
            "wgt": 421167900,
            "relevance": 100
        },
        {
            "uri": "7533180614",
            "lang": "eng",
            "isDuplicate": true,
            "date": "2023-05-07",
            "time": "14:56:00",
            "dateTime": "2023-05-07T14:56:00Z",
            "dateTimePub": "2023-05-07T14:07:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://finance.yahoo.com/news/junshi-biosciences-announces-collaboration-dr-140700630.html",
            "title": "Junshi Biosciences Announces Collaboration with Dr. Reddy's to Develop and Commercialize Toripalimab in 21 Countries",
            "body": "SHANGHAI, China, May 07, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\"Junshi Biosciences\", HKEX: 1877; SSE: 688180) announced a collaboration with Dr. Reddy's Laboratories Limited (\"Dr. Reddy's\") to develop and commercialize toripalimab, the anti-PD-1 monoclonal antibody in Latin America, India, South Africa, and at the election of Dr. Reddy's, also in Australia, New Zealand and other countries.\n\n\"We are thrilled to have established a partnership with Dr. Reddy's while toripalimab's global commercial network has been steadily expanding, reaching more than 50 countries and advancing our mission of being 'In China, For Global,'\" said Dr. Ning LI, Chief Executive Officer of Junshi Biosciences. \"Dr. Reddy's is a well-respected global pharmaceutical company and extends its business over nearly 70 countries worldwide, achieving impressive commerical presence across the globe. We hope that in the near future, leveraging Dr. Reddy's partnership and strong presence, our innovative medicines can accelerate access to new geographies and deliver better and more affordable treatment options to even more patients.\"\n\nM.V. Ramana, CEO - Branded Markets (India & Emerging Markets), Dr. Reddy's said, \"We are pleased to partner with Junshi Biosciences to take this important product to more patients. Oncology is a focus area for Dr. Reddy's. This partnership is a further step towards increasing our offerings to patients in oncology as we aim to build a robust and comprehensive portfolio in the segment. We are committed to facilitating access to innovative products as we pursue our goal of serving over 1.5 billion patients by 2030.\"\n\nUnder the license and commercialization agreement, Junshi Biosciences will grant a licence to Dr. Reddy's to develop and exclusively commercialize toripalimab in Brazil, Mexico, Colombia, Argentina, Peru, Chile, Panama, Uruguay, India and South Africa. Dr. Reddy's may elect to expand the scope of the license to cover Australia, New Zealand and nine other countries.\n\nUnder the terms of the agreement, Junshi Biosciences also grants Dr. Reddy's the exclusive right of first negotiation for commercialization, in the event that Junshi Biosciences determines to grant any third party the rights to commercialize two other products as agreed in the agreement in one or more countries within the total 21 countries of Dr. Reddy's Territory.\n\nJunshi Biosciences may receive up to an aggregate of US$728.3 million for upfront payment, potential expansion of Dr. Reddy's Territory and milestone payment, plus double-digit percentage of royalties on the net sales of products containing toripalimab.\n\nAbout Toripalimab\n\nToripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system's ability to attack and kill tumor cells.\n\nMore than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.\n\nIn China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI). Currently, there are six approved indications for toripalimab in China:\n\nThe first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma.\n\nIn the United States, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine/cisplatin, for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (FDA). The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (SCLC).\n\nIn Europe, marketing authorization applications (MAA) were accepted by the European Medicines Agency (EMA) and the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic ESCC, in December 2022 and February 2023.\n\nAbout Dr. Reddy's\n\nDr. Reddy's is a global pharmaceutical company headquartered in Hyderabad, India and listed on the New York Stock Exchange (stock code: RDY), the National Stock Exchange of India (stock code: DRREDDY), and the Bombay Stock Exchange (stock code: 500124). Established in 1984, Dr. Reddy's is committed to providing access to affordable and innovative medicines. Driven by its purpose of 'Good Health Can't Wait', Dr. Reddy's offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Dr. Reddy's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its major markets include - the United States, India, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, Dr. Reddy's continues to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, Dr. Reddy's released its first Sustainability Report in 2004. Its current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.\n\nAbout Junshi Biosciences\n\nFounded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.\n\nIn the face of the pandemic, Junshi Biosciences' response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. In 2021, JS016 (etesevimab), China's first neutralizing fully human monoclonal antibody against SARS-CoV-2 administered with bamlanivimab, was granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116 (deuremidevir hydrobromide), a novel oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, has been approved for marketing in China and Uzbekistan. The JS016 and VV116 programs are a part of the company's continuous efforts towards innovation for disease control and prevention of the global pandemic.\n\nJunshi Biosciences has about 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.\n\nCollectively, \"Dr. Reddy's Territory 1\"\n\nCollectively, \"Dr. Reddy's Territory 2\"\n\nBoth \"Dr. Reddy's Territory 1\" and \"Dr. Reddy's Territory 2\" are collectively known as \"Dr. Reddy's Territory\", totalling 21 countries.",
            "source": {
                "uri": "finance.yahoo.com",
                "dataType": "news",
                "title": "Yahoo! Finance"
            },
            "authors": [],
            "image": "https://media.zenfs.com/en/globenewswire.com/93ceb6da9d832e14ab2c5646fb8cb9e1",
            "eventUri": null,
            "sentiment": 0.2941176470588236,
            "wgt": 421167360,
            "relevance": 100
        },
        {
            "uri": "7533150568",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-07",
            "time": "14:25:00",
            "dateTime": "2023-05-07T14:25:00Z",
            "dateTimePub": "2023-05-07T14:22:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.finanznachrichten.de/nachrichten-2023-05/59016697-junshi-biosciences-announces-collaboration-with-dr-reddy-s-to-develop-and-commercialize-toripalimab-in-21-countries-399.htm",
            "title": "Junshi Biosciences Announces Collaboration with Dr. Reddy's to Develop and Commercialize Toripalimab in 21 Countries",
            "body": "SHANGHAI, China, May 07, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\"Junshi Biosciences\", HKEX: 1877; SSE: 688180) announced a collaboration with Dr. Reddy's Laboratories Limited (\"Dr. Reddy's\") to develop and commercialize toripalimab, the anti-PD-1 monoclonal antibody in Latin America, India, South Africa, and at the election of Dr. Reddy's, also in Australia, New Zealand and other countries.\n\n\"We are thrilled to have established a partnership with Dr. Reddy's while toripalimab's global commercial network has been steadily expanding, reaching more than 50 countries and advancing our mission of being 'In China, For Global,'\" said Dr. Ning LI, Chief Executive Officer of Junshi Biosciences. \"Dr. Reddy's is a well-respected global pharmaceutical company and extends its business over nearly 70 countries worldwide, achieving impressive commerical presence across the globe. We hope that in the near future, leveraging Dr. Reddy's partnership and strong presence, our innovative medicines can accelerate access to new geographies and deliver better and more affordable treatment options to even more patients.\"\n\nM.V. Ramana, CEO - Branded Markets (India & Emerging Markets), Dr. Reddy's said, \"We are pleased to partner with Junshi Biosciences to take this important product to more patients. Oncology is a focus area for Dr. Reddy's. This partnership is a further step towards increasing our offerings to patients in oncology as we aim to build a robust and comprehensive portfolio in the segment. We are committed to facilitating access to innovative products as we pursue our goal of serving over 1.5 billion patients by 2030.\"\n\nUnder the license and commercialization agreement, Junshi Biosciences will grant a licence to Dr. Reddy's to develop and exclusively commercialize toripalimab in Brazil, Mexico, Colombia, Argentina, Peru, Chile, Panama, Uruguay, India and South Africa1. Dr. Reddy's may elect to expand the scope of the license to cover Australia, New Zealand and nine other countries2.\n\nUnder the terms of the agreement, Junshi Biosciences also grants Dr. Reddy's the exclusive right of first negotiation for commercialization, in the event that Junshi Biosciences determines to grant any third party the rights to commercialize two other products as agreed in the agreement in one or more countries within the total 21 countries of Dr. Reddy's Territory3.\n\nJunshi Biosciences may receive up to an aggregate of US$728.3 million for upfront payment, potential expansion of Dr. Reddy's Territory and milestone payment, plus double-digit percentage of royalties on the net sales of products containing toripalimab.\n\nAbout Toripalimab\n\nToripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system's ability to attack and kill tumor cells.\n\nMore than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.\n\nIn China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYIÂ®). Currently, there are six approved indications for toripalimab in China:\n\nunresectable or metastatic melanoma after failure of standard systemic therapy;recurrent or metastatic NPC after failure of at least two lines of prior systemic therapy;locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma (\"ESCC\");in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (\"NSCLC\").\n\nThe first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma.\n\nIn the United States, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine/cisplatin, for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (FDA). The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (SCLC).\n\nIn Europe, marketing authorization applications (MAA) were accepted by the European Medicines Agency (EMA) and the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic ESCC, in December 2022 and February 2023.\n\nAbout Dr. Reddy's\n\nDr. Reddy's is a global pharmaceutical company headquartered in Hyderabad, India and listed on the New York Stock Exchange (stock code: RDY), the National Stock Exchange of India (stock code: DRREDDY), and the Bombay Stock Exchange (stock code: 500124). Established in 1984, Dr. Reddy's is committed to providing access to affordable and innovative medicines. Driven by its purpose of 'Good Health Can't Wait', Dr. Reddy's offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Dr. Reddy's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its major markets include - the United States, India, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, Dr. Reddy's continues to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, Dr. Reddy's released its first Sustainability Report in 2004. Its current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.\n\nAbout Junshi Biosciences\n\nFounded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.\n\nIn the face of the pandemic, Junshi Biosciences' response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. In 2021, JS016 (etesevimab), China's first neutralizing fully human monoclonal antibody against SARS-CoV-2 administered with bamlanivimab, was granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116 (deuremidevir hydrobromide), a novel oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, has been approved for marketing in China and Uzbekistan. The JS016 and VV116 programs are a part of the company's continuous efforts towards innovation for disease control and prevention of the global pandemic.\n\nJunshi Biosciences has about 3,100 employees in the United States.\n\nJunshi Biosciences Contact Information\n\nIR Team:\n\nJunshi Biosciences\n\ninfo@junshipharma.com\n\n+ 86 021-6105 8800\n\nPR Team:\n\nJunshi Biosciences\n\nZhi Li\n\nzhi_li@junshipharma.com\n\n+ 86 021-6105 8800\n\n1 Collectively, \"Dr. Reddy's Territory 1\"\n\n2 Collectively, \"Dr. Reddy's Territory 2\"\n\n3 Both \"Dr. Reddy's Territory 1\" and \"Dr. Reddy's Territory 2\" are collectively known as \"Dr. Reddy's Territory\", totalling 21 countries.",
            "source": {
                "uri": "finanznachrichten.de",
                "dataType": "news",
                "title": "FinanzNachrichten.de"
            },
            "authors": [],
            "image": "https://ml.globenewswire.com/media/NGY0MDAwNjMtYzRkMS00YzFhLThlNjAtMjgwM2VmNmU5MmZiLTEyMDY5Mjg=/tiny/Junshi-Biosciences.png",
            "eventUri": null,
            "sentiment": 0.2941176470588236,
            "wgt": 421165500,
            "relevance": 100
        },
        {
            "uri": "7533145531",
            "lang": "eng",
            "isDuplicate": true,
            "date": "2023-05-07",
            "time": "14:22:00",
            "dateTime": "2023-05-07T14:22:00Z",
            "dateTimePub": "2023-05-07T14:07:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://sports.yahoo.com/junshi-biosciences-announces-collaboration-dr-140700630.html",
            "title": "Junshi Biosciences Announces Collaboration with Dr. Reddy's to Develop and Commercialize Toripalimab in 21 Countries",
            "body": "SHANGHAI, China, May 07, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\"Junshi Biosciences\", HKEX: 1877; SSE: 688180) announced a collaboration with Dr. Reddy's Laboratories Limited (\"Dr. Reddy's\") to develop and commercialize toripalimab, the anti-PD-1 monoclonal antibody in Latin America, India, South Africa, and at the election of Dr. Reddy's, also in Australia, New Zealand and other countries.\n\n\"We are thrilled to have established a partnership with Dr. Reddy's while toripalimab's global commercial network has been steadily expanding, reaching more than 50 countries and advancing our mission of being 'In China, For Global,'\" said Dr. Ning LI, Chief Executive Officer of Junshi Biosciences. \"Dr. Reddy's is a well-respected global pharmaceutical company and extends its business over nearly 70 countries worldwide, achieving impressive commerical presence across the globe. We hope that in the near future, leveraging Dr. Reddy's partnership and strong presence, our innovative medicines can accelerate access to new geographies and deliver better and more affordable treatment options to even more patients.\"\n\nM.V. Ramana, CEO - Branded Markets (India & Emerging Markets), Dr. Reddy's said, \"We are pleased to partner with Junshi Biosciences to take this important product to more patients. Oncology is a focus area for Dr. Reddy's. This partnership is a further step towards increasing our offerings to patients in oncology as we aim to build a robust and comprehensive portfolio in the segment. We are committed to facilitating access to innovative products as we pursue our goal of serving over 1.5 billion patients by 2030.\"\n\nUnder the license and commercialization agreement, Junshi Biosciences will grant a licence to Dr. Reddy's to develop and exclusively commercialize toripalimab in Brazil, Mexico, Colombia, Argentina, Peru, Chile, Panama, Uruguay, India and South Africa. Dr. Reddy's may elect to expand the scope of the license to cover Australia, New Zealand and nine other countries.\n\nUnder the terms of the agreement, Junshi Biosciences also grants Dr. Reddy's the exclusive right of first negotiation for commercialization, in the event that Junshi Biosciences determines to grant any third party the rights to commercialize two other products as agreed in the agreement in one or more countries within the total 21 countries of Dr. Reddy's Territory.\n\nJunshi Biosciences may receive up to an aggregate of US$728.3 million for upfront payment, potential expansion of Dr. Reddy's Territory and milestone payment, plus double-digit percentage of royalties on the net sales of products containing toripalimab.\n\nAbout Toripalimab\n\nToripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system's ability to attack and kill tumor cells.\n\nMore than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.\n\nIn China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI). Currently, there are six approved indications for toripalimab in China:\n\nThe first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma.\n\nIn the United States, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine/cisplatin, for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (FDA). The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (SCLC).\n\nIn Europe, marketing authorization applications (MAA) were accepted by the European Medicines Agency (EMA) and the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic ESCC, in December 2022 and February 2023.\n\nAbout Dr. Reddy's\n\nDr. Reddy's is a global pharmaceutical company headquartered in Hyderabad, India and listed on the New York Stock Exchange (stock code: RDY), the National Stock Exchange of India (stock code: DRREDDY), and the Bombay Stock Exchange (stock code: 500124). Established in 1984, Dr. Reddy's is committed to providing access to affordable and innovative medicines. Driven by its purpose of 'Good Health Can't Wait', Dr. Reddy's offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Dr. Reddy's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its major markets include - the United States, India, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, Dr. Reddy's continues to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, Dr. Reddy's released its first Sustainability Report in 2004. Its current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.\n\nAbout Junshi Biosciences\n\nFounded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.\n\nIn the face of the pandemic, Junshi Biosciences' response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. In 2021, JS016 (etesevimab), China's first neutralizing fully human monoclonal antibody against SARS-CoV-2 administered with bamlanivimab, was granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116 (deuremidevir hydrobromide), a novel oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, has been approved for marketing in China and Uzbekistan. The JS016 and VV116 programs are a part of the company's continuous efforts towards innovation for disease control and prevention of the global pandemic.\n\nJunshi Biosciences has about 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.\n\nCollectively, \"Dr. Reddy's Territory 1\"\n\nCollectively, \"Dr. Reddy's Territory 2\"\n\nBoth \"Dr. Reddy's Territory 1\" and \"Dr. Reddy's Territory 2\" are collectively known as \"Dr. Reddy's Territory\", totalling 21 countries.",
            "source": {
                "uri": "sports.yahoo.com",
                "dataType": "news",
                "title": "Yahoo Sports"
            },
            "authors": [],
            "image": "https://media.zenfs.com/en/globenewswire.com/93ceb6da9d832e14ab2c5646fb8cb9e1",
            "eventUri": null,
            "sentiment": 0.2941176470588236,
            "wgt": 421165320,
            "relevance": 100
        },
        {
            "uri": "7533139651",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-07",
            "time": "14:22:00",
            "dateTime": "2023-05-07T14:22:00Z",
            "dateTimePub": "2023-05-07T14:07:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://ca.sports.yahoo.com/news/junshi-biosciences-announces-collaboration-dr-140700630.html",
            "title": "Junshi Biosciences Announces Collaboration with Dr. Reddy's to Develop and Commercialize Toripalimab in 21 Countries",
            "body": "SHANGHAI, China, May 07, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\"Junshi Biosciences\", HKEX: 1877; SSE: 688180) announced a collaboration with Dr. Reddy's Laboratories Limited (\"Dr. Reddy's\") to develop and commercialize toripalimab, the anti-PD-1 monoclonal antibody in Latin America, India, South Africa, and at the election of Dr. Reddy's, also in Australia, New Zealand and other countries.\n\n\"We are thrilled to have established a partnership with Dr. Reddy's while toripalimab's global commercial network has been steadily expanding, reaching more than 50 countries and advancing our mission of being 'In China, For Global,'\" said Dr. Ning LI, Chief Executive Officer of Junshi Biosciences. \"Dr. Reddy's is a well-respected global pharmaceutical company and extends its business over nearly 70 countries worldwide, achieving impressive commerical presence across the globe. We hope that in the near future, leveraging Dr. Reddy's partnership and strong presence, our innovative medicines can accelerate access to new geographies and deliver better and more affordable treatment options to even more patients.\"\n\nM.V. Ramana, CEO - Branded Markets (India & Emerging Markets), Dr. Reddy's said, \"We are pleased to partner with Junshi Biosciences to take this important product to more patients. Oncology is a focus area for Dr. Reddy's. This partnership is a further step towards increasing our offerings to patients in oncology as we aim to build a robust and comprehensive portfolio in the segment. We are committed to facilitating access to innovative products as we pursue our goal of serving over 1.5 billion patients by 2030.\"\n\nUnder the license and commercialization agreement, Junshi Biosciences will grant a licence to Dr. Reddy's to develop and exclusively commercialize toripalimab in Brazil, Mexico, Colombia, Argentina, Peru, Chile, Panama, Uruguay, India and South Africa. Dr. Reddy's may elect to expand the scope of the license to cover Australia, New Zealand and nine other countries.\n\nUnder the terms of the agreement, Junshi Biosciences also grants Dr. Reddy's the exclusive right of first negotiation for commercialization, in the event that Junshi Biosciences determines to grant any third party the rights to commercialize two other products as agreed in the agreement in one or more countries within the total 21 countries of Dr. Reddy's Territory.\n\nJunshi Biosciences may receive up to an aggregate of US$728.3 million for upfront payment, potential expansion of Dr. Reddy's Territory and milestone payment, plus double-digit percentage of royalties on the net sales of products containing toripalimab.\n\nAbout Toripalimab\n\nToripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system's ability to attack and kill tumor cells.\n\nMore than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.\n\nIn China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI). Currently, there are six approved indications for toripalimab in China:\n\nThe first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma.\n\nIn the United States, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine/cisplatin, for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (FDA). The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (SCLC).\n\nIn Europe, marketing authorization applications (MAA) were accepted by the European Medicines Agency (EMA) and the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic ESCC, in December 2022 and February 2023.\n\nAbout Dr. Reddy's\n\nDr. Reddy's is a global pharmaceutical company headquartered in Hyderabad, India and listed on the New York Stock Exchange (stock code: RDY), the National Stock Exchange of India (stock code: DRREDDY), and the Bombay Stock Exchange (stock code: 500124). Established in 1984, Dr. Reddy's is committed to providing access to affordable and innovative medicines. Driven by its purpose of 'Good Health Can't Wait', Dr. Reddy's offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Dr. Reddy's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its major markets include - the United States, India, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, Dr. Reddy's continues to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, Dr. Reddy's released its first Sustainability Report in 2004. Its current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.\n\nAbout Junshi Biosciences\n\nFounded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.\n\nIn the face of the pandemic, Junshi Biosciences' response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. In 2021, JS016 (etesevimab), China's first neutralizing fully human monoclonal antibody against SARS-CoV-2 administered with bamlanivimab, was granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116 (deuremidevir hydrobromide), a novel oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, has been approved for marketing in China and Uzbekistan. The JS016 and VV116 programs are a part of the company's continuous efforts towards innovation for disease control and prevention of the global pandemic.\n\nJunshi Biosciences has about 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.\n\nCollectively, \"Dr. Reddy's Territory 1\"\n\nCollectively, \"Dr. Reddy's Territory 2\"\n\nBoth \"Dr. Reddy's Territory 1\" and \"Dr. Reddy's Territory 2\" are collectively known as \"Dr. Reddy's Territory\", totalling 21 countries.",
            "source": {
                "uri": "ca.sports.yahoo.com",
                "dataType": "news",
                "title": "Yahoo Sports"
            },
            "authors": [],
            "image": "https://media.zenfs.com/en/globenewswire.com/93ceb6da9d832e14ab2c5646fb8cb9e1",
            "eventUri": null,
            "sentiment": 0.2941176470588236,
            "wgt": 421165320,
            "relevance": 100
        },
        {
            "uri": "7533139896",
            "lang": "eng",
            "isDuplicate": true,
            "date": "2023-05-07",
            "time": "14:15:00",
            "dateTime": "2023-05-07T14:15:00Z",
            "dateTimePub": "2023-05-07T14:12:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.aktiespararna.se/analysguiden/nyheter/junshi-biosciences-announces-collaboration-dr-reddys-develop-and-commercialize-toripalimab",
            "title": "Junshi Biosciences Announces Collaboration with Dr. Reddy's to Develop and Commercialize Toripalimab in 21 Countries - Analysguiden",
            "body": "SHANGHAI, China, May 07, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\"Junshi Biosciences\", HKEX: 1877; SSE: 688180) announced a collaboration with Dr. Reddy's Laboratories Limited (\"Dr. Reddy's\") to develop and commercialize toripalimab, the anti-PD-1 monoclonal antibody in Latin America, India, South Africa, and at the election of Dr. Reddy's, also in Australia, New Zealand and other countries.\n\n\"We are thrilled to have established a partnership with Dr. Reddy's while toripalimab's global commercial network has been steadily expanding, reaching more than 50 countries and advancing our mission of being 'In China, For Global,'\" said Dr. Ning LI, Chief Executive Officer of Junshi Biosciences. \"Dr. Reddy's is a well-respected global pharmaceutical company and extends its business over nearly 70 countries worldwide, achieving impressive commerical presence across the globe. We hope that in the near future, leveraging Dr. Reddy's partnership and strong presence, our innovative medicines can accelerate access to new geographies and deliver better and more affordable treatment options to even more patients.\"\n\nM.V. Ramana, CEO - Branded Markets (India & Emerging Markets), Dr. Reddy's said, \"We are pleased to partner with Junshi Biosciences to take this important product to more patients. Oncology is a focus area for Dr. Reddy's. This partnership is a further step towards increasing our offerings to patients in oncology as we aim to build a robust and comprehensive portfolio in the segment. We are committed to facilitating access to innovative products as we pursue our goal of serving over 1.5 billion patients by 2030.\"\n\nUnder the license and commercialization agreement, Junshi Biosciences will grant a licence to Dr. Reddy's to develop and exclusively commercialize toripalimab in Brazil, Mexico, Colombia, Argentina, Peru, Chile, Panama, Uruguay, India and South Africa1. Dr. Reddy's may elect to expand the scope of the license to cover Australia, New Zealand and nine other countries2.\n\nUnder the terms of the agreement, Junshi Biosciences also grants Dr. Reddy's the exclusive right of first negotiation for commercialization, in the event that Junshi Biosciences determines to grant any third party the rights to commercialize two other products as agreed in the agreement in one or more countries within the total 21 countries of Dr. Reddy's Territory3.\n\nJunshi Biosciences may receive up to an aggregate of US$728.3 million for upfront payment, potential expansion of Dr. Reddy's Territory and milestone payment, plus double-digit percentage of royalties on the net sales of products containing toripalimab.\n\nAbout Toripalimab\n\nToripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system's ability to attack and kill tumor cells.\n\nMore than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.\n\nIn China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYIÂ®). Currently, there are six approved indications for toripalimab in China:\n\nThe first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma.\n\nIn the United States, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine/cisplatin, for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (FDA). The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (SCLC).\n\nIn Europe, marketing authorization applications (MAA) were accepted by the European Medicines Agency (EMA) and the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic ESCC, in December 2022 and February 2023.\n\nAbout Dr. Reddy's\n\nDr. Reddy's is a global pharmaceutical company headquartered in Hyderabad, India and listed on the New York Stock Exchange (stock code: RDY), the National Stock Exchange of India (stock code: DRREDDY), and the Bombay Stock Exchange (stock code: 500124). Established in 1984, Dr. Reddy's is committed to providing access to affordable and innovative medicines. Driven by its purpose of 'Good Health Can't Wait', Dr. Reddy's offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Dr. Reddy's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its major markets include - the United States, India, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, Dr. Reddy's continues to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, Dr. Reddy's released its first Sustainability Report in 2004. Its current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.\n\nAbout Junshi Biosciences\n\nFounded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.\n\nIn the face of the pandemic, Junshi Biosciences' response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. In 2021, JS016 (etesevimab), China's first neutralizing fully human monoclonal antibody against SARS-CoV-2 administered with bamlanivimab, was granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116 (deuremidevir hydrobromide), a novel oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, has been approved for marketing in China and Uzbekistan. The JS016 and VV116 programs are a part of the company's continuous efforts towards innovation for disease control and prevention of the global pandemic.\n\nJunshi Biosciences has about 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.\n\n1 Collectively, \"Dr. Reddy's Territory 1\"\n\n2 Collectively, \"Dr. Reddy's Territory 2\"\n\n3 Both \"Dr. Reddy's Territory 1\" and \"Dr. Reddy's Territory 2\" are collectively known as \"Dr. Reddy's Territory\", totalling 21 countries.",
            "source": {
                "uri": "aktiespararna.se",
                "dataType": "news",
                "title": "Aktiespararna"
            },
            "authors": [],
            "image": null,
            "eventUri": null,
            "sentiment": 0.2941176470588236,
            "wgt": 421164900,
            "relevance": 100
        },
        {
            "uri": "7533138070",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-07",
            "time": "14:13:00",
            "dateTime": "2023-05-07T14:13:00Z",
            "dateTimePub": "2023-05-07T14:12:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.marketscreener.com//quote/stock/SHANGHAI-JUNSHI-BIOSCIENC-55886669/news/Junshi-Biosciences-Announces-Collaboration-with-Dr-Reddy-s-to-Develop-and-Commercialize-Toripalimab-43770938/",
            "title": "Junshi Biosciences Announces Collaboration with Dr. Reddy's to Develop and Commercialize Toripalimab in 21 Countries | MarketScreener",
            "body": "SHANGHAI, China, May 07, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\"Junshi Biosciences\", HKEX: 1877; SSE: 688180) announced a collaboration with Dr. Reddy's Laboratories Limited (\"Dr. Reddy's\") to develop and commercialize toripalimab, the anti-PD-1 monoclonal antibody in Latin America, India, South Africa, and at the election of Dr. Reddy's, also in Australia, New Zealand and other countries.\n\n\"We are thrilled to have established a partnership with Dr. Reddy's while toripalimab's global commercial network has been steadily expanding, reaching more than 50 countries and advancing our mission of being 'In China, For Global,'\" said Dr. Ning LI, Chief Executive Officer of Junshi Biosciences. \"Dr. Reddy's is a well-respected global pharmaceutical company and extends its business over nearly 70 countries worldwide, achieving impressive commerical presence across the globe. We hope that in the near future, leveraging Dr. Reddy's partnership and strong presence, our innovative medicines can accelerate access to new geographies and deliver better and more affordable treatment options to even more patients.\"\n\nM.V. Ramana, CEO - Branded Markets (India & Emerging Markets), Dr. Reddy's said, \"We are pleased to partner with Junshi Biosciences to take this important product to more patients. Oncology is a focus area for Dr. Reddy's. This partnership is a further step towards increasing our offerings to patients in oncology as we aim to build a robust and comprehensive portfolio in the segment. We are committed to facilitating access to innovative products as we pursue our goal of serving over 1.5 billion patients by 2030.\"\n\nUnder the license and commercialization agreement, Junshi Biosciences will grant a licence to Dr. Reddy's to develop and exclusively commercialize toripalimab in Brazil, Mexico, Colombia, Argentina, Peru, Chile, Panama, Uruguay, India and South Africa1. Dr. Reddy's may elect to expand the scope of the license to cover Australia, New Zealand and nine other countries2.\n\nUnder the terms of the agreement, Junshi Biosciences also grants Dr. Reddy's the exclusive right of first negotiation for commercialization, in the event that Junshi Biosciences determines to grant any third party the rights to commercialize two other products as agreed in the agreement in one or more countries within the total 21 countries of Dr. Reddy's Territory3.\n\nJunshi Biosciences may receive up to an aggregate of US$728.3 million for upfront payment, potential expansion of Dr. Reddy's Territory and milestone payment, plus double-digit percentage of royalties on the net sales of products containing toripalimab.\n\nAbout Toripalimab\n\nToripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system's ability to attack and kill tumor cells.\n\nMore than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.\n\nIn China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYIÂ®). Currently, there are six approved indications for toripalimab in China:\n\nunresectable or metastatic melanoma after failure of standard systemic therapy;recurrent or metastatic NPC after failure of at least two lines of prior systemic therapy;locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma (\"ESCC\");in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (\"NSCLC\").\n\nThe first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma.\n\nIn the United States, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine/cisplatin, for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (FDA). The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (SCLC).\n\nIn Europe, marketing authorization applications (MAA) were accepted by the European Medicines Agency (EMA) and the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic ESCC, in December 2022 and February 2023.\n\nAbout Dr. Reddy's\n\nDr. Reddy's is a global pharmaceutical company headquartered in Hyderabad, India and listed on the New York Stock Exchange (stock code: RDY), the National Stock Exchange of India (stock code: DRREDDY), and the Bombay Stock Exchange (stock code: 500124). Established in 1984, Dr. Reddy's is committed to providing access to affordable and innovative medicines. Driven by its purpose of 'Good Health Can't Wait', Dr. Reddy's offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Dr. Reddy's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its major markets include - the United States, India, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, Dr. Reddy's continues to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, Dr. Reddy's released its first Sustainability Report in 2004. Its current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.\n\nAbout Junshi Biosciences\n\nFounded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.\n\nIn the face of the pandemic, Junshi Biosciences' response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. In 2021, JS016 (etesevimab), China's first neutralizing fully human monoclonal antibody against SARS-CoV-2 administered with bamlanivimab, was granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116 (deuremidevir hydrobromide), a novel oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, has been approved for marketing in China and Uzbekistan. The JS016 and VV116 programs are a part of the company's continuous efforts towards innovation for disease control and prevention of the global pandemic.\n\nJunshi Biosciences has about 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.\n\nJunshi Biosciences Contact Information\n\nIR Team:\n\nJunshi Biosciences\n\ninfo@junshipharma.com\n\n+ 86 021-6105 8800\n\nPR Team:\n\nJunshi Biosciences\n\nZhi Li\n\nzhi_li@junshipharma.com\n\n+ 86 021-6105 8800\n\n1 Collectively, \"Dr. Reddy's Territory 1\"\n\n2 Collectively, \"Dr. Reddy's Territory 2\"\n\n3 Both \"Dr. Reddy's Territory 1\" and \"Dr. Reddy's Territory 2\" are collectively known as \"Dr. Reddy's Territory\", totalling 21 countries.\n\nSource: Junshi Biosciences\n\n2023 GlobeNewswire, Inc., source Press Releases",
            "source": {
                "uri": "marketscreener.com",
                "dataType": "news",
                "title": "Market Screener"
            },
            "authors": [],
            "image": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "eventUri": null,
            "sentiment": 0.2941176470588236,
            "wgt": 421164780,
            "relevance": 100
        },
        {
            "uri": "7533136644",
            "lang": "eng",
            "isDuplicate": true,
            "date": "2023-05-07",
            "time": "14:12:00",
            "dateTime": "2023-05-07T14:12:00Z",
            "dateTimePub": "2023-05-07T14:07:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.wallstreet-online.de/nachricht/16897579-junshi-biosciences-announces-collaboration-with-dr-reddy-s-to-develop-and-commercialize-toripalimab-21-countries",
            "title": "Junshi Biosciences Announces Collaboration with Dr. Reddy's to Develop and Commercialize Toripalimab in 21 Countries",
            "body": "SHANGHAI, China, May 07, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\"Junshi Biosciences\", HKEX: 1877; SSE: 688180) announced a collaboration with Dr. Reddy's Laboratories Limited (\"Dr. Reddy's\") to develop and commercialize toripalimab, the anti-PD-1 monoclonal antibody in Latin America, India, South Africa, and at the election of Dr. Reddy's, also in Australia, New Zealand and other countries.\n\n\"We are thrilled to have established a partnership with Dr. Reddy's while toripalimab's global commercial network has been steadily expanding, reaching more than 50 countries and advancing our mission of being 'In China, For Global,'\" said Dr. Ning LI, Chief Executive Officer of Junshi Biosciences. \"Dr. Reddy's is a well-respected global pharmaceutical company and extends its business over nearly 70 countries worldwide, achieving impressive commerical presence across the globe. We hope that in the near future, leveraging Dr. Reddy's partnership and strong presence, our innovative medicines can accelerate access to new geographies and deliver better and more affordable treatment options to even more patients.\"",
            "source": {
                "uri": "wallstreet-online.de",
                "dataType": "news",
                "title": "wallstreet:online"
            },
            "authors": [],
            "image": "https://assets.wallstreet-online.de/_media/6/source1280/size_645/globenewswire-1280.png",
            "eventUri": null,
            "sentiment": 0.4588235294117646,
            "wgt": 421164720,
            "relevance": 100
        },
        {
            "uri": "7533134641",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-07",
            "time": "14:10:00",
            "dateTime": "2023-05-07T14:10:00Z",
            "dateTimePub": "2023-05-07T14:07:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://financialpost.com/globe-newswire/junshi-biosciences-announces-collaboration-with-dr-reddys-to-develop-and-commercialize-toripalimab-in-21-countries",
            "title": "Junshi Biosciences Announces Collaboration with Dr. Reddy's to Develop and Commercialize Toripalimab in 21 Countries",
            "body": "SHANGHAI, China, May 07, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\"Junshi Biosciences\", HKEX: 1877; SSE: 688180) announced a collaboration with Dr. Reddy's Laboratories Limited (\"Dr. Reddy's\") to develop and commercialize toripalimab, the anti-PD-1 monoclonal antibody in Latin America, India, South Africa, and at the election of Dr. Reddy's, also in Australia, New Zealand and other countries.\n\n\"We are thrilled to have established a partnership with Dr. Reddy's while toripalimab's global commercial network has been steadily expanding, reaching more than 50 countries and advancing our mission of being 'In China, For Global,'\" said Dr. Ning LI, Chief Executive Officer of Junshi Biosciences. \"Dr. Reddy's is a well-respected global pharmaceutical company and extends its business over nearly 70 countries worldwide, achieving impressive commerical presence across the globe. We hope that in the near future, leveraging Dr. Reddy's partnership and strong presence, our innovative medicines can accelerate access to new geographies and deliver better and more affordable treatment options to even more patients.\"",
            "source": {
                "uri": "financialpost.com",
                "dataType": "news",
                "title": "Financial Post"
            },
            "authors": [],
            "image": null,
            "eventUri": null,
            "sentiment": 0.4588235294117646,
            "wgt": 421164600,
            "relevance": 100
        },
        {
            "uri": "7533134577",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-07",
            "time": "14:09:00",
            "dateTime": "2023-05-07T14:09:00Z",
            "dateTimePub": "2023-05-07T14:07:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.benzinga.com/pressreleases/23/05/g32256431/junshi-biosciences-announces-collaboration-with-dr-reddys-to-develop-and-commercialize-toripalimab",
            "title": "Junshi Biosciences Announces Collaboration with Dr. Reddy's to Develop and Commercialize Toripalimab in 21 Countries ",
            "body": "SHANGHAI, China, May 07, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\"Junshi Biosciences\", HKEX: 1877; SSE: 688180) announced a collaboration with Dr. Reddy's Laboratories Limited (\"Dr. Reddy's\") to develop and commercialize toripalimab, the anti-PD-1 monoclonal antibody in Latin America, India, South Africa, and at the election of Dr. Reddy's, also in Australia, New Zealand and other countries.\n\n\"We are thrilled to have established a partnership with Dr. Reddy's while toripalimab's global commercial network has been steadily expanding, reaching more than 50 countries and advancing our mission of being 'In China, For Global,'\" said Dr. Ning LI, Chief Executive Officer of Junshi Biosciences. \"Dr. Reddy's is a well-respected global pharmaceutical company and extends its business over nearly 70 countries worldwide, achieving impressive commerical presence across the globe. We hope that in the near future, leveraging Dr. Reddy's partnership and strong presence, our innovative medicines can accelerate access to new geographies and deliver better and more affordable treatment options to even more patients.\"\n\nM.V. Ramana, CEO - Branded Markets (India & Emerging Markets), Dr. Reddy's said, \"We are pleased to partner with Junshi Biosciences to take this important product to more patients. Oncology is a focus area for Dr. Reddy's. This partnership is a further step towards increasing our offerings to patients in oncology as we aim to build a robust and comprehensive portfolio in the segment. We are committed to facilitating access to innovative products as we pursue our goal of serving over 1.5 billion patients by 2030.\"\n\nUnder the license and commercialization agreement, Junshi Biosciences will grant a licence to Dr. Reddy's to develop and exclusively commercialize toripalimab in Brazil, Mexico, Colombia, Argentina, Peru, Chile, Panama, Uruguay, India and South Africa. Dr. Reddy's may elect to expand the scope of the license to cover Australia, New Zealand and nine other countries.\n\nUnder the terms of the agreement, Junshi Biosciences also grants Dr. Reddy's the exclusive right of first negotiation for commercialization, in the event that Junshi Biosciences determines to grant any third party the rights to commercialize two other products as agreed in the agreement in one or more countries within the total 21 countries of Dr. Reddy's Territory.\n\nJunshi Biosciences may receive up to an aggregate of US$728.3 million for upfront payment, potential expansion of Dr. Reddy's Territory and milestone payment, plus double-digit percentage of royalties on the net sales of products containing toripalimab.\n\nAbout Toripalimab\n\nToripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system's ability to attack and kill tumor cells.\n\nMore than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.\n\nIn China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI). Currently, there are six approved indications for toripalimab in China:\n\nThe first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma.\n\nIn the United States, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine/cisplatin, for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (FDA). The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (SCLC).\n\nIn Europe, marketing authorization applications (MAA) were accepted by the European Medicines Agency (EMA) and the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic ESCC, in December 2022 and February 2023.\n\nAbout Dr. Reddy's\n\nDr. Reddy's is a global pharmaceutical company headquartered in Hyderabad, India and listed on the New York Stock Exchange (stock code: RDY), the National Stock Exchange of India (stock code: DRREDDY), and the Bombay Stock Exchange (stock code: 500124). Established in 1984, Dr. Reddy's is committed to providing access to affordable and innovative medicines. Driven by its purpose of 'Good Health Can't Wait', Dr. Reddy's offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Dr. Reddy's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its major markets include - the United States, India, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, Dr. Reddy's continues to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, Dr. Reddy's released its first Sustainability Report in 2004. Its current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.\n\nAbout Junshi Biosciences\n\nFounded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.\n\nIn the face of the pandemic, Junshi Biosciences' response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. In 2021, JS016 (etesevimab), China's first neutralizing fully human monoclonal antibody against SARS-CoV-2 administered with bamlanivimab, was granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116 (deuremidevir hydrobromide), a novel oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, has been approved for marketing in China and Uzbekistan. The JS016 and VV116 programs are a part of the company's continuous efforts towards innovation for disease control and prevention of the global pandemic.\n\nJunshi Biosciences has about 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.\n\nCollectively, \"Dr. Reddy's Territory 1\"\n\nCollectively, \"Dr. Reddy's Territory 2\"\n\nBoth \"Dr. Reddy's Territory 1\" and \"Dr. Reddy's Territory 2\" are collectively known as \"Dr. Reddy's Territory\", totalling 21 countries.",
            "source": {
                "uri": "benzinga.com",
                "dataType": "news",
                "title": "Benzinga"
            },
            "authors": [],
            "image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "eventUri": null,
            "sentiment": 0.2941176470588236,
            "wgt": 421164540,
            "relevance": 100
        },
        {
            "uri": "7532577764",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-07",
            "time": "05:06:00",
            "dateTime": "2023-05-07T05:06:00Z",
            "dateTimePub": "2023-05-07T05:05:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://economictimes.indiatimes.com/markets/stocks/news/msci-rejig-q4-results-econ-data-among-top-8-factors-to-drive-dalal-street-this-week/articleshow/100046824.cms",
            "title": "MSCI rejig, Q4 results, Econ data among top 8 factors to drive Dalal Street this week",
            "body": "Bulls have had a good time since last month in Dalal Street due to continued buying by foreign investors and better corporate earnings. However, a series of events, economic data points, and earnings are due next week, resulting in some likely volatility in markets despite the positive trend. The coming week will include a review by the Bank of England and earnings releases by many Indian companies, along with various macro data points and an MSCI index review. Additionally, investors will watch the primary market as Mankind Pharma is expected to debut.Barring the fall seen on Friday, Dalal Street bulls have had a good time since the last month due to continued buying by foreign investors and largely better corporate earnings.\n\nThe overall trend for the market remains positive, but a series of events, economic data points, and earnings are due next week.\n\nTherefore, some volatility in the markets is likely, according to market participants.\n\n\"Although domestic undertone remains bullish, markets may remain choppy and move in tandem with the global mood,\" said Amol Athawale, technical analyst at Kotak Securities.\n\nHere are the 8 major factors that will drive both bulls and bears on Dalal Street next week:\n\nGlobal Markets\n\nIn early trade, domestic equities will take cues from the trend in global markets. A slew of key economic data points are scheduled to be released in the US, UK, and China. These data points will decide the course of action in the respective markets.\n\nMacro Data\n\nThe consumer price inflation print for April will be released in the US on May 10. Further, the monthly budget statement and initial jobless claims will also be released next week.\n\nIndia will also release its consumer price inflation number for April and industrial production data for March in the coming week.\n\nIn the UK, the Bank of England is scheduled to meet to review its policy and announce an interest rate decision on May 11. Meanwhile, China will release its trade data on May 9, inflation numbers on May 11, and current account balance on May 12.\n\nQ4 Earnings\n\nThe week ahead will see a plethora of companies releasing their quarterly earnings.\n\nLarsen & Toubro, Dr Reddy's Laboratories, Asian Paints, Eicher Motors, Tata Motors, Cipla, Vedanta, Hindustan Petroleum Corp, Siemens, Godrej\n\nConsumer Products, UPL, Lupin, Pidilite Industries, Canara Bank, Apollo Tyres, and Raymond are a few names.\n\nBesides, companies like Hero MotoCorp, Britannia Industries, Adani Power, and Paytm, which released earnings on Friday, will also see some action in their shares.\n\nCorporate Action\n\nOracle Financial Services stock will trade ex-date on May 9 for the interim dividend of Rs 225 announced by the company.\n\nCoforge and Laurus Labs will trade ex-date for their respective dividends of Rs 19 and Rs 1.20 on May 10.\n\nIndiaMART InterMESH will trade ex-date on May 11 for the Rs 20/share final dividend announced last week.\n\nFII Flows\n\nFrom being the worst-performing market at the start of 2023, India became the best-performing market in April, thanks to the strong foreign institutional money that poured into the domestic market, alongside steady domestic flows.\n\nIn just 7 trading sessions, FIIs have poured $1.9 billion into Indian equities.\n\n\"FPIs are likely to continue buying in India. The appreciation in rupee and good Q4 results will aid in increasing capital flows to India,\" said V K Vijayakumar, chief investment strategist, Geojit Financial Services.\n\nMSCI Rejig\n\nThe MSCI index review for May is scheduled to take place on May 11, and foreign investors will closely track the same to make adjustments to their portfolios.\n\nTwo stocks that will be in focus are Adani Total Gas and Adani Transmission, as MSCI will reduce the free float for them during the index review.\n\nMSCI sees Adani Total Gas' free float at 14% against 25% earlier. For Adani Transmission, it sees it at 10% against 25% earlier.\n\nFurther, HDFC Bank and Housing Development Finance Corporation will also be in the limelight as MSCI is expected to add the bank to its largecap segment.\n\nThe addition with an adjustment factor of 0.5 could result in outflows of $150-200 million, according to Nuvama Alternative & Quantitative Research.\n\nTechnical Talk\n\nWhile the fall in HDFC twins did weigh on the Nifty 50 and pulled down markets on Friday, the trend hasn't turned bearish. \"We believe that if there is no aberration globally, we may see buying resuming at key supports,\" said Sameet Chavan, head - technical and derivatives, Angel One.\n\nAs far as the levels are concerned, 18000 followed by 17900 are likely to be crucial support levels for the 50-stock index. On the flip side, the sturdy wall once again stands at 18150-18250, Chavan said, adding that it would be interesting to see how things shape up in the first half of the week.\n\nIPO Watch\n\nThe coming week will also have investors' attention in the primary market as Mankind Pharma is likely to debut on Monday, The SME IPOs like De Neer Tools and Innokaiz India will open for subscription next week.\n\n(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)",
            "source": {
                "uri": "economictimes.indiatimes.com",
                "dataType": "news",
                "title": "Economic Times"
            },
            "authors": [],
            "image": "https://img.etimg.com/thumb/msid-100046836,width-1070,height-580,imgsize-146227,overlay-etmarkets/photo.jpg",
            "eventUri": null,
            "sentiment": 0.2,
            "wgt": 421131960,
            "relevance": 26
        },
        {
            "uri": "7530621680",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-05",
            "time": "16:10:00",
            "dateTime": "2023-05-05T16:10:00Z",
            "dateTimePub": "2023-05-05T16:05:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.thehindu.com/business/usfda-observation-for-dr-reddys-unit/article66816803.ece",
            "title": "U.S.FDA observation for Dr. Reddy's unit",
            "body": "Dr. Reddy's Laboratories has been issued a Form 483 with one observation by the United States Food and Drug Administration following an inspection of the company's active pharmaceutical ingredient (API) manufacturing facility in Bollaram, Hyderabad.\n\nIt was a routine GMP inspection of the facility (CTO 1) conducted from May 1-5. \"We have been issued a Form 483 with one observation, which we will address within the stipulated timeline,\" Dr. Reddy's said in an intimation to the stock exchange on Friday. The company's shares closed 0.66% lower to Rs.4,936.90 each on the BSE.\n\nThrough Form 483, the U.S. FDA notifies the management of the company whose facility it inspected of objectionable conditions observed by its officials that may constitute violations of the Food Drug and Cosmetic Act and related Acts.\n\nUnveils Lexiscan generic in U.S.\n\nIn another development, Dr. Reddy's Laboratories said it has introduced Regadenoson Injection 0.4 mg/5 mL, a generic therapeutic equivalent of Astellas US LLC's Lexiscan (Regadenoson) injection, in the U.S. market.\n\nDr. Reddys said the product has been launched following U.S. FDA approval and supplied as single-dose pre-filled syringes, 0.4 mg/5 mL (0.08 mg/mL). A pharmacologic stress agent, the injection is indicated for radionuclide myocardial perfusion imaging (MPI) in patients who are unable to undergo adequate exercise stress test to detect coronary artery disease (CAD).",
            "source": {
                "uri": "thehindu.com",
                "dataType": "news",
                "title": "The Hindu"
            },
            "authors": [],
            "image": "https://th-i.thgim.com/public/business/9swvun/article66816805.ece/alternates/LANDSCAPE_1200/05.05.2023%20Dr.%20Reddy%27s%20Building.jpg",
            "eventUri": null,
            "sentiment": 0.0117647058823529,
            "wgt": 420999000,
            "relevance": 100
        },
        {
            "uri": "7530610617",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-05",
            "time": "16:02:00",
            "dateTime": "2023-05-05T16:02:00Z",
            "dateTimePub": "2023-05-05T14:27:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.intellasia.net/dr-reddys-laboratories-announces-the-launch-of-regadenoson-injection-0-4-mg5-ml-in-the-u-s-11-1168112",
            "title": "Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.",
            "body": "HYDERABAD, India--(BUSINESS WIRE)--$RDY #DrReddys--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as \"Dr. Reddy's\"), today announced the launch of Regadenoson Injection in the U.S. market, a generic therapeutic equivalent of LexiscanÂ® (Regadenoson) injection, approved by U. S. Food and Drug Administration (USFDA).\n\nDr. Reddy's Regadenoson Injection is supplied as single-dose pre-filled syringes, 0.4 mg/5 mL (0.08 mg/mL).\n\nPlease click here to see the full prescribing information: https://www.drreddys.com/pi/150092149-REGADENOSON-Leaflet.pdf\n\nLexiscanÂ® is a registered trademark of Astellas US LLC.\n\nRDY-0423-551\n\nAbout Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of 'Good Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include - USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.\n\nDisclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words \"may\", \"will\", \"should\", \"expects\", \"plans\", \"intends\", \"anticipates\", \"believes\", \"estimates\", \"predicts\", \"potential\", or \"continue\" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the \"Risk Factors\" and \"Forward-Looking Statements\" sections of our Annual Report on Form 20-F for the year ended March 31, 2022. The company assumes no obligation to update any information contained herein.",
            "source": {
                "uri": "intellasia.net",
                "dataType": "news",
                "title": "IntellAsia"
            },
            "authors": [],
            "image": null,
            "eventUri": null,
            "sentiment": 0.1450980392156862,
            "wgt": 420998520,
            "relevance": 100
        },
        {
            "uri": "7530240164",
            "lang": "eng",
            "isDuplicate": true,
            "date": "2023-05-05",
            "time": "11:54:00",
            "dateTime": "2023-05-05T11:54:00Z",
            "dateTimePub": "2023-05-05T11:46:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://pragativadi.com/dr-reddys-regadenoson-injection-launched-in-us-market/",
            "title": "Dr Reddy's Regadenoson Injection Launched In US Market",
            "body": "Hyderabad: Dr Reddy's Laboratories Ltd on Friday announced the launch of Regadenoson injection, used as an agent in the imaging of heart muscle to check blood flow, in the US market.\n\nRegadenoson injection is supplied as single-dose pre-filled syringes, 0.4mg/5ml (0.08 mg/ml). It is a generic therapeutic equivalent of Lexiscan injection, approved by US Food and Drug Administration (USFDA), Dr Reddy's said in a regulatory filing.\n\nThe injection is a pharmacologic stress agent for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress.\n\nIn a separate filing, Dr Reddy's said it has issued a Form 483 with one observation by the USFDA after a routine GMP inspection at its API manufacturing facility (CTO 1) in Bollaram, Hyderabad.\n\n\"The inspection was conducted from May 1, 2023 to May 5, 2023. We have been issued a Form 483 with one observation, which we will address within the stipulated timeline,\" the company said.\n\nAs per USFDA, Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.",
            "source": {
                "uri": "pragativadi.com",
                "dataType": "news",
                "title": "Pragativadi: Leading Odia Dailly"
            },
            "authors": [],
            "image": "https://pragativadi.com/wp-content/uploads/2022/11/Dr-Reddy-Laboratory.jpg",
            "eventUri": null,
            "sentiment": -0.08235294117647063,
            "wgt": 420983640,
            "relevance": 51
        },
        {
            "uri": "7530217025",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-05",
            "time": "11:38:00",
            "dateTime": "2023-05-05T11:38:00Z",
            "dateTimePub": "2023-05-05T11:12:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.business-standard.com/companies/news/dr-reddy-s-laboratories-launches-regadenoson-injection-in-us-market-123050500635_1.html",
            "title": "Dr Reddy's Laboratories launches Regadenoson injection in US market",
            "body": "Dr Reddy's Laboratories Ltd on Friday announced the launch of Regadenoson injection, used as an agent in the imaging of heart muscle to check blood flow, in the US market.\n\nRegadenoson injection is supplied as single-dose pre-filled syringes, 0.4mg/5ml (0.08 mg/ml). It is a generic therapeutic equivalent of Lexiscan injection, approved by US Food and Drug Administration (USFDA), Dr Reddy's said in a regulatory filing.\n\nThe injection is a pharmacologic stress agent for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress.\n\nIn a separate filing, Dr Reddy's said it has issued a Form 483 with one observation by the USFDA after a routine GMP inspection at its API manufacturing facility (CTO 1) in Bollaram, Hyderabad.\n\n\"The inspection was conducted from May 1, 2023 to May 5, 2023. We have been issued a Form 483 with one observation, which we will address within the stipulated timeline,\" the company said.\n\nAs per USFDA, Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.",
            "source": {
                "uri": "business-standard.com",
                "dataType": "news",
                "title": "Business Standard"
            },
            "authors": [],
            "image": "https://bsmedia.business-standard.com/_media/bs/img/article/2022-05/22/full/1653236018-1419.jpg",
            "eventUri": null,
            "sentiment": -0.08235294117647063,
            "wgt": 420982680,
            "relevance": 51
        },
        {
            "uri": "7530206399",
            "lang": "eng",
            "isDuplicate": true,
            "date": "2023-05-05",
            "time": "11:31:00",
            "dateTime": "2023-05-05T11:31:00Z",
            "dateTimePub": "2023-05-05T11:22:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://za.investing.com/news/dr-reddys-labs-launches-regadenoson-injection-04-mg5-ml-in-the-us-432SI-2756792",
            "title": "Dr. Reddys Labs Launches Regadenoson Injection 0.4 mg/5 mL in the U.S. By Investing.com",
            "body": "Dr. Reddy's Laboratories Ltd. (RDY), today announced the launch of Regadenoson Injection in the U.S. market, a generic therapeutic equivalent of LexiscanÂ® (Regadenoson) injection, approved by U. S. Food and Drug Administration (USFDA).\n\nDr. Reddy's Regadenoson Injection is supplied as single-dose pre-filled syringes, 0.4 mg/5 mL (0.08 mg/mL).\n\nPlease click here to see the full prescribing information: https://www.drreddys.com/pi/150092149-REGADENOSON-Leaflet.pdf\n\nLexiscanÂ® is a registered trademark of Astellas US LLC.\n\nRDY-0423-551\n\nAbout Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of 'Good Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include - USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.\n\nDisclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words \"may\", \"will\", \"should\", \"expects\", \"plans\", \"intends\", \"anticipates\", \"believes\", \"estimates\", \"predicts\", \"potential\", or \"continue\" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the \"Risk Factors\" and \"Forward-Looking Statements\" sections of our Annual Report on Form 20-F for the year ended March 31, 2022. The company assumes no obligation to update any information contained herein.",
            "source": {
                "uri": "za.investing.com",
                "dataType": "news",
                "title": "Investing.com South Africa"
            },
            "authors": [],
            "image": "https://i-invdn-com.investing.com/news/World_News_10_800x533_L_1420026292.jpg",
            "eventUri": null,
            "sentiment": 0.1294117647058823,
            "wgt": 420982260,
            "relevance": 100
        },
        {
            "uri": "7530201304",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-05",
            "time": "11:29:00",
            "dateTime": "2023-05-05T11:29:00Z",
            "dateTimePub": "2023-05-05T11:18:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.marketscreener.com//quote/stock/DR-REDDY-S-LABORATORIES-6492671/news/Dr-Reddy-s-Laboratories-Announces-the-Launch-of-Regadenoson-Injection-0-4-mg-5-mL-in-the-U-S-43760001/",
            "title": "Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S. | MarketScreener",
            "body": "Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as \"Dr. Reddy's\"), today announced the launch of Regadenoson Injection in the U.S. market, a generic therapeutic equivalent of LexiscanÂ® (Regadenoson) injection, approved by U. S. Food and Drug Administration (USFDA).\n\nDr. Reddy's Regadenoson Injection is supplied as single-dose pre-filled syringes, 0.4 mg/5 mL (0.08 mg/mL).\n\nPlease click here to see the full prescribing information: https://www.drreddys.com/pi/150092149-REGADENOSON-Leaflet.pdf\n\nLexiscanÂ® is a registered trademark of Astellas US LLC.\n\nRDY-0423-551\n\nAbout Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of 'Good Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include - USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.\n\nDisclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words \"may\", \"will\", \"should\", \"expects\", \"plans\", \"intends\", \"anticipates\", \"believes\", \"estimates\", \"predicts\", \"potential\", or \"continue\" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the \"Risk Factors\" and \"Forward-Looking Statements\" sections of our Annual Report on Form 20-F for the year ended March 31, 2022. The company assumes no obligation to update any information contained herein.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230505005202/en/",
            "source": {
                "uri": "marketscreener.com",
                "dataType": "news",
                "title": "Market Screener"
            },
            "authors": [],
            "image": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "eventUri": null,
            "sentiment": 0.1294117647058823,
            "wgt": 420982140,
            "relevance": 100
        },
        {
            "uri": "7530202573",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-05",
            "time": "11:29:00",
            "dateTime": "2023-05-05T11:29:00Z",
            "dateTimePub": "2023-05-05T11:20:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.investing.com/news/assorted/dr-reddys-labs-launches-regadenoson-injection-04-mg5-ml-in-the-us-432SI-3074268",
            "title": "Dr. Reddys Labs Launches Regadenoson Injection 0.4 mg/5 mL in the U.S. By Investing.com",
            "body": "Dr. Reddy's Laboratories Ltd. (RDY), today announced the launch of Regadenoson Injection in the U.S. market, a generic therapeutic equivalent of LexiscanÂ® (Regadenoson) injection, approved by U. S. Food and Drug Administration (USFDA).\n\nDr. Reddy's Regadenoson Injection is supplied as single-dose pre-filled syringes, 0.4 mg/5 mL (0.08 mg/mL).\n\nPlease click here to see the full prescribing information: https://www.drreddys.com/pi/150092149-REGADENOSON-Leaflet.pdf\n\nLexiscanÂ® is a registered trademark of Astellas US LLC.\n\nRDY-0423-551\n\nAbout Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of 'Good Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include - USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.\n\nDisclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words \"may\", \"will\", \"should\", \"expects\", \"plans\", \"intends\", \"anticipates\", \"believes\", \"estimates\", \"predicts\", \"potential\", or \"continue\" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the \"Risk Factors\" and \"Forward-Looking Statements\" sections of our Annual Report on Form 20-F for the year ended March 31, 2022. The company assumes no obligation to update any information contained herein.",
            "source": {
                "uri": "investing.com",
                "dataType": "news",
                "title": "Investing.com"
            },
            "authors": [],
            "image": "https://i-invdn-com.investing.com/news/World_News_10_800x533_L_1420026292.jpg",
            "eventUri": null,
            "sentiment": 0.1294117647058823,
            "wgt": 420982140,
            "relevance": 100
        },
        {
            "uri": "7530196065",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-05",
            "time": "11:28:00",
            "dateTime": "2023-05-05T11:28:00Z",
            "dateTimePub": "2023-05-05T11:17:00Z",
            "dataType": "news",
            "sim": 0.4431372582912445,
            "url": "https://www.wallstreet-online.de/nachricht/16893615-dr-reddy-s-laboratories-announces-the-launch-of-regadenoson-injection-0-4-mg-5-ml-the-u-s",
            "title": "Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.",
            "body": "Dr. Reddy's Regadenoson Injection is supplied as single-dose pre-filled syringes, 0.4 mg/5 mL (0.08 mg/mL).\n\nPlease click here to see the full prescribing information: https://www.drreddys.com/pi/150092149-REGADENOSON-Leaflet.pdf\n\nLexiscan is a registered trademark of Astellas US LLC.\n\nRDY-0423-551\n\nAbout Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of 'Good Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include - USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.\n\nDisclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words \"may\", \"will\", \"should\", \"expects\", \"plans\", \"intends\", \"anticipates\", \"believes\", \"estimates\", \"predicts\", \"potential\", or \"continue\" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the \"Risk Factors\" and \"Forward-Looking Statements\" sections of our Annual Report on Form 20-F for the year ended March 31, 2022. The company assumes no obligation to update any information contained herein.",
            "source": {
                "uri": "wallstreet-online.de",
                "dataType": "news",
                "title": "wallstreet:online"
            },
            "authors": [],
            "image": "https://assets.wallstreet-online.de/_media/6/source1280/size_645/businesswire-1280.png",
            "eventUri": "eng-8596131",
            "sentiment": 0.08235294117647052,
            "wgt": 420982080,
            "relevance": 100
        },
        {
            "uri": "7530196669",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-05",
            "time": "11:28:00",
            "dateTime": "2023-05-05T11:28:00Z",
            "dateTimePub": "2023-05-05T11:24:00Z",
            "dataType": "news",
            "sim": 0.4039215743541718,
            "url": "https://www.streetinsider.com/Corporate+News/Dr.+Reddys+Labs+%28RDY%29+Launches+Regadenoson+Injection+0.4+mg5+mL+in+the+U.S./21618159.html",
            "title": "Dr. Reddys Labs (RDY) Launches Regadenoson Injection 0.4 mg/5 mL in the U.S.",
            "body": "News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.\n\nDr. Reddy's Laboratories Ltd. (NYSE: RDY), today announced the launch of Regadenoson Injection in the U.S. market, a generic therapeutic equivalent of LexiscanÃ‚Â® (Regadenoson) injection, approved by U. S. Food and Drug Administration (USFDA).\n\nDr. ReddyÃ¢Â€Â™s Regadenoson Injection is supplied as single-dose pre-filled syringes, 0.4 mg/5 mL (0.08 mg/mL).\n\nPlease click here to see the full prescribing information: https://www.drreddys.com/pi/150092149-REGADENOSON-Leaflet.pdf\n\nLexiscanÃ‚Â® is a registered trademark of Astellas US LLC.\n\nRDY-0423-551\n\nAbout Dr. ReddyÃ¢Â€Â™s: Dr. ReddyÃ¢Â€Â™s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of Ã¢Â€Â˜Good Health CanÃ¢Â€Â™t WaitÃ¢Â€Â™, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include Ã¢Â€\" USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.\n\nDisclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the managementÃ¢Â€Â™s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words \"may\", \"will\", \"should\", \"expects\", \"plans\", \"intends\", \"anticipates\", \"believes\", \"estimates\", \"predicts\", \"potential\", or \"continue\" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customersÃ¢Â€Â™, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the \"Risk Factors\" and \"Forward-Looking Statements\" sections of our Annual Report on Form 20-F for the year ended March 31, 2022. The company assumes no obligation to update any information contained herein.",
            "source": {
                "uri": "streetinsider.com",
                "dataType": "news",
                "title": "StreetInsider.com"
            },
            "authors": [],
            "image": "http://www.streetinsider.com/images/silogo-new.png",
            "eventUri": "eng-8596131",
            "sentiment": 0.1372549019607843,
            "wgt": 420982080,
            "relevance": 51
        },
        {
            "uri": "7530196668",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-05",
            "time": "11:27:00",
            "dateTime": "2023-05-05T11:27:00Z",
            "dateTimePub": "2023-05-05T11:24:00Z",
            "dataType": "news",
            "sim": 0.407843142747879,
            "url": "https://www.streetinsider.com/Business+Wire/Dr.+Reddys+Laboratories+Announces+the+Launch+of+Regadenoson+Injection+0.4+mg5+mL+in+the+U.S./21618155.html",
            "title": "Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.",
            "body": "Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.\n\nHYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as \"Dr. Reddy's\"), today announced the launch of Regadenoson Injection in the U.S. market, a generic therapeutic equivalent of LexiscanÃ‚Â® (Regadenoson) injection, approved by U. S. Food and Drug Administration (USFDA).\n\nDr. ReddyÃ¢Â€Â™s Regadenoson Injection is supplied as single-dose pre-filled syringes, 0.4 mg/5 mL (0.08 mg/mL).\n\nPlease click here to see the full prescribing information: https://www.drreddys.com/pi/150092149-REGADENOSON-Leaflet.pdf\n\nLexiscanÃ‚Â® is a registered trademark of Astellas US LLC.\n\nRDY-0423-551\n\nAbout Dr. ReddyÃ¢Â€Â™s: Dr. ReddyÃ¢Â€Â™s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of Ã¢Â€Â˜Good Health CanÃ¢Â€Â™t WaitÃ¢Â€Â™, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include Ã¢Â€\" USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.\n\nDisclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the managementÃ¢Â€Â™s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words \"may\", \"will\", \"should\", \"expects\", \"plans\", \"intends\", \"anticipates\", \"believes\", \"estimates\", \"predicts\", \"potential\", or \"continue\" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customersÃ¢Â€Â™, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the \"Risk Factors\" and \"Forward-Looking Statements\" sections of our Annual Report on Form 20-F for the year ended March 31, 2022. The company assumes no obligation to update any information contained herein.",
            "source": {
                "uri": "streetinsider.com",
                "dataType": "news",
                "title": "StreetInsider.com"
            },
            "authors": [],
            "image": "http://www.streetinsider.com/images/silogo-new.png",
            "eventUri": "eng-8596131",
            "sentiment": 0.1372549019607843,
            "wgt": 420982020,
            "relevance": 100
        },
        {
            "uri": "7530191622",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-05",
            "time": "11:23:00",
            "dateTime": "2023-05-05T11:23:00Z",
            "dateTimePub": "2023-05-05T11:17:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.benzinga.com/pressreleases/23/05/b32235602/dr-reddys-laboratories-announces-the-launch-of-regadenoson-injection-0-4-mg5-ml-in-the-u-s",
            "title": "Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S. - Dr Reddy's Laboratories (NYSE:RDY)",
            "body": "Dr. Reddy's Laboratories Ltd. ((BSE: 500124,DRREDDYRDYDRREDDY along with its subsidiaries together referred to as \", Dr. Reddy', s\", )), today announced the launch of Regadenoson Injection in the U.S. market, a generic therapeutic equivalent of LexiscanÂ® (Regadenoson) injection, approved by U. S. Food and Drug Administration (USFDA).\n\nDr. Reddy's Regadenoson Injection is supplied as single-dose pre-filled syringes, 0.4 mg/5 mL (0.08 mg/mL).\n\nPlease click here to see the full prescribing information: https://www.drreddys.com/pi/150092149-REGADENOSON-Leaflet.pdf\n\nLexiscanÂ® is a registered trademark of Astellas US LLC.\n\nRDY-0423-551\n\nAbout Dr. Reddy's: Dr. Reddy's Laboratories Ltd. ((BSE: 500124,DRREDDYRDYDRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of 'Good Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include - USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.\n\nDisclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words \"may\", \"will\", \"should\", \"expects\", \"plans\", \"intends\", \"anticipates\", \"believes\", \"estimates\", \"predicts\", \"potential\", or \"continue\" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the \"Risk Factors\" and \"Forward-Looking Statements\" sections of our Annual Report on Form 20-F for the year ended March 31, 2022. The company assumes no obligation to update any information contained herein.",
            "source": {
                "uri": "benzinga.com",
                "dataType": "news",
                "title": "Benzinga"
            },
            "authors": [],
            "image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "eventUri": null,
            "sentiment": 0.1294117647058823,
            "wgt": 420981780,
            "relevance": 100
        },
        {
            "uri": "7530174272",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-05",
            "time": "11:10:00",
            "dateTime": "2023-05-05T11:10:00Z",
            "dateTimePub": "2023-05-05T10:59:00Z",
            "dataType": "news",
            "sim": 0.4627451002597809,
            "url": "https://www.verifiedmarketresearch.com/blog/top-small-molecule-api-companies/",
            "title": "Top 10 small molecule API companies - Verified Market Research",
            "body": "APIs and excipients are two significant components in medication production. An excipient is a substance that works as a medium to aid the body in absorbing the drugs. The API is a chemical, and medication is generated from it. API is generally expounded as any material intended to be applied as the active ingredient in the formulation of a medical product. The mushrooming demand for pharmaceuticals has pushed small molecule API companies into the forefront. Small molecule API with rising research for new drugs with rising functions for a specific disorder is what propels the companies to innovate.\n\nThe global world has witnessed a rise in diseases like cancers and autoimmune diseases. Chronic problems like diabetes, cardiovascular problems, neurology disorders, and many more have increased demand for medical products. Moreover, the rise in geriatric populations has increased the demand for pharmaceuticals. The increasing healthcare spending has opened new avenues for small molecule API companies. Innovation in medications and developing infrastructure have given small molecule API companies opportunities.\n\nThe rising focus on research and developments with small molecule API has given a boost to small molecule API companies. Governments' investments and funding to enhance efficiency have also inspired small molecule API companies.\n\nAs per the research done by VMR experts in the Global Small Molecule API Companies Market report, the market size is anticipated to grow remarkably quickly. Download a sample report to gain better insights.\n\nAbbVie was established in 2012 and is based in Illinois, U.S. It specializes in biopharmaceuticals and is one the leading companies across the globe. It is dedicated to the development of products for the treatment of various diseases. It is one of the best small molecule API companies across the globe.\n\nAlbemarle was founded in 1994 and is based in North Carolina, U.S. It is a global leader in the chemical industry. Its principal products include lithium salts and metals and bromine and derivatives.\n\nAurobindo Pharma was formed in 1986 and is homed in Hyderabad, India. The company was founded by V Ramprasad Reddy and K. Nityananda Reddy. It is specialized in active pharmaceutical ingredients and generic pharmaceuticals.\n\nBoehringer Ingelheim was established in 1885 and based in Ingelheim, Germany. It was founded by Albert Boehringer. It is a world leader in pharmaceuticals. Its principal areas of focus include metabolism, oncology, immunology, and respiratory diseases.\n\nCipla was formed in 1935 and is homed in Mumbai, India. It was founded by Khwaja Abdul Hamid. It sells active pharmaceutical ingredients to manufacturers as well as personal care products. It has manufacturing locations across the globe and sells its products in various countries. It has been recognized many times for its products.\n\nMerck was founded in 1891 and based in New Jersey, U.S. It was established by Theodore Weicker and George Merck. It has hegemony in pharmaceutical companies. It has drugs and products for anti-diabetic medication and cancer immunotherapy. It is a developer of vaccines, animal health products, and biological therapies.\n\nDr. Reddy's Laboratories was established in 1984 and has its headquarters in Hyderabad, India. The company was founded by Anji Reddy. It is a leading manufacturer of pharmaceuticals in India and abroad. It has more than fifty active pharmaceutical ingredients for drug manufacture, critical care, and diagnostic kits. It is one of the best small molecule API companies across the globe.\n\nSun Pharmaceutical was founded in 1983 and is based in Mumbai, India. It was founded by Dilip Sanghvi. It is a larger manufacturer and seller of active pharmaceutical ingredients. It has a wide range of product portfolios. It is the largest company in India in the pharmaceuticals domain. It is one of the most reputed small molecule API companies in the world.\n\nTeva Pharmaceuticals was founded in 1901 by Gunther Friedlander. It is specialized principally in generic drugs and active pharmaceutical ingredients. It has a global fame in its domain. It is based in Tel Aviv, Israel. It is one of the most notable small molecule API companies in the world.\n\nViatris was founded in 2020 and based in Pennsylvania, U.S. It is specializes in healthcare and global pharmaceuticals. It produces a variety of medicines with approved therapeutic molecules. It has been recognized as one of the most responsible companies in its domain. Needless to say, it is one of the most popular small molecule API companies.",
            "source": {
                "uri": "verifiedmarketresearch.com",
                "dataType": "news",
                "title": "Verified Market Research"
            },
            "authors": [
                {
                    "uri": "yash_rajan@verifiedmarketresearch.com",
                    "name": "Yash Rajan",
                    "type": "author",
                    "isAgency": false
                }
            ],
            "image": "https://www.verifiedmarketresearch.com/wp-content/uploads/2023/05/Top-10-small-molecule-API-companies.png",
            "eventUri": null,
            "sentiment": 0.08235294117647052,
            "wgt": 420981000,
            "relevance": 1
        },
        {
            "uri": "7530175906",
            "lang": "eng",
            "isDuplicate": false,
            "date": "2023-05-05",
            "time": "11:10:00",
            "dateTime": "2023-05-05T11:10:00Z",
            "dateTimePub": "2023-05-05T10:56:00Z",
            "dataType": "news",
            "sim": 0,
            "url": "https://www.bqprime.com/business/dr-reddys-laboratories-launches-regadenoson-injection-in-us-market",
            "title": "Dr Reddy's Laboratories Launches Regadenoson Injection In U.S. Market",
            "body": "Dr Reddy's Laboratories Ltd. announced on Friday the launch of Regadenoson injection, used as an agent in the imaging of heart muscle to check blood flow, in the U.S. market.Regadenoson injection is supplied as single-dose pre-filled syringes, 0.4 mg/5 ml (0.08 mg/ml). It is a generic therapeutic equivalent of Lexiscan injection, approved by the U.S. Food and Drug Administration (USFDA), Dr Reddy's said in a regulatory filing.The inj...\n\nDr Reddy's Laboratories Ltd. announced on Friday the launch of Regadenoson injection, used as an agent in the imaging of heart muscle to check blood flow, in the U.S. market.\n\nRegadenoson injection is supplied as single-dose pre-filled syringes, 0.4 mg/5 ml (0.08 mg/ml). It is a generic therapeutic equivalent of Lexiscan injection, approved by the U.S. Food and Drug Administration (USFDA), Dr Reddy's said in a regulatory filing.\n\nThe injection is a pharmacologic stress agent for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress.\n\nIn a separate filing, Dr Reddy's said it has issued a Form 483 with one observation by the U.S. FDA after a routine GMP inspection at its API manufacturing facility (CTO 1) in Bollaram, Hyderabad.\n\n\"The inspection was conducted from May 1, 2023, to May 5, 2023. We have been issued a Form 483 with one observation, which we will address within the stipulated timeline\", the company said.\n\nAs per the U.S. FDA, Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.",
            "source": {
                "uri": "bqprime.com",
                "dataType": "news",
                "title": "BQ"
            },
            "authors": [],
            "image": "https://gumlet.assettype.com/bloombergquint%2F2022-05%2Fcb546329-63c6-4067-a8d8-c50b6d98b5da%2FDr__Reddy_s_Laboratories_Ltd__s_UK_facility.png?rect=0%2C38%2C276%2C145&w=1200&auto=format%2Ccompress&ogImage=true",
            "eventUri": null,
            "sentiment": 0.02745098039215677,
            "wgt": 420981000,
            "relevance": 75
        }
    ]
}